EXTERNAL SCIENTIFIC REPORT

Literature searches and reviews related to the prevalence of food allergy in Europe

CFT/EFSA/NUTRI/2012/02¹

University of Portsmouth

ABSTRACT

In 2011, the European Food Safety Authority (EFSA) received a mandate from the Food Safety Authority of Ireland (FSAI) to review the available scientific data on the prevalence of each food allergy in Europe, to derive threshold concentrations for each allergen in foods when possible, and to review the analytical methods available for the detection/quantification of food allergens. This report presents the findings of a series of systematic reviews of the literature related to these aims. Systematic searches of relevant bibliographic databases and the grey literature were conducted, studies were selected for inclusion according to pre-specified criteria, relevant data was extracted from all included studies, and the quality of included studies assessed. The first systematic review examined the literature on the prevalence of food allergy (IgE-mediated and non-IgE mediated) in different regions of the World and in individual European countries for different age groups in relation to each of the following food allergens: milk/dairy, eggs, cereals, peanuts, nuts, celery, crustaceans, fish, molluscs, soy, lupin, mustard and sesame. For each of these allergens changes in prevalence trends over time were also examined. Additionally, emerging food allergens in different European countries were identified. Of the 7333 articles identified by the searches, data from 92 studies was included, 52 of which reported on studies conducted within Europe. The second systematic review examined the effects of food processing on the allergenicity of foods in relation to each of the following food allergens: milk/dairy, eggs, cereals, peanuts, nuts, celery, crustaceans, fish, molluscs, soy, lupin, mustard and sesame. From 1040 articles identified by the searches, 25 studies were included in this review. The final systematic review examined the evidence regarding the new analytical methods available to analyse/detect the food allergens considered in the previous systematic reviews in processed foods. From 1475 articles identified by the searches, 84 studies were included.

KEY WORDS

food allergy, prevalence, population study, systematic review, allergen, allergenicity

DISCLAIMER

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the author(s).

Suggested citation: University of Portsmouth; Literature searches and reviews related to the prevalence of food allergy in Europe. EFSA supporting publication 2013:EN-506, 343 pp.

Available online: www.efsa.europa.eu/publications

¹ Question No EFSA-Q-2012-00376

Any enquiries related to this output should be addressed to nda@efsa.europa.eu

SUMMARY

In 2011, the European Food Safety Authority (EFSA) received a mandate from the Food Safety Authority of Ireland (FSAI) to review the available scientific data on the prevalence of each food allergy in Europe, to derive threshold concentrations for each allergen in foods when possible, and to review the analytical methods available for the detection/quantification of food allergens. Hence, EFSA commissioned this research project, the objectives of which were to carry out a series of systematic reviews of the literature reviews. This project followed systematic review methodology: systematic searches of relevant bibliographic databases and the grey literature were conducted; studies were selected for inclusion according to pre-specified criteria; relevant data was extracted from all included studies; and the quality of included studies assessed.

The first systematic review examined the literature on the prevalence of food allergy (IgE-mediated and non-IgE mediated) in different regions of the World and in individual European countries for different age groups in relation to each of the following food allergens: milk/dairy, eggs, cereals, peanuts, nuts, celery, crustaceans, fish, molluscs, soy, lupin, mustard and sesame. For each of these allergens changes in prevalence trends over time were also examined. Additionally, emerging food allergens in different European countries were identified.

Of the 7333 articles identified by the searches, 92 articles were included in this systematic review, 52 of which reported on studies conducted within Europe, presenting data for the following countries: Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Sweden, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Turkey, United Kingdom and Estonia. In the included studies, the prevalence of food allergy was assessed using a variety of methods of diagnosis, and prevalence data has been presented in this report accordingly. Fifty-seven studies utilised questionnaire or interview methods to assess the prevalence of either self-reported allergy and/or clinician-diagnosed allergy. Twenty-five studies presented data on sensitisation to foods, measured by either skin prick testing and/or serum-specific IgE testing. Some studies (27) combined information from self-reports of adverse reactions with the results of skin prick or serum-specific IgE testing to present the prevalence of allergy to a specific food. Only 21 of the included studies utilised food challenges to determine the prevalence of food allergy. Of the included studies, 55 were considered to have utilised a method of diagnosis at high risk of bias, 11 used a sampling method considered to be at high risk of bias (the sampling method was unclear in 16 studies) and seven failed to consider reasons for non-response and/or explore withdrawal/loss-to-follow-up (for 69 studies this was unclear). Worldwide milk/dairy was the most common allergen examined (by 40 European studies and 29 non-European), followed by egg (35 European studies, 26 non-European), fish/shellfish/molluscs (34 European studies, 27 non-European) and peanut (27 European studies, 26 non-European). The least examined allergens were celery (four European studies, one non-European), mustard (one European study) and lupin (no studies).

Although some allergens were widely studied, such as milk, peanut and fish/shellfish/molluscs, the systematic review revealed that there are many gaps in the evidence base for the prevalence of allergies to some individual foods (e.g. lupin and celery). Moreover, there are gaps in the evidence base related to the prevalence of food allergies in specific age groups and countries. An important issue is that many studies focus on the prevalence of self-reported rather than challenge-proven food allergy. Even in studies utilising food challenges there was a huge variety in the approach taken, which hinders comparisons across allergens, age groups and countries. For example, in many studies aspects of the challenge protocol were unclear and several studies utilising food challenges did so as part of an algorithm drawing upon other information (e.g. sensitisation data, symptom reports) to diagnose food allergy and such algorithms differed between studies. Time trends are particularly difficult to describe based upon the current evidence base given the lack of studies utilising similar methodologies with comparable age groups in the same country.

EFSA supporting publication 2013:EN-506

3

The second systematic review examined the effects of food processing on the allergenicity of foods in relation to each of the following food allergens: milk/dairy, eggs, cereals, peanuts, nuts, celery, crustaceans, fish, molluscs, soy, lupin, mustard and sesame. This review was concerned with studies that used food challenges to assess changes in the allergenicity of foods processed using a wide variety of methods. From 1040 articles identified by the searches, 25 studies were included in this review. The included studies investigated the allergenicity of the following reported allergens: celery (one study), wheat (one study), egg (six studies), hazelnut (two studies), milk and dairy (14 studies) and peanut oil (one study).

The majority of studies focussed on the effect of heat; commonly boiling, roasting or baking. The exceptions were the studies investigating hydrolysis and fractioning of milk for infant milk formulas and one study investigating the effect of maturation time for cheese production for those with allergy to the additive lysozyme (from egg) or milk allergens. There were no included studies investigating the effect of using egg or milk as fining agents within the wine making industry. Additionally, although a large number of studies were carried out on peanut allergy no studies were identified that challenged participants with two forms of peanut, for example raw and roasted. However, we did find one study that investigated the allergenicity of crude versus refined peanut oil.

Most studies utilized a cross-over design where each participant underwent challenge to two forms of the food. The order in which the participants were allocated to the challenge with each type of food was determined randomly for only a small proportion of studies. The remaining cross-over studies used a non-random order, usually because the participants were challenged to the food considered least allergenic first since the studies were designed to investigate whether a diet including extensively heated egg or milk could lead to increased tolerance rather than the effect of processing on allergenicity. In all cases, data was extracted only for those participants who were challenge positive to one or more of the forms of the food being examined. Studies did not tend to include a high proportion of participants with severe allergy. In the large majority of studies that carried out a double-blind placebo-controlled food challenge the challenge procedure (for example the method of masking (and its validity), the method of generating the random sequence, the ratio of active to placebo challenge and the way in which the sequence was concealed from the participants and the study personnel) was not clearly reported.

The evidence suggests that the allergenicity of foods can be altered by food processing. However, although there are trends for certain foods, for example, that extensive heating of egg, milk, celery, and to some extent hazelnut, reduces allergenicity, this reduction will not be experienced by all people with that allergy. The included studies were small and not representative of the wider allergic population. More high quality research is required to determine if certain types of processing increase allergenicity, especially for foods such as peanut where this is suggested by the in vitro research evidence. It would be useful to identify groups of people more likely to tolerate certain types of processed foods, so that more specific diagnostic challenges can be accessed and lead to individualised management strategies.

The final systematic review examined the evidence regarding the new analytical methods available to analyse/detect the food allergens considered in the previous systematic reviews in processed foods. The review set out to include studies investigating extraction and detection of the food/proteins in a food matrix of relevance to the real world setting. Studies investigating food matrixes spiked with allergen were included. From 1475 articles identified by the searches, 84 studies were included.

This review revealed that there are a large number of studies that have investigated the effectiveness of assays for detecting allergens in foods published since 2004. The foods with the most research conducted was tree nuts, followed by peanut, milk and dairy and egg. For most allergens there are tests developed that can detect down to 10μ g/ml. However the food matrix used could affect the performance of the extraction processes and assays. There was variability in the types of experiments

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

carried out, the format and statistical analysis of the data presented and in specific techniques such as the method of spiking and in the source of extracts used to validate the assay in the studies retrieved for this review. In a large proportion of studies there was a potential high risk of bias for at least one item. There are a range of criteria that could be used to validate assays and ensure that there is consistent quality control across institutions. We focused on the accuracy as determined by the percentage recovery of a spiked sample and the limit of detection of each allergen within a suitable food matrix; this is just one aspect of quality control. The limit of detection reported by some of these studies showed that the values reported by manufacturers are not always achieved in practice. Reasons for variation could be the type of matrix used, for example manufacturers may report the sensitivity of the assay when the allergen standard is diluted in assay buffer rather than being within a complex food matrix. Before funding or adopting an assay and extraction procedure it is recommended that all key quality and validation data are reviewed in accordance with the relevant standards and that each laboratory carry out their own validation experiments to assess the performance of the assay within their specific context. The organisations providing guidance for quality assurance are discussed.

EFSA supporting publication 2013:EN-506

5

TABLE OF CONTENTS

| Abstract | | 1 |
|---------------------|---|------|
| Summary | | 2 |
| Table of contents. | | 5 |
| List of Tables Sect | ion 1 | 8 |
| List of Tables Sect | ion 2 | 9 |
| List of Tables Sect | ion 3 | 9 |
| Background | | . 11 |
| Objectives | | . 11 |
| Terms of reference | 3 | . 12 |
| Introduction and C | Dejectives | . 13 |
| 1. THE PREVAL | ENCE OF FOOD ALLERGY IN DIFFERENT REGIONS OF THE WORLD AND | |
| INDIVIDUAL] | EUROPEAN COUNTRIES (OBJECTIVES 1-3) | . 15 |
| 1.1. Materials | s and Methods | . 15 |
| 1.1.1. Liter | rature search strategy | . 15 |
| 1.1.1.1. | Bibliographic databases and grey literature searching | . 15 |
| 1.1.1.2. | Search terms and Boolean operators | . 15 |
| 1.1.1.3. | Management of search results | . 19 |
| 1.1.1.4. | Specific search strategy for identifying articles related to the prevalence of | |
| | emerging allergens | . 19 |
| 1.1.1.5. | Specific search strategy for identifying the clinical reactivity to emerging allerger | ns19 |
| 1.1.1.6. | Specific search strategy for identifying the prevalence of allergy to any food | . 19 |
| 1.1.2. Stud | y selection general approach | . 20 |
| 1.1.3. Stud | y selection specific approach: objectives 1-3 | . 20 |
| 1.1.3.1. | Types of studies | . 20 |
| 1.1.3.2. | Types of participants | . 21 |
| 1.1.3.3. | Types of outcome measure | . 21 |
| 1.1.4. Stud | y selection specific approach for identifying the prevalence of allergy to any food | 21 |
| 1.1.5. Data | i collection general approach | . 22 |
| 1.1.6. Data | collection specific approach for emerging allergens (Objective 3) | . 22 |
| 1.1.7. Data | collection specific approach for allergy to any food | . 23 |
| 1.1.8. Asse | essing the quality of included studies | . 23 |
| 1.1.9. Data | ι synthesis and presentation | . 23 |
| 1.1.9.1. | General approach | . 23 |
| 1.1.9.2. | Objectives 1 and 3 | . 24 |
| 1.1.9.3. | Objective 2 | . 24 |
| 1.2. Results | | . 24 |
| 1.2.1. Resu | Ilts of the search | . 24 |
| 1.2.2. Inclu | ıded studies | . 25 |
| 1.2.4. Qua | lity of included studies | . 58 |
| 1.2.5. Furt | her information about diagnostic procedures employed by all studies | 61 |
| 1.2.6. Resu | Its for Prevalence with age in different countries and regions | . 94 |
| 1.2.6.1. | Celery allergy prevalence across Europe | . 94 |
| 1.2.6.2. | Celery allergy prevalence of different regions of the world | . 94 |
| 1.2.6.3. | Cereals allergy prevalence across Europe | . 94 |
| 1.2.6.4. | Cereals allergy prevalence in different regions of the world | . 96 |
| 1.2.6.5. | Egg allergy prevalence across Europe | . 97 |
| 1.2.6.6. | Egg allergy prevalence in different regions of the world | . 98 |
| 1.2.6.7. | Fish and Shellfish prevalence across Europe | . 98 |
| 1.2.6.8. | Fish and Shellfish prevalence in different regions of the world | 100 |
| 1.2.6.9. | Fruit allergy prevalence across Europe | 101 |
| 1.2.6.10. | Fruit allergy prevalence in different regions of the world | 102 |

EFSA supporting publication 2013:EN-506

| 1.2.6.11. | Milk/dairy allergy prevalence across Europe | 102 |
|-------------------------------|---|--------------------|
| 1.2.6.12. | Milk/dairy allergy prevalence in different regions of the world | 103 |
| 1.2.6.13. | Mustard allergy prevalence across Europe | 104 |
| 1.2.6.14. | Mustard allergy prevalence in different regions of the world | 104 |
| 1.2.6.15. | Peanut allergy prevalence across Europe | 104 |
| 1.2.6.16. | Peanut allergy prevalence in different regions of the world | 105 |
| 1.2.6.17. | Sesame allergy prevalence across Europe | 106 |
| 1.2.6.18. | Sesame allergy prevalence in different regions of the world | 107 |
| 1.2.6.19. | Soya allergy prevalence across Europe | 107 |
| 1.2.6.20. | Soya allergy prevalence in different regions of the world | 108 |
| 1.2.6.21. | Tree Nuts allergy prevalence across Europe | 108 |
| 1.2.6.22. | Tree Nuts allergy prevalence in different regions of the world | 110 |
| 1.2.6.23. | All other foods, allergy prevalence across Europe | 110 |
| 1.2.6.24. | All other foods, allergy prevalence in different regions of the world | 111 |
| 1.2.6.25. | Prevalence of allergy to any food across Europe | 111 |
| 1.2.6.26. | Prevalence of allergy to any food in different regions of the world | 113 |
| 1.2.7. Tim | e Trends | 200 |
| 1.2.7.1. | Celery | 200 |
| 1.2.7.2. | Cereals | 200 |
| 1.2.7.3. | Egg | 200 |
| 1.2.7.4. | Fish and Shellfish | 201 |
| 1.2.7.5. | Fruits | 201 |
| 1.2.7.6. | Milk/dairy | 201 |
| 1.2.7.7. | Mustard | 201 |
| 1.2.7.8. | Peanut | 201 |
| 1.2.7.9. | Sesame | 201 |
| 1.2.7.10. | Sova | |
| 1.2.7.11. | Tree Nuts | 202 |
| 1.2.7.12. | Other Foods | 202 |
| 1.2.8. Dis | cussion | 202 |
| 1.3. List of I | ncluded Studies | 208 |
| 1.4. List of F | Excluded Studies | 214 |
| 1.5. Addition | jal references | 216 |
| THE EFFECT | OF FOOD PROCESSING ON THE ALLERGENICITY IN RELATION TO EACH OF | гне. |
| FOLLOWING | FOOD ALLERGENS: MILK/DAIRY, EGGS, CEREALS, BUCKWHEAT, PEANUTS, | NUTS. |
| CELERY, CR | USTACEANS, FISH, MOLLUSCS, SOY, LUPIN, MUSTARD AND SESAME? (OBJEC | TIVE |
| 4A) | | 217 |
| 2.1 Introduc | tion | 217 |
| 2.1.1. Ass | essing allergenicity of the processed food | 217 |
| 2.1.2 Part | ticinants | 217 |
| 2.1.2. Fun | d processing methods | 217 |
| 2.1.5. 100 2.2 Material | s and Methods | 217 |
| 2.2. 1014401141 2.2.1 Lite | rature search strategy | 217 |
| 2211 | Selection procedure | <u>2</u> 17 220 |
| 2.2.1.1. | Types of studies | 220 |
| 2.2.1.2. | Types of studies. | 220 221 |
| 2.2.1.3. | Methods of food processing | 221 |
| 2.2.1.4. | Types of outcome measure | 221 221 |
| 2.2.1.3. 222 Evt | raction of data | 221 221 |
| 2.2.2. EAU 2.2.2 Acc | essing the quality of studies | 221 ววว |
| 2.2.3. And $2.2.4$ | lusis of Data | 222 771 |
| 2.2.7. Alla | | 224 224 |
| 2.3. Results. 2.3. Res | ults of Search | 224 771 |
| 2.3.1. KCS | | 224 |
| A supporting pi | 1011cation 2013:EN-506 | 6 |

2.

7

| 2.3.2. Description of Studies | 226 |
|---|----------|
| 2.3.3. Participants | 229 |
| 2.3.4. Processing methods | 233 |
| 2.3.5. Challenge procedure | |
| 2.3.6. Study design | |
| 2.3.7. The Quality of studies | |
| 2.3.8. Findings on effect of processing on allergenicity | |
| 2.3.8.1. Celery | |
| 2.3.8.2. Cows' milk | |
| 2.3.8.3. Egg | |
| 2.3.8.4. Tree nuts | |
| 2.3.8.5. Wheat | |
| 2.3.8.6. Peanut | |
| 2.4. Discussion and Conclusions | |
| 2.5. List of included studies | |
| 2.6. List of Excluded Studies | |
| 2.7. Additional References | |
| 3. WHAT NEW ANALYTICAL METHODS ARE AVAILABLE TO ANALYSE/DETECT THE F | OLLOWING |
| FOOD ALLERGENS IN PROCESSED FOODS: MILK/DAIRY, EGGS, CEREALS, BUCKWH | EAT, |
| PEANUTS, NUTS, CELERY, CRUSTACEANS, FISH, MOLLUSCS, SOY, LUPINE, MUSTAR | D AND |
| SESAME? (OBJECTIVE 4B) | |
| 3.1. Search Strategy | |
| 2.1.1.1 Turnes of studies | |
| 2.1.1.2 Types of studies | |
| 3.1.1.2. Types of detection methods | |
| 2.1.2. Extraction of data | |
| 3.1.2. Extraction of utila | |
| 3.1.4 Data synthesis and presentation | |
| 3.1.4. Data synthesis and presentation | |
| 3.2. Almond | |
| 3.2.7. Rrazil nut | 268 |
| 3.2.2. Bluzh hut | 260 |
| 3.2.4 Cashew | 209 |
| 3.2.5. Celery | |
| 3.2.6. Cereals | |
| 3.2.7. Egg | |
| 3.2.8. Fish and Shellfish | |
| 3.2.9. Hazelnut | |
| 3.2.10. Lupine | |
| 3.2.11. Milk | |
| 3.2.12. Peanut | |
| 3.2.13. Sesame | |
| 3.2.14. Soy | |
| 3.2.15. Walnut | |
| 3.2.16. Other | |
| 3.2.17. Quality of studies | |
| 3.3. Discussion and Conclusions | 333 |
| 3.4. List of Included Studies | |
| 3.5. List of Excluded Studies | |
| 3.6. Additional references | |
| Abbreviations | |

EFSA supporting publication 2013:EN-506

LIST OF TABLES SECTION 1

| Table 1.1: | Search terms for the prevalence of food allergy (objectives 1, 2 and 3) | 16 |
|-------------|---|----|
| Table 1.2: | Search terms to identify articles related to the clinical reactivity of emerging allergens. | 20 |
| Table 1.3: | Quality assessment criteria | 23 |
| Table 1.4: | Key characteristics of included studies | 27 |
| Table 1.5: | Study designs of included studies | 50 |
| Table 1.6: | Quality assessment of all studies | 58 |
| Table 1.7: | Further information about questionnaire-based methods employed by studies | 61 |
| Table 1.8: | Further information about skin-prick test and serum-specific IgE testing performed by | |
| | studies | 72 |
| Table 1.9: | Further information about food challenge procedures performed by studies | 84 |
| Table 1.10: | Celery allergy prevalence in European countries by age group | 14 |
| Table 1.11: | Celery allergy prevalence in non-European countries by age group 1 | 14 |
| Table 1.12: | Cereals allergy prevalence in European countries by age group | 15 |
| Table 1.13: | Cereals allergy prevalence in non-European countries by age group1 | 19 |
| Table 1.14: | Egg allergy prevalence in European countries by age group | 21 |
| Table 1.15: | Egg allergy prevalence in non-European countries by age group 12 | 26 |
| Table 1.16: | Fish and Shellfish allergy prevalence in European countries by age group 13 | 30 |
| Table 1.17: | Fish and Shellfish allergy prevalence in non-European countries by age group 13 | 35 |
| Table 1.18: | Fruits allergy prevalence in European countries by age group 14 | 42 |
| Table 1.19: | Fruits allergy prevalence in non-European countries by age group14 | 48 |
| Table 1.20: | Milk/Dairy allergy prevalence in European countries by age group 15 | 51 |
| Table 1.21: | Milk/Dairy allergy prevalence in non-European countries by age group 15 | 59 |
| Table 1.22: | Mustard allergy prevalence in European countries by age group 10 | 63 |
| Table 1.23: | Peanut allergy prevalence in European countries by age group 10 | 64 |
| Table 1.24: | Peanut allergy prevalence in non-European countries by age group 10 | 67 |
| Table 1.25: | Sesame allergy prevalence in European countries by age group 1 | 71 |
| Table 1.26: | Sesame allergy prevalence in non-European countries by age group 1 | 72 |
| Table 1.27: | Soya allergy prevalence in European countries by age group 1 | 73 |
| Table 1.28: | Soya allergy prevalence in non-European countries by age group 1 | 75 |
| Table 1.29: | Tree nuts allergy prevalence in European countries by age group 17 | 77 |
| Table 1.30: | Tree nuts allergy prevalence in non-European countries by age group 18 | 81 |
| Table 1.31: | All Other Foods allergy prevalence in European countries by age group | 82 |
| Table 1.32: | All Other Foods allergy prevalence in non-European countries by age group 19 | 93 |
| Table 1.33: | Studies excluded from the systematic review | 14 |

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

9

LIST OF TABLES SECTION 2

| Table 2.1: | Search strategy in Web of Knowledge. Each group was combined with the terms | |
|-------------|---|-------|
| | within a group were linked with 'or' and the groups were linked with 'and' | . 218 |
| Table 2.2: | The method for assessing the quality of the included studies | . 223 |
| Table 2.3: | Summary of description of studies (alphabetical order by food) | . 226 |
| Table 2.4: | Participants included in the studies (alphabetical order by study author) | . 229 |
| Table 2.5: | Method of processing comparison and test food. Wet weight indicates the weight of | |
| | the processed or unprocessed food was used without adjusting for the moisture or | |
| | protein content (alphabetical order by author) | . 234 |
| Table 2.6: | Challenge procedure for comparison food (study author order) | . 240 |
| Table 2.7: | Challenge procedures for test food (alphabetical order by author) if different to | |
| | comparison food | . 244 |
| Table 2.8: | Study design and outcome assessment (alphabetical order by author) | . 246 |
| Table 2.9: | Quality of Studies (alphabetical order by author) | . 248 |
| Table 2.10: | Allergenicity of processed foods (alphabetical order by food) | . 251 |
| | | |

LIST OF TABLES SECTION 3

| Table 3.1: | Search terms for identifying assays that detect allergenic foods | 262 |
|-------------|--|-------|
| Table 3.2: | Quality assessment of studies | 265 |
| Table 3.3: | Almond: characteristics of included studies | 266 |
| Table 3.4: | Almond: description of assay | 267 |
| Table 3.5: | Almond: accuracy and limit of detection and quantification | 267 |
| Table 3.6: | Brazil nut: characteristics of included studies | 268 |
| Table 3.7: | Brazil nut: description of assay | 269 |
| Table 3.8: | Brazil nut: accuracy and limit of detection and quantification | 269 |
| Table 3.9: | Buckwheat: characteristics of included studies | 270 |
| Table 3.10: | Buckwheat: description of assay | 270 |
| Table 3.11: | Buckwheat: accuracy and limit of detection and quantification | 271 |
| Table 3.12: | Cashew: characteristics of included studies | 272 |
| Table 3.13: | Cashew: description of assay | 273 |
| Table 3.14: | Cashew: accuracy and limit of detection and quantification | 273 |
| Table 3.15: | Celery: characteristics of included studies | 274 |
| Table 3.16: | Celery: description of assay | 275 |
| Table 3.17: | Celery: accuracy and limit of detection and quantification | 275 |
| Table 3.18: | Cereals: characteristics of included studies | 276 |
| Table 3.19: | Cereals: description of assay | . 277 |
| Table 3.20: | Cereals: accuracy and limit of detection and quantification | 278 |
| Table 3.21: | Egg: characteristics of included studies | 282 |
| Table 3.22: | Egg: description of assay | 283 |
| Table 3.23: | Egg: accuracy and limit of detection and quantification | 285 |
| Table 3.24: | Fish and Shellfish: characteristics of included studies | 287 |
| Table 3.25: | Fish and Shellfish: description of assay | 288 |
| Table 3.26: | Fish and Shellfish: accuracy and limit of detection and quantification | 289 |

EFSA supporting publication 2013:EN-506

| Hazelnut: characteristics of included studies | 292 |
|--|---|
| Hazelnut: description of assay | 294 |
| Hazelnut: accuracy and limit of detection and quantification | 296 |
| Lupine: characteristics of included studies | 299 |
| Lupine: description of assay | 300 |
| Lupine: accuracy and limit of detection and quantification | 301 |
| Milk: characteristics of included studies | 302 |
| Milk: description of assay | 304 |
| Milk: accuracy and limit of detection and quantification | 306 |
| Peanut: characteristics of included studies | 309 |
| Peanut: description of assay | 312 |
| Peanut: accuracy and limit of detection and quantification | 315 |
| Sesame: characteristics of included studies | 319 |
| Sesame: description of assay | 320 |
| Sesame: accuracy and limit of detection and quantification | 321 |
| Soy: characteristics of included studies | 322 |
| Soy: description of assay | 323 |
| Soy: accuracy and limit of detection and quantification | 324 |
| Walnut: characteristics of included studies | 325 |
| Walnut: Description of Assay | 326 |
| Walnut: accuracy and limit of detection and quantification | 327 |
| Other: characteristics of included studies | 327 |
| Other: Description of Assay | 328 |
| Other: accuracy and limit of detection and quantification | 329 |
| Quality of the included studies | 329 |
| | Hazelnut: characteristics of included studies |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

11

BACKGROUND

In 2011, the European Food Safety Authority (EFSA) received a mandate from the Food Safety Authority of Ireland (FSAI) to review the available scientific data on the prevalence of each food allergy in Europe, to derive threshold concentrations for each allergen in foods when possible, and to review the analytical methods available for the detection/quantification of food allergens. In order to address this mandate, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) will update its opinion, published in 2004², relating to the evaluation of allergenic foods for labelling purposes which provides the scientific basis for the identification of foods, food components and food ingredients which may trigger allergic reactions in susceptible individuals, as well as an overview on the prevalence of food allergy, on the setting of threshold concentrations/minimal eliciting doses for individual food allergens, and on the analytical methods for the detection/quantification of these food allergens in raw and processed foods.

OBJECTIVES

The objectives of the contract resulting from the present procurement procedure are the collection, collation and analysis of published and unpublished data related to:

- 1. The prevalence of food allergy (IgE-mediated and non-IgE mediated) in different regions of the World (e.g. North America, Canada, Australia and New Zealand) and primarily in individual European countries for different age groups in relation to each of the following food allergens: milk/dairy, eggs, cereals, peanuts, nuts, celery, crustaceans, fish, molluscs, soy, lupin, mustard and sesame.
- 2. The natural history of food allergy to each allergen listed above (changes in prevalence and/or severity with age) and on changes in prevalence trends over time at a population level, whenever available.
- 3. The most prevalent (emerging) food allergies in different European countries (i.e. food allergens other than those listed above) and changes in sensitisation patterns where known or emerging.
- 4. The effects of food processing on the allergenicity of foods in relation to each of the following food allergens: milk/dairy, eggs, cereals, peanuts, nuts, celery, crustaceans, fish, molluscs, soy, lupin, mustard and sesame; and on the new analytical methods available to analyse/detect these food allergens in processed foods.

To achieve these objectives the contractor should carry out comprehensive literature searches to identify and retrieve all related information/data published in peer-reviewed journals and should make reasonable efforts to identify and retrieve unpublished data. The data retrieved should be further analysed following well-accepted methodologies and criteria in order to identify relevant scientific data. The information should be transferred in a concise way to EFSA including the full list of references used for each single food allergen. References not considered pertinent should be listed and a reasoning why these references were not considered pertinent should be provided, in both raw and processed foods.

² EFSA (European Food Safety Authority), 2004. Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission relating to the evaluation of allergenic foods for labelling purposes. The EFSA Journal 32, 1-197

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

TERMS OF REFERENCE

This contract was awarded by EFSA to: University of Portsmouth

Contractor: Dr Elizabeth Bartle, University of Portsmouth Higher Education Corporation

Contract title: Literature searches and reviews related to the prevalence of food allergy in Europe.

Contract number: CFT/EFSA/NUTRI/2012/02

EFSA supporting publication 2013:EN-506

INTRODUCTION AND OBJECTIVES

In order to address the four objectives we have brought together a team of academics with expertise in the field of food allergy research and systematic reviews. The overall approach was a series of systematic reviews of the literature, using the following stages:

| Stage 1. | Conduct a comprehensive and systematic search of the (published and unpublished) literature to identify all potentially relevant studies. | | |
|----------|---|--|--|
| Stage 2. | Screen all identified studies against pre-specified eligibility criteria for their relevance to the objective. | | |
| Stage 3. | For all included studies, extract data relevant to the objective (using pre-specified data collection forms). | | |
| Stage 4. | For all included studies, assess the validity of the findings (using pre-specified quality assessment criteria). | | |
| Stage 5. | Synthesise the results of the included studies (as appropriate) and present the characteristics and findings. | | |

These literature reviews would adhere to the nomenclature for food allergy as specified by the World Allergy Organisation and so will not include non-allergic food hypersensitivity (i.e. where immunologic mechanisms have not been implicated).

The objectives are to carry out systematic literature reviews:

- 1. on the prevalence of food allergy (IgE-mediated and non-IgE mediated) in different regions of the World (e.g. North America, Canada, Australia and New Zealand) and primarily in individual European countries for different age groups in relation to each of the following food allergens: milk/dairy, eggs, cereals, peanuts, nuts, celery, crustaceans, fish, molluscs, soy, lupin, mustard and sesame;
- 2. and for each allergen listed above to present changes in prevalence trends over time at a population level for specific age groups, whenever available;
- 3. to identify emerging food allergens in different European countries (i.e. food allergens other than those listed above, where there is a significantly high prevalence) and present the prevalence and changes in prevalence with time, whenever available;
- 4. (4a) on the effects of food processing on the allergenicity of foods in relation to each of the following food allergens: milk/dairy, eggs, cereals, peanuts, nuts, celery, crustaceans, fish, molluscs, soy, lupin, mustard and sesame;

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

5. (4b) on the new analytical methods available to analyse/detect these food allergens in processed foods.

The methods and the results for objectives 1-3 are reported in the same section as they share the same search strategy. The methods and the results for objectives 4a and 4b are presented separately as the search strategies and the assessment criteria are distinct.

EFSA supporting publication 2013:EN-506

1. THE PREVALENCE OF FOOD ALLERGY IN DIFFERENT REGIONS OF THE WORLD AND INDIVIDUAL EUROPEAN COUNTRIES (OBJECTIVES 1-3)

1.1. Materials and Methods

1.1.1. Literature search strategy

1.1.1.1. Bibliographic databases and grey literature searching

We searched the following databases: Web of Science including Social Science Citation Index Expanded (1970-present), Social Sciences Citation Index (1970-present), Conference Proceedings Citation Index Science (1990-present), Book Citation Index Science (2005-present), and PubMed.

Searches of conference proceedings were carried out using the Conference Proceedings Citations Index in which studies reported in the proceedings of a comprehensive range of allergy conferences (including the World Allergy Congress, the Annual meeting of the American Academy of Asthma, Allergy and Immunology and the Congress of the European Academy of Allergy and Clinical Immunology) can be identified.

Grey literature was sought via direct contact with a list of topic experts and examination of the lists of awards made by known funders of research in the field (see Box 1). To ensure thoroughness, a snowball approach was taken, whereby the experts were asked whether they knew of any others working in fields directly related to the objectives whom we should contact.

| Dr Katie Allen | Dr Scott Sicherer |
|-------------------------------|------------------------------|
| Professor S Hasan Arshad | Dr Bodo Niggemann |
| Professor Peter Burney | Professor Ulrich Wahn |
| Dr Kirsten Beyer | Professor Jonathan Hourihane |
| Professor Gideon Lack | Dr Graham Roberts |
| Dr Montserrat Fernandez Rivas | Professor Susan Prescott |
| Professor Hugh Sampson | |

Box 1. Topic experts and known funders of research in the field.

1.1.1.2. Search terms and Boolean operators

Specific search strategies were tailored for the requirements of each database. In order to identify all relevant articles, no language or date restrictions were employed and searches were not limited by study type. The team evaluated the sensitivity of the search strategy by checking that the search results included studies on this topic known by experts within the field.

In PubMed the terms were searched for in the title and abstract fields and using MeSH terms where appropriate. In Web of Science the terms were searched for in the 'Topic Search' field (which includes title, abstract and keywords). Within groups of terms the terms were combined using OR, the groups of terms themselves were then combined in the following manner: #1 AND #2 AND #3.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Topics | Search terms ³ | Search terms for PubMed | Search terms for Web of Science |
|------------------------|--|---|---|
| Group 1. Prevalence | | | |
| Prevalence | Prevalence, point prevalence | prevalence[Tiab] OR "point prevalence"[Tiab] OR prevalence[MeSH Terms] | prevalence OR "point prevalence" |
| Incidence | Incidence, cumulative incidence | incidence[Tiab] OR "cumulative incidence"[Tiab] OR incidence[MeSH Terms] | incidence OR "cumulative incidence" |
| Natural history | Natural history | <pre>"natural history"[tiab] OR ((change[tiab] OR changes[tiab]) AND (severity[tiab] OR prevalence[tiab]) AND time[tiab])</pre> | "natural history" OR ((change OR changes) AND (severity OR prevalence) AND time) |
| Group 2. Food | | food[Tiab] | food |
| Milk and dairy | Milk, lactose, dairy, butter, cream, infant formula, cheese, yoghurt, petit filous, casein, whey | milk[Tiab] OR milk[MeSH Terms] OR lactose[MeSH Terms] OR lactose[Tiab] OR dairy[Tiab] OR butter[Tiab] OR cream[Tiab] OR "infant formula"[Tiab] OR cheese[Tiab] OR yoghurt[Tiab] OR "petit filous"[Tiab] OR casein[Tiab] OR whey[Tiab] | milk OR lactose OR dairy OR butter OR cream OR "infant formula" OR cheese OR yoghurt OR "petit filous" OR casein OR whey |
| Egg | Egg, eggs | egg[Tiab] OR eggs[Tiab] | egg OR eggs |
| Cereals | Cereal, gluten, wheat, rye, barley, oats, spelt, kamut | cereals[MeSH Terms] OR cereal[Tiab] OR cereals[Tiab] OR glutens[MeSH Terms] OR glutens[Tiab] OR gluten[Tiab] OR wheat[Tiab] OR rye[Tiab] OR barley[Tiab] OR oats [Tiab] OR oat[Tiab] OR spelt[Tiab] OR kamut[Tiab] | cereal OR cereals OR gluten OR glutens OR wheat OR rye OR barley OR oats OR oat OR spelt OR kamut |
| Peanut | Peanut, arachis | peanut[Tiab] OR arachis[Tiab] | peanut OR arachis |

Table 1.1:Search terms for the prevalence of food allergy (objectives 1, 2 and 3)

³ As indicated in technical offer and updated in light of kick-off meeting (e.g. expanded the range of terms included for specific types of fish and shellfish)

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Topics | Search terms ³ | Search terms for PubMed | Search terms for Web of Science |
|-------------|---|---|---|
| Nuts | Nut, almond, hazelnut, walnut, cashew, pecan, macadamia, pistachio, beechnut, filbert, tree nuts | nuts[MeSH Terms] OR nuts[Tiab] OR nut[Tiab] OR almond[Tiab] OR almonds[Tiab] OR hazelnut[Tiab] OR hazelnuts[Tiab] OR walnut[Tiab] OR walnuts[Tiab] OR cashew[Tiab] OR cashews[Tiab] OR pecan[Tiab] OR pecans[Tiab] OR macadamia[Tiab] OR macadamias[Tiab] OR pistachio[Tiab] OR pistachios[Tiab] OR beechnut[Tiab] OR pistachios[Tiab] OR filberts[Tiab] | nuts OR nut OR almond OR almonds OR hazelnut OR hazelnuts OR walnut OR walnuts OR cashew OR cashews OR pecan OR pecans OR macadamia OR macadamias OR pistachio OR pistachios OR beechnut OR beechnuts OR filbert OR filberts |
| Celery | Celery | celery[tiab] | celery |
| Crustaceans | Crustacean, crab, lobster, shrimp, prawn, crayfish, shellfish, langoustine | crustacean[MeSH Terms] OR crustacea[Tiab] OR crustacean[Tiab] OR crustaceans[Tiab] OR crab[Tiab] OR crabs[Tiab] OR lobster[Tiab] OR lobsters[Tiab] OR shrimp[Tiab] OR shrimps[Tiab] OR prawn[Tiab] OR prawns[Tiab] OR crayfish[Tiab] OR shellfish[MeSH Terms] OR shellfish[Tiab] OR langoustine[Tiab] OR langoustines[Tiab] | crustacea OR crustacean OR crustaceans OR crab OR crabs OR lobster OR lobsters OR shrimp OR shrimps OR prawn OR prawns OR crayfish OR shellfish OR langoustine OR langoustines |
| Fish | Fish, pollock, carp, cod, mackerel, salmon, tuna, shark, sea bass, swordfish, hake, sole, megrim, sardines, halibut, anchovy, catfish, trout | fishes[MeSH Terms] OR fish[Tiab] OR pollock[Tiab] OR carp[Tiab] OR cod[Tiab] OR mackerel[Tiab] OR salmon[Tiab] OR tuna[Tiab] OR shark[tiab] OR "sea bass"[tiab] OR swordfish[tiab] OR hake[tiab] OR sole[tiab] OR megrim[tiab] OR sardine[tiab] OR sardines[tiab] OR halibut[tiab] OR anchovy[tiab] OR anchovies[tiab] OR catfish[tiab] OR trout[tiab] | fish OR pollock OR carp OR cod OR mackerel OR salmon OR tuna OR shark OR "sea bass" OR swordfish OR hake OR sole OR megrim OR sardine OR sardines OR halibut OR anchovy OR anchovies OR catfish OR trout |
| Molluses | Mollusc, oyster, snail, squid, mussels, clams, abalone, octopus, scallop | mollusca[MeSH Terms] OR mollusc[Tiab] OR molluscs[Tiab] OR oyster[Tiab] OR oysters[Tiab] OR snail [Tiab] OR snails[Tiab] OR squid[Tiab] OR mussel[Tiab] OR mussels[Tiab] OR clam[Tiab] OR clams[Tiab] OR abalone[tiab] OR octopus[tiab] OR scallop[tiab] OR scallops[tiab] | mollusc OR molluscs OR oyster OR oysters OR snail OR snails OR squid OR mussel OR mussels OR clam OR clams OR abalone OR octopus OR scallop OR scallops |
| Soy | Soy, soya, soybean | soy[Tiab] OR soybeans[MeSH Terms] OR soybean[Tiab] OR soybeans[Tiab] OR soya[Tiab] | soy OR soybean OR soybeans OR soya |
| Lupin | Lupin, lupinus-albus | lupinus[MeSH Terms] OR lupin[Tiab] | lupin |
| Mustard | Mustard | "mustard plant" [MeSH Terms] OR mustard [Tiab] | mustard |

| Topics | Search terms ³ | Search terms for PubMed | Search terms for Web of Science |
|------------------|--|---|--|
| | | | |
| Sesame | Sesame | sesamum[MeSH Terms] OR "sesame"[Tiab] | sesame |
| Group 3. Allergy | | | |
| Allergy | Hypersensitivity, allergy, immunology, sensitivity, intolerance, anaphylaxis, adverse reaction | hypersensitivity[MeSH Terms] OR hypersensitivity[Tiab] OR allergy[Tiab] OR "allergy and immunology"[MeSH Terms] or immunology[Tiab] OR sensitivity[Tiab] OR intolerance[Tiab] OR anaphylaxis[MeSH Terms] OR anaphylaxis [Tiab] OR "adverse reaction"[Tiab] | hypersensitivity OR allergy OR immunology OR sensitivity OR intolerance OR anaphylaxis OR "adverse reaction" |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

1.1.1.3. Management of search results

Search results were managed using reference management software (EndNote) and duplicates removed. Search results were then imported into EPPI Reviewer 4 (systematic review software) prior to screening for relevance. English language versions of articles were obtained via the British Library's document supply service (the British Library holds more than 500,000 articles translated into English). Where articles were not available, translation services were used. Searches were updated prior to data analysis/synthesis.

1.1.1.4. Specific search strategy for identifying articles related to the prevalence of emerging allergens

It was anticipated that many of the articles which report the prevalence of food allergy to common allergens such as peanut and milk, would do so in the context of a larger study that screened participants for adverse reactions to a number of (or, in some cases, to any) foods. Hence, for such studies data was presented for allergens other than those listed in Objective 1. These studies were identified by the search strategy outlined in Section 1.1.1.2. Nevertheless, there may also be some smaller studies which have specifically explored the prevalence of allergens that have the potential to be 'emerging'. Hence, within the main search strategy to foods other than those specifically listed in Objective 1.

1.1.1.5. Specific search strategy for identifying the clinical reactivity to emerging allergens

For the key emerging allergens identified, we have also reported information on clinical reactivity and reports of severe reactions. If available, this was sourced from challenge data provided within the relevant articles. However, if no challenge data was presented in the prevalence studies (i.e. they present sensitivity data only) we searched for smaller observational studies, particularly case reports of anaphylaxis.

1.1.1.6. Specific search strategy for identifying the prevalence of allergy to any food

In addition to the key objectives, we also sought to summarise the prevalence of allergies to any food. Since this was not part of the original objectives, only those studies already included in the review were identified for screening.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Topics | Search terms ⁴ | Search terms for PubMed | Search terms for Web of Science |
|--------------|----------------------------|-----------------------------------|------------------------------------|
| Group 1. | Anaphylaxis, asthma, | Anaphylaxis[MeSH Terms] OR | Anaphylaxis OR asthma |
| Clinical | oedema, odema. | anaphylaxis[Tiab] OR | OR oedema OR odema. |
| reactivity | | asthma[Tiab] OR oedema[Tiab] | |
| | | OR odema[Tiab] | |
| Group 2. | This will be a list of | The search terms provided will be | The search terms |
| Emerging | emerging food allergens | adapted for use in PubMed. | provided will be adapted |
| allergens | identified for objective 3 | | for use in Web of |
| | (with specific search | | Science. |
| | terms as described in | | |
| | Table 1.1). | | |
| Group 3. | Hypersensitivity, allergy, | hypersensitivity[MeSH Terms] OR | hypersensitivity OR |
| Allergy | immunology, sensitivity, | hypersensitivity[Tiab] OR | allergy OR immunology |
| | intolerance, | allergy[Tiab] OR "allergy and | OR sensitivity OR |
| | | immunology"[MeSH Terms] or | intolerance OR |
| | | immunology[Tiab] OR | anaphylaxis OR "adverse |
| | | sensitivity[Tiab] OR | reaction" |
| | | intolerance[Tiab] | |
| Group 4. | Case report, case study, | "case report"[Tiab] OR "case | "case report" OR "case |
| Case reports | case history | study"[Tiab] OR "case | study" OR "case history" |
| | | history"[Tiab] OR "case | |
| | | reports"[MeSH] | |

| Table 1.2: | Search terms to identif | y articles related to the clinical | l reactivity of emerging allergens |
|------------|-------------------------|------------------------------------|------------------------------------|
|------------|-------------------------|------------------------------------|------------------------------------|

1.1.2. Study selection general approach

All identified articles were screened for inclusion in the review as follows. Firstly, the titles and abstracts of all identified articles were screened for potential relevance by one review author (a team approach was taken whereby references were divided amongst the review team for screening). At this stage, articles were excluded if, for example, they were obviously unrelated to the topic of the review (e.g. Diagnostic value of D-dimer in outpatients with suspected deep venous thrombosis receiving oral anticoagulation); the sample was inappropriate for the scope of the review (e.g. Prevalence of soy protein hypersensitivity in cow's milk protein-sensitive children in Korea) or because they did not present primary research (e.g. Gastrointestinal allergy to food: a review). An inclusive approach was taken, whereby if the review author was unsure of the potential relevance of an article it was marked as 'potentially eligible'. The full-text of all potentially eligible studies was then retrieved and assessed against the criteria outlined in section 1.1.3. If the review author was unsure about the eligibility of the paper for inclusion in the review, the paper was discussed with another review author. Reasons for exclusion were recorded.

1.1.3. Study selection specific approach: objectives 1-3

1.1.3.1. Types of studies

We have included population-based cross-sectional studies and cohort studies examining the prevalence of food allergy (IgE-mediated and non-IgE mediated). To be included all studies must have presented an identifiable point (or period) in time at which the prevalence of food allergy was measured.

⁴ As indicated in technical offer and updated in light of kick-off meeting

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

1.1.3.2. Types of participants

We included participants of all age groups from any country. Studies that did not present region or country-specific data were excluded from the review. Studies must have been population based, using either a fixed cohort or an appropriate sampling strategy. Studies conducted in a clinical setting (e.g. a survey of the prevalence of specific food allergies in current patients at an allergy clinic) or in selected patient groups (e.g. measuring the prevalence of food allergy in patients with asthma) were excluded since they do not provide information about the general prevalence of food allergies.

1.1.3.3. Types of outcome measure

Objectives 1 and 2 are interested in one outcome - the prevalence of food allergies (IgE and/or non-IgE mediated) to any one of the following allergens: milk/dairy, eggs, cereals, peanuts, nuts, celery, crustaceans, fish, molluscs, soy, lupin, mustard and sesame. Objective 3 is interested in the prevalence of food allergies to emerging allergens. Hence, all studies reporting the prevalence of food allergies to specific allergens were eligible for inclusion in the review.

Studies employing at least one of the following methods of diagnosis to determine the prevalence of allergies to one or more of the above food allergens were eligible for inclusion in the review for Objectives 1-3:

- Self-reported food allergy
- Clinical history of adverse reactions to foods and positive SPT (for IgE-mediated food allergy)
- Clinical history of adverse reactions to foods and positive serum-specific IgE (for IgEmediated food allergy)
- Clinical history of adverse reactions to foods and positive food challenge (open or doubleblind placebo-controlled: for IgE and non-IgE mediated food allergy, allowing for delayed reactions in the case of non-IgE mediated food allergy)

Studies which presented data regarding sensitisation as determined by the following methods were also eligible for inclusion in the review for Objective 1:

- Positive SPT
- Positive serum-specific IgE

Studies that did not present separate prevalence data for individual allergens were excluded from the review.

1.1.4. Study selection specific approach for identifying the prevalence of allergy to any food

All included studies were screened for the inclusion of data for the prevalence of allergy to any food. The methods and outcome measures used to identify this data needed to meet the criteria outlined for Objectives 1-3 (Section 1.1.3) to be eligible for inclusion in the review.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

1.1.5. Data collection general approach

As described in the technical offer, data extraction and management was facilitated by the EPPI Reviewer software (EPPI Centre, 2011), which has been developed to aid the management of systematic reviews. The software facilitates the following activities: reference management, study classification/screening, data extraction and retrieval, collaborative working (i.e. allocation of screening and comparison of screening decisions), data analysis and reporting.

As has been piloted for articles related to the prevalence of peanut allergy, we used data collection forms developed in EPPI Reviewer to extract relevant data for objectives 1-3 according to predetermined criteria. The following was extracted for **all** included studies:

- 1. General information: Authors' contact details, research funder, year(s) study conducted, country/countries in which conducted.
- 2. Methods: Study design (cross-sectional or cohort study, and for cohort studies additional information regarding at what ages articles have reported), type of food allergy considered (IgE mediated, non-IgE mediated or both), food(s) assessed (including potential emerging allergens), method of diagnosis (to include additional information with regard to the procedure, e.g. whether extracts or prick-to-prick method has been used for skin prick testing), sampling strategy (e.g. local or general population, random or non-random) and sample characteristics (e.g. age group, ethnic background, response rate, withdrawal).
- 3. Outcomes [for ease of reporting, this data has been recorded in a Microsoft Excel spread sheet]: Information on reported outcomes and relevant data (percentage prevalence, raw data and confidence intervals; presented by allergen, year of study, method of diagnosis and age).

Additional information was collected if reported by a study, as follows:

- Where a study has reported the prevalence of sensitisation to a food (indicated by either a positive skin prick test or serum-specific IgE test), and where relevant (e.g. in the case of wheat and grass) and reported by the study, data was recorded regarding cross-reactivity. Where such data was relevant but not reported, this was also recorded.
- Objective 3 (emerging allergens): Where studies have been sought which provide evidence regarding the clinical reactivity of emerging allergens, information regarding the nature of reactions reported was extracted. This included information regarding the symptoms of the reaction, the time between ingestion and reaction and the treatment required.

Where there was ambiguity in the reporting of results, all efforts were made within the given timeframe to contact the study authors to provide additional information.

Upon completion of data collection, those studies included in the review were exported from EPPI Reviewer into EndNote reference management software. Where available in electronic format (and when compliant with copyright and data sharing rules), the full-text of articles not currently accessible within EFSA's current subscriptions have been provided within the EndNote file.

1.1.6. Data collection specific approach for emerging allergens (Objective 3)

Objective 3 is interested in the prevalence of allergies (IgE and/or non-IgE mediated) to any emerging allergens. Emerging allergens have been defined as any allergen <u>other than</u>: milk/dairy, eggs, cereals, peanuts, nuts, celery, crustaceans, fish, molluscs, soy, lupin, mustard and sesame that has either increasing prevalence or was reported to have a significant prevalence in at least one country in Europe.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

It was anticipated that articles which report the prevalence of food allergy to common allergens such as peanut and milk, do so in the context of a larger study which has screened participants for adverse reactions to a number of (or, in some cases, to any) foods. Hence, for such studies data has often been presented for allergens other than those listed in Objective 1. Additional studies may also have been identified which have examined the prevalence of less common allergens that have the potential to be defined as 'emerging'. Data from such studies have been included. All studies have been screened on the criteria outlined in Section 1.1.3. and data has been collected in accordance with section 1.1.4. Prevalence data has been extracted for all foods reported in a report of a study, in order to identify those allergens which may be considered 'emerging'.

1.1.7. Data collection specific approach for allergy to any food

In addition to the key objectives, data has also been collected and reported related to the prevalence of allergies to any food. This data was collected only from, and in the same manner as, the studies included within the systematic reviews conducted for objectives 1-3.

1.1.8. Assessing the quality of included studies

Studies were assessed as being at low or high risk of bias on the basis of three quality criteria (Table 1.3). The first related to the risk of bias of the diagnostic method employed by the study. In studies utilising more than one method of diagnosis, the risk of bias of the highest quality method was judged. The second criterion related to the method of sampling, in particular, whether the sample utilised the whole population (for example, all consecutive births), a random sample or a non-random sample. The third criterion related to whether the study had explored the reasons for non-response (in cross-sectional studies) or withdrawal/loss o follow-up (in cohort studies).

| Quality assessment criteria | Diagnostic method | Sampling strategy: method | Reasons for non-response or withdrawal/loss to follow-up |
|-----------------------------------|---|---|--|
| Low risk of bias | Food challenges (open or double-blind) with or without clinical history Sensitisation (skin prick test and/or serum- specific IgE) with clinical history | Whole populationRandom | Yes |
| High risk of bias | Sensitisation (skin prick test and/or serum specific IgE) without clinical history Clinical history alone Clinician diagnosed Self-report | • Non-random | No |

Table 1.3:Quality assessment criteria

1.1.9. Data synthesis and presentation

1.1.9.1. General approach

Our general approach to the synthesis of data was as follows. For all objectives a narrative approach was taken, presenting data in tables reporting the mean and, where possible, the confidence intervals. Confidence intervals were calculated for proportions using Wilson's correction for continuity. Where

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

raw data was not presented in the article, confidence intervals have been presented as per the article or marked 'unknown' if not reported.

Europe has been defined geographically rather than by membership of the European Union. Key characteristics of the included studies have been presented (Table 1.4), including (but not limited to) information about study design (e.g. cohort study), country studied, allergens assessed and the method of diagnosis. Information has also been presented regarding the quality of the evidence (Table 1.6).

1.1.9.2. Objectives 1 and 3

As described in the technical offer, in addition to the approach described above, for Objective 1 and 3, for each allergen we have presented a table which maps the data (percentage prevalence and 95% confidence intervals, where possible) according to country and then by age (this has been grouped however is meaningful dependent upon the approach taken by the included studies). The prevalence data has been presented by method of diagnosis, and information has also been included on the year, country and age group for which data is being presented, and on whether the study assessed IgE-mediated allergy, non-IgE-mediated allergy or both (it is important to note that this was assessed across the whole study rather than by individual food; where a study provides only self-report data and has not distinguished between symptoms typical of either IgE and non-IgE mediated reactions this has been classified as examining both IgE and non-IgE mediated allergies although it has been noted that the presence of allergy to any food both across Europe and for countries outside of Europe.

1.1.9.3. Objective 2

In addition to the general approach, for each listed allergen (milk/dairy, eggs, cereals, peanuts, nuts, celery, crustaceans, fish, molluscs, soy, lupin, mustard and sesame) we have provided a narrative summary of changes in prevalence over time. We have discussed this by country and age group.

1.2. Results

1.2.1. Results of the search

After removal of duplicates 7323 references were identified with a further ten papers identified through the expert panel thereby totalling 7333. Of these 7145 were excluded based on the title and abstract. The full-text was obtained for 187 references (the full text could not be obtained for Wang 1990). After full text screening a further 99 studies were excluded. The flow chart and the reasons for exclusion are outlined in Figure 1.1. One of the most common reasons for exclusion was that the article reported data that was reproduced in another included paper, for example a conference abstract subsequently presented in a full journal article or a report of a subset of a population that was reported in full in another reason for exclusion was that the study utilised an unsuitable design such as case-control or a case series within a clinic setting as the samples would not be representative of the general population. The excluded studies are presented in Table 1.33. After screening the full text 89 studies were included in the final systematic review (Figure 1.1).

EFSA supporting publication 2013:EN-506



Figure 1.1.: Flowchart of search results and screening for all studies.

1.2.2. Included studies

We included 92 articles, 52 of which were conducted within Europe. Of these, five were based in Denmark, one in Estonia, three in Finland, three in France, three in Germany, two in Greece, one in Hungary, one in Iceland and Sweden combined, two in Italy, one in the Netherlands, two in Norway, one in Portugal, one in Spain, four in Sweden, six in Turkey, thirteen in the United Kingdom, and lastly one in Estonia (Table 1.4).

Of the 40 studies conducted outside of Europe, one was conducted in West Africa (Ghana), ten in Eastern Asia (China, Korea, Hong Kong, Japan, and Taiwan), one in South-Central Asia (India), four in South-East Asia (Philippines, Singapore, Thailand), two in the Middle East (Israel, United Arab Emirates), 18 in North America (Canada, USA), one in North-West South America (Colombia) and three in Australia. The key characteristics of these studies are shown for each country in alphabetical order (Table 1.4)

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

The majority of studies (66) employed a cross-sectional design and 25 used a cohort design. Further information about the included studies are presented in a series of tables. The method of identifying food allergy is outlined in Table 1.4 and additional tables provide further information about the method utilised for questionnaire or interview based approaches (Table 1.7), sensitisation testing (Table 1.8), and food challenge (Table 1.9). Some studies presented the findings for more than one method of identification enabling comparison of methods as exemplified by Schäfer 2001 in Germany, Mustafayev 2010 in Turkey, Venter 2006 and Nicolaou 2010 in the UK and Woods 2002 in Australia. Many studies reported using a combination of methods within an algorithm; almost without exception this two or three step process was applied to food challenges where only those who either self-reported food allergy in a questionnaire or who had a positive clinical history were challenged.

Questionnaire or interview methods for assessing suspected food allergy were presented in 57 studies. The sensitivity and specificity of these questionnaire-based methods was not available for some of the studies (for example, Murrugo 2008 used a ten item questionnaire with no reference to validation) whereas some studies used tools that had undergone some pretesting (such as Ben Shoshan 2010, Sicherer 1999, 2002 and 2010 and others such as Martinez-Gimeno 2000 who used tools that had undergone rigorous validation ref http://isaac.auckland.ac.nz/, Table 1.7). Although we provide data under the headings self-reported, clinician diagnosed and clinical history it should be noted that there is overlap between these identification methods as some self-report questionnaires include questions on 'do you have doctor diagnosed allergies' and some of the 'clinical histories' were collected using a structured format questionnaire.

The IgE sensitisation of the entire study population was assessed using skin prick test for 19 studies and serum specific IgE in eight. In total 25 studies used either or both methods. Rates of sensitisation were consistently higher than rates of prevalence of food allergy. For example, Woods (2002) tested sensitisation to milk using a skin prick test and found sensitisation of 0.7% (95% CI: 0.2-2.1), but when this was combined with clinical history the rate was 0.0% (95% CI: 0.0-1.0); when testing for peanut sensitisation using SPT, Grundy 2002 reported a rate of 3.3% (95% CI: 2.4-4.5), but this fell to 0.7% (95% CI: 0.3-1.3) upon food challenge. Although sensitisation to food allergens has poor specificity for food allergy this measure does allow for comparisons between countries and over time.

Twenty-seven studies reported data on the prevalence of food allergy as determined by combining sensitisation data from the whole study population with self-reports of allergy, for example Tariq 1996, Orhan 2009 and Ostblom 2008a. In contrast, oral food challenges were usually carried out on a subset of the study population who reported allergy to a particular food or foods (via a questionnaire or clinical interview) and/or were sensitised to a specific food allergen (determined by SPT or SIgE). It is important to note, however, that in the majority of studies utilising food challenges, a subset of participants (typically individuals with a convincing clinical history of severe reactions, and clear elevated specific IgE and or skin prick test) were not challenged since it is unethical to do so. This aligns with the management of patients in practice, and these individuals were typically considered to be allergic and, for prevalence calculations, had been counted alongside those who experienced a positive oral food challenge.

EFSA supporting publication 2013:EN-506

27

| Study ID | Study | Year | Country | Target | Allergens assessed | Type of | Methods of | Sample characteris | | istics |
|--------------------------|------------------------------|-----------------|--|---------------|---|-----------------------------|---|--------------------------------|--------------|----------------|
| | design | conducted | (s) | age group | | food allergy | diagnosis employed | Age Mean (SD) | Age (Range) | Sample size |
| Al- Hammadi (2010) | Cross- sectional study | 2006 | United Arab Emirates | 6-9 years | Main list: Cereal (wheat), Eggs, Fish, Milk/dairy, Peanuts, Tree nuts Additional food(s) Fruit and/or vegetables | Both IgE and non- IgE | • Clinician diagnosed | 7 years (±1.06) | Not reported | 397 |
| Altintas (1995) | Cross- sectional study | 1992- 1993 | Turkey; Adana | Newborn | Main List: Eggs, Milk/dairy, (cow's milk) | Both IgE and non- IgE | •Clinician diagnosed | Not reported | 0-2 years | 1700 |
| Arbes (2005) | Cross- sectional study | 1988- 1994 | United States | All ages | Main list: Peanuts | IgE- only | Positive skin prick test without clinical history | Not reported | 6-19 years | 10508 |
| Arshad (2001) | Cohort study | 1993- 1994 | United Kingdom; Isle of Wight | 4 years | Main list: Cereals (wheat), Eggs, Fish (cod), Milk/dairy, Soy | IgE- only | Positive skin prick test without clinical history | Not reported | 4 years | 981 |
| Babu (2008) | Cross- sectional study | Not reported | India | 5-60 years | Additional food(s): Eggplant, Aubergine | IgE only | Self-report Positive skin prick test without clinical history Positive serum-specific IgE with clinical history | Mean 35.6 years (± 17.0) | Not reported | 741 |

Table 1.4:Key characteristics of included studies

EFSA supporting publication 2013:EN-506

| Study ID | Study | Year | Country | Target | Allergens assessed | Type of | Methods of | Samp | ole character | istics |
|---------------------------|------------------------------|----------------|------------------|---|--|--|---|----------------------------|------------------|----------------|
| | design | conducted | (s) | age group | | food allergy | diagnosis employed | Age Mean (SD) | Age (Range) | Sample size |
| Bakos (2006) | Cross- sectional study | 2004 | Hungary | Elderly people mean age of 77 years | Main list: Celery, Cereals (wheat, rye) Crustaceans (crab), Eggs (egg yolk and egg white), Fish (cod), Milk/dairy (milk, casein), Peanuts, Sesame, Soy, Tree nuts (hazelnut, walnut, almond) Additional food(s): Apple, Banana, Carrot Orange, Potato, Tomato | IgE- only | Positive skin prick test without clinical history Positive serum-specific IgE without clinical history | Mean 77 years (±9.3) | 20-97 years | 109 |
| Ben- Shoshan (2009) | Cross- sectional study | 2005- 2007 | Canada | 5-9 years | Main list: Peanuts | IgE- only | • Other | Mean 7.1 years | 5-9 years | 5161 |
| Ben- Shoshan (2010) | Cross- sectional study | 2008- 2009 | Canada | All ages | Main list: Crustaceans, Fish, Peanuts, Sesame, Tree nuts | Both IgE and non- IgE- mediated | Self-report Clinician diagnosed Clinical history | Not reported | Not reported | 9667 |
| Bjornsson (1996) | Cross- sectional study | 1991- 1992 | Sweden | 20-44 years | Main list: Cereals (wheat), Eggs Fish, Milk/dairy Peanuts, Soy | IgE- only | Positive serum-specific IgE without clinical history | Not reported | 20-44 years | 1397 |
| Bock (1987) | Cohort study | 1980 - 1981 | United States | < 3years | Main list: Cereals (corn, rice, wheat), Eggs, Milk/dairy, Peanuts, Soy Additional food(s): Chocolate | Both IgE and non- IgE | • Self-report • Other | Not reported | Birth-3 years | 480 |

| Study ID | Study | Year | Country | Target | Allergens assessed | Type of | Methods of | Samp | ole character | istics |
|-------------------|------------------------------|---------------|--------------------------------------|----------------|---|-----------------------------|---|------------------|-----------------|----------------|
| | design | conducted | (s) | age group | | food allergy | diagnosis employed | Age Mean (SD) | Age (Range) | Sample size |
| Branum (2009) | Cross- sectional study | 2005- 2006 | United States | < 18 years | Main list: Crustaceans (shrimp), Eggs, Milk/dairy, Peanuts | IgE- only | Positive serum-specific IgE without clinical history | Not reported | Not reported | 3500 |
| Brugman (1998) | Cross- sectional study | 1993- 1994 | Netherlands | 4-15 years | Main list: Fish, Crustaceans Milk/dairy, (cow's milk, Soy, Tree nuts, Peanuts Additional food(s): Additives and Colourings, Apple juice, Banana, Chocolate, Lemonade, Mayonnaise, Pork, Strawberry, Sugar, Tomato | Both IgE and non- IgE | • Self-report | Not reported | 4-15 years | 4400 |
| Chen (2011) | Cross- sectional study | 2009 | China | <12 months | Main list: Cereals (wheat), Crustaceans (shrimp), Eggs (yolk and white), Fish, Milk/dairy, Peanuts, Soy Additional food(s): Carrot, Orange | IgE- only | Positive skin prick test without clinical history Positive open food challenge with clinical history | Not reported | 0-12 months | 497 |
| Chen (2012) | Cross- sectional study | 2009- 2010 | China | <2years | Main list: Eggs, Milk/dairy | Both IgE and non- IgE | • Other | Not reported | 0-2 years | 573 |
| Connett (2012) | Cross- sectional study | 2007- 2008 | Philippines Singapore Thailand | 14-16 years | Main list: Fish | Both IgE and non- IgE | Self-report Clinical history | Not reported | 14-16 years | 19966 |

30

| Study ID | Study | Year | Country | Target | Allergens assessed | Type of | Methods of | Samp | ole character | istics |
|-------------------|--|---------------------------------|-------------------|--|---|-----------------------------|--|---|---|--|
| | design | conducted | (s) | age group | | food allergy | diagnosis employed | Age Mean (SD) | Age (Range) | Sample size |
| Dalal (2002) | Cross- sectional study | Not reported | Israel | <2years | Main list: Eggs, Fish, Milk/dairy Peanuts, Sesame, Soy, Tree nuts Additional food(s) Beef, Chicken, Chocolate, Garlic, Strawberry, Tomato | IgE- only | Clinical history Positive skin prick test with clinical history | Not reported | 0-2years | 9070 |
| Eggesbo (1999) | Cohort study 2 maternity clinics in Oslo | 1992- 1993; 1993- 1995 | Norway | <24 months | Main list: Cereals, Eggs, Fish Milk/dairy, Peanuts Additional food(s) Chocolate Fruit and/or Vegetables | Both IgE and non- IgE | • Self-report | Not reported | Not reported | 3366 |
| Eller (2009) | Cohort study | 1998- 2005 | Denmark | Followed up birth cohort at 3, 6, 9, 12, 18, 36 and 72 months of age | Main list: Eggs, Milk/dairy, Peanuts | Both IgE and non- IgE | Positive open food challenge with clinical history | Not applicable (cohort study following up at defined ages) | Not applicable (cohort study following up at defined ages) | unknown |
| Emmett (1999) | Cross- sectional study | 1995- 1996 | United Kingdom | 15+ years | Main list: Cereals (wheat, flour, gluten), Eggs, Fish, Milk/dairy, Peanuts, Sesame, Soy, Tree nuts Additional food(s) Cheese, Chocolate, Fruit and/or Vegetables, Pulses | Both IgE and non- IgE | Self-report Clinical history | Not reported | Not reported | 16420 (stage 1), 1253 (stage 2) |

EFSA supporting publication 2013:EN-506

| Study ID | Study | Year | Country | Target | Allergens assessed | Type of | Methods of | Samp | ole character | istics |
|----------------------|------------------------------|---|------------------|-----------------|---|--|---|--------------------|-----------------|----------------|
| | design | conducted | (S) | age group | | food allergy | diagnosis employed | Age Mean (SD) | Age (Range) | Sample size |
| Falcao (2004) | Cross- sectional study | Not reported possibly 2000 | Portugal | >39 years | Main list: Eggs, Fish, Milk/dairy Molluscs, (squid, octopus) Additional food(s): Chocolate, Kiwi, Meat (sausages, pork), Strawberry | Both IgE and non- IgE | • Self-report | Not reported | Not reported | 659 |
| Frongia (2005) | Cross- sectional | 2003 | Italy | 12-24 months | Eggs, Milk/dairy | Both IgE and non- IgE | Clinician diagnosed | Mean 18.5 years | 12-24 months | 4602 |
| Gelincik (2008) | Cross- sectional study | Not reported (published in 2008) | Turkey | 18+ years | Main list: Eggs, Hens, Milk/dairy Tree nuts Additional food(s): Banana, Chocolate, Eggplant, Garlic, Grape Mushroom, Peach, Pickle, Seafood, Spices, Strawberry, Tomato | Both IgE and non- IgE | Self-report Positive skin prick test with clinical history Positive serum-specific IgE with clinical history Positive DBPCFC with clinical history | Not reported | 18+ years | 11816 |
| Gerrard (1973) | Cross- sectional study | Not reported | Canada | 6-36 months | Main list: Milk/dairy | Both IgE and non- IgE | Clinical history | Not reported | 6-36 months | 803 |
| Greenha wt (2009) | Cross- sectional study | Not reported | United States | 18+ years | Main list: Cereals (wheat), Eggs Fish, Milk/dairy, Peanuts Soy, Tree nuts Additional food(s): shellfish | IgE and non_IgE (but unclear) | • Self-report | Not reported | 18+ years | 513 |

| Study ID | Study | Year | Country | Target | Allergens assessed | Type of | Methods of | Samp | ole character | istics |
|---------------------|------------------------------|-----------------|-------------------|----------------|--|-----------------------------|--|-------------------|----------------|----------------|
| | design | conducted | (S) | age group | | food allergy | diagnosis employed | Age Mean (SD) | Age (Range) | Sample size |
| Grundy (2002) | Cohort study | 1999- 2000 | United Kingdom | 3-4 years | Main list: Peanuts | IgE- only | Self report Positive skin prick test without clinical history Positive open food challenge with clinical history | Mean 3.2 years | 3-4 years | 1246 |
| Gupta (2011) | Cross- sectional study | 2009- 2010 | United States | <18 years | Main list: Cereals (wheat), Crustaceans, Eggs, Fish Milk/dairy, Peanuts, Soy, Tree nuts Additional food(s): Strawberry | Both IgE and non- IgE | Clinical history | Mean 8.5 years | 0-17 years | 10514 |
| Haahtela (1980) | Cross- sectional study | Not reported | Finland | 15-17 years | Main list: Fish | IgE- only | Positive skin prick test without clinical history | Not reported | 15-17 years | 708 |
| Host (2002) | Cohort | 1985- 2000 | Denmark | 0-15 years | Main list: Cow's milk | Both IgE and non- IgE | Clinical history Positive open food challenge with clinical history | Not reported | 0-15 years | 1749 |
| Hourihane (2007) | Cross- sectional study | 2003- 2005 | United Kingdom | 3-6 years | Main list: Peanuts | IgE- only | Positive skin prick test without clinical history • Positive | Not reported | 3-6 years | 1072 |

| Study ID | Study | Year | Country | Target | Allergens assessed | Type of | Methods of | Sample characteris | | istics |
|---------------------|------------------------------|---|-------------------|----------------------------------|---|--|--|--------------------|----------------|----------------|
| | design | conducted | (s) | age group | | food allergy | diagnosis employed | Age Mean (SD) | Age (Range) | Sample size |
| | | | | | | | DBPCFC with clinical history | | | |
| Hu (2010) | Cross- sectional study | 1999 2009 (2 cross sectional studies) | China | <24 months | Main list: Cereals (wheat), Crustaceans (shrimp), Eggs, Fish, Milk/dairy Peanuts, Soy Additional food(s): Orange | Both IgE and non- IgE | Positive skin prick test with clinical history Positive open food challenge with clinical history | Not reported | 0-24 months | 382 |
| Isolauri (2004) | Cross- sectional study | 1990- 1997 | Finland | 7, 27, 47 and 67 year olds | Main list: Cereals (Wheat), Eggs, Fish (cod), Milk, | IgE- only | Positive serum-specific IgE without clinical history | Not reported | 7-67 years | 400 |
| Julge (2001) | Cohort study | 1994- 1999 | Sweden Estonia | <5 years | Main list: Eggs, Milk/dairy | IgE- only | Positive skin prick test without clinical history • Positive serum-specific IgE without clinical history | Not reported | 0-5years | 222 |
| Kagan (2003) | Cross- sectional study | 2000- 2002 | Canada | 5-9 years | Main list: Peanuts | IgE- only | • Other | Mean 7.4 (±1.2) | 5-9 years | 4339 |
| Kajosaari (1982) | Cross- sectional study | 1980- 1981 | Finland | 1,2,3 and 6 years | Main list: Cereals (wheat), Eggs, Fish, Milk/dairy, Tree nuts Additional food(s) Apple, Chocolate, Citrus, Pea, Strawberry, Tomato | Both – not clearly specififed | Self-report Positive open food challenge with clinical history | Not reported | 1-6 years | 261 |

| Study ID | Study | Year | Country | Target | Allergens assessed | Type of | Methods of | Samp | ole character | istics |
|---------------------|------------------------------|-----------------|-------------------|------------------|---|-----------------------------|---|------------------|----------------|----------------|
| | design | conducted | (S) | age group | | food allergy | diagnosis employed | Age Mean (SD) | Age (Range) | Sample size |
| Katz (2010) | Cohort | 2004- 2006 | Israel | 0-2 year s | Main list: Cow's milk | Both IgE and non- IgE | Self-report Positive open food challenge with clinical history Positive skin prick test with clinical history | Not reported | 0-2 years | 13019 |
| Keet (2012) | Cross- sectional study | 2005- 2006 | United States | 1-21 years | Main list: Eggs, Milk/dairy, Peanuts | IgE- only | Positive serum-specific IgE without clinical history | Not reported | 1-21 years | 3550 |
| Kilgallen (1996) | Cross- sectional study | Not reported | United Kingdom | <48 months | Main list: Eggs, Milk/dairy (milk and milk products) Additional food(s): Additives and colourings, Artificial colourings and e- numbers (sweets, soft drinks), Yoghurt | Both IgE and non- IgE | • Self-report | Not reported | 0-48 months | 600 |
| Kim (2011) | Cohort study | 2006- 2007 | Korea | <12 months | Main list: Crustaceans, Seafood Eggs, Milk/dairy, Soy Tree nuts, Peanuts Additional food(s): Fruit and/or Vegetables | IgE- only | Clinician diagnosed | Not reported | 0-12 months | 1177 |
| Krause (2002) | Cross- sectional study | 1998 | Greenland | 5-18 years | Main list: Cereals (Wheat), Eggs, Fish, Milk/dairy, Peanuts, Soy | IgE- only | • Positive serum-specific IgE with clinical history | Not reported | 7-15 years | 1031 |

| Study ID | Study | Year | Country | Target | Allergens assessed | Type of | Methods of | Samj | ple character | istics |
|--------------------------------|------------------------------|-----------------|-------------------|---|--|-----------------|--|--|------------------|----------------|
| | design | conducted | (s) | age group | | food allergy | diagnosis employed | Age Mean (SD) | Age (Range) | Sample size |
| Kristjanss on (1999) | Cross- sectional study | 1994 - 1995 | Iceland Sweden | 18 months | Main list: Cereals, Crustaceans, Eggs, Fish, Milk/dairy, Peanuts, Soy, Tree nuts Additional food(s): Apple, Banana, Carrot, Cherry, Chicken, Chocolate, Lemon, Orange, Pea, Plum, Tomato | IgE- only | Self report Positive skin prick test with clinical history | Mean Icelandic children 18.8 years Mean Swedish children 19.3 years | 18- 19 months | 328 |
| Kucukos manoglu (2008 a) | Cross- sectional study | 2002- 2004 | Turkey | 8-18 months | Main list: Eggs | IgE- only | Positive skin prick test without clinical history | Median12 months | 8-18 months | 1015 |
| Kucukos manoglu (2008 b) | Cohort study | 2002 - 2003 | Turkey | 8-18 months | Main list: Milk/dairy | IgE- only | Positive skin prick test without clinical history Positive serum-specific IgE with clinical history Positive open food challenge with clinical history | Mean 12.5 months (± 2.5) | Not reported | 1015 |
| Kumar (2011) | Cohort study | Not reported | United States | Recruite d 24 to 72 hours after birth | Main list: Eggs, Milk/dairy, Peanuts | IgE- only | Positive serum-specific IgE without clinical history | Not reported | 0-6 years | 1104 |

| Study ID | Study design | Year conducted | Country (s) | Target age group | Allergens assessed | Type of food allergy | Methods of diagnosis employed | Sample characteristics | | |
|---------------------|------------------------------|-------------------|----------------------|---|--|-----------------------------|--|------------------------|----------------|----------------|
| | | | | | | | | Age Mean (SD) | Age (Range) | Sample size |
| | | | | schedule d visits at 6-12 months, 2, 4 and 6 years | | | | | | |
| Lack (2003) | Cohort study | 1997- 1998 | United Kingdom | <38 months | Main list: Peanuts | IgE- only | Clinical history Positive skin prick test with clinical history Positive DBPCFC with clinical history | Not reported | 0-38 months | 12090 |
| Lao-araya (2012) | Cross- sectional study | 2010 | Northern Thailand | 3-7 years | Main list: Cereals (wheat) Crustaceans (shrimp, crab),Eggs, Fish, Milk/dairy Molluscs, (squid, mollusc not specified) Additional food(s) Ant eggs, Beef, Chocolate, Coconut, Insect | IgE- only | Self-report Positive open food challenge without clinical history | Mean 5.3 (± 1.0) | 3-7 years | 452 |
| Leung (2009) | Cross- sectional study | 2006- 2007 | Hong Kong | 2-7 years | Main list: Crustaceans, Eggs, Fish, Milk/dairy, Peanuts, Tree nuts Additional food(s): Beef, Chocolate, Citrus Fruit and/or Vegetables, | Both IgE and non- IgE | • Self-report • Other | Not reported | 2-7 years | 3677 |
| Study ID | Study | Year | Country | Target | Allergens assessed | Type of | Methods of | Samp | ole character | istics |
|-------------------------------|------------------------------|-----------------|------------------|---------------|--|-----------------------------|--|------------------|-----------------|----------------|
| | design | conducted | (s) | age group | | food allergy | diagnosis employed | Age Mean (SD) | Age (Range) | Sample size |
| | | | | | Orange, Banana, Lamb, Tomato | | | | | |
| Liu (2010) | Cross- sectional study | 2005- 2006 | United States | All ages | Main list: Crustaceans (shrimp), Eggs (egg white), Milk/dairy, Peanuts | IgE- only | Positive serum-specific IgE without clinical history • Other | Not reported | Not reported | 8203 |
| Marrugo (2008) | Cross- sectional study | Not reported | Colombia | 1-83 years | Main list: Eggs, Milk/dairy Additional food(s): Additives and colourings, Alcohol, Fruit and/or vegetables, Meat, Seafood | Both IgE and non- IgE | • Self-report | Not reported | 1-83 years | 3099 |
| Martinez- Gimeno (2000) | Cross- sectional study | Not reported | Spain | 6-13 years | Main list: Eggs, Fish, Milk/dairy, Peanuts Additional food(s) Fruits, legumes | Both IgE and non- IgE | • Self-report | Not reported | 6-13 years | 5163 |
| Morita (2012) | Cross- sectional study | 2009 - 2010 | Japan | Adults | Main list: Cereals (wheat) | IgE only | Self-report Positive skin prick test with clinical history Positive serum-specific IgE with clinical history Positive serum-specific IgE without clinical history | Not reported | 24-93 years | 935 |

| Study ID | Study | Year | Country | Target | Allergens assessed | Type of | Methods of | Samp | ole character | istics |
|-----------------------|------------------------------|---------------|-------------------|----------------|--|-----------------|--|--------------------|----------------|----------------|
| | design | conducted | (S) | age group | | food allergy | diagnosis employed | Age Mean (SD) | Age (Range) | Sample size |
| Mortz (2005) | Cohort study | 1995- 1996 | Denmark | 14 years | Main list: Peanuts | IgE- only | Positive skin prick test without clinical history Positive serum-specific IgE without clinical history Positive open food challenge with clinical history | Mean 14.1 years | 14 years | 862 |
| Mustafay ev (2012) | Cross- sectional study | 2010 | Turkey | 10-11 years | Main list: Eggs, Fish, Milk/dairy Cow's milk, Peanuts, Tree nuts (pistachio, walnut, hazelnut) | IgE- only | Self-report Positive skin prick test without clinical history Positive open food challenge with clinical history | Not reported | 10-11 years | 6963 |
| Nicolaou (2010) | Cohort study | 2003 | United Kingdom | 8 years | Main list: Peanuts | IgE- only | Positive skin prick test without clinical history Positive serum-specific IgE without clinical history Other | Not reported | 8 years | 1029 |

| Study ID | Study | Year | Country | Target | Allergens assessed | Type of | Methods of | Samp | ole character | istics |
|-----------------|------------------------------|---------------|---------|-------------------------------------|--|-----------------------------|---|------------------|----------------------------------|----------------|
| | design | conducted | (s) | age group | | food allergy | diagnosis employed | Age Mean (SD) | Age (Range) | Sample size |
| Obeng (2011) | Cross- sectional study | 2006- 2008 | Ghana | 5-16 years | Main list: Cereals (wheat) Crustaceans (shrimp) Eggs, Fish, Milk/dairy Peanuts, Soy Additional food(s): Apple, Avocado, Banana, Beans, Carrot, Cassava, Coconut, Cocoyam, Corn, Kontomire, Mango, Melon, Millet, Okro, Orange, Palm nut, Pawpaw, Pineapple, Potato, Nutmeg, Rice, Sorghum, Sweet potato, Water yam | Both IgE and non- IgE | • Self-report | Not reported | 5-16 years | 1431 |
| Oh (2004) | Cross- sectional study | 1995- 2000 | Korea | 6-12 years and 12-15 years | Main list: Cereals (wheat), Eggs, Fish, Milk/dairy (cow's milk), Peanuts, Soy Additional food(s): Apple, Banana, Beef, Buckwheat, Chicken, Peach, Pork, Seafood, Tomato | Both IgE and non- IgE | • Self-report | Not reported | 6-12 years and 12-15 years | 27425 |
| Orhan (2009) | Cross- sectional study | 2006 | Turkey | 6-9 years | Main list: Eggs, Fish, Milk/dairy, Peanuts, Tree nuts (hazelnut, walnut) Additional food(s): Banana, Beef, Black Pepper, Chickpea, Cocoa, | IgE only | Self-report Positive skin prick test with clinical history Positive DBPCFC with clinical history | Not reported | 6-9 years | 2739 |

| Study ID | Study | Year | Country | Target | Allergens assessed | Type of | Methods of | Samj | ple character | istics |
|-----------------------|-----------------|---------------|-----------|--|---|-----------------------------|--|--|---|----------------|
| | design | conducted | (s) | age group | | food allergy | diagnosis employed | Age Mean (SD) | Age (Range) | Sample size |
| | | | | | Corn, Kiwi, Potato, Strawberry, Tomato | | | | | |
| Osborne (2011) | Cohort study | 2007-2010 | Australia | 11-15 months | Main list: Crustaceans, Eggs, Milk/dairy, Peanuts, Sesame | Both IgE and non- IgE | Self-report Clinical history Positive skin prick test without clinical history | Not reported | 11-15 months | 2768 |
| Ostblom (2008 a) | Cohort study | 1999- 2000 | Sweden | 4 years | Main list: Cereals (wheat), Eggs (egg white), Fish (cod), Milk/dairy, Peanuts, Soy Additional food(s): Banana, Chocolate, Citrus, Pea, Stone fruit | Both IgE and non- IgE | Self-report Positive serum-specific IgE with clinical history Positive serum-specific IgE without clinical history | Not reported | 4 years | 2563 |
| Ostblom (2008 b) | Cohort study | 1995- 2004 | Sweden | 1, 2, 4 and 8 years (same cohort) | Main list: Cereals (wheat),Eggs, Fish, Milk/dairy, Peanuts, Soy, Tree nuts | Both IgE and non- IgE | Self-report Clinician diagnosed | Not reported | 1, 2, 4 and 8 years | 3104 |
| Österball e (2005) | Cohort study | 2001-2002 | Denmark | Group 1: 3 years, Group 2: <3 years, Group 3: Children > 3 years, | Main list: Cereals (wheat), Crustaceans (shrimp), Eggs, Fish (codfish), Milk/dairy, Peanuts, Soy Additional food(s): Additives and colourings Fruit and/or V egetables | Both IgE and non- IgE | Positive open food challenge with clinical history Positive DBPCFC with clinical history Other | Group 1,2 and 3 median age 3, 0.7, 7.6 and 33.7 years respectivel y | Group 1: 3 years, Group 2: 0.1 - 2 years, Group 3: 4-22 years, | 936 |

| Study ID | Study | Year | Country | Target | Allergens assessed | Type of | Methods of | Samp | ole character | istics |
|-----------------------|--|---------------|-------------------|--------------------|--|-----------------------------|---|------------------|----------------------------|--|
| | design | conducted | (s) | age group | | food allergy | diagnosis employed | Age Mean (SD) | Age (Range) | Sample size |
| | | | | Group 4: Adults | | | | | Group 4: 21-58 years | |
| Osterball e (2009) | Cohort study | 2001- 2002 | Denmark | 22 years | Main list: Cereals (wheat), Crustaceans (shrimp), Eggs, Fish (cod) Milk/dairy, Molluscs, (octopus), Peanuts, Soy Additional food(s): Additives and colourings | Both IgE and non- IgE | • Self-report • Other | Not reported | 22 years | 843 |
| Pereira (2005) | Cohort study 2 birth cohorts used: 1991-1992 and 1987- 1988 | 2002- 2003 | United Kingdom | 11 and 15 years | Main list: Cereals (wheat), Crustaceans (shellfish), Eggs, Fish, Milk/dairy, Peanuts, Tree nuts Additional food(s): Additives and colourings | Both IgE and non- IgE | Self-report Positive skin prick test without clinical history | Not reported | 11 and 15 years | 757 11 year olds 775 15 year olds |
| Pyrhonen (2009) | Cross- sectional study | 2001- 2009 | Finland | 1-4 years | Main list: Cereals (wheat, barley, rye, oat, maize, rice, millet/buckwheat) Eggs, Fish, Milk/dairy, Peanuts, Tree nuts Additional food(s): Chocolate, Citrus, Fruit and/or vegetables, Apple, Pear, Cherry, Peach, Banana, Strawberry, Tomato | Both IgE and non- IgE | Self-report Clinician diagnosed | Not reported | 1-4years | 853 |

| Study ID | Study | Year | Country | Target | Allergens assessed | Type of | Methods of | Samj | ple character | ristics |
|---------------------|------------------------------|---------------|-------------------|---------------|---|-----------------------------|---|--|--|---|
| | design | conducted | (s) | age group | | food allergy | diagnosis employed | Age Mean (SD) | Age (Range) | Sample size |
| Rance (2005) | Cross- sectional study | 2002 | France | 2-14 years | Main list: Crustaceans (shrimp), Eggs, Fish, Milk/dairy, Peanuts, Tree nuts Additional food(s): Kiwi | Both IgE and non- IgE | • Self-report | Mean 8.9 years (2.6) | 2.5-14 years | 2716 |
| Ro (2012) | Cohort study | 2002- 2006 | Norway | 2 years | Main list: Eggs (egg white), Fish Milk/dairy, Peanuts, Tree nuts (hazelnut) | IgE- only | Positive skin prick test without clinical history Positive serum-specific IgE without clinical history | Mean 26.6 months | 2 years | 668 (although only 352 complete d testing) |
| Roberts (2005) | Cohort study | 1998- 2000 | United Kingdom | 7 years | Main list: Eggs, Fish (cod), Milk/dairy, Peanuts, Sesame, Soy, Tree nuts (cashew, almond, walnut, hazelnut, brazil nut, pecan) | IgE- only | Positive skin prick test without clinical history | 90 months (median) | Interquarti le range 89-91 months | 6213 (main panel), approx. 2000 (subpane l) |
| Ronchetti (2008) | Cross- sectional study | 2005-2006 | Italy Rome | 9-13 years | Main list: Cereals (wheat flour) Eggs, Milk/dairy Additional food(s): Tomato | Both IgE and non- IgE | Positive skin prick test without clinical history • Other | Group 1: 12.6 years (± 0.89) Group 2: 8.71 years (± 1.41) | 9-13 years | 196 |

| Study ID | Study | Year | Country | Target | Allergens assessed | Type of | Methods of | Sam | ple character | istics |
|------------------------|------------------------------|-----------------|----------|-----------------------|--|-----------------------------|---|----------------------|-----------------------|----------------|
| | design | conducted | (s) | age group | | food allergy | diagnosis employed | Age Mean (SD) | Age (Range) | Sample size |
| Saarinen (1999) | Cohort study | 1994- 1997 | Finland | 0-34 mon ths | Main list: Cow's milk | Both IgE and non- IgE | Self-report Positive open food challenge with clinical history | 6. 2.3 | 0-34 months | 6209 |
| Sai (2011) | Cross- sectional study | 2008- 2009 | China | Not reported | Main List: Cereals, Crustaceans, Eggs, Fish, Milk/dairy, Molluscs, Soy Additional food(s): Beef, Chicken, Corn, Mushroom, Pork, Rice, Seafood, Tomato | IgG | Other | 46.57± 7.91 years | Not reported | 12766 |
| Sakellario u (2008) | Cross- sectional study | 2007 | Greece | 20-54 years | Main list: Eggs, Fish Additional food(s): Chocolate, Processed meats | Both IgE and non- IgE | • Self-report | Not reported | 20-54 years | 2003 |
| Santadusi t (2005) | Cross- sectional study | Not reported | Thailand | 6 months - 6 years | Main list: Crustaceans (shrimp), Eggs (egg yolk and egg white), Fish, Milk/dairy, Molluscs (crab, mollusc, squid), Soy Additional food(s): Duck | Both IgE and non- IgE | • Self-report | Not reported | 6 months - 6 years | 656 |
| Schafer (1999) | Cross- sectional study | 1994 | Germany | 5-7 years | Main list: Eggs, Milk/dairy | Both IgE and non- IgE | Positive skin prick test without clinical history | Not reported | 5-7 years | 1235 |

| Study ID | Study | Year | Country | Target | Allergens assessed | Type of | Methods of | Samp | ole character | istics |
|---------------------|---|---------------|--------------------------|---------------------------------|---|----------------------------------|---|--|------------------------------|----------------|
| | design | conducted | (s) | age group | | food allergy | diagnosis employed | Age Mean (SD) | Age (Range) | Sample size |
| Schafer (2001) | Cross- sectional study nested case- control study | 1997- 1998 | Germany | 25-74 years | Main list: Celery, Cereals (flour), Crustaceans (crab), Eggs, Fish, Milk/dairy Peanuts, Soy, Tree nuts Additional food(s): Additives and colourings, Citrus, Fruit and/or vegetables, Meat, Pork, Seafood, Spices, Herbs Sugar, wine sparkling, Tomato | Both IgE and non- IgE | Self-report Positive skin prick test without clinical history | 50.4% female had a median age of 50 years | 25-74 years | 4178 |
| Schrander (1993) | Cohort study | 1985- 1989 | The Netherland s | 0-1 years | Main list: Cow's milk | Both IgE and non- IgE | Self-report Positive open food challenge with clinical history | Not reported | 0-1years | 1158 |
| Shek (2010) | Cross- sectional study | 2007- 2008 | Philippines Singapore | 4-6 years, 14-16 years | Main list: Crustaceans, Peanuts, Tree nuts | Both IgE and non- IgE | • Self-report • Clinical history | Not reported | 4-6 years, 14-16 years | 11322 |
| Sicherer (1999) | Cross- sectional study | 1997 | United States | All ages | Main list: Peanuts, Tree nuts | IgE- only (no SPT or SIgE) | Clinical history | Not reported | Not reported | 8049 |
| Sicherer (2003) | Cross- sectional study | 2002 | United States | All ages | Main list: Peanuts, Tree nuts | IgE- only (no SPT or SIgE) | Clinical history | Not reported | Not reported | 1809 |
| Sicherer (2004) | Cross- sectional study | 2002 | United States | All ages | Main list: Fish Additional food(s): | Both IgE and non- IgE | Self-report Clinical history | Not reported | All ages | 4336 |

| Study ID | Study | Year | Country | Target | Allergens assessed | Type of | Methods of | Samp | ole character | istics |
|--------------------|------------------------------|---|-------------------|---------------|--|----------------------------------|--|------------------|-----------------|--------------------------------|
| | design | conducted | (s) | age group | | food allergy | diagnosis employed | Age Mean (SD) | Age (Range) | Sample size |
| | | | | | shellfish (crustacean, mollusc) | | | | | |
| Sicherer (2010) | Cross- sectional study | 2008 | United States | All ages | Main list: Peanuts, Sesame, Tree nuts | IgE- only (no SPT or SIgE) | • Clinical history | Not reported | Not reported | 13534 |
| Soller (2012) | Cross- sectional study | 2008- 2009 | Canada | All ages | Main list: Cereals (wheat), Eggs, Fish, Milk/dairy, Peanuts, Sesame, Soy, Tree nuts Additional food(s): Fruit and/or vegetables Shellfish | Both IgE and non- IgE | • Self-report | Not reported | Not reported | 9667 from 10596 homes |
| Tariq (1996) | Cross- sectional study | Not reported possibly 1993 – 1994 | United Kingdom | 4 years | Main list: Peanuts, Tree nuts Peanut, Hazelnut, Cashew | IgE only | Self report Positive skin prick test with clinical history Positive skin prick test without clinical history | Not reported | 4 years | 1218 |
| Touraine (2002) | Cross- sectional study | 2000- 2001 | France | 5-17 years | Main list: Celery, Cereals (wheat) Crustaceans, Eggs, Fish Milk/dairy, Molluscs (oyster), Mustard, Peanuts, Sesame, Tree nuts (cashew, hazelnut, almond, pistachio) Additional food(s): | Both IgE and non- IgE | • Self-report | Not reported | 5-17 years | 1086 |

| Study ID | Study | Year | Country | Target | Allergens assessed | Type of | Methods of | Samp | ole character | istics |
|------------------|------------------------------|---------------|-------------------|-----------------|---|-----------------------------|--|------------------|-----------------|----------------|
| | design | conducted | (s) | age group | | food allergy | diagnosis employed | Age Mean (SD) | Age (Range) | Sample size |
| | | | | | Apple, Banana, Carrot, Cherry, Chocolate, Fruits, Garlic, Kiwi, Melon, Peach, Pear, Pork, Raspberry, Chestnut | | | | | |
| Venter (2006) | Cohort study | 2003- 2004 | United Kingdom | 6 years | Main list: Cereals (wheat),Eggs, Fish, Milk/dairy, Peanuts, Sesame, Tree nuts Additional food(s): Additives and colourings Strawberry | Both IgE and non- IgE | Self-report Positive skin prick test without clinical history Positive DBPCFC with clinical history | Not reported | 6 years | 798 |
| Venter (2008) | Cohort study | 2002- 2005 | United Kingdom | Birth cohort | Main list: Cereals (wheat, corn), Eggs, Fish, Milk/dairy, Peanuts, Sesame Additional food(s): Additives and colourings, Kiwi, Pineapple | Both IgE and non- IgE | Positive skin prick test with clinical history Other | Not reported | 1-3 years | 891 |
| Vierk (2007) | Cross- sectional study | 2001 | United States | ≥18 years | Main list: Cereals (wheat/gluten) Crustaceans, Eggs, Fish, Milk/dairy, Peanuts, Soy, Tree nuts Additional food(s): Additives and colourings, Chocolate, Fruit and/or vegetables | Both IgE and non- IgE | • Self-report • Other | Not reported | Not reported | 4482 |

| Study ID | Study | Year | Country | Target | Allergens assessed | Type of | Methods of | Samp | le character | istics |
|-----------------|------------------------------|-----------------|-----------|----------------|--|-----------------------------|--|------------------|----------------|----------------|
| | design | conducted | (S) | age group | | allergy | diagnosis employed | Age Mean (SD) | Age (Range) | Sample size |
| Wan (2012) | Cross- sectional study | Not reported | Taiwan | 6-8 years | Main list: Celery, Crustaceans (lobster), Milk/dairy (goat, cheese, casein) Molluscs (clam, squid, oyster. scallop, abalone, pacific squid, octopus), Tree nuts, Pistachio Additional food(s): Cacao, Fruits, Litchi, Garlic, Grape, Melon, Onion | IgE only | Positive serum-specific IgE with clinical history | Not reported | 6-8 years | 1010 |
| Woods (1998) | Cross- sectional study | 1992- 1994 | Australia | 20-44 years | Main list: Cereals (wheat products, bread/plain cereal), Eggs, Milk/dairy (milk, cheese, yoghurt, ice cream), Peanuts (Including peanut butter and coconut) Additional food(s): Additional food(s): Additives and colourings, Alcohol, Chocolate, Fats/Oils, Fruits Dried, High fat foods, Meat and Poultry, Processed meats, Restaurant/takeaway meals, Sauces, Seafood, Spices, Herbs, Condiments, Sugar, Syrup and Jam, Tea/coffee, Vegetables | Both IgE and non- IgE | • Self-report | Not reported | 20-44 years | 669 |

| Study ID | Study | Year | Country | Target | Allergens assessed | Type of | Methods of | Samp | ole character | istics |
|--------------------|---|---|-------------------|-----------------|--|-----------------------------|--|------------------|-------------------------------|---|
| | design | conducted | (s) | age group | | food allergy | diagnosis employed | Age Mean (SD) | Age (Range) | Sample size |
| Woods (2002) | Cohort study follow up of European Community Respiratory Health Survey | 1992- 1994 (sub- sample in 1998) | Australia | 20-44 years | Main list: Cereals (wholegrain wheat), Crustaceans (shrimp) Eggs, Milk/dairy, Peanuts | IgE mediated only | Self-report Positive skin prick test with clinical history Positive skin prick test without clinical history | Not reported | 20-44 years | 457 |
| Wu (2012) | Cross- sectional study | 2004 | Taiwan | All ages | Main list: Crustaceans (shrimp, crab), Eggs, Fish, Milk/dairy, Molluscs, Peanuts, Soy Additional food(s): Kiwi, Mango | Both IgE and non- IgE | • Clinician diagnosed | Not reported | <3 years 4-18 years >19 | 30018 (813 <3 years, 15169 4- 18 years, 14036 >19 years) |
| Young (1994) | Cross- sectional study | Not reported | United Kingdom | Not reported | Main list: Cereals, Crustaceans, Eggs, Fish, Milk/dairy, Soy Additional food(s): Additives and colourings, Alcohol, Caffeine, Cheese, Chocolate, Citrus, Fruit and/or vegetables, Meat, Tomato | Both IgE and non- IgE | • Self-report | Not reported | Not reported | 18880 |
| Zannikos (2008) | Cross- sectional study | 2007 | Greece | 7-13 years | Main list: Cereals, Wheat, Eggs Additional food(s): Chocolate, Fruits, shellfish | Both IgE and non- IgE | • Self-report | Not reported | 7-13 years | 3821 |

49

| Study ID | Study | Year | Country | Target | Allergens assessed | Type of | Methods of | Samp | ole character | istics |
|---------------------|------------------------------|---------------|---------|--------------|---|-----------------------------|--|------------------|----------------|----------------|
| | design | conducted | (\$) | age group | | allergy | employed | Age Mean (SD) | Age (Range) | Sample size |
| Zuberbier (2004) | Cross- sectional study | 1999- 2000 | Germany | All ages | Main list: Celery, Cereals (barley, wheat, rye, flour, oat meal), Crustaceans (crab), Eggs (hen), Fish (herring, mackerel), Milk/dairy (cow's milk), Molluscs (mussels), Peanuts, Sesame, Soy, Tree nuts (hazelnut, walnut) Additional food(a); | Both IgE and non- IgE | Positive skin prick test with clinical history Positive DBPCFC with clinical history Other | Not reported | 0-80+ years | 4093 |
| | | | | | Additional food(s): Apple, Apricot, Carob Carrot, Cherry, Grape, Guar gum, Nectarine, Peach, Pear, Plum, Potato (raw),Pork, Seeds (poppy) | | | | | |

EFSA supporting publication 2013:EN-506

Table 1.5:Study designs of included studies

| Study ID | Study design | Cross-sectional: utilising existing survey | Cohort: reported single or multiple time-points | Cohort: cohort utilised | Target age group or age at recruitment and follow up |
|--------------------|--------------------------|--|---|--------------------------------|--|
| Al-Hammadi (2010) | Cross-sectional study | No | N/A | N/A | 6-9 years |
| Altintas (1995) | Cross-sectional study | No | N/A | N/A | Newborn |
| Arbes (2005) | Cross-sectional study | No | N/A | N/A | All ages |
| Arshad (2001) | Cohort study | N/A | Single time point | Isle of Wight 1989- 1990 | 4 years |
| Babu (2008) | Cross-sectional study | No | N/A | N/A | 5-60 years |
| Bakos (2006) | Cross-sectional study | No | N/A | N/A | Elderly people mean age of 77 years |
| Ben-Shoshan (2009) | Cross-sectional study | No | N/A | N/A | 5-9 years |
| Ben-Shoshan (2010) | Cross-sectional study | No | N/A | N/A | All ages |
| Bjornsson (1996) | Cross-sectional study | Yes - European Community Respiratory Health Survey 1991-1992 | N/A | N/A | 20-44 years |
| Bock (1987) | Cohort study | N/A | Multiple time points | Fort Collins Youth Centre | Birth- 3years |
| Branum (2009) | Cross-sectional study | Yes - NHANES 2005-2006 | N/A | N/A | < 18 years |
| Brugman (1998) | Cross-sectional study | No | N/A | N/A | 2, 4 and 7 or 8 primary school and 2^{nd} yr of secondary school |

EFSA supporting publication 2013:EN-506

51

| Study ID | Study design | Cross-sectional: utilising existing survey | Cohort: reported single or multiple time-points | Cohort: cohort utilised | Target age group or age at recruitment and follow up |
|------------------|--------------------------|---|---|---|--|
| Chen (2011) | Cross-sectional study | No | N/A | N/A | <12 months |
| Chen (2012) | Cross-sectional study | No | N/A | N/A | 0-2years |
| Connett (2012) | Cross-sectional study | No | N/A | N/A | 14-16 years |
| Dalal (2002) | Cross-sectional study | No | N/A | N/A | 0-2years |
| Eggesbo (1999) | Cohort study | N/A | Multiple time points | Population based cohort (2 maternity clinics in Oslo) | Birth, 12,18,24 months |
| Eller (2009) | Cohort study | N/A | Multiple time points | DARC 1998-1999 | Birth, 3, 6, 9, 12, 18, 36, 72 months |
| Emmett (1999) | Cross-sectional study | No | N/A | N/A | ≥ 15 years |
| Falcao (2004) | Cross-sectional study | No | N/A | N/A | >39 years |
| Frongia (2005) | Cross-sectional study | Yes - linked to ICONA 2003 | N/A | N/A | 12-24 months |
| Gelincik (2008) | Cross-sectional study | No | N/A | N/A | ≥18 years |
| Gerrard (1973) | Cross-sectional study | No | N/A | N/A | 6-36 months |
| Greenhawt (2009) | Cross-sectional study | No | N/A | N/A | 18> years |
| Grundy (2002) | Cohort study | N/A | Single time point | Isle of Wight 1994-1996 | 3-4 years |

EFSA supporting publication 2013:EN-506

52

| Study ID | Study design | Cross-sectional: utilising | Cohort: reported | Cohort: | Target age group or age at |
|------------------|--------------------------|--|-------------------------|---|----------------------------|
| | | existing survey | time-points | utilised | recruitment and follow up |
| Gupta (2011) | Cross-sectional study | No | N/A | N/A | <18 years |
| Haahtela (1980) | Cross-sectional study | No | N/A | N/A | 15-17 years |
| Host (2002) | Cohort | N/A | Multiple time points | Odense University Hospital 1985-2000 | 0-15 years |
| Hourihane (2007) | Cross-sectional study | No | N/A | N/A | 3-6 years |
| Hu (2010) | Cross-sectional study | Yes - repeated 1999 methodology in 2009 | N/A | N/A | 0-24 months |
| Julge (2001) | Cohort study | N/A | Multiple time points | Tartu women's clinic, Estonia | 6 months, 1, 2 and 5 years |
| Kagan (2003) | Cross-sectional study | No | N/A | N/A | 5-9 years |
| Kajosaari (1982) | Cross-sectional study | No | N/A | N/A | 1,2,3 and 6 years |
| Katz (2010) | Cohort | N/A | Multiple time points | Assaf- Harofeh Hospital (Zerifin, Israel) 2004- 2006 | 0-2 years |
| Keet (2012) | Cross-sectional study | Yes - NHANES 2005-2006 | N/A | N/A | 1-21 years |
| Kilgallen (1996) | Cross-sectional study | No | N/A | N/A | 0-48 months |
| Kim (2011) | Cohort study | N/A | Single time point | Samsung Medical | 0-12 months |

EFSA supporting publication 2013:EN-506

| Study ID | Study design | Cross-sectional: utilising existing survey | Cohort: reported single or multiple time-points | Cohort: cohort utilised | Target age group or age at recruitment and follow up |
|---------------------------|--------------------------|---|---|-------------------------------|--|
| | | | | Centre 2006-2007 | |
| Krause (2002) | Cross-sectional study | No | N/A | N/A | 7-15 years |
| Kristjansson (1999) | Cross-sectional study | No | N/A | N/A | 18 months |
| Kucukosmanoglu (2008a) | Cross-sectional study | No | N/A | N/A | 8-18 months |
| Kucukosmanoglu (2008b) | Cross-sectional study | No | N/A | N/A | 8-18months |
| Kumar (2011) | Cohort study | N/A | Single time point | Boston birth Cohort | 2 years |
| Lack (2003) | Cohort study | N/A | Single time point | ALSPAC 1991-1992 | 38 months |
| Lao-araya (2012) | Cross-sectional study | No | N/A | N/A | 3-7 years |
| Leung (2009) | Cross-sectional study | No | N/A | N/A | 2-7 years |
| Liu (2010) | Cross-sectional study | Yes - NHANES 2005-2006 | N/A | N/A | All ages |
| Marrugo (2008) | Cross-sectional study | No | N/A | N/A | 1-83 years |
| Martinez-Gimeno (2000) | Cross-sectional study | Yes - Extension of the International Study of Asthma and Allergy in Children (ISAAC) | N/A | N/A | 6-13 years |
| Morita (2012) | Cross-sectional study | No | N/A | N/A | Adults |
| Mortz (2005) | Cohort study | N/A | Single time point | TOACS | 14 years |

54

| Study ID | Study design | Cross-sectional: utilising existing survey | Cohort: reported single or multiple time-points | Cohort: cohort utilised | Target age group or age at recruitment and follow up |
|-------------------|---|---|---|---|---|
| | | | | 1995-1996 | |
| Mustafayev (2012) | Cross-sectional study | No | N/A | N/A | 10-11 years |
| Nicolaou (2010) | Cohort study | N/A | Single time point | Manchester Asthma and Allergy Study 1995 | 8 years |
| Obeng (2011) | Cross-sectional study | No | N/A | N/A | 5-16 years |
| Oh (2004) | Cross-sectional study | No | N/A | N/A | 2 age groups, 6-12 year olds and 12-15 year olds |
| Orhan (2009) | Cross-sectional study | No | N/A | N/A | 6-9 years |
| Osborne (2011) | Cohort study | N/A | Single time point | HealthNuts 2007 | 11-15 months |
| Ostblom (2008a) | Cohort study | N/A | Single time point | BAMSE 1994-1996 | 4 years |
| Ostblom (2008b) | Cohort study | N/A | Multiple time points | BAMSE 1994-1996 | 1, 2, 4 and 8 years (same cohort) |
| Osterballe (2005) | Cohort study | N/A | Single time point | DARC 1998-1999 | Group 1: 3 years, Group 2: <3 years, Group 3: Children > 3 years, Group 4: Adults |
| Osterballe (2009) | Cohort study | N/A | Single time point | TOACS 1995-1996 | 22 years |
| Pereira (2005) | Cohort study 2 birth cohorts used: 1991-1992 and 1987-1988 | N/A | Single time point | Isle of Wight 2002-2003 | Birth cohort 1991-1992 – 11years Birth cohort 1987-1988 - 15 years |

EFSA supporting publication 2013:EN-506

| Study ID | Study design | Cross-sectional: utilising existing survey | Cohort: reported single or multiple | Cohort: cohort | Target age group or age at recruitment and follow up |
|--------------------|--------------------------|---|-------------------------------------|---|---|
| | | | time-points | utilised | • |
| Pyrhonen (2009) | Cross-sectional study | No | N/A | N/A | 1-4 years |
| Rance (2005) | Cross-sectional study | No | N/A | N/A | 2-14 years |
| Ro (2012) | Cohort study | N/A | Single time point | PACT 2002-2006 | 2 years |
| Roberts (2005) | Cohort study | N/A | Single time point | ALSPAC 1991-1992 | 7 years |
| Ronchetti (2008) | Cross-sectional study | No | N/A | N/A | 9-13 years |
| Saarinen (1999) | Cohort study | N/A | Single time point | Recruited from Helsinki maternity hospital | 034 months |
| Sai (2011) | Cross-sectional study | No | N/A | N/A | Not reported |
| Sakellariou (2008) | Cross-sectional study | Yes EUROPREVALL | N/A | N/A | Not reported |
| Santadusit (2005) | Cross-sectional study | No | N/A | N/A | 3 months- 6 years |
| Schafer (1999) | Cross-sectional study | No | N/A | N/A | 5-7 years |
| Schafer (2001) | Cross-sectional study | No | N/A | N/A | 25-74 years |
| Schrander (1993) | Cohort study | N/A | Single time point | Recruited from health care centres in Maastricht | 0-1 years |
| Shek (2010) | Cross-sectional | No | N/A | N/A | 4-6 years, 14-16 years |

56

| Study ID | Study design | Cross-sectional: utilising existing survey | Cohort: reported single or multiple time-points | Cohort: cohort utilised | Target age group or age at recruitment and follow up |
|-----------------|--------------------------|---|---|-------------------------------|--|
| | study | | | | |
| Sicherer (1999) | Cross-sectional study | No | N/A | N/A | All ages |
| Sicherer (2003) | Cross-sectional study | No | N/A | N/A | All ages |
| Sicherer (2004) | Cross-sectional study | No | N/A | N/A | All ages |
| Sicherer (2010) | Cross-sectional study | No | N/A | N/A | All ages |
| Soller (2012) | Cross-sectional study | No | N/A | N/A | All ages |
| Tariq (1996) | Cross-sectional study | No | N/A | N/A | 4 years |
| Touraine (2002) | Cross-sectional study | No | N/A | N/A | 5-17 years |
| Venter (2006) | Cohort study | N/A | Single time point | Isle of Wight 1997-1998 | 6 year olds |
| Venter (2008) | Cohort study | N/A | Multiple time points | Isle of Wight 2001-2002 | 1,2,3 years |
| Vierk (2007) | Cross-sectional study | No | N/A | N/A | ≥18 years |

EFSA supporting publication 2013:EN-506

57

| Study ID | Study design | Cross-sectional: utilising existing survey | Cohort: reported single or multiple time-points | Cohort: cohort utilised | Target age group or age at recruitment and follow up |
|------------------|---------------------------------------|---|---|-------------------------------|--|
| Wan (2012) | Cross-sectional study ⁵ | No | N/A | N/A | 6-8 years |
| Woods (1998) | Cross-sectional study | No | N/A | N/A | 20-44 years |
| Woods (2002) | Cohort study | N/A | Multiple time points | ECRHS | Not reported |
| Wu (2012) | Cross-sectional study | No | N/A | N/A | All ages |
| Young (1994) | Cross-sectional study | No | N/A | N/A | Not reported |
| Zannikos (2008) | Cross-sectional study | Yes EUROPREVALL | N/A | N/A | 7-13 years |
| Zuberbier (2004) | Cross-sectional study | No | N/A | N/A | All |

⁵ Although suggests a cohort study it appears to be a cross sectional study in which there were stages of detection, i.e, questionnaire which led to further testing

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

1.2.4. Quality of included studies

Table 1.6. presents the quality assessment for all included studies.

Table 1.6:Quality assessment of all studies

| nethod for withdrawal/non- response Al-Hammadi (2010) High risk of bias Low risk of bias Unclear Altinas (1995) High risk of bias Low risk of bias Unclear Arbes (2005) High risk of bias Low risk of bias Unclear Arbes (2005) High risk of bias Low risk of bias Unclear Babos (2006) High risk of bias Low risk of bias Unclear Babos (2006) High risk of bias Low risk of bias Unclear (2009) Dow risk of bias Low risk of bias Unclear (2010) High risk of bias Low risk of bias Unclear (2010) High risk of bias Low risk of bias Unclear (2010) High risk of bias Low risk of bias Unclear BorsShoshan High risk of bias Low risk of bias Unclear Brauma (2009) High risk of bias Low risk of bias Unclear Chen (2011) Low risk of bias Low risk of bias Unclear Chen (2012) Low risk of bias Unclear Unclear | Study ID | (1) Method of diagnosis | (2) Sampling strategy: | (3) Explored reasons |
|--|------------------|-------------------------|------------------------|----------------------|
| Al-Hammadi (2010) Withdrawal/non- response Al-Hammadi (2010) High risk of bias Low risk of bias Unclear Arbes (2005) High risk of bias Unclear Low risk of bias Unclear Arbes (2001) High risk of bias Low risk of bias Low risk of bias Unclear Babu (2008) Low risk of bias Low risk of bias Low risk of bias Unclear Bakos (2006) High risk of bias Low risk of bias Unclear Unclear Babus (2009) Low risk of bias Low risk of bias Unclear (2009) Ion risk of bias Low risk of bias Unclear (2010) High risk of bias Low risk of bias Unclear Bock (1987) Low risk of bias Low risk of bias Unclear Brugman (1998) High risk of bias Low risk of bias Unclear Chen (2012) Low risk of bias Low risk of bias Unclear Chen (2012) Low risk of bias Low risk of bias Unclear Dalal (2002) Low risk of bias Low risk of bias Unclear <th></th> <th></th> <th>method</th> <th>for</th> | | | method | for |
| Al-Hammali (2010) High risk of bias Low risk of bias Unclear Altintas (1995) High risk of bias Low risk of bias Unclear Low risk of bias Unclear Arbas (2005) High risk of bias Low risk of bias Unclear Low risk of bias Unclear Babu (2008) Low risk of bias Low risk of bias Unclear Babus (2006) High risk of bias Unclear Bakos (2006) High risk of bias Low risk of bias Unclear (2009) Unclear Ben-Shoshan Low risk of bias Low risk of bias Unclear (2009) Unclear Bjornsson (1996) High risk of bias Low risk of bias Unclear Unclear Bock (1987) Low risk of bias Low risk of bias Unclear Unclear Chen (2011) Low risk of bias Low risk of bias Unclear Unclear Chen (2012) Low risk of bias Low risk of bias Unclear Chen (2012) Low risk of bias Unclear Unclear Eggesbo (1999) High risk of bias Low risk of | | | | withdrawal/non- |
| Al-Hammadi (2010) High risk of bias Low risk of bias Unclear Altintas (1995) High risk of bias Low risk of bias Unclear Arbes (2005) High risk of bias Low risk of bias Low risk of bias Babu (2008) Low risk of bias Low risk of bias Unclear Bakos (2006) High risk of bias Low risk of bias Unclear Babos (2006) High risk of bias Low risk of bias Unclear (2009) Low risk of bias Low risk of bias Unclear (2010) High risk of bias Low risk of bias Unclear (2010) High risk of bias Low risk of bias Unclear Bock (1987) Low risk of bias Low risk of bias Unclear Brugman (1998) High risk of bias Low risk of bias Unclear Chen (2011) Low risk of bias Low risk of bias Unclear Chen (2012) Low risk of bias Low risk of bias Unclear Chen (2012) Low risk of bias Low risk of bias Unclear Eggesbo (1999) High risk of bias Low risk of bias Unclear <t< th=""><th></th><th></th><th></th><th>response</th></t<> | | | | response |
| (2010) (2010) Altintas (1995) High risk of bias Low risk of bias Unclear Arbes (2005) High risk of bias Low risk of bias Low risk of bias Babu (2008) Low risk of bias Low risk of bias Unclear Bakos (2006) High risk of bias Low risk of bias Unclear Bakos (2006) High risk of bias Low risk of bias Unclear (2009) Low risk of bias Low risk of bias Unclear (2009) Ben-Shoshan High risk of bias Low risk of bias Unclear (2010) Ben-Shoshan High risk of bias Low risk of bias Unclear (2010) Bernanum (2009) High risk of bias Low risk of bias Unclear Bock (1987) Low risk of bias Low risk of bias Unclear Brugman (1998) High risk of bias Low risk of bias Unclear Chen (2011) Low risk of bias Low risk of bias Unclear Chen (2012) Low risk of bias Low risk of bias Unclear Eggesbo (1999) High risk of bias Low risk of bias Unclear | Al-Hammadi | High risk of bias | Low risk of bias | Unclear |
| Altintas (1995) High risk of bias Low risk of bias Unclear Arbes (2005) High risk of bias Low risk of bias Low risk of bias Babu (2008) Low risk of bias Low risk of bias Unclear Bakos (2006) High risk of bias High risk of bias Low risk of bias Ben-Shoshan Low risk of bias Low risk of bias Unclear (2009) Biornsson (1996) High risk of bias Low risk of bias Unclear (2010) Biornsson (1996) High risk of bias Low risk of bias Unclear Branum (2009) High risk of bias Low risk of bias Unclear Branum (2009) High risk of bias Low risk of bias Unclear Chen (2011) Low risk of bias Low risk of bias Unclear Connett (2012) Low risk of bias Low risk of bias Unclear Eggesbo (1999) High risk of bias Low risk of bias Unclear Falca (2004) High risk of bias Low risk of bias Unclear Falca (2004) High risk of bias Low risk of bias | (2010) | | | |
| Arbas (2005)High risk of biasUnclearLow risk of biasArshad (2001)High risk of biasLow risk of biasLow risk of biasLow risk of biasBakos (2006)High risk of biasHigh risk of biasLow risk of biasUnclearBen-ShoshanLow risk of biasLow risk of biasUnclear(2009)Ibin risk of biasLow risk of biasUnclearBen-ShoshanHigh risk of biasLow risk of biasUnclear(2010)Ibin risk of biasLow risk of biasUnclearBock (1987)Low risk of biasLow risk of biasUnclearBrugman (1998)High risk of biasLow risk of biasUnclearBrugman (1998)High risk of biasLow risk of biasUnclearChen (2011)Low risk of biasLow risk of biasUnclearChen (2012)Low risk of biasLow risk of biasUnclearDalal (2002)Low risk of biasLow risk of biasUnclearBernett (1999)High risk of biasLow risk of biasUnclearEller (2009)Low risk of biasLow risk of biasUnclearFalcao (2004)High risk of biasLow risk of biasUnclearFrongia (2005)High risk of biasLow risk of biasUnclearGerard (1973)High risk of biasLow risk of biasLow risk of biasGrundy (2002)Low risk of biasLow risk of biasUnclearGrundy (2002)Low risk of biasLow risk of biasUnclearHahela (1980)High risk o | Altintas (1995) | High risk of bias | Low risk of bias | Unclear |
| Arshad (2001)High risk of biasLow risk of biasLow risk of biasBakou (2008)Low risk of biasLow risk of biasUnclearBakou (2006)High risk of biasLow risk of biasLow risk of biasBen-ShoshanLow risk of biasLow risk of biasUnclear(2009) | Arbes (2005) | High risk of bias | Unclear | Low risk of bias |
| Babu (2008)Low risk of biasLow risk of biasUnclearBakos (2006)High risk of biasHigh risk of biasLow risk of biasLow risk of biasBen-Shoshan (2009)Low risk of biasLow risk of biasUnclearBen-Shoshan (2010)High risk of biasLow risk of biasUnclearBjornsson (1996)High risk of biasLow risk of biasUnclearBranum (2009)High risk of biasLow risk of biasUnclearBranum (2009)High risk of biasLow risk of biasUnclearBrugman (1998)High risk of biasLow risk of biasUnclearChen (2011)Low risk of biasLow risk of biasUnclearChen (2012)Low risk of biasLow risk of biasUnclearChen (2012)Low risk of biasLow risk of biasUnclearDalal (2002)Low risk of biasLow risk of biasUnclearEller (2009)High risk of biasLow risk of biasUnclearFacao (2004)High risk of biasLow risk of biasUnclearFrongia (2005)High risk of biasLow risk of biasUnclearGernard (1973)High risk of biasLow risk of biasUnclearGrundy (2002)Low risk of biasLow risk of biasUnclearGrundy (2002)Low risk of biasLow risk of biasUnclearHuahtela (1980)High risk of biasLow risk of biasUnclearGereandurt (1992)High risk of biasLow risk of biasUnclearGereandurt (2002) <td< td=""><td>Arshad (2001)</td><td>High risk of bias</td><td>Low risk of bias</td><td>Low risk of bias</td></td<> | Arshad (2001) | High risk of bias | Low risk of bias | Low risk of bias |
| Bakos (2006)High risk of biasLow risk of biasLow risk of biasBen-Shoshan (2009)Low risk of biasLow risk of biasUnclearBen-Shoshan (2010)High risk of biasLow risk of biasUnclearBock (1987)Low risk of biasLow risk of biasUnclearBranum (2009)High risk of biasLow risk of biasUnclearBraum (2009)High risk of biasLow risk of biasUnclearBrugman (1998)High risk of biasLow risk of biasUnclearBrugman (1998)High risk of biasLow risk of biasUnclearChen (2011)Low risk of biasLow risk of biasUnclearChen (2012)Low risk of biasLow risk of biasUnclearDalal (2002)Low risk of biasLow risk of biasUnclearElgesbo (1999)High risk of biasLow risk of biasUnclearEller (2009)Low risk of biasLow risk of biasUnclearFalcao (2004)High risk of biasLow risk of biasUnclearFrongia (2005)High risk of biasLow risk of biasUnclearGernard (1973)High risk of biasLow risk of biasUnclearGreenhawt (2009)High risk of biasLow risk of biasUnclearGreard (1973)High risk of biasLow risk of biasUnclearGreard (1973)High risk of biasLow risk of biasUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearHuahela (1980)High risk of bias | Babu (2008) | Low risk of bias | Low risk of bias | Unclear |
| Ben-Shoshan (2009)Low risk of biasLow risk of biasUnclearBen-Shoshan (2010)High risk of biasLow risk of biasUnclearBjornsson (1996)High risk of biasLow risk of biasUnclearBock (1987)Low risk of biasLow risk of biasHigh risk of biasBranum (2009)High risk of biasLow risk of biasUnclearBrugman (1998)High risk of biasLow risk of biasUnclearChen (2011)Low risk of biasLow risk of biasUnclearChen (2012)Low risk of biasLow risk of biasUnclearDalal (2002)Low risk of biasUnclearUnclearEller (2009)High risk of biasLow risk of biasUnclearEller (2009)Low risk of biasLow risk of biasUnclearFalcao (2004)High risk of biasLow risk of biasUnclearFrongia (2005)High risk of biasLow risk of biasUnclearGelincik (2008)Low risk of biasLow risk of biasUnclearGerrard (1973)High risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearGupta (2002)Low risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearHoripa (2005)High risk of biasLow risk of biasUnclearGelincik (2008)Low risk of biasLow risk of biasUnclearGelincik (2009)High risk of biasLow risk of | Bakos (2006) | High risk of bias | High risk of bias | Low risk of bias |
| (2009)High risk of biasLow risk of biasUnclear(2010)Bjornsson (1996)High risk of biasLow risk of biasUnclearBock (1987)Low risk of biasLow risk of biasHigh risk of biasBranum (2009)High risk of biasLow risk of biasUnclearBrugman (1998)High risk of biasLow risk of biasUnclearChen (2011)Low risk of biasLow risk of biasUnclearChen (2012)Low risk of biasLow risk of biasUnclearConnett (2012)Low risk of biasLow risk of biasUnclearDalal (2002)Low risk of biasLow risk of biasUnclearEller (2009)High risk of biasLow risk of biasUnclearEller (2009)Low risk of biasLow risk of biasUnclearFalcao (2004)High risk of biasLow risk of biasUnclearFrongia (2005)High risk of biasLow risk of biasLow risk of biasGerard (1973)High risk of biasLow risk of biasLow risk of biasGreenhawt (2009)High risk of biasLow risk of biasUnclearGrundy (2002)Low risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearHahrela (1980)High risk of biasLow risk of biasUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasL | Ben-Shoshan | Low risk of bias | Low risk of bias | Unclear |
| Ben-Shoshan (2010)High risk of biasLow risk of biasUnclearBjornsson (1996)High risk of biasLow risk of biasUnclearBock (1987)Low risk of biasLow risk of biasHigh risk of biasBrauman (2009)High risk of biasLow risk of biasUnclearBrugman (1998)High risk of biasUnclearUnclearChen (2011)Low risk of biasLow risk of biasUnclearChen (2012)Low risk of biasLow risk of biasUnclearDalal (2002)Low risk of biasLow risk of biasUnclearEggesbo (1999)High risk of biasLow risk of biasUnclearEller (2009)Low risk of biasLow risk of biasUnclearFalcao (2004)High risk of biasLow risk of biasUnclearFalcao (2004)High risk of biasLow risk of biasUnclearForngia (2005)High risk of biasLow risk of biasLow risk of biasGernard (1973)High risk of biasLow risk of biasUnclearGrundy (2002)Low risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearHuahtela (1980)High risk of biasLow risk | (2009) | | | |
| (2010)High risk of biasLow risk of biasUnclearBock (1987)Low risk of biasLow risk of biasHigh risk of biasBranum (2009)High risk of biasLow risk of biasUnclearBrugman (1998)High risk of biasUnclearUnclearChen (2011)Low risk of biasLow risk of biasUnclearChen (2012)Low risk of biasLow risk of biasUnclearConnett (2012)High risk of biasLow risk of biasUnclearDalal (2002)Low risk of biasLow risk of biasUnclearElgesbo (1999)High risk of biasLow risk of biasUnclearEller (2009)Low risk of biasLow risk of biasUnclearFacao (2004)High risk of biasLow risk of biasUnclearFrongia (2005)High risk of biasLow risk of biasUnclearGerrard (1973)High risk of biasLow risk of biasUnclearGrundy (2002)Low risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearGupta (2002)Low risk of biasLow risk of biasUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearHu (2 | Ben-Shoshan | High risk of bias | Low risk of bias | Unclear |
| Bjornsson (1996)High risk of biasLow risk of biasUnclearBock (1987)Low risk of biasLow risk of biasHigh risk of biasBranum (2009)High risk of biasLow risk of biasUnclearBrugman (1998)High risk of biasUnclearUnclearChen (2011)Low risk of biasLow risk of biasUnclearChen (2012)Low risk of biasLow risk of biasUnclearConnett (2012)High risk of biasLow risk of biasUnclearDalal (2002)Low risk of biasLow risk of biasUnclearEggesbo (1999)High risk of biasLow risk of biasUnclearEller (2009)Low risk of biasLow risk of biasUnclearFalcao (2004)High risk of biasLow risk of biasUnclearFrongia (2005)High risk of biasLow risk of biasUnclearGerrard (1973)High risk of biasLow risk of biasUnclearGrundy (2002)Low risk of biasLow risk of biasUnclearGrundy (2002)Low risk of biasLow risk of biasUnclearGuta (2011)High risk of biasLow risk of biasUnclearHaahtela (1980)High risk of biasLow risk of biasUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclear <td>(2010)</td> <td></td> <td></td> <td></td> | (2010) | | | |
| Bock (1987)Low risk of biasLow risk of biasHigh risk of biasBranum (2009)High risk of biasLow risk of biasUnclearBrugman (1998)High risk of biasUnclearUnclearChen (2011)Low risk of biasLow risk of biasUnclearChen (2012)Low risk of biasLow risk of biasUnclearConnett (2012)High risk of biasLow risk of biasUnclearDalal (2002)Low risk of biasUnclearUnclearEggesbo (1999)High risk of biasLow risk of biasUnclearEller (2009)Low risk of biasLow risk of biasUnclearFalcao (2004)High risk of biasLow risk of biasUnclearFrongia (2005)High risk of biasLow risk of biasUnclearGeriard (1973)High risk of biasLow risk of biasLow risk of biasGreenhawt (2009)High risk of biasLow risk of biasUnclearGupta (2002)Low risk of biasLow risk of biasUnclearGupta (2009)High risk of biasLow risk of biasUnclearGerard (1973)High risk of biasLow risk of biasUnclearGupta (2002)Low risk of biasLow risk of biasUnclearGupta (2001)High risk of biasLow risk of biasUnclearHaahtela (1980)High risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclear <td>Bjornsson (1996)</td> <td>High risk of bias</td> <td>Low risk of bias</td> <td>Unclear</td> | Bjornsson (1996) | High risk of bias | Low risk of bias | Unclear |
| Branum (2009)High risk of biasLow risk of biasUnclearBrugman (1998)High risk of biasUnclearUnclearChen (2011)Low risk of biasLow risk of biasUnclearChen (2012)Low risk of biasLow risk of biasUnclearConnett (2012)High risk of biasLow risk of biasUnclearDalal (2002)Low risk of biasUnclearUnclearEggesbo (1999)High risk of biasLow risk of biasUnclearEller (2009)Low risk of biasLow risk of biasUnclearEller (2009)High risk of biasLow risk of biasUnclearFalcao (2004)High risk of biasLow risk of biasUnclearFrongia (2005)High risk of biasLow risk of biasUnclearGerrard (1973)High risk of biasLow risk of biasUnclearGrundy (2002)Low risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearHaahtela (1980)High risk of biasLow risk of biasUnclearHou risk of biasLow risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearHu (2010)L | Bock (1987) | Low risk of bias | Low risk of bias | High risk of bias |
| Brugman (1998)High risk of biasUnclearUnclearChen (2011)Low risk of biasLow risk of biasUnclearChen (2012)Low risk of biasLow risk of biasUnclearConnett (2012)High risk of biasLow risk of biasUnclearDalal (2002)Low risk of biasUnclearUnclearEggesbo (1999)High risk of biasLow risk of biasUnclearEller (2009)Low risk of biasLow risk of biasUnclearFalcao (2004)High risk of biasLow risk of biasUnclearFrongia (2005)High risk of biasLow risk of biasUnclearGerrard (1973)High risk of biasLow risk of biasUnclearGreenhawt (2009)High risk of biasLow risk of biasUnclearGrundy (2002)Low risk of biasLow risk of biasUnclearGrundy (2002)Low risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearHaahtela (1980)High risk of biasLow risk of biasUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasLow risk of bias | Branum (2009) | High risk of bias | Low risk of bias | Unclear |
| Chen (2011)Low risk of biasLow risk of biasUnclearChen (2012)Low risk of biasLow risk of biasUnclearConnett (2012)High risk of biasLow risk of biasUnclearDalal (2002)Low risk of biasUnclearUnclearEggesbo (1999)High risk of biasLow risk of biasUnclearEller (2009)Low risk of biasLow risk of biasHigh risk of biasEmmett (1999)High risk of biasLow risk of biasUnclearFalcao (2004)High risk of biasLow risk of biasUnclearFrongia (2005)High risk of biasLow risk of biasUnclearGenrard (1973)High risk of biasLow risk of biasUnclearGerenhawt (2009)High risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearHaahtela (1980)High risk of biasLow risk of biasUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasUnclearKatz (2010)Low risk of biasLow risk of biasUnclear | Brugman (1998) | High risk of bias | Unclear | Unclear |
| Chen (2012)Low risk of biasLow risk of biasUnclearConnett (2012)High risk of biasLow risk of biasUnclearDalal (2002)Low risk of biasUnclearUnclearEggesbo (1999)High risk of biasLow risk of biasUnclearEller (2009)Low risk of biasLow risk of biasUnclearEller (2009)Low risk of biasUnclearUnclearFalcao (2004)High risk of biasUnclearUnclearFrongia (2005)High risk of biasLow risk of biasUnclearGerard (1973)High risk of biasLow risk of biasUnclearGerenhawt (2009)High risk of biasLow risk of biasUnclearGrundy (2002)Low risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearHaahtela (1980)High risk of biasLow risk of biasUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasUnclearKagan (2003)Low risk of biasLow risk of biasUnclearKatz (2010)Low risk of biasLow risk of biasHigh risk of bias | Chen (2011) | Low risk of bias | Low risk of bias | Unclear |
| Connett (2012)High risk of biasLow risk of biasUnclearDalal (2002)Low risk of biasUnclearUnclearEggesbo (1999)High risk of biasLow risk of biasUnclearEller (2009)Low risk of biasLow risk of biasHigh risk of biasEmmett (1999)High risk of biasUnclearUnclearFalcao (2004)High risk of biasLow risk of biasUnclearFrongia (2005)High risk of biasLow risk of biasLow risk of biasGerrard (1973)High risk of biasLow risk of biasUnclearGreenhawt (2009)High risk of biasLow risk of biasUnclearGrundy (2002)Low risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearHaahtela (1980)High risk of biasLow risk of biasUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasUnclearKagan (2003)Low risk of biasLow risk of biasUnclearKatz (2010)Low risk of biasLow risk of biasUnclearKatz (2010)Low risk of biasLow risk of biasHigh risk of bias | Chen (2012) | Low risk of bias | Low risk of bias | Unclear |
| Dalal (2002)Low risk of biasUnclearUnclearEggesbo (1999)High risk of biasLow risk of biasUnclearEller (2009)Low risk of biasLow risk of biasHigh risk of biasEmmett (1999)High risk of biasUnclearUnclearFalcao (2004)High risk of biasLow risk of biasUnclearFrongia (2005)High risk of biasLow risk of biasLow risk of biasGelincik (2008)Low risk of biasLow risk of biasUnclearGerard (1973)High risk of biasLow risk of biasUnclearGreenhawt (2009)High risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearHaahtela (1980)High risk of biasLow risk of biasUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasUnclearJulge (2001)Low risk of biasLow risk of biasUnclearKatz (2010)Low risk of biasLow risk of biasUnclear | Connett (2012) | High risk of bias | Low risk of bias | Unclear |
| Eggesbo (1999)High risk of biasLow risk of biasUnclearEller (2009)Low risk of biasLow risk of biasHigh risk of biasEmmett (1999)High risk of biasUnclearUnclearFalcao (2004)High risk of biasLow risk of biasUnclearFrongia (2005)High risk of biasLow risk of biasLow risk of biasGelincik (2008)Low risk of biasLow risk of biasUnclearGerard (1973)High risk of biasLow risk of biasLow risk of biasGreenhawt (2009)High risk of biasLow risk of biasUnclearGrundy (2002)Low risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearHahtela (1980)High risk of biasLow risk of biasUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasUnclearJulge (2003)Low risk of biasLow risk of biasUnclearKatz (2010)Low risk of biasLow risk of biasUnclear | Dalal (2002) | Low risk of bias | Unclear | Unclear |
| Eller (2009)Low risk of biasLow risk of biasHigh risk of biasEmmett (1999)High risk of biasUnclearUnclearFalcao (2004)High risk of biasLow risk of biasUnclearFrongia (2005)High risk of biasLow risk of biasLow risk of biasGelincik (2008)Low risk of biasLow risk of biasUnclearGerrard (1973)High risk of biasHigh risk of biasLow risk of biasGreenhawt (2009)High risk of biasLow risk of biasUnclearGrundy (2002)Low risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearHaahtela (1980)High risk of biasLow risk of biasLow risk of biasHourihane (2007)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasLow risk of biasKatz (2010)Low risk of biasLow risk of biasLow risk of biasKatz (2010)Low risk of biasLow risk of biasHigh risk of bias | Eggesbo (1999) | High risk of bias | Low risk of bias | Unclear |
| Emmett (1999)High risk of biasUnclearUnclearFalcao (2004)High risk of biasLow risk of biasUnclearFrongia (2005)High risk of biasLow risk of biasLow risk of biasGelincik (2008)Low risk of biasLow risk of biasUnclearGerrard (1973)High risk of biasLow risk of biasUnclearGreenhawt (2009)High risk of biasLow risk of biasUnclearGrundy (2002)Low risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearHaahtela (1980)High risk of biasLow risk of biasUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasUnclearKagan (2003)Low risk of biasLow risk of biasUnclearKatz (2010)Low risk of biasLow risk of biasUnclear | Eller (2009) | Low risk of bias | Low risk of bias | High risk of bias |
| Falcao (2004)High risk of biasLow risk of biasUnclearFrongia (2005)High risk of biasLow risk of biasLow risk of biasGelincik (2008)Low risk of biasLow risk of biasUnclearGerrard (1973)High risk of biasHigh risk of biasLow risk of biasGreenhawt (2009)High risk of biasLow risk of biasUnclearGrundy (2002)Low risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearHaahtela (1980)High risk of biasLow risk of biasUnclearHourihane (2002)Low risk of biasLow risk of biasUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasUnclearJulge (2003)Low risk of biasLow risk of biasUnclearKatz (2010)Low risk of biasLow risk of biasUnclearKatz (2010)Low risk of biasLow risk of biasUnclear | Emmett (1999) | High risk of bias | Unclear | Unclear |
| Frongia (2005)High risk of biasLow risk of biasLow risk of biasGelincik (2008)Low risk of biasLow risk of biasUnclearGerrard (1973)High risk of biasHigh risk of biasLow risk of biasGreenhawt (2009)High risk of biasLow risk of biasUnclearGrundy (2002)Low risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearHaahtela (1980)High risk of biasLow risk of biasLow risk of biasHourihane (2002)Low risk of biasLow risk of biasUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasUnclearKagan (2003)Low risk of biasLow risk of biasHigh risk of biasKatz (2010)Low risk of biasLow risk of biasUnclear | Falcao (2004) | High risk of bias | Low risk of bias | Unclear |
| Gelincik (2008)Low risk of biasLow risk of biasUnclearGerrard (1973)High risk of biasHigh risk of biasLow risk of biasGreenhawt (2009)High risk of biasLow risk of biasUnclearGrundy (2002)Low risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearHaahtela (1980)High risk of biasLow risk of biasLow risk of biasHost (2002)Low risk of biasLow risk of biasUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasLow risk of biasKagan (2003)Low risk of biasLow risk of biasUnclearKatz (2010)Low risk of biasLow risk of biasUnclearKatz (2010)Low risk of biasLow risk of biasHigh risk of bias | Frongia (2005) | High risk of bias | Low risk of bias | Low risk of bias |
| Gerrard (1973)High risk of biasHigh risk of biasLow risk of biasGreenhawt (2009)High risk of biasLow risk of biasUnclearGrundy (2002)Low risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearHaahtela (1980)High risk of biasLow risk of biasLow risk of biasHost (2002)Low risk of biasLow risk of biasUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasLow risk of biasKagan (2003)Low risk of biasLow risk of biasUnclearKatz (2010)Low risk of biasLow risk of biasUnclearKatz (2010)Low risk of biasLow risk of biasHigh risk of bias | Gelincik (2008) | Low risk of bias | Low risk of bias | Unclear |
| Greenhawt (2009)High risk of biasLow risk of biasUnclearGrundy (2002)Low risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearHaahtela (1980)High risk of biasLow risk of biasLow risk of biasHost (2002)Low risk of biasLow risk of biasUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasLow risk of biasKagan (2003)Low risk of biasLow risk of biasUnclearKatz (2010)Low risk of biasLow risk of biasUnclear | Gerrard (1973) | High risk of bias | High risk of bias | Low risk of bias |
| Grundy (2002)Low risk of biasLow risk of biasUnclearGupta (2011)High risk of biasLow risk of biasUnclearHaahtela (1980)High risk of biasLow risk of biasLow risk of biasHost (2002)Low risk of biasLow risk of biasUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasLow risk of biasKagan (2003)Low risk of biasLow risk of biasHigh risk of biasKatz (2010)Low risk of biasLow risk of biasUnclear | Greenhawt (2009) | High risk of bias | Low risk of bias | Unclear |
| Gupta (2011)High risk of biasLow risk of biasUnclearHaahtela (1980)High risk of biasLow risk of biasLow risk of biasHost (2002)Low risk of biasLow risk of biasUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasLow risk of biasKagan (2003)Low risk of biasLow risk of biasHigh risk of biasKatz (2010)Low risk of biasLow risk of biasUnclear | Grundy (2002) | Low risk of bias | Low risk of bias | Unclear |
| Haahtela (1980)High risk of biasLow risk of biasLow risk of biasHost (2002)Low risk of biasLow risk of biasUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasLow risk of biasKagan (2003)Low risk of biasLow risk of biasHigh risk of biasKajosaari (1982)Low risk of biasLow risk of biasUnclearKatz (2010)Low risk of biasLow risk of biasHigh risk of bias | Gupta (2011) | High risk of bias | Low risk of bias | Unclear |
| Host (2002)Low risk of biasLow risk of baisUnclearHourihane (2007)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasLow risk of biasKagan (2003)Low risk of biasLow risk of biasHigh risk of biasKajosaari (1982)Low risk of biasLow risk of biasUnclearKatz (2010)Low risk of biasLow risk of biasHigh risk of bias | Haahtela (1980) | High risk of bias | Low risk of bias | Low risk of bias |
| Hourihane (2007)Low risk of biasLow risk of biasUnclearHu (2010)Low risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasLow risk of biasKagan (2003)Low risk of biasLow risk of biasHigh risk of biasKajosaari (1982)Low risk of biasLow risk of biasUnclearKatz (2010)Low risk of biasLow risk of biasHigh risk of bias | Host (2002) | Low risk of bias | Low risk of bais | Unclear |
| Hu (2010)Low risk of biasLow risk of biasUnclearJulge (2001)High risk of biasLow risk of biasLow risk of biasKagan (2003)Low risk of biasLow risk of biasHigh risk of biasKajosaari (1982)Low risk of biasLow risk of biasUnclearKatz (2010)Low risk of biasLow risk of biasHigh risk of bias | Hourihane (2007) | Low risk of bias | Low risk of bias | Unclear |
| Julge (2001)High risk of biasLow risk of biasLow risk of biasKagan (2003)Low risk of biasLow risk of biasHigh risk of biasKajosaari (1982)Low risk of biasLow risk of biasUnclearKatz (2010)Low risk of biasLow risk of biasHigh risk of bias | Hu (2010) | Low risk of bias | Low risk of bias | Unclear |
| Kagan (2003)Low risk of biasLow risk of biasHigh risk of biasKajosaari (1982)Low risk of biasLow risk of biasUnclearKatz (2010)Low risk of biasLow risk of biasHigh risk of bias | Julge (2001) | High risk of bias | Low risk of bias | Low risk of bias |
| Kajosaari (1982)Low risk of biasLow risk of biasUnclearKatz (2010)Low risk of biasLow risk of biasHigh risk of bias | Kagan (2003) | Low risk of bias | Low risk of bias | High risk of bias |
| Katz (2010)Low risk of biasLow risk of biasHigh risk of bias | Kajosaari (1982) | Low risk of bias | Low risk of bias | Unclear |
| | Katz (2010) | Low risk of bias | Low risk of bias | High risk of bias |

EFSA supporting publication 2013:EN-506

58

| Study ID | (1) Method of diagnosis | (2) Sampling strategy: | (3) Explored reasons |
|---------------------------|-------------------------|------------------------|----------------------|
| | | method | for |
| | | | withdrawal/non- |
| | | | response |
| Keet (2012) | High risk of bias | Low risk of bias | Unclear |
| Kilgallen (1996) | High risk of bias | Unclear | Unclear |
| Kim (2011) | High risk of bias | Unclear | Unclear |
| Krause (2002) | Low risk of bias | Low risk of bias | Unclear |
| Kristjansson (1999) | Low risk of bias | High risk of bias | Unclear |
| Kucukosmanoglu (2008a) | High risk of bias | Unclear | Unclear |
| Kucukosmanoglu (2008b) | Low risk of bias | High risk of bias | Unclear |
| Kumar (2011) | High risk of bias | High risk of bias | Unclear |
| Lack (2003) | Low risk of bias | Low risk of bias | Unclear |
| Lao-araya (2012) | Low risk of bias | Low risk of bias | Unclear |
| Leung (2009) | High risk of bias | Low risk of bias | Unclear |
| Liu (2010) | High risk of bias | Low risk of bias | Unclear |
| Marrugo (2008) | High risk of bias | Low risk of bias | Unclear |
| Martinez-Gimeno (2000) | High risk of bias | Low risk of bias | Unclear |
| Morita (2012) | Low risk of bias | High risk of bias | Unclear |
| Mortz (2005) | Low risk of bias | Unclear | Unclear |
| Mustafayev (2012) | Low risk of bias | Unclear | Unclear |
| Nicolaou (2010) | Low risk of bias | Low risk of bias | Unclear |
| Obeng (2011) | High risk of bias | Unclear | Unclear |
| Oh (2004) | High risk of bias | Low risk of bias | Unclear |
| Orhan (2009) | Low risk of bias | Low risk of bias | Unclear |
| Osborne (2011) | High risk of bias | High risk of bias | Unclear |
| Ostblom (2008a) | Low risk of bias | Unclear | Unclear |
| Ostblom (2008b) | High risk of bias | Unclear | Unclear |
| Osterballe (2005) | Low risk of bias | Low risk of bias | Unclear |
| Osterballe (2009) | High risk of bias | Low risk of bias | Unclear |
| Pereira (2005) | High risk of bias | Low risk of bias | Low risk of bias |
| Pyrhonen (2009) | High risk of bias | Low risk of bias | Unclear |
| Rance (2005) | High risk of bias | Low risk of bias | Unclear |
| Ro (2012) | High risk of bias | Unclear | Unclear |
| Roberts (2005) | High risk of bias | Low risk of bias | Unclear |
| Ronchetti (2008) | High risk of bias | Low risk of bias | Unclear |
| Saarinen (1999) | | High risk of bias | High risk of bias |
| Sai (2011) | Low risk of bias | Low risk of bias | Unclear |
| Sakellariou (2008) | High risk of bias | Unclear | Unclear |
| Santadusit (2005) | High risk of bias | Low risk of bias | Unclear |
| Schafer (1999) | High risk of bias | High risk of bias | Unclear |

59

| Study ID | (1) Method of diagnosis | (2) Sampling strategy: | (3) Explored reasons |
|------------------|-------------------------|------------------------|----------------------|
| | | method | for |
| | | | withdrawal/non- |
| | | | response |
| Schafer (2001) | High risk of bias | Low risk of bias | Unclear |
| Schrander (1993) | Low risk of bias | Low risk of bias | Low risk of bias |
| Shek (2010) | High risk of bias | Low risk of bias | Unclear |
| Sicherer (1999) | High risk of bias | Low risk of bias | Low risk of bias |
| Sicherer (2003) | High risk of bias | Low risk of bias | Low risk of bias |
| Sicherer (2004) | High risk of bias | Low risk of bias | Low risk of bias |
| Sicherer (2010) | High risk of bias | Low risk of bias | Unclear |
| Soller (2012) | High risk of bias | Low risk of bias | High risk of bias |
| Tariq (1996) | Low risk of bias | Low risk of bias | Low risk of bias |
| Touraine (2002) | High risk of bias | High risk of bias | Unclear |
| Venter (2006) | Low risk of bias | Low risk of bias | Low risk of bias |
| Venter (2008) | Low risk of bias | Low risk of bias | Unclear |
| Vierk (2007) | High risk of bias | Low risk of bias | Low risk of bias |
| Wan (2012) | Low risk of bias | Unclear | Unclear |
| Woods (1998) | High risk of bias | Low risk of bias | Unclear |
| Woods (2002) | Low risk of bias | High risk of bias | Unclear |
| Wu (2012) | High risk of bias | Low risk of bias | Unclear |
| Young (1994) | High risk of bias | Low risk of bias | High risk of bias |
| Zannikos (2008) | High risk of bias | Unclear | Unclear |
| Zuberbier (2004) | Low risk of bias | Low risk of bias | Unclear |

 Low risk of bias = food challenges (open or double-blind) with or without clinical history or sensitisation (skin prick test and/or serum-specific IgE) with clinical history; High risk of bias = Sensitisation (skin prick test and/or serum specific IgE) without clinical history, clinical history alone, clinician diagnosed or self-report.

(2) Low risk of bias = whole population, random; High risk of bias = non-random.

(3) Low risk of bias = reasons for non-response or withdrawal/loss to follow-up explored; High risk of bias = reasons for non-response or withdrawal/loss to follow-up not explored.

1.2.5. Further information about diagnostic procedures employed by all studies

Table 1.7: Further information about questionnaire-based methods employed by studies

| Study ID | Self-report | Clinician diagnosed | Clinical history |
|--------------------|--|--|------------------|
| Al- Hammadi (2010) | Not applicable | Questions regarding allergic disease and atopic family history were asked through a questionnaire for parents to complete. A child was considered to have food allergy or other allergic illness only if it was diagnosed by a physician. | Not applicable |
| Altintas (1995) | Not applicable | The diagnosis of cow's milk allergy was based on a) the presence of symptoms in response to a diet containing cow's milk, b) the disappearance of symptoms upon withdrawal of cow's milk, and c) at least two positive milk challenges. | Not applicable |
| Babu (2008) | A detailed case history was taken based on a structured questionnaire containing information regarding demographics, age at onset of disease and the present allergic status. In addition type of complaints, allergy to other foods and/or pollens and insects, and duration of onset of allergic symptoms after ingestion of the offending food were taken. | Not applicable | Not applicable |

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Self-report | Clinician diagnosed | Clinical history |
|--------------------|--|---|--|
| Ben-Shoshan (2010) | A standardised questionnaire developed | Confirmed allergy only if one of the following | A convincing history of an IgE-mediated |
| | previously by Sicherer et al (1999; 2004) to | was fulfilled: a) Convincing history of an IgE- | reaction to a specific food was defined as a |
| | determine the general population prevalence of | mediated reaction attributed to food and | minimum of 2 mild signs/symptoms or 1 |
| | peanut, tree nut, fish, and shellfish allergy in the | physician confirmation of a positive SPT, serum | moderate or 1 severe sign/symptom that was |
| | United States, and modified it to incorporate | food-specific IgE >0.35 kU/L or a positive food | likely IgE-mediated and occurred within 120 |
| | questions regarding sesame allergy | challenge. b) Never exposed to the food or had | minutes after ingestion or contact (or inhalation |
| | | an uncertain history of an IgE-mediated reaction | in the case of fish and shellfish). Reactions were |
| | | and physician confirmation of a positive SPT | classified as mild, moderate or severe based on |
| | | and a food-specific IgE above previously | the same criteria outlined for Ben-Shoshan |
| | | published thresholds (i.e., >15 kU/L for peanut | 2010. |
| | | and tree nut and $>20 \text{ kU/L}$ for fish) or a positive | |
| | | SPT and a positive food challenge or a positive | |
| | | food challenge alone | |
| Bock (1987) | At each visit to the clinic, parents were asked to | Not applicable | Not applicable |
| | complete a dietary questionnaire that inquired | | |
| | about the infant's current diet and whether any | | |
| | adverse reactions to foods had been noted. The | | |
| | parents were also asked about any restrictions | | |
| | on the child's diet. | | |
| Brugman (1998) | A questionnaire on food hypersensitivity was | Not applicable | Not applicable |
| | mailed to parents. Once completed this was then | | |
| | checked by the school physician or nurse, where | | |
| | some aspects of the child's health were added | | |
| | based on school records of absence, medicinal | | |
| | use, medical treatment and overall health | | |
| | evaluation. | | |
| Chen (2011) | Not applicable | Not applicable | Information collected by questionnaire about |
| | | | medical history of adverse reactions to foods |
| | | | and fisk factors, such as derivery, feeding |
| | | | pattern, family history of allergy, and other |
| | | | allergic co-morbidities |

| Study ID | Self-report | Clinician diagnosed | Clinical history |
|----------------|--|---|---|
| Dalal (2002) | Not applicable | Not applicable | Information was obtained from patient medical records at the family health centre, and from the family health centre staff, including nurses and dieticians. |
| Eggesbo (1999) | The parents of infants were asked to complete a self-administrered questionnaire on the maternity ward. Further information was collected by postal questionnaire every 6 months until the child reached the age of two. The operational definition of the outcome, parentally perceived reactions to food, was based on the question 'does the child react to any food items?'. Possible symptoms were listed for parents to mark of what symptoms the child had experienced. | Not applicable | Not applicable |
| Emmett (1999) | Identification of food allergies suffered within the household. | Not applicable | Questions on source of diagnosis, doctor consultation, number of reactions, age at first reaction, type of contact with peanuts causing the reactions, amount of peanuts taken, symptoms occurring, medication taken, and hospitalisation if necessary |
| Falcoa (2004) | Participants completed a large questionnaire as part of an on-going health and nutrition survey of residents of Porto. | Not applicable | Not applicable |
| Frongia (2005) | Not applicable | An interview with the parents of the children was carried out with a healthcare professional, guided by a questionnaire. Food allergy was only included when it had been diagnosed by a doctor. | Not applicable |

| Study ID | Self-report | Clinician diagnosed | Clinical history |
|------------------|--|---------------------|--|
| Gelinick (2008) | An initial screening questionnaire contained two questions relating to foods, those who disclosed food-related complaints were called once more and a similar questionnaire was repeated. Those suspected of having a food allergy were invited for a personal investigation at the clinic. | Not applicable | Not applicable |
| Gerrard (1973) | Not applicable | Not applicable | Case histories were obtained by a nurse and included the following data: the age, marital status and ethnic origin of the parents; the prevalence in parents and siblings of a history of eczema, hay fever, urticaria, recurrent bronchitis, allergies to food/drugs, enuresis and recurrent headaches; and the attitudes of parents and siblings to milk. Additional medical records and follow up examinations were taken at each age. |
| Greenhawt (2009) | Questions asked about the occurence of a specific allergic reaction, the symptoms and foods attrituable to the reaction, emergency medications maintained. | Not applicable | Not applicable |
| Grundy (2002) | Parents of children completed a questionnaire asking information about past and current atopic symptoms on the basis of the ISAAC questionnaire. | Not applicable | Not applicable |
| Gupta (2011) | Not applicable | Not applicable | A convincing food allergy based on self report in conjunction with one or more of the following reaction symptoms: anaphylaxis, angioedema, coughing, other oropharyngeal symptoms, eczema, flushing, hives, low blood pressure, pruritus, trouble breathing, vomiting, or wheezing. A confirmed food allergy also included report of physician-diagnosis with serum-specific immunoglobulin E testing, skin prick testing, or an oral food challenge |

| Study ID | Self-report | Clinician diagnosed | Clinical history |
|------------------|---|---|---|
| Host (2002) | Not applicable | Not applicable | The diagnosis of CMPA/CMPI was established by the following, generally accepted, criteria; definite disappearance of symptoms after each of two dietary eliminations of cow's milk and cow's milk products; recurrence of identical symptoms after one challenge; exclusion of lactose intolerance and coincidental infection |
| Kajosaari (1982) | Information was obtained from the mothers by questionnaire. The family history of atopy, the child's possible atopic symptoms and signs, duration of breast feeding, and the introduction age for fish, citrus and eggs were recorded. The history was confirmed and checked by telephone interviews whenever symptoms or signs of atopy were suspected. | Not applicable | Not applicable |
| Katz (2010) | Initial contact made by telephone interview in 95.8% infants and by questionnaire for the remaining 4.2% | Not applicable | Sixty-six infants were given diagnoses of IgE- cow's milk allergy, forty-eight fulfilled all criteria, including suggestive history of an immediate response, a positive SPT response, and a positive challenge result to cow's milk protein. Common symptoms of IgE-mediated cow's milk allergy were cutaneous reactions, including urticarias, angioedema and pruritus, followed by gastrointestinal and respiratory symptoms. |
| Kilgallen (1996) | An interview-assisted questionnaire was designed for use with parents. It contained four sections and covered the presence or absence of perceived food allergy, symptoms, foods implicated and infant feeding history. | Not applicable | Not applicable |
| Kim (2011) | Not applicable | Food allergy was defined as a convincing history of reproducible symptoms within 2 hours after ingestion of single food | Not applicable |

| Study ID | Self-report | Clinician diagnosed | Clinical history |
|---------------------------|---|---------------------|--|
| Kristjansson (1999) | A questionnaire was designed based on a questionnaire developed by the Allergology section of the Swedish Paediatric Association. It included 17 questions relating to the duration of breast feeding, food habits, symptoms relating to adverse food reactions, other manifestations of allergy and family atopic history. | Not applicable | Not applicable |
| Lack (2003) | Not applicable | Not applicable | Children identified up to 38 months old having peanut allergy, based on responses to questions about food avoidance and reactions to particular foods. Affected children were also identified from responses to questions on the questionnaire regarding previous hospitalizations and clinical investigations |
| Lao-araya (2012) | Parents were asked about the child's demographics, number of siblings, feeding history during infancy and the child's and family history of atopic disease. | Not applicable | Not applicable |
| Leung (2009) | Parents were asked about the occurrence and frequency of any AFR (adverse food reaction) in their children. 'Current' symptoms referred to symptoms in the past 12 months, whereas 'AFR ever' was defined as suffering from AFR in the subjects' life time | Not applicable | Not applicable |
| Marrugo (2008) | Questions were asked about personal data and occupation and personal history of atopic disease. | Not applicable | Not applicable |
| Martinez-Gimeno (2000) | Extension of the International Study of Asthma and Allergy in Children (ISAAC study) questionnaire. | Not applicable | Not applicable |
| Morita (2012) | Participants were screened for wheat allergy by a questionnaire-based examination. | Not applicable | Not applicable |

| Study ID | Self-report | Clinician diagnosed | Clinical history |
|-------------------|--|--|------------------|
| Mustafayev (2012) | Any person answering yes to the question 'did your child have any allergic complaint after any food intake within the last year' was contacted via telephone by a paediatrician trained in food allergy. | Not applicable | Not applicable |
| Obeng (2011) | The questionnaire included questions from the EuroPrevall study on the symptoms of adverse reactions to food (www.europrevall.org) | Not applicable | Not applicable |
| Oh (2004) | The Korean version of the ISAAC questionnaire was administered to the parents of the children and to the student themselves in middle schools. | Not applicable | Not applicable |
| Orhan (2009) | Questionnaire asking 'Has your child ever had an adverse reaction to any food within two hours following consumption?'. If the parent responded 'yes' then a further series of questions were asked to gain information about the reaction. | Not applicable | Not applicable |
| Ostblom (2008a) | Any of the following parentally reported symptoms related to ingestion of a certain food were defined as food allergy: asthma, itchy eyes and/or runny nose, oedema of lips/eyes, urticaria, eczema or vomiting/diarrhoea | Not applicable | Not applicable |
| Ostblom (2008b) | Parents asked to report on any reactions to foods experienced by their child | Parental report of doctor diagnosed food allergy | Not applicable |
| Osterballe (2009) | A questionnaire with the main question: 'do you suspect hypersensitivity to foods and/or drinks?' | Not applicable | Not applicable |
| Pereira (2005) | Questionnaires were completed by the parent and child and where a current adverse reaction to any food was stated, they were asked to describe the symptoms that they experienced. | Not applicable | Not applicable |

| Study ID | Self-report | Clinician diagnosed | Clinical history |
|--------------------|---|---|------------------|
| Pyrhonen (2009) | The baseline questionnaire asked structured | The definition of food allergy and food | Not applicable |
| | questions about the child's background and food | hypersensitivity was based on a diagnosis | |
| | allergy or hypersensitivity. Parents were asked | reached by a physician. | |
| | to indicate, per food, whether they never | | |
| | perceived symptoms, never tasted the foods, | | |
| | parents perceived allergy, physician diagnosed | | |
| | allergy, symptoms occurred in last 12 months | | |
| | and symptoms occurred more than 12 months | | |
| | ago. | | |
| Rance (2005) | A standard, anonymous questionnaire asked | Not applicable | Not applicable |
| | 'Has your child ever had an allergic reaction to | | |
| | food?' If 'Yes' parents were asked additional | | |
| | questions about clinical and treatment data and | | |
| | the results of allergy tests. | | |
| Saarinen (1999) | For the first 8 weeks mothers asked to record | Not applicable | Not applicable |
| | daily feeding regime and return the records. | | |
| | Also completed a questionnaire on parental | | |
| | atopy. | | |
| Sakellariou (2208) | A survey was conducted in the context of | Not applicable | Not applicable |
| | EUROPREVALL. | | |
| Santadusit (2005) | A 16-item food allergy questionnaire was | Not applicable | Not applicable |
| | answered by parents. Families reporting adverse | | |
| | food reactions were invited to participate in | | |
| | further diagnostic investigations. | | |
| Schafer (2001) | A computer-assisted standardised interview | Not applicable | Not applicable |
| | asked whether participants had allergic reactions | | |
| | to foods and if so the type of reaction was | | |
| | recorded in detail. The reported reactions were | | |
| | catergorised according to reaction site, | | |
| | furthermore history and doctor's diagnosis were | | |
| | recorded. | | |

| Study ID | Self-report | Clinician diagnosed | Clinical history |
|-----------------|---|---------------------|--|
| Schrander (1993 | A standard form was used by the four health care doctors for entering data concerning family history, symptoms and dietary interventions. | Not applicable | Family history regarding atopic disease as well as possible food intolerance in first and second degree relatives was recorded. When present for more than two weeks the following complaints were considered suspect for the presence of cow's milk protein intolerance: Symptoms, gastrointestinal, respiratory and cutaneous manifestations. Symptoms crying/colic were considered when present for more than two hours per day. |
| Shek (2010) | Survey conducted using a structured questionnaire used in the US population (Sicherer et al. 2003). | Not applicable | Reactions considered convincing if organ systems were affected and symptoms were typical of allergic reactions (skin: hives and angioedema; respiratory system: trouble breathing, wheezing, and throat tightness; gastrointestinal system: vomiting and diarrhoea) occurring within 2 hours of ingestion. |
| Sicherer (1999) | Not applicable | Not applicable | Telephone script with computerized algorithms. Reactions considered "convincing" if organ systems were affected and symptoms typical of allergic reactions (skin system: hives and angioedema; respiratory system: trouble breathing, wheezing, throat tightness; gastrointestinal system: vomiting and diarrhoea) occurring within 1 hour of ingestion |
| Sicherer (2004) | Not applicable | Not applicable | Telephone script with computerized algorithms. Screening questions, to identify individuals, additional questions administered depending on responses and included those regarding, severe reactions, lifetime recurrence, seafood related medical history. Algorithms categorised people into no allergy, physician diagnosed (self reported), convincing allergy (levels 1-4) and probable allergy (levels 1-3). |

| Study ID | Self-report | Self-report Clinician diagnosed Clini | | |
|-----------------|---|---------------------------------------|--|--|
| Sicherer (2010) | Not applicable | Not applicable | As reported for Sicherer et al. (1999) | |
| Soller (2012) | A cross-sectional telephone interview asked if anyone in the household had a food allergy, and to which foods. | Not applicable | Not applicable | |
| Tariq (1996) | Data was obtained on feeding, atopic disease, family history, parental smoking. Exposure to pets, housing conditions, and current illness from records. Questions about eating nuts were asked only at age 4 years. | Not applicable | Not applicable | |
| Touraine (2002) | Questionnaire distributed to schools for parents to answer. The questionnaire asked 'Does your child have a food allergy?'. If answered yes, further information was gathered about the types of symptoms, and the presence of allergies to pollen, house dust mites and mould. Also asked about family atopic disease and any treatment received. | Not applicable | Not applicable | |
| Venter (2006) | Parents completed a questionnaire, asking 'Does your child currently have a problem with any of the following foods? Milk, egg, peanut, tree nuts (e.g. almond, brazil), wheat, fish, sesame and other. If yes to any of the above foods, can you describe the problem' | Not applicable | Not applicable | |
| Woods (1998) | Participants completed detailed second phase ECRHS questionnaire administered by a trained interviewer. The questionnaire covered respiratory symptoms during the last 12 months, history of asthma, home and work environment, allergic symptoms, smoking, demographics, medications and dietary information. | Not applicable | Not applicable | |

| Study ID | Study ID Self-report Clinician diagnosed Clinica | | | |
|-----------------|---|---|----------------|--|
| Woods (2002) | Four questions relating to diet were asked in the | Not applicable | Not applicable | |
| | ECRHS questionnaire. The first three gathered | | | |
| | information on the amount of convenience-type | | | |
| | food and drinks consumed, the fourth asked | | | |
| | whether responders had ever suffered from any | | | |
| | illness/trouble from food ingestion. | | | |
| Wu (2012) | Not applicable | Self-administered questionnaire. Six reviewed | Not applicable | |
| | | and analysed questionnaire descriptions of | | |
| | | symptoms and records of physicians' | | |
| | | evaluations to distinguish food allergy from | | |
| | | non-immunologic adverse food reactions. Cases | | |
| | | diagnosed by clinicians and confirmed by | | |
| | | positive laboratory tests were enrolled as | | |
| | | definite cases. If symptoms occurred within | | |
| | | minutes diagnosis was presumed to be food | | |
| | | allergy on the basis of type I immediate | | |
| | | hypersensitivity reaction. Non-allergic food | | |
| | | hypersensitivity was usually characterized by a | | |
| | | delayed reaction, occurring hours or even days | | |
| | | after eating certain food. Allergic reactions did | | |
| | | not depend on the amount of ingested food, | | |
| | | whereas food intolerance worsened as more | | |
| | | food was consumed. | | |
| Young (1994) | Questions were about perceived connection | Not applicable | Not applicable | |
| | between food ingestion and allergic symptoms. | | | |
| Zannikos (2008) | A survey was conducted in the context of EUROPREVALL. | Not applicable | Not applicable | |

| Study ID | | Skin prick test | | | | fic IgE |
|---------------|---|--------------------------|--|-----------------------------------|---|----------------|
| | Method of determining positive test | Time to read response | Allergen for testing | Was cross-reactivity explored? | Method of determining positive test | Test used |
| Arbes (2005) | Wheal with mean diameter >3mm larger than the negative control | 15 minutes | Extracts Only house dust mite, cat, and short ragweed allergens were standardized | Not reported | Not applicable | Not applicable |
| Arshad (2001) | Wheal with mean diameter >3mm larger than the negative control | 15 minutes | Extracts Standardized extracts were used when available. All extracts were from Biodiagnostics (Reinbek, Germany) Histamine (0.1%) in phosphate buffered saline and physiologic saline as positive and negative controls, respectively | Not reported | Not applicable | Not applicable |
| Babu (2008) | Wheal with mean diameter >3mm | >15 minutes | Extracts Eggplant allergenic extracts, EE and EC, along with controls (positive: histamine dihydrochloride equivalent to 1 mg/mL histamine base, and | Not reported | Cut-off value twofold higher readings than those of normal subjects. Only those SPT positive tested | ELISA |

Table 1.8: Further information about skin-prick test and serum-specific IgE testing performed by studies

EFSA supporting publication 2013:EN-506
| Study ID | | ł | Skin prick test | | Serum Speci | Serum Specific IgE | |
|--------------------|--|--------------------------|--|-----------------------------------|---|--------------------|--|
| | Method of determining positive test | Time to read response | Allergen for testing | Was cross-reactivity explored? | Method of determining positive test | Test used | |
| | | | negative: 50% glycerinated PBS) were used for SPT | | | | |
| Bakos (2006) | Wheal with mean diameter >5mm | Not reported | Extracts Lofarma, Milan, Italy | Not reported | 0.35 kU/l (class 1) and above | Allergyscreen | |
| Ben-Shoshan (2009) | Wheal size greater than negative control | <15 minutes | Extracts Glycerinated peanut extract supplied by ALK-Abello (Hørsholm, Denmark) Prick-to-prick Children with convincing or uncertain history having a negative SPT response with commercial extract, test repeated with crude extract (i.e., peanut butter) | Not reported | Peanut specific IgE >15 kU/L those never or rarely ingested peanut or had an uncertain history Peanut-specific IgE >0.35 kU/L for those with a convincing history | CAP FEIA | |
| Bjornsson (1996) | Not applicable | Not applicable | Not applicable | Not applicable | > 0.35 kU/L for single allergens, only those with a positive reaction to the panel (fx5) were analysed for the single allergens | Pharmacia CAP | |

74

| Study ID | | | Skin prick test | Serum Specific IgE | | |
|------------------|---|--------------------------|--|-----------------------------------|--|-------------------|
| | Method of determining positive test | Time to read response | Allergen for testing | Was cross-reactivity explored? | Method of determining positive test | Test used |
| Branum (2009) | Not applicable | Not applicable | Not applicable | Not applicable | The range of detectable serum IgE levels was 0.35 to 1000 kU/L | ImmunoCAP 1000 |
| Chen (2011) | Wheal with mean diameter >3mm larger than the negative control | 15 minutes | Extracts GREER, Lenoir, NC, USA | Not reported | Not applicable | Not applicable |
| Dalal (2002) | Wheal with mean diameter >3mm | Not reported | Extracts Commercial extracts (Centre laboratories, Port Washington, NY, USA) | Not reported | Not applicable | Not applicable |
| Gelincik (2008) | Wheal with mean diameter >3mm | Not reported | Prick-to-prick | Not reported | Detection limit 0.35kU/L | Pharmacia CAP |
| Grundy (2002) | Wheal with mean diameter >3mm | 15 minutes | Unclear | Not reported | Not applicable | Not applicable |
| Haahtela (1980) | Not reported | >15 minutes | Not reported | Not reported | Not applicable | Not reported |
| Hourihane (2007) | Wheal with mean diameter >3mm | 15 minutes | Extracts ALK-Abello, Hungerford, UK | Not reported | Not applicable | Not applicable |
| Hu (2010) | Wheal with mean diameter >3mm | 15 minutes | Extracts Glycerinated food extract supplied by Greer Company | Not reported | Not applicable | Not applicable |

EFSA supporting publication 2013:EN-506

75

| Study ID | | ł | Serum Specific IgE | | | |
|--------------|---|--------------------------|--|-----------------------------------|--|------------|
| | Method of determining positive test | Time to read response | Allergen for testing | Was cross-reactivity explored? | Method of determining positive test | Test used |
| | | | (Taibei, China) | | | |
| Julge (2001) | Wheal with mean diameter >3mm | 15 minutes | Prick-to-prick Solu-prick SQ, ALK- Abello, Horsholm, Denmark | Not reported | Detection level was 0.5 standardised units per ml (SU/mL) corresponding to approx 0.09 paper RAST units (PRU) | Magic Lite |
| Kagan (2003) | Wheal with mean diameter >3mm larger than the negative control | <15 minutes | Extracts SPT performed by standard technique. Lots of glycerinated extract from the same manufacturer used throughout the study. Prick-to-prick When SPT response was negative and clinical history convincing or uncertain, SPT was repeated with crude extract | Not reported | Peanut-specific IgE >15 kU/L assumed allergic without a DBPCFC | CAP FEIA |
| Katz (2010) | Wheal with mean diameter >3mm | 20 minutes | SPTs were done to CMP, soy, a negative control, and histamine (1mg/mL; ALK-Abello, Port Washington, NY) | | | |

EFSA supporting publication 2013:EN-506

| Study ID | | | Skin prick test | | Serum Speci | Serum Specific IgE | |
|---------------------------|---|--------------------------|--|-----------------------------------|--|---|--|
| | Method of determining positive test | Time to read response | Allergen for testing | Was cross-reactivity explored? | Method of determining positive test | Test used | |
| Keet (2012) | Not applicable | Not applicable | Not applicable | Not applicable | A specific IgE level of at least 0.35 kU/L to milk, egg, or peanut. | ImmunoCAP 1000 | |
| Krause (2002) | Not applicable | Not applicable | Not applicable | Not applicable | The cut off for a positive reaction was set at ≥0.7 kU/L | Pharmacia CAP | |
| Kristjansson (1999) | Wheal with mean diameter >3mm | >15 minutes | Prick-to-prick | Not reported | Not applicable | Not applicable | |
| Kucukosmanoglu (2008a) | Wheal with mean diameter >3mm | 15 minutes | Extracts code no: 0145, STAL- LARGENES, France | Not reported | Not applicable | Not applicable | |
| Kucukosmanoglu (2008b) | Wheal with mean diameter >3mm | >15 minutes | Extracts Standardised allergen extracts from whole CM extract (Hollister- Stier Laboratories USA) | Not reported | Not reported | Pharmacia CAP | |
| Kumar (2011) | Not applicable | Not applicable | Not applicable | Not applicable | Sensitisation defined as $sIgE \ge 0.35 \text{ kUA/L}$ at 2-year visit for egg white, cow's milk, peanut, soy, shrimp, walnut, wheat, and cod. Number of food sensitisations for each | ImmunoCAP at Quest Diagnostics (Madison, NJ) | |

| Study ID | | £ | Serum Specif | Serum Specific IgE | | |
|----------|---|--------------------------|----------------------|-----------------------------------|--|-----------|
| | Method of determining positive test | Time to read response | Allergen for testing | Was cross-reactivity explored? | Method of determining positive test | Test used |
| | | | | | subject was categorised as 0 (reference) 1 or 2 or >= 3 foods. Peanut sIgE levels were dichotomised at >= 5 kUA/L, a level associated with greater likelihood of clinical reactivity among children 1 to 5 years. Milk and egg sIgE levels were dichotomised as 5 and 2 kUA/L, respectively, corresponding to 95th percentile positive predictive values for children <= 2 years of age. These cut off points, rather than those for children > 5 years of age (15 kVA/L for milk and 7 kUA/L for egg) were chosen due to the ages of children in the cohort. For assessment of cut off points, the control group included all children with lavels | |

| Study ID | | S | Skin prick test | | Serum Specific IgE | |
|-------------|---|--------------------------|---|-----------------------------------|---|-------------------|
| | Method of determining positive test | Time to read response | Allergen for testing | Was cross-reactivity explored? | Method of determining positive test | Test used |
| | | | | | below the cut off points | |
| Lack (2003) | Wheal with mean diameter >3mm | 15 minutes | Extracts Skin testing was performed with peanut (concentration, 1:20 [wt/vol] in 50 percent glycerol) (Soluprick, ALK-Abelló) | Not reported | Not applicable | Not applicable |
| Liu (2010) | Not applicable | Not applicable | Not applicable | Not applicable | The following 95% predictive levels have been proposed, based on positive predictive values for clinical reactivity: egg, 7 kU/L; milk, 15 kU/L; and peanut, 14 kU/L.1 Clinical studies determined that 95% predictive levels differ for young children (i.e., <2 years old): egg, 2 kU/L14; milk, 5 kU/L.15 There is a lack of data correlating outcomes of allergy for shrimp with IgE levels, and thus no well established IgE cut off point for likely shrimp | ImmunoCAP 1000 |

| Study ID | | i | Skin prick test | | Serum Speci | Serum Specific IgE | |
|-------------------|---|--------------------------|---|-----------------------------------|---|--------------------|--|
| | Method of determining positive test | Time to read response | Allergen for testing | Was cross-reactivity explored? | Method of determining positive test | Test used | |
| | | | | | allergy. Therefore, shrimp was treated in accordance with the typical patterns described, using a threshold of 5 kU/L. | | |
| Morita (2012) | Wheal with mean diameter >3mm | >15 minutes | Extracts Wheat and bread extract | Not applicable | CAP > 0.35 kUA/L | ImmunoCAP | |
| Mortz (2005) | Not applicable | Not applicable | Not applicable | Not applicable | A serum level > 0.35 kU/l (corresponding to class 1) for specific IgE was considered positive | CAP FEIA | |
| Mustafayev (2012) | Wheal with mean diameter >3mm | Not reported | Prick-to-prick | Not reported | Not reported | Pharmacia CAP | |
| Nicolaou (2010) | Wheal with mean diameter >3mm larger than the negative control | 15 minutes | Extracts Hollister-Stier Laboratories | Not reported | sIgE ≥0.2 kUa/L | ImmunoCAP | |
| Orhan (2009) | Wheal with mean diameter >3mm | 15 minutes | Extracts SPT carried out with commercially available extracts of standard food allergens (Allergopharma, | Not reported | Not applicable | Not applicable | |

| Study ID | | S | Skin prick test | | Serum Specific IgE | |
|-------------------|---|--------------------------|---|--|---|---|
| | Method of determining positive test | Time to read response | Allergen for testing | Was cross-reactivity explored? | Method of determining positive test | Test used |
| | | | Reinbek, Germany) Prick-to-prick Sensitisation to fresh fruits or vegetables or beef was tested using prick-to-prick testing | | | |
| Osborne (2011) | Wheal with mean diameter >3mm | Not reported | Extracts ALK, Madrid | Not reported | Not applicable | Not applicable |
| Ostblom (2008a) | Not applicable | Not applicable | Not applicable | Not applicable | An IgE antibody level ≥0.35 kUA/L was considered positive. Serum samples scoring positive for fx5® were further analyzed towards the individual allergens included in the mix | ImmunoCAP |
| Osterballe (2005) | Wheal with mean diameter >3mm larger than the negative control | 15 minutes | Prick-to-prick Skin prick test was performed by the prick-prick technique using a selected panel of fresh unprocessed foods | Yes, and reported both primary allergy (allergy independent of pollen sensitisation) and secondary allergy (reactions to pollen related fruit and vegetables in pollen sensitised | Measurable specific IgE was classified as a positive test result (ML > 1.43 SU/ml, CAP > 0.35 kUA/l) | Pharmacia CAP Adults and siblings only. Magic Lite 3 year olds, adults and siblings |

81

| Study ID | | | Skin prick test | | Serum Speci | Serum Specific IgE | |
|-------------------|---|--------------------------|---|--|---|--------------------|--|
| | Method of determining positive test | Time to read response | Allergen for testing | Was cross-reactivity explored? | Method of determining positive test | Test used | |
| | | | | individuals) | | | |
| Osterballe (2009) | Wheal with mean diameter >3mm | 15 minutes | Prick-to-prick Skin prick test was performed with the suspected food (fresh unprocessed foods) | Primary food allergy defined as being independent of pollen sensitisation, whereas secondary food allergy was defined as reactions to pollen related fruits and vegetables in pollen allergic patients. Food allergy included both immunoglobulin E (IgE)- and non-IgE-mediated reactions. | Not applicable | Not applicable | |
| Pereira (2005) | Wheal with mean diameter >3mm | >15 minutes | Not reported | Wheat and grass cross- reactivity in 72/80 15 year olds and 76/80 11 year olds | Not applicable | Not applicable | |
| Ro (2012) | Wheal with mean diameter >3mm larger than the negative control | 15 minutes | Extracts SPT allergen extracts were purchased from Soluprick® (ALKAbello, Copenhagen, Denmark) Prick-to-prick For SPTs to milk, | Not reported | The reference value for total IgE in two-year- old children, specified by the manufacturer, was 0–45 kU/L. The detection limit for sIgE tests was 0.1 kU/L. Concentrations of 0.35 kU/L or above were regarded as positive | Immulite 2000 | |

EFSA supporting publication 2013:EN-506

82

| Study ID | | ſ | Skin prick test | | Serum Specific IgE | |
|------------------|---|--------------------------|--|---|---|----------------|
| | Method of determining positive test | Time to read response | Allergen for testing | Was cross-reactivity explored? | Method of determining positive test | Test used |
| | | | undiluted fresh skimmed milk was used. | | | |
| Roberts (2005) | Wheal with mean diameter >3mm | <15 minutes | Not reported | Not reported, although recognised as a potential limitation within the discussion | Not applicable | Not applicable |
| Ronchetti (2008) | Wheal with mean diameter >3mm | <15 minutes | Not reported | Not reported | Serum studies are mentioned in the methodology however no raw data has been presented | Not reported |
| Schafer (1999) | Wheal with mean diameter >3mm >2mm | >15 minutes | Not reported | Not reported | Not applicable | Not applicable |
| Schafer (2001) | Wheal with mean diameter >3mm >2mm | >15 minutes | Unclear | Not reported | Not applicable | Not applicable |
| Tariq (1996) | Wheal with mean diameter >3mm | >15 minutes | Not reported | Not reported | Not applicable | Not applicable |
| Venter (2006) | Wheal with mean diameter >3mm | 15 minutes | Extracts Conducted with commercially prepared extracts of technically optimized standard allergens (Soluprick | Cross-reactivity was explored between grass and wheat. If a participant tested positive to wheat and grass but ate wheat without problem, this was | Not applicable | Not applicable |

EFSA supporting publication 2013:EN-506

| Study ID | | | Skin prick test | | Serum Specific IgE | |
|------------------|---|--------------------------|--|---|---|-------------------|
| | Method of determining positive test | Time to read response | Allergen for testing | Was cross-reactivity explored? | Method of determining positive test | Test used |
| | | | SQ allergens-ALK Allergologisk Laboratorium A/S, Horsholm, Denmark) to a predefined panel of foods (milk, egg, wheat, cod fish, peanut and sesame) and to additional foods reported to be a problem. Prick-to-prick In the case of fruits and vegetables, prick-to- prick testing to the fresh product was conducted | defined as cross-reactivity and not reported as wheat allergy/sensitisation | | |
| Venter (2008) | Wheal with mean diameter >3mm | Not reported | Not reported | Not reported | Not applicable | Not applicable |
| Wan (2012) | Not applicable | Not applicable | Not applicable | Not applicable | Not reported | ImmunoCAP RAST |
| Woods (2002) | Wheal with mean diameter >3mm | >15 minutes | Not reported | Not reported | Not applicable | Not applicable |
| Zuberbier (2004) | Wheal with mean diameter >3mm | Not reported | Prick-to-prick | Not reported | Not reported | Pharmacia CAP |

| Study ID | Time-frame for monitoring reactions | Active and placebo food carriers | Dosing schedule | Method of determining positive test | Total food to be ingested | Additional information |
|--------------------|--|-------------------------------------|---|--|--|------------------------|
| Ben-Shoshan (2009) | See Kagan 2003 | See Kagan 2003 | See Kagan 2003 | See Kagan 2003 | See Kagan 2003 | See Kagan 2003 |
| Bock (1987) | Not reported | Not reported | Initial amount given was less than parents thought would produce a reaction, amounts then increased until a reaction was produced | Not reported | Not reported | Not reported |
| Chen (2011) | 15-20 minute intervals | Not reported | Cow's milk challenge; a drop of ordinary formula/milk was put on the lips at first. If no reaction after 20 min, the dose increased stepwise (1.0, 2.0, 5.0, 10, 20, 40, 80–120/150 ml). In the egg challenge, boiled egg was used, and 1/16 of yolk/white (depending on the SPT or history, or else started with yolk then followed by white) were the starting dose and the amount doubled every 20 min (1/16, 1/8, 1/4, 1/2) | Observed for at least 2h after last dose. Parents reported any symptoms occurring within the 3 days after challenge. Food allergy confirmed if evidence of an unequivocal allergic reaction i.e. urticaria, angioedema, vomiting, diarrhoea, acute eczema flare up, or respiratory and cardiovascular symptoms during the challenge procedure. Parents of those demonstrating no reactions on test day were asked to the research paediatrician by phone daily for 3 days, if suspicious reactions were reported, the child should return to hospital immediately | Highest dose administered was the normal daily intake of the food in question, adjusted for the age of the children | Not reported |

Table 1.9: Further information about food challenge procedures performed by studies

EFSA supporting publication 2013:EN-506

| Study ID | Time-frame for monitoring reactions | Active and placebo food carriers | Dosing schedule | Method of determining positive test | Total food to be ingested | Additional information |
|-----------------|--|--|---|--|------------------------------|--|
| Chen (2012) | 2 hours | Not reported | Not reported | Not reported | Not reported | Not reported |
| Eller (2009) | Not reported, although did classify late reactions as those >2 hours and monitored for late reactions via telephone interview | DBPCFC was performed with peanut, shrimp, cow's milk and hen's egg, all masked as previously described (see Osterballe, 2005). Vehicle foods were used as placebo reference | Administered in increasing doses according to guidelines | Not reported | Not reported | The standardized open food challenge was performed in all children 3 years of age. The double-blind placebo- controlled food challenge was performed in children >3 years of age |
| Gelincik (2008) | 2-12 hours depending on patient history | Peppermint oil, pure cacao powder, cereal flakes, wheat flour, lemon juice, honey, sugar, mashed potato, milkshake, rice- pudding, carob, cinnamon and various vegetables | Not reported | Not reported | Not reported | Not reported |
| Grundy (2002) | Observed for 15 minutes for any symptoms, if no reaction an oral challenge (stage 2) was performed | Increasing amounts of peanut butter spread on bread or a flapjack biscuit that contained peanut were given | Offered a portion containing 0.25 g of peanut, then 0.5 g, 1 g, 2 g, and 4.25 g (total 8 g) | Not reported | 8g | Not reported |

| Study ID | Time-frame for monitoring reactions | Active and placebo food carriers | Dosing schedule | Method of determining positive test | Total food to be ingested | Additional information |
|------------------|--|---|---|--|---|------------------------|
| Host (2002) | Varied within in age groups | Not reported | Not reported | Not reported | Not reported | Not reported |
| Hourihane (2007) | 30 minutes | Peanut flour-based biscuits, prepared in Southampton by an experienced dietician (K.E.C.G.) | 1 mg, 10 mg, 100 mg, 1 g, and 5 g | Identification of an objective allergic reaction with clinical signs or completion of the full challenge with no such signs up to 2 hours after the last dose | 5g | Not reported |
| Hu (2010) | 2 hours | Not reported | 0.5, 1.0, 2.0, 5.0, 10, 20, 40, 80, 100, 150 mL | Respiratory rate, heart rate, blood pressure and any symptoms | Usual dietary weight | Not reported |
| Kagan (2003) | 15-30 minutes | Peanut flakes served as the source of peanut, and cracker crumbs served as the placebo. The peanut and placebo were disguised with either applesauce or grape jelly, depending on preference | Challenges started with 10 mg of either peanut or placebo, if tolerated, the dose was increased to 25 mg, 50 mg, 100 mg, 250 mg, 500mg, 1 g, and 2.5 g | A challenge was considered positive if at least 2 of the mild manifestations described previously as characterizing a convincing clinical history (i.e.; involving only pruritus, urticaria, flushing, or rhinoconjunctivitis) or at least 1 of the moderate (i.e. involving angioedema, throat tightness, gastrointestinal complaints, or breathing difficulties (other than wheeze)) or severe manifestations occurred | If 2.5 g of peanut was tolerated, 14 g was administered in an open challenge | Not reported |
| Kajosaari (1982) | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported |
| Katz (2010) | 2 weeks | Not reported | Increasing doses of Materna infant formula, 1:10 diluted formula 1.0mL (2.7mg of CMP) up to 120mL (3.24g of | Not reported | Not reported | Not reported |

| Study ID | Time-frame for monitoring reactions | Active and placebo food carriers | Dosing schedule | Method of determining positive test | Total food to be ingested | Additional information |
|---------------------------|--|---|--|---|--|---|
| | | | CMP) every 30 minutes | | | |
| Kucukosmanoglu (2008b) | Min 4 hours | Not reported | Not reported | Not reported | Not reported | Not reported |
| Lack (2003) | Not reported | Not reported | Use of graded doses until a reaction or 8 g of dry-weight equivalent had been consumed | Not reported | 8g of dry-weight equivalent, followed by an open challenge with a peanut butter sandwich in the case of a negative result | Not reported |
| Lao-araya (2012) | Min 4hours | Not reported | Not reported | Not reported | Not reported | Not reported |
| Mortz (2005) | 2 hours | Chocolate bar | 0.16, 0.32, 1.28, 2.56, 5.12, 10.24, 30.50g | Followed EAACI guidelines | 50g | Not reported |
| Mustafayev (2012) | 20 minute intervals | Not reported | Not reported | Not reported | Not reported | Not reported |
| Nicolaou (2010) | 30 minute intervals for open challenges. DBPCFC lasted 8 hours (including the 2-hour observation period after the administration of the final dose) | Peanut concealed in brownies for open challenges | 10 mg, 100 mg, 1 g, and 5 g peanut protein for open and DBPC challenges | Challenge was considered positive after development of at least 2 objective signs i.e. skin rash, sneezing, vomiting, cough, wheeze, >20% fall in FEV1 | 5g | Sensory evaluation by individuals not participating in the study confirmed no differences between placebo and active brownies could be detected |
| Orhan (2009) | Negative DBPCFCs were followed by open challenges. Duration between a | A wide variety of foods were used to mask the active doses. All active and | 15 minutes | DBPCFC were considered positive if a single or a combination of the clinical reactions, including cutaneous | The titrated doses used for hazelnut, peanut, walnut, | Not reported |

| Study ID | Time-frame for monitoring reactions | Active and placebo food carriers | Dosing schedule | Method of determining positive test | Total food to be ingested | Additional information |
|-------------------|---|---|-----------------------|--|--|------------------------|
| | 0 | | | * | 8 | |
| | monitoring reactions negative DBPCFC and open challenge was 2 hours. In the open challenge, patients received a larger quantity of food (a meal-size portion for age) | food carriers placebo foods were as similar as possible in colour, flavour- taste, consistency, and texture so as not to be differentiated by the patients | | (eruption, itching, rash, swelling), nasal (sneezing, itching, secretion, blockage), ocular (redness, itching, secretion), bronchial (cough, wheezing, shortness of breath), gastrointestinal (vomiting, diarrhoea), laryngeal (difficulty in swallowing, difficulty in speaking), cardiovascular (tachycardia, hypotension), and other (sweating, pallor, fainting, loss of consciousness) symptoms were noted | ingested chickpea, and corn was of the same magnitude: 0.1, 0.3, 0.6, 1.5, 2.5, 5, and 15 g, in total 25 g of the respective food. The dose steps for cow's milk were 5, 10, 40, 75, and 150 mL, in total 280 mL; 0.1, 0.3, 0.6, 1.5, 2.5, 5, 15, and 25 g for hen's egg, kiwi fruit, banana, and tomato, in total 50 g; 1, 2, 5, 7, and 10 g for cocoa, in total 25 g; 1, 2, 7, 15, 25, and 50 g for beef and fish, in total 100 g; and 0.1, | information |
| | | | | | 0.3, 0.6, 1.5, 2.5, and 5 g for black | |
| | | | | | pepper, in total | |
| | | | | | 10 g | |
| Osterballe (2005) | The dose interval was | Codfish, hazelnut, | The titrated doses of | Not reported | 63.5g (unclear, | The open |
| | 15 minutes. A positive | peanut and walnut | codfish were: 125, | | but appears to be | controlled |

| Study ID | Time-frame for | Active and placebo | Dosing schedule | Method of determining | Total food to be | Additional |
|-------------------|--|---|--|-----------------------|---|--|
| | monitoring reactions | food carriers | | positive test | ingested | information |
| | challenge was divided into immediate or late reactions. The immediate reactions were defined as a reaction taking place within 2 h after the last dose administered, whereas late reactions occurred between 2 and 24 h after the last dose. All participants with a positive outcome in food challenge were examined for late reactions by telephone interview and reported symptoms were subsequently verified/excluded by clinical examination | were masked in chocolate bars with basic ingredients of margarine, dark chocolate, salt, icing sugar, oat grains, soy flour, oat flour and mint. Cow's milk and hen's egg were masked in a coloured cup (with top) with basic ingredients of sugar, cocoa, vanilla sugar and oat drink (placebo).Challenge with additives comprised the same type of candy as suspected by the participants; i.e. containing natural dyes [carmine (E120), turmeric (E100), copper chlorophyll (E141) | 250, 1000, 2000, 4000, 8000 and 23,750 mg of codfish, in total 39 g, whereas the doses used for hazelnut, peanut and walnut challenges were of the same magnitude: 80, 160, 640, 1280, 2560, 5120 and 15,200 mg, in total 25 g of the respective food. The titrated doses of cow's milk were: 5, 10, 40, 80 and 160 g of fresh cow's milk, in total 295 ml, whereas the dose steps for hen's egg were 11, 44, 250, 500, 1000, 2500, 5000 and 40,000 mg of pasteurized whole-egg (49,305 mg, approx one egg). OCFC were performed with the following dose steps: 0.5, 1, 2, 4, 8, 16 and 32 g | | for all foods except additives, for which total dose on 90 g wine gum in children and 160 g wine gum in adults was given) | standardized food challenge was performed in all children <3 yr of age. The double-blind placebo controlled food challenge was performed in children older than 3 yr of age |
| Osterballe (2009) | A positive challenge was divided into | Codfish and peanut were masked in | The dose interval was 15 min | Not reported | Open controlled standardized | Open controlled standardized |
| | immediate or late | chocolate bars with | | | food challenge | food challenge |

| Study ID | Time-frame for monitoring reactions | Active and placebo food carriers | Dosing schedule | Method of determining positive test | Total food to be ingested | Additional information |
|----------|--|-------------------------------------|-----------------|--|------------------------------|------------------------|
| | reactions. The | basic ingredients of | | | (OCFC) was | (OCFC) was |
| | immediate reactions | margarine, dark | | | performed with | performed with |
| | were defined as a | chocolate, salt, icing | | | the following | additives, |
| | reaction taking place | sugar, oat grains, soy | | | dose steps: 0.5, | octopus and |
| | within 2 h after the | flour, oat flour and | | | 1, 2, 4, 8, 16, 32 | shrimp as no |
| | last dose | mint. Cow's milk and | | | g, in total 63.5 g | standardized |
| | administered, whereas | hen's egg were | | | of octopus and | procedures for |
| | late reactions occurred | masked in a coloured | | | shrimp. Oral | masking the |
| | between 2 and 24 h | cup (with top) with | | | challenge with | culprit food in |
| | after the last dose of | basic ingredients of | | | additives was | double-blind |
| | the food had been | sugar, cocoa, vanilla | | | performed with | placebo- |
| | administered. All | sugar and oat drink | | | the same type of | controlled food |
| | participants with a | (placebo). Hen's egg | | | wine gum | challenge |
| | positive immediate | challenge was | | | (containing | (DBPCFC) were |
| | reaction after food | performed with fresh | | | natural dyes) as | available. |
| | challenge were | pasteurized whole- | | | suspected by the | Double-blind |
| | examined for late | egg and disguised | | | participants and | placebo- |
| | reactions by telephone | according to | | | a total dose of | controlled food |
| | interview and reported | Norgaard and | | | 160 g wine gum | challenge was |
| | symptoms were | Bindslev-Jensen | | | was given. The | performed with |
| | subsequently | | | | titrated doses of | codfish, cow's |
| | evaluated by clinical | | | | codfish were: | milk, hen's egg, |
| | examination | | | | 125, 250, 1000, | peanut and soy |
| | | | | | 2000, 4000, | according to |
| | | | | | 8000, 23,750 mg | EAACI |
| | | | | | of codfish, in | guidelines |
| | | | | | total 39 g, | |
| | | | | | whereas the | |
| | | | | | doses used for | |
| | | | | | peanut and soy | |
| | | | | | challenges were | |
| | | | | | of the same | |

| Study ID | Time-frame for monitoring reactions | Active and placebo food carriers | Dosing schedule | Method of determining positive test | Total food to be ingested | Additional information |
|-----------------|--|-------------------------------------|--|---|---|------------------------|
| | | | | | magnitude: 80, 160, 640, 1280, 2560, 5120, 15,200 mg, in total 25 g of peanut or soy. The titrated doses of cow's milk were: 5, 10, 40, 80, 160 g of fresh cow's milk, in total 295 ml. Dose steps for Hen's egg were 11, 44, 250, 500, 1000, 2500, 5000, 40,000 mg of pasteurized whole-egg (totally 49,305 mg, approximately | |
| Saarinen (1999) | Initially infants were fed cow's milk formula every 30 to 60 minutes. All those without symptoms were examined for delayed symptoms 5 days after challenge test. | Not reported | Cow's milk formula was given in quantities of 1,10,50 and 100 ml at intervals of 30 to 60 minutes | Challenge was considered positive if one or more of the following symptoms appeared; urticaria, exanthema, atopic dermatitis, vomiting, diarrhoea, wheezing or allergic rhinitis. | Maximum 100 ml | |

| Study ID | Time-frame for monitoring reactions | Active and placebo food carriers | Dosing schedule | Method of determining positive test | Total food to be ingested | Additional information |
|------------------|--|-------------------------------------|---|--|--|------------------------|
| Schrander (1993) | Not reported | Not reported | Challenges in patients with gastrointestinal symptoms were done with full amounts of milk. In children with an increased risk of anaphylaxis were performed with increasing amounts of milk. 5, 10, 30. 50, 100 ml. | A positive challenge was defined as the recurrence of the patients original complaints. Two positive elimination challenge tests after exclusion of lactose intolerance were consider diagnostic for cow's milk protein intolerance | 100 ml | Not reported |
| Venter (2006) | 1 day in hospital for immediate and 1 week at home for non- generalized late reactions | Not reported | Not reported | Not reported | One-day challenge protocols were based on the consumption of the equivalent of 8-10g of dried food, unless the history clearly indicated a different approach. If negative, the parent was asked to give the child further doses of the food at home. One week challenges were based on normal daily | Not reported |

| Study ID | Time-frame for monitoring reactions | Active and placebo food carriers | Dosing schedule | Method of determining positive test | Total food to be ingested | Additional information |
|------------------|--|---|-----------------|--|--|--|
| | | | | | consumption for the specific age group | |
| Zuberbier (2004) | Not reported | On one day a range of food additives known to cause non- allergic intolerance reactions were given in 13 capsules, on another day the same number of capsules filled with mannit and silcium dioxide were given as a placebo | Not reported | Not reported | Not reported | Food items were blinded by the nutritionist using Sinlac, orange flavour, carotine, cereal flakes and or pure cacao powder. Blinding was confirmed by tasting panels |

1.2.6. Results for Prevalence with age in different countries and regions

1.2.6.1. Celery allergy prevalence across Europe

Four studies reported the prevalence of celery allergy in a European country. These studies were published between 2001 and 2006 and reported prevalence data from France, Germany and Hungary. The studies assessed the prevalence of celery allergy in those aged 5 years or more.

Self reported celery allergy was presented in only one study, which found that 5.5% (95% CI: 4.3-7.1%) of 5 -17 year olds in France reported a problem with eating celery (Touraine 2002). Two studies performed SPT to celery and reported rates of sensitisation of 9.1% (95% CI: not reported) in adults in Germany (Schafer 2001), 11.1% (95% CI: 3.6-27.0%) in adults in Hungary (Bakos 2006) declining to 3.7% (95% CI: 1.2-9.7%) in elderly people in Hungary (Bakos 2006). One study (Bakos 2006) also assessed serum SIgE levels to celery in Hungarian adults and the elderly and reported sensitisation rates of 2.8% (95% CI: 0.2-16.2%) and 9.2% (95% CI: 4.7-16.6%) respectively (Bakos et al, 2006). One population-based study reported the prevalence of celery allergy based on a positive SPT and clinical history as 3.5% (95% CI: 2.9-4.2%) (Zuberbier 2004).

Aside from the self-report data, for which it is not clear whether the researchers detected delayed reactions to celery, the only study to assess the prevalence of allergy, rather than sensitisation, to celery appears to be detecting IgE-mediated allergies (since they have used skin prisk testing in combination with a positive clinical history). The majority of studies, however, assessed sensitisation to celery rather than allergy. Furthermore, there were no studies that reported the prevalence of celery allergy based on open or double blind food challenge.

1.2.6.2. Celery allergy prevalence of different regions of the world

Only one study investigating the prevalence of celery allergy could be identified in other regions of the world. A study conducted in Taiwan found that 1.8% (95% CI: 1.1-2.9%) of 6-8 year olds in Taiwan suffer from celery allergy based on positive serum SIgE level and a good clinical history (Wan 2012). Hence, at present only IgE mediated allergy has been investigated.

1.2.6.3. Cereals allergy prevalence across Europe

The prevalence data for cereal allergy was derived from 13 countries (22 studies), including Denmark, Finland, France, Germany, Greece, Greenland, Hungary, Iceland, Italy, Norway, Sweden, Turkey and the UK. The data was published from 1980 to 2009 and the age range of the participants ranged from birth - 97 years. The majority of the studies focused on wheat allergy, but a number of studies also reported data on rye, barley, oat, corn or mixed grains.

Mixed grains

Three studies presented the prevalence rates of self reported allergy to mixed grains or cereals. The rates reported ranged between 0.2% (95% CI: 0.1-0.5%) in 18 month olds in Norway (Eggesbo 1999) to 2.3% (95% CI: 1.5-3.7%) in one year olds in Finland (Pyrhonen 2009). Pyrhonen 2009 also report rates of clinician diagnosed cereal allergy at 1.1% (95% CI: 0.5-2.1%) of one year olds, 0.9% (95% CI: 0.4-1.9%) of 2 year olds and 2% of 3 (95% CI: 0.9-2.9%) and 4 (95% CI: 1.2-3.2%) year olds. All of these studies examined IgE and non-IgE mediated allergy, although only two of the three studies tested for the presence or absence of IgE; Eggesbo 1999 presented self-reported allergy and did not attempt to distinguish between IgE or non-IgE mediated reactions.

Rye, Barley and oatmeal

One study reported data on rye/barley allergy, one study reported on rye allergy only and one more on barley and oatmeal allergy. Self reported allergy to rye/barley ranged between 1.3 (95% CI: 0.7-2.4%)

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

- 1.8% (95%CI:1.1-3.1%). Clinician diagnosed rye/barley allergy was reported for 1.3% (95% CI: 0.7-2.4%) of one year olds, 1.8% (95% CI: 1.0-3%) of 2 year olds, 2% (95% CI: 1.2-3.4%) of 3 year olds and 2.7% (95%CI:1.7-4.1%) of 4 year olds (Pyrhonen 2009). One study (Zuberbier 2004) diagnosed food allergy in Germany based upon a positive skin prick test and clinical history and reported the following prevalence rates: barley allergy in 2.2% (95% CI: 1.7-2.8%), rye allergy in 1.2% (95% CI: 0.8-1.6%) and oatmeal allergy in 1.2% (95% CI: 0.9-1.7%). The study presenting the prevalence of self-reported allergy did not attempt to distinguish between IgE or non-IgE mediated reactions. Pryhonen 2009 also reported prevalence rates that included both IgE and non-IgE-mediated allergy. The diagnostic methods utilised by Zuberbier 2004 detected IgE-mediated allergy only.

Corn

Two studies looked at the prevalence of corn allergy. A study conducted in Turkey (Orhan 2009) found that only 0.1% (95% CI: 0.0 - 0.4) of the study population of 6-9 year olds reported allergy to corn all of whom were sensitised to it. However, in all cases corn allergy was not confirmed by DBPCFC (95%CI:0-0.2%). This study detected IgE-mediated allergy only. In the UK, corn allergy was confirmed by DBPCFC in 0.1% (95%CI: 0.0-0.8%) of 1, 2 and 3 year old children, in a study that monitored patients for sufficient time to identify both IgE and non-IgE mediated allergy (Venter 2008).

Flour

Two studies reported prevalence rates of reactions to "flour" where the type of flour was unspecified, both of which were conducted in Germany. Schafer 2001 found that 0.7% of their study population (95% CI: not reported) reported symptoms upon ingestion of flour (which may have been either IgE or non-IgE mediated). Examining IgE and non-IgE mediated allergy separately, Zuberbier 2004 reported a prevalence, for all ages, of 0.5% (95% CI: 0.3-0.8) and 0.1% (95% CI: 0.0-0.3) respectively.

Wheat/Gluten

Twenty studies assessed the prevalence of self-reported wheat allergy/gluten sensitivity. The lowest rates of self-reported wheat allergy were presented for a group of 7-13 year olds in Greece (0.2% (95% CI: 0.0-0.5%)) (Zannikos 2008). The highest rates were reported by a Finnish study of 1-year-olds (2.1% (95% CI: 1.3-3.4%)) (Pyrhonen 2009). Clinician-diagnosed wheat allergy was reported by two studies. Prevalence rates of clinician-diagnosed wheat allergy were reported to be 0.3% (95% CI: 0.1-0.6%) of 1 year olds and 8 year olds in Sweden (Ostblom 2008b). A higher rate (3.4% (95% CI: 2.3-5%)) was reported for a group of 4 years olds in Finland (Pyrhonen 2009).

Sensitisation to wheat, as measured by SPT, was reported in seven studies and, as measured by specific IgE, in four studies. The lowest rate of sensitisation (determined via SPT) was 0% (95% CI: 0-0.6%) reported for 1 and 3 year olds in the UK (Venter 2008). The highest rate, 13.9% (95% CI: 5.2-30.3%), was reported by a Hungarian study of 20-69 year olds (Bakos 2006). Only three studies reported prevalence of wheat allergy based on a positive SPT and clinical history. Based on this method of diagnosis, the lowest prevalence of wheat allergy was reported in a group of 18 month-old children in Sweden (0% (95% CI: 0-1.4%)) and Iceland 0% (95% CI: 0-1.5%)) (Kristjansson 1999) and the highest rate, 1.2% (95% CI: 0.9-1.7%), was reported for all ages in Germany (Zuberbier 2004) . Only one study (Ostblom 2008b) reported a prevalence rate based on positive specific IgE levels and clinical history. Using this method in a Swedish population, the prevalence rate was 1.3% (95% CI: 1.0-1.9%) of 4 year olds (Ostblom 2008b). In the only study to combine clinical history with a positive OFC/DBPCFC outcome, Osterballe 2005 did not identify a single confirmed case of wheat allergy in any age group.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

A number of studies used other methods of diagnosing wheat allergy. Using atopy patch tests in an Italian population, Ronchetti 2008 reported the prevalence of wheat allergy to be 5.6% (95% CI; 3.0-10.1%) of 13 year olds and 6% (95% CI: 3.2-10.7%) of 9 year olds. Using a combination of history and SPT and/or OFC and DBPCFC, the prevalence of wheat allergy was 0.4% (95% CI: 0.1-1.2%) in one year olds, 0.3% (95% CI: 0.1-1.1) in two year olds, 0.2% (95% CI: 0.0-0.9%) in 3 year olds and 0.3% (95% CI: 0-1.0%) in six year olds in the United Kingdom (Venter 2008; Venter 2006). Of the studies that assessed the prevalence of wheat/gluten allergy in Europe, 17 assessed both IgE and non-IgE mediated wheat/gluten allergy (although four of these did not perform any tests to determine the presence or absence of IgE) and four IgE-mediated allergy only.

1.2.6.4. Cereals allergy prevalence in different regions of the world

A number of studies (N=14) have looked into cereal allergy outside of the EU. Studies were conducted in Australia, Canada, China, Ghana, Japan, Korea, Thailand, United Arab Emirates, and the United States.

Corn and Millet

One study looked at IgE-mediated cereal allergy in 5-16 year olds in Ghana and found reported allergy to corn in 0.2% (95% CI: not reported) of children and millet in 0.1% (95% CI: not reported) (Obeng 2011). In the United States, one study reported a prevalence rate for corn allergy (both IgE and non-IgE mediated) based on food challenges of 0.2% (95% CI:0-1.3%) in 0-3 year olds (Bock 1987).

Wheat

Nine studies looked at the reported prevalence of wheat allergy. The lowest rates were reported by a study conducted in Korea in a group of 6-12 year old children (0% (95%CI:0.0-0.1%)) (Oh 2004). The highest rate was found in the United States, where 2.3% (95% CI: 1.3-4.2%) of the adult study population reported having wheat allergy (Greenhawt 2009). One study, conducted in the United States, looked at the prevalence of a reported clinical diagnosis of wheat allergy across different age groups (Gupta 2011). The prevalence ranged between 0.3% for both 0-2 year olds (95% CI: 0.1-0.5) and 14-17 year olds (95% CI: 0.2-0.4). Two studies presented prevalence rates for clinician diagnosed wheat allergy. These were 0.1% (95% CI: 0-0.5%) for a group of 0-12 month olds in Korea (Kim 2011) and 0.5% (95% CI: 0.1-2.0%) for a group of 6-9 year olds in the United Arab Emirates (Al-Hammadi 2006).

Three studies measured the prevalence of sensitization to wheat by either SPT (n=2) or serum specific IgE levels (n=1). In an Australian adult population, the prevalence of sensitization to wheat was found to be 2.2% (95% CI: 1.1 - 4.1) (Woods 2002). A study conducted in 0-24 month olds in China in 1999 and 2009 reported wheat sensitisation rates (assessed by SPT) of 0.3% (95% CI: 0.0-2.1%) and 0.5% (95% CI: 0.1-2.1%) respectively (Hu 2010). The prevalence of sensitisation to wheat in a group of 0-12 month olds in Japan, as determined by positive serum specific IgE levels, was 1.4% (95% CI: not reported) (Morita 2012).

Two studies used a positive SPT/specific IgE level in combination with clinical history to estimate the prevalence of wheat allergy. These studies reported prevalence rates of between 0% (95% CI: 0.0-0.1%) for Australian adults (Woods 2002) and 0.2% (95% CI: 0.0-0.9%) for Japanese adults (Morita 2012). A higher prevalence rate (1.2% (95% CI: 1.0-1.4%)) was reported by a Chinese study which utilised IgG levels to diagnose wheat allergy (Sai 2011). In the United States the prevalence of wheat allergy in 0-3 year olds has been found to be 0.2% (95% CI: 0-1.3%) when using food challenges (Bock 1987). Also in the United States, self-reports of clinician diagnosed wheat allergy yielded a prevalence rate of 0.5% (95% CI: 0.3-0.8%) (Vierk 2007).

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

The minority of adverse reactions to wheat are considered to be IgE-mediated. Of the studies reporting the prevalence of wheat allergy outside of Europe, five assessed IgE-mediated allergy only, nine considered both IgE and non-IgE mediated allergy (of which seven did not perform tests to determine the presence or absence of IgE) and one assessed IgG-mediated allergy.

1.2.6.5. Egg allergy prevalence across Europe

The prevalence of egg allergy has been assessed in 17 countries (35 studies), including Denmark, Estonia, Finland, France, Germany, Greece, Greenland, Hungary, Iceland, Ireland, Italy, Norway, Portugal, Spain, Sweden, Turkey and the UK. The included studies were published between 1980 and 2012 and the age range of the participants ranged from birth -97 years.

None of the included studies reported prevalence rates for egg allergy based on self-report or clinical history. Three studies focussed on clinician diagnosed egg allergy with the lowest prevalence figures seen in 8 year olds from Sweden (1.6% (95% CI: 1.2-2.1)) (Ostblom 2008) and the highest in 4 year olds from Finland (3.9% (95% CI:2.7-5.5%)) (Pyrhonen 2009).

Eleven studies reported sensitisation rates based on skin prick test results and six on specific IgE levels. In the younger cohorts (0-3 years old), sensitisation rates as determined by SPT ranged from 1.3% (95% CI: 0.7-2.3%)(Venter 2008) to 5.2% (95% CI :not reported) (Julge 2001). In this age group, rates determined by sIgE ranged between 4.2% (95% CI: not reported) (Julge 2001) and 20.6% (95% CI: not reported) (Julge 2001). In children older than 3 years, sensitisation rates as determined by SPT ranged from 0% (95% CI: not reported) (Julge 2001; Roncetti 2008) to 2.8% (95% CI: 1.9-3.9%) (Schafer 1999), and as determined by sIgE, from 0.4% (95% CI: 0.1-1.1%) (Krause 2002) to as high as 22.7% (95% CI: not reported) (Julge 2001). Sensitisation rates in adults ranged between 0.4% (95%: not reported) (Schafer 2001) and 1.9% (95% CI: not reported) (Schafer 2001) when SPTs were utilised. When sensitisation in adults was determined via sIgE testing to egg yolk, sensitisation rates were 0% (95% CI: 0-12%) in ages 20-69 years and 60-97 years (Bakos 2006).When the sIgE to egg white was tested, sensitisation rates were reported to be 2.8% (95% CI: 0.2-16.2%) in ages 20-69 years and 2.8% (95% CI: 0.7-8.4%) in ages 60 – 97 years (Bakos 2006).

Four studies based egg allergy prevalence rates on a good clinical history plus a positive SPT, and reported rates ranging from 0.1% (95% CI: 0-0.1%) in 18 year olds in Turkey (Gelincik 2008) to 1.5% (95% CI: 0.6 - 3.7%) in 18 month olds in Sweden (Kristjansson et al. 1999). Two studies based egg allergy prevalence rates on a good clinical history plus a positive serum specific IgE result. One was conducted in Sweden and reported the prevalence of egg allergy to be 0.6% (95% CI: 0.3-1.0%) (Ostblom 2008a). The other found the prevalence of egg allergy in Turkey to be 0.1% (95% CI: 0.0-0.1%)(Gelinicik 2008).

Several studies utilised food challenges (four used open food challenges and four DBPCFC), in combination with clinical history, to diagnose egg allergy. Based on open food challenge and a good clinical history the highest prevalence rate was 2.6% (95% CI: not reported) in 18 month old children in Denmark (Eller 2009). In contrast, based on DBPCFC and history the highest prevalence rate reported was 1.6% (95% CI: 0.1-3.4%) (Osterballe 2005) in 3 year old children also from Denmark. Five studies combined a variety of methods to determine egg allergy prevalence. Of these, the highest reported prevalence of egg allergy was a very high rate of 10.2% (95% CI: 6.5-15.5%) diagnosed using the atopy patch test in 13 year old children (Ronchetti 2008).

Egg allergy is classically considered as an IgE mediated food allergy. We tried to understand from the included studies if the symptoms related to egg were considered IgE or non-IgE mediated. In Europe, 24 studies covered both IgE and non-IgE mediated food allergies. Apart from the study by Venter et al.which clearly indicate the presence of IgE and non-IgE mediated egg allergy, it is very difficult to

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

98

tell from the other papers if the egg allergy per se was IgE or non-IgE mediated or both. In fact 11 of the studies who indicated that they studied both IgE and non-IgE mediated allergies, did not perform any tests to determine the presence or absence of IgE. Ten studies focussed on IgE mediated egg allergy.

1.2.6.6. Egg allergy prevalence in different regions of the world

A number of studies outside of Europe have looked at the prevalence rates of egg allergy. The countries studies include Australia, Canada, China, Colombia, Ghana, Hong Kong, Israel, Korea, Taiwan, Thailand, United Arab Emirates and the USA. The studies were reported between 1998 and 2012 and included participants of all ages.

Twelve studies looked into the self-reported prevalence of egg allergy. The lowest prevalence rate, 0.1% (95% CI: not reported), was reported in 5-16 year olds from Ghana (Obeng 2011). The highest prevalence, 1.6% (95% CI: 0.7%-3.2%), was reported in a group of US adults (Greenhawt 2009). Two studies reported prevalence based on a reported clinical history of egg allergy ranging from 0.4% (95% CI: 0.3 - 0.5%) in 14-17 years olds in the US to 1.3% (95% CI: 0.9 - 1.7%) in 3-5 year olds (Gupta et al. 2011). Only three studies focussed on clinician diagnosed egg allergy with the lowest prevalence figures seen in adults from Taiwan (0.3% (95% CI: 0.2-0.4%)) (Wu 2012) and the highest in 6-9 year olds from the UAE (3% (95% CI: 1.8-5.7%)) (Al-Hammadi 2010).

Four studies reported sensitisation rates based on skin prick test results and four as determined by specific IgE levels. High rates of sensitisation to egg, as measured by SPT, are reported with, for example, a sensitisation rate of 11.8% (95% CI: 10.6-13.0) in 12-15 month olds in Australia (Osborne 2011) and 16.2% (95% CI: 12.8-20.4%) in 0-24 month olds in China (Hu 2010). Sensitisation rates as measured by serum specific IgE levels ranged between 2.1% (95% CI: not reported) in 20-39 year olds in the US (Liu 2010) and 21% (95% CI: 18.7-23.6%) in 6 months – 6 year olds in the US (Kumar 2011).

Only two studies based egg prevalence rates on a good clinical history plus a positive SPT. Dalal 2002 found a prevalence for egg allergy of 0.5% (95% CI: 0.3-0.6%) in 0-2 year olds in Israel and Woods 2002 reported a rate of 0.2% (95% CI: 0.0-1.4%) in 26-50 year olds in Australia. No study based egg allergy prevalence rates on a good clinical history plus a positive serum specific IgE result or a positive DBPCFC and a good clinical history. However, three studies based a diagnosis of egg allergy on a positive OFC plus history. Chen 2011 reported egg allergy prevalence rates of 0.5% in 0-12 month olds in China. A different study in the same country reported prevalence rates of 2.9% (95% CI: 1.4-5.6%) in 0-24 month olds in 1999 and 5% (95% CI: 3.2-7.7%) in 0-24 month olds in 2009 (Hu 2010). Osborne 2011 reported a prevalence of 9% (95% CI: 7.9-10.0) in 12-15 months olds in Australia.

Five studies utilised other methods to diagnose egg allergy. The methodologies varied widely from using a combination of history, sensitisation status and/or food challenges, to less credible methods such as IgG levels. Many studies conducted on egg allergy outside of Europe utilised questionnaire based methods to determine the prevalence of egg allergy, which in some cases focussed on IgE mediated allergy, but did not confirm a history of immediate type symptoms with specific IgE or SPT. Only three studies reported on IgE and non-IgE mediated egg allergy, and one of these studies did not determine the presence of IgE, with 20 studies reporting on IgE mediated food allergies and 8 of these not testing for the presence of IgE. One study used IgG testing.

1.2.6.7. Fish and Shellfish prevalence across Europe

There were 34 studies which looked at the prevalence of fish and shellfish allergies in Europe (the countries studied were Denmark, Finland, France, Germany, Greece, Greenland, Hungary, Iceland,

EFSA supporting publication 2013:EN-506

Norway, Portugal, Spain, Sweden, The Netherlands, Turkey and the United Kingdom). Data was published between 1980 and 2012. The prevalence of seafood allergy was assessed in participants from 6 months to 97 years. Prevalence rates based on self-reported allergy were presented in 22 studies; sensitisation rates were assessed in eight studies using skin prick tests and five studies using serum SIgE tests; sensitisation plus clinical history was obtained in four studies and seven studies adopted open and/or double blind food challenges.

IgE-mediated allergy was considered in 11 studies (Arshad 2001; Bakos 2006; Bjornsson 1996; Haahtela 1980; Kajosaari 1982; Krause 2002; Kristjansson 1999; Mustafayev 2012; Orhan 2009; Ro 2012; Roberts 2005). The methods adopted by these studies included skin prick and specific IgE tests to assess sensitisation, and food challenges and/or self-reported allergy where only IgE-associated symptoms were considered a positive indication of allergy. In the remaining 23 studies both IgE-mediated and non-IgE mediated allergy were included in the reported prevalence figures.

The highest self-reported prevalence of fish allergy was found in Finland, with 7% (95% CI: not reported) (Kajosaari 1982) of parents of 1 year olds reporting that their child had an adverse reaction to fish. A similar prevalence rate, 6.9% (95% CI: 6.2-7.6%) (Martinez-Gimeno 2000), was found in 6-13 year olds in a Spanish population. The lowest rate was found in Denmark where only 0.2 % (95% CI: 0-1%) (Osterballe 2009) of 22 year olds reported an adverse reaction to fish, however this study only asked about an allergy to cod, and so the neglect of other fish species could account for the low prevalence. Studies reporting prevalence of clinician diagnosed allergy or a diagnosis based on clinical history of fish allergy ranged from 0.2% (95% CI: 0-0.9%) (Pyrhonen 2009) of 1 year olds in Finland and 0.2% (95% CI: 0.1-0.4%) (Ostblom 2008 b) of 1 year olds in Sweden to 1.0% (95% CI: 0.5-2.0%) (Pyrhonen 2009) of 4 and 5 year olds in Finland.

Looking at sensitisation, the highest prevalence of fish sensitisation as detected by skin prick tests was seen in Finland, with 2.7% (95% CI: 1.7-4.2%) (Haahtela 1980) of 15-17 year olds being sensitised. The lowest rates were found in the UK where 0% (95% CI: 0-0.3%) (Roberts 2005) of 7 year olds had a positive skin prick test to cod, and in Hungary where 0% (95% CI: 0-4.2%) (Bakos2006) of 60-97 year olds showed sensitisation to cod on a SIgE test. When sensitisation plus a convincing clinical history was obtained, the highest rate for fish allergy was 0.6% (95% CI: 0.1-2.5%) (Kristjansson,1999) was reported in Iceland at 18 months of age. The lowest rate was found in Turkey in 0.2% (95% CI: 0.1-0.5%) of 6-9 year olds (Orhan 2009). Four of the studies that adopted open and/or double-blind food challenges to diagnose fish allergy reported 0% prevalence to fish, however one study in a Finnish population found a prevalence of 1% (95% CI: not reported) of 6 year olds (Kajosaari,1982).

With regard to crustacean allergy, the prevalence of self-reported crustacean-related adverse food reactions ranged from 0.3% (95% CI: 0.1-1.0%) of 11 year olds in the UK (Pereira, 2005) to 5.5% (95% CI: 4.3-7.1%) of 5-17 year olds in France (Touraine, 2002). Sensitisation rates for crustacean allergy were similar in Germany 1.9% (95% CI: not reported) based on skin prick tests (Schafer, 2001) and Hungary 1.8% (95% CI: 0.3-7.1%)) based on SIgE testing (Bakos 2006. Only one study, conducted in Denmark, reported challenge proven prevalence data for crustacean allergy, which found a prevalence of 0% (95% CI: 0.0-2.0%) in 0-22 year olds and 0.3% (95% CI: 0.1-1.0%) in individuals 22 years or older (Osterballe, 2005).

Where mollusc allergy is concerned, only three studies collected data on self-reported mollusc-related adverse reactions in Europe, with the highest prevalence reported in France where 1.5% (95% CI: 0.9-2.4%) of 5-17 year olds reported an allergy to oysters (Touraine 2002) and the lowest prevalence in Denmark, with only 0.4% (95% CI: 0.1-1.1%) of 22 year olds self-reporting an allergy to octopus (Osterballe 2009). Prevalence of allergy to mollusc, as diagnosed using positive SPT and convincing

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

clinical history, was presented by only one study, conducted in Germany, which reported a prevalence of 0% (95% CI: 0.0-0.2) for mussel allergy (Zuberbier 2004). There were no studies in Europe that adopted food challenges to confirm mollusc allergy.

1.2.6.8. Fish and Shellfish prevalence in different regions of the world

Twenty-seven studies looked at the prevalence of fish and shellfish allergy across the rest of the world. Two studies have been conducted in Australia, one in Canada, three in China, one in Colombia, one in Ghana, one in Hong Kong, one in Israel, two in Korea, eight in South-East Asia, two in Taiwan, one in the United Emirates, and the rest of the studies were all conducted in the USA. Data was published between 1998 and 2012 with participant ages ranging from 0- 83 years of age. Self-reported allergy was presented in 16 studies, 10 studies combined clinical history with a clinician diagnosed seafood allergy, seven studies measured sensitisation rates, with a further three studies also taking into account a convincing clinical history as well as sensitisation. Only two studies adopted food challenges to confirm suspected allergy.

IgE-mediated allergy was considered in 11 studies (Ben-Shoshan 2009; Branum 2009; Chen 2011; Dalal 2002; Greenhawt 2009; Kim 2011; Lao-araya 2012; Liu 2010; Osborne 2011; Wan 2012; Woods 2002). The methods adopted by these studies included skin prick and specific IgE tests to assess sensitisation, and food challenges and/or self-reported allergy where only IgE-associated symptoms were considered a positive indication of allergy. In the remaining 16 studies both IgE-mediated and non-IgE mediated allergy were included in the reported prevalence figures.

The highest prevalence of self-reported fish-related adverse reactions was seen in adults in the United States (2.7% (95%CI:1.6-4.7%)) (Greenhawt 2009) compared with 0.6% (95% CI: 0.4-0.8) (Ben-Shoshan 2010) of adults in Canada. In children in Canada, 0.2% (95% CI: 0.0-0.4%) (Ben-Shoshan 2010) self-reported a fish allergy, which lowered to 0% (95% CI: not reported) (Ben-Shoshan 2010) confirmed with a clinician diagnosed fish allergy. The highest prevalence of clinician diagnosed fish allergy in Non-European countries is 2.8% (95% CI: 1.5-5.1%) (Al-Hammadi 2010) seen in 6-9 year olds in the United Arab Emirates; the lowest prevalence rates were reported in 0-2 year olds in Israel (0% (95% CI: 0-0.1%) (Dalal 2002) and 0-5 year olds in the United States (0% (95% CI: 0.0-0.5%) (Sicherer 2004).

Two studies measured sensitisation, reporting prevalence ranges from 0.2% (95% CI: 0.0-1.3%) (Chen 2011) in 0-12 month olds to 0.8 % (95% CI: 0.2-2.5%) (Hu 2010) of 0-2 year olds both in China. In Israel, 0% (95% CI: 0.0-0.1%) (Dalal 2002) prevalence of fish allergy was found in 0-2 year olds when a convincing clinical history plus sensitisation was the method of diagnosis. Open food challenges were performed in 3-7 year olds in Thailand, revealing a 0.2% (95% CI: 0.0-1.4%) prevalence of allergy to fish (Lao-araya, 2012).

With regard to shellfish allergy, self-reported shellfish allergy varied from a very low rate of 0.1% (95% CI: not reported) in 5-16 year olds in Ghana (Obeng 2011) to a very high rate of 24.5% (95% CI: not reported) in adults in China (Sai 2011). The lowest prevalence for clinician diagnosed shellfish allergy was 0.1% (95% CI: 0.0-0.1%) (Ben-Shoshan 2010), for under 18 year olds in Canada, and the highest prevalence based on a convincing clinical history was seen in Singapore, with 5.2% (95% CI: 4.5-6.1%) of 14-16 year olds suggesting a positive shellfish allergy (Shek 2010). Based on a positive skin prick test, crustacean sensitisation was 0% (95% CI: 0-1.6%) in 0-2 year olds from China (Hu 2010) compared with 17.3% (95% CI: 15.1-19.8%) of Taiwanese 6-8 year olds sensitised to lobster, determined using serum specific IgE testing (Wan 2012). Despite the large number of studies looking at the prevalence of shellfish allergy based on self reports of adverse reactions, convincing clinical history and a clinician diagnosis, only one study was found to perform

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

open food challenges to crustaceans, reporting a prevalence between 0.2% (95% CI: 0.0-1.4%) for crab and 0.9 (95% CI: 0.3-2.4%) for shrimp in 3-7 year olds in Thailand (Lao-araya 2012).

Self-reported mollusc allergy was found to be 0.2% (95% CI: 0.0-1.4) for 3-7 year olds in Thailand (Lao-Araya 2012). In Taiwan, mollusc allergy defined by a clinician diagnosis varied from 0.1% (95% CI: 0.0-0.8) in under 3 year olds to 1.5% (95% CI: 1.3-1.7) in adults (Wu 2012). Sensitisation, as determined by serum-specific IgE testing, has been reported for 6-8 year old children in Taiwan for scallop (24.9% (95% CI: 22.2-27.7%)) and abalone (25.1% (95% CI: 22.4-27.9%)) sensitised to mollusc (abalone) (Wan 2012). There were no studies conducted outside of Europe reporting data on challenge proven mollusc allergy.

Six studies reported seafood allergy, which one can only presume to include both fish and shellfish allergy, with the highest prevalence rate found in Colombia with 4% (95% CI: 3.3-4.7%) of all ages self-reporting an allergy (Marrugo 2008). The lowest prevalence was seen in Korea, with 0.4% (95% CI: 0.3-0.4%) of 6-12 year olds self-reporting a seafood allergy (Oh 2004). In addition, one study from China reported high prevalence of allergy to fish 11.2% (95% CI: 10.7-11.8%) crab 24.5% (95% CI: 23.8-25.3%) and shrimp 10.0% (95% CI: 9.5-10.6%) (Sai 2011) however data was calculated by IgG measurements, which do not report allergy. Furthermore, it was not clear how the clinical history was taken. Hence, caution should be taken when interpreting these findings.

1.2.6.9. Fruit allergy prevalence across Europe

A large number of studies (n=14) reported on fruit and in some cases vegetable allergies. Within Europe, the countries where the studies were performed include: Denmark, Finland, France, Germany, Greece, Hungary, Iceland, Norway, Portugal, Spain, Sweden, The Netherlands, Turkey and the UK. The data was published from 1982 to 2012 and the age range of the participants ranged from birth - 97 years.

A large variety of fruits have been studied including: a mixture of fruit and vegetables (n=13), apple (n=5), citrus/orange fruits (n=11), strawberry (n=6), kiwi (n=3), pear (n=3), apricot (n=1), cherry (n=2), grape (n=2), nectarine (n=1), peach (n=4), plum (n=2), banana (n=8), and pineapple (n=1). A number of these fruits have been implicated in Oral Allergy Syndrome (pear, apple, cherry and peach) and banana has been shown to cross react with latex, although this is outside the remit of this report.

The highest rate of citrus fruit allergy, 11% (95%CI: not reported), was reported using a self-report method in a sample of 3 year old children in Finland (Kajosaari 1982). In the same study, using open food challenges, the prevalence of citrus fruit allergy was 2% (95%CI: not reported) in 6 year old children. This was the only study to use food challenges to diagnose citrus fruit allergy in a paediatric sample). Only two studies used food challenges, reporting a prevalence of 2% (95% CI: not reported) in 6 year olds in Finland (Kajosaari 1982) and 0% (95% CI: 0.0-0.1%) of adults in Turkey (Gelincik 2008).

Strawberry allergy was examined in six studies. Similar to the pattern for citrus fruits, the highest rates were presented for young children in Finland: 7% (95% CI: not reported) at age 1, 4% at age 2 and 7% at age 3 years, however all were measured using self-report methods (Kajosaari 1982). Lower rates of self-reported strawberry allergy were reported for adults in Turkey (0.7% (95% CI: 0.5-0.8%)), which translated to a 0% (95% CI: 0.0-0.1%) prevalence when diagnosis was made using DBPCFC (Gelincik 2008). Similarly low rates 0% (95% CI: 0.0-0.2%) were reported in children in Turkey using DBPCFC (Orhan 2009).

Kiwi fruit, which is sometimes cited as the "15th" major allergen was found to have a 0.8% (95% CI: 0.5-1.0%) allergy prevalence in a sample children in France, using a self report method (Rance 2005).

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

The only other studies examining kiwi allergy prevalence were both conducted with children in Turkey. One study identified the prevalence of self-reported kiwi allergy as 0.3% (95% CI: 0.1-0.6%) decreasing to 0.1 % (95% CI: 0-0.4%) when a DBPCFC method was employed (Orhan 2009). More recently, a prevalence of 0.1% (95% CI: 0.0-0.8%) was also found using open food challenges (Mustafayev 2012).

It is difficult to truly distinguish IgE mediated from non-IgE mediated food allergies or even chemical intolerances in fruit induced reactions. Nineteen studies in Europe report to have studied both IgE and non-IgE mediated reactions but only ten of these reported to have performed SPT or specific IgE tests and it was not clear if these tests have been performed to the fruit in question. Only two studies have reported IgE mediated reactions and both have utilised SPT/specific IgE testing, but it was once again not clear if these tests have been carried out the fruit in question.

1.2.6.10. Fruit allergy prevalence in different regions of the world

There were a total of 16 studies conducted in countries outside Europe that reported fruit allergy prevalence rates. The countries where the studies were performed include Australia, Canada, China, Colombia, Ghana, Hong Kong, Israel, Korea, Taiwan, United Arab Emirates and the United States. The data was published from 1987 to 2012 and the age range of the participants ranged from birth - 44 years.

In addition to the fruits that were reported as allergens in Europe (orange, apple, banana, pineapple, peach, grape, kiwi, strawberry and "fruits" not specified), additional fruit allergies were reported in these non-European countries. These were pawpaw, mango and melon in Ghana (Obeng 2011); mango, melon and litchi in Taiwan (Wu 2012), "fruit juice" in USA (Bock 1987) and "dried fruit" in Australia (Woods 1998). Conversely, cherry, plum and apricot were reported as causing adverse reactions in Europe, but not in countries outside.

Food challenges were rarely used, with the majority of studies reliant on self-report methods. The highest prevalence rate was 10.8% (95% CI: 8.3-14%), which was reported to fruit juice in a study of one year old children in the United States (Bock 1987), which converted to a 7.9% (95% CI: 5.7-10.8%) rate of "probable or convincing allergy" using a combination of SPT, sIgE, clinical history and food challenge. Indeed, this study was the only one to use food challenges as a method of diagnosis. Skin prick testing was only used by two further studies; Chen 2011 (orange) and Dalal 2002 (strawberry) and sIgE by one study (Wan 2012) (lychee, melon and grape), perhaps reflecting the lack of valid diagnostic tests available for fruit allergens.

As with the studies from Europe, it is very difficult to say with certainty if the fruit-related reactions were IgE mediated or not. Three studies reported on both IgE and non-IgE mediated reactions, but only one study tested for the presence of IgE and it is not clear if the test were performed to the particular fruit. Thirteen studies reported on IgE mediated reactions but only five of these tested SPT/Specific IgE, once again it was not clear if the reactions were IgE mediated or not.

1.2.6.11. Milk/dairy allergy prevalence across Europe

In total, forty studies looked at the prevalence of cow's milk allergy in Europe. The studies were from Denmark, Estonia, France, Finland, Germany, Greenland, Hungary, Iceland, Ireland, Italy, Norway, Portugal, Spain, Sweden, The Netherlands, Turkey and the United Kingdom. Data was published between the years 1982 and 2012 and included all age groups.

Twenty-two studies reported prevalence rates based on self (or parentally) reported allergy. The highest self-reported rate of cow's milk allergy was 21% (95% CI: 19.9-22.1%), in a large Spanish

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

study of 6-13 year old children (Martinez-Gimeno 2000). The lowest rate of parentally reported cow's milk allergy was 0% (95% CI: 0-6.1%) in Ireland (Kilgallen 1996), however this was in a study of infants aged 0-6 months, which is an age at which symptoms may not yet have fully manifested. The same study reported a 0% (95% CI: 0-3.1%) prevalence of parentally reported allergy to yoghurt at age 24-36 months old. The lowest self-reported prevalence was found in a large study of adults in Turkey (0.2% (95% CI: 0.2-0.4%)) (Gelinicik 2008).

Seventeen studies reported sensitisation rates; seven using sIgE, ten using SPT only and three using both SPT and sIgE. The highest rate of positive sIgE was 25.8% (95% CI: not reported) in 2 year old children in Estonia (Julge 2001), although very surprisingly 0% (95% CI: not reported) of this sample had positive skin prick tests, which was the lowest reported level of positive SPT overall. The lowest rate of positive sIgE in adults was 1.0 (95% CI: 0.0–5.5) (Isolauri 2004). The lowest rate of positive sIgE in children was 0.5% (95% CI: 0.2-1.2%) in a study of children aged 5-18 years from Greenland (Krause 2002). The highest rate of positive SPT in adults was 14.7% (95% CI: 8.9-23.0%) in Hungary (Bakos 2006) and in children 3.9% (95% CI: 2.9-5.2%), in a study of German children aged 5-6 years (Schafer 1999).

Prevalence of milk/dairy allergy as determined by sensitisation (SPT or specific IgE) plus clinical history was reported in six studies. The only study to do so in an adult population reported a rate of 0.1% (95%CI:0.0-0.3%) based on SPT and history (Zuberbier 2004). A prevalence of 0.2% (95% CI: 0.0-0.8%) was reported in 8-18 month old infants in Turkey using specific IgE testing and history (Kucukosmanoglu 2008b). One study assessed the prevalence in older children, aged 4 years old, finding a prevalence of 1.8% (95% CI: 1.3-2.4%) (using specific IgE testing and history) in Sweden (Ostblom 2008a).

Twelve studies used either open or double blind food challenges. The highest rates of challengeproven cow's milk allergy was 2.3% (95% CI: 1.5-3.3%) in a Dutch study of infants (Schrander 1993). The lowest prevalence rate reported was 0.0% (95% CI: 0.0-4.2%), in a study of <3 year old children in Denmark (Osterballe 2005). In an adult population from Turkey, one study reported a prevalence of 0.0% (95% CI: 0-0.4%) using history and DBPCFC (Gelincik 2008). The highest rate in adults was 0.2% (95% CI: 0.1-1.0%) in a study conducted in Denmark (Osterballe 2005). One study used atopy patch testing (Ronchetti 2008) and reported a prevalence rate of 4.1 % (95% CI: 1.9-8.2%) in 13 year old children.

Milk allergy is by far the most difficult food allergy to classify in terms of IgE and non-IgE mediated symptoms. It is the clinically most complex food allergy seen in young children with many of them suffering from both IgE and non-IgE mediated symptoms. Twenty-nine studies reported symptoms of both IgE and non-IgE mediated cow's milk allergy with only 14 studies confirming the presence of IgE by SPT or specific IgE testing. Nine studies reported rates of IgE mediated cow's milk allergy only and these studies have all utilised SPT or specific IgE tests.

1.2.6.12. Milk/dairy allergy prevalence in different regions of the world

Twenty-nine studies looked at the prevalence of cow's milk allergy outside Europe. This included studies from Australia, Canada, China, Colombia, Ghana, Hong Kong, Israel, Korea, Taiwan, Thailand, United Arab Emirates and United States of America. Data was published between the years 1973 and 2012 and included all age groups.

Fourteen studies reported prevalence rates based on self (or parentally) reported allergy. The highest rates in children and adults were both reported in studies from the USA; 13.1 % (95% CI: 10.3-16.6%) for a group of one year olds (Bock 1987) and 10.5% (95% CI: 8.1-13.6%) in a study of adults (Greenhawt 2009). The lowest parentally reported prevalence rate was 0.2% (95% CI: not reported) in

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

a study of 5-16 year old children in Ghana (Obeng 2011). The lowest self reported rate in adults was 1.9% (95% CI: 1.56-2.21%) in a Canadian study (Soller 2012).

Eight studies reported sensitisation rates; four using sIgE and four using SPT. No studies measured both sIgE and SPT. A study conducted in the US reported the highest rate of positive sIgE in adults (4.9% (95% CI: not reported)) and children (22% (95% CI: not reported)) (Liu 2010). The only study that measured SPT in adults (Woods 2002), reported a sensitisation rate of 0.7% (95% CI: 0.2-2.1%). In children, the lowest sensitisation rate using SPT was 2.7% (95% CI: 1.5-4.7%) in China (Chen 2011) and the highest 6.5% (95% CI: 4.4-9.6%), also in China (Hu 2010).

Sensitisation plus clinical history was reported as a method of diagnosis in only three studies, the first of which reported a 0% (95% CI: 0-1.0%) prevalence rate in a sample of adults in Australia. A similar prevalence, 0.3% (95% CI: 0.2-0.5%), was reported by a study of children aged 0-2 years old in Israel (Dalal 2002). A study of children aged 6-8 years in Taiwan reported much higher prevalence rates of between 6.2-14.5% using sIgE plus clinical history (Wan 2012).

Three studies used open food challenges to determine the prevalence of milk/dairy allergy. A study of 3-7 year olds in Thailand reported the lowest prevalence rate, 0% (95% CI: 0-1.1%), of confirmed milk allergy (Lao-araya 2012). The other two studies (Hu 2010, Chen 2011) were both conducted in infants in China and reported prevalence rates of 3.5% (95% CI: 2-5.9%) and 1.3% (95% CI: 0.5-2.9%) respectively.

Bock 1987 reported a prevalence of 5% (95% CI: 3.3-7.4%) in one year old children using a combination of history, SPT and oral food challenge to determine a diagnosis of "probable or confirmed" food allergy. Similarly, Chen 2012 reported a prevalence of 3.5% (95% CI: 2.2-5.4%) in children under 2 years old in China, using a combination of clinical history and/or SPT and/or oral food challenge and/or elimination diet. A study of 0-2 year old children in Israel reported a lower prevalence rate of 1.1% (95% CI: 0.9 - 1.2), also using a combined method of a clear history, SPT and/or food challenge (Katz 2010).One study used IgG tests to diagnosis cow's milk allergy, reporting a very high prevalence rate of 24.5% (95% CI: 23.8-25.3%) in adults in China (Sai 2011), although as noted before prevalence data from IgG testing should be interpreted with caution.

The picture of IgE vs. Non-IgE mediated cow's milk allergy is very different in the rest of the world than what is reported in Europe. Twenty one studies reported on IgE mediated cow's milk allergy, with eight studies not confirming the presence of IgE by appropriate tests. Only five studies reported on symptoms of both IgE and non-IgE mediated cow's milk allergy and three of these did not test for the presence of IgE. One study used IgG tests for diagnosis.

1.2.6.13. Mustard allergy prevalence across Europe

There was only one study which examined the prevalence of allergy to mustard. This was conducted in a French population of 5-17 year olds, 3% (95% CI: 2.1-4.3%) of which self-reported adverse reactions to mustard (no distinction was made between likely IgE or non-IgE mediated reactions; Touraine 2002).

1.2.6.14. Mustard allergy prevalence in different regions of the world

There were no studies on mustard allergy in other regions of the world.

1.2.6.15. Peanut allergy prevalence across Europe

The peanut allergy prevalence data was derived from 11 countries, including Denmark, France, Germany, Greenland, Hungary, Iceland, Norway, Sweden, The Netherlands, Turkey and the UK. The

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

data was published from 1996 to 2012 and the age range of the participants ranged from birth -97 years.

Fifteen studies looked into the self-reported prevalence of peanut allergy. The lowest prevalence rate, 0% (95% CI: 0-1.5%) was reported in 18 month olds from Iceland (Kristjansson 1998). The highest was reported for a group of 15-17 year olds from France ((15% (95% CI:13-17.3%)) (Touraine 2002). Two studies, both conducted in the UK, reported prevalence based on a clinical history of peanut allergy. This ranged from 0.2% in 0-14 year olds (Emmett 1999) to 0.4% in 4-6 year olds (Lack 2003) to 0.5% in those older than 15 years (Emmett 1999). Only one study focussed on clinician diagnosed peanut allergy with the lowest prevalence figures seen in 1 year olds from Sweden (0.2% (95% CI: 0.1-0.4)) (Ostblom 2008) and the highest from 8 year olds in the same study (4% (95% CI:3.4-4.8)) (Ostblom 2008).

Thirteen studies reported prevalence of peanut sensitisation based on skin prick test results and seven determined by serum-specific IgE levels. In the younger cohorts (0-3 years old), the rates of positive SPT ranged from 0.4% (95% CI: 0.0-1.2%) (Venter 2008) to 2.8% (95% CI: 1.5-5.3%) (Ro 2012). In the older children (>3 years) positive SPT results ranged from 0.7% (95% CI: 0.5-1.0%) (Mustafayev 2012) to 5.1% (95% CI: 3.8-6.8%) (Nicolaou 2010). In adults, the sensitisation rates determined by positive SPT were between 6.4% (95% CI: 2.8-13.2%)(Bakos 2006) and 6.8% (95% CI:not reported) (Schafer 2001). Similarly, for specific IgE levels, in the younger cohorts (0-3 years old) only one study from Norway determined specific IgE levels in younger children reporting a rate of sensitisation to peanut ranged between 2.6% (95% CI: 1.8 – 3.8%) (Krause 2002) and 12.2% (95% CI: 9.7 – 15.2%) (Nicolaou). In adults sensitisation rates to peanut were reported between 0% (95% CI: 0 – 12.0%) (Bakos 2006) and 3.1% (95% CI: 2.3 – 4.2%) (Bjornsson 1996).

Six studies based peanut allergy prevalence rates on a good clinical history plus a positive SPT. The prevalence rates determined using this method ranged from 0.0% in 18 month olds in Iceland (95% CI: 0-1.5%) (Kristjansson 1999) and 18 years olds in Turkey (95% CI: 0.0 - 0.1%) (Gelincik 2008) to 0.6 (95% CI: 0.4-1.0%) in a whole population in Germany (Zuberbier 2004). Only one study based peanut allergy prevalence rates on a good clinical history plus a positive serum specific IgE result. This study was conducted in Sweden and found a prevalence of 2.4% (95% CI: 1.9-3.1%) (Ostblom 2008a)

Five studies used open food challenge and a good clinical history and eight studies used a good clinical history plus DBPCFC to diagnose peanut allergy. Based on OFC and a good clinical history the highest prevalence rate was 1.4% (95% CI: 0.9-2.3%) reported in 3-4 year olds children (Grundy 2002) and based on DBPCFC and history the highest prevalence rate reported was 2.8% (95% CI: 1.8-3.8%) in 3-6 year old children (Hourihane 2007). Both of these studies were conducted in the UK. Four studies utilised a good clinical history plus positive SPT, and/or a positive food challenge (either OFC or DBPCFC) to determine prevalence rates. The highest rate was reported by Nicolaou 2010 in 8 year old children as 1.9% (95% CI:1.2-2.9%).

Peanut allergy is classically considered to be an IgE-mediated allergy. Of the studies examining the prevalence of peanut allergy in Europe, 15 assessed both IgE and non-IgE mediated peanut allergy (although in two of these studies, they did not perform tests to determine the presence or absence of IgE) and 13 IgE-mediated allergy only.

1.2.6.16. Peanut allergy prevalence in different regions of the world

A number of studies outside of Europe have looked at the prevalence rates of peanut allergy. The countries included Australia, Canada, China, Ghana, Hong Kong, Israel, Korea, Philippines,

EFSA supporting publication 2013:EN-506

105

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

Singapore, Taiwan, United Emirates and the USA. The studies were published between 1987 and 2012 and included all ages.

Nine studies looked into the self-reported prevalence of peanut allergy. The lowest prevalence rate (0.1% (95% CI: 0.1-0.2%)) was reported in 12 – 15 year olds from Korea (Oh 2004) and the highest in an adult group from the US (8.4% (95% CI: 6.2%-11.2%)) (Greenhawt 2009). Seven studies, mostly questionnaire based studies from the US and Canada, reported prevalence based on a reported clinical history (in some cases with reported history of a clinician diagnosis) of peanut allergy ranging from 0.1% (95% CI: 0.0 – 0.2%) in 0-2 years olds in Israel (Dalal 2002) to 2.8% (95% CI: 2.3 – 3.4%) in 3-5 year olds in the US (Gupta et al. 2011). Only three studies focussed on clinician diagnosed peanut allergy with the lowest prevalence figures reported in a study of adults from Canada (0.3% (95% CI:0.18-0.34)) (Ben-Shoshan 2010) and the highest in a study of 6-9 year olds from the UAE (2.3% (95% CI:1.1-4.4)) (AI-Hammadi 2010).

Five studies reported data on skin prick test results and four studies determined specific IgE levels. In the younger cohorts (0-3 years old), the rates of positive SPT ranged from 0.3% (95% CI: 0.0-2.1%) (Hu 2010) to 6.4% (95% CI: 5.5-7.3%) (Osborne 2011). Woods 2002 reported figures of 5.7% (95% CI: 3.8-8.3%) in adults in Australia and Arbes 2005 a figure of 8.6% (95% CI: 8.1-9.2%) in all ages in the US, indicating the lack of studies of using SPT data in countries outside of Europe. Different age cut-offs were used to describe sensitisation rates to peanut allergens measured by specific IgE levels, but Kumar 2011 report a very high sensitisation rate of 13.5% (95% CI: 11.6-15.7%) in children under 6 years in the US. The highest reported sensitisation rates in adults were 8.7% (95% CI: not reported) in 20 - 39 year olds in the US (Liu 2010). This study also reported a sensitisation rate of 7.6% (95% CI:not reported) for all ages (Liu 2010).

Only two studies based peanut prevalence rates on a good clinical history plus a positive SPT. Dalal 2002 found no peanut allergy in 0-2 year olds in Israel and Woods 2002 reported a rate of 0.4% (95% CI: 0.1-1.8%) in 26-50 year olds in Australia. In the only study outside of Europe to utilise food challenges to assess the prevalence of peanut allergy Osborne 2011 2.9% (95% CI: 2.2-3.5) of 12-15 month olds had peanut allergy, based on open food challenges. Four studies utilised other methods to diagnose peanut allergy. These studies have used varied methodologies which makes them difficult to compare, but the prevalence rates reported range between 0.3% in an elderly US population (Liu 2010) up to 2.7% (95% CI: not reported) in 6-19 year olds in the US.

Peanut allergy is classically considered to be an IgE-mediated allergy. Of the studies examining the prevalence of peanut allergy outside of Europe, two assessed both IgE and non-IgE mediated peanut allergy. The remainder of the studies assessed IgE-mediated allergy only, although of these nine did not utilise SPT or SIgE to determine the presence or absence of IgE and one did not clearly define how they determined that the allergy was IgE-mediated.

1.2.6.17. Sesame allergy prevalence across Europe

Studies looking at the prevalence of sesame allergy in Europe were from four countries: France, Germany, Hungary and the United Kingdom. Eight studies from Europe were reported between 1999 and 2008 and all ages were studied.

Self-reported sesame allergy was investigated in three studies, with the highest prevalence seen in France where 1.5% (95% CI: 0.9-2.4%) of 5-17 year olds self-reported an adverse reaction (Touraine 2002). The lowest rate was found in the United Kingdom where, across all age groups, 0% (95% CI: 0.0-0.1%) self-reported sesame allergy (Emmett 1999). Sensitisation to sesame measured by SPT was reported in four studies. Roberts 1999 reported the lowest rate of sensitisation, 0.1% (95% CI: 0.0-0.5%), in 7-year-old children in the UK and Venter 2008 the highest, 1.4% (95% CI: 0.7-2.7%), in 3

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

year olds also from the UK. Only one study determined specific IgE levels to sesame and found 0% (95% CI: 0.0-4.2%) of the 60-97 year olds in Hungary investigated were sensitised (Bakos 2006). In Germany, a population based study reported prevalence rates based on a positive skin prick test plus a convincing clinical history of 2.2% (95% CI: 1.7-2.7%) (Zuberbier 2004). In the United Kingdom, two studies challenged those with suspected sesame allergy reporting prevalence of between 0.1% (95% CI: 0.0-0.8%) in 6 year olds (Venter 2006) and 0.6% (95% CI: 0.2-1.4%) in 3 year olds (Venter 2008). Pereira 2005 performed a DBCPCFC to sesame in a 15-year old on the IOW, who did not have a positive result (not shown in table).

For those studies examining the prevalence of sesame allergy in Europe, six looked at both IgE and non-IgE mediated allergy (one of which did not utilise SPT or SIgE to determine the presence or absence of IgE) and two IgE-mediated allergy only.

1.2.6.18. Sesame allergy prevalence in different regions of the world

Only four studies that investigated the prevalence of sesame allergy could be identified in other regions of the world, these were from Australia, Canada, Israel and the United States. Studies were reported between 2002 and 2011 and all ages were studied. Self reported sesame allergy was investigated in a Canadian study, with the highest prevalence reported in children under the age of 18 years 0.2% (95% CI: 0.0-0.4%) (Ben-Shoshan 2010) and the lowest rate in adults 0.1% (95% CI: 0.0-0.1%) (Ben-Shoshan 2010). Sensitisation (determined by skin prick test) to sesame was observed in 1.6% (95% CI: 1.2-2.1%) of 12-15 month olds in Australia (Osborne 2011). Three studies looked at a clinical history of sesame allergy and reported figures ranging from 0% (95% CI: 0.0-0.1%) in the US (Sicherer 2010) to 0.2% (95% CI: 0.0-0.4%) in Canada (Ben-Shoshan 2010) and 0.2% (95% CI: 0.1-0.3%) in Israel (Dalal 2002). Two studies reported prevalence rates for sesame allergy based on open food challenges, with a study conducted in the UK reporting prevalence rates of 0.6% (95% CI: 0.2-1.4) in 3 year olds and 0.1% (95% CI: 0-0.8) in 6 year olds (Venter 2008), and a study conducted in Australia reporting a rate of 0.7% (95% CI: 0.4-1.0) in 12-15 month olds (Osborne 2011). For those studies examining the prevalence of sesame allergy outside of Europe, two looked at both IgE and non-IgE mediated allergy (one of which did not utilise SPT or SIgE to determine the presence or absence of IgE) and two IgE-mediated allergy only.

1.2.6.19. Soya allergy prevalence across Europe

There were 15 studies that looked at soya allergy prevalence across Europe. The countries included Denmark, Germany, Hungary, Iceland, Sweden, The Netherlands and the United Kingdom. The data was reported from 1994 to 2008 and all ages were included.

Eight studies reported prevalence based on self-reported soya allergy with the highest prevalence reported by a study conducted in Sweden in 4 year olds (1.2%, 95% CI: 0.8-1.7%) (Ostblom 2008a) and the lowest prevalence reported by a study conducted in the United Kingdom, with 0% (95% CI: 0.0-0.1%) of those older than 15 years self-reporting an adverse reaction to soya (Emmett 1999). Only one study reported the prevalence of clinician diagnosed soya allergy, which found the following prevalence rates: 0.2% (95% CI: 0.1-0.4%) in 1 year olds and 0.8% (95% CI: 0.5-1.2%) in 4 and 8 year olds in Sweden (Ostblom 2008a).

Four studies reported sensitisation data based on a positive skin prick test with the highest sensitisation rate reported by a Hungarian study of 20-69 year olds (8.3%, 95% CI: 2.2-23.6%) (Bakos 2006) and the lowest in a group of 7 year olds from the United Kingdom, with only 0.2% (95% CI: 0.0-0.7%) having a positive skin prick test to soya. Four studies used serum-SIgE tests and reported sensitisation rates ranging from 2.1% (95% CI: 1.4-3.0%) in a group of 20-44 year olds in Sweden (Bjornsson 1996) to 3.7% (95% CI: 1.2-9.7%) in 60-97 year olds in Hungary (Bakos 2006). When a

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

convincing history was combined with sensitisation, prevalence of soya allergy ranged from 0% (95% CI: 0.0-1.4%) in 18 month olds in Sweden (Kristjansson 1999) to 1.6% (95% CI: 1.1-2.1%) of 4 year olds, also in Sweden (Ostblom 2008a). Only one study performed a double-blind placebo-controlled food challenge, reporting 0% prevalence to soya in 0-22 year olds (Osterballe 2009). For those studies examining the prevalence of soya allergy in Europe, ten looked at both IgE and non-IgE mediated allergy (two of which did not utilise SPT or SIgE to determine the presence or absence of IgE) and five IgE-mediated allergy only.

1.2.6.20. Soya allergy prevalence in different regions of the world

There were 13 studies conducted in Canada, China, Ghana, Israel, Korea, Taiwan, Thailand and the United States. The data was published from 1987 to 2012 and all ages were included. Seven studies presented data for self-reported adverse reactions to soya with the lowest rate found in Korea; affecting in 0.1% (95% CI: 0.1-0.2%) of 12-15 year olds (Oh 2004). The highest rate was reported by Bock 1987, with 2.7% (95% CI: 1.2-4.2%) of 0-3 year olds in the United States reporting soya allergy. Four studies reported the prevalence of soya allergy based on clinical history and/or clinician diagnosis soya allergy with 0% (95% CI: 0.0-0.2%) of 0-2 year olds in Israel (Dalal 2002) and 0.6% (95% CI: 0.4-0.8%) of 11-13 year olds in the United States (Gupta 2011) diagnosed with soya allergy. One study reported sensitisation based on skin prick test data, with sensitisation rates varying from 0.5% (95% CI: 0.1-2.1%) in 0-2 year olds in 2009 to 1% (95% CI: 0.3-3.1%) of 0-2 year olds in 1999 (Hu 2010). One study combined clinical history and sensitisation reporting a prevalence of soya allergy of 0% (95% CI: 0.0-0.1%) in 0-2 year olds in Israel (Dalal 2002). No studies outside of Europe used food challenges to confirm soya allergy. One study measured IgG levels reporting a prevalence of 7.2% (95% CI: 6.6-7.7%) of adults in China (Sai, 2010) however caution should be applied to these results as IgG is not a true and accurate measure of food allergy. For those studies examining the prevalence of soya allergy outside of Europe, 11 looked at both IgE and non-IgE mediated allergy (seven of which did not utilise SPT or SIgE to determine the presence or absence of IgE), four IgE-mediated allergy only and one IgG-mediated only.

1.2.6.21. Tree Nuts allergy prevalence across Europe

The tree nut prevalence data was derived from 11 countries, including Finland, Germany, Greenland, Hungary, Iceland, Norway, Spain, Sweden, The Netherlands, Turkey and the UK. The data was published from 1982 to 2009 and all ages were included. The discussion will divide the results into all nuts- unspecified, hazelnuts, walnuts, almond, pistachio nuts, brazil nuts, cashew nuts and pecan nuts.

All nuts unspecified

Studies where the particular nut(s) studied were not reported have mainly focussed on self-reported "nut" allergy. The lowest rate of self-reported nut allergy was in Turkey amongst a group of adult respondents (0.1% (95% CI: 0-0.6%) (Gelincik 2008) and the highest rates were reported in Spain amongst 6-13 year olds (6.9% (95% CI: 6.2-7.6%)) (Martinez-Gimeno 2000).

Only one study (conducted in Sweden) reported results based on SPT and a clinical history, which found that no parents reported their 18 month old to have a "nut" allergy (Kristjansson 1999). In addition, one study looked at clinician diagnosed nut allergy and found that 0.1% (95% CI: 0-0.6) of one year olds, 0% (95% CI: 0-0.6%) of two year olds, 0.5% (95% CI: 0.2-1.4%) of three year olds and 0.4% (95% CI: 0.1-1.2%) of four year olds in Finland suffered from a "nut" allergy (Pyrhonen 2009). For those studies examining the prevalence of unspecified tree nut allergy in Europe, all ten looked at both IgE and non-IgE mediated allergy, six of which did not utilise SPT or SIgE to determine the presence or absence of IgE.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.
Hazelnuts

Nine studies have examined the prevalence of hazelnut allergy. The lowest rate of reported hazelnut allergy was amongst 6-9 year olds in Turkey (0.3% (95% CI: 0.1-0.6%)) (Orhan 2006) and the highest rates amongst 10-11 year olds, also in Turkey (1.5% (95% CI:1.2-1.8%)) (Mustayev 2012). Sensitisation to hazelnut was tested by using SPT in five studies, with the lowest rates reported by Roberts 2005 in a 7-year-old cohort in the UK (0.1% (95% CI:0-0.5%)) and the highest in a group of of 25-74 year olds in Germany (11.3% (95% CI: not reported)) (Schafer 2001). Only one study measured specific IgEs to hazelnut in an adult and elderly population in Hungary and found rates of 0.0% - 9.7% with the highest figures seen in the 60 - 97 year group (Bakos 2006). When prevalence rates were determined by combining SPT and a good clinical history (four studies), the lowest rates were reported for those older than 18 years in Turkey (0% (95% CI: 0-0.1%)) (Gelincik 2008) and the highest rates in Germany in a whole population (5.9% (95% CI: 5.1-6.8%), Zuberbier 2004). Utilising a good clinical history, positive SPT and/or a positive OFC/DBPCFC, Venter 2008 found that 0.1% (95% CI: 0.0-0.2%) of 3 year olds suffer from a hazelnut allergy in the UK. For those studies examining the prevalence of hazelnut allergy in Europe, four looked at both IgE and non-IgE mediated allergy and five IgE-mediated allergy only.

Walnut allergy

Only six studies in Europe investigated self-reported rates of adverse symptoms to walnut, sensitisation to walnut or prevalence of walnut allergy. In terms of sensitisation, Roberts 2005 found that 0.5% (95% CI: 0.3-1%) of 7 year olds in the UK have a positive SPT to walnut (Roberts 2005). Bakos 2006 found that 3.7% (95% CI: 1.2-9.7%) of 60 - 97 year olds in Hungary showed sensitisation to walnut measured by specific IgE levels (Bakos 2006). A study conducted in Germany found that 1.4% (95% CI: 1.1-1.8%) of respondents were diagnosed with a walnut allergy based on history and SPT and 1.0% (95% CI: 0.7-1.4%) based on history and a positive DBPCFC outcome (Zuberbier 2004).

Three studies from Turkey investigated walnut allergy. Orhan 2009 found that, in a group of 6-9 year olds, 0.3% (95% CI: 0.1-0.6%) reported a problem on ingestion of walnut, 0.1% (95% CI: 0.0-0.3%) were diagnosed with a walnut allergy based on a good clinical history and positive SPT, and 0.0% (95% CI: 0-0.2%) were diagnosed based on DBPCFC and a good clinical history. A further study found that 1.2% (95% CI: 1.0-1.5%) of 10 -11 year olds in Turkey reported a problem on ingestion of walnut and reported prevalence of 0.4% (95% CI: 0.1-1.2%) based on an OFC and a good clinical history (Mustayev 2012). Gelincik 2008 reported that 0.1% (95% CI: 0.1-1.2%) of adults suffered from walnut allergy based on DBPCFC outcome and a good clinical history (Gelincik 2008). For those studies examining the prevalence of walnut allergy in Europe, two looked at both IgE and non-IgE mediated allergy and four IgE-mediated allergy only.

Almond

Five studies in Europe investigated almond allergy. Ostblom 2008a reported that 3.8% (95% CI: 3.1-4.7%) of 4 year olds in Sweden reported problems with almond. In terms of sensitisation, Venter 2008 determined that 0.3% (95% CI: 0.0-1.2%) of 3 year olds in the United Kingdom had a positive SPT to almond and that 0.2% (95% CI: 0.0-0.9%) of 3 year olds had either a positive SPT with a good clinical history and/or a positive OFC/DBPCFC outcome. Also in the UK Roberts 2005 found that 0.5% (95% CI: 0.2-0.9%) of 7 year olds are sensitised to walnut. Bakos 2009 found that no 60-97 year olds in Hungary had positive specific IgE levels to almond. Furthermore, in a study conducted in Iceland and Sweden, the prevalence rates for almond allergy in 18 months old were reported to be 0% (95% CI: 0-1.4%) and 0% (95% CI:0-1.5%) respectively based on skin prick test and history (Kristjansson 1999). For those studies examining the prevalence of almond allergy in Europe, three looked at both IgE and non-IgE mediated allergy and two IgE-mediated allergy only.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

Pistachio

Only one study in Europe investigated pistachio allergy which reported that 0.8 % (95% CI: 0.6-1.1%) of 10-11 year olds in Turkey reported a problem on ingestion of pistachio (Musatayev 2012). This study examined IgE-mediated allergy only.

Pecan

Pecan allergy was only reported in one study in Europe, indicating that 0.2% (95% CI: 0.0-0.5%) of 7-year-olds in the UK are sensitised to Pecan (Roberts 2005). This study examined IgE-mediated allergy only.

Brazil

Sensitisation and allergy to brazil nut was reported in only two, UK-based, studies, one of which examined both IgE and non-IgE mediated allergy and the other IgE-mediated allergy. In younger children Venter 2008 reported 0.3% (95% CI: 0.0-1.2%) of 3 year olds and 0.2% (95% CI: 0.0-0.9%) of 3 year olds to be sensitised to brazil nut. In older children, Roberts 2005 found that 0.5% (95% CI: 0.3-1%) of 7-year-olds in the UK are sensitised to brazil nut.

Cashew

Three studies from the UK (one of which examined both IgE and non-IgE mediated allergy and the other two IgE-mediated allergy) found that 0.2% (95% CI: 0.0-1.0) of 3 year olds (Venter 2008), 0.1% (95% CI: 0.0-0.2%) of 4 year olds (Tarik 1996) and 0.4% (95% CI: 0.2-0.8%) of 7-year olds (Roberts 2005) are sensitised to cashew nut. One study confirmed cashew nut allergy by food challenge in 0.1% (95% CI: 0.0-0.2%) of 3 year olds (Venter 2008).

1.2.6.22. Tree Nuts allergy prevalence in different regions of the world

Nine studies conducted in non-European countries investigated tree nut allergies with the majority of studies coming from the US and Canada. The studies were published between 1997 and 2008 and included all ages.

All nuts unspecified

Self-reported allergy to "nuts" was reported in three studies. The lowest rates were reported in 22 - 44 year olds in Australia (0.6% (95% CI: 0.2-1.6%) (Woods 1998) and the highest rates reported in 4-6 year olds in Singapore (4.7% (95% CI: 4.1-5.4%)) (Shek 2010). Prevalence of "nut" allergy based on clinical history was reported in four studies with the lowest rates from the US in those under 18 years old (0.2% (95% CI: 0.1-0.3%)) (Sicherer 1997, Sicherer 2002) and the highest in those over 18 years old (1.6% (95% CI: 1.4-1.9%)) (Sicherer 1997). One study from Korea reported the prevalence of clinician diagnosed nut allergy in 0-12 months old children to be 0.7% (95% CI: 0.3-1.4%) (Kim 2011). For those studies examining the prevalence of unspecified tree nut allergy outside of Europe, two looked at both IgE and non-IgE mediated allergy and four IgE-mediated allergy only (although two did not test for the presence or absence of IgE).

Pistachio allergy

Only one study conducted outside of Europe reported (IgE mediated) prevalence to a particular tree nut. Wan 2012 reported that 2.2% (95% CI: 1.4-3.3%) of 6-8 year old Taiwanese children suffer from pistachio allergy based on history and a positive specific IgE level.

1.2.6.23. All other foods, allergy prevalence across Europe

Unsurprisingly, allergies to numerous less common foods have been reported in the literature in a wide number of countries, both in and outside Europe and at all ages. In Europe, 27 studies looked at the prevalence of allergy to "other foods". The less common food allergens that were reported

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

included (but were not limited to): vegetables, such as peas, tomato, spinach, eggplant and carrot, in addition to chocolate, garlic, honey, pork, black pepper, pickle, cocoa, potato, sugar, chicken and beef. Generic terms such as "colourings" "additives "junk food" and "soft drinks" were also reported as allergens in the titles of journal articles. The majority of such studies used self-report methods to determine prevalence. SPT plus clinical history was used by only two studies reporting prevalence of allergies to carob, carrageen and guar gum in adults in Germany (all < 1%) (Zuberbier 2004) and to pea of 0% (95% CI: 0.0-1.5%) in 18 month old infants in Iceland (Kristjansson 1999).

Only seven studies used food challenges when reporting prevalence rates (Gelincik 2008; Mustafayev 2012; Orhan 2009; Osterballe 2005; Venter 2006; Venter 2008; Zuberbier 2004). It is difficult and perhaps illogical to combine and summarise these studies due to the heterogenity of the allergens and populations studied. However, with the exception of Zuberbier 2004, who reported a 1.8% (95% CI: 1.4-2.4%) prevalence of challenge proven allergy to "vegetables" (n = 3156), the other six studies all reported prevalence rates of less than 0.5%. For those studies examining the prevalence of other food allergies in Europe, 25 looked at both IgE and non-IgE mediated allergy (11 of which did not test for the presence or absence of IgE) and three IgE-mediated allergy only.

1.2.6.24. All other foods, allergy prevalence in different regions of the world

Outside of Europe, 16 studies looked at the prevalence of allergy to "other foods". The studies were conducted in Australia, Canada, China, Colombia, Ghana, Hong Kong, India, Israel, Korea, Taiwan, Thailand, United Arab Emirates and the United States. Unusual allergens that were reported in countries outside of Europe that were not reported in Europe included cassava, cocoyam, sorghum and okra in Ghana (Obeng 2011); perilla seeds and buckwheat in Korea (Kim 2011; Oh 2004); duck in Thailand (Santadusit 2005); and monosodium glutamate in Australia (Woods 1998). The majority of the studies relied on self-report measures as a means of diagnosis, with none of the studies using food challenges. Sai (2011) used IgG as a measure of food allergy, and Leung (2009) reported self-reported clinician-diagnosed prevalence of allergy to several foods. For those studies examining the prevalence of other food allergies outside of Europe, three looked at both IgE and non-IgE mediated allergy (one of which did not test for the presence or absence of IgE), twelve IgE-mediated allergy only (seven of which did not test for the presence or absence of IgE) and one IgG-mediated allergy only.

1.2.6.25. Prevalence of allergy to any food across Europe

We have reviewed all the included European studies in our systematic review to identify those studies which have reported on rates of diagnosed food allergy based on objective measures including clinician diagnosed food allergy/good clinical history plus supporting test or those who had either an open (OFC) or double blind placebo controlled food challenges (DBPCFC). We were able to identify a total of eight studies carried out in Denmark, Finland, Germany, United Kingdom and Turkey.

Denmark

Eller 2009 investigated food allergy in Danish children aged 0-6 years and reported that 3.6% of children suffered from any food allergy by 6 years based on OFC or DBPCFC (95% CI: 2.3 - 5.4%). Self-reported FA to any food by the age of 6 years was 11.6% (95% CI: 9.2-14.5). The main foods implicated were milk, egg and peanut. Osterballe 2005 reported OFC/DBPCFC confirmed FHS in young adults in Denmark as 1.7% (95% CI: 1.1 - 2.95%). Self-reported FHS was 19.6% (95% CI: 17.0-22.4). The most common allergenic food was peanut followed by additives, shrimp, codfish, cow's milk, octopus and soy.

Looking at young children (0-3 year olds), older siblings and parents of the young children, OFC/DBPCFC-confirmed FHS was 2.4% (95% CI: 1.8-3.2) in the whole population studied and 1.6%

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

(95% CI: 0.9-2.6) in the children (Osterballe 2005). Breaking the point prevalence figures into specific age groups the data was: 2.3% (95% CI: 1.3-4.0) at the age of 3 years, 0.0% (95% CI: 0.0-3.3) in those under 3 years, 1.0% (95% CI: 0.3-2.9) in those children over 3 years and 3.2% (95% CI: 2.3-4.5) in the adults. The point prevalence of reported FHS in this study was: 13.0% (95% CI: 11.6-14.7) in all of those studied, 14.1% (95% CI: 12.0-16.5) in the adults and 11.9% (95% CI: 10.0-14.1) in children of all ages. The most common allergenic foods were hen's egg affecting the children 3 years of age and peanut in the adults. Codfish and shrimp allergies were seen in the adults but not in the children.

Germany

Zuberbier 2004 conducted a whole population study in the Germany. The point prevalence of adverse reactions to food confirmed by DBPCFC tests in the Berlin population as a mean of all age groups was 3.6% (95% CI: 3.0-4.2%) and 3.7% in the adult population (18-79 years, 95% CI: 3.1-4.4%). Two and a half percent were IgE-mediated and 1.1% non-IgE-mediated. In the children (0-17 years), the prevalence of all FHS was 4.2%; IgE-mediated was 3.5% (95% CI: 2.4-5.1%) and non-IgE-mediated was 0.7% (95% CI: 0.3-1.6%). Foods most commonly identified by oral challenges were apple, hazelnut, soy, kiwi, carrot and wheat. The self-reported lifetime prevalence of any adverse reaction to food in the Berlin population (mean age 41 years) was 34.9%.

Turkey

Gelincik 2008 reported FHS based on DBPCFC in adults (>18 years) in Turkey as 0.1% (95% CI: 0.05-0.18). Adding those with non-allergic FA, the figures were 0.3% (95% CI: 0.2 - 0.4). The foods most commonly implicated in the reactions were tomato, cocoa and egg. The lifetime prevalence or self-reported FA and NAFA of all ages reported in the paper was 9.5% (95% CI: 8.9-10.0). Orhan 2009 reported DBPCFC confirmed FA in 6-9 year old Turkish children as 0.8% (95% CI: 0.5 - 1.1). Using a positive SPT and a clear history as the diagnostic end point, the recorded prevalence was 1.8% (95% CI: 1.3-2.3). The most common allergenic foods were beef, cow's milk, cocoa, egg and kiwi. Self-reported food allergy in this group was 5.7% (95% CI: 4.8-6.6). In another study focusing on IgE-mediated FA only, Mustayev 2012 reported a prevalence rate of 0.1% (9/6963; 95% CI: 0.1-0.3) in adolescents in Turkey. The most common foods involved in allergic reactions were walnut and beef, followed by egg, peanut, spinach, kiwi, cheese, hazelnut and peach. A total of 2.2% (152/6963; 95% CI 1.9-2.6) of parents reported a food related problem.

United Kingdom

Pereira 2005 studied 11 and 15 year old children in the UK. In the 11 year old cohort FHS confirmed by DBPCFC was 0.1% (95% CI: 0-0.7%) and OFC-confirmed FHS: 1.0% (95% CI: 0.5-2.0%). In the 15 year old cohort, DBPCFC-confirmed FHS was 0.5% (95% CI: 0.2-1.4%) and OFC-confirmed FHS 1.1% (95% CI: 0.5-2.1%). Using a positive SPT and/or a good clinical history or a positive food challenge as diagnostic end point, the figures were (at 11 years) 2.3% (95% CI: 1.5-3.6) based on a clear clinical history and/or OFC or 1.4% (0.8-2.5) based and/or a clear clinical history or DBPCFC. At 15 years, based on a clear clinical history and/or OFC, the rates were 2.2% (95% CI: 1.4-3.6) or 2.1% (95% CI: 1.3-3.4) based on a clear clinical history and/or DBPCFC. Among the 11-year-olds, the foods most commonly implicated in FHS were peanuts, tree nuts, egg, milk, shell fish, gluten, green beans, cheese, kiwi, tomato, and additives. Among the 15-year-olds, the foods implicated were peanut, tree nuts, gluten, wheat, shellfish, egg, milk, and additives. Self-reported rates of FHS were 11.6% (95% CI: 9.5-14.1%) at 11 years and 12.4% (95% CI: 10.3-15.0%) at 15 years.

Venter et al studied a birth cohort age 1-3 years and a separate cohort at the age of 6 years. The prevalence of FHS defined by a positive OFC was 2.8% (95% CI: 1.9-4.1) at 1 year, 1.0% (95% CI: 0.6-2.0) at two years and 0.8% (95% CI: 0.4-1.6) at 3 years. FHS diagnosed using a positive DBPCFC was 1.3% (95% CI: 0.8-2.3) at one year, 0.1% (95% CI: 0.0-0.7) at two years and 0.0% at 3 years. Using a clear clinical history and/or a positive OFC/DBPCFC as diagnostic end point the figures were

EFSA supporting publication 2013:EN-506

for OFC: 3.0% (95% CI: 2.1-4.3) at one year, 2.5% (95% CI: 1.5-3.7) at two years and 3.0% (95% CI: 2.1-4.4) at 3 years. For DBPCFC this was 2.7% (95% CI: 1.8-3.9) at one year, 2.1% (95% CI: 1.3-3.3) at two years and 2.9% (95% CI: 2.0-4.2) at 3 years. Using open food challenge and a good clinical history, the cumulative incidence of FHS was 6.0% (95% CI: 4.6-7.7). Based on DBPCFC and a good clinical history, the cumulative incidence was 5.0% (95% CI: 3.7-6.5). Overall, 33.7% of parents reported a food-related problem. The main foods implicated in the allergic reactions were milk, egg and peanut.

Looking at different group of children recruited at 6 years of age, based on open food challenge and/or suggestive history and skin tests, the prevalence of FHS was 2.5% (95% CI: 1.5-3.8). Based on double-blind challenges, a clinical diagnosis or suggestive history and positive skin tests, the prevalence was 1.6% (95% CI: 0.9-2.7). Self-reported prevalence of FHS was 11.8% (95% CI: 9.6-14.2) in this cohort. Milk, peanut and wheat were the key food allergens amongst those with positive challenges.

1.2.6.26. Prevalence of allergy to any food in different regions of the world

Very few studies outside of Europe used food challenge outcome as the final diagnostic point to determine the prevalence of food allergy. Looking at the studies we have identified from our systematic review a total 4 studies have reported on overall food allergy based on food challenge.

China

Chen 2011 studied the prevalence of FA in 0-1 year old children in Chongqing, China and found an overall prevalence of challenge-proven FA of 3.8% in infants (95% CI: 2.5-5.9%). The main foods implicated were egg and milk. Among the parents, 9.3% (46/ 497; 95% CI: 6.9-12.2) reported that their child had adverse food reactions. Looking at the prevalence of FA in 0-2 year olds, Chen 2012 reported an overall prevalence of challenge-proven FA of 5.9% (95% CI: 4.9-7.2%). The most common food allergy was to egg, but cow's milk, shrimp and fish were also common allergens. Hu 2010 reported on FA in 1999 and 2009 in China and reported that food allergy prevalence increased significantly from 3.5% (11/314; 95% CI: 1.9-6.4) in 1999 to 7.7% (31/401; 95% CI: 5.4-10.9) in 2009 (p= 0.017). The main foods implicated were egg and milk and the rates did not change over the 10 year period. Reported rates of FA was 13.7% (43/314; 95% CI: 10.2-18.1) in 1999 and 16.7% (67/401; 95% CI: 13.3-20.8) in 2009.

Thailand

The study by Lao-araya 2012 focused on IgE mediated food allergy only. The prevalence of IgEmediated FA confirmed by OFC was 1.1% (95% CI: 0.4-3.0). The five main allergens reported were shrimp, cow's milk, fish, chicken eggs, and ant eggs. Forty-two children (9.3%; 42/452; 95% CI: 6.9-12.4) were reported to have FA.

United States

The study reported by Bock 1987 is one of the first papers reporting FHS based on oral food challenge outside of Europe and the only one ever from the US. Bock 1987 showed that of the 501 children enrolled into the study, 37 (7.7%; 95% CI: 5.6-10.6) were diagnosed with FHS by means of either OFC or DBPCFC. However, 27.7% (95% CI: 23.8-32.0) were thought to have symptoms produced during food ingestion, due to parental reported problems. The most common foods implicated in the allergic reactions were egg and milk.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questi | onnaire-based me | ethods | Sensitis | ation | Sensitisation w | ith clinical history | Food challeng hist | e with clinical ory | Other |
|---------------------|---------|---------------------|-------------|---------------|---|---|------------------|-------------------------|---|---|----------------------------|----------------------|-----------------------|------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Prev | alence (CI) | | | | |
| Touraine (2002) | France | 2000- 2001 | 5-17 years | celery/carrot | Both IgE and non-IgE mediated (no SPT or SIgE) | 5.5 [†] (4.3-7.1) n=1086 | - | - | - | - | - | - | - | - | - |
| Zuberbier (2004) | Germany | 1999- 2000 | 0-80+ years | celery | Both IgE and non-IgE mediated | - | - | - | - | - | 3.5 (2.9-4.2) n=3156 | - | - | - | - |
| Schafer (2001) | Germany | 1997- 1998 | 25-74 years | celery | Both IgE and non-IgE mediated | - | - | - | 9.1 [†] (nr) n=nr | - | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002- 2004 | 20-69 years | celery | IgE mediated only | - | - | - | 11.1 [†] (3.6-27.0) n=36 | $\begin{array}{c} 2.8^{\dagger} \\ (0.2-16.2) \\ n=36 \end{array}$ | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002- 2004 | 60-97 years | celery | IgE mediated only | - | - | - | 3.7 [†] (1.2-9.7) n=109 | $ \begin{array}{r} 9.2^{\dagger} \\ (4.7-16.6) \\ n=109 \end{array} $ | - | - | - | - | - |

Table 1.10: Celery allergy prevalence in European countries by age group

[†]Percentage prevalence and/or confidence intervals calculated from raw data provided in the paper

[‡]Percentage prevalence inferred from graph provided (no raw data reported).

[#] Data has been subject to correction or estimation by the authors (presented as reported in the paper).

Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

| Table 1.11: | Celery allergy | prevalence in | non-European | countries by | age group |
|--------------------|----------------|---------------|--------------|--------------|-----------|
|--------------------|----------------|---------------|--------------|--------------|-----------|

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | Questionnaire-based methods | | | isation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical ory | Other |
|------------|---------|---------------------|-----------|----------|-------------------------|---------------------|--|---|---|---------|-----------------------|----------------------------|-----------------------|------------------------|-------|
| | | | | | | Self-reported | Clinical historyClinician- diagnosedSkin prick testSerum-specific IgE | | | | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | 95% Prevalence (CI) | | | | | | | | | |
| Wan (2012) | Taiwan | Not Reported | 6-8 years | celery | IgE mediated only | - | - | - | - | - | - | 1.8 (1.1-2.9) n=1010 | - | - | - |

[†]Percentage prevalence and/or confidence intervals calculated from raw data provided in the paper

[‡]Percentage prevalence inferred from graph provided (no raw data reported).

[#]Data has been subject to correction or estimation by the authors (presented as reported in the paper).

Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

EFSA supporting publication 2013:EN-506

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | onnaire-based n | nethods | Sensit | isation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical ory | Other |
|----------------------|---------|---------------------|------------|--|---|---|---------------------|--|-----------------|-----------------------|-----------------------|----------------------|-----------------------|--------------------------------------|--------------------------------------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | · | 95% Preva | alence (CI) | | | · | |
| Osterballe (2005) | Denmark | 2000-2001 | < 3 years | wheat | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | 0 (nr) n= 111 | - | 0 [†] (0.0-4.2) n=111 |
| Osterballe (2005) | Denmark | 2000-2001 | 3 years | wheat | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0 [†] (0 - 1) n=486 | 0 [†] (0 - 1) n=486 |
| Osterballe (2005) | Denmark | 2000-2001 | 3-22 years | wheat | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0 (0 - 2) n=301 | 0 (0 - 2) n=301 |
| Osterballe (2009) | Denmark | 2001-2002 | 22 years | wheat | Both IgE and non-IgE mediated | 0.8^{\dagger} (0.4 - 1.8) n=843 | - | - | - | - | - | - | - | - | - |
| Osterballe (2005) | Denmark | 2000-2001 | >22 years | wheat | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0 [†] (0 - 0.5) n=936 | 0.1 [†] (0 - 1) n=936 |
| Pyrhonen (2009) | Finland | 2001-2009 | 1 year | barley/rye | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.5 [†] (0.9-2.7) n=853 | - | 1.3 [†] (0.7 - 2.4) n=853 | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 2 years | barley/rye | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.8 [†] (1.0-3.0) n=852 | - | 1.8 [†] (1.0-3) n=852 | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 3 years | barley/rye | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.3 [†] (0.7-2.4) n=784 | - | 2 [†] (1.2-3.4) n=784 | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 4 years | barley/rye | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.8 [†] (1.1-3.1) n=819 | - | 2.7 [†] (1.7 - 4.1) n=819 | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 1 year | cereals (oat/maize/rice/ millet/buckwhe at) | Both IgE and non-IgE mediated (no SPT or SIgE) | 2.3 [†] (1.5-3.7) n=853 | - | 1.1 [†] (0.5 - 2.1) n=853 | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 2 years | cereals (oat/maize/rice/ millet/buckwhe at) | Both IgE and non-IgE mediated (no SPT or SIgE) | 2 [†] (1.2-3.3) n=852 | - | 0.9 [†] (0.4-1.9) n=852 | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 3 years | cereals (oat/maize/rice/ millet/buckwhe at) | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.2 [†] (0.6-2.3) n=784 | - | 2 [†] (0.9 - 2.9) n=784 | - | - | - | - | - | - | - |

Table 1.12: Cereals allergy prevalence in European countries by age group

EFSA supporting publication 2013:EN-506

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | nnaire-based | methods | Sensit | isation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical ory | Other |
|---------------------|---------|---------------------|-------------|--|---|--|---------------------|--|-----------------|-----------------------|----------------------------|----------------------|-----------------------|----------------------------|----------------------------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Pyrhonen (2009) | Finland | 2001-2009 | 4 years | cereals (oat/maize/rice/ millet/buckwhe at) | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.5 [†] (0.8 - 2.6) n=819 | - | 2 [†] (1.2-3.2) n=819 | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 1 year | wheat | Both IgE and non-IgE mediated (no SPT or SIgE) | 1 (nr) n=261 | - | - | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 1 year | wheat | Both IgE and non-IgE mediated (no SPT or SIgE) | 2.1 [†] (1.3-3.4) n=853 | - | 1.6 [†] (0.9 - 2.8) n=853 | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 2 years | wheat | Both IgE and non-IgE mediated (no SPT or SIgE) | 1 (nr) n=202 | - | - | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 2 years | wheat | Both IgE and non-IgE mediated (no SPT or SIgE) | 2 [†] (1.2-3.3) n=852 | - | 2.4 [†] (1.5-3.7) n=852 | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 3 years | wheat | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.9 (0.4-1.9) n=784 | - | 3.1 [†] (2.0-4.6) n=784 | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 4 years | wheat | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.1 [†] (0.5 - 2.2) n=819 | - | 3.4 (2.3-5) n=819 | - | - | - | - | - | - | - |
| Touraine (2002) | France | 2000-2001 | 5-17 years | wheat | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.5 [†] (0.9-2.4) n=1086 | - | - | - | - | - | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | barley | Both IgE and non-IgE mediated | - | - | - | - | - | 2.2 (1.7-2.8) n=3156 | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | flour | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0.5 (0.3-0.8) n=3156 | 0.1 (0.0-0.3) n=3156 |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | flour | Both IgE and non-IgE mediated | 0.7 [†] (nr) n=nr | - | - | - | - | - | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | oatmeal | Both IgE and non-IgE mediated | - | - | - | - | - | 1.2 (0.9-1.7) n=3156 | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | rye flour | Both IgE and non-IgE mediated | - | - | - | - | - | 1.2 (0.8-1.6) n=3156 | - | - | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | onnaire-based 1 | methods | Sensit | isation | Sensitisation hist | with clinical tory | Food challeng hist | e with clinical tory | Other |
|------------------------|-----------|---------------------|-------------|-----------|--|---|---------------------|-------------------------|---|--|------------------------------------|-----------------------|-----------------------|-------------------------|---|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | L L | 0 | | 95% Prev | alence (CI) | 0 | | | |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | wheat | Both IgE and non-IgE mediated | - | - | - | - | - | 1.2 (0.9-1.7) n=3156 | - | - | - | - |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | wheat | Both IgE and non-IgE mediated | - | - | - | 2.8 [†] (nr) n=nr | - | - | - | - | - | - |
| Zannikos (2008) | Greece | 2007 | 7-13 years | wheat | Both IgE and non-IgE mediated (no SPT and SIgE) | 0.2 [†] (0.0-0.5) n=1988 | - | - | - | - | - | - | - | - | - |
| Krause (2002) | Greenland | 1998 | 5-18 years | wheat | IgE mediated only | - | - | - | - | 2.4 [†] (1.6-3.6) n=1031 | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 20-69 years | rye | IgE mediated only | - | - | - | 11.1 [†] (3.6-27.0) n=36 | $ \begin{array}{c} 0^{\dagger} \\ (0-12.0) \\ n=36 \end{array} $ | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 60-97 years | rye flour | IgE mediated only | - | - | - | 7.3 [†] (3.5-14.4) n=109 | 2.8 [†] (0.7-8.4) n=109 | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 20-69 years | wheat | IgE mediated only | - | - | - | 13.9 [†] (5.2-30.3) n=36 | $\begin{array}{c} 2.8^{\dagger} \\ (0.2-16.2) \\ n=36 \end{array}$ | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 60-97 years | wheat | IgE mediated only | - | - | - | 9.2 [†] (4.7-16.6) n=109 | 5.5 [†] (2.3-12.1) n=109 | - | - | - | - | - |
| Kristjansson (1999) | Iceland | 1994 | 18 months | cereals | Both IgE and non-IgE mediated | 0.6 [†] (0.1-2.5) n=324 | - | - | - | - | 0 [†] (0-1.5) n=324 | - | - | - | - |
| Ronchetti (2008) | Italy | 2005 - 2006 | 9 years | wheat | Both IgE and non-IgE mediated | - | - | - | 0.5 [†] (0.0-3.5) n=184 | - | - | - | - | - | 6 [†] (3.2-10.7) n=184 |
| Ronchetti (2008) | Italy | 2005 - 2006 | 13 years | wheat | Both IgE and non-IgE mediated | - | - | - | 1.5 [†] (0.4-4.8) n=196 | - | - | - | - | - | 5.6 [†] (3.0-10.1) n=196 |
| Eggesbo (1999) | Norway | 1993-1995 | 1 year | cereals | Both IgE and non-IgE mediated | 0.8 (0.6-1.2) n=3366 | - | - | - | - | - | - | - | - | - |
| Eggesbo (1999) | Norway | 1993-1995 | 18 months | cereals | Both IgE and non-IgE mediated | 0.2 (0.1-0.5) n=3278 | - | - | - | - | - | - | - | - | - |
| Eggesbo (1999) | Norway | 1993-1995 | 2 years | cereals | Both IgE and non-IgE mediated | 0.5 (0.3-0.8) n=2979 | - | - | - | - | - | - | - | - | - |
| Kristjansson (1999) | Sweden | 1994 | 18 months | cereals | Both IgE and non-IgE mediated | 1.2 [†] (0.4-3.3) n=328 | - | - | - | - | 0 [†] (0-1.4) n=328 | - | - | - | - |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | nnaire-based | methods | Sensit | isation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical ory | Other |
|---------------------|-------------------|---------------------|-------------|------------|-------------------------------------|---|---------------------|---|--|---|---|----------------------------|-----------------------|---------------------------------------|--|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | - | - | | 95% Preva | alence (CI) | - | | | |
| Ostblom (2008 b) | Sweden | 1995-2004 | 1 year | wheat | Both IgE and non-IgE mediated | 0.8 [†] (0.5-1.2) n=3104 | - | 0.3 [†] (0.1-0.6) n=3104 | - | - | - | - | - | - | - |
| Ostblom (2008 b) | Sweden | 1996-1998 | 2 years | wheat | Both IgE and non-IgE mediated | 0.8 [†] (0.5-1.2) n=3104 | - | 0.4 [†] (0.2-0.7) n=3104 | - | - | - | - | - | - | - |
| Ostblom (2008 b) | Sweden | 1998-2000 | 4 years | wheat | Both IgE and non-IgE mediated | 0.5^{\dagger} (0.3-0.9) n=3104 | - | 0.4 [†] (0.2-0.7) n=3104 | - | - | - | - | - | - | - |
| Ostblom (2008 a) | Sweden | 1999-2000 | 4 years | wheat | Both IgE and non-IgE mediated | 0.7 [†] (0.5-1.2) n=2563 | - | - | - | 4 [†] (3.3-4.9) n=2563 | - | 1.3 (1.0-1.9) n=2563 | - | - | - |
| Ostblom (2008 b) | Sweden | 2002-2004 | 8 years | wheat | Both IgE and non-IgE mediated | 0.4^{\dagger} (0.2-0.7) n=3104 | - | 0.3 [†] (0.1-0.6) n=3104 | - | - | - | - | - | - | - |
| Bjornsson (1996) | Sweden | 1991-1992 | 20-44 years | wheat | IgE mediated only | - | - | - | - | 3.1 [†] (2.3-4.2) n=1397 | - | - | - | - | - |
| Orhan (2009) | Turkey | 2006 | 6-9 years | corn | IgE mediated only | 0.1 [†] (0.0 - 0.4) n=2739 | - | - | - | - | 0.1 [†] (0 - 0.3) n=2739 | - | - | 0 [†] (0 - 0.2) n=2739 | - |
| Venter (2008) | United Kingdom | 2001-2005 | 3 years | corn | Both IgE and non-IgE mediated | - | - | - | 0.2 [†] (0-1.0) n=642 | - | - | - | - | - | 0.1 [†] (0.0-0.2) n=891 |
| Venter (2008) | United Kingdom | 2001-2005 | 1 year | corn flour | Both IgE and non-IgE mediated | - | - | - | $\begin{array}{c} 0.1 \\ (0.0-0.8) \\ n=763 \end{array}$ | - | - | - | - | - | 0.1 [†] (0.0-0.7) n=900 |
| Venter (2008) | United Kingdom | 2001-2005 | 2 years | corn flour | Both IgE and non-IgE mediated | - | - | - | 0.2 ⁺ (0.0-1.0) n=658 | - | - | - | - | - | 0.1^{+} (0.0-0.8) n=858 |
| Venter (2008) | United Kingdom | 2001-2005 | 1 year | gluten | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | - | 0 (0-0.5) n=900 |
| Venter (2008) | United Kingdom | 2001-2005 | 2 years | gluten | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | - | 0.1 (0.0-0.8) n=858 |
| Venter (2008) | United Kingdom | 2001-2005 | 3 years | gluten | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | - | 0.1 ' (0.0-0.2) n=891 |
| Venter (2008) | United Kingdom | 2001-2005 | 1 year | wheat | Both IgE and non-IgE mediated | - | - | - | $ \begin{array}{c} 0^{+} \\ (0-0.6) \\ n=763 \end{array} $ | - | - | - | - | - | 0.4 ⁺ (0.1-1.2) n=900 |
| Venter (2008) | United Kingdom | 2001-2005 | 2 years | wheat | Both IgE and non-IgE mediated | - | - | - | 0.2 [†] (0.0-1.0) n=658 | - | - | - | - | - | 0.3 [†] (0.1-1.1) n=858 |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | onnaire-based n | nethods | Sensit | tisation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical ory | Other |
|----------------|-------------------|---------------------|------------|--------------|-------------------------------------|--|---------------------|-------------------------|--|-----------------------|-----------------------|----------------------|-----------------------|------------------------|--|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Venter (2008) | United Kingdom | 2001-2005 | 3 years | wheat | Both IgE and non-IgE mediated | - | - | - | 0^{\dagger} (0-0.1) n=642 | - | - | - | - | - | 0.2 [†] (0.0-0.9) n=891 |
| Arshad (2001) | United Kingdom | 1993-1994 | 4 years | wheat | IgE mediated only | - | - | - | 0.3 [†] (0.1-1) n=981 | - | - | _ | - | - | - |
| Venter (2006) | United Kingdom | 2003-2004 | 6 years | wheat | Both IgE and non-IgE mediated | 1.3 [†] (0.6-2.4) n=798 | _ | - | 0.4 [†] (0.1-1.4) n=700 | - | - | - | - | - | 0.3 [†] (0-1.0) n=798 |
| Pereira (2005) | United Kingdom | 2002-2003 | 11 years | wheat | Both IgE and non-IgE mediated | 1.3 [†] (0.7-2.4) n=775 | - | - | 0.6 [†] (0.2-1.6) n=699 | - | - | - | - | - | - |
| Pereira (2005) | United Kingdom | 2002-2003 | 15 years | wheat | Both IgE and non-IgE mediated | 1.2 [†] (0.6-2.3) n=757 | - | - | 1.2 [†] (0.6-2.5) n=649 | - | - | - | - | - | - |
| Young (1994) | United Kingdom | nr | All ages | wheat | Both IgE and non-IgE mediated | 0.9 [†] (0.8-1.1) n=18880 | - | - | - | - | - | - | - | - | - |
| Emmett (1999) | United Kingdom | 1995-1996 | 15 + years | wheat/gluten | Both IgE and non-IgE mediated | 0.4 [†] (0.3-0.5) n=16420 | - | - | - | - | - | - | - | - | - |

[†]Percentage prevalence and/or confidence intervals calculated from raw data provided in the paper

^{*}Percentage prevalence inferred from graph provided (no raw data reported).

[#]Data has been subject to correction or estimation by the authors (presented as reported in the paper).

Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

| Table 1.13: | Cereals allergy | prevalence in | n non-European | countries b | y age | group |
|--------------------|-----------------|---------------|----------------|-------------|-------|-------|
|--------------------|-----------------|---------------|----------------|-------------|-------|-------|

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Question | nnaire-based n | nethods | Sensit | tisation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical ory | Other |
|---------------|-----------|---------------------|-------------|----------------|--|--|---------------------|-------------------------|--|-----------------------|------------------------------------|----------------------|-----------------------|------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | 95% Prevalence (CI) | | | | | | | | | |
| Woods (2002) | Australia | 1992-1998 | 26-50 years | wheat | IgE mediated only | 1.3 [†] (0.5-3.0) n=457 | - | - | 2.2 [†] (1.1-4.1) n=457 | - | 0 [†] (0-1.0) n=457 | - | - | - | - |
| Woods (1998) | Australia | 1998 | 20-44years | wheat products | Both I gE and non IgE mediated | 0.4 [†] (0.1-1.4) n=669 | - | - | - | - | - | - | - | - | - |
| Soller (2012) | Canada | 2008-2009 | <18 years | wheat | "likely" IgE mediated (no SPT or SIgE) | 0.45 (0.08-0.83) n= nr | - | - | - | - | - | - | - | - | - |

EFSA supporting publication 2013:EN-506

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | nnaire-based | methods | Sensit | isation | Sensitisation hist | with clinical tory | Food challeng hist | e with clinical ory | Other |
|----------------------|--|---------------------|-------------|------------------|--|--|---------------------|--|--|----------------------------------|--|---------------------------|-----------------------|------------------------|--|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Soller (2012) | Canada | 2008-2009 | >18 years | wheat | "likely" IgE mediated (no SPT or SIgE) | 0.86 (0.63-1.08) n= nr | - | - | - | - | - | - | - | - | - |
| Hu (2010) | China | 1999 | 0-24 months | wheat | IgE mediated only | - | - | - | 0.3 [†] (0.0-2.1) n=304 | - | - | - | - | - | - |
| Hu (2010) | China | 2009 | 0-24 months | wheat | IgE mediated only | - | - | - | 0.5 [†] (0.1-2.1) n=382 | - | - | - | - | - | - |
| Sai (2011) | China | 2008-2009 | adults | wheat | IgG mediated only | - | - | - | - | - | - | - | - | - | 1.2 [†] (1.0-1.4) n=12765 |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | cereals (millet) | IgE mediated only | 0.1 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | corn | IgE mediated only | 0.2 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | wheat | IgE mediated only | 0.3 (nr) n= 1407 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | wheat flour | IgE mediated only | 0 (nr) n= 1407 | - | - | - | - | - | - | - | - | - |
| Morita (2012) | Japan | 2009-2010 | 24-93 years | wheat | IgE mediated only | 1.2^{\dagger} (0.6-2.2) n=935 | - | - | - | 1.4^{\dagger} (nr) n=935 | 0.2 [†] (0.0-0.9) n=935 | 0.2 (0.0-0.9) n=935 | - | - | - |
| Kim (2011) | Korea | 2006-2007 | 0-12 months | wheat | IgE mediated only (no SPT or SIgE) | - | - | 0.1 [†] (0-0.5) n=1177 | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 6-12 years | wheat | IgE mediated only (no SPT or SIgE) | 0 [†] (0.0-0.1) n=27425 | - | - | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 12-15 years | wheat | IgE mediated only (no SPT or SIgE) | 0.1 [†] (0.0-0.1) n=14777 | - | - | - | - | - | - | - | - | - |
| Lao-araya (2012) | Thailand | 2010 | 3-7years | wheat | IgE mediated only | 0.2 [†] (0.0-1.4) n=452 | - | - | - | - | - | - | - | - | - |
| Al-Hammadi (2010) | United Arab Emirates (Emirate of Abu Dhabi) | 2006 | 6-9 years | wheat | IgE mediated only (no SPT or SIgE) | - | - | 0.5 [†] (0.1-2.0) n=397 | - | - | - | - | - | - | - |
| Bock (1987) | United States | 1980-1984 | 0-3 years | corn | Both IgE and non-IgE mediated | 1.2 [†] (0.4-2.6) n=408 | - | - | - | - | - | - | - | - | 0.2 [†] (0-1.3) n=480 |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Question | nnaire-based 1 | nethods | Sensit | tisation | Sensitisation hist | with clinical tory | Food challeng his | ge with clinical tory | Other |
|---------------------|---------------|---------------------|-------------|--------------|--|---|-----------------------------|-------------------------|-----------------|-----------------------|-----------------------|-----------------------|----------------------|--------------------------|---|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Gupta (2011) | United States | 2009-2010 | 0-2 years | wheat | IgE mediated (no SPT or SIgE) | - | 0.3 (0.1-0.5) n=5429 | - | - | - | - | - | - | - | - |
| Bock (1987) | United States | 1980-1984 | 0-3 years | wheat | Both IgE and non-IgE mediated | 0.9^{\dagger} (0.3-2.3) n=408 | - | - | - | - | - | - | - | - | 0.2 [†] (0-1.3) n=480 |
| Gupta (2011) | United States | 2009-2010 | 3-5 years | wheat | IgE mediated (no SPT or SIgE) | - | 0.5 (0.3-0.7) n=5910 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 6-10 years | wheat | IgE mediated (no SPT or SIgE) | - | 0.4 (0.3-0.5) n=9911 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 11-13 years | wheat | IgE mediated (no SPT or SIgE) | - | 0.7 (0.5-0.9) n=6716 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 14-17 years | wheat | IgE mediated (no SPT or SIgE) | - | 0.3 (0.2-0.4) n=10514 | - | - | - | - | - | - | - | - |
| Greenhawt (2009) | United States | nr | 18 years+ | wheat | IgE mediated (no SPT or SIgE) | 2.3 [†] (1.3-4.2) n=513 | - | - | _ | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | All ages | wheat | IgE mediated (no SPT or SIgE) | - | 0.4 (0.3-0.5) n=3339 | - | - | - | - | - | - | - | - |
| Vierk (2007) | United States | 2001 | 18 years + | wheat/gluten | IgE mediated only (no SPT or SIgE) | 0.6 [†] (0.4-0.9) n=4482 | - | - | - | - | - | - | - | - | 0.5 [†] (0.3-0.8) n=4482 |

[†]Percentage prevalence and/or confidence intervals calculated from raw data provided in the paper

*Percentage prevalence inferred from graph provided (no raw data reported).

[#]Data has been subject to correction or estimation by the authors (presented as reported in the paper).

Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

Table 1.14:Egg allergy prevalence in European countries by age group

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questionnaire-based methods | | Sensitisation Sensitisat | | with clinical tory | Food challenge with clinical history | | Other | |
|--------------|---------|---------------------|-----------|----------|-------------------------------------|-----------------------------|----------|--------------------------|--------------------------------|-----------------------|--------------------------------------|---------------------|-------------|---|
| | | | | | | Self-reported | Clinical | Clinician- | Skin prick test Serum-specific | History and | History and | History and | History and | |
| | | | | | | | history | diagnosed | IgE | SPT | SIgE | OFC | DBPCFC | |
| | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Eller (2009) | Denmark | 1999-2000 | 3 months | egg | Both Ige and non-IgE | - | - | - | | - | - | 0 (nr) | - | - |
| | | | | | mediated | | | | | | | n=nr | | |
| Eller (2009) | Denmark | 1999-2000 | 6 months | egg | Both Ige and non-IgE mediated | - | - | - | | - | - | 0.2 (nr) n=nr | - | - |

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questi | stionnaire-based methods Sensitisati | | tisation | Sensitisation | with clinical | Food challeng | ge with clinical | Other | |
|----------------------|---------|---------------------|------------|-----------|---|--|--------------------------------------|--|----------------------|-----------------------|--------------------|---------------------|---------------------|---|--|
| | | study | | | unor gy | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific | History and SPT | History and SloE | History and OFC | History and DBPCFC | |
| | | | | | | | motory | ulughoseu | | 95% Preva | lence (CI) | | 010 | | |
| Eller (2009) | Denmark | 1999-2000 | 9 months | egg | Both Ige and non-IgE | - | - | - | - | - | - | - | 0.2 (nr) | - | - |
| Eller (2009) | Denmark | 1999-2000 | 1 year | egg | Both Ige and non-IgE | - | - | - | - | - | - | - | 0.6 (nr) | - | - |
| Eller (2009) | Denmark | 2000-2001 | 18 months | egg | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | 2.6 (nr) n=nr | - | - |
| Osterballe (2005) | Denmark | 2000-2001 | < 3 years | egg | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | 0 (nr) n=111 | - | 1.8 [†] (0.3 - 7) n=111 |
| Osterballe (2005) | Denmark | 2000-2001 | 3 years | egg | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | - | 1.6^{\dagger} (0.1 - 3.4) n=486 | 2.9 (1.7 - 4.9) n=486 |
| Eller (2009) | Denmark | 2001-2002 | 3 years | egg | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | 2.3 (nr) n=nr | - | - |
| Eller (2009) | Denmark | 2004-2005 | 6 years | egg | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | 0.7 (nr) n=nr | - | - |
| Osterballe (2005) | Denmark | 2000-2001 | 3-22 years | egg | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | - | 0^{\dagger} (0 - 2) n=301 | 0 [†] (0 - 2) n=301 |
| Osterballe (2009) | Denmark | 2001-2002 | 22 years | egg | Both Ige and non-IgE mediated | $ \begin{array}{c} 0.9^{\dagger} \\ (0.4 - 1.9) \\ n = 843 \end{array} $ | - | - | - | - | - | - | - | - | 0 (0) n=843 |
| Osterballe (2005) | Denmark | 2000-2001 | >22 years | egg | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | - | 0.1 [†] (0 - 0.7) n=936 | 0.2 [†] (0 - 1) n=936 |
| Julge (2001) | Estonia | 1993-1999 | 6 months | egg white | IgE mediated only | - | - | - | 5.2 (nr) n=172 | 4.2 (nr) n=118 | - | - | - | - | - |
| Julge (2001) | Estonia | 1993-1999 | 1 year | egg white | IgE mediated only | - | - | - | 4.1 (nr) n=220 | 5.6 (nr) n=126 | - | - | - | - | - |
| Julge (2001) | Estonia | 1993-1999 | 2 years | egg white | IgE mediated only | - | - | - | 1.8 (nr) n=222 | 20.6 (nr) n=141 | - | - | - | - | - |
| Julge (2001) | Estonia | 1993-1999 | 5 years | egg white | IgE mediated only | - | - | - | 0 (nr) n=208 | 22.7 (nr) n=208 | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 1 year | egg | Both IgE and non-IgE mediated (no SPT or SIgE) | 6 (nr) n=261 | - | - | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 1 year | egg | Both IgE and non-IgE mediated (no SPT or SIgE) | 2.7 [†] (1.8-4.1) n=853 | - | $ \begin{array}{c} 1.9^{\dagger} \\ (1.1 - 3.1) \\ n = 853 \end{array} $ | - | - | - | - | - | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

Prevalence of food allergy in Europe

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | onnaire-based 1 | methods | Sensi | tisation | Sensitisation | with clinical | Food challeng | ge with clinical | Other |
|-----------------------|------------------|---------------------|-------------|----------|---|---|---------------------|--|---|-------------------------|----------------------------|---------------------|--------------------|--------------------------|-------|
| | | Study | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | t Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | lence (CI) | | | | |
| Kajosaari (1982) | Finland | 1980-1981 | 2 years | egg | Both IgE and non-IgE mediated (no SPT or SIgE) | 7 (nr) n=202 | - | - | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 2 years | egg | Both IgE and non-IgE mediated (no SPT or SIgE) | 4 [†] (2.8-5.6) n=852 | - | 2.2 [†] (1.4-3.5) n=852 | _ | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 3 years | egg | Both IgE and non-IgE mediated (no SPT or SIgE) | 9 (nr) n=200 | - | - | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 3 years | egg | Both IgE and non-IgE mediated (no SPT or SIgE) | 3.6 [†] (2.4-5.2) n=784 | - | 3.4 [†] (2.3-5.0) n=784 | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 4 years | egg | Both IgE and non-IgE mediated (no SPT or SIgE) | 3.4 [†] (2.3-5.0) n=819 | - | 3.9 [†] (2.7 - 5.5) n=819 | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 6 years | egg | Both IgE and non-IgE mediated (no SPT or SIgE) | 1 (nr) n=203 | - | - | - | - | - | - | 1 (nr) n=203 | - | - |
| Rance (2005) | France | 2002 | 2-14 years | egg | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.8 [†] (0.6 - 1.3) n=2716 | - | - | - | - | - | - | - | - | - |
| Touraine (2002) | France | 2000-2001 | 5-17 years | egg | Both IgE and non-IgE mediated (no SPT or SIgE) | 3 [†] (2.1-4.3) n=1086 | - | - | - | - | - | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | egg | Both IgE and non IgE mediated | - | - | - | - | - | 0.2 (0.1-0.5) n=3156 | - | - | 0.1 (0-0.3) n=3156 | - |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | egg | Both IgE and non IgE mediated | 0.4 [†] (nr) n=nr | - | - | 1.9 [†] (nr) n=nr | - | - | - | - | - | - |
| Schafer (1999) | Germany | 1994 | 5-6 years | egg | Both IgE and non IgE mediated | - | - | - | 2.8 [†] (1.9-3.9) n=1235 | - | - | - | - | - | - |
| Sakellariou (2008) | Greece | 2007 | 20-54 years | egg | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.4 [†] (nr) n=2003 | - | - | - | - | - | - | - | - | - |
| Zannikos (2008) | Greece | 2007 | 7-13 years | egg | Both IgE and non-IgE mediated (no SPT or SIgE) | 2.1 [†] (1.5-2.9) n=1988 | - | - | - | - | - | - | - | - | - |
| EFSA supporting | g publication 20 |)13:EN-506 | | | | | | | | | | | | | 123 |

| Study ID | Country | Year(s) of | Age group | Allergen | Type of food | Questio | onnaire-based r | nethods | Sensit | isation | Sensitisation | with clinical | Food challeng | ge with clinical | Other |
|-----------------------|-----------|-------------|--------------|-----------|---|--|---------------------|---|--|--|--|---------------------|--------------------|-----------------------|--|
| | | study | | | ancigy | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | lence (CI) | | | | |
| Krause (2002) | Greenland | 1998 | 5-18 years | egg | IgE mediated only | - | - | - | - | 0.4^{\dagger} (0.1-1.1) n=1031 | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 20-69 years | egg white | IgE mediated only | - | _ | - | 8.3^{\dagger} (2.2-23.6) n=36 | $ \begin{array}{c} 1.1 \\ 2.8^{\dagger} \\ (0.2 \\ 16.2) \\ n \\ -36 \end{array} $ | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 60-97 years | egg white | IgE mediated only | - | - | - | $ \begin{array}{c} 10.1^{\dagger} \\ (5.4-17.7) \\ n=109 \end{array} $ | $ \begin{array}{r} 1.30 \\ 2.8^{\dagger} \\ (0.7-8.4) \\ n=109 \end{array} $ | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 20-69 years | egg yolk | IgE mediated only | - | - | - | $ \begin{array}{c} 11.1 \\ (3.6-27.0) \\ n=36 \end{array} $ | 0^{\dagger} (0-12.0) n=36 | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 60-97 years | egg yolk | IgE mediated only | - | - | - | 7.3 [†] (3.5-14.4) n=109 | 0^{\dagger} (0-4.2) n=109 | - | - | - | - | - |
| Kristjanson (1999) | Iceland | 1994 | 18 months | egg | Both IgE and non IgE mediated | 3.1 [†] (1.6-5.8) n=324 | - | - | - | - | 1.2 [†] (0.4-3.3) n=324 | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 0-6 months | egg | Both IgE and non-IgE mediated (no SPT or SIgE) | 0 [†] (0-6.1) n=75 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 12-24 months | egg | Both IgE and non-IgE mediated (no SPT or SIgE) | 2 [†] (0.5-6.2) n=150 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 24-36 months | egg | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.3 [†] (0.2-5.2) n=150 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 36-48 months | egg | Both IgE and non-IgE mediated (no SPT or SIgE) | 2 [†] (0.5-6.2) n=150 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 6-12 months | egg | Both IgE and non-IgE mediated (no SPT or SIgE) | 0 [†] (0-6.1) n=75 | - | - | - | - | - | - | - | - | - |
| Frongia (2005) | Italy | 2003 | 12-24 months | egg | Both IgE and non-IgE mediated (no SPT or SIgE) | - | - | 1.9 [†] (1.5-2.3) n=4602 | - | - | - | - | - | - | - |
| Ronchetti (2008) | Italy | 2005 - 2006 | 9 years | egg | Both IgE and non-IgE mediated | - | - | - | 0 [†] (0-2.6) n=184 | - | - | - | - | - | 8.2 [†] (4.8-13.3) n=184 |
| Ronchetti (2008) | Italy | 2005 - 2006 | 13 years | egg | Both IgE and non-IgE mediated | - | - | - | 1 [†] (0.2-4.0) n=196 | - | - | - | - | - | 10.2 [†] (6.5-15.5) n=196 |
| Eggesbo (1999) | Norway | 1993-1995 | 1 year | egg | Both IgE and non-IgE mediated | 1.5 (1.1-2.0) n=3366 | - | - | - | - | - | - | - | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

Prevalence of food allergy in Europe

| Study ID | Country | Year(s) of | Age group | Allergen | Type of food | Questio | onnaire-based 1 | methods | Sensit | isation | Sensitisation | with clinical | Food challeng | e with clinical | Other |
|-----------------------------|----------|------------|-------------|----------|---|---|---------------------|---|--|--|---|-----------------------------|--|--|-------|
| | | study | | | anergy | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Eggesbo (1999) | Norway | 1993-1995 | 18 months | egg | Both IgE and non-IgE mediated | 2.9 (2.3-3.5) n=3278 | - | - | - | - | - | - | - | - | - |
| Eggesbo (1999) | Norway | 1993-1995 | 2 years | egg | Both IgE and non-IgE mediated | 3 (2.4-3.7) n=2979 | - | - | - | - | - | - | - | - | - |
| Ro (2012) | Norway | 2002-2006 | 2 years | egg | IgE mediated only | - | - | - | $\begin{array}{c} 2.8 \\ (1.5 - 5.3) \\ n = 352 \end{array}$ | $ \begin{array}{c} 11.4^{\dagger} \\ (8.3 - 15.3) \\ n=352 \end{array} $ | - | - | - | - | - |
| Falcao (2004) | Portugal | nr | >39 years | egg | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.6 [†] (0.2-1.7) n=659 | - | - | - | - | - | - | - | - | - |
| Martinez- Gimeno (2000) | Spain | nr | 6-13 years | egg | Both IgE and non-IgE mediated (no SPT or SIgE) | 13 [†] (12.1-14) n=5163 | - | - | - | - | - | - | - | - | - |
| Ostblom (2008 b) | Sweden | 1995-2004 | 1 year | egg | Both IgE and non-IgE mediated | $\begin{array}{c} 2.5^{\dagger} \\ (2.0-3.1) \\ n=3104 \end{array}$ | - | 2.6 [†] (2.1-3.2) n=3104 | - | - | - | - | - | - | - |
| Kristjanrson (1999) | Sweden | 1994 | 18 months | egg | Both IgE and non-IgE mediated | 4 [†] (2.2-6.9) n=324 | - | - | - | - | 1.5 [†] (0.6-3.7) n=328 | - | - | - | - |
| Ostblom (2008 b) | Sweden | 1996-1998 | 2 years | egg | Both IgE and non-IgE mediated | 3^{\dagger} (2.4-3.7) n=3104 | - | 1.8^{\dagger} (1.4-2.4) n=3104 | - | - | - | - | - | - | - |
| Ostblom (2008 b) | Sweden | 1998-2000 | 4 years | egg | Both IgE and non-IgE mediated | $\begin{array}{c} 2.6^{\dagger} \\ (2.1-3.3) \\ n=3104 \end{array}$ | - | $ \begin{array}{r} 2.0^{\dagger} \\ (1.6-2.6) \\ n=3104 \end{array} $ | - | - | - | - | - | - | - |
| Ostblom (2008 a) | Sweden | 1999-2000 | 4 years | egg | Both IgE and non-IgE mediated | 3.7 [†] (3.0-4.5) n=2563 | - | - | - | 5 [†] (4.2-5.9) n=2563 | - | 0.6 (0.3-1.0) n=2563 | - | - | - |
| Ostblom (2008 b) | Sweden | 2002-2004 | 8 years | egg | Both IgE and non-IgE mediated | 1.6^{\dagger} (1.2-2.1) n=3104 | - | 1.6 [†] (1.2-2.1) n=3104 | - | - | - | - | - | - | - |
| Bjornnson (1996) | Sweden | 1991-1992 | 20-44 years | egg | IgE mediated only | - | - | - | - | 0.8 [†] (0.4-1.5) n=1397 | - | - | - | - | - |
| Kucukosmanogl u (2008 a) | Turkey | 2002-2004 | 8-18 months | egg | IgE mediated only | - | - | - | 1.9 [†] (1.2-3.0) n=1015 | - | - | - | - | - | - |
| Orhan (2009) | Turkey | 2006 | 6-9 years | egg | IgE mediated only | 1.9 [†] (1.4 - 2.5) n=2739 | - | - | - | - | 0.9 [†] (0.6 - 1.4) n=2739 | - | - | 0.1^{\dagger} (0 - 0.4) n=2739 | - |
| Mustafayev (2012) | Turkey | 2010 | 10-11 years | egg | IgE mediated only | 5.6 [†] (5.1-6.2) n=6963 | - | - | - | - | - | - | 0.1 [†] (0.0-0.8) n=813 | - | - |
| Gelincik (2008) | Turkey | nr | 18 years + | egg | Both IgE and non-IgE mediated | 2 [‡] (1.7-2.3) n=11816 | - | - | - | - | 0.1 [†] (0.0-0.1) n=11816 | 0.1 (0.0-0.1) n=11816 | - | 0.1 [†] (0.0-0.1) n=11816 | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

Prevalence of food allergy in Europe

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | onnaire-based 1 | methods | Sensit | tisation | Sensitisatior his | with clinical tory | Food challeng hist | e with clinical tory | Other |
|----------------------|-------------------|---------------------|--------------|-----------|---|--|---------------------|-------------------------|---|-----------------------|----------------------|---------------------|-----------------------|-----------------------|--|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Mustafayev (2012) | Turkey | 2010 | 10-11 years | egg white | IgE mediated only | - | - | - | $\begin{array}{c} 0.3 \\ (0.2-0.5) \\ n=6134 \end{array}$ | - | - | - | - | - | - |
| Venter (2008) | United Kingdom | 2001-2005 | 1 year | egg | Both IgE and non-IgE mediated | - | - | - | 1.8 [†] (1.0-3.1) n=763 | - | - | - | - | - | 1.8 [†] (1.1-2.9) n=900 |
| Venter (2008) | United Kingdom | 2001-2005 | 2 years | egg | Both IgE and non-IgE mediated | - | - | - | 2.1 [†] (1.2-3.6) n=658 | - | - | - | - | - | 1.3^{\dagger} (0.7-2.3) n=858 |
| Venter (2008) | United Kingdom | 2001-2005 | 3 years | egg | Both IgE and non-IgE mediated | - | - | - | 1.4 [†] (0.7-2.7) n=642 | - | - | - | - | - | 1^{\dagger} (0.5-2.0) n=891 |
| Arshad (2001) | United Kingdom | 1993-1994 | 4 years | egg | IgE mediated only | - | - | - | 0.8 [†] (0.4 - 2) n=980 | - | - | - | - | - | - |
| Venter (2006) | United Kingdom | 2003-2004 | 6 years | egg | Both IgE and non-IgE mediated | 1.9 [†] (1.1-3.2) n=798 | - | - | 0.9^{\dagger} (0.4 - 2) n=700 | - | - | - | - | - | 0.3 [†] (0-1.0) n=798 |
| Roberts (2005) | United Kingdom | 1998-2000 | 7 years | egg | IgE mediated only | - | - | - | 0.4 [†] (0.3 - 0.6) n=5066 | - | - | - | - | - | - |
| Pereira (2005) | United Kingdom | 2002-2003 | 11 year olds | egg | Both IgE and non-IgE mediated | 1.5 [†] (0.8-2.8) n=775 | - | - | 0.3 [†] (0.1-1.2) n=699 | - | - | - | - | - | - |
| Emmett (1999) | United Kingdom | 1995-1996 | 15 + years | egg | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.7 [†] (0.6-0.8) n=16420 | - | - | - | - | - | - | - | - | - |
| Pereira (2005) | United Kingdom | 2002-2003 | 15 year olds | egg | Both IgE and non-IgE mediated | 3 [†] (2.0-4.6) n=757 | - | - | 0.2 [†] (0.0-1.0) n=649 | - | - | - | - | - | - |
| Young (1994) | United Kingdom | nr | All ages | egg | Both IgE and non-IgE mediated | 2.3 [†] (2.1-2.5) n=18880 | - | - | - | - | - | - | - | - | - |

[†]Percentage prevalence and/or confidence intervals calculated from raw data provided in the paper

[‡]Percentage prevalence inferred from graph provided (no raw data reported).

[#]Data has been subject to correction or estimation by the authors (presented as reported in the paper).

Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

| Jр |
|----|
| J |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questionnaire-based methods | | | Sensit | isation | Sensitisation hist | with clinical ory | Food |
|----------|-----------|---------------------|--------------|-----------|-------------------------|-----------------------------|---------------------|-------------------------|--------------------|------------------------|-----------------------|----------------------|------------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | Histo O |
| | | | | | | | | | | 95% Preva | alence (CI) | | |
| Osborne | Australia | 2007-2010 | 12-15 months | egg (raw) | IgE mediated | - | - | - | 11.8 | - | - | - | 9 |

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

Prevalence of food allergy in Europe

| challeng hist | e with clinical ory | Other | |
|------------------|------------------------|-------|--|
| ry and FC | History and DBPCFC | | |
| | | | |
| 9# | - | - | |
| | | | |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Question | nnaire-based | methods | Sensit | isation | Sensitisation | with clinical tory | Food challeng hist | e with clinical ory | Other |
|-------------------|----------------------|---------------------|-------------|-----------|---|---|---------------------|-------------------------|---|------------------------|--------------------------------------|-----------------------|--|------------------------|---|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | L | - | | | 95% Prev | alence (CI) | | | | |
| (2011) | | | | | only | | | | (10.6-13.0) n=2768 | | | | (7.9-10.0) n=2768 | | |
| Woods (1998) | Australia | 1998 | 20-44years | egg | Both IgE and non-IgE mediated | 0.7 [†] (0.3-1.8) n=669 | - | - | - | - | - | - | - | - | - |
| Woods (2002) | Australia | 1992-1998 | 26-50 years | egg white | IgE mediated only | 1.3 [†] (0.5-3.0) n=457 | - | - | 1.8 [†] (0.8-3.6) n=457 | - | 0.2 [†] (0-1.4) n=457 | - | - | - | - |
| Soller (2012) | Canada | 2008-2009 | <18 years | egg | "Likely" IgE mediated (no SPT or SIgE) | 1.23 (0.69-1.77) n=nr | - | - | - | - | - | - | - | - | - |
| Soller (2012) | Canada | 2008-2009 | >18 years | egg | "Likely" IgE mediated (no SPT or SIgE) | 0.67 (0.48-0.86) n=nr | - | - | - | - | - | - | - | - | - |
| Chen (2011) | China | 2009 | 0-12 months | egg | IgE mediated only | - | - | - | 9.4 [†] (7-12.5) n=477 | - | - | - | 2.5 [†] (1.4-4.5) n=477 | - | - |
| Hu (2010) | China | 1999 | 0-24 months | egg | IgE mediated only | - | - | - | 7.6 [†] (5.0-11.3) n=304 | - | - | - | 2.9 [†] (1.4-5.6) n=314 | - | - |
| Hu (2010) | China | 2009 | 0-24 months | egg | IgE mediated only | - | - | - | $ \begin{array}{c} 16.2^{\dagger} \\ (12.8-20.4) \\ n=382 \end{array} $ | - | - | - | 5 [†] (3.2-7.7) n=401 | - | - |
| Sai (2011) | China | 2008-2009 | adults | egg | IgG mediated only | - | - | - | - | - | - | - | - | - | 28.5 [†] (27.7-29.2) n=12766 |
| Chen (2012) | China (Chongqing) | 2009-2010 | 0-2 years | egg | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | - | 12.0 [†] (9.5-15.1) n=550 |
| Chen (2012) | China (Hangzhou) | 2009-2010 | 0-2 years | egg | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | - | 4.2 [†] (2.6-6.5) n=481 |
| Chen (2012) | China (Zhuhai) | 2009-2010 | 0-2 years | egg | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | - | 3 [†] (1.8-4.8) n=573 |
| Marrugo (2008) | Colombia | nr | All ages | egg | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.4 [†] (0.3-0.8) n=3099 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | egg | IgE mediated only | 0.1 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Leung (2009) | Hong Kong | 2006-2007 | 2-7 years | egg | IgE mediated only (no SPT or SIgE) | 0.7 [†] (0.5-1.1) n=3677 | - | - | - | - | - | - | - | - | 0.4 [†] (0.2-0.7) n=3677 |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Question | nnaire-based 1 | nethods | Sensit | isation | Sensitisation | with clinical tory | Food challeng hist | e with clinical cory | Other |
|----------------------|--|---------------------|-----------------------|-----------|--|--|---|--|--------------------|------------------------|---|-----------------------|-----------------------|-------------------------|--------------------------------------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | • | 95% Preva | alence (CI) | | | | |
| Dalal (2002) | Israel | nr | 0-2years | egg | IgE mediated only | - | 0.7 [†] (0.6 - 1.0) n=9070 | - | - | - | 0.5 [†] (0.3-0.6) n=9070 | - | - | - | - |
| Kim (2011) | Korea | 2006-2007 | 0-12 months | egg | IgE mediated only (no SPT or SIgE) | - | - | 2.8 [†] (2.0-4.0) n=1177 | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 6-12 years | egg | IgE mediated only (no SPT or SIgE) | 1^{+} (0.9-1.1) n=27425 | - | - | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 12-15 years | egg | IgE mediated only (no SPT or SIgE) | 0.6 [†] (0.5-0.8) n=14777 | - | - | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | <3 years | egg | IgE mediated only (no SPT or SIgE) | - | - | 0.4 [†] (0.1-1.2) n=813 | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | 4-18 years | egg | IgE mediated only (no SPT or SIgE) | - | - | 0.5 [†] (0.4-0.6) n=15169 | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | >19 years | egg | IgE mediated only (no SPT or SIgE) | - | - | 0.3 [†] (0.2-0.4) n=14036 | - | - | - | - | - | - | - |
| Lao-araya (2012) | Thailand | 2010 | 3-7 years | egg | IgE mediated only | 0.9 [†] (0.3-2.4) n=452 | - | - | - | - | - | - | - | - | - |
| Santadusit (2005) | Thailand | nr | 6 months – 6 years | egg white | IgE mediated only | 0.6 [†] (0.2 - 1.7) n=656 | - | - | - | - | - | - | - | - | - |
| Santadusit (2005) | Thailand | Nr | 6 months – 6 years | egg yolk | IgE mediated only | 0.9 [†] (0.4 - 2.1) n=656 | - | - | - | - | - | - | - | - | - |
| Al-Hammadi (2010) | United Arab Emirates (Emirate of Abu Dhabi) | 2006 | 6-9 years | egg | IgE mediated only (no SPT or SIgE) | - | - | 3.3 [†] (1.8-5.7) n=397 | - | - | - | - | - | - | - |
| Branum (2009) | United States | 2005-2006 | < 18 years | egg | IgE mediated only (not clearly defined) | - | - | - | - | 6.7 (nr) n=nr | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 0-2 years | egg | IgE mediated (no SPT or SIgE) | - | 1 (0.7-1.3) n=5429 | - | - | - | - | - | - | - | - |
| Bock (1987) | United States | 1980-1984 | 0-3 years | egg | Both IgE and non-IgE mediated | 2.7 [†] (1.2-4.2) n=408 | - | - | - | - | - | - | - | - | 0.6 [†] (0.2-2) n=480 |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Question | nnaire-based | methods | Sensit | isation | Sensitisation hist | with clinical tory | Food challeng hist | e with clinical tory | Other |
|---------------------|---------------|---------------------|-----------------------|----------|--|---|-----------------------------|-------------------------|--------------------|--|-----------------------|-----------------------|-----------------------|-------------------------|---|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Prev | alence (CI) | | | | |
| Kumar (2011) | United States | 2011 | 6 months - 6 years | egg | IgE mediated only | - | - | - | - | 21 [†] (18.7-23.6) n=1104 | - | - | - | - | - |
| Liu (2010) | United States | 2005-2006 | 1-5 years | egg | IgE mediated only | - | - | - | - | 13.9 (nr) n=909 | - | - | - | - | 1.8 (nr) n=nr |
| Keet (2012) | United States | 2005-2006 | 1-21 years | egg | IgE mediated only | - | - | - | - | 6 (nr) n=3550 | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 3-5 years | egg | IgE mediated (no SPT or SIgE) | - | 1.3 (0.9-1.7) n=5910 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 6-10 years | egg | IgE mediated (no SPT or SIgE) | - | 0.8 (0.6-1.1) n=9911 | - | - | - | - | - | - | - | - |
| Liu (2010) | United States | 2005-2006 | 6-19 years | egg | IgE mediated only | - | - | - | - | 4.1 (nr) n=2869 | - | - | - | - | 0.1 (nr) n=nr |
| Gupta (2011) | United States | 2009-2010 | 11-13 years | egg | IgE mediated (no SPT or SIgE) | - | 0.5 (0.4-0.8) n=6716 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 14-17 years | egg | IgE mediated (no SPT or SIgE) | - | 0.4 (0.3-0.5) n=10514 | - | - | - | - | - | - | - | - |
| Vierk (2007) | United States | 2001 | 18 years + | egg | IgE mediated only (no SPT or SIgE) | 0.7 [†] (0.5-1.1) n=4482 | - | - | - | - | - | - | - | - | 0.5 [†] (0.3-0.8) n=4482 |
| Greenhawt (2009) | United States | nr | 18 years+ | egg | IgE mediated only (no SPT or SIgE) | 1.6 [†] (0.7-3.2) n=513 | - | - | - | - | - | - | - | - | - |
| Liu (2010) | United States | 2005-2006 | 20-39 years | egg | IgE mediated only | - | - | - | - | 2.1 (nr) n=1672 | - | - | - | - | 0.1 (nr) n=nr |
| Liu (2010) | United States | 2005-2006 | 40-59 years | egg | IgE mediated only | - | - | - | - | 3.8 (nr) n=1361 | - | - | - | - | 0.2 (nr) n=nr |
| Liu (2010) | United States | 2005-2006 | 60+ years | egg | IgE mediated only | - | - | - | - | 3.9 (nr) n=1392 | - | - | - | - | 0.6 (nr) n=nr |
| Liu (2010) | United States | 2005-2006 | All ages | egg | IgE mediated only | - | - | - | - | 3.9 (nr) n=8203 | - | - | - | - | 0.2 (nr) n=nr |
| Gupta (2011) | United States | 2009-2010 | All ages | egg | IgE mediated (no SPT or SIgE) | - | 0.8 (0.7-0.9) n=3339 | - | - | - | - | - | - | - | - |

[†]Percentage prevalence and/or confidence intervals calculated from raw data provided in the paper

EFSA supporting publication 2013:EN-506

[‡]Percentage prevalence inferred from graph provided (no raw data reported).

[#]Data has been subject to correction or estimation by the authors (presented as reported in the paper).

Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | onnaire-based n | nethods | Sensi | tisation | Sensitisation his | with clinical tory | Food challeng hist | e with clinical ory | Other |
|----------------------|---------|---------------------|------------|-------------------------|---|---|---------------------|--------------------------------------|----------------|-------------------------|----------------------|-----------------------|---------------------------|--|---|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick tes | t Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Osterballe (2005) | Denmark | 2000-2001 | < 3 years | crustaceans (shrimp) | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | 0.0 (0.0-4.2) n=111 | - | 0 [†] (0.0-4.2) n=111 |
| Osterballe (2005) | Denmark | 2000-2001 | 3 years | crustaceans (shrimp) | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0 [†] (0 - 1) n=486 | 0 [†] (0 - 1) n=486 |
| Osterballe (2005) | Denmark | 2000-2001 | 3-22 years | crustaceans (shrimp) | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0 [†] (0 - 2) n=301 | 0.3 [†] (0 - 2.1) n=301 |
| Osterballe (2009) | Denmark | 2001-2002 | 22 years | crustaceans (shrimp) | Both IgE and non-IgE mediated | 2^{\dagger} (1.2 - 3.3) n=843 | - | - | - | - | - | - | - | - | 0.2 (0.01-0.9) n=843 |
| Osterballe (2005) | Denmark | 2000-2001 | >22 years | crustaceans (shrimp) | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0.3 [†] (0.1 - 1.0) n=936 | 1.1^{+} (1 - 2.0) n=936 |
| Osterballe (2005) | Denmark | 2000-2001 | < 3 years | Fish (cod) | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | 0.0 (0.0-4.2) n=111 | - | $ \begin{array}{r} 0^{\gamma} \\ (0 - 1) \\ n = 111 \end{array} $ |
| Osterballe (2005) | Denmark | 2000-2001 | 3 years | Fish (cod) | Both IgE and non-IgE mediated | - | - | - | _ | - | - | - | - | 0 [†] (0 - 1) n=486 | 0.8 [†] (0.3 - 2.2) n=486 |
| Osterballe (2005) | Denmark | 2000-2001 | 3-22 years | Fish (cod) | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0^{\dagger} (0 - 2) n=301 | 0.3^{\dagger} (0.1 - 2.6) n=301 |
| Osterballe (2009) | Denmark | 2001-2002 | 22 years | Fish (cod) | Both IgE and non-IgE mediated | 0.2 [†] (0 - 1) n=843 | - | - | - | - | - | - | - | - | 0.1 (0.0-0.8) n=843 |
| Osterballe (2005) | Denmark | 2000-2001 | >22 years | Fish (cod) | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0.2 [†] (0 - 0.9) n=936 | 0.6 [†] (0.3 - 1.5) n=936 |
| Osterballe (2009) | Denmark | 2001-2002 | 22 years | mollusc (octopus) | Both IgE and non-IgE mediated | $0.4^{\dagger} \\ (0.1 - 1.1) \\ n = 843$ | - | - | - | - | - | - | - | - | 0.1 (0.0-0.8) n=843 |
| Kajosaari (1982) | Finland | 1980-1981 | 1 year | fish | Both IgE and non-IgE mediated (no SPT or SIgE) | 7 (nr) n=261 | - | - | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 1 year | fish | Both IgE and non-IgE mediated (no SPT or SIgE) | 3.5 [†] (2.4-5.1) n=853 | - | 0.2 [†] (0-0.9) n=853 | - | - | - | - | - | - | - |

Table 1.16: Fish and Shellfish allergy prevalence in European countries by age group

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | nnaire-based 1 | nethods | Sensit | isation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical ory | Other |
|---------------------|---------|---------------------|-------------|-------------------------|---|---|---------------------|--|--|-----------------------|----------------------------|----------------------|-----------------------|------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | L | | | | 95% Preva | alence (CI) | | | | |
| Kajosaari (1982) | Finland | 1980-1981 | 2 years | fish | Both IgE and non-IgE mediated (no SPT or SIgE) | 6 (nr) n=202 | - | - | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 2 years | fish | Both IgE and non-IgE mediated (no SPT or SIgE) | 5 [†] (3.4-6.4) n=852 | - | 0.4 [†] (0.1-1.1) n=852 | - | - | _ | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 3 years | fish | Both IgE and non-IgE mediated (no SPT or SIgE) | 5 (nr) n=200 | - | - | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 3 years | fish | Both IgE and non-IgE mediated (no SPT or SIgE) | 3.6 [†] (2.4-5.2) n=784 | - | $ \begin{array}{c} 1^{\dagger} \\ (0.4-1.9) \\ n=784 \end{array} $ | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 4 years | fish | Both IgE and non-IgE mediated (no SPT or SIgE) | 4.2 [†] (2.9 - 5.8) n=819 | - | $ \begin{array}{c} 1^{\dagger} \\ (0.5-2.0) \\ n=819 \end{array} $ | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 6 years | fish | Both IgE and non-IgE mediated (no SPT or SIgE) | 1 (nr) n=203 | - | - | - | - | - | - | 1 (nr) n=203 | - | - |
| Haahtela (1980) | Finland | nr | 15-17 years | fish | IgE mediated only | - | - | - | 2.7 [†] (1.7-4.2) n=708 | - | - | - | - | - | - |
| Touraine (2002) | France | 2000-2001 | 5-17 years | crustaceans | Both IgE and non-IgE mediated (no SPT or SIgE) | 5.5 [†] (4.3-7.1) n=1086 | - | - | - | - | - | - | - | - | - |
| Rance (2005) | France | 2002 | 2-14 years | crustaceans (shrimp) | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.5 [†] (0.3 - 0.9) n=2716 | - | _ | - | _ | _ | _ | _ | - | - |
| Rance (2005) | France | 2002 | 2-14 years | fish | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.7 [†] (0.4 - 1.1) n=2716 | - | - | - | - | - | - | - | - | - |
| Touraine (2002) | France | 2000-2001 | 5-17 years | fish | Both IgE and non-IgE mediated (no SPT or SIgE) | 4 [†] (2.9-5.3) n=1086 | - | - | - | - | - | - | - | - | - |
| Touraine (2002) | France | 2000-2001 | 5-17 years | mollusc (oyster) | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.5 [†] (0.9-2.4) n=1086 | - | - | - | - | - | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | crustaceans (crab) | Both IgE and non-IgE mediated | - | - | - | - | - | 0.3 (0.2-0.6) n=3156 | - | - | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | nnaire-based | methods | Sensi | itisation | Sensitisation hist | with clinical tory | Food challeng | e with clinical ory | Other |
|------------------------|-----------|---------------------|-------------|-----------------------|---|---|---------------------|-------------------------|----------------------------------|---|---------------------------------------|-----------------------|--------------------|------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick tes | st Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | • | 95% Preva | alence (CI) | | | | |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | crustaceans (crab) | Both IgE and non-IgE mediated | - | - | - | 1.9 [†] (nr) n=nr | - | - | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | fish (herring) | Both IgE and non-IgE mediated | - | - | - | - | - | 0.1 (0.0-0.4) n=3156 | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | fish (mackerel) | Both IgE and non-IgE mediated | - | - | - | - | - | 0.1 (0.0-0.3) n=3156 | - | - | - | - |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | fish (mackerel) | Both IgE and non-IgE mediated | - | - | - | 1.8 [†] (nr) n=nr | - | - | - | - | - | - |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | fish/seafood | Both IgE and non-IgE mediated | 1^{\dagger} (nr) n=nr | - | - | - | - | - | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | mollusc (mussels) | Both IgE and non-IgE mediated | - | - | - | - | - | 0.0 (0.0-0.2) n=3156 | - | - | - | - |
| Zannikos (2008) | Greece | 2007 | 7-13 years | fish | Both IgE and non IgE mediated (no SPT or SIgE) | 1.9 [†] (1.3-2.6) n=1988 | - | _ | - | - | _ | - | - | - | - |
| Sakellariou (2008) | Greece | 2007 | 20-54 years | fish | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.5 (nr) [†] n=2003 | - | - | - | - | - | - | - | - | - |
| Zannikos (2008) | Greece | 2007 | 7-13 years | shellfish | Both IgE and non IgE mediated (no SPT or SIgE) | 0.1 [†] (0.0-0.2) n=3821 | - | - | - | - | - | - | - | - | - |
| Krause (2002) | Greenland | 1998 | 5-18 years | fish | IgE mediated only | - | - | - | - | 0.7 [†] (0.3-1.5) n=1031 | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 20-69 years | crustaceans (crab) | IgE mediated only | - | - | - | - | - | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 60-97 years | crustaceans (crab) | IgE mediated only | - | - | - | - | 1.8 [†] (0.3-7.1) n=109 | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 20-69 years | fish (cod) | IgE mediated only | - | - | - | - | - | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 60-97 years | fish (cod) | IgE mediated only | - | - | - | - | 0^{\dagger} (0-4.2) n=109 | - | - | - | - | - |
| Kristjansson (1999) | Iceland | 1994 | 18 months | fish | Both IgE and non-IgE mediated | 2.2 [†] (1.0-4.6) n=324 | - | - | - | - | 0.6^{\dagger} (0.1-2.5) n=324 | - | - | - | - |
| Kristjansson (1999) | Iceland | 1994 | 18 months | shellfish | Both IgE and non-IgE mediated | 1.5 [†] (0.6-3.8) n=324 | - | - | - | - | - | - | - | - | - |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | onnaire-based 1 | methods | Sensi | itisation | Sensitisation hist | with clinical tory | Food challeng | e with clinical ory | Other |
|----------------------------|----------|---------------------|-------------|------------|---|---|---------------------|---|---|---|--|----------------------------|--------------------|------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick tes | t Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Eggesbo (1999) | Norway | 1993-1995 | 1 year | fish | Both IgE and non-IgE mediated | 1.2 (0.9-1.7) n=3366 | - | - | - | - | - | - | - | - | - |
| Eggesbo (1999) | Norway | 1993-1995 | 18 months | fish | Both IgE and non-IgE mediated | 1.5 (1.1-2.0) n=3278 | - | - | - | - | - | - | - | - | - |
| Eggesbo (1999) | Norway | 1993-1995 | 2 years | fish | Both IgE and non-IgE mediated | 1.5 (1.1-2.1) n=2979 | - | - | - | - | - | - | - | - | - |
| Ro (2012) | Norway | 2002-2006 | 2 years | fish | IgE mediated only | - | - | - | $0.3^{\dagger} \\ (0 - 1.8) \\ n = 352$ | 1.1^{\dagger} (0.4 - 3.1) n=352 | - | - | - | - | - |
| Falcao (2004) | Portugal | nr | >39 years | fish | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.9 [†] (0.4-2.1) n=659 | - | - | - | - | - | - | - | - | - |
| Falcao (2004) | Portugal | nr | >39 years | Molluses | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.5 [†] (0.1-1.4) n=659 | - | _ | - | - | _ | - | - | - | - |
| Martinez- Gimeno (2000) | Spain | nr | 6-13 years | fish | Both IgE and non-IgE mediated (no SPT or SIgE) | 6.9 [†] (6.2-7.6) n=5163 | - | - | - | - | - | - | - | - | - |
| Ostblom (2008 b) | Sweden | 1995-2004 | 1 year | fish | Both IgE and non-IgE mediated | 1.5 [†] (1.1-2.0) n=3104 | - | 0.2 [†] (0.1-0.4) n=3104 | - | - | - | - | - | - | - |
| Kristjansson (1999) | Sweden | 1994 | 18 months | fish | Both IgE and non-IgE mediated | 3.1 [†] (1.6-5.7) n=328 | - | - | - | - | 0.3 [†] (0.0-2.0) n=328 | - | - | - | - |
| Ostblom (2008 b) | Sweden | 1996-1998 | 2 years | fish | Both IgE and non-IgE mediated | 1.8^{\dagger} (1.4-2.4) n=3104 | - | $ \begin{array}{r} 0.6^{\dagger} \\ (0.4-1.0) \\ n=3104 \end{array} $ | - | - | - | - | - | - | - |
| Ostblom (2008 b) | Sweden | 1998-2000 | 4 years | fish | Both IgE and non-IgE mediated | 1.2^{\dagger} (0.9-1.7) n=3104 | - | $\begin{array}{c} 0.8 \\ (0.5-1.2) \\ n=3104 \end{array}$ | - | - | - | - | - | - | - |
| Ostblom (2008 b) | Sweden | 2002-2004 | 8 years | fish | Both IgE and non-IgE mediated | 0.8 [†] (0.5-1.2) n=3104 | - | 0.6 [†] (0.4-1.0) n=3104 | - | - | - | - | - | - | - |
| Bjornsson (1996) | Sweden | 1991-1992 | 20-44 years | fish | IgE mediated only | - | - | - | - | 0.3 [†] (0.1-0.8) n=1397 | - | - | - | - | - |
| Ostblom (2008 a) | Sweden | 1999-2000 | 4 years | Fish (cod) | Both IgE and non-IgE mediated | 1.6 [†] (1.2-2.2) n=2563 | - | - | - | 1^{\dagger} (0.7-1.5) n=2563 | - | 0.4 (0.2-0.8) n=2563 | - | - | - |
| Kristjansson (1999) | Sweden | 1994 | 18 months | shellfish | Both IgE and non-IgE mediated | 1.2 [†] (0.4-3.3) n=328 | - | - | - | - | - | - | - | - | - |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | onnaire-based 1 | methods | Sensi | tisation | Sensitisation hist | with clinical tory | Food challeng | e with clinical ory | Other |
|----------------------|--------------------|---------------------|--------------|------------------------|---|--|---------------------|-------------------------|--|-------------------------|---|-----------------------|--------------------|---------------------------------------|--|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | t Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Brugman (1998) | The Netherlands | 1993- 1994 | 4-15 years | fish/crustacean | Both IgE and non-IgE (no SPT or SIgE) | 0.7^{\dagger} (0.5-1.0) n=4400 | - | - | - | - | - | - | - | - | - |
| Orhan (2009) | Turkey | 2006 | 6-9 years | fish | IgE mediated only | 0.3 [†] (0.2 - 1) n=2739 | - | - | - | - | 0.2 [†] (0.1 - 0.5) n=2739 | - | - | 0 [†] (0 - 0.2) n=2739 | - |
| Mustafayev (2012) | Turkey | 2010 | 10-11 years | fish | IgE mediated only | 2.3 [†] (2.0-2.7) n=6963 | - | - | - | - | - | - | - | - | - |
| Gelincik (2008) | Turkey | nr | 18 years + | fish | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | - | 0 [†] (0-0.0) n=11816 | - |
| Gelincik (2008) | Turkey | nr | 18 years + | seafood | Both Ige and non-IgE mediated | 0.4 [‡] (0.3-0.5) n=11816 | - | - | - | - | - | - | - | 0 [†] (0-0.0) n=11816 | - |
| Pereira (2005) | United Kingdom | 2002-2003 | 11 year olds | crustaceans (prawn) | Both IgE and non-IgE mediated | 0.3 [†] (0.1-1.0) n=775 | - | - | - | - | - | - | - | - | - |
| Pereira (2005) | United Kingdom | 2002-2003 | 15 year olds | crustaceans (prawn) | Both IgE and non-IgE mediated | 0.7 [†] (0.2-1.6) n=757 | - | - | - | - | - | - | - | - | - |
| Pereira (2005) | United Kingdom | 2002-2003 | 11 year olds | fish | Both IgE and non-IgE mediated | 0.9 [†] (0.4-1.9) n=775 | - | - | 1.3 [†] (0.6-2.5) n=699 | - | - | - | - | - | - |
| Pereira (2005) | United Kingdom | 2002-2003 | 15 year olds | fish | Both IgE and non-IgE mediated | 1.8 [†] (1.1-3.2) n=757 | - | - | 1.4 [†] (0.7-2.7) n=649 | - | - | - | - | - | - |
| Emmett (1999) | United Kingdom | 1995-1996 | 15 + years | fish | Both Ige and non-IgE mediated | 0.5 [†] (0.4-0.6) n=16420 | - | - | - | - | - | - | - | - | - |
| Venter (2008) | United Kingdom | 2001-2005 | 1 year | fish (cod) | Both IgE and non-IgE mediated | - | - | - | 0.3 [†] (0.0-1.0) n=763 | - | - | - | - | - | 0.1 [†] (0.0-0.7) n=900 |
| Venter (2008) | United Kingdom | 2001-2005 | 2 years | fish (cod) | Both IgE and non-IgE mediated | - | - | - | 0.5 [†] (0.1-1.4) n=658 | - | - | - | - | - | 0 [†] (0-0.6) n=858 |
| Venter (2008) | United Kingdom | 2001-2005 | 3 years | fish (cod) | Both IgE and non-IgE mediated | - | - | - | 0.5 [†] (0.1-1.5) n=642 | - | - | - | - | - | 0 [†] (0-0.5) n=891 |
| Arshad (2001) | United Kingdom | 1993-1994 | 4 years | fish (cod) | IgE mediated only | - | - | - | $ \begin{array}{c} 0.7^{\dagger} \\ (0.3 - 2) \\ n = 981 \end{array} $ | - | - | - | - | - | - |
| Venter (2006) | United Kingdom | 2003-2004 | 6 years | fish (cod) | Both IgE and non-IgE mediated | 0.3 [†] (0-1.0) n=798 | - | - | 1 [†] (0.4-2.1) n=700 | - | - | - | - | - | 0 [†] (0-0.6) n=798 |
| Roberts (2005) | United Kingdom | 1998-2000 | 7 years | fish (cod) | IgE mediated only | - | - | - | $ \begin{array}{c} 0^{\dagger} \\ (0 - 0.3) \\ n = 2061 \end{array} $ | - | - | - | - | - | - |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | onnaire-based m | nethods | Sensit | isation | Sensitisation hist | with clinical ory | Food challeng hist | ge with clinical tory | Other |
|--------------|---------|---------------------|-----------|-----------------|-------------------------|--|-----------------|-----------|--------|-------------|-----------------------|----------------------|-----------------------|--------------------------|-------|
| | | | | | | Self-reported Clinical Clinician- Skin prick test Serum-specific History history diagnosed IgE IgE | | | | History and | History and | History and | History and | | |
| | | | | | | _ | history | diagnosed | | IgE | SPT | SIgE | OFC | DBPCFC | |
| | | | | | | history diagnosed IgE 95% Prevalence | | | | alence (CI) | | • | | | |
| Young (1994) | United | nr | All ages | fish/crustacean | Both IgE and | 2.9 [†] | - | - | - | - | - | - | - | - | - |
| | Kingdom | | | | non-IgE | (2.7-3.1) | | | | | | | | | |
| | | | | | mediated | n=18880 | | | | | | | | | |

[†]Percentage prevalence and/or confidence intervals calculated from raw data provided in the paper

[‡]Percentage prevalence inferred from graph provided (no raw data reported).

[#]Data has been subject to correction or estimation by the authors (presented as reported in the paper).

Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

Table 1.17:Fish and Shellfish allergy prevalence in non-European countries by age group

| Study ID | Country | Year(s) of study | Age group | Allergen | Tyoe of food allergy | Questi | onnaire-based n | nethods | Sensit | tisation | Sensitisation his | with clinical tory | Food challeng hist | e with clinical ory | Other |
|-----------------------|-----------|---------------------|--------------|-------------------------|--|--|--|--|--|-----------------------|--|-----------------------|-----------------------|------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Woods (2002) | Australia | 1992-1998 | 26-50 years | crustaceans (shrimp) | IgE mediated only | 3.3 [†] (1.9-5.5) n=457 | - | - | 3.7 [†] (2.3-6.0) n=457 | - | 0.9 [†] (0.3-2.4) n=457 | - | - | - | - |
| Woods (1998) | Australia | 1998 | 20-44years | fish/shellfish | Both IgE and non IgE mediated | 2.1 [†] (1.2-3.6) n=669 | - | - | - | - | - | - | - | - | - |
| Osborne (2011) | Australia | 2007-2010 | 12-15 months | shellfish | | - | - | - | 0.4 (0.2-0.7) n=2375 | - | - | - | - | - | - |
| Ben-Shoshan (2010) | Canada | 2008-2009 | < 18 years | fish | Both IgE and non-IgE mediated only | 0.18 (0.00-0.36) n=nr | 0.18 [#] (0.00-0.36) n=nr | 0 [#] (nr) n=nr | - | - | - | - | - | - | - |
| Ben-Shoshan (2010) | Canada | 2008-2009 | > 18 years | fish | Both IgE and non-IgE mediated only | 0.6 (0.43-0.78) n=nr | 0.56 [#] (0.39-0.73) n=nr | 0.12 [#] (0.08-0.16) n=nr | - | - | - | - | - | - | - |
| Ben-Shoshan (2010) | Canada | 2008-2009 | < 18 years | shellfish | Both IgE and non-IgE mediated only | 0.55 (0.21-0.88) n=nr | 0.5 [#] (0.18-0.82) n=nr | 0.06 [#] (0.01-0.10) n=nr | - | - | - | - | - | - | - |
| Ben-Shoshan (2010) | Canada | 2008-2009 | > 18 years | shellfish | Both IgE and non-IgE mediated only | 1.91 (1.60-2.23) n=nr | 1.69 [#] (1.39-1.98) n=nr | 0.71 [#] (0.58-0.84) n=nr | - | - | - | - | - | - | - |
| Chen (2011) | China | 2009 | 0-12 months | crustaceans (shrimp) | IgE mediated only | - | - | - | 0.2 [†] (0-1.3) n=477 | - | - | - | - | - | - |
| Hu (2010) | China | 1999 | 0-24 months | crustaceans (shrimp) | IgE mediated only | - | - | - | 0 [†] (0-1.6) n=304 | - | - | - | - | - | - |
| Hu (2010) | China | 2009 | 0-24 months | crustaceans (shrimp) | IgE mediated only | - | - | - | 0.3 [†] (0.0-1.7) n=382 | - | - | - | - | - | - |

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

Prevalence of food allergy in Europe

| Study ID | Country | Year(s) of study | Age group | Allergen | Tyoe of food allergy | Questio | nnaire-based | methods | Sensi | tisation | Sensitisation hist | with clinical ory | Food challeng | ge with clinical tory | Other |
|-------------------|-----------|---------------------|-------------|-------------------------|---|--|---------------------------------------|---|--|-----------------------|---------------------------------------|----------------------|--------------------|--------------------------|---|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | • | | 95% Preva | lence (CI) | L | | • | |
| Sai (2011) | China | 2008-2009 | adults | crustaceans (shrimp) | IgGmediated only | - | - | - | - | - | - | - | - | - | 10 [†] (9.5-10.6) n=12766 |
| Sai (2011) | China | 2008-2009 | adults | crustaceans (crab) | IgG mediated only | 24.5 (nr) n=nr | - | - | - | - | - | - | - | - | 24.5 [†] (23.8-25.3) n=12765 |
| Chen (2011) | China | 2009 | 0-12 months | fish | IgE mediated only | - | - | - | 0.2 [†] (0-1.3) n=477 | - | - | - | - | - | - |
| Hu (2010) | China | 1999 | 0-24 months | fish | IgE mediated only | - | - | - | $0.3^{\dagger} \\ (0.0-2.1) \\ n=304$ | - | - | - | - | - | - |
| Hu (2010) | China | 2009 | 0-24 months | fish | IgE mediated only | - | - | - | $\begin{array}{c} 0.8^{\dagger} \\ (0.2-2.5) \\ n=382 \end{array}$ | - | - | - | - | - | - |
| Sai (2011) | China | 2008-2009 | adults | fish | IgG mediated only | - | - | - | - | - | - | - | - | - | 11.2 [†] (10.7-11.8) n=12766 |
| Marrugo (2008) | Colombia | nr | All ages | seafood | Both IgE and non-IgE mediated (no SPT or SIgE) | 4 [†] (3.3-4.7) n=3099 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | crustaceans (shrimp) | IgE mediated only | 0.1 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | fish | IgE mediated only | 0.3 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Leung (2009) | Hong Kong | 2006-2007 | 2-7 years | crustaceans | IgE mediated only (no SPT or SIgE) | 1.3 [†] (1.0-1.7) n=3677 | - | - | - | - | - | - | - | - | 0.9 [†] (0.6-1.3) n=3677 |
| Leung (2009) | Hong Kong | 2006-2007 | 2-7 years | fish | IgE mediated only (no SPT or SIgE) | 0.3 [†] (0.2-0.6) n=3677 | - | - | - | - | - | - | - | - | 0.2 [†] (0.1-0.5) n=3677 |
| Dalal (2002) | Israel | nr | 0-2years | fish | IgE mediated only | - | 0 [†] (0 - 0.1) n=9070 | - | - | - | 0 [†] (0 - 0.1) n=9070 | - | - | - | - |
| Oh (2004) | Korea | 2000 | 6-12 years | fish | IgE mediated only (no SPT or SIgE) | 0.7 [†] (0.6 - 0.8) n=27425 | - | - | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 12-15 years | fish | IgE mediated only (no SPT or SIgE) | 0.6 [†] (0.5-0.8) n=14777 | - | - | - | - | - | - | - | - | - |
| Kim (2011) | Korea | 2006-2007 | 0-12 months | seafood | IgE mediated only (no SPT or SIgE) | - | - | 0.5 [†] (0.2-1.2) n=1177 | - | - | - | - | - | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID Country | | Year(s) of study | Age group | Allergen | Tyoe of food allergy | Questio | nnaire-based r | nethods | Sensi | tisation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical ory | Other |
|------------------|-------------|---------------------|---------------|-------------------------|--|--|--|--|----------------|-------------------------|-----------------------|-------------------------------|-----------------------|------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick tes | t Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | lence (CI) | | | | |
| Oh (2004) | Korea | 2000 | 6-12 years | seafood | IgE mediated only (no SPT or SIgE) | 0.4 [†] (0.3-0.4) n=27425 | - | - | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 12-15 years | seafood | IgE mediated only (no SPT or SIgE) | 0.8 [†] (0.7-1.0) n=14777 | - | - | - | - | - | - | - | - | - |
| Connett (2012) | Philippines | 2007 - 2008 | 14 - 16 years | fish | Both IgE and non-IgE mediated only | 4.3 [†] (3.9-4.7) n=11434 | 2.3 [†] (2.0-2.6) n=11434 | - | - | - | - | - | - | - | - |
| Shek (2010) | Philippines | 2007-2008 | 14-16 years | shellfish | Both IgE and non IgE mediated | 8.7 [†] (8.2-9.2) n=11158 | 5.1 [†] (4.3-6.1) n=11158 | - | - | - | - | - | - | - | - |
| Connett (2012) | Singapore | 2007-2008 | 14 - 16 years | fish | Both IgE and non-IgE mediated only | 0.6 [†] (0.4-0.8) n=6498 | 0.3 [†] (0.2-0.4) n=6498 | - | - | - | - | - | - | - | - |
| Shek (2010) | Singapore | 2007-2008 | 4-6 years | shellfish | Both IgE and non IgE mediated | 7.2 [†] (6.5-8.1) n=4115 | 1.2 [†] (0.9-1.6) n=4115 | - | - | - | - | - | - | - | - |
| Shek (2010) | Singapore | 2007-2008 | 14-16 years | shellfish | Both IgE and non IgE mediated | 11.6 [†] (10.8-12.4) n=6342 | 5.2 [†] (4.5-6.1) n=6342 | - | - | - | - | - | - | - | - |
| Wan (2012) | Taiwan | nr | 6-8 years | crustacean (lobster) | IgE mediated only | - | - | - | - | - | - | 17.3 (15.1-19.8) n=1010 | - | - | - |
| Wu (2012) | Taiwan | 2004 | <3 years | crustaceans (shrimp) | IgE mediated only (no SPT or SIgE) | - | - | 0.6 [†] (0.2-1.5) n=813 | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | 4-18 years | crustaceans (shrimp) | IgE mediated only (no SPT or SIgE) | - | - | 4 [†] (3.7-4.4) n=15169 | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | >19 years | crustaceans (shrimp) | IgE mediated only (no SPT or SIgE) | - | - | 3.3 [†] (3.0-3.6) n=14036 | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | <3 years | crustceans (crab) | IgE mediated only (no SPT or SIgE) | - | - | $\begin{array}{c} 0.4 \\ (0.1-1.2) \\ n=813 \end{array}$ | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | 4-18 years | crustceans (crab) | IgE mediated only (no SPT or SIgE) | - | - | 2.6 [†] (2.3-2.8) n=15169 | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | >19 years | crustceans (crab) | IgE mediated only (no SPT or SIgE) | - | - | 2.3 [†] (2.0-2.5) n=14036 | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | <3 years | fish | IgE mediated only (no SPT or SIgE) | - | - | 0.5 [†] (0.2-1.3) n=813 | - | - | - | - | - | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Tyoe of food allergy | Questio | onnaire-based 1 | methods | Sensi | tisation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical ory | Other |
|----------------------|----------|---------------------|----------------------|-------------------------|--|---|---|--|-----------------|-----------------------|-----------------------|-------------------------------|--|------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Wu (2012) | Taiwan | 2004 | 4-18 years | fish | IgE mediated only (no SPT or SIgE) | - | - | 1.5 [†] (1.3-1.7) n=15169 | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | >19 years | fish | IgE mediated only (no SPT or SIgE) | - | - | 1.2 [†] (1.0-1.4) n=14036 | - | - | - | - | - | - | - |
| Wan (2012) | Taiwan | nr | 6-8 years | mollusc (abalone) | IgE mediated only | - | - | - | - | - | - | 25.1 (22.4-27.9) n=1010 | - | - | - |
| Wan (2012) | Taiwan | nr | 6-8 years | mollusc (clam) | IgE mediated only | - | - | - | - | - | - | 4.8 (3.6-6.3) n=1010 | - | - | - |
| Wan (2012) | Taiwan | nr | 6-8 years | mollusc (octopus) | IgE mediated only | - | - | - | - | - | - | 7.5 (6.0-9.4) n=1010 | - | - | - |
| Wan (2012) | Taiwan | nr | 6-8 years | mollusc (oyster) | IgE mediated only | - | - | - | - | - | - | 9.9 (8.2-12) n=1010 | - | - | - |
| Wan (2012) | Taiwan | nr | 6-8 years | mollusc (scallop) | IgE mediated only | - | - | - | - | - | - | 24.9 (22.2-27.7) n=1010 | - | - | - |
| Wan (2012) | Taiwan | nr | 6-8 years | mollusc (squid) | IgE mediated only | - | - | - | - | - | - | 2.3 (1.5-3.5) n=1010 | - | - | - |
| Wan (2012) | Taiwan | nr | 6-8 years | mollusc (squid) | IgE mediated only | - | - | - | - | - | - | 6.8 (5.4-8.6) n=1010 | - | - | - |
| Wu (2012) | Taiwan | 2004 | <3 years | Molluses | IgE mediated only (no SPT or SIgE) | - | - | 0.1^{\dagger} (0.0-0.8) n=813 | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | 4-18 years | Molluses | IgE mediated only (no SPT or SIgE) | - | - | 1.1 [†] (1.0-1.3) n=15169 | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | >19 years | Molluses | IgE mediated only (no SPT or SIgE) | - | - | 1.5 [†] (1.3-1.7) n=14036 | - | - | - | - | - | - | - |
| Lao-araya (2012) | Thailand | 2010 | 3-7years | crustaceans (shrimp) | IgE mediated only | 3.1 [†] (1.8-5.3) n=452 | - | - | - | - | - | - | 0.9 [†] (0.3-2.4) n=452 | - | - |
| Santadusit (2005) | Thailand | nr | 6 months - 6years | crustaceans (shrimp) | IgE mediated only | 1.2^{\dagger} (0.6 - 2.5) n=656 | - | - | - | - | - | - | - | - | - |
| Lao-araya (2012) | Thailand | 2010 | 3-7years | crustaceans (crab) | IgE mediated only | 0.7^{\dagger} (0.2-2.1) n=452 | - | - | - | - | - | - | 0.2 [†] (0.0-1.4) n=452 | - | - |
| Connett (2012) | Thailand | 2007-2008 | 14 - 16 years | fish | Both IgE and non-IgE mediated only | 0.4 [†] (0.2-0.8) n=2034 | 0.3 [†] (0.1-0.7) n=2034 | - | - | - | _ | - | - | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Tyoe of food allergy | Questio | nnaire-based | methods | Sensi | tisation | Sensitisation hist | with clinical tory | Food challeng | e with clinical ory | Other |
|----------------------|--|---------------------|----------------------|-----------------------------------|---|---|------------------------------------|--|-----------------|-----------------------|-----------------------|---------------------|--|------------------------|---|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | lence (CI) | | | | |
| Lao-araya (2012) | Thailand | 2010 | 3-7years | fish | IgE mediated only | 1.1 [†] (0.4-2.7) n=452 | - | _ | - | - | - | - | 0.2 [†] (0.0-1.4) n=452 | - | - |
| Santadusit (2005) | Thailand | nr | 6 months - 6years | fish | IgE mediated only | $\begin{array}{r} 0.3 \\ (0.1 - 1.2) \\ n = 656 \end{array}$ | - | - | - | - | - | - | - | - | - |
| Lao-araya (2012) | Thailand | 2010 | 3-7years | mollusc (squid) | IgE mediated only | $\begin{array}{c} 0.2^{\dagger} \\ (0.0\text{-}1.4) \\ n=\!452 \end{array}$ | - | - | - | - | - | - | - | - | - |
| Lao-araya (2012) | Thailand | 2010 | 3-7years | molluscs | IgE mediated only | 0.2 [†] (0.0-1.4) n=452 | - | - | - | - | - | - | - | - | - |
| Santadusit (2005) | Thailand | Nr | 6 months - 6years | seafood (crab. mollusc, squid) | IgE mediated only | 0.5 [†] (0.1 - 1.5) n=656 | - | - | - | - | - | - | - | - | - |
| Al-Hammadi (2010) | United Arab Emirates (Emirate of Abu Dhabi) | 2006 | 6-9 years | fish | IgE mediated only (no SPT or SIgE) | - | - | 2.8 [†] (1.5-5.1) n=397 | - | - | - | - | - | - | - |
| Vierk (2007) | United States | 2001 | 18 years + | crustaceans | IgE mediated only (no SPT or SIgE) | 0.7 [†] (0.5-1.0) n=4482 | - | - | - | - | - | - | - | - | 0.4 [†] (0.2-0.7) n=4482 |
| Branum (2009) | United States | 2005-2006 | < 18 years | crustaceans (shrimp) | IgE mediated only (not clearly defined) | - | - | - | - | 5.2 (nr) n=nr | - | - | - | - | - |
| Liu (2010) | United States | 2005-2006 | 6-19 years | crustaceans (shrimp) | IgE mediated only | - | - | - | - | 6.1 (nr) n=2869 | - | - | - | - | 1.1 (nr) n=nr |
| Liu (2010) | United States | 2005-2006 | 20-39 years | crustaceans (shrimp) | IgE mediated only | - | - | - | - | 6.7 (nr) n=1672 | - | - | - | - | 1.2 (nr) n=nr |
| Liu (2010) | United States | 2005-2006 | 40-59 years | crustaceans (shrimp) | IgE mediated only | - | - | - | - | 5.9 (nr) n=1361 | - | - | - | - | 0.9 (nr) n=nr |
| Liu (2010) | United States | 2005-2006 | 60+ years | crustaceans (shrimp) | IgE mediated only | - | - | - | - | 4.6 (nr) n=1392 | - | - | - | - | 0.7 (nr) n=nr |
| Liu (2010) | United States | 2005-2006 | All ages | crustaceans (shrimp) | IgE mediated only | - | - | - | - | 5.9 (nr) n=8203 | - | - | - | - | 1 (nr) n=nr |
| Sicherer (2004) | United States | 2002 | 0-5 years | fish | Both IgE and non IgE mediated | - | 0 [†] (0-0.5) n=997 | - | - | - | - | - | - | - | - |
| Sicherer (2004) | United States | 2002 | 6-17 years | fish | Both IgE and non IgE mediated | - | 0.2 (0.1-0.5) n=2610 | - | - | - | - | - | - | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Tyoe of food allergy | Questio | onnaire-based | methods | Sensit | tisation | Sensitisation hist | with clinical tory | Food challeng hist | e with clinical ory | Other |
|---------------------|---------------|---------------------|-------------|-----------------|--|---|--|-------------------------|-----------------|-----------------------|-----------------------|-----------------------|-----------------------|------------------------|---|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | _ | | | | 95% Preva | lence (CI) | • | | | |
| Vierk (2007) | United States | 2001 | 18 years + | fish | IgE mediated only (no SPT or SIgE) | 0.7 [†] (0.5-1.0) n=4482 | - | - | - | - | - | - | - | - | 0.6 [†] (0.4-0.9) n=4482 |
| Greenhawt (2009) | United States | nr | 18 years+ | fish | IgE mediated (no SPT or SIgE) | 2.7 [†] (1.6-4.7) n=513 | - | - | - | - | - | - | - | - | - |
| Sicherer (2004) | United States | 2002 | 18-40 years | fish | Both IgE and non IgE mediated | - | 0.5 [†] (0.3-0.8) n=4336 | - | - | - | - | - | - | - | - |
| Sicherer (2004) | United States | 2002 | 41-60 years | fish | Both IgE and non IgE mediated | - | 0.5 [†] (0.3-0.8) n=3604 | - | - | - | - | - | - | - | - |
| Sicherer (2004) | United States | 2002 | 61 + | fish | Both IgE and non IgE mediated | - | 0.3 [†] (0.1-0.7) n=1876 | - | - | - | - | - | - | - | - |
| Sicherer (2004) | United States | 2002 | All ages | fish | Both IgE and non IgE mediated | 0.8 [†] (0.7-1) n=14948 | 0.4 [†] (0.3-0.5) n=14948 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 0-2 years | fish (fin fish) | IgE mediated (no SPT or SIgE) | - | 0.3 (0.1-0.4) n=5429 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 3-5 years | fish (fin fish) | IgE mediated (no SPT or SIgE) | - | 0.5 (0.3-0.8) n=5910 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 6-10 years | fish (fin fish) | IgE mediated (no SPT or SIgE) | - | 0.5 (0.3-0.7) n=9911 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 11-13 years | fish (fin fish) | IgE mediated (no SPT or SIgE) | - | 0.6 (0.4-0.8) n=6716 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 14-17 years | fish (fin fish) | IgE mediated (no SPT or SIgE) | - | 0.6 (0.4-0.9) n=10514 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | All ages | fish (fin fish) | IgE mediated (no SPT or SIgE) | - | 0.5 (0.4-0.6) n=3339 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 0-2 years | shellfish | IgE mediated (no SPT or SIgE) | - | 0.5 (0.3-0.8) n=5429 | - | - | - | - | - | - | - | - |
| Sicherer (2004) | United States | 2002 | 0-5 years | shellfish | Both IgE and non IgE mediated | - | 0.1 [†] (0-0.6) n=997 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 3-5 years | shellfish | IgE mediated (no SPT or SIgE) | - | 1.2 (0.8-1.6) n=5910 | - | - | - | - | - | - | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Tyoe of food allergy | Questio | nnaire-based 1 | nethods | Sensi | tisation | Sensitisation hist | with clinical tory | Food challeng | ge with clinical tory | Other |
|---------------------|---------------|---------------------|-------------|-----------|--|---|---|-------------------------|-----------------|-------------------------|-----------------------|---------------------|--------------------|--------------------------|---|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | t Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | • | | | | 95% Preva | alence (CI) | | | | |
| Gupta (2011) | United States | 2009-2010 | 6-10 years | shellfish | IgE mediated (no SPT or SIgE) | - | 1.3 (1.1-1.6) n=9911 | - | - | - | - | - | - | - | - |
| Sicherer (2004) | United States | 2002 | 6-17 years | shellfish | Both IgE and non IgE mediated | - | 0.7 [†] (0.4-1.1) n=2610 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 11-13 years | shellfish | IgE mediated (no SPT or SIgE) | - | 1.7 (1.3-2.1) n=6716 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 14-17 years | shellfish | IgE mediated (no SPT or SIgE) | - | 2 (1.7-2.5) n=10514 | - | - | - | - | - | - | - | - |
| Vierk (2007) | United States | 2001 | 18 years + | shellfish | IgE mediated only (no SPT or SIgE) | 1.7 [†] (1.3-2.1) n=4482 | - | - | - | - | - | - | - | - | 1.1 [†] (0.8-1.5) n=4482 |
| Greenhawt (2009) | United States | nr | 18 years+ | shellfish | IgE mediated only (no SPT or SIgE) | 9 [†] (6.7-11.9) n=513 | - | - | - | - | - | - | - | - | - |
| Sicherer (2004) | United States | 2002 | 18-40 years | shellfish | Both IgE and non IgE mediated | - | 2.2 [†] (1.8-2.7) n=4336 | - | - | - | - | - | - | - | - |
| Sicherer (2004) | United States | 2002 | 41-60 years | shellfish | Both IgE and non IgE mediated | - | 3.1 [†] (2.5-3.7) n=3604 | - | - | - | - | - | - | - | - |
| Sicherer (2004) | United States | 2002 | 61 + | shellfish | Both IgE and non IgE mediated | - | 2.6 [†] (2-3.5) n=1876 | - | - | - | - | - | - | - | - |
| Sicherer (2004) | United States | 2002 | All ages | shellfish | Both IgE and non IgE mediated | 2.7 [†] (2.5-3) n=14948 | 2 [†] (1.8-2.3) n=14948 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | All ages | shellfish | IgE mediated only (no SPT or SIgE) | - | 1.4 (1.2-1.5) n=3339 | - | - | - | - | - | - | - | - |

[†]Percentage prevalence and/or confidence intervals calculated from raw data provided in the paper

[‡]Percentage prevalence inferred from graph provided (no raw data reported).

[#]Data has been subject to correction or estimation by the authors (presented as reported in the paper).

Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

EFSA supporting publication 2013:EN-506

| Prevalence | of food | allergy | in | Europe |
|------------|---------|---------|----|--------|
| | | | | r- |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Good y Questionnaire-based methods Self-reported Clinical | | Sensitisation | | Sensitisation with clinical history | | al Food challenge with clinical history | | Other | |
|----------------------|---------|---------------------|------------|---|---|--|---------------------|--|--------------------|--|--------------------|---|--------------------|--|--|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Osterballe (2005) | Denmark | 2000-2001 | < 3 years | fruit/ vegetables | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | 0 (nr) N=111 | - | 9 [†] (4.6 - 16.3) n=111 |
| Osterballe (2005) | Denmark | 2000-2001 | 3 years | fruit/ vegetables | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0 [†] (0 - 1) n=486 | 1.4^{\dagger} (0.6 - 3.1) n=486 |
| Osterballe (2005) | Denmark | 2000-2001 | 3-22 years | fruit/ vegetables | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 1^{\dagger} (0.3-3.1) n=301 | 5.6 [†] (3.4 - 9.1) n=301 |
| Osterballe (2005) | Denmark | 2000-2001 | >22 years | fruit/ vegetables | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 2.7 [†] (1.8 - 4) n=936 | 8.1 [†] (7 - 10.1) n=936 |
| Kajosaari (1982) | Finland | 1980-1981 | 3 years | fruits (apple) | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.5 (nr) n=200 | - | - | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 6 years | fruits (apple) | Both IgE and non-IgE mediated (no SPT or SIgE) | 1 (nr) n=203 | - | - | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 1 year | fruits (apple, pear, cherry, peach, banana) | Both IgE and non-IgE mediated (no SPT or SIgE) | 6.6 [†] (5.0-8.5) n=853 | - | 0.4 [†] (0.1 - 1.1) n=853 | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 2 years | fruits (apple, pear, cherry, peach, banana) | Both IgE and non-IgE mediated (no SPT or SIgE) | 7 [†] (5.3-8.8) n=852 | - | $0.2^{\dagger} \\ (0.0 - 0.9) \\ n=852$ | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 3 years | fruits (apple, pear, cherry, peach, banana) | Both IgE and non-IgE mediated (no SPT or SIgE) | 6.6 [†] (5.0 - 8.7) n=784 | - | 1 [†] (0.3-1.8) n=784 | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 4 years | fruits (apple, pear, cherry, peach, banana) | Both IgE and non-IgE mediated (no SPT or SIgE) | 6 [†] (4.5 - 7.9) n=819 | - | 1.3 [†] (0.7 - 2.5) n=819 | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 1 year | fruits (citrus) | Both IgE and non-IgE mediated (no SPT or SIgE) | 8 (nr) n=261 | - | - | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 1 year | fruits (citrus) | Both IgE and non-IgE mediated (no SPT or SIgE) | 3.5 [†] (2.4-5.1) n=853 | - | 0.1 [†] (0-0.8) n=853 | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 2 years | fruits (citrus) | Both IgE and non-IgE mediated (no SPT or SIgE) | 9 (nr) n=202 | - | - | - | - | - | - | - | - | - |

Table 1.18:Fruits allergy prevalence in European countries by age group

EFSA supporting publication 2013:EN-506

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | food gy Questionnaire-based methods Self-reported Clinical Clinician- | | | Sensit | isation | Sensitisation hist | with clinical ory | Food challeng | e with clinical ory | Other |
|---------------------|---------|---------------------|------------|--|---|---|---------------------|--|--------------------|------------------------|-----------------------|----------------------|--------------------|------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | I | | | | 95% Prev | alence (CI) | | | | |
| Pyrhonen (2009) | Finland | 2001-2009 | 2 years | fruits (citrus) | Both IgE and non-IgE mediated (no SPT or SIgE) | 7.2 [†] (5.6-9.2) n=852 | - | $ \begin{array}{c} 0^{\dagger} \\ (0.0 - 0.6) \\ n = 852 \end{array} $ | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 3 years | fruits (citrus) | Both IgE and non-IgE mediated (no SPT or SIgE) | 11 (nr) n=200 | - | - | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 3 years | fruits (citrus) | Both IgE and non-IgE mediated (no SPT or SIgE) | 6.5 [†] (4.9 - 8.5) n=784 | - | 0.4 [†] (0.1-1.2) n=784 | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 4 years | fruits (citrus) | Both IgE and non-IgE mediated (no SPT or SIgE) | 5.1 [†] (3.8 - 6.9) n=819 | - | $\begin{array}{c} 1.3 \\ (0.7 - 2.5) \\ n=819 \end{array}$ | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 6 years | fruits (citrus) | Both IgE and non-IgE mediated (no SPT or SIgE) | 2 (nr) n=203 | - | - | - | - | - | - | 2 (nr) n=203 | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 1 year | fruits (strawberry) | Both IgE and non-IgE mediated (no SPT or SIgE) | 7 (nr) n=261 | - | - | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 2 years | fruits (strawberry) | Both IgE and non-IgE mediated (no SPT or SIgE) | 4 (nr) n=202 | - | - | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 3 years | fruits (strawberry) | Both IgE and non-IgE mediated (no SPT or SIgE) | 7 (nr) n=200 | - | - | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 6 years | fruits (strawberry) | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.5 (nr) n=203 | - | - | - | - | - | - | - | - | - |
| Touraine (2002) | France | 2000-2001 | 5-17 years | fruits | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.5 [†] (0.9-2.4) n=1086 | - | - | - | - | - | - | - | - | - |
| Touraine (2002) | France | 2000-2001 | 5-17 years | fruits (apple/peach/r aspberry/cherr y) | Both IgE and non-IgE mediated (no SPT or SIgE) | 16 [†] (13.9-18.4) n=1086 | - | - | - | - | - | - | - | - | - |
| Rance (2005) | France | 2002 | 2-14 years | fruits (kiwi) | Both IgE and non-IgE mediated (no SPT or SIgE) | $\begin{array}{c} 0.8^{\text{T}} \\ (0.5 - 1.3) \\ n = 2716 \end{array}$ | - | - | - | - | - | - | - | - | - |
| Touraine (2002) | France | 2000-2001 | 5-17 years | fruits (pear) | Both IgE and non-IgE mediated (no | 1.5 [†] (0.9-2.4) n=1086 | - | - | - | - | - | - | - | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | nnaire-based | methods | Sensit | isation | Sensitisation hist | with clinical tory | Food challeng hist | e with clinical ory | Other |
|---------------------|---------|---------------------|-------------|-----------------------|---|---|---------------------|-------------------------|--------------------|------------------------|----------------------------|-----------------------|-----------------------|----------------------------|----------------------------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Prev | alence (CI) | | | | |
| | | | | | SPT or SIgE) | | | | | | | | | | |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | fruits | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 1.1 (0.8-1.5) n=3156 | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | Fruits | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | - | 0.3 (0.1-0.6) n=3156 |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | fruits | Both IgE and non-IgE mediated | 3.8 [†] (nr) n=nr | - | - | - | - | - | - | - | - | - |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | fruits (apple etc) | Both IgE and non-IgE mediated | 3.9 [†] (nr) n=nr | - | - | - | - | - | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | fruits (apple) | Both IgE and non-IgE mediated | - | - | - | - | - | 4.2 (3.6-4.8) n=4093 | - | - | 2.2 (1.8-2.8) n=3156 | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | fruits (apricot) | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0.2 (0.1-0.4) n=3156 | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | fruits (cherry) | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0.9 (0.6-1.3) n=3156 | - |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | fruits (citrus) | Both IgE and non-IgE mediated | 4.5^{\dagger} (nr) n=nr | - | - | - | - | - | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | fruits (grape) | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0.1 (0.0-0.3) n=3156 | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | fruits (nectarine) | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0.4 (0.2-0.7) n=3156 | - |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | fruits (peach etc) | Both IgE and non-IgE mediated | 3.7 [†] (nr) n=nr | - | - | - | - | - | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | fruits (peach) | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0.7 (0.4-1.0) n=3156 | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | fruits (pear) | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0.4 (0.2-0.7) n=3156 | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | fruits (plum) | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0.5 (0.3-0.8) n=3156 | - |
| Zannikos (2008) | Greece | 2007 | 7-13 years | Fruits | Both IgE and non IgE mediated (no SPT or SIgE) | 3.1 [†] (2.4-4.0) n=1988 | - | - | - | - | - | - | - | - | - |
| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | nnaire-based | methods | Sensit | isation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical ory | Other |
|-------------------------------|----------|---------------------|-------------|-------------------------|---|---|---------------------|-------------------------|---|--|-----------------------|----------------------|-----------------------|------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Prev | alence (CI) | | | | |
| Bakos (2006) | Hungary | 2002-2004 | 20-69 years | fruits (apple) | IgE mediated only | - | - | - | 5.6^{\dagger} (1.0-20.0) n=36 | 0^{\dagger} (0-12.0) n=36 | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 60-97 years | fruits (apple) | IgE mediated only | - | - | - | 9.2 † (5.0-17.0) n=109 | $ \begin{array}{c} 0^{\dagger} \\ (0-4.2) \\ n=109 \end{array} $ | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 20-69 years | fruits (banana) | IgE mediated only | - | - | - | 0 [†] (0-12.0) n=36 | - | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 60-97 years | fruits (banana) | IgE mediated only | - | - | - | 8.3 [†] (4.1-15.5) n=109 | - | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 20-69 years | fruits (orange) | IgE mediated only | - | - | - | - | - | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 60-97 years | fruits (orange) | IgE mediated only | - | - | - | - | 4.6 [†] (1.7-10.9) n=109 | - | - | - | - | - |
| Kristjansson (1999) | Iceland | 1994 | 18 months | fruits (apple) | Both IgE and non-IgE mediated | 0.9 [†] (0.2-2.9) n=324 | - | - | - | - | - | - | - | - | - |
| Kristjansson (1999) | Iceland | 1994 | 18 months | fruits (banana) | Both IgE and non-IgE mediated | 1.2 [†] (0.4-3.3) n=324 | - | - | - | - | - | - | - | - | - |
| Kristjansson (1999) | Iceland | 1994 | 18 months | fruits (citrus) | Both IgE and non-IgE mediated | 6.8 [†] (4.4-10.3) n=324 | - | - | - | - | - | - | - | - | - |
| Kristjansson (1999) | Iceland | 1994 | 18 months | fruits (plum/cherry) | Both IgE and non-IgE mediated | 0.9^{\dagger} (0.2-2.9) n=324 | - | - | - | - | - | - | - | - | - |
| Eggesbo (1999) | Norway | 1993-1995 | 1 year | fruits | Both IgE and non-IgE mediated | 7.6 (6.7-8.7) n=3366 | - | - | - | - | - | - | - | - | - |
| Eggesbo (1999) | Norway | 1993-1995 | 18 months | fruits | Both IgE and non-IgE mediated | 9.3 (8.3-10.4) n=3278 | - | - | - | - | - | - | - | - | - |
| Eggesbo (1999) | Norway | 1993-1995 | 2 years | fruits | Both IgE and non-IgE mediated | 11.5 (10.4-12.7) n=2979 | - | - | - | - | - | - | - | - | - |
| Falcao (2004) | Portugal | nr | >39 years | fruits | Both IgE and non-IgE mediated (no SPT or SIgE) | 2 [†] (1.1-3.4) n=659 | - | - | - | - | - | - | - | - | - |
| Martinez- Gimeno (2000) | Spain | nr | 6-13 years | fruits | Both IgE and non-IgE mediated (no SPT or SIgE) | 21 [†] (19.9 -22.1) n=5163 | - | - | - | - | - | - | - | - | - |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Question | nnaire-based | methods | Sensit | isation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical ory | Other |
|------------------------|--------------------|---------------------|-------------|-------------------------|---|---|---------------------|-------------------------|--------------------|------------------------|---|---------------------------|--|--------------------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | L | | | | 95% Preva | alence (CI) | | | | |
| Kristjansson (1999) | Sweden | 1994 | 18 months | fruits (apple) | Both IgE and non-IgE mediated | 0.9 [†] (0.2-2.9) n=328 | - | - | - | - | - | - | - | - | - |
| Kristjansson (1999) | Sweden | 1994 | 18 months | fruits (banana) | Both IgE and non-IgE mediated | 0.9 [†] (0.2-2.9) n=328 | - | - | - | - | - | - | - | - | - |
| Ostblom (2008 a) | Sweden | 1999-2000 | 4 years | fruits (banana) | Both IgE and non-IgE mediated | 0.3 [†] (0.1-0.6) n=2563 | - | - | - | - | - | - | - | - | - |
| Kristjansson (1999) | Sweden | 1994 | 18 months | fruits (citrus) | Both IgE and non-IgE mediated | 6.7 [†] (4.4-10-1) n=328 | - | - | - | - | - | - | - | - | - |
| Ostblom (2008 a) | Sweden | 1999-2000 | 4 years | fruits (citrus) | Both IgE and non-IgE mediated | 5 [†] (4.2-5.9) n=2563 | - | - | - | - | - | - | - | - | - |
| Kristjansson (1999) | Sweden | 1994 | 18 months | fruits (plum/cherry) | Both IgE and non-IgE mediated | 0.9 [†] (0.2-2.9) n=328 | - | - | - | - | - | - | - | - | - |
| Ostblom (2008 a) | Sweden | 1999-2000 | 4 years | fruits (stonefruit) | Both IgE and non-IgE mediated | 3.4 [†] (2.7-4.2) n=2563 | - | - | - | - | - | - | - | - | - |
| Brugman (1998) | The Netherlands | 1993- 1994 | 4-15 years | fruits (apple) | Both IgE and non-IgE (no SPT or SIgE) | 0.6 [†] (0.4-0.9) n=4400 | - | - | - | - | - | - | - | - | - |
| Brugman (1998) | The Netherlands | 1993- 1994 | 4-15 years | fruits (banana) | Both IgE and non-IgE (no SPT or SIgE) | 0.4 [†] (0.2-0.6) n=4400 | - | - | - | - | - | - | - | - | - |
| Brugman (1998) | The Netherlands | 1993- 1994 | 4-15 years | fruits (orange) | Both IgE and non-IgE (no SPT or SIgE) | 0.5 [†] (0.4-0.8) n=4400 | - | - | - | - | - | - | - | - | - |
| Brugman (1998) | The Netherlands | 1993- 1994 | 4-15 years | fruits (strawberry) | Both IgE and non-IgE (no SPT or SIgE) | 0.6 [†] (0.4-0.9) n=4400 | - | - | - | - | - | - | - | - | - |
| Gelincik (2008) | Turkey | nr | 18 years + | fruits (banana) | Both Ige and non-IgE mediated | 0.2 [‡] (0.1-0.3) n=11816 | - | - | - | - | 0 [†] (0.0-0.1) n=11816 | 0 (0.0-0.1) n=11816 | - | 0 [†] (0-0.1) n=11816 | - |
| Orhan (2009) | Turkey | 2006 | 6-9 years | fruits (banana) | IgE mediated only | 0.1 [†] (0.0 - 0.4) n=2739 | - | - | - | - | 0.1 [†] (0 - 0.3) n=2739 | - | - | 0 [†] (0- 0.2) n=2739 | - |
| Gelincik (2008) | Turkey | nr | 18 years + | fruits (grape) | Both Ige and non-IgE mediated | 0.2 [‡] (0.1-0.3) n=11816 | - | - | - | - | - | - | - | 0 [†] (0-0.0) n=11816 | - |
| Mustafayev (2012) | Turkey | 2010 | 10-11 years | fruits (kiwi) | IgE mediated only | - | - | - | - | - | - | - | 0.1 [†] (0.0-0.8) n=813 | - | - |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Question | nnaire-based | methods | Sensit | tisation | Sensitisation hist | with clinical tory | Food challeng hist | e with clinical ory | Other |
|----------------------|-------------------|---------------------|-------------|------------------------|---|---|---------------------|-------------------------|--------------------------------------|------------------------|---|---------------------------|--|---|--|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Prev | alence (CI) | | | | |
| Orhan (2009) | Turkey | 2006 | 6-9 years | fruits (kiwi) | IgE mediated only | 0.3 [†] (0.1 - 0.6) n=2739 | - | - | - | - | 0.3 [†] (0.1 - 0.6) n=2739 | - | - | 0.1 [†] (0 - 0.4) n=2739 | - |
| Gelincik (2008) | Turkey | nr | 18 years + | fruits (orange) | Both Ige and non-IgE mediated | 0.2 [‡] (0.1-0.3) n=11816 | - | - | - | - | 0 [†] (0.0-0.1) n=11816 | 0 (0.0-0.1) n=11816 | - | 0 [†] (0.0-0.1) n=11816 | - |
| Mustafayev (2012) | Turkey | 2010 | 10-11 years | fruits (peach) | IgE mediated only | - | - | - | - | - | - | - | 0.1 [†] (0.0-0.8) n=813 | - | - |
| Gelincik (2008) | Turkey | nr | 18 years + | fruits (peach) | Both Ige and non-IgE mediated | 0.3 [‡] (0.2-0.4) n=11816 | - | - | - | - | - | - | - | 0 [†] (0-0.0) n=11816 | - |
| Gelincik (2008) | Turkey | nr | 18 years + | fruits (pear) | Both Ige and non-IgE mediated | - | - | - | - | - | 0 [†] (0-0.1) n=11816 | 0 (0-0.1) n=11816 | - | 0 [†] (0-0.1) n=11816 | - |
| Gelincik (2008) | Turkey | nr | 18 years + | fruits (strawberry) | Both Ige and non-IgE mediated | 0.7 [‡] (0.5-0.8) n=11816 | - | - | - | - | 0 [†] (0-0.1) n=11816 | 0 (0-0.1) n=11816 | - | 0 [†] (0-0.1) n=11816 | - |
| Orhan (2009) | Turkey | 2006 | 6-9 years | fruits (strawberry) | IgE mediated only | 0.1 [†] (0 - 0.3) n=2739 | - | - | - | - | 0 [†] (0 - 0.2) n=2739 | - | - | 0 [†] (0 - 0.2) n=2739 | - |
| Emmett (1999) | United Kingdom | 1995-1996 | 15 + years | fruits | Both Ige and non-IgE mediated | 0.5 [†] (0.4-0.6) n=16420 | - | - | - | - | - | - | - | - | - |
| Venter (2006) | United Kingdom | 2003-2004 | 6 years | fruits (banana) | Both IgE and non-IgE mediated | - | - | - | 0.1 [†] (0-0.9) n=700 | - | - | - | - | - | 0.1 [†] (0-0.8) n=798 |
| Young (1994) | United Kingdom | nr | nr | fruits (citrus) | Both IgE and non IgE mediated (no SPT or SIgE) | 3.2 [†] (3.2-3.8) n=18880 | - | - | - | - | - | - | - | - | - |
| Young (1994) | United Kingdom | nr | nr | fruits (non citrus) | Both IgE and non IgE mediated (no SPT or SIgE) | 1 [†] (0.9-1.2) n=18880 | - | - | - | - | - | - | - | - | - |
| Venter (2008) | United Kingdom | 2001-2005 | 1 year | fruits (pineapple) | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | - | 0 [†] (0-0.5) n=900 |
| Venter (2008) | United Kingdom | 2001-2005 | 2 years | fruits (pineapple) | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | - | 0 [†] (0-0.6) n=858 |
| Venter (2008) | United Kingdom | 2001-2005 | 3 years | fruits (pineapple) | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | - | 0.1 [†] (0.0-0.2) n=891 |
| Venter (2006) | United Kingdom | 2003-2004 | 6 years | fruits (strawberry) | Both IgE and non-IgE mediated | 0.8 [†] (0.3-1.7) n=798 | - | - | - | - | - | - | - | - | - |

^{*}Percentage prevalence inferred from graph provided (no raw data reported).

[#] Data has been subject to correction or estimation by the authors (presented as reported in the paper).

Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Question | nnaire-based 1 | methods | Sensit | isation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical cory | Other |
|-------------------|-----------|---------------------|-------------|----------------------|---|---|---------------------|-------------------------|--------------------------------------|------------------------|-----------------------|----------------------|-----------------------|-------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Woods (1998) | Australia | 1998 | 20-44years | fruits | Both IgE and non IgE mediated | 2.8 [†] (1.8-4.5) n=669 | - | - | _ | - | - | - | - | - | - |
| Woods (1998) | Australia | 1998 | 20-44years | fruits (dried) | IgE mediated only | 0.3 [†] (0.1-1.2) n=669 | - | - | - | - | - | - | - | - | - |
| Soller (2012) | Canada | 2008-2009 | <18 years | fruits | "likely" IgE mediated (no SPT or SIgE) | 1.14 (0.68-1.60) n=nr | - | - | - | - | - | - | - | - | - |
| Soller (2012) | Canada | 2008-2009 | >18 years | fruits | "likely" IgE mediated (no SPT or SIgE) | 1.61 (1.32-1.89) n=nr | - | - | - | - | - | - | - | - | - |
| Chen (2011) | China | 2009 | 0-12 months | fruits (orange) | IgE mediated only | - | - | - | 0.2 [†] (0-1.3) n=477 | - | - | - | - | - | - |
| Hu (2010) | China | 1999 | 0-24 months | fruits (orange) | IgE mediated only | - | - | - | 1^{\dagger} (0.3-3.1) n=304 | - | - | - | - | - | - |
| Hu (2010) | China | 2009 | 0-24 months | fruits (orange) | IgE mediated only | - | - | - | 0 [†] (0-1.2) n=382 | - | - | - | - | - | - |
| Marrugo (2008) | Colombia | nr | All ages | fruit/ vegetables | Both IgE and non-IgE mediated (no SPT or SIgE) | 6.2 [†] (5.4-7.2) n=3099 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | fruits (apple) | IgE mediated only | 0.1 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | fruits (banana) | IgE mediated only | 0.1 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | fruits (mango) | IgE mediated only | 0.4 (nr) n=1407 | - | - | - | - | - | - | - | - | - |

| up |
|----|
| |

EFSA supporting publication 2013:EN-506

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | nnaire-based | methods | Sensit | isation | Sensitisation | with clinical tory | Food challeng | e with clinical cory | Other |
|--------------|-----------|---------------------|-------------|----------------------------|--|--|---|---|--------------------|------------------------|--------------------------------------|-----------------------|--------------------|-------------------------|---|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | fruits (melon) | IgE mediated only | 0.3 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | fruits (orange) | IgE mediated only | 0 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | fruits (pawpaw) | IgE mediated only | 0.3 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | fruits (pineapple) | IgE mediated only | 1.1 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Leung (2009) | Hong Kong | 2006-2007 | 2-7 years | fruits (orange/ banana) | IgE mediated only (no SPT or SIgE) | 0.1 [†] (0.10.3) n=3677 | - | - | - | - | - | - | - | _ | 0.1 [†] (0.1-0.3) n=3677 |
| Dalal (2002) | Israel | nr | 0-2years | fruits (strawberry) | IgE mediated only | - | 0 [†] (0.0 - 0.2) n=9070 | - | - | - | 0^{\dagger} (0 - 0.1) n=9070 | - | - | - | - |
| Kim (2011) | Korea | 2006-2007 | 0-12 months | fruits | IgE mediated only (no SPT or SIgE) | - | - | 0.6 [†] (0.3-1.3) n=1177 | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 6-12 years | fruits | IgE mediated only (no SPT or SIgE) | 0.1 [†] (0.1-0.2) n=27425 | - | - | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 12-15 years | fruits | IgE mediated only (no SPT or SIgE) | 0.3 [†] (0.2-0.4) n=14777 | - | - | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 6-12 years | fruits (apple) | IgE mediated only (no SPT or SIgE) | 0 [†] (0.0-0.1) n=27425 | - | - | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 12-15 years | fruits (apple) | IgE mediated only (no SPT or SIgE) | 0.1 [†] (0.1-0.2) n=14777 | - | - | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 6-12 years | fruits (banana) | IgE mediated only (no SPT or SIgE) | 0 [†] (0.0-0.0) n=27425 | - | - | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 12-15 years | fruits (banana) | IgE mediated only (no SPT or SIgE) | 0 [†] (0.0-0.1) n=14777 | - | - | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 6-12 years | fruits (peach) | IgE mediated only (no SPT or SIgE) | 0.2 [†] (0.2-0.3) n=27425 | - | - | - | - | - | - | - | - | - |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | nnaire-based | methods | Sensit | tisation | Sensitisation his | with clinical tory | Food challeng | e with clinical cory | Other |
|----------------------|--|---------------------|-------------|-----------------|--|--|---------------------|--|--------------------|------------------------|----------------------|----------------------------|--------------------|-------------------------|---|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Prev | alence (CI) | | | | |
| Oh (2004) | Korea | 2000 | 12-15 years | fruits (peach) | IgE mediated only (no SPT or SIgE) | 0.7 [†] (0.5-0.8) n=14777 | - | - | - | - | - | - | - | - | - |
| Wan (2012) | Taiwan | nr | 6-8 years | fruits (grape) | IgE mediated only | - | - | - | - | - | - | 0.7 (0.3-1.5) n=1010 | - | - | - |
| Wu (2012) | Taiwan | 2004 | <3 years | fruits (kiwi) | IgE mediated only (no SPT or SIgE) | - | - | 0.1 [†] (0.0-0.8) n=813 | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | >19 years | fruits (kiwi) | IgE mediated only (no SPT or SIgE) | - | - | 0.1 [†] (0.1-0.2) n=14036 | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | 4-18 years | fruits (kiwi) | IgE mediated only (no SPT or SIgE) | - | - | 0.3 [†] (0.2-0.4) n=15169 | - | - | - | - | - | - | - |
| Wan (2012) | Taiwan | nr | 6-8 years | fruits (litchi) | IgE mediated only | - | - | - | - | - | - | 3.4 (2.4-4.7) n=1010 | - | - | - |
| Wu (2012) | Taiwan | 2004 | <3 years | fruits (mango) | IgE mediated only (no SPT or SIgE) | - | - | $\begin{array}{c} 0.1 \\ (0.0-0.8) \\ n=813 \end{array}$ | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | >19 years | fruits (mango) | IgE mediated only (no SPT or SIgE) | - | - | 1.2^{\dagger} (1.0-1.4) n=14036 | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | 4-18 years | fruits (mango) | IgE mediated only (no SPT or SIgE) | - | - | 1.4 [†] (1.2-1.6) n=15169 | - | - | - | - | - | - | - |
| Wan (2012) | Taiwan | nr | 6-8 years | fruits (melon) | IgE mediated only | - | - | - | - | - | - | 2.4 (2.4-4.7) n=1010 | - | - | - |
| Al-Hammadi (2010) | United Arab Emirates (Emirate of Abu Dhabi) | 2006 | 6-9 years | fruits | IgE mediated only (no SPT or SIgE) | - | - | 3.3 [†] (1.8-5.7) n=397 | - | - | - | - | - | - | - |
| Bock (1987) | United States | 1980-1984 | 1 year | fruit juice | Both IgE and non-IgE mediated | 10.8 [†] (8.3-14) n=480 | - | - | - | - | - | - | - | - | 7.9 [†] (5.7-10.8) n=480 |
| Bock (1987) | United States | 1980-1984 | 2 years | fruit juice | Both IgE and non-IgE mediated | 5 [†] (3.3-7.4) n=480 | - | - | - | - | - | - | - | - | 4.4 [†] (3-6.7) n=480 |
| Bock (1987) | United States | 1980-1984 | 3 years | fruit juice | Both IgE and non-IgE mediated | 1.7 [†] (0.8-3.4) n=480 | - | - | - | - | - | - | - | - | 1.3 [†] (0.5-2.8) n=480 |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | nnaire-based 1 | methods | Sensit | isation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical ory | Other |
|--------------|---------------|---------------------|-------------|------------------------|--|---|-----------------------------|-------------------------|--------------------|------------------------|-----------------------|----------------------|-----------------------|------------------------|---------------------------------------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | • | | |
| Gupta (2011) | United States | 2009-2010 | 0-2 years | fruits (strawberry) | IgE mediated (no SPT or SIgE) | - | 0.5 (0.3-0.7) n=5429 | - | _ | - | - | _ | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 3-5 years | fruits (strawberry) | IgE mediated (no SPT or SIgE) | - | 0.5 (0.3-0.8) n=5910 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 6-10 years | fruits (strawberry) | IgE mediated (no SPT or SIgE) | - | 0.4 (0.3-0.5) n=9911 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 11-13 years | fruits (strawberry) | IgE mediated (no SPT or SIgE) | - | 0.4 (0.3-0.6) n=6716 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 14-17 years | fruits (strawberry) | IgE mediated (no SPT or SIgE) | - | 0.4 (0.3-0.6) n=10514 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | All ages | fruits (strawberry) | IgE mediated (no SPT or SIgE) | - | 0.4 (0.4-0.5) n=3339 | - | - | - | - | - | - | - | - |
| Vierk (2007) | United States | 2001 | 18 years + | fruit/ vegetables | IgE mediated only (no SPT or SIgE) | 3.3 [†] (2.9-3.9) n=4482 | - | - | - | - | - | - | - | - | 2 [†] (1.7-2.5) n=4482 |

^{*}Percentage prevalence inferred from graph provided (no raw data reported).

[#]Data has been subject to correction or estimation by the authors (presented as reported in the paper).

Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

| Table 1.20: | Milk/Dairy allergy p | revalence in European | countries by age group |
|--------------------|----------------------|-----------------------|------------------------|
|--------------------|----------------------|-----------------------|------------------------|

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | nnaire-based 1 | methods | Sensit | isation | Sensitisation hist | with clinical cory | Food challeng hist | ge with clinical tory | Other |
|--------------|---------|---------------------|-----------|------------|-------------------------------------|---------------|---------------------|-------------------------|--------------------|------------------------|-----------------------|-----------------------|----------------------------|--------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Host (2002 | Denmark | 1985-2000 | 0-1 years | cow's milk | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | 2.2 (1.6-3.1) n=1749 | - | - |
| Eller (2009) | Denmark | 1999-2000 | 6 months | cow's milk | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | 0.4 (nr) n= nr | - | - |
| Eller (2009) | Denmark | 1999-2000 | 1 year | cow's milk | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | 0.8 (nr) n= nr | - | - |
| Host (2002 | Denmark | 1985-2000 | 1 year | cow's milk | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | 1.0 0.6-1.6 n=1749 | - | - |

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Question | naire-based | methods | Sensit | tisation | Sensitisation hist | with clinical tory | Food challeng hist | e with clinical ory | Other |
|----------------------|---------|---------------------|------------|------------|-------------------------------------|--|---------------------|-------------------------|----------------------|------------------------|-----------------------|-----------------------|----------------------------|--|--|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | I | | | |
| Eller (2009) | Denmark | 2000-2001 | 18 months | cow's milk | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | 1.1 (nr) n= nr | - | - |
| Host (2002) | Denmark | 1985-2000 | 2 years | cow's milk | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | 0.5 (0.3-1.0) n=1749 | - | - |
| Osterballe (2005) | Denmark | 2000-2001 | < 3 years | cow's milk | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | 0.0 (0.0-4.2) n= 111 | - | 0.9 [†] (0.1 - 5.6) n=111 |
| Eller (2009) | Denmark | 2001-2002 | 3 years | cow's milk | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | 0.7 (nr) n= nr | - | - |
| Host (2002) | Denmark | 1985-2000 | 3 years | cow's milk | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | 0.3 (0.1-0.7) n=1749 | - | - |
| Osterballe (2005) | Denmark | 2000-2001 | 3 years | cow's milk | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0.6^{\dagger} (0.2 - 2) n=486 | 1.6 [†] (0.1 - 3.4) n=486 |
| Osterballe (2005) | Denmark | 2000-2001 | 3-22 years | cow's milk | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0.3 [†] (0.1 - 2.6) n=301 | 1.1 [†] (0 - 2.1) n=301 |
| Host (2002) | Denmark | 1985-2000 | 5 years | cow's milk | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | 0.2 (0.0-0.5) n=1749 | - | - |
| Eller (2009) | Denmark | 2004-2005 | 6 years | cow's milk | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | 0 (nr) $n = nr$ | - | - |
| Host (2002) | Denmark | 1985-2000 | 10 years | cow's milk | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | 0.2 (0.0-0.5) n=1749 | - | - |
| Host (2002) | Denmark | 1985-2000 | 15 years | cow's milk | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | 0.1 (0.0-0.4) n=1749 | - | - |
| Osterballe (2009) | Denmark | 2001-2002 | 22 years | cow's milk | Both IgE and non-IgE mediated | 3.3 [†] (2.3 - 4.8) n=843 | - | - | - | - | - | - | - | - | 0.1 (0.0-0.8) n=843 |
| Osterballe (2005) | Denmark | 2000-2001 | >22 years | cow's milk | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0.3 [†] (0.1 - 1.0) n=936 | 0.8 [†] (0.4 - 1.7) n=936 |
| Julge (2001) | Estonia | 1993-1999 | 6 months | cow's milk | IgE mediated only | - | - | - | 1.7 (nr) n=172 | 12 (nr) n=92 | - | - | - | - | - |
| Julge (2001) | Estonia | 1993-1999 | 1 year | cow's milk | IgE mediated only | - | - | - | 0.9 (nr) n=220 | 20.7 (nr) n=116 | - | - | - | - | - |
| Julge (2001) | Estonia | 1993-1999 | 2 years | cow's milk | IgE mediated only | - | - | - | 0 (nr) n=222 | 25.8 (nr) n=120 | - | - | - | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Question | nnaire-based 1 | nethods | Sensit | isation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical ory | Other |
|---------------------|---------|---------------------|------------------------------|------------|---|--|---------------------------|--|--------------------|----------------------------|-----------------------|----------------------|---------------------------|------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | • | | 95% Preva | alence (CI) | | | | |
| Julge (2001) | Estonia | 1993-1999 | 5 years | cow's milk | IgE mediated only | - | - | - | - | 23.2 (nr) n=207 | - | - | - | - | - |
| Saarinen (1999) | Finland | 1994-1996 | 0-34 months | cow's milk | Both IgE and non-IgE mediated (no SPT or SIgE) | 10.0 (9.3-10.8) n=6209 | - | - | - | - | - | - | 1.9 (1.6-2.3) n=555 | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 1 year | cow's milk | Both IgE and non-IgE mediated ((no SPT or SIgE)) | 2 (nr) n=261 | - | - | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 1 year | cow's milk | Both IgE and non-IgE mediated ((no SPT or SIgE)) | 5.4 [†] (4.0-7.2) n=853 | - | 5.6 [†] (4.2 - 7.5) n=853 | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 2 years | cow's milk | Both – not clearly specified | 5 (nr) n=202 | - | - | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 2 years | cow's milk | Both IgE and non-IgE mediated (no SPT or SIgE) | 6.8 [†] (5.3-8.8) n=852 | - | 6.7 [†] (5.2-8.6) n=852 | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 3 years | cow's milk | Both IgE and non-IgE mediated (no SPT or SIgE) | 2 (nr) n=200 | - | - | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 3 years | cow's milk | Both IgE and non-IgE mediated (no SPT or SIgE) | 5.9 [†] (4.4 -7.8) n=784 | - | 7.5 [†] (5.8 - 9.7) n=784 | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 4 years | cow's milk | Both IgE and non-IgE mediated (no SPT or SIgE) | 7.6 [†] (5.9 - 9.7) n=819 | - | 6 [†] (4.5 - 7.9) n=819 | - | - | - | - | - | - | - |
| Isolauri (2004) | Finland | nr | 7 years (born 1990) | cow's milk | Both IgE and non IgE mediated | - | 14 (7.9-22.4) n=100 | - | - | 9 (4.2-16.4) n=100 | - | | - | - | - |
| Isolauri (2004) | Finland | nr | 27 years (born 1963-1966 | cow's milk | Both IgE and non IgE mediated | - | 10 (4.9-17.6) n=100 | - | - | 4.4 (1.2-10.8) n=100 | - | | - | - | - |
| Isolauri (2004) | Finland | nr | 47 years (born 1943-1946 | cow's milk | Both IgE and non IgE mediated | - | 14 (8.0-22.6) n=100 | - | - | 1.0 (0.03-5.5) n=100 | - | | - | - | - |
| Isolauri (2004) | Finland | nr | 67 years (born 1923-1926) | cow's milk | Both IgE and non IgE mediated | - | 13 (7.1-21.2) n=100 | - | - | 7.1 (2.9-14.0) n=100 | - | | - | - | - |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Question | nnaire-based | methods | Sensit | tisation | Sensitisation hist | with clinical ory | Food challeng | ge with clinical tory | Other |
|------------------------|-----------|---------------------|-------------|---------------|---|--|---------------------|-------------------------|--|---|--|----------------------|--------------------|----------------------------|----------------------------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Prev | alence (CI) | | | | |
| Rance (2005) | France | 2002 | 2-14 years | cow's milk | Both IgE and non-IgE mediated ((no SPT or SIgE)) | 1.1 [†] (0.7 - 1.6) n=2716 | - | - | - | - | - | - | - | - | - |
| Touraine (2002) | France | 2000-2001 | 5-17 years | cow's milk | Both IgE and non-IgE mediated (no SPT or SIgE) | 5.5 [†] (1.3-7.1) n=1086 | - | - | - | - | - | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | cow's milk | Both IgE and non_IgE mediated | - | - | - | - | - | 0.2 (0.1-0.4) n=3156 | - | - | 0.2 (0.1-0.4) n=3156 | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | cow's milk | Both IgE and non_IgE mediated | - | - | - | - | - | - | - | - | - | 0.2 (0.1-0.5) n=3156 |
| Schafer (1999) | Germany | 1994 | 5-6 years | cow's milk | Both IgE and non_IgE mediated | - | - | - | 3.9 [†] (2.9-5.2) n=1235 | - | - | - | - | - | - |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | cow's milk | Both IgE and non_IgE mediated | $ \begin{array}{c} 1.8^{\dagger} \\ (nr) \\ n=nr \end{array} $ | - | - | 2.3^{\dagger} (nr) n= nr | - | - | - | - | - | - |
| Krause (2002) | Greenland | 1998 | 5-18 years | cow's milk | IgE mediated only | - | - | - | - | 0.5 [†] (0.2-1.2) n=1031 | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 20-69 years | cow's milk | IgE mediated only | - | - | - | 13.9 [†] (5.2-30.3) n=36 | 8.3 [†] (2.2-23.6) n=36 | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 60-97 years | cow's milk | IgE mediated only | - | - | - | 12.8 [†] (7.5-20.9) n=109 | 4.6 [†] (1.7-10.9) n=109 | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 20-69 years | milk (casein) | IgE mediated only | - | - | - | 5.6 [†] (1.0-20.0) n=36 | 13.9 [†] (2.2-23.6) n=36 | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 60-97 years | milk (casein) | IgE mediated only | - | - | - | 14.7 [†] (8.9-23.0) n=109 | 8.3 [†] (4.1-15.5) n=109 | - | - | - | - | - |
| Kristjansson (1999) | Iceland | 1994 | 18 months | cow's milk | Both IgE and non-IgE mediated | 10.8 [†] (7.7-14.8) n=324 | - | - | - | - | 0.3 [†] (0.0-2.0) n=324 | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 0-6 months | cow's milk | Both IgE and Non-IgE mediated(no SPT or SIgE) | 0 [†] (0-6.1) n=75 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 6-12 months | cow's milk | Both IgE and Non-IgE mediated(no SPT or SIgE) | 5.3 [†] (1.7-13.8) n=75 | - | - | - | - | - | - | - | - | - |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Question | nnaire-based | methods | Sensit | isation | Sensitisation | with clinical tory | Food challeng | e with clinical tory | Other |
|---------------------|---------|---------------------|--------------|-----------------------------|---|---|---------------------|-------------------------|--------------------|------------------------|--------------------|-----------------------|--------------------|-------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | · | | | 95% Preva | alence (CI) | Ũ | | | |
| Kilgallen (1996) | Ireland | nr | 12-24 months | cow's milk | Both IgE and Non-IgE mediated(no | 5.3 [†] (2.5-10.6) n=150 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 24-36 months | cow's milk | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.3 [†] (0.2-5.2) n=150 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 36-48 months | cow's milk | Both IgE and non-IgE mediated (no SPT or SIgE) | 2.7 [†] (0.9-7.1) n=150 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 0-6 months | dairy products | Both IgE and non-IgE mediated (no SPT or SIgE) | 0 [†] (0-6.1) n=75 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 6-12 months | dairy products | Both IgE and non-IgE mediated (no SPT or SIgE) | 4 [†] (1.0-12.0) n=75 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 12-24 months | dairy products | Both IgE and non-IgE mediated (no SPT or SIgE) | 4.7 [†] (2.1-9.8) n=150 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 24-36 months | dairy products | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.7 [†] (0.0-4.2) n=150 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 36-48 months | dairy products | Both IgE and non-IgE mediated (no SPT or SIgE) | 2 [†] (0.5-6.2) n=150 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 0-6 months | dairy products (yoghurt) | Both IgE and non-IgE mediated (no SPT or SIgE) | 0 [†] (0-6.1) n=75 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 6-12 months | dairy products (yoghurt) | Both IgE and non-IgE mediated (no SPT or SIgE) | 0 [†] (0-6.1) n=75 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 12-24 months | dairy products (yoghurt) | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.3 [†] (0.2-5.2) n=150 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 24-36 months | dairy products (yoghurt) | Both IgE and non-IgE mediated (no SPT or SIgE) | 0 [†] (0-3.1) n=150 | - | - | - | - | - | - | - | - | - |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Question | naire-based | methods | Sensit | isation | Sensitisation hist | with clinical tory | Food challeng | e with clinical ory | Other |
|----------------------------|----------|---------------------|--------------|-----------------------------|---|--|---------------------|---|--|--|--|-----------------------|--------------------|------------------------|--|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Kilgallen (1996) | Ireland | nr | 36-48 months | dairy products (yoghurt) | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.3 [†] (0.2-5.2) n=150 | - | - | - | - | - | - | - | - | - |
| Frongia (2005) | Italy | 2003 | 12-24 months | cow's milk | Both IgE and non-IgE mediated (no SPT or SIgE) | - | - | 5.4 [†] (4.7-6.1) n=4602 | - | - | - | - | - | - | - |
| Ronchetti (2008) | Italy | 2005 - 2006 | 9 years | cow's milk | Both IgE and non-IgE mediated | - | - | - | 0.5 [†] (0.0-3.5) n=184 | - | - | - | - | - | 11.4 [†] (7.4-17.1) n=184 |
| Ronchetti (2008) | Italy | 2005 - 2006 | 13 years | cow's milk | Both IgE and non-IgE mediated | - | - | - | 2 [†] (0.7-5.5) n=196 | - | - | - | - | - | 4.1 [†] (1.9-8.2) n=196 |
| Eggesbo (1999) | Norway | 1993-1995 | 1 year | cow's milk | Both IgE and non-IgE mediated | 7.5 (6.6-8.6) n=3366 | - | - | - | - | - | - | - | - | - |
| Eggesbo (1999) | Norway | 1993-1995 | 18 months | cow's milk | Both IgE and non-IgE mediated | 5.5 (4.7-6.4) n=3278 | - | - | - | - | - | - | - | - | - |
| Eggesbo (1999) | Norway | 1993-1995 | 2 years | cow's milk | Both IgE and non-IgE mediated | 5 (4.3-5.9) n=2979 | - | - | - | - | - | - | - | - | - |
| Ro (2012) | Norway | 2002-2006 | 2 years | cow's milk | IgE mediated only | - | - | - | 0.9 [†] (0.2 - 2.7) n=352 | 4.8 [†] (2.9 - 7.8) n=352 | - | - | - | - | - |
| Falcao (2004) | Portugal | 2000 | >39 years | cow's milk | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.3 [†] (0-1.2) n=659 | - | - | - | - | - | - | - | - | - |
| Martinez- Gimeno (2000) | Spain | nr | 6-13 years | cow's milk | Both IgE and non-IgE mediated (no SPT or SIgE) | 21 [†] (19.9 - 22.1) n=5163 | - | - | - | - | - | - | - | - | - |
| Ostblom (2008 b) | Sweden | 1995-2004 | 1 year | cow's milk | Both IgE and non-IgE mediated | 4.5 [†] (3.8-5.3) n=3104 | - | 2.2 [†] (1.7-2.8) n=3104 | - | - | - | - | - | - | - |
| Kristjansson (1999) | Sweden | 1994 | 18 months | cow's milk | Both IgE and non-IgE mediated | 5.2 [†] (3.1-8.3) n=328 | - | - | - | - | 0.6 [†] (0.1-2.4) n=328 | - | - | - | - |
| Ostblom (2008 b) | Sweden | 1996-1998 | 2 years | cow's milk | Both IgE and non-IgE mediated | 4 [†] (3.3-4.8) n=3104 | - | 2.2 [†] (1.7-2.8) n=3104 | - | - | - | - | - | - | - |
| Ostblom (2008 b) | Sweden | 1998-2000 | 4 years | cow's milk | Both IgE and non-IgE mediated | 3.6 [†] (3.0-4.3) n=3104 | - | $ \begin{array}{r} 2.0^{\dagger} \\ (1.6-2.6) \\ n=3104 \end{array} $ | - | - | - | _ | - | - | - |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Question | nnaire-based | methods | Sensit | isation | Sensitisation hist | with clinical tory | Food challeng hist | e with clinical ory | Other |
|-----------------------------|--------------------|---------------------|-------------|------------|--|---|---------------------|---|---|---|---|----------------------------|---|---|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | I | | | | 95% Prev | alence (CI) | | | | |
| Ostblom (2008 a) | Sweden | 1999-2000 | 4 years | cow's milk | Both IgE and non-IgE mediated | 5 [†] (4.2-6.0) n=2563 | - | - | - | 8 [†] (7.0-9.1) n=2563 | - | 1.8 (1.3-2.4) n=2563 | - | - | - |
| Ostblom (2008 b) | Sweden | 2002-2004 | 8 years | cow's milk | Both IgE and non-IgE mediated | 2.8 [†] (2.3-3.5) n=3104 | - | 1.8 [†] (1.4-2.4) n=3104 | - | - | - | - | - | - | - |
| Bjornsson (1996) | Sweden | 1991-1992 | 20-44 years | cow's milk | IgE mediated only | - | - | - | - | 1.1 [†] (0.6-1.8) n=1397 | - | - | - | - | - |
| Schrander | The Netherlands | Unclear | 0-1 years | cow's milk | Both IgE and non-IgE mediated (no SPT or SIgE) | 18.2 [†] (16.2-20.6) 1158 | - | - | - | - | - | - | 2.3 [†] (1.5-3.3) n=1158 | - | - |
| Brugman (1998) | The Netherlands | 1993- 1994 | 4-15 years | cow's milk | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.5 [†] (1.2-1.9) n=4400 | - | - | - | - | - | - | - | - | - |
| Mustafayev (2012) | Turkey | 2010 | 10-11 years | cheese | IgE mediated only | - | - | - | - | - | - | - | $0.1^{\dagger} \\ (0.0-0.8) \\ n=813$ | - | - |
| Altintas (1995) | Turkey | 1992-1993 | 0-1 years | cow's milk | Both IgE and non-IgE mediated (no SPT or SIgE) | - | - | 1.4 [†] (0.9-2.2) n=1348 | - | - | - | - | - | - | - |
| Kucukosmano glu (2008 b) | Turkey | 2002-2003 | 8-18months | cow's milk | IgE mediated only | - | - | - | 0.6 [†] (0.2 - 1.4) n=1015 | - | - | 0.2 (0.0-0.8) n=1015 | 0.3 [†] (0.1-0.9) n=1015 | - | - |
| Altintas (1995) | Turkey | 1992-1993 | 1-2 years | cow's milk | Both IgE and non-IgE mediated | - | - | 1.2 [†] (0.7-2.0) n=1348 | - | - | - | - | - | - | - |
| Orhan (2009) | Turkey | 2006 | 6-9 years | cow's milk | IgE mediated only | 0.9 [†] (0.6 - 1.4) n=2739 | - | - | - | - | 0.4 [†] (0.2 - 0.7) n=2739 | - | - | 0.1 [†] (0.1 - 0.4) n=2739 | - |
| Mustafayev (2012) | Turkey | 2010 | 10-11 years | cow's milk | IgE mediated only | 1.5 [†] (1.2-1.8) n=6963 | - | - | 1.1 [†] (0.9-1.4) n=6134 | - | - | - | - | - | - |
| Gelincik (2008) | Turkey | nr | 18 years + | cow's milk | Both IgE and non-IgE mediated | 0.2 [‡] (0.2-0.4) n=11816 | - | - | - | - | - | - | - | 0.1 [†] (0.0-0.1) n=11816 | - |
| Emmett (1999) | United Kingdom | 1995-1996 | 15 + years | cheese | Both IgE and non-IgE mediated (no SPT or Spes IgE) | 0.2 [†] (0.1-0.3) n=16420 | - | - | - | - | - | - | - | - | - |
| Young (1994) | United Kingdom | nr | All ages | cheese | Both IgE and non-IgE mediated (no | 2.5 [†] (2.3-2.7) n=18880 | - | - | - | - | - | - | - | - | - |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Question | nnaire-based 1 | nethods | Sensit | isation | Sensitisation hist | with clinical tory | Food challeng hist | e with clinical tory | Other |
|----------------|-------------------|---------------------|--------------|------------|-------------------------------------|--|---------------------|-------------------------|---|------------------------|-----------------------|-----------------------|-----------------------|-------------------------|--|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| | | | | | SPT or Spes IgE) | | | | | | | | | | |
| Venter (2008) | United Kingdom | 2001-2005 | 1 year | cow's milk | Both IgE and non-IgE mediated | - | - | - | 0.3 [†] (0.0-1.0) n=763 | - | - | - | - | - | 2.4 [†] (1.6-3.7) n=900 |
| Venter (2008) | United Kingdom | 2001-2005 | 2 years | cow's milk | Both IgE and non-IgE mediated | - | - | - | 0.5 [†] (0.1-1.4) n=658 | - | - | - | - | - | 1.2 [†] (0.1-2.2) n=858 |
| Venter (2008) | United Kingdom | 2001-2005 | 3 years | cow's milk | Both IgE and non-IgE mediated | - | - | - | 0.5 [†] (0.1-1.5) n=642 | - | - | - | - | - | 0.4 [†] (0.1-1.2) n=891 |
| Arshad (2001) | United Kingdom | 1993-1994 | 4 years | cow's milk | IgE only | - | - | - | 1.3 [†] (0.7 - 2.3) n=981 | - | - | - | - | - | - |
| Venter (2006) | United Kingdom | 2003-2004 | 6 years | cow's milk | Both IgE and non-IgE mediated | 3.6 [†] (2.5-5.2) n=798 | - | - | 0.4 [†] (0.1 -1.4) n=700 | - | - | - | - | - | 0.8 [†] (0.3-1.7) n=798 |
| Roberts (2005) | United Kingdom | 1998-2000 | 7 years | cow's milk | IgE mediated | - | - | - | 0.2 [†] (0.1 - 0.6) n=2007 | - | - | - | - | - | - |
| Emmett (1999) | United Kingdom | 1995-1996 | 15 + years | cow's milk | Both IgE and non-IgE mediated | 0.7 [†] (0.6-0.8) n=16420 | - | - | - | - | - | - | - | - | - |
| Young (1994) | United Kingdom | nr | All ages | cow's milk | Both IgE and non-IgE mediated | 2.7 [†] (2.5-3.0) n=18880 | - | - | - | - | - | - | - | - | - |
| Pereira (2005) | United Kingdom | 2002-2003 | 11 year olds | milk/dairy | Both IgE and non-IgE mediated | 2.8 [†] (1.8-4.3) n=775 | - | - | 0.3 [†] (0.1-1.2) n=699 | - | - | - | - | - | - |
| Pereira (2005) | United Kingdom | 2002-2003 | 15 year olds | milk/dairy | Both IgE and non-IgE mediated | 3.4 [†] (2.3-5.1) n=757 | - | - | 0.3 [†] (0.1-1.2) n=649 | - | - | - | - | - | - |

^{*}Percentage prevalence inferred from graph provided (no raw data reported).

[#]Data has been subject to correction or estimation by the authors (presented as reported in the paper).

Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

EFSA supporting publication 2013:EN-506

| Study ID | Country | Year(s) of study | Age group | Allergen | Types of food allergy | | Questi | onnaire-based 1 | nethods | Sensit | isation | Sensitisatior his | with clinical tory | Food o with his | hallenge clinical story | Other |
|-------------------|----------------------|---------------------|--------------|-------------------|---|---|---------------------|--|--------------------|--|--------------------|------------------------------------|-----------------------|--|-------------------------------|---|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | Histo DB | ory and PCFC | |
| | | | | | | | | | | 95 | % Prevalence (C | CI) | | | | |
| Osborne (2011) | Australia | 2007-2010 | 12-15 months | cow's milk | IgE mediated only | 6.1 (5.1-7.0) n= nr | - | 2.7 (2.1-3.4) n= nr | - | 5.6 (3.2-8.0) n=355 | - | - | - | - | - | - |
| Woods (2002) | Australia | 1992-1998 | 26-50 years | cow's milk | IgE mediated only | 4.8 [†] (3.1-7.3) n=457 | - | - | - | 0.7 [†] (0.2-2.1) n=457 | - | 0 [†] (0-1.0) n=457 | - | - | - | - |
| Woods (1998) | Australia | 1998 | 20-44years | dairy products | Both IgE and non-IgE mediated | 1.9 [†] (1.1-3.4) n=669 | - | - | - | - | - | - | - | - | - | - |
| Soller (2012) | Canada | 2008-2009 | <18 years | cow's milk | "likely" IgE mediated (no SPT or SIgE) | 2.23 (1.51-2.95) n= nr | - | - | - | - | - | - | - | - | - | - |
| Soller (2012) | Canada | 2008-2009 | >18 years | cow's milk | "likely" IgE mediated (no SPT or SIgE | 1.89 (1.56-2.21) n= nr | - | - | - | - | - | - | - | - | - | - |
| Gerrard (1973) | Canada | nr | 6-36 months | cow's milk | Both IgE and non-IgE mediated (no SPT or SIgE) | - | - | 7.5 [†] (5.8-9.6) n=787 | - | - | - | - | - | - | - | - |
| Chen (2011) | China | 2009 | 0-12 months | cow's milk | IgE mediated only | - | | - | - | 2.7 [†] (1.5-4.7) n=477 | - | _ | - | 1.3 [†] (0.5- 2.9) n=477 | - | - |
| Hu (2010) | China | 1999 | 0-24 months | cow's milk | IgE mediated only | - | - | - | - | 3.3 [†] (1.7-6.2) n=304 | - | - | - | 1.6 [†] (0.6- 3.9) n=314 | - | - |
| Hu (2010) | China | 2009 | 0-24 months | cow's milk | IgE mediated only | - | - | - | - | 6.5 [†] (4.4-9.6) n=382 | - | - | - | 3.5 [†] (2-5.9) n=401 | - | - |
| Sai (2011) | China | 2008-2009 | adults | cow's milk | IgG mediated only | - | - | - | - | - | - | - | - | - | - | 24.5 [†] (23.8-25.3) n=12765 |
| Chen (2012) | China (Chongqing) | 2009-2010 | 0-2 years | cow's milk | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | - | - | 3.5 [†] (2.2-5.4) n=550 |
| Chen (2012) | China (Hangzhou) | 2009-2010 | 0-2 years | cow's milk | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | - | - | 0.8^{\dagger} (0.3-2.3) n=481 |
| Chen (2012) | China (Zhuhai) | 2009-2010 | 0-2 years | cow's milk | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | - | - | 2.8 [†] (1.7-4.6) n=573 |
| Marrugo (2008) | Colombia | nr | All ages | cow's milk | IgE and non- IgE mediated (no SPT or SIgE) | 1.4 [†] (1.1-1.9) n=3099 | - | - | - | - | - | - | - | - | - | - |

| Study ID | Country | Year(s) of study | Age group | Allergen | Types of food allergy | | Questi | onnaire-based 1 | nethods | Sensit | isation | Sensitisation his | n with clinical tory | Food o with his | challenge clinical story | Other |
|--------------|-----------|---------------------|-------------|--------------------------|---|--|---------------------|--|--|------------------------|--------------------|---|-------------------------------|-----------------------|--------------------------------|--|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | Histo DB | ory and PCFC | |
| | | | | | | | | | | 95 | % Prevalence (C | CI) | | | | |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | cow's milk | IgE mediated only | 0.2 (nr) n=1407 | - | - | - | - | - | - | - | - | - | - |
| Leung (2009) | Hong Kong | 2006-2007 | 2-7 years | cheese | IgE mediated only (no SPT or SIgE) | 0.2 [†] (0.1-0.5) n=3677 | - | - | - | - | - | - | - | - | - | 0.2 [†] (0.1-0.5) n=3677 |
| Leung (2009) | Hong Kong | 2006-2007 | 2-7 years | cow's milk | IgE mediated only (no SPT or SIgE) | $\begin{array}{c} 0.5 \\ (0.3-0.8) \\ n=3677 \end{array}$ | - | - | - | - | - | - | - | - | - | 0.3 [†] (0.2-0.6) n=3677 |
| Dalal (2002) | Israel | nr | 0-2years | cow's milk | IgE mediated only | - | - | 0.4 [†] (0.3 -0.6) n=9070 | - | - | - | 0.3 [†] (0.2-0.5) n=9070 | - | - | - | - |
| Katz (2010) | Israel | 2004-2006 | 0-2 years | cow's milk | Both IgE and non-IgE mediated | 2.9 (2.6-3.2) n=13019 | - | - | - | - | - | - | - | | - | -71 + 66 out of 13019 – (1.1%) based on hx or SPT and pos challenge |
| Kim (2011) | Korea | 2006-2007 | 0-12 months | cow's milk | IgE mediated only((no SPT or SIgE)) | - | - | - | 1.7 [†] (1.1-2.7) n=1177 | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 6-12 years | cow's milk | IgE mediated only (no SPT or SIgE) | $\begin{array}{c} 0.7 \\ (0.6-0.8) \\ n=27425 \end{array}$ | - | - | - | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 12-15 years | cow's milk | IgE mediated only (no SPT or SIgE) | 0.4 [†] (0.3-0.5) n=14777 | - | - | - | - | - | - | - | - | - | - |
| Wan (2012) | Taiwan | nr | 6-8 years | alpha lactalbumi n | IgE mediated only | - | - | - | - | - | - | - | 14.5 (12.4-16.8) n=1010 | - | - | - |
| Wan (2012) | Taiwan | nr | 6-8 years | BLG | IgE mediated only | - | - | - | - | - | - | - | 6.7 (5.3-8.5) n=1010 | - | - | - |
| Wan (2012) | Taiwan | nr | 6-8 years | cheese | IgE mediated only | - | - | - | - | - | - | - | 6.2 (4.9-8.0) n=1010 | - | - | - |
| Wu (2012) | Taiwan | 2004 | <3 years | cow's milk | IgE mediated only (no SPT or SIgE) | - | - | - | 1.1 [†] (0.5-2.2) n=813 | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | >19 years | cow's milk | IgE mediated only (no SPT or SIgE) | - | - | - | 0.5 [†] (0.4-0.6) n=14036 | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | 4-18 years | cow's milk | IgE mediated only (no SPT or SIgE) | - | - | - | 0.9 [†] (0.8-1.1) n=15169 | - | - | - | - | - | - | - |
| Wan (2012) | Taiwan | nr | 6-8 years | milk | IgE mediated | - | - | - | - | - | - | - | 13.3 | - | - | - |

| Study ID | Country | Year(s) of study | Age group | Allergen | Types of food allergy | | Questie | onnaire-based r | nethods | Sensit | isation | Sensitisation his | n with clinical tory | Food ch with c hist | nallenge linical tory | Other |
|----------------------|--|---------------------|---------------------|-------------|--|---|---------------------|----------------------------|-------------------------------------|------------------------|--|----------------------|------------------------------|------------------------------------|-----------------------------|--------------------------------------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | Histor DBP | ry and CFC | |
| | | | | | | | | | | 95 | % Prevalence (| CI) | | | | |
| | | | | (casein) | only | | | | | | | | (11.3-15.5) n=1010 | | | |
| Wan (2012) | Taiwan | nr | 6-8 years | milk (goat) | IgE mediated only | - | - | - | - | - | - | - | 10.7 (8.9-12.8) n=1010 | - | - | - |
| Santadusit (2005) | Thailand | nr | 6 months - 6yrs | cow's milk | IgE mediated only | 1.7 [†] (0.9 -3.1) n=656 | - | - | - | - | - | - | - | - | - | - |
| Lao-araya (2012) | Thailand | 2010 | 3-7years | cow's milk | IgE mediated only | 2 [†] (1.0-3.9) n=452 | - | - | - | - | - | - | - | 0 [†] (0-1.1) n=452 | - | - |
| Al-Hammadi (2010) | United Arab Emirates (Emirate of Abu Dhabi) | 2006 | 6-9 years | cow's milk | IgE mediated only (no SPT or SIgE) | - | - | - | 1^{\dagger} (0.3-2.7) n=397 | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 0-2 years | cow's milk | IgE mediated only (no SPT or SIgE) | - | - | 2 (1.6-2.4) n=5429 | - | - | - | - | - | - | - | - |
| Branum (2009) | United States | 2005-2006 | < 18 years | cow's milk | IgE mediated only (not clearly defined) | - | - | - | - | - | 12.2 (nr) n=nr | - | - | - | - | - |
| Kumar (2011) | United States | 2011 (yr pub) | 6 months - 6 yrs | cow's milk | IgE mediated only | - | - | - | - | - | 21.6 [†] (19.3-24.2) n=1104 | - | - | - | - | - |
| Bock (1987) | United States | 1980-1984 | 1 year | cow's milk | Both IgE and non-IgE mediated | 13.1 [†] (10.3-16.6) n=480 | - | - | - | - | - | - | - | - | - | 5 [†] (3.3-7.4) n=480 |
| Liu (2010) | United States | 2005-2006 | 1-5 years | cow's milk | IgE mediated only | - | - | - | - | - | 22 (nr) n=909 | - | - | - | - | 1.8 (nr) n=nr |
| Keet (2012) | United States | 2005-2006 | 1-21 years | cow's milk | IgE mediated only | - | - | - | - | - | 11 (nr) n=3550 | - | - | - | - | - |
| Bock (1987) | United States | 1980-1984 | 2 years | cow's milk | Both IgE and non-IgE mediated | 1.3 [†] (0.5-3.0) n=480 | - | - | - | - | - | - | - | - | - | 0.2 [†] (0-1.3) n=480 |
| Bock (1987) | United States | 1980-1984 | 3 years | cow's milk | Both IgE and non-IgE mediated | 0.6 [†] (0.2-2) n=480 | - | - | - | - | - | - | - | - | - | 0 [†] (0-1) n=480 |
| Gupta (2011) | United States | 2009-2010 | 3-5 years | cow's milk | IgE mediated (no SPT or SIgE) | - | - | 2 (1.7-2.5) n=5910 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 6-10 years | cow's milk | IgE mediated (no SPT or SIgE) | - | - | 1.5 (1.2-1.8) n=9911 | - | - | - | - | - | - | - | - |

| Study ID | Country | Year(s) of study | Age group | Allergen | Types of food allergy | | Questio | onnaire-based 1 | nethods | Sensit | isation | Sensitisation his | n with clinical tory | Food challenge with clinical history | Other |
|---------------------|---------------|---------------------|-------------|------------|--|--|---------------------|-----------------------------|--------------------|------------------------|-----------------------|----------------------|-------------------------|--|---|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum- specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | - | _ | 95 | % Prevalence (0 | CI) | - | | |
| Liu (2010) | United States | 2005-2006 | 6-19 years | cow's milk | IgE mediated only | - | - | - | - | - | 8.1 (nr) n=2869 | - | - | | 0.3 (nr) n=nr |
| Gupta (2011) | United States | 2009-2010 | 11-13 years | cow's milk | IgE mediated (no SPT or SIgE) | - | - | 1.4 (1.1-1.8) n=6716 | - | - | - | - | - | | - |
| Gupta (2011) | United States | 2009-2010 | 14-17 years | cow's milk | IgE mediated (no SPT or SIgE) | - | - | 1.6 (1.3-1.9) n=10514 | - | - | - | - | - | | - |
| Greenhawt (2009) | United States | nr | 18 years+ | cow's milk | IgE mediated (no SPT or SIgE) | 10.5 [†] (8.1-13.6) n=513 | - | - | - | - | - | - | - | | - |
| Liu (2010) | United States | 2005-2006 | 20-39 years | cow's milk | IgE mediated only | - | - | - | - | - | 3.2 (nr) n=1672 | - | - | | 0.2 (nr) n=nr |
| Liu (2010) | United States | 2005-2006 | 40-59 years | cow's milk | IgE mediated only | - | - | - | - | - | 4.9 (nr) n=1361 | - | - | | 0.5 (nr) n=nr |
| Liu (2010) | United States | 2005-2006 | 60+ years | cow's milk | IgE mediated only | - | - | - | - | - | 3.8 (nr) n=1392 | - | - | | 0.3 (nr) n=nr |
| Liu (2010) | United States | 2005-2006 | All ages | cow's milk | IgE mediated only | - | - | - | - | - | 5.7 (nr) n=8203 | - | - | | 0.4 (nr) n=nr |
| Gupta (2011) | United States | 2009-2010 | All ages | cow's milk | IgE mediated (no SPT or SIgE) | - | - | 1.7 (1.5-1.8) n=3339 | - | - | - | - | - | | - |
| Vierk (2007) | United States | 2001 | 18 years + | milk/dairy | IgE mediated only (no SPT or SIgE) | 2.4 [†] (2.0-2.9) n=4482 | - | - | - | - | - | - | - | | 1.4 [†] (1.1-1.8) n=4482 |

[‡]Percentage prevalence inferred from graph provided (no raw data reported).

[#]Data has been subject to correction or estimation by the authors (presented as reported in the paper).

Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | onnaire-based n | nethods | Sensit | isation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical ory | Other |
|--------------------|---------|---------------------|------------|----------|---|---------------------------------------|---------------------|-------------------------|-----------------|-----------------------|-----------------------|----------------------|-----------------------|------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Touraine (2002) | France | 2000-2001 | 5-17 years | mustard | Both IgE and non-IgE mediated (no SPT or SIgE) | 3 [†] (2.1-4.3) n=1086 | - | - | - | - | - | - | - | - | - |

Table 1.22: Mustard allergy prevalence in European countries by age group

[†] Percentage prevalence and/or confidence intervals calculated from raw data provided in the paper

[‡]Percentage prevalence inferred from graph provided (no raw data reported).

[#]Data has been subject to correction or estimation by the authors (presented as reported in the paper).

Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

No Non-European studies looking at mustard where included within this review

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen) | Type of food allergy | Question | nnaire-based n | nethods | Sensit | isation | Sensitisation hist | with clinical tory | Food challeng hist | ge with clinical tory | Other |
|----------------------|---------|---------------------|------------|-----------|---|---|---------------------|-------------------------|--|--|-----------------------|-----------------------|--|--|--|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | L | | I | | 95% Preva | lence (CI) | | | | |
| Osterballe (2005) | Denmark | 2000-2001 | < 3 years | peanut | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | 0 [†] (0.0-4.2) n=111 | - | 0 [†] (0.0-4.2) n=111 |
| Osterballe (2005) | Denmark | 2000-2001 | >22 years | peanut | Both IgE and non IgE mediated | - | - | - | - | - | - | - | - | 0.4 [†] (0.1-1.2) n=936 | 1.2 [†] (0.6-2.2) n=936 |
| Eller (2009) | Denmark | 1998-1999 | 3 months | peanut | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | 0 (nr) n=nr | - | - |
| Eller (2009) | Denmark | 1999-2000 | 6 months | peanut | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | 0 (nr) n=nr | - | - |
| Eller (2009) | Denmark | 1999-2000 | 9 months | peanut | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | 0 (nr) n=nr | - | - |
| Eller (2009) | Denmark | 1999-2000 | 1 year | peanut | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | 0 (nr) n=nr | - | - |
| Osterballe (2005) | Denmark | 2000-2001 | 3 years | peanut | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | - | 0.2 [†] (0.0-1.3) n=486 | 1.6 [↑] (0.8-3.4) n=486 |
| Eller (2009) | Denmark | 2001-2002 | 3 years | peanut | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | 0.4 (nr) n=nr | - | - |
| Osterballe (2005) | Denmark | 2000-2001 | 3-22 years | peanut | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | - | 0 [†] (0.0-1.6) n=301 | 1^{\dagger} (0.3-3.1) n=301 |
| Eller (2009) | Denmark | 2004-2005 | 6 years | peanut | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | 0.4 (nr) n=nr | - | - |
| Mortz (2005) | Denmark | 1995-1996 | 14 years | peanut | IgE mediated only | - | - | - | 3.4 [†] (2.1-5.4) n=558 | 5.8 [†] (4.4-7.6) n=862 | - | - | 0.5 [†] (0.2-1.3) n=979 | - | - |
| Osterballe (2009) | Denmark | 2001-2002 | 22 years | peanut | Both Ige and non-IgE mediated | 5.3 [†] (4.0-7.1) n=843 | - | - | - | - | - | - | - | - | 0.6 (0.2-1.4) n=843 |
| Rance (2005) | France | 2002 | 2-14 years | peanut | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.7 [†] (0.5 - 1.2) n=2716 | - | - | - | - | - | - | - | - | - |
| Touraine (2002) | France | 2000-2001 | 5-17 years | peanut | Both IgE and non-IgE mediated (no SPT or SIgE) | 15 [†] (13-17.3) n=1086 | - | - | - | - | - | - | - | - | - |

Table 1.23: Peanut allergy prevalence in European countries by age group

EFSA supporting publication 2013:EN-506

| Study ID | Country | Year(s) of study | Age group | Allergen) | Type of food allergy | Questio | onnaire-based 1 | nethods | Sensit | isation | Sensitisation hist | with clinical tory | Food challeng | ge with clinical tory | Other |
|------------------------|-----------|---------------------|-------------|-----------|-------------------------------------|--|---------------------|---|---|--|------------------------------------|----------------------------|--|--------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | peanut | Both IgE and non-IgE mediated | - | - | - | - | - | 0.6 (0.4-1.0) n=3156 | - | - | - | - |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | peanut | Both IgE and non-IgE mediated | $ \begin{array}{c} 1.3^{\dagger} \\ (nr) \\ n=nr \end{array} $ | - | - | 6.8 [†] (nr) n=nr | - | - | - | - | - | - |
| Krause (2002) | Greenland | 1998 | 5-18 years | peanut | IgE mediated only | - | - | - | - | 2.6 [†] (1.8-3.8) n=1031 | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 20-69 years | peanut | IgE mediated only | - | - | - | 5.6 [†] (1.0-20.0) n=36 | $ \begin{array}{c} 0^{\dagger} \\ (0-12.0) \\ n=36 \end{array} $ | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 60-97 years | peanut | IgE mediated only | - | - | - | 6.4 [†] (2.8-13.2) n=109 | 1.8 [†] (0.3-7.1) n=109 | - | - | - | - | - |
| Kristjansson (1999) | Iceland | 1994 | 18 months | peanut | Both IgE and non-IgE mediated | 0 [†] (0-1.5) n=324 | - | - | - | - | 0 [†] (0-1.5) n=324 | - | - | - | - |
| Ro (2012) | Norway | 2002-2006 | 2 years | peanut | IgE mediated only | - | - | - | 2.8 [†] (1.5-5.3) n=352 | 3.4 [†] (1.9-6.0) n=352 | - | - | - | - | - |
| Ostblom (2008 b) | Sweden | 1995-1997 | 1 year | peanut | Both IgE and non-IgE mediated | 0.4 [†] (0.2-0.7) n=3104 | - | 0.2 [†] (0.1-0.4) n=3104 | - | - | - | - | - | - | - |
| Kristjansson (1999) | Sweden | 1994 | 18 months | peanut | Both IgE and non-IgE mediated | 0.3 [†] (0.0-2.0) n=328 | - | - | - | - | 0 [†] (0-1.4) n=328 | - | - | - | - |
| Ostblom (2008 b) | Sweden | 1996-1998 | 2 years | peanut | Both IgE and non-IgE mediated | 1.2 [†] (0.9-1.7) n=3104 | - | $\begin{array}{c} 0.8^{\dagger} \\ (0.5-1.2) \\ n=3104 \end{array}$ | - | - | - | - | - | - | - |
| Ostblom (2008 b) | Sweden | 1998-2000 | 4 years | peanut | Both IgE and non-IgE mediated | 2.8 [†] (2.3-3.5) n=3104 | - | 2.2 [†] (1.7-2.8) n=3104 | - | - | - | - | - | - | - |
| Ostblom (2008 a) | Sweden | 1999-2000 | 4 years | peanut | Both IgE and non-IgE mediated | 4 [†] (3.3-4.8) n=2563 | - | - | - | 5 [†] (4.2-5.9) n=2563 | - | 2.4 (1.9-3.1) n=2563 | - | - | - |
| Ostblom (2008 b) | Sweden | 2002-2004 | 8 years | peanut | Both IgE and non-IgE mediated | 5.2 [†] (4.5-6.0) n=3104 | - | 4 [†] (3.4-4.8) n=3104 | - | - | - | - | - | - | - |
| Bjornsson (1996) | Sweden | 1991-1992 | 20-44 years | peanut | IgE mediated only | - | - | - | - | 3.1 [†] (2.3-4.2) n=1397 | - | - | - | - | - |
| Mustafayev (2012) | Turkey | 2010 | 10-11 years | peanut | IgE mediated only | 1.4 [†] (1.1-1.7) n=6963 | - | - | 0.7 [†] (0.5-1.0) n=6134 | - | - | - | 0.1 [†] (0.0-0.8) n=813 | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen) | Type of food allergy | Questio | onnaire-based 1 | nethods | Sensit | tisation | Sensitisatior his | n with clinical tory | Food challeng | ge with clinical tory | Other |
|---------------------|-------------------|---------------------|--------------|-----------|-------------------------------------|---|--|-------------------------|--|--|--|-------------------------|---|--|---|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Gelincik (2008) | Turkey | nr | 18 years + | peanut | Both Ige and non-IgE mediated | - | - | - | - | - | 0 [†] (0.0-0.1) n=11816 | 0 (0-0.1) n=11816 | - | 0 [†] (0-0.0) n=11816 | - |
| Orhan (2009) | Turkey | 2006 | 6-9 years | peanut | IgE mediated only | 0.1 [†] (0.0-0.4) n=2739 | - | - | - | - | 0.1 [†] (0 - 0.3) n=2739 | - | - | 0 [†] (0 - 0.2) n=2739 | - |
| Emmett (1999) | United Kingdom | 1995-1996 | 0-14 years | peanut | Both Ige and non-IgE mediated | - | 0.2 [†] (0.1-0.3) n=16420 | - | - | - | - | - | - | - | - |
| Venter (2008) | United Kingdom | 2001-2005 | 1 year | peanut | Both Ige and non-IgE mediated | - | - | - | $\begin{array}{c} 0.4 \\ (0.0-1.2) \\ n=763 \end{array}$ | - | - | - | - | - | - |
| Venter (2008) | United Kingdom | 2001-2005 | 2 years | peanut | Both Ige and non-IgE mediated | - | - | - | 2 [†] (1.1-3.4) n=658 | - | - | - | - | - | - |
| Venter (2008) | United Kingdom | 2001-2005 | 3 years | peanut | Both Ige and non-IgE mediated | - | - | - | 2^{\dagger} (1.1-3.5) n=642 | - | - | - | - | - | 1.2 [†] (0.6-2.3) n=891 |
| Grundy (2002) | United Kingdom | 1999-2000 | 3-4 years | peanut | IgE mediated only | 1 [†] (0.6-1.8) n=1273 | - | - | 3.3 [†] (2.4-4.5) n=1246 | - | - | - | 1.4 [†] (0.9-2.3) n=1246 | - | - |
| Hourihane (2007) | United Kingdom | 2003-2005 | 3-6 years | peanut | IgE mediated only | - | - | - | 2.8 (1.8-3.8) n=1072 | - | - | - | - | 1.8 [#] (1.1-2.7) n=1072 | - |
| Tariq (1996) | United Kingdom | 1993-1994 | 4 years | peanut | IgE mediated only | 0.5 [†] (0.2-1.1) n=1218 | - | - | 1.3 [†] (0.7-2.3) n=981 | - | 0.5 [†] (0.2-1.1) n=1218 | - | - | - | - |
| Lack (2003) | United Kingdom | 1997-1998 | 4-6 years | peanut | IgE mediated only | - | 0.4 [†] (0.3-0.6) n=12090 | - | - | - | 0.2 [†] (0.2-0.4) n=12090 | - | - | 0.2 [†] (0.1-0.3) n=12090 | - |
| Venter (2006) | United Kingdom | 2003-2004 | 6 years | peanut | Both Ige and non-IgE mediated | 1.9 [†] (1.1-3.2) n=798 | - | - | 2.6 [†] (1.6-4.1) n=700 | - | - | - | - | - | 0.9 [†] (0.4-1.9) n=798 |
| Roberts (2005) | United Kingdom | 1998-2000 | 7 years | peanut | IgE mediated only | - | - | - | 1.4 [†] (1.2-1.8) n=6213 | - | - | - | - | - | - |
| Nicolaou (2010) | United Kingdom | 2003 | 8 years | peanut | IgE mediated only | - | - | - | 5.1 [†] (3.8-6.8) n=919 | 12.2 [†] (9.7-15.2) n=582 | - | - | - | - | 1.9 [†] (1.2-2.9) n=1029 |
| Pereira (2005) | United Kingdom | 2002-2003 | 11 year olds | peanut | Both IgE and non-IgE mediated | 1.8 [†] (1.0-3.1) n=775 | - | - | 3.7 [†] (2.5-5.5) n=699 | - | - | - | - | - | - |
| Pereira (2005) | United Kingdom | 2002-2003 | 15 year olds | peanut | Both IgE and non-IgE mediated | 2.5 [†] (1.6-4.0) n=757 | - | - | 2.6 [†] (1.6-4.3) n=649 | - | - | - | - | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen) | Type of food allergy | Questio | onnaire-based n | nethods | Sensit | isation | Sensitisation hist | with clinical cory | Food challeng hist | e with clinical ory | Other |
|---------------|-------------------|---------------------|------------|-----------|-------------------------------------|---|--|-------------------------|-----------------|-----------------------|-----------------------|-----------------------|-----------------------|------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | lence (CI) | | | | |
| Emmett (1999) | United Kingdom | 1995-1996 | 15 + years | peanut | Both Ige and non-IgE mediated | 0.4^{\dagger} (0.3-0.5) n=16420 | 0.5 [†] (0.4-0.7) n=16420 | - | - | - | - | - | - | - | - |

[‡]Percentage prevalence inferred from graph provided (no raw data reported).

[#]Data has been subject to correction or estimation by the authors (presented as reported in the paper).

Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

Table 1.24:Peanut allergy prevalence in non-European countries by age group

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | onnaire-based n | nethods | Sensi | tisation | Sensitisation hist | with clinical tory | Food challeng hist | e with clinical ory | Other |
|-----------------------|-----------|---------------------|--------------|----------|--|--|--|--|--|-------------------------|--|-----------------------|-----------------------------|------------------------|---|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | t Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Osborne (2011) | Australia | 2007-2010 | 12-15 months | peanut | IgE mediated only | - | - | - | 6.4 (5.5-7.3) n=2757 | - | - | - | 2.9# (2.2-3.5) N=2757 | - | - |
| Woods (2002) | Australia | 1992-1998 | 26-50 years | peanut | IgE mediated only | 1.1 [†] (0.4-2.7) n=457 | - | - | 5.7 [†] (3.8-8.3) n=457 | - | 0.4 [†] (0.1-1.8) n=457 | - | - | - | - |
| Ben-Shoshan (2010) | Canada | 2008-2009 | < 18 years | peanut | Both IgE and non-IgE mediated only | 1.77 [#] (1.21-2.33) n=nr | 1.68 [#] (1.14-2.23) n=nr | 1.03 [#] (0.67-1.39) n=nr | - | - | - | - | - | - | - |
| Ben-Shoshan (2010) | Canada | 2008-2009 | > 18 years | peanut | Both IgE and non-IgE mediated only | 0.78 [#] (0.58-0.97) n=nr | 0.71 [#] (0.52-0.90) n=nr | 0.26 [#] (0.18-0.34) n=nr | - | - | - | - | - | - | - |
| Kagan (2003) | Canada | 2000-2002 | 5-9 years | peanut | IgE mediated only | - | - | - | - | - | - | - | - | - | 1.5 [†] (1.2-1.9) n=4254 |
| Ben-Shoshan (2009) | Canada | 2000-2002 | 7 year | peanut | IgE mediated only | - | - | - | - | - | - | - | - | - | 1.34 (1.08-1.64) n=nr |
| Ben-Shoshan (2009) | Canada | 2005-2007 | 7 year | peanut | IgE mediated only | - | - | - | - | - | - | - | - | - | 1.62 (1.31-1.98) n=nr |
| Chen (2011) | China | 2009 | 0-12 months | peanut | IgE mediated only | - | - | - | 0.4 [†] (0.1-1.7) n=477 | - | - | - | - | - | - |
| Hu (2010) | China | 1999 | 0-24 months | peanut | IgE mediated only | - | - | - | $\begin{array}{c} 0.3 \\ (0.0-2.1) \\ n=304 \end{array}$ | - | - | - | - | - | - |
| Hu (2010) | China | 2009 | 0-24 months | peanut | IgE mediated only | - | - | - | 1.6 [†] (0.6-3.6) n=382 | - | - | - | - | - | - |

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

Prevalence of food allergy in Europe

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | onnaire-based | methods | Sensit | isation | Sensitisation hist | with clinical | Food challeng hist | e with clinical ory | Other |
|----------------------|--|---------------------|-------------|----------|---|--|---|--|-----------------|-----------------------|---|---------------------|-----------------------|------------------------|---|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | peanut | IgE mediated only | 1 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Leung (2009) | Hong Kong | 2006-2007 | 2-7 years | peanut | IgE mediated only (no SPT or SIgE) | 0.7 [†] (0.4-1.0) n=3677 | - | - | - | - | - | - | - | - | 0.5 [†] (0.3-0.8) n=3677 |
| Dalal (2002) | Israel | Nr | 0-2years | peanut | IgE mediated only | - | 0.1 [†] (0.0 - 0.2) n=9070 | - | - | - | 0 [†] (0.0 - 0.1) n=9070 | - | - | - | - |
| Oh (2004) | Korea | 2000 | 6-12 years | peanut | IgE mediated only (no SPT or SIgE) | $\begin{array}{c} 0.1 \\ (0.1-0.2) \\ n=27425 \end{array}$ | - | - | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 12-15 years | peanut | IgE mediated only (no SPT or SIgE) | 0.1 [†] (0.1-0.2) n=14777 | - | - | - | - | - | - | - | - | - |
| Shek (2010) | Philippines | 2007-2008 | 14-16 years | peanut | Both IgE and non IgE mediated | 1.3 [†] (1.1-1.5) n=11322 | 0.4 [†] (0.3-0.6) n=11322 | - | - | - | - | - | - | - | - |
| Shek (2010) | Singapore | 2007-2008 | 14-16 years | peanut | Both IgE and non IgE mediated | $\begin{array}{c} 1.2 \\ (0.9-1.5) \\ n=6450 \end{array}$ | 0.5 [†] (0.4-0.6) n=6450 | - | - | - | - | - | - | - | - |
| Shek (2010) | Singapore | 2007-2008 | 4-6 years | peanut | Both IgE and non IgE mediated | 3.6 [†] (3.1-4.2) n=4390 | 0.6 [†] (0.4-1.0) n=4390 | - | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | <3 years | peanut | IgE mediated only (no SPT or SIgE) | - | - | $\begin{array}{c} 0.4 \\ (0.1-1.2) \\ n=813 \end{array}$ | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | >19 years | peanut | IgE mediated only (no SPT or SIgE) | - | - | 0.5 [†] (0.4-0.6) n=14036 | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | 4-18 years | peanut | IgE mediated only (no SPT or SIgE) | - | - | 0.9^{\dagger} (0.8-1.1) n=15169 | - | - | - | - | - | - | - |
| Al-Hammadi (2010) | United Arab Emirates (Emirate of Abu Dhabi) | 2006 | 6-9 years | peanut | IgE mediated only (no SPT or SIgE) | - | - | 2.3 [†] (1.1-4.4) n=397 | - | - | - | - | - | - | - |
| Branum (2009) | United States | 2005-2006 | < 18 years | peanut | IgE mediated only (not clearly defined) | - | - | - | - | 9.3 (nr) n=nr | - | - | - | - | - |
| Sicherer (1999) | United States | 1997 | <18 years | peanut | IgE mediated only (no SPT or SIgE) | - | 0.4 [†] (0.2-0.7) n=2998 | - | - | - | - | - | - | - | - |
| Sicherer (1999) | United States | 1997 | ≥18 years | peanut | IgE mediated only (no SPT or SIgE) | - | 0.7 [†] (0.6-1.0) n=8049 | - | - | - | - | - | - | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Question | nnaire-based | methods | Sensit | isation | Sensitisation hist | with clinical tory | Food challeng hist | e with clinical ory | Other |
|-----------------|---------------|---------------------|-----------------------|----------|--|--|---|-------------------------|-----------------|-------------------------------|-----------------------|---------------------|-----------------------|------------------------|--|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Sicherer (2003) | United States | 2002 | ≥65 years | peanut | IgE mediated only (no SPT or SIgE) | - | 0.5 [†] (0.2-1.0) n=1345 | - | - | - | - | - | - | - | - |
| Sicherer (2010) | United States | 2008 | ≥65 years | peanut | IgE mediated only (no SPT or SIgE) | - | 0.7 (0.4-1.2) n=2481 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 0-2 years | peanut | IgE mediated (no SPT or SIgE) | - | 1.4 (1.1-1.8) n=5429 | - | - | - | - | - | - | - | - |
| Bock (1987) | United States | 1980-1984 | 0-3 years | peanut | Both IgE and non-IgE mediated | 1.4 [†] (0.5-2.8) n=408 | - | - | - | - | - | - | - | - | 0.8 [†] (0.3-2.3) n=480 |
| Sicherer (2003) | United States | 2002 | 0-5 years | peanut | IgE mediated only (no SPT or SIgE) | - | 0.8 [†] (0.4-1.7) n=869 | - | - | - | - | - | - | - | - |
| Sicherer (2010) | United States | 2008 | 0-5 years | peanut | IgE mediated only (no SPT or SIgE) | - | 0.9 [†] (0.4-1.9) n=860 | - | - | - | - | - | - | - | - |
| Kumar (2011) | United States | 2011 | 6 months - 6 years | peanut | IgE mediated only | - | - | - | - | 13.5 (11.6-15.7) n=1104 | - | - | - | - | - |
| Keet (2012) | United States | 2005-2006 | 1-21 years | peanut | IgE mediated only | - | - | - | - | 10 (nr) n=3550 | - | - | - | - | - |
| Liu (2010) | United States | 2005-2006 | 1-5 years | peanut | IgE mediated only | - | - | - | - | 7.1 (nr) n=909 | - | - | - | - | 1.8 (nr) n=nr |
| Gupta (2011) | United States | 2009-2010 | 3-5 years | peanut | IgE mediated (no SPT or SIgE) | - | 2.8 (2.3-3.4) n=5910 | - | - | - | - | - | - | - | - |
| Sicherer (2003) | United States | 2002 | 6-10 years | peanut | IgE mediated only (no SPT or SIgE) | - | 0.6 [†] (0.2-1.4) n=851 | - | - | - | - | - | - | - | - |
| Sicherer (2010) | United States | 2008 | 6-10 years | peanut | IgE mediated only (no SPT or SIgE) | - | 1.3 [†] (0.7-2.3) n=861 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 6-10 years | peanut | IgE mediated (no SPT or SIgE) | - | 1.9 (1.6-2.3) n=9911 | - | - | - | - | - | - | - | - |
| Liu (2010) | United States | 2005-2006 | 6-19 years | peanut | IgE mediated only | - | - | - | - | 10.7 (nr) n=2869 | - | - | - | - | 2.7 (nr) n=nr |
| Gupta (2011) | United States | 2009-2010 | 11-13 years | peanut | IgE mediated (no SPT or SIgE) | - | 2.3 (1.9-2.8) n=6716 | - | - | - | - | - | - | - | - |
| Sicherer (2003) | United States | 2002 | 11-17 years | peanut | IgE mediated only (no SPT or SIgE) | - | 0.2 [†] (0-0.6) n=1228 | - | - | - | - | - | - | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | nnaire-based | methods | Sensi | tisation | Sensitisation hist | with clinical tory | Food challeng hist | e with clinical ory | Other |
|---------------------|---------------|---------------------|-------------|----------|--|---|---|-------------------------|-----------------|-------------------------|-----------------------|-----------------------|-----------------------|------------------------|---|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | t Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | • | 95% Preva | alence (CI) | 0 | | | |
| Sicherer (2010) | United States | 2008 | 11-17 years | peanut | IgE mediated only (no SPT or SIgE) | - | 0.7 [†] (0.3-1.4) n=1151 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 14-17 years | peanut | IgE mediated (no SPT or SIgE) | - | 1.7 (1.4-2.1) n=10514 | - | - | - | - | - | - | - | - |
| Vierk (2007) | United States | 2001 | 18 years + | peanut | IgE mediated only (no SPT or SIgE) | 0.7 [†] (0.5-1.0) n=4482 | - | - | - | - | - | - | - | - | 0.5 [†] (0.3-0.8) n=4482 |
| Greenhawt (2009) | United States | nr | 18 years+ | peanut | IgE mediated (no SPT or SIgE) | 8.4 (6.2-11.2) n=513 | - | - | - | - | - | - | - | - | - |
| Sicherer (2003) | United States | 2002 | 18-20 years | peanut | IgE mediated only (no SPT or SIgE) | - | 0.5 [†] (0.1-1.6) n=579 | - | - | - | - | - | - | - | - |
| Sicherer (2010) | United States | 2008 | 18-20 years | peanut | IgE mediated only (no SPT or SIgE) | - | 0.4 [†] (0.1-1.7) n=456 | - | - | - | - | - | - | - | - |
| Liu (2010) | United States | 2005-2006 | 20-39 years | peanut | IgE mediated only | - | - | - | - | 8.7 (nr) n=1672 | - | - | - | - | 1 (nr) n=nr |
| Sicherer (2003) | United States | 2002 | 21-30 years | peanut | IgE mediated only (no SPT or SIgE) | - | 0.4 [†] (0.1-0.9) n=1491 | - | - | - | - | - | - | - | - |
| Sicherer (2010) | United States | 2008 | 21-30 years | peanut | IgE mediated only (no SPT or SIgE) | - | 0.2 [†] (0-0.8) n=1019 | - | - | - | - | - | - | - | - |
| Sicherer (2003) | United States | 2002 | 31-40 years | peanut | IgE mediated only (no SPT or SIgE) | - | 0.5 [†] (0.2-1) n=1556 | - | - | - | - | - | - | - | - |
| Sicherer (2010) | United States | 2008 | 31-40 years | peanut | IgE mediated only (no SPT or SIgE) | - | 0.6 [†] (0.3-1.2) n=1311 | - | - | - | - | - | - | - | - |
| Liu (2010) | United States | 2005-2006 | 40-59 years | peanut | IgE mediated only | - | - | - | - | 6.5 (nr) n=1361 | - | - | - | - | 1.1 (nr) n=nr |
| Sicherer (2003) | United States | 2002 | 41-50 years | peanut | IgE mediated only (no SPT or SIgE) | - | 0.2 [†] (0.1-0.6) n=1809 | - | - | - | - | - | - | - | - |
| Sicherer (2010) | United States | 2008 | 41-50 years | peanut | IgE mediated only (no SPT or SIgE) | - | 0.6 [†] (0.3-1.1) n=1754 | - | - | - | - | - | - | - | - |
| Sicherer (2003) | United States | 2002 | 51-60 years | peanut | IgE mediated only (no SPT or SIgE) | - | 0.4^{\dagger} (0.2-1.0) n=1352 | - | - | - | - | - | - | - | - |
| Sicherer (2010) | United States | 2008 | 51-60 years | peanut | IgE mediated only (no SPT or SIgE) | - | 0.4 [†] (0.2-0.8) n=1894 | - | - | - | - | - | - | - | _ |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Question | nnaire-based n | nethods | Sensiti | isation | Sensitisation his | with clinical tory | Food challeng hist | e with clinical ory | Other |
|-----------------|---------------|---------------------|-------------|----------|--|---------------|--|-------------------------|--|-----------------------|----------------------|-----------------------|-----------------------|------------------------|---------------------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | motory | ulugiloseu | | 95% Preva | alence (CI) | | 010 | | |
| Liu (2010) | United States | 2005-2006 | 60+ years | peanut | IgE mediated only | - | - | - | - | 4.5 (nr) n=1392 | - | - | - | - | 0.3 (nr) n=nr |
| Sicherer (2003) | United States | 2002 | 61-64 years | peanut | IgE mediated only (no SPT or SIgE) | - | 0.3 [†] (0-1.8) n=355 | - | - | - | - | - | - | - | - |
| Sicherer (2010) | United States | 2008 | 61-64 years | peanut | IgE mediated only (no SPT or SIgE) | - | 0.3 [†] (0.1-1.3) n=610 | - | - | - | - | - | - | - | - |
| Arbes (2005) | United States | 1988-1994 | All ages | peanut | IgE mediated | - | - | - | 8.6 [†] (8.1-9.2) n=10508 | - | - | - | - | - | - |
| Liu (2010) | United States | 2005-2006 | All ages | peanut | IgE mediated only | - | - | - | - | 7.6 (nr) n=8203 | - | - | - | - | 1.3 (nr) n=nr |
| Gupta (2011) | United States | 2009-2010 | All ages | peanut | IgE mediated (no SPT or SIgE) | - | 2 (1.8-2.2) n=3339 | - | - | - | - | - | - | - | - |

^{*}Percentage prevalence inferred from graph provided (no raw data reported).

[#]Data has been subject to correction or estimation by the authors (presented as reported in the paper).

Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | onnaire-based n | nethods | Sensit | isation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical ory | Other |
|---------------------|-------------------|---------------------|-------------|----------|---|---|---------------------|-------------------------|--|------------------------------------|----------------------------|----------------------|-----------------------|------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Touraine (2002) | France | 2000-2001 | 5-17 years | sesame | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.5 [†] (0.9-2.4) n=1086 | - | - | - | - | - | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | sesame | Both IgE and non-IgE mediated | - | - | - | - | - | 2.2 (1.7-2.7) n=4093 | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 60-97 years | sesame | IgE mediated only | - | - | - | - | 0 [†] (0-4.2) n=109 | - | - | - | - | - |
| Venter (2008) | United Kingdom | 2001-2005 | 1 years | sesame | Both IgE and non IgE mediated | - | - | - | 0.3 [†] (0.0-1.0) n=763 | - | - | - | - | - | - |

| Table 1.25: | Sesame allergy p | revalence in Europea | n countries by age | group |
|-------------|------------------|----------------------|--------------------|-------|
| | | | | 0 |

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Prevalence | of food | allergy | in | Europe |
|------------|---------|---------|----|-------------|
| | | | | · · · · · · |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | onnaire-based n | nethods | Sensit | isation | Sensitisation hist | with clinical tory | Food challeng hist | e with clinical ory | Other |
|----------------|-------------------|---------------------|------------|----------|-------------------------------------|--|---------------------|-------------------------|---|-----------------------|-----------------------|-----------------------|-----------------------|------------------------|--|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Venter (2008) | United Kingdom | 2001-2005 | 2 years | sesame | Both IgE and non IgE mediated | - | - | - | 0.8 [†] (0.3-1.9) n=658 | - | - | - | - | - | - |
| Venter (2008) | United Kingdom | 2001-2005 | 3 years | sesame | Both IgE and non IgE mediated | - | - | - | 1.4 [†] (0.7-2.7) n=642 | - | - | - | - | - | 0.6 [†] (0.2-1.4) n=891 |
| Venter (2006) | United Kingdom | 2003-2004 | 6 years | sesame | Both IgE and non IgE mediated | 0.6 [†] (0.2-1.6) n=798 | - | - | 0.4 [†] (0.1 -1.4) n=700 | - | - | - | - | - | 0.1 [†] (0-0.8) n=798 |
| Roberts (2005) | United Kingdom | 1998-2000 | 7 years | sesame | IgE mediated only | - | - | - | 0.1^{\dagger} (0 - 0.5) n=2003 | - | - | - | - | - | - |
| Pereira (2005) | United Kingdom | 2002-2003 | 11 years | sesame | Both IgE and non-IgE mediated | - | - | - | 0.6 [†] (0.2-1.6) n=699 | - | - | - | - | - | - |
| Pereira (2005) | United Kingdom | 2002-2003 | 15 years | sesame | Both IgE and non-IgE mediated | - | - | - | 0.9 [†] (0.4-2.1) n=649 | - | - | - | - | - | - |
| Emmett (1999) | United Kingdom | 1995-1996 | 15 + years | sesame | Both Ige and non-IgE mediated | $ \begin{array}{c} 0^{\dagger} \\ (0-0.1) \\ n=16420 \end{array} $ | - | - | - | - | - | - | - | - | - |

[‡]Percentage prevalence inferred from graph provided (no raw data reported). [#]Data has been subject to correction or estimation by the authors (presented as reported in the paper). Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

| Table 1.20. Sesame anergy prevalence in non-European countries by age grou | Table 1.26: | Sesame allergy prev | alence in non-Europe | an countries by age grou |
|---|-------------|---------------------|----------------------|--------------------------|
|---|-------------|---------------------|----------------------|--------------------------|

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | onnaire-based n | nethods | Sensit | isation | Sensitisation his | with clinical tory | Food challeng hist | ge with clinical tory | Other |
|-----------------------|-----------|---------------------|--------------|----------|-------------------------------------|----------------------------|--|--|----------------------------|-----------------------|----------------------|-----------------------|-----------------------------|--------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | · | | 95% Preva | alence (CI) | | | • | |
| Osborne (2011) | Australia | 2007-2010 | 12-15 months | sesame | IgE mediated only | - | - | - | 1.6 (1.2-2.1) n=2695 | - | - | - | 0.7# (0.4-1.0) N=2695 | - | - |
| Ben-Shoshan (2010) | Canada | 2008-2009 | < 18 years | sesame | Both IgE and non-IgE mediated | 0.2 (0.03-0.43) n=nr | 0.23 [#] (0.03-0.43) n=nr | 0.03 [#] (0.00-0.06) n=nr | - | - | - | - | - | - | - |
| Ben-Shoshan (2010) | Canada | 2008-2009 | > 18 years | sesame | Both IgE and non-IgE mediated | 0.1 (0.01-0.13) n=nr | 0.05 [#] (0.00-0.11) n=nr | 0.01 [#] (0.00-0.02) n=nr | - | - | - | - | - | - | - |

EFSA supporting publication 2013:EN-506

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | onnaire-based n | nethods | Sensit | isation | Sensitisation hist | with clinical tory | Food challeng hist | e with clinical tory | Other |
|-----------------|---------------|---------------------|-----------|----------|-------------------------|---------------|---------------------|-------------------------|-----------------|-----------------------|-----------------------|-----------------------|-----------------------|-------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | 11150019 | unglioben | | 95% Preva | alence (CI) | ~-9 | 010 | 221010 | |
| Dalal (2002) | Israel | nr | 0-2years | sesame | IgE mediated | - | 0.2 [†] | - | - | - | 0.2 [†] | - | - | - | - |
| | | | | | only | | (0.1 - 0.3) | | | | (0.1-0.3) | | | | |
| | | | | | | | n=9070 | | | | n=9070 | | | | |
| Sicherer (2010) | United States | 2008 | <18 years | sesame | IgE- only (no | - | 0 † | - | - | - | - | - | - | - | - |
| | | | | | SPT or SIgE) | | (0-0.1) | | | | | | | | |
| | | | | | | | n=13534 | | | | | | | | |
| Sicherer (2010) | United States | 2008 | >18 years | sesame | IgE- only (no | - | 0.1 † | - | - | - | - | - | - | - | - |
| | | | | | SPT or SIgE) | | (0-0.1) | | | | | | | | |
| | | | | | | | n=13534 | | | | | | | | |
| Sicherer (2010) | United States | 2008 | All ages | sesame | IgE- only (no | - | 0.1 † | - | - | - | - | - | - | - | - |
| | | | | | SPT or SIgE) | | (0.1-0.2) | | | | | | | | |
| | | | | | | | n=13534 | | | | | | | | |

[‡]Percentage prevalence inferred from graph provided (no raw data reported).

[#]Data has been subject to correction or estimation by the authors (presented as reported in the paper).

Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

| Table 1.27: Soya allergy prevalence in European countries by age |
|--|
|--|

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | onnaire-based n | nethods | Sensit | isation | Sensitisation hist | with clinical tory | Food challeng hist | e with clinical ory | Other |
|----------------------|---------|---------------------|-------------|----------|-------------------------------------|--|---------------------|-------------------------|-----------------|-----------------------|----------------------------|-----------------------|---|--------------------------------------|--|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | 05% Provola | nce (CI) | | | | | |
| Osterballe (2005) | Denmark | 2000-2001 | < 3 years | soya | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | $ \begin{array}{c} 0\\ (nr)\\ n=111 \end{array} $ | - | 0^{\dagger} (0.0-4.2) n=111 |
| Osterballe (2005) | Denmark | 2000-2001 | 3 years | soya | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0 [†] (0 - 1) n=486 | $ \begin{array}{c} 0.4^{\dagger} \\ (0.1 - 1.6) \\ n = 486 \end{array} $ |
| Osterballe (2005) | Denmark | 2000-2001 | 3-22 years | soya | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0 (0 - 2) n=301 | 0.3 (0 - 2.1) n=301 |
| Osterballe (2009) | Denmark | 2001-2002 | 22 years | soya | Both IgE and non-IgE mediated | 0.6 [†] (0.2 - 1.5) n=843 | - | - | - | - | - | - | - | - | 0.1 (0.0-0.8) n=843 |
| Osterballe (2005) | Denmark | 2000-2001 | >22 years | soya | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 0 [†] (0 - 0.5) n=936 | 0.3 [†] (0.1 - 1.0) n=936 |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | soya | Both IgE and non-IgE mediated | - | - | - | - | - | 0.9 (0.6-1.3) n=3156 | - | - | - | - |

EFSA supporting publication 2013:EN-506

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | onnaire-based 1 | nethods | Sensit | isation | Sensitisation hist | with clinical tory | Food challeng hist | e with clinical ory | Other |
|------------------------|--------------------|---------------------|-------------|----------|---|--|---------------------|---|---|---|------------------------------------|----------------------------|-----------------------|------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | 95% Prevale | ence (CI) | | | | | |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | soya | Both IgE and non-IgE mediated | 0.3^{\dagger} (nr) n=nr | - | - | 1.7 [†] (nr) n=nr | - | - | - | - | - | - |
| Krause (2002) | Greenland | 1998 | 5-18 years | soya | IgE mediated only | - | - | - | - | 2.1 [†] (1.4-3.3) n=1031 | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 20-69 years | soya | IgE mediated only | - | - | - | 8.3 [†] (2.2-23.6) n=36 | 2.8 [†] (0.2-16.2) n=36 | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 60-97 years | soya | IgE mediated only | - | - | - | 7.3 [†] (3.5-14.4) n=109 | 3.7 (1.2-9.7) n=109 | - | - | - | - | - |
| Kristjansson (1999) | Iceland | 1994 | 18 months | Soya | Both IgE and non-IgE mediated | 0.3 [†] (0.0-2.0) n=324 | - | - | - | - | 0 [†] (0-1.5) n=324 | - | - | - | - |
| Ostblom (2008 b) | Sweden | 1995-1997 | 1 year | soya | Both IgE and non-IgE mediated | 0.6 [†] (0.4-1.0) n=3104 | - | 0.2 [†] (0.1-0.4) n=3104 | - | - | - | - | - | - | - |
| Kristjansson (1999) | Sweden | 1994 | 18 months | Soya | Both IgE and non-IgE mediated | 0 [†] (0-1.4) n=328 | - | - | - | - | 0 [†] (0-1.4) n=328 | - | - | - | - |
| Ostblom (2008 b) | Sweden | 1996-1998 | 2 years | soya | Both IgE and non-IgE mediated | 0.6 [†] (0.4-1.0) n=3104 | - | 0.6 [†] (0.4-1.0) n=3104 | - | - | - | - | - | - | - |
| Ostblom (2008 b) | Sweden | 1998-2000 | 4 years | soya | Both IgE and non-IgE mediated | $ 1^{\dagger} (0.7-1.4) n=3104 $ | - | 0.8 [†] (0.5-1.2) n=3104 | - | - | - | - | - | - | - |
| Ostblom (2008 a) | Sweden | 1999-2000 | 4 years | soya | Both IgE and non-IgE mediated | 1.2 [†] (0.8-1.7) n=2563 | - | - | - | 3 [†] (2.4-3.8) n=2563 | - | 1.6 (1.1-2.1) n=2563 | - | - | - |
| Ostblom (2008 b) | Sweden | 2002-2004 | 8 years | soya | Both IgE and non-IgE mediated | 0.8 [†] (0.5-1.2) n=3104 | - | 0.8 [†] (0.5-1.2) n=3104 | - | - | - | - | - | - | - |
| Bjornsson (1996) | Sweden | 1991-1992 | 20-44 years | soya | IgE mediated only | - | - | - | - | 2.1 [†] (1.4-3.0) n=1397 | - | - | - | - | - |
| Brugman (1998) | The Netherlands | 1993- 1994 | 4-15 years | soya | Both IgE and non-IgE (no SPT or SIgE) | 0.6 [†] (0.4-0.9) n=4400 | - | - | - | - | - | - | - | - | - |
| Arshad (2001) | United Kingdom | 1993-1994 | 4 years | soya | IgE mediated only | - | - | - | 0.3 [†] (0.1 - 1) n=981 | - | - | - | - | - | - |
| Roberts (2005) | United Kingdom | 1998-2000 | 7 years | soya | IgE mediated only | - | - | - | 0.2 [†] (0 - 0.7) n=1173 | - | - | - | - | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | onnaire-based n | nethods | Sensit | isation | Sensitisation hist | with clinical tory | Food challenge with clinical history | | Other |
|---------------|-------------------|---------------------|------------|----------|---|--|---------------------|-------------------------|-----------------|-----------------------|-----------------------|-----------------------|--------------------------------------|-----------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | 95% Prevale | ence (CI) | | | | | |
| Emmett (1999) | United Kingdom | 1995-1996 | 15 + years | soya | Both Ige and non-IgE mediated | 0 [†] (0-0.1) n=16420 | - | - | - | - | - | - | - | - | - |
| Young (1994) | United Kingdom | nr | All ages | soya | Both IgE and non IgE mediated (no SPT or SIgE) | 0.3 [†] (0.3-0.4) n=18880 | - | - | - | - | - | - | - | - | - |

[‡]Percentage prevalence inferred from graph provided (no raw data reported).

[#]Data has been subject to correction or estimation by the authors (presented as reported in the paper).

Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

| Table 1.28: | Soya allergy prevalence in non-European countries by age group |
|--------------------|--|
| 1 abic 1.20. | boyd anergy prevalence in non-European countries by age group |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questi | onnaire-based r | nethods | Sensitisation Skin prick test Serum-specific IgE | | Sensitisation hist | with clinical cory | Food challeng hist | e with clinical ory | Other |
|---------------|---------|---------------------|-------------|----------|--|-----------------------------|---|-------------------------|--|-----------------------|---|-----------------------|-----------------------|------------------------|--|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95 | 5% Prevalence (| CI) | | | |
| Soller (2012) | Canada | 2008-2009 | <18 years | soya | "likely" IgE mediated (no SPT or SIgE) | 0.32 (0.08-0.55) n=nr | - | - | - | - | - | - | - | - | - |
| Soller (2012) | Canada | 2008-2009 | >18 years | soya | "likely" IgE mediated (no SPT or SIgE) | 0.16 (0.07-0.25) n=nr | - | - | - | - | - | - | - | - | - |
| Hu (2010) | China | 1999 | 0-24 months | soya | IgE mediated only | - | - | - | 1 [†] (0.3-3.1) n=304 | - | - | - | - | - | - |
| Hu (2010) | China | 2009 | 0-24 months | soya | IgE mediated only | - | - | - | 0.5 [†] (0.1-2.1) n=382 | - | - | - | - | - | - |
| Sai (2011) | China | 2008-2009 | adults | soya | IgG mediated only | - | - | - | - | - | - | - | - | - | 7.2 [†] (6.6-7.7) n=12766 |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | soya | IgE mediated only | 0.2 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Dalal (2002) | Israel | nr | 0-2years | soya | IgE mediated only | - | 0 [†] (0.0 - 0.2) n=9070 | - | - | - | 0 [†] (0.0 - 0.1) n=9070 | - | - | - | - |

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | nnaire-based r | nethods | Sensit | isation | Sensitisation his | a with clinical tory | Food challeng hist | e with clinical tory | Other |
|----------------------|---------------|---------------------|----------------------|----------|--|--|-----------------------------|--|-----------------|-----------------------|----------------------|-------------------------|-----------------------|-------------------------|---|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | - | 95 | % Prevalence (| (CI) | | | |
| Kim (2011) | Korea | 2006-2007 | 0-12 months | soya | IgE mediated only (no SPT or SIgE) | - | - | 0.3 [†] (0.1-0.9) n=1177 | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 6-12 years | soya | IgE mediated only (no SPT or SIgE) | $\begin{array}{c} 0.2 \\ (0.1-0.2) \\ n=27425 \end{array}$ | - | - | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 12-15 years | soya | IgE mediated only (no SPT or SIgE) | 0.1 [†] (0.1-0.2) n=14777 | - | - | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | <3 years | soya | IgE mediated only (no SPT or SIgE) | - | - | 0 [†] (0.0-0.6) n=813 | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | >19 years | soya | IgE mediated only (no SPT or SIgE) | - | - | 0.2 [†] (0.1-0.3) n=14036 | - | - | - | - | - | - | - |
| Wu (2012) | Taiwan | 2004 | 4-18 years | soya | IgE mediated only (no SPT or SIgE) | - | - | $\begin{array}{c} 0.2 \\ (0.2 \text{-} 0.3^{\dagger}) \\ n \text{=} 15169 \end{array}$ | - | - | - | - | - | - | - |
| Santadusit (2005) | Thailand | nr | 6 months - 6years | soya | IgE mediated only | 0.2 [†] (0.0 - 1.0) n=656 | - | - | - | - | - | - | - | - | _ |
| Gupta (2011) | United States | 2009-2010 | 0-2 years | soya | IgE mediated (no SPT or SIgE) | - | 0.3 (0.2-0.4) n=5429 | - | - | - | - | - | - | - | _ |
| Bock (1987) | United States | 1980-1984 | 0-3 years | soya | Both IgE and non-IgE mediated | 2.7 [†] (1.2-4.2) n=408 | - | - | - | - | - | - | - | - | 0.8 [†] (0.3-2.3) n=480 |
| Gupta (2011) | United States | 2009-2010 | 3-5 years | soya | IgE mediated (no SPT or SIgE) | - | 0.5 (0.3-0.7) n=5910 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 6-10 years | soya | IgE mediated (no SPT or SIgE) | - | 0.3 (0.2-0.5) n=9911 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 11-13 years | soya | IgE mediated (no SPT or SIgE) | - | 0.6 (0.4-0.8) n=6716 | - | - | - | - | - | - | - | - |
| Gupta (2011) | United States | 2009-2010 | 14-17 years | soya | IgE mediated (no SPT or SIgE) | - | 0.3 (0.2-0.4) n=10514 | - | - | - | - | - | - | - | - |
| Vierk (2007) | United States | 2001 | 18 years + | soya | IgE mediated only (no SPT or SIgE) | 0.1^{+} (0.0-0.3) n=4482 | - | - | - | - | - | - | - | - | 0.1 [†] (0.0-0.2) n=4482 |
| Greenhawt (2009) | United States | nr | 18 years+ | soya | IgE mediated only (no SPT or SIgE) | 1.8 [†] (0.9-3.4) n=513 | - | - | - | - | - | - | - | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | onnaire-based 1 | nethods | Sensit | isation | Sensitisation hist | with clinical tory | Food challeng hist | e with clinical ory | Other |
|--------------|---------------|---------------------|-----------|----------|--|--|----------------------------|---------|-----------------|-----------------------|-----------------------|-----------------------|-----------------------|------------------------|-------|
| | | | | | | Self-reported Clinical Clinician- history diagnosed S | | | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95 | % Prevalence (| CI) | | | |
| Gupta (2011) | United States | 2009-2010 | All ages | soya | IgE mediated only (no SPT or SIgE) | - | 0.4 (0.3-0.4) n=3339 | - | - | - | - | - | - | - | - |

^{*}Percentage prevalence inferred from graph provided (no raw data reported).

[#]Data has been subject to correction or estimation by the authors (presented as reported in the paper).

Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

Table 1.29: Tree nuts allergy prevalence in European countries by age group

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | nnaire-based 1 | nethods | Sensitisation | | Sensitisation with clinical history | | Food challenge with clinical history | | Other |
|---------------------|---------|---------------------|-----------|---------------------|---|---|---------------------|--|-----------------|-----------------------|--|---------------------|--------------------------------------|-----------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Kajosaari (1982) | Finland | 1980-1981 | 1 year | unspecified nuts | Both IgE and non-IgE mediated (no SPT or SIgE) | 2 (nr) n=261 | - | - | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 1 year | unspecified nuts | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.8 [†] (0.4-1.8) n=853 | - | 0.1 [†] (0 - 0.6) n=853 | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 2 years | unspecified nuts | Both IgE and non-IgE mediated (no SPT or SIgE) | 1 (nr) n=202 | - | - | - | - | _ | - | - | - | _ |
| Pyrhonen (2009) | Finland | 2001-2009 | 2 years | unspecified nuts | Both IgE and non-IgE mediated (no SPT or SIgE) | 2 [†] (1.2-3.3) n=852 | - | 0 [†] (0-0.6) n=852 | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 3 years | unspecified nuts | Both IgE and non-IgE mediated (no SPT or SIgE) | 2 (nr) n=200 | - | - | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 3 years | unspecified nuts | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.4 [†] (0.7-2.6) n=784 | - | 0.5 [†] (0.2-1.4) n=784 | - | - | _ | - | - | - | _ |
| Pyrhonen (2009) | Finland | 2001-2009 | 4 years | unspecified nuts | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.7 [†] (1.0 -2.9) n=819 | - | 0.4 [†] (0.1-1.2) n=819 | - | - | _ | - | - | - | _ |

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

Prevalence of food allergy in Europe

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questionnaire-based methods | | | Sensit | isation | Sensitisation hist | with clinical tory | Food challeng hist | Other | |
|------------------------|---------|---------------------|-------------|-------------------------|---|------------------------------------|---------------------|-------------------------|--|---|------------------------------------|-----------------------|-----------------------|----------------------------|---|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | tree nuts (hazelnut) | Both IgE and non-IgE mediated | - | - | - | - | - | 5.9 (5.1-6.8) n=3156 | - | - | 2.2 (1.8-2.8) n=3156 | - |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | tree nuts (hazelnut) | Both IgE and non-IgE mediated | - | - | - | 11.3 [†] (nr) n=nr | - | - | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | tree nuts (walnut) | Both IgE and non-IgE mediated | - | - | - | - | - | 1.8 (1.4-2.4) n=3156 | - | - | 1.0 (0.7-1.4) n=3156 | - |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | unspecified nuts | Both IgE and non-IgE mediated | 5.3 [†] (nr) n=nr | - | - | - | - | - | - | - | - | - |
| Sakellariou (2008) | Greece | 2007 | 20-54 years | unspecified nuts | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.3 [†] (nr) n=2003 | - | - | - | - | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 20-69 years | tree nuts (almond) | IgE mediated only | - | - | - | - | - | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 60-97 years | tree nuts (almond) | IgE mediated only | - | - | - | - | 0^{\dagger} (0-4.2) n=109 | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 20-69 years | tree nuts (hazelnut) | IgE mediated only | - | - | - | 2.8^{\dagger} (0.2-16.2) n=36 | 0 [†] (0-12.0) n=36 | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 60-97 years | tree nuts (hazelnut) | IgE mediated only | - | - | - | 3.7 [†] (1.2-9.7) n=109 | 9.2 [†] (4.7-16.6) n=109 | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 20-69 years | tree nuts (walnut) | IgE mediated only | - | - | - | - | - | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 60-97 years | tree nuts (walnut) | IgE mediated only | - | - | - | - | 3.7 [†] (1.2-9.7) n=109 | - | - | - | - | - |
| Kristjansson (1999) | Iceland | 1994 | 18 months | tree nuts (almond) | Both IgE and non-IgE mediated | 0 [†] (0-1.5) n=324 | - | - | - | - | 0 [†] (0-1.5) n=324 | - | - | - | - |
| Kristjansson (1999) | Iceland | 1994 | 18 months | unspecified nuts | Both IgE and non-IgE mediated | 0 [†] (0-1.5) n=324 | - | - | - | - | 0 [†] (0-1.5) n=324 | - | - | - | - |
| Eggesbo (1999) | Norway | 1993-1995 | 1 year | unspecified nuts | Both IgE and non-IgE mediated | 0.4 (0.3-0.8) n=3366 | - | - | - | - | - | - | - | - | - |
| Eggesbo (1999) | Norway | 1993-1995 | 18 months | unspecified nuts | Both IgE and non-IgE mediated | 1.2 (0.9-1.7) n=3278 | - | - | - | - | - | - | - | - | - |
| Eggesbo (1999) | Norway | 1993-1995 | 2 years | unspecified nuts | Both IgE and non-IgE mediated | 1.2 (0.9-1.7) n=2979 | - | - | - | - | - | - | - | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questionnaire-based methods | | | Sensitisation | | Sensitisation with clinical history | | Food challenge with clinical history | | Other |
|----------------------------|--------------------|---------------------|-------------|--------------------------|---|---|---------------------|-------------------------|---|-----------------------|---|-------------------------|--|---------------------------------------|------------------------------------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | v | 8 | | 95% Preva | alence (CI) | 8 | | | |
| Martinez- Gimeno (2000) | Spain | nr | 6-13 years | unspecified nuts | Both IgE and non-IgE mediated (no SPT or SIgE) | 6.9 [†] (6.2-7.6) n=5163 | - | - | - | - | - | - | - | - | - |
| Kristjansson (1999) | Sweden | 1994 | 18 months | tree nuts (almond) | Both IgE and non-IgE mediated | 0 [†] (0-1.4) n=328 | - | - | - | - | 0 [†] (0-1.4) n=328 | - | - | - | - |
| Ostblom (2008 a) | Sweden | 1999-2000 | 4 years | tree nuts (almond) | Both IgE and non-IgE mediated | 3.8 [†] (3.1-4.7) n=2563 | - | - | - | - | - | - | - | - | - |
| Kristjansson (1999) | Sweden | 1994 | 18 months | unspecified nuts | Both IgE and non-IgE mediated | 0.3 [†] (0.0-2.0) n=328 | - | - | - | - | 0 [†] (0-1.4) n=328 | - | - | - | - |
| Brugman (1998) | The Netherlands | 1993- 1994 | 4-15 years | unspecified nuts | Both IgE and non-IgE (no SPT or SIgE) | 1.3 [†] (1.0-1.7) n=4400 | - | - | - | - | - | - | - | - | - |
| Mustafayev (2012) | Turkey | 2010 | 10-11 years | tree nuts (hazelnut) | IgE mediated only | 1.5 [†] (1.2-1.8) n=6963 | - | - | 0.4 [†] (0.3-0.6) n=6134 | - | - | - | 0.1 [†] (0.0-0.8) n=813 | - | - |
| Gelincik (2008) | Turkey | nr | 18 years + | tree nuts (hazelnut) | Both Ige and non-IgE mediated | - | - | - | - | - | 0 [†] (0-0.1) n=11816 | 0 (0-0.0) n=11816 | - | 0 [†] (0-0.1) n=11816 | - |
| Orhan (2009) | Turkey | 2006 | 6-9 years | tree nuts (hazelnut) | IgE mediated only | 0.3 [†] (0.1 - 0.6) n=2739 | - | - | - | - | 0.1 [†] (0 - 0.3) n=2739 | - | - | 0 [†] (0 - 0.2) n=2739 | - |
| Mustafayev (2012) | Turkey | 2010 | 10-11 years | tree nuts (pistachio) | IgE mediated only | 0.8 [†] (0.6-1.1) n=6963 | - | - | - | - | - | - | - | - | - |
| Mustafayev (2012) | Turkey | 2010 | 10-11 years | tree nuts (walnut) | IgE mediated only | 1.2 [†] (1.0-1.5) n=6963 | - | - | 4.5 [†] (4.0-5.1) n=6134 | - | - | - | 0.4 [†] (0.1-1.2) n=813 | - | - |
| Gelincik (2008) | Turkey | nr | 18 years + | tree nuts (walnut) | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | - | 0 [†] (0-0.1) n=11816 | - |
| Orhan (2009) | Turkey | 2006 | 6-9 years | tree nuts (walnut) | IgE mediated only | 0.1 [†] (0.0 - 0.4) n=2739 | - | - | - | - | 0.1 [†] (0 - 0.3) n=2739 | - | - | 0 [†] (0- 0.2) n=2739 | - |
| Gelincik (2008) | Turkey | nr | 18 years + | unspecified nuts | Both Ige and non-IgE mediated | 0.1 [‡] (0-0.2) n=11816 | - | - | - | - | - | - | - | - | - |
| Venter (2008) | United Kingdom | 2001-2005 | 1 year | tree nuts (almond) | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | - | - | 0 [†] (0-0.5) n=900 |
| Venter (2008) | United Kingdom | 2001-2005 | 2 years | tree nuts (almond) | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | - | - | 0 [†] (0-0.6) n=858 |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questionnaire-based methods | | | Sensitisation | | Sensitisation with clinical history | | Food challenge with clinical history | | Other |
|----------------|-------------------|---------------------|-----------|-------------------------|---|--|---------------------|-------------------------|--|-----------------------|--|---------------------|--------------------------------------|-----------------------|--|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | 1 | |
| Venter (2008) | United Kingdom | 2001-2005 | 3 years | tree nuts (almond) | Both Ige and non-IgE mediated | - | - | - | 0.3 [†] (0.0-1.2) n=642 | - | - | - | - | - | 0.2 [†] (0.0-0.9) n=891 |
| Roberts (2005) | United Kingdom | 1998-2000 | 7 years | tree nuts (almond) | IgE mediated only | - | - | - | 0.5 [†] (0.2 - 0.9) n=1935 | - | - | - | - | - | - |
| Venter (2008) | United Kingdom | 2001-2005 | 3 years | tree nuts (brazil) | Both Ige and non-IgE mediated | - | - | - | $\begin{array}{c} 0.3 \\ (0.0-1.2) \\ n=642 \end{array}$ | - | - | - | - | - | 0.2 [†] (0.0-0.9) n=891 |
| Roberts (2005) | United Kingdom | 1998-2000 | 7 years | tree nuts (brazil) | IgE mediated only | - | - | - | 0.5 [†] (0.3 - 1) n=1977 | - | - | - | - | - | - |
| Venter (2008) | United Kingdom | 2001-2005 | 1 year | tree nuts (cashew) | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | - | - | 0 [†] (0-0.5) n=900 |
| Venter (2008) | United Kingdom | 2001-2005 | 3 years | tree nuts (cashew) | Both Ige and non-IgE mediated | - | - | - | $\begin{array}{c} 0.2^{\dagger} \\ (0.0-1.0) \\ n=642 \end{array}$ | - | - | - | - | - | 0.1 [†] (0.0-0.2) n=891 |
| Tariq (1996) | United Kingdom | 1993-1994 | 4 years | tree nuts (cashew) | IgE mediated only | - | - | - | - | - | 0.1 [†] (0-0.5) n=1218 | - | - | - | - |
| Roberts (2005) | United Kingdom | 1998-2000 | 7 years | tree nuts (cashew) | IgE mediated only | - | - | - | 0.4 [†] (0.2 - 0.8) n=1998 | - | - | - | - | - | - |
| Venter (2008) | United Kingdom | 2001-2005 | 3 years | tree nuts (hazelnut) | Both Ige and non-IgE mediated | - | - | - | $\begin{array}{c} 0.2^{\dagger} \\ (0.0-1.0) \\ n=642 \end{array}$ | - | - | - | - | - | 0.1 [†] (0.0-0.2) n=891 |
| Tariq (1996) | United Kingdom | 1993-1994 | 4 years | tree nuts (hazelnut) | IgE mediated only | - | - | - | - | - | 0.1 [†] (0-0.5) n=1218 | - | - | - | - |
| Roberts (2005) | United Kingdom | 1998-2000 | 7 years | tree nuts (hazelnut) | IgE mediated only | - | - | - | 0.1 [†] (0 - 0.5) n=2076 | - | - | - | - | - | - |
| Roberts (2005) | United Kingdom | 1998-2000 | 7 years | tree nuts (pecan) | IgE mediated only | - | - | - | 0.2 [†] (0 - 0.5) n=1989 | - | - | - | - | - | - |
| Roberts (2005) | United Kingdom | 1998-2000 | 7 years | tree nuts (walnut) | IgE mediated only | - | - | - | 0.5 [†] (0.3 - 1) n=1997 | - | - | - | - | - | - |
| Young (1994) | United Kingdom | nr | All ages | unspecified nuts | Both IgE and non IgE mediated (no SPT or SIgE) | 1.7 [†] (1.5-1.9) n=18880 | - | - | - | - | - | - | - | - | - |

[‡]Percentage prevalence inferred from graph provided (no raw data reported).

[#]Data has been subject to correction or estimation by the authors (presented as reported in the paper). Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

EFSA supporting publication 2013:EN-506
| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questio | onnaire-based 1 | methods | Sensit | isation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical ory | other |
|-----------------|---------------|---------------------|-------------|--------------------------|--|---|--|---|-----------------|-----------------------|-----------------------|----------------------------|-----------------------|------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | - | - | 95% Preva | alence (CI) | | · | | |
| Woods (1998) | Australia | 1998 | 20-44years | unspecified nuts | Both IgE and non IgE mediated | 0.6 [†] (0.2-1.6) n=669 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | tree nuts (palm) | IgE mediated only | 0.2 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Kim (2011) | Korea | 2006-2007 | 0-12 months | unspecified nuts | IgE mediated only (no SPT or SIgE) | - | - | 0.7 [†] (0.3-1.4) n=1177 | - | - | - | - | - | - | - |
| Shek (2010) | Philippines | 2007-2008 | 14-16 years | unspecified nuts | Both IgE and non IgE mediated | 1.7 [†] (1.5-2) n=11390 | 0.7 [†] (0.5-0.8) n=11390 | - | - | - | - | - | - | - | - |
| Shek (2010) | Singapore | 2007-2008 | 14-16 years | unspecified nuts | Both IgE and non IgE mediated | 1.5 [†] (1.2-1.8) n=6465 | 0.5 [†] (0.4-0.8) n=6465 | - | - | - | - | - | - | - | - |
| Shek (2010) | Singapore | 2007-2008 | 4-6 years | unspecified nuts | Both IgE and non IgE mediated | 4.7 [†] (4.1-5.4) n=4416 | 0.7 [†] (0.5-1.0) n=4416 | - | - | - | - | - | - | - | - |
| Wan (2012) | Taiwan | Not Reported | 6-8 years | tree nuts (pistachio) | IgE mediated only | - | - | - | - | - | - | 2.2 (1.4-3.3) n=1010 | - | - | - |
| Sicherer (2010) | United States | 2008 | < 18 years | unspecified nuts | IgE mediated only (unclear) | - | 0.4 [†] (0.3-0.6) n=13534 | - | - | - | - | - | - | - | - |
| Sicherer (1999) | United States | 1997 | <18 years | unspecified nuts | IgE- only (no SPT or SIgE) | - | 0.2 [†] (0.1-0.4) n=8049 | - | - | - | - | - | - | - | - |
| Sicherer (2003) | United States | 2002 | <18 years | unspecified nuts | IgE- only (no SPT or SIgE) | - | 0.2 [†] (0.1-0.3) n=13493 | - | - | - | - | - | - | - | - |
| Sicherer (2010) | United States | 2008 | > 18 years | unspecified nuts | IgE- only (no SPT or SIgE) | - | 1 [†] (0.8-1.1) n=13534 | - | - | - | - | - | - | - | - |
| Sicherer (2003) | United States | 2002 | >18 years | unspecified nuts | IgE- only (no SPT or SIgE) | - | 0.9 [†] (0.7-1.1) n=13493 | - | - | - | - | - | - | - | - |
| Sicherer (1999) | United States | 1997 | ≥18 years | unspecified nuts | IgE- only (no SPT or SIgE) | - | 1.6 [†] (1.4-1.9) n=8049 | - | - | - | - | - | - | - | - |

Table 1.30: Tree nuts allergy prevalence in non-European countries by age group

[†]Percentage prevalence and/or confidence intervals calculated from raw data provided in the paper

[‡]Percentage prevalence inferred from graph provided (no raw data reported).

[#]Data has been subject to correction or estimation by the authors (presented as reported in the paper).

Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

EFSA supporting publication 2013:EN-506

| Study ID | Country | Year(s) study | Age group | Allergen | Type of food allergy | Questi | ionnaire-based | methods | Sensi | itisation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical ory | Other |
|----------------------|---------|---------------|------------|-----------|---|--|---------------------|--|--------------------|-----------------------|-----------------------|----------------------|-----------------------|--|--|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | 1 | | 95% Preva | lence (CI) | | | | |
| Osterballe (2005) | Denmark | 2000-2001 | < 3 years | additives | Both IgE and non IgE mediated | - | - | - | - | - | - | - | 0 (nr) n=111 | - | 0 [†] (0 - 1) n=111 |
| Osterballe (2005) | Denmark | 2000-2001 | >22 years | additives | Both IgE and non IgE mediated | - | - | - | - | - | - | - | - | 0.1 [†] (0 - 0.7) n=936 | 0.6 [†] (0.3 - 1.5) n=936 |
| Osterballe (2005) | Denmark | 2000-2001 | 3 years | additives | Both IgE and non IgE mediated | - | - | - | - | - | - | - | - | 0^{\dagger} (0 - 1) n=486 | 2.3 [†] (1.2 - 4.1) n=486 |
| Osterballe (2005) | Denmark | 2000-2001 | 3-22 years | additives | Both IgE and non IgE mediated | - | - | - | - | - | - | - | - | 0^{\top} (0 - 2) n=301 | 0.7^{\dagger} (0.1 - 2.6) n=301 |
| Osterballe (2009) | Denmark | 2001-2002 | 22 years | additives | Both IgE and non IgE mediated | 6.6 ' (5.1 - 8.6) n=843 | - | - | - | - | - | - | - | - | 0.5 (0.1-1.3) n=843 |
| Kajosaari (1982) | Finland | 1980-1981 | 1 year | chocolate | Both IgE and non-IgE mediated (no SPT or SIgE) | 2 (nr) n=261 | - | - | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 2 years | chocolate | Both IgE and non-IgE mediated (no SPT or SIgE) | 4 (nr) n=202 | - | - | - | - | - | - | - | _ | - |
| Kajosaari (1982) | Finland | 1980-1981 | 3 years | chocolate | Both IgE and non-IgE mediated (no SPT or SIgE) | 4 (nr) n=200 | - | - | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 6 years | chocolate | Both IgE and non-IgE mediated (no SPT or SIgE) | 1 (nr) n=203 | - | - | - | - | - | - | - | _ | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 1 year | legumes | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.6 [†] (0.9-2.8) n=853 | - | 0.7 [†] (0.3-1.6) n=853 | - | - | - | - | - | _ | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 2 years | legumes | Both IgE and non-IgE mediated (no SPT or SIgE) | 3.2 [†] (2.1-4.6) n=852 | - | 0.8 [†] (0.4-1.8) n=852 | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 3 years | legumes | Both IgE and non-IgE mediated (no SPT or SIgE) | 2.8 [†] (1.8 - 4.3) n=784 | - | 1.4 [†] (0.7-2.6) n=784 | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 4 years | legumes | Both IgE and non-IgE mediated (no SPT or SIgE) | 2.9 [†] (1.9 - 4.4) n=819 | - | 1.5 [†] (0.8 - 2.6) n=819 | - | - | - | - | - | - | - |

Table 1.31: All Other Foods allergy prevalence in European countries by age group

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) study | Age group | Allergen | Type of food allergy | Questio | onnaire-based | methods | Sens | itisation | Sensitisation hist | with clinical tory | Food challeng hist | e with clinical | Other |
|---------------------|---------|---------------|-----------|---------------------------------|---|---|---------------------|--|--------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | lence (CI) | | | | |
| Pyrhonen (2009) | Finland | 2001-2009 | 1 year | strawberry/chocol ate/tomato | Both IgE and non-IgE mediated (no SPT or SIgE) | 6.6 [†] (5.0-8.5) n=853 | - | 0.1 [†] (0-0.8) n=853 | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 2 years | strawberry/chocol ate/tomato | Both IgE and non-IgE mediated (no SPT or SIgE) | 13.8 [†] (11.6-16.4) n=852 | - | 0.4 [†] (0.1 - 1.1) n=852 | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 3 years | strawberry/chocol ate/tomato | Both IgE and non-IgE mediated (no SPT or SIgE) | 13 [†] (10.4-15.2) n=784 | - | 1 [†] (0.4-1.9) n=784 | - | - | - | - | - | - | - |
| Pyrhonen (2009) | Finland | 2001-2009 | 4 years | strawberry/chocol ate/tomato | Both IgE and non-IgE mediated (no SPT or SIgE) | 13.4 [†] (11.2-16.0) n=819 | - | 2.1 ⁺ (1.3-3.4) n=819 | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 1 year | tomato | Both IgE and non-IgE mediated (no SPT or SIgE) | 7 (nr) n=261 | - | - | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 2 years | tomato | Both IgE and non-IgE mediated (no SPT or SIgE) | 7 (nr) n=202 | - | - | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 3 years | tomato | Both IgE and non-IgE mediated (no SPT or SIgE) | 11 (nr) n=200 | - | - | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 6 years | tomato | Both IgE and non-IgE mediated (no SPT or SIgE) | 2 (nr) n=203 | - | - | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 1 year | vegetables (peas) | Both IgE and non-IgE mediated (no SPT or SIgE) | 3 (nr) n=261 | - | - | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 2 years | vegetables (peas) | Both IgE and non-IgE mediated (no SPT or SIgE) | 2 (nr) n=202 | - | - | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 3 years | vegetables (peas) | Both IgE and non-IgE mediated (no SPT or SIgE) | 3 (nr) n=200 | - | - | - | - | - | - | - | - | - |
| Kajosaari (1982) | Finland | 1980-1981 | 6 years | vegetables (peas) | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.5 (nr) n=203 | - | - | - | - | _ | - | - | - | - |

| Study ID | Country | Year(s) study | Age group | Allergen | Type of food allergy | Questio | onnaire-based | methods | Sens | itisation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical | Other |
|---------------------|---------|---------------|-------------|--|---|--|---------------------|-------------------------|--------------------|-----------------------|----------------------------|----------------------|-----------------------|-----------------------|----------------------------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | lence (CI) | | | | |
| Touraine (2002) | France | 2000-2001 | 5-17 years | chocolate | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.5 [†] (0.9-2.4) n=1086 | - | - | - | - | - | - | - | - | - |
| Touraine (2002) | France | 2000-2001 | 5-17 years | garlic | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.5 [†] (0.9-2.4) n=1086 | - | - | - | - | - | - | - | - | - |
| Touraine (2002) | France | 2000-2001 | 5-17 years | honey | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.5 [†] (0.9-2.4) n=1086 | - | - | - | - | _ | _ | - | - | - |
| Touraine (2002) | France | 2000-2001 | 5-17 years | Latex- kiwi/melon/banan a/chestnut | Both IgE and non-IgE mediated (no SPT or SIgE) | 14 [†] (12.0-16.2) n=1086 | - | - | - | - | - | - | - | - | - |
| Touraine (2002) | France | 2000-2001 | 5-17 years | pork | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.5 [†] (0.9-2.4) n=1086 | - | - | - | - | - | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | additives | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | - | 0.3 (0.1-0.5) n=3156 |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | additives | Both IgE and non-IgE mediated | 0.7 [†] (nr) n=nr | - | - | - | - | - | - | - | - | - |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | alcohol (sparkling wine) | Both IgE and non-IgE mediated | 1.9 [†] (nr) n=nr | - | - | - | - | - | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | cacao | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | - | 0.1 (0.0-0.3) n=3156 |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | carob | Both IgE and non-IgE mediated | - | - | - | - | - | 0.9 (0.6-1.3) n=3156 | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | carrageen | Both IgE and non-IgE mediated | - | - | - | - | - | 0.2 (0.1-0.4) n=3156 | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | guargum | Both IgE and non-IgE mediated | - | - | - | - | - | 0.2 (0.1-0.5) n=3156 | - | - | - | - |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | herbs/spices | Both IgE and non-IgE mediated | $ \begin{array}{c} 1.1^{\dagger} \\ (nr) \\ n=nr \end{array} $ | - | - | - | - | - | - | - | - | - |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | meat | Both IgE and non-IgE mediated | 0.5 [†] (nr) n=nr | - | - | - | - | - | - | - | - | - |

| Study ID | Country | Year(s) study | Age group | Allergen | Type of food allergy | Questio | onnaire-based | methods | Sensi | itisation | Sensitisation hist | with clinical tory | Food challeng | ge with clinical tory | Other |
|-----------------------|---------|---------------|-------------|------------------------|---|--|---------------------|-------------------------|---|--|----------------------------|-----------------------|--------------------|----------------------------|----------------------------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | poppy seeds | Both IgE and non-IgE mediated | - | - | - | - | - | 0.7 (0.5-1.1) n=3156 | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | pork | Both IgE and non-IgE mediated | - | - | - | - | - | 0.2 (0.1-0.4) n=3156 | - | - | - | - |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | pork | Both IgE and non-IgE mediated | - | - | - | 2^{\dagger} (nr) n=nr | - | - | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | potato | Both IgE and non-IgE mediated | - | - | - | - | - | 4.9 (4.2-5.7) n=3156 | - | - | - | - |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | sugar | Both IgE and non-IgE mediated | 0.5^{\dagger} (nr) n=nr | - | - | - | - | - | - | - | - | - |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | tomato | Both IgE and non-IgE mediated | $ \begin{array}{c} 1.3^{\dagger} \\ (nr) \\ n=nr \end{array} $ | - | - | - | - | - | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | vegetables | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | 1.8 (1.4-2.4) n=3156 | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | vegetables | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | - | 0.3 (0.1-0.6) n=3156 |
| Schafer (2001) | Germany | 1997-1998 | 25-74 years | vegetables | Both IgE and non-IgE mediated | $ \begin{array}{c} 1.7^{\dagger} \\ (nr) \\ n=nr \end{array} $ | - | - | - | - | - | - | - | - | - |
| Zuberbier (2004) | Germany | 1999-2000 | 0-80+ years | vegetables (carrot) | Both IgE and non-IgE mediated | - | - | - | - | - | 3.6 (2.9-4.3) n=3156 | - | - | - | - |
| Zannikos (2008) | Greece | 2007 | 7-13 years | chocolate | Both IgE and non IgE mediated (no SPT or SIgE) | 1.9 [†] (1.3-2.6) n=1988 | - | - | - | - | - | - | - | - | - |
| Sakellariou (2008) | Greece | 2007 | 20-54 years | chocolate | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.9 [†] (nr) n=2003 | - | - | - | - | - | - | - | - | - |
| Sakellariou (2008) | Greece | 2007 | 20-54 years | meat | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.8 [†] (nr) n=2003 | - | - | - | - | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 20-69 years | potato | IgE mediated only | - | - | - | $ \begin{array}{c} \hline 2.8^{\dagger} \\ (0.2-16.2) \\ n=36 \end{array} $ | 0^{\dagger} (0-12.0) n=36 | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 60-97 years | Potato | IgE mediated only | - | - | - | 2.8 [†] (0.7-8.4) n=109 | 3.7 [†] (1.2-9.7) n=109 | - | - | - | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) study | Age group | Allergen | Type of food allergy | Questio | onnaire-based | methods | Sensi | tisation | Sensitisation hist | with clinical tory | Food challeng hist | e with clinical fory | Other |
|------------------------|---------|---------------|--------------|------------------------|---|--|---------------------|-------------------------|--|---|------------------------------------|-----------------------|-----------------------|-------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | lence (CI) | | | | |
| Bakos (2006) | Hungary | 2002-2004 | 20-69 years | tomato | IgE mediated only | - | - | - | - | - | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 60-97 years | tomato | IgE mediated only | - | - | - | - | 2.8 [†] (0.7-8.4) n=109 | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 20-69 years | vegetables (carrot) | IgE mediated only | - | - | - | 8.3 [†] (2.2-23.6) n=36 | 2.8^{\dagger} (0.2-16.2) n=36 | - | - | - | - | - |
| Bakos (2006) | Hungary | 2002-2004 | 60-97 years | vegetables (carrot) | IgE mediated only | - | - | - | 3.7 [†] (1.2-9.7) n=109 | 7.3 [†] (3.5-14.4) n=109 | - | - | - | - | - |
| Kristjansson (1999) | Iceland | 1994 | 18 months | Chicken | Both IgE and non-IgE mediated | 0.6^{\dagger} (0.1-2.5) n=324 | - | - | - | - | - | - | - | - | - |
| Kristjansson (1999) | Iceland | 1994 | 18 months | Chocolate | Both IgE and non-IgE mediated | $ \begin{array}{c} 1.5^{\dagger} \\ (0.6-3.8) \\ n=324 \end{array} $ | - | - | - | - | - | - | - | - | - |
| Kristjansson (1999) | Iceland | 1994 | 18 months | Tomato | Both IgE and non-IgE mediated | 3.1 [†] (1.6-5.8) n=324 | - | - | - | - | - | - | - | - | - |
| Kristjansson (1999) | Iceland | 1994 | 18 months | vegetables (carrot) | Both IgE and non-IgE mediated | $\begin{array}{c} 0.9^{+} \\ (0.2 - 2.9) \\ n = 324 \end{array}$ | - | - | - | - | - | - | - | - | - |
| Kristjansson (1999) | Iceland | 1994 | 18 months | vegetables (peas) | Both IgE and non-IgE mediated | $ \begin{array}{c} 1.5^{\dagger} \\ (0.6-3.8) \\ n=324 \end{array} $ | - | - | - | - | 0 [†] (0-1.5) n=324 | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 0-6 months | additives | Both IgE and non-IgE mediated (no SPT or SIgE) | 0 [†] (0-6.1) n=75 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 12-24 months | additives | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.3 [†] (0.2-5.2) n=150 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 24-36 months | additives | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.7 [†] (0.0-4.2) n=150 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 36-48 months | additives | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.7 [†] (0.0-4.2) n=150 | - | - | - | _ | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 6-12 months | additives | Both IgE and non-IgE mediated (no SPT or SIgE) | 0 [†] (0-6.1) n=75 | - | - | - | - | - | - | - | - | - |

| Study ID | Country | Year(s) study | Age group | Allergen | Type of food allergy | Questi | onnaire-based | methods | Sens | itisation | Sensitisation hist | with clinical tory | Food challeng hist | e with clinical tory | Other |
|---------------------|---------|---------------|--------------|-------------|---|--|---------------------|-------------------------|--------------------|-----------------------|-----------------------|-----------------------|-----------------------|-------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | 0 | | 95% Prevs | lence (CI) | 0 | | | |
| Kilgallen | Ireland | nr | 0-6 months | colourings | Both IgE and | 0 [†] | _ | - | - | - | - | - | - | - | _ |
| (1996) | | | | | non-IgE mediated (no SPT or SIgE) | (0-6.1) n=75 | | | | | | | | | |
| Kilgallen (1996) | Ireland | nr | 12-24 months | colourings | Both IgE and non-IgE mediated (no SPT or SIgE) | 2.7 [†] (0.9-7.1) n=150 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 24-36 months | colourings | Both IgE and non-IgE mediated (no SPT or SIgE) | 2^{\dagger} (0.5-6.2) n=150 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 36-48 months | colourings | Both IgE and non-IgE mediated (no SPT or SIgE) | 4.7 [†] (2.1-9.8) n=150 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 6-12 months | colourings | Both IgE and non-IgE mediated (no SPT or SIgE) | 0 [†] (0-6.1) n=75 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 0-6 months | soft drinks | Both IgE and non-IgE mediated (no SPT or SIgE) | 0 [†] (0-6.1) n=75 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 6-12 months | soft drinks | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.3 [†] (0.1-8.2) n=75 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 12-24 months | soft drinks | Both IgE and non-IgE mediated (no SPT or SIgE) | 6 [†] (3.0-11.4) n=150 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 24-36 months | soft drinks | Both IgE and non-IgE mediated (no SPT or SIgE) | 2.7 [†] (0.9-7.1) n=150 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 36-48 months | soft drinks | Both IgE and non-IgE mediated (no SPT or SIgE) | 6 [†] (3.0-11.4) n=150 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 0-6 months | sweets | Both IgE and non-IgE mediated (no SPT or SIgE) | 0 [†] (0-6.1) n=75 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 6-12 months | sweets | Both IgE and non-IgE mediated (no SPT or SIgE) | 2.7 [†] (0.5-10.2) n=75 | - | - | - | - | - | - | - | - | - |

| Study ID | Country | Year(s) study | Age group | Allergen | Type of food allergy | Questio | onnaire-based | methods | Sens | itisation | Sensitisation hist | with clinical tory | Food challeng hist | e with clinical | Other |
|---------------------|----------|---------------|--------------|------------|---|---|---------------------|---|--|-----------------------|-----------------------|---------------------|-----------------------|-----------------------|--|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | L | | | | 95% Preva | alence (CI) | | | I | |
| Kilgallen (1996) | Ireland | nr | 12-24 months | sweets | Both IgE and non-IgE mediated (no SPT or SIgE) | 4.7 [†] (2.1-9.8) n=150 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 24-36 months | sweets | Both IgE and non-IgE mediated (no SPT or SIgE) | 7.3 [†] (3.9-13.1) n=150 | - | - | - | - | - | - | - | - | - |
| Kilgallen (1996) | Ireland | nr | 36-48 months | sweets | Both IgE and non-IgE mediated (no SPT or SIgE) | 3.3 [†] (1.2-8.0) n=150 | - | - | - | - | - | - | - | - | - |
| Frongia (2005) | Italy | 2003 | 12-24 months | tomato | Both IgE and non-IgE mediated (no SPT or SIgE) | - | - | 0.6 [†] (0.4-0.8) n=4602 | - | - | - | - | - | - | - |
| Ronchetti (2008) | Italy | 2005 - 2006 | 9 years | tomato | Both IgE and non-IgE mediated | - | - | - | 1.1 [†] (0.2-4.3) n=184 | - | - | - | - | - | 4.3 [†] (2.0-8.7) n=184 |
| Ronchetti (2008) | Italy | 2005 - 2006 | 13 years | tomato | Both IgE and non-IgE mediated | - | - | - | 3.1 [†] (1.3-6.9) n=196 | - | - | - | - | - | 3.8 [†] (1.6-8.6) n=156 |
| Eggesbo (1999) | Norway | 1993-1995 | 1 year | chocolate | Both IgE and non-IgE mediated | 0.8 (0.6-1.2) n=3366 | - | - | - | - | - | - | - | - | - |
| Eggesbo (1999) | Norway | 1993-1995 | 18 months | chocolate | Both IgE and non-IgE mediated | 1.3 (0.9-1.8) n=3278 | - | - | - | - | - | - | - | - | - |
| Eggesbo (1999) | Norway | 1993-1995 | 2 years | chocolate | Both IgE and non-IgE mediated | 1.9 (1.4-2.4) n=2979 | - | - | - | - | - | - | - | - | - |
| Eggesbo (1999) | Norway | 1993-1995 | 1 year | vegetables | Both IgE and non-IgE mediated | 3.3 (2.7-4.1) n=3366 | - | - | - | - | - | - | - | - | - |
| Eggesbo (1999) | Norway | 1993-1995 | 18 months | vegetables | Both IgE and non-IgE mediated | 2.9 (2.3-3.6) n=3278 | - | - | - | - | - | - | - | - | - |
| Eggesbo (1999) | Norway | 1993-1995 | 2 years | vegetables | Both IgE and non-IgE mediated | 3.3 (2.7-4.0) n=2979 | - | - | - | - | - | - | - | - | = |
| Falcao (2004) | Portugal | nr | >39 years | Chocolate | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.3 [†] (0-1.2) n=659 | - | - | - | - | - | - | - | - | - |
| Falcao (2004) | Portugal | nr | >39 years | Legumes | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.3 [†] (0-1.2) n=659 | - | - | - | - | - | - | - | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) study | Age group | Allergen | Type of food allergy | Questio | onnaire-based | methods | Sens | itisation | Sensitisation hist | with clinical tory | Food challeng hist | ge with clinical tory | Other |
|----------------------------|--------------------|---------------|------------|------------------------|---|--|---------------------|-------------------------|--------------------|-----------------------|------------------------------------|-----------------------|-----------------------|--------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | lence (CI) | | | | |
| Falcao (2004) | Portugal | nr | >39 years | Meat | Both IgE and non-IgE mediated (no SPT or SIgE) | 1.8 [†] (1-3.2) n=659 | - | - | - | - | - | - | - | - | - |
| Falcao (2004) | Portugal | nr | >39 years | Spices | Both IgE and non-IgE mediated (no SPT or SIgE) | 0.3 [†] (0-1.2) n=659 | - | - | - | - | - | - | - | - | - |
| Martinez- Gimeno (2000) | Spain | nr | 6-13 years | legumes | Both IgE and non-IgE mediated (no SPT or SIgE) | 12.6 [†] (11.7-13.6) n=5163 | - | - | - | - | - | - | - | - | - |
| Kristjansson (1999) | Sweden | 1994 | 18 months | Chicken | Both IgE and non-IgE mediated | 0 [†] (0-1.4) n=328 | - | - | - | - | - | - | - | - | - |
| Kristjansson (1999) | Sweden | 1994 | 18 months | Chocolate | Both IgE and non-IgE mediated | 3.4 [†] (1.8-6.1) n=328 | - | - | - | - | - | - | - | - | - |
| Ostblom (2008 a) | Sweden | 1999-2000 | 4 years | Chocolate | Both IgE and non-IgE mediated | 2.6 [†] (2.0-3.3) n=2563 | - | - | - | - | - | - | - | - | - |
| Kristjansson (1999) | Sweden | 1994 | 18 months | Tomato | Both IgE and non-IgE mediated | 13.7 [†] (10.3-18.0) n=328 | - | - | - | - | - | - | - | - | - |
| Kristjansson (1999) | Sweden | 1994 | 18 months | vegetables (carrot) | Both IgE and non-IgE mediated | 1.5 [†] (0.6-3.7) n=328 | - | - | - | - | - | - | - | - | - |
| Kristjansson (1999) | Sweden | 1994 | 18 months | vegetables (peas) | Both IgE and non-IgE mediated | 0 [†] (0-1.4) n=328 | - | - | - | - | 0 [†] (0-1.4) n=328 | - | - | - | - |
| Ostblom (2008 a) | Sweden | 1999-2000 | 4 years | vegetables (peas) | Both IgE and non-IgE mediated | 1.2 [†] (0.9-1.8) n=2563 | - | - | - | - | - | - | - | - | - |
| Brugman (1998) | The Netherlands | 1993- 1994 | 4-15 years | additives | Both IgE and non-IgE (no SPT or SIgE) | 3.1 [†] (2.6-3.6) n=4400 | - | - | - | - | - | - | - | - | - |
| Brugman (1998) | The Netherlands | 1993- 1994 | 4-15 years | chocolate | Both IgE and non-IgE (no SPT or SIgE) | 2.7 [†] (2.2-3.2) n=4400 | - | - | - | - | - | - | - | - | - |
| Brugman (1998) | The Netherlands | 1993- 1994 | 4-15 years | mayonnaise | Both IgE and non-IgE (no SPT or SIgE) | 1^{\dagger} (0.7-1.3) n=4400 | - | - | - | - | - | - | - | - | - |
| Brugman (1998) | The Netherlands | 1993- 1994 | 4-15 years | pork | Both IgE and non-IgE (no SPT or SIgE) | 1.5 [†] (1.2-1.9) n=4400 | - | - | - | - | - | - | - | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) study | Age group | Allergen | Type of food allergy | Questi | onnaire-based | methods | Sens | itisation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical | Other |
|----------------------|--------------------|---------------|-------------|--------------|---|---|---------------------|-------------------------|--------------------|-----------------------|---|-------------------------|-----------------------------|---|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | lence (CI) | | | | |
| Brugman (1998) | The Netherlands | 1993- 1994 | 4-15 years | soft drinks | Both IgE and non-IgE (no SPT or SIgE) | 1.2 [†] (0.9-1.6) n=4400 | - | - | - | - | - | - | - | - | - |
| Brugman (1998) | The Netherlands | 1993- 1994 | 4-15 years | sugar | Both IgE and non-IgE (no SPT or SIgE) | 1.4 [†] (1.1-1.8) n=4400 | - | - | - | - | - | - | - | - | - |
| Brugman (1998) | The Netherlands | 1993- 1994 | 4-15 years | tomato | Both IgE and non-IgE (no SPT or SIgE) | 0.7 [†] (0.5-1.0) n=4400 | - | - | - | - | - | - | - | - | - |
| Gelincik (2008) | Turkey | nr | 18 years + | additives | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | - | 0.0^{\dagger} (0.0-0.1) n=11816 | - |
| Orhan (2009) | Turkey | 2006 | 6-9 years | beef | IgE mediated only | 1.4 ' (1 - 1.9) n=2739 | - | - | - | - | 0.3 ' (0.2 - 0.7) n=2739 | - | - | 0.3 ' (0.1 - 0.6) n=2739 | - |
| Mustafayev (2012) | Turkey | 2010 | 10-11 years | beef | IgE mediated only | - | - | - | - | - | - | - | 0.2 ' (0.0-1.0) n=813 | - | - |
| Orhan (2009) | Turkey | 2006 | 6-9 years | black pepper | IgE mediated only | 0.2 [†] (0.1 - 0.5) n=2739 | - | - | - | - | 0.1 [†] (0.1 - 0.4) n=2739 | - | - | 0^{\dagger} (0 - 0.2) n=2739 | - |
| Gelincik (2008) | Turkey | nr | 18 years + | black pepper | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | - | 0^{\dagger} (0-0.1) n=11816 | - |
| Gelincik (2008) | Turkey | nr | 18 years + | cacao | Both Ige and non-IgE mediated | 1 [†] (0.9-1.2) n=11816 | - | - | - | - | - | - | - | - | - |
| Orhan (2009) | Turkey | 2006 | 6-9 years | Chickpea | IgE mediated only | 0.2 [†] (0.1 - 0.5) n=2739 | - | - | - | - | 0.1 [†] (0 - 0.3) n=2739 | - | - | 0 [†] (0 - 0.2) n=2739 | - |
| Gelincik (2008) | Turkey | nr | 18 years + | Chocolate | Both Ige and non-IgE mediated | 1 [‡] (0.9-1.2) n=11816 | - | - | - | - | - | (0-0.0) n=11816 | - | 0 [†] (0-0.1) n=11816 | - |
| Orhan (2009) | Turkey | 2006 | 6-9 years | Cocoa | IgE mediated only | 3 [†] (2.4 - 3.7) n=2739 | - | - | - | - | 0.5 [†] (0.3 - 0.8) n=2739 | - | - | 0.1 [†] (0.1 - 0.4) n=2739 | - |
| Gelincik (2008) | Turkey | nr | 18 years + | Eggplant | Both Ige and non-IgE mediated | 0.4 [‡] (0.3-0.6) n=11816 | - | - | - | - | 0 [†] (0.0-0.1) n=11816 | 0 (0-0.1) n=11816 | - | 0 [†] (0-0.1) n=11816 | - |
| Gelincik (2008) | Turkey | nr | 18 years + | garlic | Both Ige and non-IgE mediated | 0.1 [‡] (0-0.2) n=11816 | - | - | - | - | - | - | - | - | - |
| Gelincik (2008) | Turkey | nr | 18 years + | Meat | Both Ige and non-IgE mediated | 0.3 [‡] (0.2-0.4) n=11816 | - | - | - | - | - | - | - | 0 [†] (0-0.0) n=11816 | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) study | Age group | Allergen | Type of food allergy | Questi | onnaire-based | methods | Sensi | itisation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical tory | Other |
|----------------------|-------------------|---------------|--------------|------------------------|---|---|---------------------|-------------------------|--------------------|-----------------------|--|---------------------------|--|---|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | L | | | | 95% Preva | lence (CI) | | | 11 | |
| Gelincik (2008) | Turkey | nr | 18 years + | Mushroom | Both Ige and non-IgE mediated | 0.2 [‡] (0.1-0.3) n=11816 | - | - | - | - | - | - | - | - | - |
| Gelincik (2008) | Turkey | nr | 18 years + | Pickle | Both Ige and non-IgE mediated | 0.3 [‡] (0.2-0.4) n=11816 | - | - | - | - | - | - | - | 0 [†] (0-0.0) n=11816 | - |
| Orhan (2009) | Turkey | 2006 | 6-9 years | Potato | IgE mediated only | 0.1 [†] (0 - 0.3) n=2739 | - | - | - | - | 0 [†] (0 - 0.2) n=2739 | - | - | 0 [†] (0 - 0.2) n=2739 | - |
| Gelincik (2008) | Turkey | nr | 18 years + | Potato | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | - | 0^{\dagger} (0-0.1) n=11816 | - |
| Gelincik (2008) | Turkey | nr | 18 years + | Red chilli | Both Ige and non-IgE mediated | - | - | - | - | - | - | - | - | 0^{\dagger} (0-0.1) n=11816 | - |
| Gelincik (2008) | Turkey | nr | 18 years + | Spices | Both Ige and non-IgE mediated | 0.5 * (0.4-0.6) n=11816 | - | - | - | - | - | - | - | 0' (0-0.0) n=11816 | - |
| Mustafayev (2012) | Turkey | 2010 | 10-11 years | spinach | IgE mediated only | - | - | - | - | - | - | - | 0.1 [†] (0.0-0.8) n=813 | - | - |
| Gelincik (2008) | Turkey | nr | 18 years + | Spinach | Both Ige and non-IgE mediated | - | - | - | - | - | 0 [†] (0-0.1) n=11816 | 0 (0-0.0) n=11816 | - | 0 [†] (0-0.1) n=11816 | - |
| Orhan (2009) | Turkey | 2006 | 6-9 years | Tomato | IgE mediated only | 0.3 [†] (0.1 - 0.6) n=2739 | - | - | - | - | 0.1 [†] (0 - 0.3) n=2739 | - | - | 0.0 [†] (0 - 0.2) n=2739 | - |
| Gelincik (2008) | Turkey | nr | 18 years + | Tomato | Both Ige and non-IgE mediated | 2.3 [‡] (2.0-2.5) n=11816 | - | - | - | - | 0.1 [†] (0.0-0.1) n=11816 | 0 (0.0-0.1) n=11816 | - | 0.1 [†] (0-0.1) n=11816 | - |
| Gelincik (2008) | Turkey | nr | 18 years + | vegetables (carrot) | Both Ige and non-IgE mediated | - | - | - | - | - | 0 [†] (0-0.1) n=11816 | 0 (0-0.1) n=11816 | - | 0 [†] (0-0.1) n=11816 | - |
| Pereira (2005) | United Kingdom | 2002-2003 | 11 year olds | additives | Both IgE and non-IgE mediated | 3.4 [†] (2.2-4.9) n=775 | - | - | - | - | - | - | - | - | - |
| Pereira (2005) | United Kingdom | 2002-2003 | 15 year olds | additives | Both IgE and non-IgE mediated | 1.8 [†] (1.1-3.2) n=757 | - | - | - | - | - | - | - | - | - |
| Venter (2006) | United Kingdom | 2003-2004 | 6 years | additives | Both IgE and non-IgE mediated | 1.6 [†] (0.9-2.9) n=798 | - | - | - | - | - | - | 0 [†] (0-0.6) n=798 | 0 [†] (0-0.6) n=798 | - |
| Young (1994) | United Kingdom | nr | All ages | additives | Both IgE and non IgE mediated (no SPT or SIgE) | 5.3 [†] (5.0-5.6) n=18880 | - | - | - | - | - | - | - | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) study | Age group | Allergen | Type of food allergy | Questio | onnaire-based | methods | Sensi | itisation | Sensitisation hist | with clinical tory | Food challeng hist | e with clinical tory | Other |
|---------------|-------------------|---------------|------------|------------|---|--|---------------------|-------------------------|--------------------|-----------------------|-----------------------|-----------------------|-----------------------|-------------------------|--|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | lence (CI) | | | | |
| Young (1994) | United Kingdom | nr | All ages | alcohol | Both IgE and non IgE mediated (no SPT or SIgE) | 1.4 [†] (1.2-1.6) n=18880 | - | - | - | - | - | - | - | - | - |
| Young (1994) | United Kingdom | nr | All ages | caffeine | Both IgE and non IgE mediated (no SPT or SIgE) | 1.3 [†] (1.1-1.5) n=18880 | - | - | - | - | - | - | - | - | - |
| Emmett (1999) | United Kingdom | 1995-1996 | 15 + years | Chocolate | Both Ige and non-IgE mediated | 0.2^{\dagger} (0.1-0.3) n=16420 | - | - | - | - | - | - | - | - | - |
| Young (1994) | United Kingdom | nr | All ages | chocolate | Both IgE and non IgE mediated (no SPT or SIgE) | 6.7 [†] (6.4-7.1) n=18880 | - | - | - | - | - | - | - | - | - |
| Young (1994) | United Kingdom | nr | All ages | meat | Both IgE and non IgE mediated (no SPT or SIgE) | 1.9 [†] (1.7-2.1) n=18880 | - | - | - | - | - | - | - | - | - |
| Emmett (1999) | United Kingdom | 1995-1996 | 15 + years | Pulses | Both Ige and non-IgE mediated | 0 [†] (0-0.1) n=16420 | - | - | - | - | - | - | - | - | - |
| Venter (2008) | United Kingdom | 2001-2005 | 1 year | salicylate | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | - | 0.1 [†] (0.0-0.7) n=900 |
| Venter (2008) | United Kingdom | 2001-2005 | 2 years | salicylate | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | - | 0.1^{\dagger} (0.0-0.8) n=858 |
| Venter (2008) | United Kingdom | 2001-2005 | 3 years | salicylate | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | - | 0.1^{\dagger} (0.0-0.2) n=891 |
| Venter (2008) | United Kingdom | 2001-2005 | 1 year | tomato | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | - | 0.1 [↑] (0.0-0.7) n=900 |
| Venter (2008) | United Kingdom | 2001-2005 | 2 years | tomato | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | - | 0 [†] (0-0.6) n=858 |
| Venter (2008) | United Kingdom | 2001-2005 | 3 years | tomato | Both IgE and non-IgE mediated | - | - | - | - | - | - | - | - | - | 0 [†] (0-0.5) n=891 |
| Young (1994) | United Kingdom | nr | All ages | tomato | Both IgE and non IgE mediated (no SPT or SIgE) | 1.2 [†] (1.1-1.4) n=18880 | - | - | - | - | - | - | - | - | - |
| Young (1994) | United Kingdom | nr | All ages | vegetables | Both IgE and non IgE mediated (no SPT or SIgE) | 0.5 [†] (0.4-0.6) n=18880 | - | - | - | - | - | - | - | - | - |

[†] Percentage prevalence and/or confidence intervals calculated from raw data provided in the paper

^{*}Percentage prevalence inferred from graph provided (no raw data reported).

[#]Data has been subject to correction or estimation by the authors (presented as reported in the paper).

Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questi | onnaire-based m | ethods | Sensit | isation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical ory | Other |
|--------------|-----------|---------------------|------------|---|-------------------------------------|--|------------------|-------------------------|-----------------|-----------------------|-----------------------|----------------------|-----------------------|------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | lence (CI) | | · | | |
| Woods (1998) | Australia | 1998 | 20-44years | alcohol | Both IgE and non IgE mediated | 0.9 [†] (0.4-2.1) n=669 | - | - | - | - | - | - | - | - | - |
| Woods (1998) | Australia | 1998 | 20-44years | chocolate | Both IgE and non IgE mediated | 0.7 [†] (0.3-1.8) n=669 | - | - | - | - | - | - | - | - | - |
| Woods (1998) | Australia | 1998 | 20-44years | Fats/oils, butter, margarine/ cream/ salad dressing | Both IgE and non IgE mediated | 0.7 [†] (0.3-1.8) n=669 | - | - | - | - | - | - | - | - | - |
| Woods (1998) | Australia | 1998 | 20-44years | herbs/spices/condi ments/ garlic, chilli | Both IgE and non IgE mediated | 1 [†] (0.5-2.3) n=669 | - | - | - | _ | - | - | - | - | - |
| Woods (1998) | Australia | 1998 | 20-44years | High fat foods | Both IgE and non IgE mediated | 0.6 [†] (0.2-1.6) n=669 | - | - | - | - | - | - | - | - | - |
| Woods (1998) | Australia | 1998 | 20-44years | meat | Both IgE and non IgE mediated | 0.3 [†] (0.1-1.2) n=669 | - | - | - | - | - | - | - | - | - |
| Woods (1998) | Australia | 1998 | 20-44years | meat (red) | Both IgE and non IgE mediated | 0.7 [†] (0.3-1.8) n=669 | - | - | - | - | - | - | - | - | - |
| Woods (1998) | Australia | 1998 | 20-44years | Monosodium glutamate | Both IgE and non IgE mediated | 0.9 [†] (0.4-2.1) n=669 | - | - | - | - | - | - | - | - | - |
| Woods (1998) | Australia | 1998 | 20-44years | Poultry | Both IgE and non IgE mediated | 0.3 [†] (0.1-1.2) n=669 | - | - | - | - | - | - | - | - | - |
| Woods (1998) | Australia | 1998 | 20-44years | Restaurant meals/take away meals | Both IgE and non IgE mediated | 0.3 [†] (0.1-1.2) n=669 | - | - | - | - | - | - | - | - | - |
| Woods (1998) | Australia | 1998 | 20-44years | Sauces | Both IgE and non IgE mediated | 0.3 [†] (0.1-1.2) n=669 | - | - | - | - | - | - | - | - | - |

Table 1.32: All Other Foods allergy prevalence in non-European countries by age group

EFSA supporting publication 2013:EN-506

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questi | onnaire-based m | ethods | Sensit | isation | Sensitisation hist | with clinical tory | Food challeng | e with clinical tory | Other |
|-------------------|-----------|---------------------|------------|-------------|---|---|------------------|-------------------------|-----------------|-----------------------|-----------------------|-----------------------|--------------------|-------------------------|--|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | lence (CI) | | | | |
| Woods (1998) | Australia | 1998 | 20-44years | Spicy foods | Both IgE and non IgE mediated | 0.3 [†] (0.1-1.2) n=669 | - | - | - | - | - | - | - | - | - |
| Woods (1998) | Australia | 1998 | 20-44years | sugar | Both IgE and non IgE mediated | 0.3 [†] (0.1-1.2) n=669 | - | - | - | - | - | - | - | - | - |
| Woods (1998) | Australia | 1998 | 20-44years | Tea/coffee | Both IgE and non IgE mediated | 0.3 [†] (0.1-1.2) n=669 | - | - | - | - | - | - | - | - | - |
| Woods (1998) | Australia | 1998 | 20-44years | vegetables | Both IgE and non IgE mediated | 0.7 [†] (0.3-1.8) n=669 | - | - | - | - | - | - | - | - | - |
| Soller (2012) | Canada | 2008-2009 | <18 years | vegetables | "likely" IgE mediated (no SPT or SIgE) | 0.45 (0.17-0.74) n=nr | - | - | - | - | - | - | - | - | - |
| Soller (2012) | Canada | 2008-2009 | >18 years | vegetables | "likely" IgE mediated (no SPT or SIgE) | 1.29 (1.02-1.55) n=nr | - | - | - | - | - | - | - | - | - |
| Sai (2011) | China | 2008-2009 | adults | Beef | IgG mediated only | - | - | - | - | - | - | - | - | - | 2.1 [†] (1.9-2.4) n=12766 |
| Sai (2011) | China | 2008-2009 | adults | Chicken | IgG mediated only | - | - | - | - | - | - | - | - | - | 1.6 [†] (1.4-1.9) n=12766 |
| Sai (2011) | China | 2008-2009 | adults | Mushroom | IgG mediated only | - | - | - | - | - | - | - | - | - | 1.2 [†] (1.0-1.4) n=12766 |
| Sai (2011) | China | 2008-2009 | adults | Pork | IgG mediated only | - | - | - | - | - | - | - | - | - | 0.4 [†] (0.3-0.6) n=12766 |
| Sai (2011) | China | 2008-2009 | adults | Rice | IgG mediated only | - | - | - | - | - | - | - | - | - | 2.3 [†] (2.1-2.6) n=12766 |
| Sai (2011) | China | 2008-2009 | adults | Sweetcorn | IgG mediated only | - | - | - | - | - | - | - | - | - | 4.2 [†] (3.9-4.6) n=12764 |
| Sai (2011) | China | 2008-2009 | adults | Tomato | IgG mediated only | - | - | - | - | - | - | - | - | - | 4.3 [†] (3.9-4.7) n=12766 |
| Marrugo (2008) | Colombia | Nr | All ages | additives | Both IgE and non-IgE mediated (no SPT or SIgE) | $ \begin{array}{c} 0.4^{\dagger} \\ (0.2-0.7) \\ n=3099 \end{array} $ | - | - | - | - | - | - | - | - | - |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Quest | ionnaire-based m | ethods | Sensit | tisation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical ory | Other |
|-------------------|----------|---------------------|------------|-----------|---|---|------------------|-------------------------|-----------------|-----------------------|-----------------------|----------------------|-----------------------|------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Marrugo (2008) | Colombia | Nr | All ages | alcohol | Both IgE and non-IgE mediated (no SPT or SIgE) | 2 [†] (1.5-2.5) n=3099 | - | - | - | - | - | - | - | - | - |
| Marrugo (2008) | Colombia | Nr | All ages | meat | Both IgE and non-IgE mediated (no SPT or SIgE) | 3.1 [†] (2.5-3.8) n=3099 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | Avocado | IgE mediated only | 0.3 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | Beans | IgE mediated only | 1.3 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | Cassava | IgE mediated only | 0.6 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | Coconut | IgE mediated only | 0.1 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | Cocoyam | IgE mediated only | 0.1 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | Kontomire | IgE mediated only | 0.4 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | Nutmeg | IgE mediated only | 0.3 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | Okro | IgE mediated only | 0.9 (nr) n=1407 | - | - | _ | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | Potato | IgE mediated only | 0.1 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | Rice | IgE mediated only | 0.1 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | Sorghum | IgE mediated only | 0.4 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| | | | | | | | | | | | | | | | |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questi | onnaire-based m | ethods | Sensiti | isation | Sensitisation hist | with clinical ory | Food challeng | e with clinical ory | Other |
|--------------|-----------|---------------------|------------|---------------------|--|---|---------------------------------------|-------------------------|--|-----------------------|---------------------------------------|---------------------------|--------------------|------------------------|---|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | lence (CI) | | | | |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | Sweet potato | IgE mediated only | 0.3 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | Tomato | IgE mediated only | 0 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | vegetables (carrot) | IgE mediated only | 0.1 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Obeng (2011) | Ghana | 2006-2008 | 5-16 years | Water yam | IgE mediated only | 0.1 (nr) n=1407 | - | - | - | - | - | - | - | - | - |
| Leung (2009) | Hong Kong | 2006-2007 | 2-7 years | Beef | IgE mediated only (no SPT or SIgE) | 0.5 [†] (0.3-0.8) n=3677 | - | - | - | - | - | - | - | - | 0.3 [†] (0.2-0.6) n=3677 |
| Leung (2009) | Hong Kong | 2006-2007 | 2-7 years | Chocolate | IgE mediated only (no SPT or SIgE) | 0.3 [†] (0.2-0.6) n=3677 | - | - | - | _ | - | - | - | - | 0.3 [†] (0.2-0.6) n=3677 |
| Leung (2009) | Hong Kong | 2006-2007 | 2-7 years | Lamb | IgE mediated only (no SPT or SIgE) | 0.2 [†] (0.1-0.5) n=3677 | - | - | - | - | - | - | - | - | 0.1 [†] (0.1-0.5) n=3677 |
| Leung (2009) | Hong Kong | 2006-2007 | 2-7 years | Tomato | IgE mediated only (no SPT or SIgE) | 0.2 [†] (0.1-0.5) n=3677 | - | - | - | - | - | - | - | - | 0.2 [†] (0.1-0.5) n=3677 |
| Babu (2008) | India | nr | 5-60 years | eggplant | IgE mediated only | 9.2 [†] (7.3-11.6) n=741 | - | - | 6.5 [†] (4.9-8.6) n=741 | - | - | 0.8 (0.3-1.9) n=741 | - | - | - |
| Dalal (2002) | Israel | nr | 0-2years | beef | IgE mediated only | - | 0 [†] (0 - 0.1) n=9070 | - | - | - | 0 [†] (0 - 0.1) n=9070 | - | - | - | - |
| Dalal (2002) | Israel | nr | 0-2years | chicken | IgE mediated only | - | 0 [†] (0 - 0.1) n=9070 | - | - | - | 0 [†] (0 - 0.1) n=9070 | - | - | - | - |
| Dalal (2002) | Israel | nr | 0-2years | chocolate | IgE mediated only | - | 0 [†] (0 - 0.1) n=9070 | - | - | - | 0 [†] (0 - 0.1) n=9070 | - | - | - | - |
| Dalal (2002) | Israel | nr | 0-2years | garlic | IgE mediated only | - | 0 [†] (0 - 0.1) n=9070 | - | - | - | 0 [†] (0 - 0.1) n=9070 | - | - | - | - |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questi | onnaire-based m | ethods | Sensit | isation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical ory | Other |
|--------------|---------|---------------------|-------------|---------------|--|---|---------------------------------------|---------------------------------------|-----------------|-----------------------|---------------------------------------|----------------------------|-----------------------|------------------------|-------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | lence (CI) | | | | |
| Dalal (2002) | Israel | nr | 0-2years | tomato | IgE mediated only | - | 0 [†] (0 - 0.1) n=9070 | - | - | - | 0 [†] (0 - 0.1) n=9070 | - | - | - | - |
| Oh (2004) | Korea | 2000 | 12-15 years | Beef | IgE mediated only (no SPT or SIgE) | 0.4 [†] (0.3-0.6) n=14777 | - | - | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 6-12 years | Beef | IgE mediated only (no SPT or SIgE) | $\begin{array}{c} 0.2^{\dagger} \\ (0.2 \text{-} 0.3) \\ n = 27425 \end{array}$ | - | - | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 6-12 years | Beef | IgE mediated only (no SPT or SIgE) | 0.2 [†] (0.2-0.3 n=27425 | - | - | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 12-15 years | Buckwheat | IgE mediated only (no SPT or SIgE) | 0.1 [†] (0.1-0.2) n=14777 | - | - | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 6-12 years | Buckwheat | IgE mediated only (no SPT or SIgE) | 0.1 [†] (0.1-0.1) n=27425 | - | - | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 12-15 years | chicken | IgE mediated only (no SPT or SIgE) | 0.2 [†] (0.2-0.3) n=14777 | - | - | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 6-12 years | chicken | IgE mediated only (no SPT or SIgE) | 0.3 [†] (0.3-0.4) n=27425 | - | - | - | - | - | - | - | - | - |
| Kim (2011) | Korea | 2006-2007 | 0-12 months | perilla seeds | IgE mediated only (no SPT or SIgE) | - | - | 0.1 [†] (0-0.5) n=1177 | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 12-15 years | Pork | IgE mediated only (no SPT or SIgE) | 0.3 [†] (0.3-0.5) n=14777 | - | - | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 6-12 years | Pork | IgE mediated only (no SPT or SIgE) | 0.5 [†] (0.4-0.6) n=27425 | - | - | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 12-15 years | Tomato | IgE mediated only (no SPT or SIgE) | 0 [†] (0.0-0.1) n=14777 | - | - | - | - | - | - | - | - | - |
| Oh (2004) | Korea | 2000 | 6-12 years | Tomato | IgE mediated only (no SPT or SIgE) | 0 [†] (0.0-0.1) n=27425 | - | - | - | - | - | - | - | - | - |
| Wan (2012) | Taiwan | nr | 6-8 years | bamboo shoot | IgE mediated only | - | - | - | - | - | - | 1.2 (0.7-2.1) n=1010 | - | - | - |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questi | ionnaire-based m | ethods | Sensit | isation | Sensitisation hist | with clinical ory | Food challeng hist | e with clinical ory | Other |
|----------------------|--|---------------------|----------------------|------------|--|--|------------------|--|-----------------|-----------------------|-----------------------|------------------------------|------------------------------------|------------------------|---|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | alence (CI) | | | | |
| Wan (2012) | Taiwan | nr | 6-8 years | cacao | IgE mediated only | - | - | - | - | - | - | 0.3 (0.1-1.0) n=1010 | - | - | - |
| Wan (2012) | Taiwan | nr | 6-8 years | garlic | IgE mediated only | - | - | - | - | - | - | 11.6 (9.7-13.8) n=1010 | - | - | - |
| Wan (2012) | Taiwan | nr | 6-8 years | onion | IgE mediated only | - | - | - | - | - | - | 1.6 (0.9-2.6) n=1010 | - | - | - |
| Lao-araya (2012) | Thailand | 2010 | 3-7years | ant eggs | IgE mediated only | 0.9 [†] (0.3-2.4) n=452 | - | - | - | - | - | - | - | - | - |
| Lao-araya (2012) | Thailand | 2010 | 3-7years | beef | IgE mediated only | 0.4 [†] (0.0-1.8) n=452 | - | - | - | - | - | - | 0 [†] (0-1.1) n=452 | - | - |
| Lao-araya (2012) | Thailand | 2010 | 3-7years | chocolate | IgE mediated only | 0.4 [†] (0.0-1.8) n=452 | - | - | - | - | _ | - | 0 [†] (0-1.1) n=452 | - | - |
| Lao-araya (2012) | Thailand | 2010 | 3-7years | coconut | IgE mediated only | 0.2 [†] (0.0-1.4) n=452 | - | - | - | - | - | - | - | - | - |
| Santadusit (2005) | Thailand | nr | 6 months - 6years | Duck | IgE mediated only | 0.2 [†] (0.0 - 1.0) n=656 | - | - | - | - | - | - | - | - | - |
| Lao-araya (2012) | Thailand | 2010 | 3-7years | insect | IgE mediated only | 0.4 [†] (0.0-1.8) n=452 | - | - | - | - | - | - | - | - | - |
| Santadusit (2005) | Thailand | nr | 6 months - 6years | Junk food | IgE mediated only | 0.3 [†] (0.1 - 1.2) n=656 | - | - | - | - | - | - | - | - | - |
| Al-Hammadi (2010) | United Arab Emirates (Emirate of Abu Dhabi) | 2006 | 6-9 years | vegetables | IgE mediated only (no SPT or SIgE) | - | - | 0.5 [†] (0.1-2.0) n=397 | - | - | - | - | - | - | - |
| Vierk (2007) | United States | 2001 | 18 years + | additives | IgE mediated only (no SPT or SIgE) | 0.6 [†] (0.4-0.9) n=4482 | - | - | - | - | - | - | - | - | 0.4 [†] (0.2-0.7) n=4482 |
| Bock (1987) | United States | 1980-1984 | 0-3 years | chocolate | Both IgE and non-IgE mediated | 1.9 [†] (0.8-3.4) n=408 | - | - | - | - | - | - | - | - | 0 [†] (0-1) n=480 |
| Vierk (2007) | United States | 2001 | 18 years + | Chocolate | IgE mediated only (no SPT or SIgE) | 0.6 [†] (0.4-0.9) n=4482 | - | - | - | - | - | - | - | - | 0.4 [†] (0.2-0.6) n=4482 |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Prevalence | of food | allergy | in | Europe |
|-------------|---------|---------|----|--------|
| 110.4101100 | 01 1000 | ano 8, | | -arope |

| Study ID | Country | Year(s) of study | Age group | Allergen | Type of food allergy | Questionnaire-based methods | | Sensitisation | | Sensitisation with clinical history | | Food challenge with clinical history | | Other | |
|-------------|---------------|---------------------|-----------|----------|-------------------------------------|--|------------------|-------------------------|-----------------|--|--------------------|--------------------------------------|--------------------|-----------------------|--------------------------------------|
| | | | | | | Self-reported | Clinical history | Clinician- diagnosed | Skin prick test | Serum-specific IgE | History and SPT | History and SIgE | History and OFC | History and DBPCFC | |
| | | | | | | | | | | 95% Preva | lence (CI) | | | | |
| Bock (1987) | United States | 1980-1984 | 0-3 years | rice | Both IgE and non-IgE mediated | 0.9 [†] (0.3-2.3) n=408 | - | - | - | - | - | - | - | - | 0.2 [†] (0-1.3) n=480 |

[†] Percentage prevalence and/or confidence intervals calculated from raw data provided in the paper

[‡]Percentage prevalence inferred from graph provided (no raw data reported).

[#]Data has been subject to correction or estimation by the authors (presented as reported in the paper).

Note: Where confidence intervals are missing the data has either been inferred from a graph or they have not been provided by the paper and, in the absence of raw data, could not be calculated.

EFSA supporting publication 2013:EN-506

Prevalence of food allergy in Europe

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

1.2.7. Time Trends

There are only a few cases in which it is appropriate to compare prevalence rates across decades. In these instances, studies have adopted similar methodologies in similar age groups in the same country. It would not make sense to compare across countries, where diet changes significantly, and across methodologies as each one carries its own level of risk/bias.

1.2.7.1. Celery

There are no studies available which are appropriate to compare to show any time trends in sesame allergy.

1.2.7.2. Cereals

Two studies were conducted on the prevalence of cereal allergy in Finland, one in 1980 and the other 20 years later in 2001. As similar methodologies were used comparisons can be made to reveal time trends in wheat allergy in 1 and 2 year old children. At 1 year of age, self-reported allergy to wheat in 1980 was estimated at 1% (95% CI: not reported) (Kajosaari 1982), this rose to 2.1 % (95% CI:1.3-3.4%) (Pyrhonen 2009) when studied in 2001. At 2 years of age, self-reported allergy to wheat was 1% (95% CI: not reported) (Kajosaari 1982), again doubling to 2% (95% CI: 1.2-3.2%) in 2001 (Pyrhonen 2009).

Two further studies in the UK, both measuring sensitisation to wheat using skin prick tests, found 0.3% (95% CI:0.1-1.0) sensitisation in 4 year olds in the 1993 cohort (Arshad 2001) and 0% (95% CI: 0.0-0.1) in 3 year olds in the 2001 cohort (Venter 2008). Skin prick tests were conducted using the same allergens and the same research nurses. A study conducted in China, looked at sensitisation rates to wheat, as determined by a positive skin prick test in 1999 and 10 years later in 2009 in children aged 0-24 months. They found a 0.2% increase, from 0.3% (95% CI: 0.0-2.1%) (Hu 2010) in 1999 to 0.5% (95% CI: 0.1-2.1%) in 2009 (Hu 2010).

1.2.7.3. Egg

Two studies looking at egg allergy in Finland were carried out in 1980 and 2001, and as similar methods were utilised, we are able to compare the prevalence rates, At 1 year of age, 6% (95% CI: not reported) of parents reported an adverse reaction to egg in 1980, whereas in 2001 only 2.7% (95% CI: 1.8-4.1%) (Kajosaari 1982) parents reported a problem with egg. At 2 years of age, there was a 7% (95% CI: not reported) (Kajosaari 1982) self-reported prevalence of egg allergy in 1980 compared to 4% (95% CI: 2.8-5.6%) (Pyrhonen 2009) prevalence found at the same age in 2001. At 3 years of age, 9% (95% CI: not reported) of parents reported an egg allergy in their children (Kajosaari 1982), this dropped to only 3.6% (95% CI:2.4-5.2%) reporting a problem in the same age group in 2001 (Pyrhonen 2009).

In the UK, a study was conducted in 1995 which reported self-reported egg allergy at 15 years of age, this showed a 0.7% (95% CI: 0.6-0.8%) prevalence (Emmett 1999). When compared to a later study also in the UK with 15 year olds, self-reported egg allergy had risen to 3%. (95% CI: 2.0-4.6%) (Pereira 2005). Two further studies in the UK, both measuring sensitisation to egg using skin prick tests, found 0.8% (95% CI: 0.4-2.0) sensitisation in 4 year olds in a 1993 cohort (Arshad 2001) and 1.4% (95% CI:0.7-2.7) in 3 year olds in 2001 cohort (Venter 2008). In China, sensitisation to egg increased from 7.6% (95% CI: 5.0-11.3%) in 0-24 month olds in 1999, to 16.2% (95% CI: 12.8-20.4%) in the same age group in 2009 (Hu 2010). Of note, Osborne 2011 reports the highest challenge proven rate of egg allergy in young children worldwide (9%; 95% CI: 7.9-10.0) in a study conducted in Australia, however the challenges were performed using raw egg.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the author(s).

1.2.7.4. Fish and Shellfish

The prevalence of self-reported allergy to fish in Finland in 1980 was 6% (95% CI: not reported) (Kajosaari 1982) which declined slightly when assessed in 2001 when it was reported to be 5% (95% CI: 3.4-6.4%) (Pyrhonen 2009). In 1980 5% (95% CI: not reported) of parents reported that their child experienced an adverse reaction after consumption of fish (Kajosaari 1982), this declined to 3.6% (95% CI: 2.4-5.2%) in 2001 (Pyrhonen, 2009). Two further studies in the UK, both measuring sensitisation to cod using skin prick tests, found 0.7% (95% CI:0.3-2.0) sensitisation in 4 year olds in a 1993 cohort (Arshad 2001) and 0.5% (95% CI: 0.1-1.5) in 3 year olds in a 2001 cohort (Venter 2008). In China, 0-24 month olds were skin prick tested, which resulted in 0% (95% CI: 0.0-1.6%) prevalence to shrimp in 1999 and 0.3% (95% CI: 0.0-1.7%) in 2009 (Hu, 2010). Prevalence of sensitisation to fish was 0.3% (95% CI: 0.0-2.1%) in 1999 and 0.8% (95% CI: 0.2-2.5%) in 2009 (Hu, 2010).

1.2.7.5. Fruits

At 1 year of age, self-reported allergy to citrus fruits was reported to be 8% (95% CI: not reported) in 1980 (Kajosaari 1982) and 3.5% (95% CI: 2.4-5.1%) in 2001 (Pyrhonen 2009). At 2 years of age the prevalence rates were 9% (95% CI: not reported) in 1980 (Kajosaari 1982) and 7.2% (95% CI: 5.6-9.2%) in 2001 (Pyrhonen 2009). At 3 years of age the self-reported prevalence was 11% (95% CI: not reported) in 1980 (Kajosaari 1982) compared to 6.5% (95% CI: 4.9-8.5%) in 2001 (Pyrhonen 2009). In China, sensitisation to orange fell from 1% (95% CI: 0.3-3.1%) in 1999 to 0% (95% CI:0-1.2%) in 2009 (Hu 2010).

1.2.7.6. Milk/dairy

Comparing cow's milk allergy in Finland in 1980 to 2001, self-reported rates were 2% (95% CI: not reported) at age 1, 5% (95% CI: not reported) at age 2 and 2% (95% CI: not reported) at age 3 in 1980 (Kajosaari 1982). Rates in 2001 were somewhat higher; 5.4% (95% CI: 4.0-7.2%) at age 1, 6.8% (95% CI:5.2-8.6%) at age 2 and 5.9% (95% CI: 4.4-7.8%) at age 3 (Pyrhonen 2009). Two further studies in the UK, both measuring sensitisation to milk using skin prick tests, found 1.3% (95% CI:0.7-2.3) sensitisation in 4 year olds in a 1993 cohort (Arshad 2001) and 0.5% (95% CI:0.1-1.5) in 3 year olds in a 2001 cohort (Venter 2008). In China, cow's milk sensitivity diagnosed using skin prick tests in 0-24 month olds almost doubled from 3.3% (95% CI: 1.7-6.2%) in 1999 to 6.5% (95% CI: 4.4-9.6%) in 2009 (Hu 2010).

1.2.7.7. Mustard

There was only one study found on mustard allergy and so no time trends can be assessed.

1.2.7.8. Peanut

Two cohorts of children (age 3–4 years) born on the Isle of Wight, were assessed for peanut allergy and the outcomes compared: Cohort A: Born in 1989; (Tarik) reviewed at 4 years of age (n = 2181). Cohort B: Born between 1994 and 1996; reviewed between 3 and 4 years of age (n = 1273). Peanut sensitization increased significantly from 1.3% in Cohort A to 3.3% (P = 0.003) in Cohort B (Grundy) before falling back to 2.0% in Cohort C (P = 0.145) (Venter 2008). Similarly, clinical peanut allergy increased significantly from 0.5% in Cohort A to 1.4% (P = 0.023) in Cohort B, with a subsequent fall to 1.2% in Cohort C (P = 0.850).

1.2.7.9. Sesame

There were limited studies on sesame allergy, with only two studies worldwide utilising food challenges, and both studies were done within the same decade so no time trends can be reported.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the author(s).

1.2.7.10. Soya

One study in China looked at sensitisation to soya, reporting a 1% (95% CI: 0.3-3.1) prevalence in 0-24 month olds in 1999, compared to 0.5% (95% CI: 0.1-2.1) in the same age group in 2009 (Hu 2010). In addition, in the United States Bock 1987 reported a rate of 2.7% (95% CI: 1.2-4.2) for self-reported soya allergy in 0-3 year olds in the 1980s, compared to Gupta 2011 who found a prevalence of 0.3% (95% CI: 0.2-0.4) for 0-2 year olds in 2009 when assessing a convincing clinical history.

1.2.7.11. Tree Nuts

A study conducted in Finland in 1980 reported the prevalence of self-reported allergy to nuts (unspecified). It reported a 2% (95% CI: not reported) prevalence at age 1, 0% (95% CI: not reported) prevalence at age 2 and 2% (95% CI: not reported) prevalence at 3 years of age (Kajosaari 1982). A similar study also looking at self-reported allergy to nuts in Finland in 2001 found 0.8% (95% CI: 0.4-1.8%) prevalence at 1 year of age, 2% (95% CI: 1.2-3.3%) at 2 years of age and 1.4% (95% CI: 0.7-2.6%) prevalence at 3 years of age (Pyrhonen 2009). In the US, Sicherer 1999 and Sicherer 2010 reported allergy to nuts based on a convincing clinical history in 1997 and 2008 for children under the age of 18 years and adults. In the children the prevalence of allergy to nuts was 0.2% (95% CI: 0.1-0.4%) in 1997 (Sicherer 1999), which doubled to 0.4% (95% CI: 0.3-0.6%) almost 10 years later in 2008 (Sicherer 2010). For adults, the same studies reported a prevalence rate of 1.6% (95% CI: 1.4-1.9%) prevalence in 1997 (Sicherer 1999) which dropped to 1.0% (95% CI: 0.8-1.1%) prevalence in 2008 (Sicherer 2010).

1.2.7.12. Other Foods

A vast array of allergens was included in this group and so comparing across decades is challenging. However, prevalence rates of self-reported allergy in studies published before 2000 varied between 0% in allergens such as additives and colourings, sweets, chicken, soft drinks, pulses and vegetables (Killgallen 1996; Kristjansson 1999; Emmett 1999). The highest self-reported prevalence was seen in tomato allergy at 11% (95% CI: not reported) (Kajosaari 1982). Studies published after 2000 report self-reported rates of allergy between 0.0% in tomato allergy (Oh 2004; Obeng 2011) and 14% in strawberry, chocolate, tomato, latex associated foods (kiwi, melon, banana, chestnut) (Pyrhonen 2009; Touraine 2002).

1.2.8. Discussion

In this systematic review we have focused on the 14 major allergens as identified by the EU including: milk, egg, wheat, fish, shellfish, molluscs, soya, peanut, tree nuts, sesame, mustard, lupin and celery. We have excluded sulphites from the systematic review as agreed with EFSA. Additionally, we have also looked at fruit, vegetable and other reported allergens.

Celery

Celery allergy is considered to be a big problem in mainland Europe. The main problem with studying the prevalence of celery allergy is that celery salt is considered much more allergenic than celery itself; none of the identified studies utilized celery salt in their food challenges. In fact, despite being considered as one of the major 14 food allergens, there appear to be only six studies reported on celery allergy. Two studies presented rates of self-reported allergy, three studies focused on SPT results and three reported on specific IgE levels. The best information we have on possible celery allergy is based on the data from Zuberbier 2004 indicating that 3.5% of the German population suffer from celery allergy based on SPT and a good clinical history and the data from Wan 2012 indicating that 1.8% of 6-8 year olds in Taiwan suffer from celery allergy based on serum IgE levels and a good clinical history.

Cereals (Wheat)

Wheat allergy prevalence based on food challenge is reported in three studies only. Osterballe 2004 reported no wheat allergy in all ages in Denmark, Orhan 2009 found no wheat allergy in 6-9 year old

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the author(s).

children in Turkey and Venter 2008 reported that 0.4% of 1 year olds, 0.3% of two year olds, 0.2% of three year olds, and 0.3% of six year olds suffer from wheat allergy in the UK.

Egg

Egg allergy is probably one of the most common allergies seen in early childhood and provides a clinical dilemma in terms of diagnosis and management due to the effect of heating on allergenicity as discussed in Objective 4a. A number of studies have looked at challenge-proven egg allergy in Europe. As with peanut, the two main studies using a food challenge outcome are Osterballe 2005 (Denmark) and Venter 2008 (United Kingdom). In young children (age 0-3 years) challenge-proven egg allergy prevalence rates have been found to be 1.8% (Osterballe 2005) in under 3's and at 2.9% at 3 years. Slightly lower rates are reported in the UK: 1.8% at 1 year, 1.3% at 2 year and 1% at 3 years (Venter 2008).

In older children (>3 years) rates based on food challenges were 0.7% (Eller 2009; Demark), 1% (Kajosaari 1982; Finland), 0.1% (Mustafayev 2012; Turkey), 1.9% (Orhan 2009; Turkey) and 0.3% (Venter 2006). In adults, challenge proven egg allergy data is from two studies only, showing no egg allergy in 22 year olds in Denmark (Osterballe 2005) and 0.1% of a whole population in Germany (Zuberbier 2004).

In studies from the rest of the world, the prevalence of food-challenge proven egg allergy has been reported for Australia and China and only in young children. Osborne identified egg allergy rates of 9% in 12 - 15 month old children in Melbourne, Australia. This is much higher than rates reported in Europe and other countries in the rest of the world such as China. Egg allergy rates in China were reported to be 2.5% in 0-12 month olds (Chen 2011), 2.9% in 0-24 month olds seen in 1999, and a much higher rate of 5% in 0-24 month olds in 2009 (Hu 2010). Chen 2012 also reported rates of 4.4%, 4.2% and 3% in 0-2 year olds in 2009-2010 in 3 different areas in China.

Fish and Shellfish

Challenge-proven data on the prevalence of fish allergies is surprisingly weak. In terms of fish (cod) allergy, the majority of data is derived from the UK cohort (Venter 2008), showing that 0.1% of one, two, three and six year olds suffered from a codfish allergy despite rates of sensitisation of between 0.3 - 1%. This information was echoed in Osterballe 2005 who found that none of the children under 3 years in their study had a fish allergy and only 0.6% of the adults studied had a challenge-proven allergy. Sensitisation rates for fish/cod were not available from this study. The only other adult study available, found that 0% of adults have a fish allergy in Turkey (Gelinicik 2008). In 6 year olds, 1% of a Finnish group studied showed the 6 year olds had a positive food challenge to fish (Kajosaari 1999). No fish allergy was found in the same age group in Turkey (Orhan 2009).

In terms of shellfish allergy, only one study (Osterballe 2005) showed any challenge proven data finding a prevalence rate of 0% shellfish (prawn) allergy in young children and 1.1% in adults (Osterballe 2005). Mollusc allergy has only been investigated in four studies across Europe, three of which presented self-reported allergy only. The rates of self-reported allergy were 0.5% to octopus for a group of 22 year olds in Denmark (Osterballe 2005), 0.4% to oyster in 5-7 year olds in France (Touraine 2002) and 0.5% to all molluscs in >39year olds in Spain (Falcáo 2004). Zuberbier 2004 reported a 0% prevalence of sensitisation to mollusc in all ages in Germany.

Looking at the rest of the world, despite a large number of questionnaire-based studies indicating reported rates of 0.2% (Ben-Shoshan 2010) to 4.3% (Connett 2012) and sensitization rates of 0.3% to 0.8%, only one study performed food challenges to fish reporting that 0.2% of 3-7 year olds in Thailand have a confirmed fish allergy (Lao-Araya 2012). Self-reported rates of shellfish allergy varied between 0.1%-11.7%. Sensitization rates measured by SPT were between 0-3.7% and 4.6- 6.7% as measured by

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the author(s).

SIgE testing. However only one study reported on shellfish allergy prevalence based on SPT plus a good clinical history and found that 17.3% of 6-8 year olds in Taiwan have a shellfish allergy (Wan 2012).

Data on mollusc allergy is even more sparse, with Lao-Araya showing that 0.2% of 3 -7 years olds in Thailand self-report problems to eating molluscs, Wu 2012 report clinician diagnosed mollusc allergy ranging from 0.1% in under 3 year olds to 1.5% in adults in Taiwan. Wan 2012 indicates very high sensitisation rates in the same country, based on SPT and a good clinical history ranging from 2.3% (squid) to 25.1% (abalone) in children. Importantly, there were no studies conducted worldwide that used food challenges to confirm the prevalence of mollusc allergy in children or adults. The majority of studies identified on fish and shellfish allergy reported prevalence rates of IgE-mediated and non-IgE mediated allergy collectively. However 22 studies reported IgE-mediated allergy only, using sensitisation rates and a convincing history of IgE- associated symptoms following ingestion of fish or shellfish to confirm this type of allergic reaction.

Fruit

A large variety of fruits have been studied including: a mixture of fruit and vegetables, apple, citrus/orange fruits, strawberry, kiwi, pear, apricot, cherry, grape, nectarine, peach, plum, banana, and pineapple. Those studied in the rest of the world but not in Europe included: pawpaw, mango and melon, litchi, "fruit juice", "dried fruit". Adverse reactions to cherry, plum and apricot were reported in Europe but not in the rest of the world. Considering the debates surrounding the use DBPCFC in diagnosing fruit allergies a surprisingly large number were conducted, questioning the allergenicity of the challenge food. The potential for adverse reactions to be linked to oral allergy syndrome or latex allergy and possible cross-reactions were not mentioned either.

Milk

One of the main problems with reporting the prevalence of milk allergy is that many studies have failed to distinguish between IgE and non-IgE mediated cow's milk allergy. The latter has also been incorrectly referred to as milk intolerance prior to 2004. Finally, due to the time to onset of symptoms, non-IgE mediated cow's milk allergy may be missed in many cases if food challenges were only performed over one day rather than at least 3-4 days.

Studies indicated the prevalence of food-challenge proven milk allergy in the EU as 0.9% in under 3 year olds (Osterballe 2005; Denmark) and 1.6% in 3 year olds (Osterballe 2005; Denmark). Also in Denmark, prevalence rates of 0.4% in 6 month olds, 0.6% in 9 month olds, 1.1% in 18 month olds, 0.8% in 1 year olds, 0.7% in 3 year olds and 0% in 6 year olds have been reported (Eller 2009). Similar prevalence rates have been found in the UK: 2.4% in 1 year olds, 1.2% in two year olds and 0.4% in 3 year olds (Venter 2008). Only two studies looked at milk allergies in older children which found 0.1% challenge proven milk allergy in 6 -9 year olds in Turkey (Orhan 2009) and 0.8% in 6 year olds in the UK (Venter 2008).

In adults only three studies looked at challenge-proven milk allergy reporting prevalence rates of 0.8% in over 22 year olds in Denmark (Osterballe 2005), 0% in adults in Turkey (Gelincik 2008) and 0.2% in a whole population in Germany (Zuberbier 2004). Looking at the rest of the world, milk allergy prevalence in children younger than 3 years ranged from 1.3% (Chen 2009) to 5% (Bock 1987). In older children only one study, conducted in Taiwan, reported challenge-proven milk allergy and found none of the children to be milk allergic (Loa-araya 2012). There are no studies looking at the prevalence of milk allergy in the rest of the world.

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the author(s).

Mustard

The prevalence of mustard allergy has been examined by a single study, which presented self-report data only, finding that 3% of teenagers in France self report problems with mustard (Touraine 2002). No other studies on the prevalence of mustard allergy could be found in the literature. Hence, there are huge gaps in our knowledge of the prevalence of mustard allergy, notably the prevalence of mustard allergy confirmed by food challenge.

Peanut

Peanut allergy is probably the most discussed allergen in the world and, due to the severity of the reactions, most of the studies investigating immunotherapy to foods have focused on peanut allergy. The prevalence of peanut allergy has been studied widely in the EU and the rest of world with using varied methodologies. In Europe, the landmark studies have included those conducted by Osterballe et al. (Denmark), Venter et al. (UK), Hourihane et al. (UK) and Nicolau et al. (UK). These studies provide valuable data on the prevalence of challenge-proven peanut allergy in young children with the highest rate reported as 1.8% in a group of 3-6 year olds in the UK (Hourihane 2007). In older children, Nicolau et al. (UK) reported a prevalence of 1.9% challenge-proven peanut allergy in 8 year olds (Nicolau 2009). The only data on challenge proven peanut allergy in adults in Europe is from Osterballe et al. showing that 1.2% of adults in Denmark suffer from peanut allergy (Osterballe 2005).

Studies investigating peanut allergy in the rest of the world has been dominated to some extent by questionnaire based studies in the US and Canada. In terms of challenge-proven peanut allergy, Osborne et al. (2011; Australia) found the highest prevalence (2.9%) in 12-15 month olds. Using a complex definition of peanut allergy, which included food challenges in some participants, Ben-Shoshan 2010 (Canada) reported a prevalence of 1.6% in 7 year olds in 2005; a slight increase from that reported for 7 year olds in 2000-2002 (1.3%). In the same country, Kagan 2003 reported prevalence for peanut allergy of 1.5% in 5-9 year olds using similar definitions to that of Ben-Shoshan 2010. The geographical disparities in allergies to individual foods is highlighted by the findings of Dalal 2002 who did not diagnose any peanut allergy in a group of 0-2 year olds in Israel.

Sesame

The prevalence of self-reported sesame allergy ranged between 0 - 1.5% (Touraine 2002; Emmett 1999), with only one study in Europe reporting challenge-proven sesame allergy. This study found the prevalence to be 0.6% in 3 year olds and 0.1% in 6 year olds (Venter 2006; Venter 2008). Sensitisation rates varied between 0.1 - 1.4%. In the rest of the world, the prevalence of self-reported sesame allergy ranged between 0.1 - 0.2%, although data was only available for Canada (Ben-Shoshan 2010). Sensitisation rates determined by SPT and the prevalence of challenge-proven sesame allergy was reported by only one study, which found that 1.6% of 12-15 month olds in Australia are sensitized to sesame and 0.7% (95% CI: 0.4-1.0) had challenge-proven sesame allergy (Osborne 2011). Despite the finding of a study conducted in Israel that there was no challenge-proven peanut allergy in a study group of 0-2 year olds, 0.2% of the study group did have challenge-proven sesame allergy (Dalal 2002).

Soya

Soya allergy is often mentioned in relation to cow's milk allergy IN infants and it is estimated that up to 60% of children with gastro-intestinal milk allergy may suffer from co-existing soya allergy. This figure is much lower in children with IgE-mediated allergy. Soya milk as an alternative for children with cow's milk allergy is also often debated. However, despite all the hype surrounding soya and possible soya allergy only one study conducted in Europe and another conducted in the US report challenge-proven allergy to soya. Osterballe 2005 found no soya allergy in a group of under 3 year olds from Denmark although Bock 1987 found that 0.8% of children in the same age group in the United States had soya allergies (Bock 1987). In addition, Osterballe 2005 also reported that 0.4% of 3 year olds and 0.3% of adults in Denmark suffer from a soya allergy.

EFSA supporting publication 2013:EN-506

Tree nuts

Many studies looking into tree nut allergy disappointingly did not specify the type of nuts being studied. Self-reported tree nut allergy to unspecified nuts however ranged from between 0.2 - 4.7% (Obeng 2011; Shek 2010). The studies that reported prevalence based on a challenge-proven diagnosis to specific tree nuts focused on hazelnut, walnut, almond, cashew nut and pistachio. These studies indicate that 2.2% of the German population suffer from a hazelnut allergy (Zuberbier 2004), as do 0.1% of the adult Turkish population and 0-1% of older children in Turkey (Orhan 2009; Mustayev 2012; Gelincik 2008), and 0.1% of 3 year old children in the UK (Venter 2008). Walnut allergy based on food challenges is reported in 1% of the German population (Zuberbier 2004) as well as 0.1% of Turkish adults and 0-0.4% of older children in Turkey (Orhan 2009; Mustayev 2012; Gelincik 2008). Food challenge proven almond and cashew nut allergy was reported by only one study (Venter 2008) in 0.2% and 0.1% of 3 year olds in the United Kingdom respectively. None of the studies in the rest of the world report challenge-proven tree nut allergies, apart from a 2.2% prevalence rate for pistachio allergy in 6-8 year olds in Taiwan (Wan 2012).

Other foods

Numerous foods have been reported in the literature to cause adverse reactions in individuals in both Europe and throughout the world. The majority of studies utilised self-reported methods for calculating prevalence. Before the year 2000 studies reported prevalence rates ranging from 0% to 11%, which increased to 14% in studies published after 2000. This suggests a minimum of a 3% increase in reported levels of prevalence. This could be due to the increased knowledge and awareness of allergy worldwide and also the expanding availability of different foods. However, compared to other allergens, there was a lack of studies adopting the gold standard of diagnosis which incorporates both open and double-blind placebo-controlled food challenges. This is the most effective way to determine prevalences of food allergy.

Therefore in summary, it is surprising to find such paucity of information on the prevalence of food allergy, although the published literature does give us a good indicating of the scale of the problem. The lack of information may be explained by the cost incurred of performing large scale epidemiological studies and the difficulties in performing food challenges, particularly DBPCFC. It is hoped that the evidence base will be enriched once the Europrevall studies funded by the EU are published.

Emerging allergens

This section presents a summary and analysis of the data gathered on allergens other than: milk/dairy, eggs, cereals, peanuts, nuts, celery, crustaceans, fish, molluscs, soy, lupin, mustard and sesame that have either increased in prevalence or have been highlighted as there was a significant reported prevalence in at least one country in Europe.

The prevalence of allergy to citrus fruits was found in this review to be relatively high for self-reported allergy with values between 3.2 to 11% being reported from a range of countries including Finland, Germany, Iceland, Sweden and the United Kingdom. Fewer studies reported challenge results and these tended to give a lower prevalence of 2% and under. Allergy to citrus is often reported as resulting in mild symptoms however there are reports of severe reactions including anaphylaxis. Those at risk of these more severe reactions are possible those with allergy to the lipid transfer proteins (Ebo, Ahrazem, Lopez-Torrejon, Bridts, Salcedo and Stevens; 2007).

Kiwi allergy has been reported in the wider literature as being one of the more common causes of allergy to fruit. We found that this food was not reported as a separate item by the majority of included studies. The data we could extract indicated self-report in France of 0.8% and open food challenge in Turkey at 0.1%. Although it is thought that many people with allergy to kiwi fruit experience mild symptoms, there are reports of more severe reactions including anaphylaxis recently reviewed by Lucas (2003).

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the author(s).

The prevalence of positive skin prick tests to tomato was relatively high in Italy Ronchette (2008) 3.1%. Those that used more robust methods such as food challenge gave much lower values, the highest being in Turkey, Gelincik (2008) with 0.1% for those over 18, and other studies indicating less than 01%, Orhan (2009) and Venter (2006).

Additives as a group were highlighted in a number of studies countries. Self-reported allergy could be quite high at 6.6 % Osterballe (2005), and 3.4 % in the United Kingdom Pereira (2005), however on challenge the figures were lower at less than 0.1%.

Cocoa allergy was reported in a number of countries, Orhan (2009) supplied the self-reported, skin prick test with history and challenge findings with the later indicating a 0.1% prevalence. That this could cause symptoms in 0.1% was concurred by Zurberbier (2004) and Gelincik (2008). There are very few reports of allergic reactions to cocoa in the wider literature and no reports on anaphylaxis.

Wan (2012) carried out skin prick tests on those who reported a positive history of garlic allergy and relatively high prevalence at 11.6% for children in Taiwan for children. The same study showed relatively high for onion and bamboo shoot. In European studies self-reported allergy to garlic was lower at only 1.5% in France, Touraine (2002), 0.1% in Turkey Gelincik (2008). For all other allergens the self-reported rates are higher than challenge findings and so we would expect very garlic allergy rates Europe according to our data. The wider literature does include reports of allergy to garlic including anaphylaxis, (Pérez-pimiento, Santaolalla, De Paz, Fernández-parra, Domínguez-lázaro, and Moneo; 1999).

EFSA supporting publication 2013:EN-506

1.3. List of Included Studies

- Al-Hammadi, S., Al-Maskari, F. and Bernsen, R. (2010) Prevalence of food allergy among children in Al-Ain city, United Arab Emirates, *Int Arch Allergy Immunol*, 151(4), 336-42.
- Altintas, D., Guneser, S., Evliyaoglu, N., Yuksel, B., Atici, A. and Serbest, M. (1995) A prospective study of cow's milk allergy in Turkish infants, *Acta Paediatr*, 84(11), 1320-1.
- Arbes, S. J., Jr, Gergen, P. J., Elliott, L. and Zeldin, D. C. (2005) Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey, *J Allergy Clin Immunol*, 116(2), 377-83.
- Arshad, S. H., Tariq, S. M., Matthews, S. and Hakim, E. (2001) Sensitization to common allergens and its association with allergic disorders at age 4 years: a whole population birth cohort study, *Pediatrics*, 108(2), E33.
- Babu, B. N. H., Mahesh, P. A. and Venkatesh, Y. P. (2008) A cross-sectional study on the prevalence of food allergy to eggplant (Solanum melongena L.) reveals female predominance, *Clinical and Experimental Allergy*, 38(11), 1795-1802.
- Bakos, N., Scholl, I., Szalai, K., Kundi, M., Untersmayr, E. and Jensen-Jarolim, E. (2006) Risk assessment in elderly for sensitization to food and respiratory allergens, *Immunol Lett*, 107(1), 15-21.
- Ben-Shoshan, M., Harrington, D. W., Soller, L., Fragapane, J., Joseph, L., St, P., Godefroy, S. B., Elliot, S. J. and Clarke, A. E. (2010) A population-based study on peanut, tree nut, fish, shellfish, and sesame allergy prevalence in Canada, *Journal of Allergy and Clinical Immunology*, 125(6), 1327-1335.
- Ben-Shoshan, M., Kagan, R. S., Alizadehfar, R., Joseph, L., Turnbull, E., St, P. and Clarke, A. E. (2009) Is the prevalence of peanut allergy increasing? A 5-year follow-up study in children in Montreal, J Allergy Clin Immunol, 123(4), 783-8.
- Bjornsson, E., Janson, C., Plaschke, P., Norrman, E. and Sjoberg, O. (1996) Prevalence of sensitization to food allergens in adult Swedes, *Ann Allergy Asthma Immunol*, 77(4), 327-32.
- Bock, S. A. (1987) Prospective appraisal of complaints of adverse reactions to foods in children during the first 3 years of life, *Pediatrics*, 79(5), 683-8.
- Branum, A. M. and Lukacs, S. L. (2009) Food allergy among children in the United States, *Pediatrics*, 124(6), 1549-55.
- Brugman, E., Meulmeester, J. F., Spee-van der, W., Beuker, R. J., Radder, J. J. and Verloove-Vanhorick, S. (1998) Prevalence of self-reported food hypersensitivity among school children in The Netherlands, *Eur J Clin Nutr*, 52(8), 577-581.
- Chen, J., Hu, Y., Allen, K. J., Ho, M. H. and Li, H. (2011) The prevalence of food allergy in infants in Chongqing, China, *Pediatr Allergy Immunol*, 22(4), 356-60.
- Chen, J., Liao, Y., Zhang, H. Z., Zhao, H. and Li, H. Q. (2012) Prevalence of food allergy in children under 2 years of age in three cities in China, *Zhonghua Er Ke Za Zhi*, 50(1), 5-9.
- Connett, G. J., Gerez, I., Cabrera-Morales, E. A., Yuenyongviwat, A., Ngamphaiboon, J., Chatchatee, P., Sangsupawanich, P., Soh, S. E., Yap, G. C., Shek, L. P. and Lee, B. W. (2012) A Population-Based Study of Fish Allergy in the Philippines, Singapore and Thailand, *Int Arch Allergy Immunol*, 159(4), 384-390.
- Dalal, I., Binson, I., Reifen, R., Amitai, Z., Shohat, T., Rahmani, S., Levine, A., Ballin, A. and Somekh, E. (2002) Food allergy is a matter of geography after all: sesame as a major cause of severe IgEmediated food allergic reactions among infants and young children in Israel, *Allergy*, 57(4), 362-5.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the author(s).

- Eggesbo, M., Halvorsen, R., Tambs, K. and Botten, G. (1999) Prevalence of parentally perceived adverse reactions to food in young children, *Pediatr Allergy Immunol*, 10(2), 122-32.
- Eller, E., Kjaer, H. F., Host, A., Andersen, K. E. and Bindslev-Jensen, C. (2009) Food allergy and food sensitization in early childhood: results from the DARC cohort, *Allergy*, 64(7), 1023-9.
- Emmett, S. E., Angus, F. J., Fry, J. S. and Lee, P. N. (1999) Perceived prevalence of peanut allergy in Great Britain and its association with other atopic conditions and with peanut allergy in other household members, *Allergy*, 54(4), 380-5.
- Falcao, H., Lunet, N., Lopes, C. and Barros, H. (2004) Food hypersensitivity in Portuguese adults, *Eur J Clin Nutr*, 58(12), 1621-5.
- Frongia, O. and Bellamo, A. R. (2005) Food allergies and intolerance in infants and children, *Medico Bambino*, 24, 533-8.
- Gelincik, A., Buyukozturk, S., Gul, H., Isik, E., Issever, H., Ozseker, F., Colakoglu, B., Dal, M., Ayvaz, O., Gungor, G. and Akkor, A. (2008) Confirmed prevalence of food allergy and non-allergic food hypersensitivity in a Mediterranean population, *Clin Exp Allergy*, 38(8), 1333-41.
- Gerrard, J. W., MacKenzie, J. W., Goluboff, N., Garson, J. Z. and Maningas, C. S. (1973) Cow's milk allergy: prevalence and manifestations in an unselected series of newborns, *Acta Paediatr Scand Suppl*, 234, 1-21.
- Greenhawt, M. J., Singer, A. M. and Baptist, A. P. (2009) Food allergy and food allergy attitudes among college students, *Journal of Allergy and Clinical Immunology*, 124(2), 323-327.
- Grundy, J., Matthews, S., Bateman, B., Dean, T. and Arshad, S. H. (2002) Rising prevalence of allergy to peanut in children: Data from 2 sequential cohorts, *J Allergy Clin Immunol*, 110(5), 784-9.
- Gupta, R. S., Springston, E. E., Warrier, M. R., Smith, B., Kumar, R., Pongracic, J. and Holl, J. L. (2011) The prevalence, severity, and distribution of childhood food allergy in the United States, *Pediatrics*, 128(1), e9-17.
- Haahtela, T., Bjorksten, F., Heiskala, M. and Suoniemi, I. (1980) Skin prick test reactivity to common allergens in Finnish adolescents, *Allergy*, 35(5), 425-31.
- Hatahet, R., Kirch, F., Kanny, G. and Moneretvautrin, D. A. (1994) Sensitization to peanut allergens in infants aged under 4 months – based upon 125 cases, *Revue Francaise D Allergologie Et D Immunologie Clinique*, 34(5), 377-381.
- Host, A., Halken, S., Jacobsen, H. P., Christensen, A. E., Herskind, A. M. and Plesner, K. (2002) Clinical course of cow's milk protein allergy/intolerance and atopic diseases in childhood, *Pediatr Allergy Immunol*, 13 Suppl 15, 23-8.
- Hourihane, J. O., Aiken, R., Briggs, R., Gudgeon, L. A., Grimshaw, K. E., DunnGalvin, A. and Roberts, S. R. (2007) The impact of government advice to pregnant mothers regarding peanut avoidance on the prevalence of peanut allergy in United Kingdom children at school entry, *J Allergy Clin Immunol*, 119(5), 1197-202.
- Hu, Y., Chen, J. and Li, H. (2010) Comparison of food allergy prevalence among Chinese infants in Chongqing, 2009 versus 1999, *Pediatr Int*, 52(5), 820-4.
- Isolauri, E., Huurre, A., Salminen, S. and Impivaara, O. (2004) The allergy epidemic extends beyond the past few decades, *Clinical and Experimental Allergy*, 34(7), 1007-1010.
- Jansen, J. J., Kardinaal, A. F., Huijbers, G., Vlieg-Boerstra, B. J., Martens, B. P. and Ockhuizen, T. (1994) Prevalence of food allergy and intolerance in the adult Dutch population, J Allergy Clin Immunol, 93(2), 446-56.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the author(s).

- Julge, K., Vasar, M. and Bjorksten, B. (2001) Development of allergy and IgE antibodies during the first five years of life in Estonian children, *Clin Exp Allergy*, 31(12), 1854-61.
- Kagan, R. S., Joseph, L., Dufresne, C., Gray-Donald, K., Turnbu, E., St, P. and Clarke, A. E. (2003) Prevalence of peanut allergy in primary-school children in Montreal, Canada, *Journal of Allergy and Clinical Immunology*, 112(6), 1223-1228.
- Kajosaari, M. (1982) Food allergy in Finnish children aged 1 to 6 years, *Acta Paediatr Scand*, 71(5), 815-9.
- Katz, Y., Rajuan, N., Goldberg, M. R., Eisenberg, E., Heyman, E., Cohen, A. and Leshno, M. (2010) Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy, J Allergy Clin Immunol, 126(1), 77-82 e1.
- Keet, C. A., Wood, R. A. and Matsui, E. C. (2012) Personal and parental nativity as risk factors for food sensitization, *Journal of Allergy and Clinical Immunology*, 129(1), 169-U244.
- Kilgallen, I. and Gibney, M. J. (1996) Parental perception of food allergy or intolerance in children under 4 years of age, *Journal of Human Nutrition and Dietetics*, 9(6), 473-478.
- Kim, J., Chang, E., Han, Y., Ahn, K. and Lee, S. I. (2011) The incidence and risk factors of immediate type food allergy during the first year of life in Korean infants: a birth cohort study, *Pediatr Allergy Immunol*, 22(7), 715-9.
- Krause, T. G., Koch, A., Poulsen, L. K., Kristensen, B., Olsen, O. R. and Melbye, M. (2002) Atopic sensitization among children in an arctic environment, *Clin Exp Allergy*, 32(3), 367-72.
- Kristjansson, I., Ardal, B., Jonsson, J. S., Sigurdsson, J. A., Foldevi, M. and Bjorksten, B. (1999) Adverse reactions to food and food allergy in young children in Iceland and Sweden, *Scand J Prim Health Care*, 17(1), 30-4.
- Kucukosmanoglu, E., Yazi, D., Yesil, O., Akkoc, T., Gezer, M., Bakirci, N., Bahceciler, N. N. and Barlan, I. B. (2008) Prevalence of egg sensitization in Turkish infants based on skin prick test, *Allergol Immunopathol (Madr)*, 36(3), 141-4.
- Kucukosmanoglu, E., Yazi, D., Yesil, O., Akkoc, T., Gezer, M., Ozdemir, C., Bakirci, N., Bahceciler, N. N. and Barlan, I. B. (2008) Prevalence of immediate hypersensitivity reactions to cow's milk in infants based on skin prick test and questionnaire, *Allergol Immunopathol (Madr)*, 36(5), 254-8.
- Kumar, R., Tsai, H. J., Hong, X. M., Liu, X., Wang, G. Y., Pearson, C., Ortiz, K., Fu, M., Pongracic, J. A., Bauchner, H. and Wang, X. B. (2011) Race, Ancestry, and Development of Food-Allergen Sensitization in Early Childhood, *Pediatrics*, 128(4), E821-E829.
- Lack, G., Fox, D., Northstone, K. and Golding, J. (2003) Factors associated with the development of peanut allergy in childhood, *N Engl J Med*, 348(11), 977-85.
- Lao-araya, M. and Trakultivakorn, M. (2012) Prevalence of food allergy among preschool children in northern Thailand, *Pediatr Int*, 54(2), 238-43.
- Leung, T. F., Yung, E., Wong, Y. S., Lam, C. W. and Wong, G. W. (2009) Parent-reported adverse food reactions in Hong Kong Chinese pre-schoolers: epidemiology, clinical spectrum and risk factors, *Pediatr Allergy Immunol*, 20(4), 339-46.
- Liu, A. H., Jaramillo, R., Sicherer, S. H., Wood, R. A., Bock, S. A., Burks, A. W., Massing, M., Cohn, R. D. and Zeldin, D. C. (2010) National prevalence and risk factors for food allergy and relationship to asthma: results from the National Health and Nutrition Examination Survey 2005-2006, *J Allergy Clin Immunol*, 126(4), 798-806 e13.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the author(s).

- Marrugo, J., Hernandez, L. and Villalba, V. (2008) Prevalence of self-reported food allergy in Cartagena (Colombia) population, *Allergol Immunopathol (Madr)*, 36(6), 320-4.
- Martinez-Gimeno, A., Del, C., Garcia-Hernandez, G., Luna-Paredes, C. and Garcia-Sanchez, J. A. (2000) Prevalence of food allergy/intolerance in children: Results from a population based survey, *Journal of Allergy and Clinical Immunology*, 105(1), S130-S130.
- Morita, E., Chinuki, Y., Takahashi, H., Nabika, T., Yamasaki, M. and Shiwaku, K. (2012) Prevalence of wheat allergy in Japanese adults, *Allergol Int*, 61(1), 101-5.
- Mortz, C. G., Andersen, K. E. and Bindslev-Jensen, C. (2005) The prevalence of peanut sensitization and the association to pollen sensitization in a cohort of unselected adolescents--The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis (TOACS), *Pediatr Allergy Immunol*, 16(6), 501-6.
- Mustafayev, R., Civelek, E., Orhan, F., Yuksel, H., Boz, A. B. and Sekerel, B. E. (2012) Similar prevalence, different spectrum: IgE-mediated food allergy among Turkish adolescents, *Allergol Immunopathol (Madr)*.
- Nicolaou, N., Poorafshar, M., Murray, C., Simpson, A., Winell, H., Kerry, G., Harlin, A., Woodcock, A., Ahlstedt, S. and Custovic, A. (2010) Allergy or tolerance in children sensitized to peanut: prevalence and differentiation using component-resolved diagnostics, *J Allergy Clin Immunol*, 125(1), 191-7 e1.
- Obeng, B. B., Amoah, A. S., Larbi, I. A., Yazdanbakhsh, M., van, R., Boakye, D. A. and Hartgers, F. C. (2011) Food allergy in Ghanaian schoolchildren: data on sensitization and reported food allergy, *Int Arch Allergy Immunol*, 155(1), 63-73.
- Oh, J. W., Pyun, B. Y., Choung, J. T., Ahn, K. M., Kim, C. H., Song, S. W., Son, J. A., Lee, S. Y. and Lee, S. I. (2004) Epidemiological change of atopic dermatitis and food allergy in school-aged children in Korea between 1995 and 2000, *J Korean Med Sci*, 19(5), 716-23.
- Orhan, F., Karakas, T., Cakir, M., Aksoy, A., Baki, A. and Gedik, Y. (2009) Prevalence of immunoglobulin E-mediated food allergy in 6-9-year-old urban schoolchildren in the eastern Black Sea region of Turkey, *Clin Exp Allergy*, 39(7), 1027-35.
- Osborne, N. J., Koplin, J. J., Martin, P. E., Gurrin, L. C., Lowe, A. J., Matheson, M. C., Ponsonby, A. L., Wake, M., Tang, M. L., Dharmage, S. C. and Allen, K. J. (2011) Prevalence of challenge-proven IgEmediated food allergy using population-based sampling and predetermined challenge criteria in infants, *J Allergy Clin Immunol*, 127(3), 668-76 e1.
- Ostblom, E., Lilja, G., Pershagen, G., van, H. and Wickman, M. (2008) Phenotypes of food hypersensitivity and development of allergic diseases during the first 8 years of life, *Clin Exp Allergy*, 38(8), 1325-32.
- Ostblom, E., Wickman, M., van, H. and Lilja, G. (2008) Reported symptoms of food hypersensitivity and sensitization to common foods in 4-year-old children, *Acta Paediatrica*, 97(1), 85-90.
- Osterballe, M., Hansen, T. K., Mortz, C. G., Host, A. and Bindslev-Jensen, C. (2005) The prevalence of food hypersensitivity in an unselected population of children and adults, *Pediatr Allergy Immunol*, 16(7), 567-73.
- Osterballe, M., Mortz, C. G., Hansen, T. K., Andersen, K. E. and Bindslev-Jensen, C. (2009) The prevalence of food hypersensitivity in young adults, *Pediatr Allergy Immunol*, 20(7), 686-92.
- Pereira, B., Venter, C., Grundy, J., Clayton, B., Arshad, S. H. and Dean, T. (2005) Prevalence of sensitization to food allergens, reported adverse reaction to foods, food avoidance, and food hypersensitivity among teenagers, *Journal of Allergy and Clinical Immunology*, 116(4), 884-892.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the author(s).

- Pyrhonen, K., Nayha, S., Kaila, M., Hiltunen, L. and Laara, E. (2009) Occurrence of parent-reported food hypersensitivities and food allergies among children aged 1-4 yr, *Pediatr Allergy Immunol*, 20(4), 328-38.
- Rance, F., Grandmottet, X. and Grandjean, H. (2005) Prevalence and main characteristics of schoolchildren diagnosed with food allergies in France, *Clin Exp Allergy*, 35(2), 167-72.
- Ro, A. D., Saunes, M., Smidesang, I., Storro, O., Oien, T., Moen, T. and Johnsen, R. (2012) Agreement of specific IgE and skin prick test in an unselected cohort of two-year-old children, *Eur J Pediatr*, 171(3), 479-484.
- Roberts, G., Peckitt, C., Northstone, K., Strachan, D., Lack, G., Henderson, J. and Golding, J. (2005) Relationship between aeroallergen and food allergen sensitization in childhood, *Clin Exp Allergy*, 35(7), 933-40.
- Ronchetti, R., Jesenak, M., Trubacova, D., Pohanka, V. and Villa, M. P. (2008) Epidemiology of atopy patch tests with food and inhalant allergens in an unselected population of children, *Pediatr Allergy Immunol*, 19(7), 599-604.
- Saarinen, K. M., Juntunen-Backman, K., Jarvenpaa, A. L., Kuitunen, P., Lope, L., Renlund, M., Siivola, M. and Savilahti, E. (1999) Supplementary feeding in maternity hospitals and the risk of cow's milk allergy: A prospective study of 6209 infants, *J Allergy Clin Immunol*, 104(2 Pt 1), 457-61.
- Sai, X. Y., Zheng, Y. S., Zhao, J. M. and Hao, W. (2011) A cross sectional survey on the prevalence of food intolerance and its determinants in Beijing, China, *Zhonghua Liu Xing Bing Xue Za Zhi*, 32(3), 302-5.
- Sakellariou, A., Zannikos, K., Tzannis, K., Michopoulou, C., Emmanouil, E., Vassilopoulou, E., Sinaniotis, A., Saxoni-Papageorgiou, P. and Papadopoulos, N. (2008) The prevalence of perceived food hypersensitivity in adults in the city of Athens, *Allergy*, 63, 583-583.
- Santadusit, S., Atthapaisalsarudee, S. and Vichyanond, P. (2005) Prevalence of adverse food reactions and food allergy among Thai children, *J Med Assoc Thai*, 88 Suppl 8, S27-32.
- Schafer, T., Bohler, E., Ruhdorfer, S., Weigl, L., Wessner, D., Heinrich, J., Filipiak, B., Wichmann, H. E. and Ring, J. (2001) Epidemiology of food allergy/food intolerance in adults: associations with other manifestations of atopy, *Allergy*, 56(12), 1172-9.
- Schafer, T., Kramer, U., Dockery, D., Vieluf, D., Behrendt, H. and Ring, J. (1999) What makes a child allergic? Analysis of risk factors for allergic sensitization in preschool children from East and West Germany, *Allergy Asthma Proc*, 20(1), 23-7.
- Schrander, J. J., van den, B., J, P., Forget, P. P., Schrander-Stumpel, C. T., Kuijten, R. H. and Kester, A. D. (1993) Cow's milk protein intolerance in infants under 1 year of age: a prospective epidemiological study, *Eur J Pediatr*, 152(8), 640-4.
- Shek, L. P., Cabrera-Morales, E. A., Soh, S. E., Gerez, I., Ng, P. Z., Yi, F. C., Ma, S. and Lee, B. W. (2010) A population-based questionnaire survey on the prevalence of peanut, tree nut, and shellfish allergy in 2 Asian populations, *J Allergy Clin Immunol*, 126(2), 324-31, 331 e1.
- Sicherer, S. H., Munoz-Furlong, A., Burks, A. W. and Sampson, H. A. (1999) Prevalence of peanut and tree nut allergy in the US determined by a random digit dial telephone survey, *J Allergy Clin Immunol*, 103(4), 559-62.
- Sicherer, S. H., Munoz-Furlong, A., Godbold, J. H. and Sampson, H. A. (2010) US prevalence of selfreported peanut, tree nut, and sesame allergy: 11-year follow-up, *J Allergy Clin Immunol*, 125(6), 1322-6.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the author(s).

- Sicherer, S. H., Munoz-Furlong, A. and Sampson, H. A. (2003) Prevalence of peanut and tree nut allergy in the United States determined by means of a random digit dial telephone survey: a 5-year follow-up study, *J Allergy Clin Immunol*, 112(6), 1203-7.
- Sicherer, S. H., Munoz-Furlong, A. and Sampson, H. A. (2004) Prevalence of seafood allergy in the United States determined by a random telephone survey, *J Allergy Clin Immunol*, 114(1), 159-65.
- Soller, L., Ben-Shoshan, M., Harrington, D. W., Fragapane, J., Joseph, L., St, P., Godefroy, S. B., La, V., Elliott, S. J. and Clarke, A. E. (2012) Overall prevalence of self-reported food allergy in Canada, J Allergy Clin Immunol, 130(4), 986-8.
- Tariq, S. M., Stevens, M., Matthews, S., Ridout, S., Twiselton, R. and Hide, D. W. (1996) Cohort study of peanut and tree nut sensitisation by age of 4 years, *BMJ*, 313(7056), 514-7.
- Touraine, F., Ouzeau, J. F., Boullaud, C., Dalmay, F. and Bonnaud, F. (2002) Survey on the prevalence of food allergy in school children, *Revue Francaise D Allergologie Et D Immunologie Clinique*, 42(8), 763-768.
- Venter, C., Pereira, B., Grundy, J., Clayton, C. B., Arshad, S. H. and Dean, T. (2006) Prevalence of sensitization reported and objectively assessed food hypersensitivity amongst six-year-old children: a population-based study, *Pediatr Allergy Immunol*, 17(5), 356-63.
- Venter, C., Pereira, B., Voigt, K., Grundy, J., Clayton, C. B., Higgins, B., Arshad, S. H. and Dean, T. (2008) Prevalence and cumulative incidence of food hypersensitivity in the first 3 years of life, *Allergy*, 63(3), 354-9.
- Vierk, K. A., Koehler, K. M., Fein, S. B. and Street, D. A. (2007) Prevalence of self-reported food allergy in American adults and use of food labels, *J Allergy Clin Immunol*, 119(6), 1504-10.
- Wan, K. S. and Chiu, W. H. (2012) Food hypersensitivity in primary school children in Taiwan: relationship with asthma, *Food and Agricultural Immunology*, 23(3), 247-254.
- Woods, R. K., Abramson, M., Raven, J. M., Bailey, M., Weiner, J. M. and Walters, E. H. (1998) Reported food intolerance and respiratory symptoms in young adults, *Eur Respir J*, 11(1), 151-5.
- Woods, R. K., Stoney, R. M., Raven, J., Walters, E. H., Abramson, M. and Thien, F. C. (2002) Reported adverse food reactions overestimate true food allergy in the community, *Eur J Clin Nutr*, 56(1), 31-6.
- Wu, T. C., Tsai, T. C., Huang, C. F., Chang, F. Y., Lin, C. C., Huang, I. F., Chu, C. H., Lau, B. H., Wu, L., Peng, H. J. and Tang, R. B. (2012) Prevalence of Food Allergy in Taiwan: A Questionnaire-based Survey, *Intern Med J*.
- Young, E., Stoneham, M. D., Petruckevitch, A., Barton, J. and Rona, R. (1994) A population study of food intolerance, *Lancet*, 343(8906), 1127-30.
- Zannikos, K., Sakellariou, A., Emmanouil, E., Tzannis, K., Michopoulou, C., Sinaniotis, A., Xepapadaki, P., Saxoni-Papegeorgiou, P. and Papadopoulos, N. (2008) The prevalence of parentally perceived food hypersensitivity in Greek schoolchildren, *Allergy*, 63, 318-318.
- Zuberbier, T., Edenharter, G., Worm, M., Ehlers, I., Reimann, S., Hantke, T., Roehr, C. C., Bergmann, K. E. and Niggemann, B. (2004) Prevalence of adverse reactions to food in Germany a population study, *Allergy*, 59(3), 338-45.

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the author(s).

1.4. List of Excluded Studies

Below is a table of studies excluded from the review and their reasons for exclusion. These have been selected on the basis that they might be expected to have been included in the review (e.g. they have been included in previous systematic reviews), but did not meet the eligibility criteria (Table 1.12).

| Short Title | Title | Reason for exclusion |
|------------------------|--|---|
| Aardoom | Food intolerance (food hypersensitivity) and chronic | Food intolerance rather than food |
| (1997) | complaints in children: the parents' perception | allergy |
| Aba-Alkhail (2000) | Prevalence of food allergy in asthmatic patients | Sample, all had asthma |
| Altman (1996) | Public perception of food allergy | Duplicate |
| Avila (2002) | Hypersensitivity detected by skin tests to food in allergic patients in the Hospital Infantil de Mexico Federico Gomez | Inappropriate sample (allergic patients only) |
| Bernardini (1998) | Prevalence and risk factors of latex sensitization in an unselected pediatric population | No separated data for each allergen |
| Biagini (2004) | Evaluation of the prevalence of antiwheat-, anti- flour dust, and anti-alpha-amylase specific IgE antibodies in US blood donors | Sample, not a representative population |
| Bival'kevich (1990) | Allergic diathesis in infants in the first year of life | Торіс |
| Garcia (2003) | Incidence of allergy to cow's milk protein in the first year of life and its effect on consumption of hydrolyzed formulae | Sample, all had suspected cow's milk allergy |
| Gislason (2000) | Allergy and intolerance to food in an Icelandic urban population 20-44 years of age | Sample, enriched with participants with asthma |
| Hill (1997) | The frequency of food allergy in Australia and Asia | Sample inappropriate (Limited to children of atopic parents only) |
| Hossny (2011) | Peanut sensitization in a group of allergic Egyptian children | Inappropriate sample (allergic patients only) |
| Host (1990) | A prospective study of cow milk allergy in Danish infants during the first 3 years of life. Clinical course in relation to clinical and immunological type of hypersensitivity reaction | Linked to Host 2002 |

| Table 1.33: Studies excluded from the systematic revi | ew |
|---|----|
|---|----|

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the author(s).

| Short Title | Title | Reason for exclusion |
|---------------------------|--|---|
| Isolauri (2004) | The allergy epidemic extends beyond the past few decades | Excluded in error for extraction |
| Jansen (1994) | Prevalence of food allergy and intolerance in the adult Dutch population | Excluded in error for extraction |
| Kaczmarski (1999) | The prevalence of food allergies in infants in North- Eastern Poland | Review article |
| Kanny (2001) | Population study of food allergy in France | Data not provided by individual allergen |
| Keiding, (1997) | Asthma, allergy and other types of hypersensitivity in Denmark: and the development | Unable to locate article |
| Levin (2011) | Associations between asthma and bronchial hyper- responsiveness with allergy and atopy phenotypes in urban black South African teenagers | Topic, mainly concerning allergy to inhalant allergens |
| Lunet (2005) | Self-reported food and drug allergy in Maputo, Mozambique | Reports allergy to foods collectively i.e not per allergen |
| Marklund (2004) | Health-related quality of life among adolescents with allergy-like conditions - with emphasis on food hypersensitivity | Sample, not cross section of community |
| Marklund (2006) | Health-related quality of life in food hypersensitive schoolchildren and their families: parents' perceptions | Sample, not cross section of community |
| Ouahidi (2010) | The effect of thermic and acid treatment on the allergenicity of peanut proteins among the population of the region of Fes-Meknes in Morocco | Topic not suitable |
| Penard-Morand (2005) | Prevalence of food allergy and its relationship to asthma and allergic rhinitis in schoolchildren | Topic not suitable |
| Ramos (1993) | Hypersensitivity to common allergens in the central region of Coahuila | Review article |
| Rodriguez-Ortiz (2009) | Epidemiological characteristics of patients with food allergy assisted at Regional Center of Allergies and Clinical Immunology of Monterrey | Sample, all had allergy |
| Roehr (2004) | Food allergy and non-allergic food hypersensitivity in children and adolescents | Excluded in error |
| Schrander (1993) | Cow's milk protein intolerance in infants under 1 year of age: a prospective epidemiological study | Included for extraction |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the author(s).

| Short Title | Title | Reason for exclusion |
|-------------------------------------|---|---|
| Takahashi (1998) | Buckwheat allergy in 90,000 school children in Yokohama | Incidence rather than prevalence |
| Tariq (2000) | Egg allergy in infancy predicts respiratory allergic disease by 4 years of age | Data reported elsewhere |
| van Bockel- Geelkerken (1992) | Prevalence of putative food hypersensitivity in young children | Excluded |
| Venter (2006) | Incidence of parentally reported and clinically diagnosed food hypersensitivity in the first year of life | Prevalence data reported elsewhere |
| Westritschnig (2003) | Analysis of the sensitization profile towards allergens in central Africa | Sample all participants had allergy |
| Woods (2001) | International prevalences of reported food allergies and intolerances. Comparisons arising from the European Community Respiratory Health Survey (ECRHS) 1991-1994 | Australian data presented in Woods 2002 and no separated data for individual countries for specific allergens. |
| Woods (2002) | Prevalence of food allergies in young adults and their relationship to asthma, nasal allergies, and eczema | Inappropriate sample (the sample has been enriched from a group reporting asthma-like symptoms) |

1.5. Additional references

Ebo DG, Ahrazem O, Lopez-Torrejon G, Bridts CH, Salcedo G and Stevens WJ, 2013. Anaphylaxis from Mandarin (Citrus reticulata): Identification of Potential Responsible Allergens. International Archives of Allergy and Immunology, 144, 39-43.

Lucas JSA, Lewis SA and Hourihane JOB, 2003. Kiwi fruit allergy: A review. 14, 420-428.

Pérez-pimiento A, Santaolalla M, De Paz S, Fernández-parra B, Domínguez-lázaro AR and Moneo I, 1999. Anaphylactic reaction to young garlic. Allergy, 54, 626-629.

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the author(s).
2. THE EFFECT OF FOOD PROCESSING ON THE ALLERGENICITY IN RELATION TO EACH OF THE FOLLOWING FOOD ALLERGENS: MILK/DAIRY, EGGS, CEREALS, BUCKWHEAT, PEANUTS, NUTS, CELERY, CRUSTACEANS, FISH, MOLLUSCS, SOY, LUPIN, MUSTARD AND SESAME? (OBJECTIVE 4A)

2.1. Introduction

2.1.1. Assessing allergenicity of the processed food

Guidelines indicate that double blind placebo controlled food challenges are the method of choice assessing allergenicity of foods and diagnosis of allergy for those with immediate and delayed type reactions in Europe (Bindslev-Jensen et al., 2004; Fiocchi et al., 2010) and the United States of America (Boyce et al., 2010). However open challenges can be used for specific situations (Bindslev-Jensen, et al., 2004) and have been shown to have reasonable negative predictive values (Venter, 2007). In food challenges participants are challenged with increasing doses of the food and once symptoms are experienced the challenge halted. Allergenicity of that food for an individual may be expressed as the dose eliciting a reaction, or the dose combined with the type of symptoms experienced (Hourihane et al., 2005) (Nowak-Wegrzyn et al., 2009) but there are no agreed standards for doing this.

Skin prick tests with food allergens and measurement of specific IgE in serum without clinical history or challenge results have been shown to have poor accuracy for diagnosis of food allergy (Fiocchi et al., 2002; Järvinen & Sicherer, 2012), and these tests do not indicate accurately enough the intensity of reaction on food challenge or the threshold dose that could elicit symptoms (Hourihane, et al., 2005) (Osterballe & Bindslev-Jensen, 2003). In addition these tests are not appropriate for non IgE mediated allergy (Fiocchi et al., 2010).

Therefore changes in the allergenicity of the processed foods have been assessed using evidence from studies comparing open or blind challenge data, studies comparing ability to bind specific IgE or ability to provoke a positive skin prick test will not be included in this review. This review presents details of the challenge procedure for quality assessment and comparability.

2.1.2. Participants

The participants involved with challenge studies are key to the quality of the research; hence one of the quality criteria for assessing the studies was whether the participants are representative of those with food allergy. A random sample would reduce the risk of bias. As person specific factors affect symptoms experienced by individuals on exposure to a particular food it is of paramount importance that the population studies were described in detail so that the generalisability of the findings to specific populations could be assessed.

2.1.3. Food processing methods

A wide range of methods were assessed. We have distinguished between studies of laboratory prepared foods and those using commercially available or kitchen prepared foods that could be less reliable but more relevant to real world situations.

2.2. Materials and Methods

2.2.1. Literature search strategy

The following databases were searched from Web of Science (1970-November 2012), BIOSIS Citation Index (1969-November 2012), BIOSIS reviews (1969-2008), Medline (1950-November 2012), Pubmed (-November 2012), using the search terms shown (Table 2.1). No limits were used.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the author(s).

Table 2.1: Search strategy in Web of Knowledge. Each group was combined with the terms within a group were linked with 'or' and the groups were linked with 'and'

| Topics | Search terms Web of Knowledge | Search terms (Including appropriate MeSH terms) PubMed |
|----------------|--|---|
| Group 1. Food | | |
| Milk and dairy | milk OR butter or cream or dairy or cheese or yoghurt or petit filous or casein or whey or lacto Infant NEAR/2 formula | milk[Tiab] OR milk[MeSH Terms] OR lactose[MeSH Terms] OR lactose[Tiab] OR dairy[Tiab] OR butter[Tiab] OR cream[Tiab] OR "infant formula"[Tiab] OR cheese[Tiab] OR yoghurt[Tiab] OR "petit filous"[Tiab] OR casein[Tiab] OR whey[Tiab] |
| Egg | Egg | egg[Tiab] OR eggs[Tiab] |
| Cereals | Cereal or gluten or wheat or rye or barley or oats or spelt or kamut | cereals[Tiab] OR glutens[MeSH Terms] OR glutens[Tiab] OR gluten[Tiab] OR wheat[Tiab] OR rye[Tiab] OR barley[Tiab] OR oats [Tiab] OR oat[Tiab] OR spelt[Tiab] OR kamut[Tiab] |
| Peanuts | peanut or arachis | peanut[Tiab] OR arachis[Tiab] |
| Nuts | nut or arachis or cashew or brasil or almond or hazel or walnut or pecan or macadamia or pistachio or filbert | nuts[MeSH Terms] OR nuts[Tiab] OR nut[Tiab] OR almond[Tiab] OR almonds[Tiab] OR hazelnut[Tiab] OR hazelnuts[Tiab] OR walnut[Tiab] OR walnuts[Tiab] OR cashew[Tiab] OR cashews[Tiab] OR pecan[Tiab] OR pecans[Tiab] OR macadamia[Tiab] OR macadamias[Tiab] OR pistachio[Tiab] OR pistachios[Tiab] OR beechnut[Tiab] OR beechnuts[Tiab] OR filbert[Tiab] OR filberts[Tiab] |
| Celery | Celery | celery[tiab] |
| Crustaceans | crustacea OR crustacean OR crustaceans OR crab OR crabs OR lobster OR lobsters OR shrimp OR shrimps OR prawn OR prawns OR crayfish OR shellfish OR langoustine OR langoustines | crustacea[MeSH Terms] OR crustacea[Tiab] OR crustacean[Tiab] OR crustaceans[Tiab] OR crab[Tiab] OR crabs[Tiab] OR lobster[Tiab] OR lobsters[Tiab] OR shrimp[Tiab] OR shrimps[Tiab] OR prawn[Tiab] OR prawns[Tiab] OR crayfish[Tiab] OR shellfish[MeSH Terms] OR shellfish[Tiab] OR langoustine[Tiab] OR langoustines[Tiab] |

EFSA supporting publication 2013:EN-506

| Topics | Search terms Web of Knowledge | Search terms (Including appropriate MeSH terms) |
|--|---|--|
| | | PubMed |
| Fish | fish OR pollock OR carp OR cod OR mackerel OR salmon OR tuna OR shark OR "sea bass" OR swordfish OR hake OR sole OR megrim OR sardine OR sardines OR halibut OR anchovy OR anchovies OR catfish OR trout | fishes[MeSH Terms] OR fish[Tiab] OR pollock[Tiab] OR carp[Tiab] OR cod[Tiab] OR mackerel[Tiab] OR salmon[Tiab] OR tuna[Tiab] OR shark[tiab] OR "sea bass"[tiab] OR swordfish[tiab] OR hake[tiab] OR sole[tiab] OR megrim[tiab] OR sardine[tiab] OR sardines[tiab] OR halibut[tiab] OR anchovy[tiab] OR anchovies[tiab] OR catfish[tiab] OR trout[tiab] |
| | | mollusca[MeSH Terms] OR mollusc[Tiab] OR molluscs[Tiab] OR oyster[Tiab] OR oysters[Tiab] OR snail [Tiab] OR snails[Tiab] OR squid[Tiab] OR mussel[Tiab] OR mussels[Tiab] OR clam[Tiab] OR clams[Tiab] OR abalone[tiab] OR octopus[tiab] OR scallop[tiab] OR scallops[tiab] |
| Soy | Soy* | soy[Tiab] OR soybeans[MeSH Terms] OR soybean[Tiab] OR soybeans[Tiab] OR soya[Tiab] |
| Lupin | LUPINUS-ALBUS, Lupin* | lupinus[MeSH Terms] OR lupin[Tiab] |
| Mustard | Mustard | "mustard plant"[MeSH Terms] OR mustard[Tiab] |
| Sesame | Sesame* | sesamum[MeSH Terms] OR "sesame"[Tiab] |
| Group 2. Food Challen | ge | |
| Open food challenge | (Food or oral or open or mucosal or ingestion) near/2 Challenge | Challenge*[tiab] |
| Double blind placebo controlled food challenge | ((food or oral or mucosal or ingestion) near/2 challenge*) OR (DBPC) | DBPC*[tiab] "double blind placebo controlled" |

| Topics | Search terms Web of Knowledge | Search terms (Including appropriate MeSH terms) PubMed |
|---|---|---|
| Group 3. Food process | ing | |
| Heat and chemical Cooking, heavy salting,, microwaving, filtration, fermenting, smoking, drying, UV treatment for sterilisation, acid, alkaline (lyme treatment) treatment in powder production e.g. coffee, other heating treatments (ohmic) and chemical peeling of fruit (lipid transfer protein in skin). | (heat* or cook* or roast* or fry* or pasteuri* or boil) or (heavy near/2 salting) or dying or microwav* OR ferment* or smoking or drying or (UV NEAR/2 treatment) or lyme or ohmic OR (chemical near/4 peeling)) or Hydrostatic pressure or (food near/1 process*) or (food near/1 process*) or (digest*) or (hydrol*) or filtration | Heat*[tiab] OR cook*[tiab] OR roast* [tiab] OR fry*[tiab] OR pasteuri*[tiab] OR boil[tiab] OR Hydrolysis [tiab] OR digestion [tiab] OR enzymatic treatment [tiab] OR fermented [tiab] OR Hydrostatic pressure[tiab] OR food process* [tiab] OR "heavy salting" [tiab] OR dying [tiab] OR microwav* [tiab] OR ferment* [tiab] OR smoking [tiab] OR drying [tiab] OR UV [tiab] OR lyme [tiab] OR ohmic [tiab] OR |
| Filtration/specific product related | (wine OR beer OR clarif*) | wine [tiab] OR beer [tiab] Or clarify* [tiab] |

2.2.1.1. Selection procedure

All titles and abstracts were imported to Endnote and duplicates removed. One reviewer, SK, screened the titles and abstracts to remove studies not relevant to the objective. The full texts were obtained for the remaining studies; a second screen by SK then removed studies that were not relevant to the research question and the reasons identified.

2.2.1.2. Types of studies

We included any study that reported on the effect of food processing on the allergenicity of the named foods, a wide range of sampling designs were acceptable including those involving people from:

- a random sample from a cross-section of a community or clinic population.
- a non-random sample from a cross-section of a community or clinic population.
- convenience or self or clinician selected volunteers with food allergy.

Studies that used the following designs were included:

• cross-over with challenge with a comparison form of the food against another test form of the food or a test from that has a different intensity of treatment, for example oven treatment at 200°C at 30 minutes versus 300 °C for 1 hour. Studies with random or non-random order of cross over were included.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the author(s).

- Random or non random between group comparisons in which a group with proven allergy (with positive challenge) to the food are allocated to exposure to a comparison form of the food or a test form of the food using random or non random methods. Each participant being exposed to either the comparison or test form of the food only. For example infants with allergy to cow milk being allocated to partially hydrolysed or fully hydrolysed cow milk formula.
- Non-comparison studies were included only if those being challenged had a recent diagnosis of allergy to that food using a valid method that included food challenge. We did not include non comparison studies where the participants did not have a recent positive food challenge result to the comparison food.

2.2.1.3. Type of participants

We included studies whose participants were either adults or children (residing in any country) with gastro intestinal food allergies such as eosinophilic esophagitis, eosinophilic gastroenteritis, food protein induced allergic proctocolitis, food protein induced enterocolitis syndrome, oral allergy syndrome, those with cutaneous reactions to foods such as acute urticaria, angiodema, atopic dermatitis, allergic contact dermatitis, contact urticaria, and respiratory symptoms (Boyce et al, 2010) with a positive diagnosis using recognized procedures such as of a history of symptoms and a positive serum specific IgE or skin prick test to the relevant food (any foods containing milk/dairy, eggs, cereals, peanuts, nuts, celery, crustaceans, fish, molluscs, soy, lupin, mustard and sesame), or a positive food challenge (Boyce et al 2010).

2.2.1.4. Methods of food processing

We included studies comparing different types of processing (e.g. frying, boiling, dry oven, sterilisation, pasteurisation, enzyme degradation or heating and/or pressure; mechanical concentration or fractionation; chemical treatment including action of enzymes) or different intensities (e.g. duration or temperature) of processing methods or processing methods compared to the raw or native product. The full list is included in the group 3 terms of the search strategy (Table 2.1).

2.2.1.5. Types of outcome measure

The review included studies that assessed allergenicity of the food determined by observation of:

- Type and intensity of symptoms (self reported or clinician assessed)
- Dose to elicit a reaction
- Combination of the above

on contact with or ingestion of the food product within a clinic or office setting, using open or double blind placebo controlled challenge by participants with the relevant food allergy (see definition above).

2.2.2. Extraction of data

Data on the methods of recruiting participants, description of participants, diagnosis, food processing methods, challenge procedures and allergenicity of the foods was collected, by SK. A second reviewer checked that the data extraction and interpretation was accurate, and any differences resolved by discussion. Data was collected and stored in EPPI-Reviewer 4 software (Social Science Research Unit at the Institute of Education, University of London, UK).

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the author(s).

2.2.3. Assessing the quality of studies

We assessed the quality of the studies using the following categories:

- 1. Quality of diagnosis of food allergy for the study participants
- 2. Sampling procedure
- 3. How representative the sample is likely to be if people with severe allergy
- 4. Challenge procedure, i.e. is it accurate for the individual food
- 5. Comparison of challenge findings between processed foods

The methods for doing this quality assessment are outlined in Table 2.2.

EFSA supporting publication 2013:EN-506

| Criteria | Very low risk of bias | Low risk of bias | High risk of bias | Unclear |
|--|---|--|---|------------|
| Quality of diagnosis | Double blind placebo controlled food challenge | Open challenge or convincing history with sensitization (serum specific IgE &/or SPT) (if appropriate)Sensitisation (skin prick test and/or serum specific IgE) without clinical history Clinical history aloneOpen challenge or convincing history with sensitization (serum specific IgE &/or SPT) (if | | Not stated |
| Sampling procedure | NA | Random sampling, clearly defined population | Non random sampling | Not stated |
| How representative the sample is likely to be if people with severe allergy | NA | random sampling from a group with severe allergy | Non random sampling | Not stated |
| Challenge procedure, i.e. is it accurate for each individual form of food | Double blind placebo controlled food challenge with random sequence of placebo/active, and taste tested masking recipe | Stated as double blind placebo controlled food challenge | Open challenge | Not stated |
| Comparison of challenge findings between different forms of processed foods or raw foods | NA | Individual challenges had low risk of bias and all participants underwent challenges with both forms of the food | Individual challenges had high risk of bias, or not all participants underwent challenge with both forms of the food. | Not stated |

Table 2.2: The method for assessing the quality of the included studies

EFSA supporting publication 2013:EN-506

2.2.4. Analysis of Data

We classified the two or more forms of the food used in the challenge as comparison or test, if there was more than one test food these were labeled sequentially. Normally the form of the food that was used to select participants was considered to be the comparison food e.g. 'we recruited people with allergy to raw peanut', comparison food= raw peanut. In studies that were not specific about whether the selection criteria was allergy was to processed or unprocessed forms of the food we selected the least processed food form as the comparison e.g. 'we recruited people with egg allergy and then challenged to extensively heated and raw egg (comparison =raw egg, test =extensively heated egg). For dichotomous data such as percentage demonstrating a positive challenge if possible we presented the findings as Odds Ratio or Risk Ratio. For continuous data such as the minimum dose to elicit symptoms we presented the findings as mean difference.

2.3. Results

2.3.1. Results of Search

After removal of duplicates 1040 references were retrieved of these 86 were potentially eligible after full text screening (Figure 2.1). The types of studies excluded at this stage were listed as those without human participants, not involving food allergy, did not involve one of the listed foods, and studies where there was no comparison of different processing methods on the allergenicity of the foods (Figure 2.1). Within the 'other' category studies were excluded because data was not available for individual foods or the study involved only one or two cases.

The studies excluded after full text screening are show (Section 2.5 List of excluded studies), common reasons for exclusion at this stage were that participants were only challenged to one form of the food and that the majority of challenges were negative, therefore current food allergy could not be confirmed. Other groups of excluded studies were those investigated immune reactivity and not challenge findings, being represented by studies that investigated how IgE binding to food proteins within ELISA, or western blotting are altered by different processing methods. Studies investigating primary prevention of allergy by introduction of special infant milk formulas were also excluded at this stage as they were beyond the remit of this review.

We attempted to find studies investigating the effect of using egg or milk as fining agents within the wine making industry. However we were unable to find studies that included egg and milk allergic participants who were confirmed with oral food challenges and who also underwent challenges with the wine products.

Although a large number of studies are carried out on peanut allergy we could not find studies that challenged participants with two forms of peanut, for example raw and roasted, however we did find one study that investigated the allergenicity of crude or refined peanut oil.

We included 25 studies and they are detailed in the following section.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the author(s).

Figure 2.2.: PRISMA flow diagram, ending with included studies, and number included for each food, Full text screening excluded and reasons



225

2.3.2. Description of Studies

The studies included investigated the allergenicity of the following reported allergens celery (1), wheat (1), egg (6), hazelnut (2), milk and dairy (14), peanut oil (1) these studies are listed in food order (Table 2.3). Studies tended to focus on the effect of heat, commonly, boiling, roasting or baking. The exceptions were the studies investigating hydrolysis and fractioning of milk for infant milk formulas, Ammar (1999), Burks (2008), Caffarelli (2002), Giampietro (2001), Kaczmarski (2005), Niggemann (2008), Ragno (1993), Rugo (1992), Sampson (1991) and one study investigating the effect of maturation time for cheese production for those with allergy to the additive lysozyme (from egg), Marseglia (2012) or milk allergens Alessandri (2012).

The majority of studies utilized a cross-over design with each participant underwent challenge to two forms of the food. The order in which the participants were allocated to the challenge with each type of food was determined randomly for only a small proportion of studies and these investigated milk, Giampietro (2001), Host (1988), Ragno (1993), Sampson (1991) and one peanut oil, Hourihane (1997). A random order of challenge reduces the risk of bias for the study, as those that are challenge positive to one form of food could refuse challenge with the second form of food, or one type of food is perceived as being more allergenic than another.

The remaining cross-over studies used a non-random order, usually because the participants were challenged to the food considered least allergenic first as exemplified by Nowak-Wegrzyn (2008). Within this study participants were challenged with heated milk, only those that were challenge negative then went on to have the challenge with un-heated milk. A similar study was carried out with egg, Lemon-Mule (2008), where challenges were first carried out to baked eggs and again only those that tolerated this challenge went on to be challenged with regular egg (scrambled or cooked in French toast). The authors designed these studies to investigate whether a diet including extensively heated egg or milk could lead to increased tolerance rather than the effect of processing on allergenicity.

In one study, a large group of participants was challenged to raw hazelnut first and then a subset challenged to the roasted product. This study was considered as a between group comparison as the paired cross-over data was not available Worm (2009). The selection procedure for this subset was not clear and so the group receiving challenge with the roasted product could have been naturally more or less sensitive to hazelnut protein than the main group.

| Study ID | Food | Type of allergy | Source | Comparison processing method | Test processing method | Design |
|-----------------------------|------------------|--|--|------------------------------------|-------------------------------|--------------------------|
| Ballmer- Weber (2002) | Celery | Both IgE and non IgE mediated | Clinic Allergy Unit of University Hospital Zurich | Raw | Baked 110 °C for 15 min | Cross over non random |
| Scibilia (2006) | Cereals Wheat | IgE mediated allergy | Clinic Allergy Units in Europe, Niguarda Ca Granda Hospital, Milan, Italy; Milan University Hospital, Milan, Italy; or Odense University | Raw | Boiled | Cross over non random |

Table 2.3:Summary of description of studies (alphabetical order by food)

EFSA supporting publication 2013:EN-506

226

| Study ID | Food | Type of allergy | Source | Comparison processing method | Test processing method | Design |
|------------------------------|------------------|--|--|---|--|--|
| | | | Hospital, Odense, Denmark | | | |
| Alessandri (2012) | Egg | IgE mediated allergy | Clinic Centre for Molecular Allergology, IDI- IRCSS, Rome, Italy | Raw | Boiled 10 min | Cross over non random |
| Ando (2008) | Egg | IgE mediated allergy | Clinic | Raw egg white | Extensively heated 90 °C for 60 min | Cross over non random |
| Lemon- Mule (2008) | Egg | IgE mediated allergy | Clinic Mount Sinai Medical Centre New York | Heated (regular) Scrambled/Fr ench toast | Extensively heated | Cross over non random |
| Boyano Martinez (2001) | Egg | Both IgE and non IgE mediated | Not reported | Raw | Boiled 10 min | Cross over non random |
| Urisu (1997) | Egg white | IgE mediated allergy | Not reported | Raw | Extensively heated 90 °C for 60 min | Cross over non random |
| Marseglia (2012) | Egg, Lysozyme | IgE mediated allergy | Clinic Pediatric Unit, University Hospital Pavia, Italy | Unclear if raw or heated egg | Cheese; Granda Padano 12 month matured; Granda Padano 24 month matured | Cross over Non random |
| Hansen (2003) | Hazelnut | IgE mediated allergy | Clinic Allergy units, University Hospitals in Copenhagen and Zurich | Raw | Roasted 140 °C 40 min | Cross over non random |
| Worm (2009) | Hazelnut | IgE mediated allergy | Clinic Dermatology outpatient clinic | Raw | Roasted 144 °C | Between group comparison non random |
| Alessandri (2012) | Milk/ Dairy | IgE mediated allergy | Clinic Centre for Molecular Allergology, IDI- IRCSS, Rome, Italy | Pasteurized | Cheese; Parmigiano- Reggiano | Cross over non random |
| Ammar (1999) | Milk/ Dairy | Both IgE and non IgE mediated | Clinic | Hydrolysed A range of products | Amino acid– based formulas; Neocate | Cross over non random |
| Burks (2008) | Milk/ Dairy | IgE mediated allergy | Clinic Fourteen clinical sites in the USA | Pasteurized | Amino acid– based formulas; | Cross over non random |
| Caffarelli (2002) | Milk/ Dairy | IgE mediated allergy | Not reported | Pasteurized | Whey partially hydrolysed; Whey extensively | Cross over non random |

227

| Study ID | Food | Type of allergy | Source | Comparison processing method | Test processing method | Design |
|-----------------------------|----------------|--|--|------------------------------------|--|--------------------------|
| | | | | | hydrolysed; Casein extensively hydrolysed; | |
| Giampietro (2001) | Milk/ Dairy | IgE mediated allergy | Clinic Tertiary referral centres in Italy and Sweden | Pasteurized | Whey extensively hydrolysed; Nutrilon Pepti | Cross over random |
| Host (1988) | Milk/ Dairy | Both IgE and non IgE mediated | Not reported | Raw | Pasteurised Cow's milk | Cross over random |
| Kaczmarski (2005) | Milk/ Dairy | IgE mediated allergy | Clinic Hospitalised children | Low lactose Cow's milk | Casein extensively hydrolysed; Nutramigen | Cross over non random |
| Komata (2009) | Milk/ Dairy | IgE mediated allergy | Not reported | Pasteurized | Extensively heated | Cross over non random |
| Niggeman (2008) | Milk/ Dairy | IgE mediated allergy | Not reported | Pasteurized | Extensively hydrolysed | Cross over non random |
| Nowak- Wegrzyn (2008) | Milk/ Dairy | IgE mediated allergy | Clinic Mount Sinai Pediatric Allergy Clinic | Pasteurized | Extensively heated | Cross over non random |
| Ragno (1993) | Milk/ Dairy | IgE mediated allergy | Clinic Allergy and Immunology Division, Depart. Paediatrics, University of Rome "La Sapienza" Italy | Pasteurized | Casein hydrolysate; Nutramigen | Cross over random |
| Rugo (1992) | Milk/ Dairy | IgE mediated allergy | Clinic | Pasteurized | Whey hydrolysate;; Profylac Whey hydrolysate; Nidina Casein hydrolysate Nutramigen Casein hydrolysate Pregestimil Whey hydrolysate; Alfare Whey hydrolysate; Beba HA Whey hydrolysate; Ultrafiltered | Cross over non random |
| Sampson (1991) | Milk/ Dairy | IgE mediated allergy | Clinic John Hopkins Paediatric Clinical Research Unit | Pasteurized | Casein Hydrolysate; Alimentum | Cross over random |

228

| Study ID | Food | Type of allergy | Source | Comparison processing method | Test processing method | Design |
|---------------------|---|----------------------------|---|------------------------------------|---|--------------------------|
| Kim (2011) | Milk/ Dairy Cow's milk and cheese | IgE mediated allergy | Clinic Mount Sinai Pediatric Allergy Clinic | Pasteurized | Baked 350 °C for 30 min | Cross over non random |
| Hourihane (1997) | Peanut | IgE mediated allergy | Community Those responding to a survey and who volunteered | Roasted, salted peanuts | Crude peanut oil Refines peanut oil | Cross over random |

2.3.3. Participants

The details of the study participants are presented in study author order for easy reference (Table 2.4). All studies of egg and milk were carried out with children (Table 2.4), perhaps reflecting the higher prevalence within these age groups. Studies involving adults were carried out for celery Ballmer-Weber (2002), for wheat Scibilia (2006), and a mixed population for milk, Hansen (2003), Nowak-Wegrzyn (2008) and, Ragno (1993), and for peanuts, Hourihane (1997).

We made the decision to include only those individuals who were challenge positive to one or more of the forms of the food. Therefore, we excluded the data from those who were challenge negative to both forms of the food. So for example using this rule we excluded from our analysis in the study by Nowak-Wegrzyn (2008) on milk 9 of the 100 participants, for the by Boyano Martinez on reactivity to egg we excluded 17 of 56 participants and for the study on peanut oil , by Hourihane (1997) we excluded two of the 62 potential participants.

Of the 25 studies, 20 included participants with either skin prick test or specific IgE sensitivity to the allergen, in addition to the food challenge findings. Studies did not tend to include a high proportion of participants with severe allergy, although many did enroll at least one person with a history of anaphylaxis and within one study, Komata (2009), 49% of participants had a history of anaphylaxis.

| Study ID | Food | Type of Allergy | Sensitisation | History of Symptoms | Challenge | Country | Sex | Age Range |
|------------------------|---------------------|----------------------------|----------------------------|--|-------------------|---------------|---------------|------------------------|
| Alessandri (2012 a) | Milk/ Dairy | IgE mediated allergy | Either SPT or specific IgE | Not reported | DBPCFC | Italy | Female 23% | Children |
| Alessandri (2012 b) | Egg Whole egg | IgE mediated allergy | IgE and SPT | Anaphylaxis, Gastrointestinal, Oral allergy syndrome, Rhinitis, Respiratory Urticaria, Other: Worsening of eczema, conjunctivitis | DBPCFC | Italy Rome | Female 36% | Children 1-11y |
| Ammar | Milk/ Dairy | Both IgE and non | Either SPT or specific IgE | Gastrointestinal Other | Open challenge | France | Female 73% | Children 15 days –3 |

Table 2.4: Participants included in the studies (alphabetical order by study author)

EFSA supporting publication 2013:EN-506

| Study ID | Food | Type of Allergy | Sensitisation | History of Symptoms | Challenge | Country | Sex | Age Range |
|------------------------------|----------------|--|--|--|---|------------------------|-----------------|---|
| (1999) | | IgE mediated | 13 positive SPT, 6 specific IgE Not reported | Failure to thrive | | | | months |
| Ando (2008) | Egg | IgE mediated allergy | Specific IgE | Anaphylaxis Gastrointestinal Respiratory Atopic dermatitis/ eczema | DBPCFC | Japan | Female 41% | Children median 30, range 14- 72 months |
| Ballmer- Weber (2002) | Celery | Both IgE and non IgE mediated | Not reported | Not reported | DBPCFC (12) | Switzerland | Female 58% | Adults Mean 27.9, SD ±7.3y (range 21- 42 y) |
| Boyano Martinez (2001) | Egg | Both IgE and non IgE mediated | Specific IgE SPT | Gastrointestinal Oral allergy syndrome: Sneezing, nasal itching and or congestion. Respiratory Urticaria, Angioedema | Open challenge | Spain Madrid | Female 39.5% | Children 11–24 months |
| Burks (2008) | Milk/ Dairy | IgE mediated allergy | Specific IgE SPT | Atopic dermatitis/ eczema | DBPCFC (Five Cow's milk +ve by DBPCFC; 24 +ve specific IgE not included in this review) | USA | Not reported | Children |
| Caffarelli (2002) | Milk/ Dairy | IgE mediated allergy | Specific IgE SPT | Respiratory Urticaria Atopic dermatitis/ eczema Angioedema | Open DBPCFC | Italy | Not reported | Children |
| Giampietro (2001) | Milk/ Dairy | IgE mediated allergy | Not reported | Urticaria Atopic dermatitis/ eczema | Open Elimination | Italy Sweden | Not reported | Children Mean 37 months |
| Hansen (2003) | Hazelnuts | IgE mediated allergy | Specific IgE CAP- raw or roasted. SPT Prick to prick- raw or roasted | Oral allergy syndrome 17/17 Systemic reaction 3/17 | DBPCFC All except for one patient with a convincing clinical history | Denmark Switzerland | Female 65% | Adults and children median 24.5; range 14–65 years |

| Study ID | Food | Type of Allergy | Sensitisation | History of Symptoms | Challenge | Country | Sex | Age Range |
|-----------------------------|---------------------------------|--|-------------------------------|--|-----------------------------|-------------------|------------------|---|
| Host (1988) | Milk/ Dairy | Both IgE and non IgE mediated | Not reported | Gastrointestinal: Vomiting, Oral allergy syndrome: Allergic rhinitis, Respiratory: Asthma. Atopic dermatitis/ eczema, Urticaria | Open Elimination diet | Denmark Odense | Female 80% | Children 12-40 months |
| Hourihane (1997) | Peanut | IgE mediated allergy | Specific IgE SPT | Pruritus, urticarial, swollen lips, erythema, facial swelling, oedema, wheeze and anaphylaxis | Open and DBPCFC | UK | Female 78% | Adults and children Mean 26, range 14- 48 years |
| Kaczmarski (2005) | Milk/ Dairy | IgE mediated allergy | Either SPT or specific IgE | Atopic dermatitis/ eczema | Open | Poland | Female 36% | Children mean 11.34 months, range 1 - 28 months |
| Kim (2011) | Milk/ Dairy Cows' milk | IgE mediated allergy | Either SPT or specific IgE | Not reported (Exclusion criteria: recent reaction to baked milk) | Open challenge | USA | Not reported | Children mean 6.6 y, range 2.1- 17.3 y |
| Komata (2009) | Milk/ Dairy | IgE mediated allergy | Either SPT or specific IgE | Anaphylaxis 48.6 % Atopic dermatitis/ eczema 91.9 % Angioedema 91.9 % | Open challenge | Japan | Female 13.5 % | Children mean 63.2 years, SD (±6.3) |
| Lemon- Mule (2008) | Egg | IgE mediated allergy | either SPT or specific IgE | Not reported (exclusion criteria: recent reaction to extensively heated egg) | Open challenge | USA New York | Not reported | Children mean 6.9 y, range 1.6- 18.6 y |
| Marseglia (2012) | Egg Lysozyme | IgE mediated allergy | Specific IgE | | Open challenge | | | unclear |
| Niggeman (2008) | Milk/ Dairy | IgE mediated allergy | SPT | Yes, but not described | DBPCFC | Germany | Female 60% | Infants approx. 36 weeks old |
| Nowak- Wegrzyn (2008) | Milk/ Dairy | IgE mediated allergy | Specific IgE SPT | Not reported (exclusion criteria: recent | Open | USA New York | Not reported | Mean 7.5 y range 0.5 - 21 y |

231

| Study ID | Food | Type of Allergy | Sensitisation | History of Symptoms | Challenge | Country | Sex | Age Range |
|--------------------|---|----------------------------|---|--|-------------------|-----------------------|-----------------|--|
| | | | | reaction to heated milk) | | | | |
| Ragno (1993) | Milk/ Dairy | IgE mediated allergy | Either SPT or specific IgE | Gastrointestinal Respiratory: Asthma. Urticaria Angioedema | Open challenge | Italy | Not reported | Children 15 -76 months |
| Rugo (1992) | Milk/ Dairy | IgE mediated allergy | Specific IgE Fluorescence Immunoassay SPT | Gastrointestinal Respiratory Asthma Urticaria Atopic dermatitis/ eczema | Open challenge | Germany | Female 24% | Children Median 16 months, range 5 months - 9.5 y |
| Sampson (1991) | Milk/ Dairy | IgE mediated allergy | Specific IgE SPT | Gastrointestinal Oral allergy syndrome Respiratory Atopic dermatitis/ eczema Urticaria Other Skin rash | DBPCFC | USA | Not reported | Children 8 months - 9.5 y |
| Scibilia (2006) | Cereals Wheat | IgE mediated allergy | Not reported | Gastrointestinal Oral allergy syndrome Rhinitis Respiratory Atopic dermatitis/ eczema Urticaria. Exercise-induced Angioedema | DBPCFC | Denmark Italy | Female 67% | Adults 19-60y Children 14-16y |
| Urisu (1997) | Egg | IgE mediated allergy | Specific IgE | Anaphylaxis Erythema Gastrointestinal Respiratory Urticaria. Atopic dermatitis/ eczema | DBPCFC | Japan | Female 39% | Children 1–10 y |
| Worm (2009) | Hazelnut and mostly birch pollen sensitive | IgE mediated allergy | Specific IgE Phadia CAP SPT Prick to prick and ALK extract- raw and roasted | Oral allergy syndrome Systemic group no data Urticaria | DBPCFC | Germany (presumed) | Not reported | Not reported |

2.3.4. Processing methods

The summary of the processing methods are shown (Table 2.5), in study author order. Many of the methods used are relevant to commercial and home cooking such as baking milk within a muffin. For the comparison food we listed the form of the food that we considered being least processed. In most cases, this was listed by the authors as being the more allergenic form as exemplified by raw egg, compared to egg baked within a cake. The study authors reported wet weight or volume rather than standardizing challenges by dry weight or protein concentration.

EFSA supporting publication 2013:EN-506

| Table 2.5: | Method of processing comparison and test food. | Wet weight indicates the | e weight of the processed of | or unprocessed food was u | ised without adjusting for the |
|-------------------|--|--------------------------|------------------------------|---------------------------|--------------------------------|
| | moisture or protein content (alphabetical order by | y author). | | | |

| Study ID | Comparison processing method | Comparison supplier | Comparison variety | Comparison quantified by | Test processing method | Test brand and supplier | Test variety | Test quantified by |
|-------------------------|---|------------------------|-----------------------|--|--|---|-------------------------|--|
| Alessandri (2012 b) | Raw Prepared by Laboratory prepared | Not reported | Unclear | Other 1 whole egg | Test 1 Boiled 10 min Prepared by Laboratory prepared | Not reported | Unclear | Dry weight 1 whole egg |
| Alessandri (2012a) | Pasteurised Prepared by Unclear | Not reported | Unclear | Wet weight | Cheese Parmigiano- Reggiano (PR) Prepared by Unclear | Not reported | Parmigiano- Reggiano | Wet weight or volume 200 ml Cow's milk = 13.3 g PR |
| Ammar (1999) | Hydrolysed A range of products Prepared by Shop bought | Not reported | Not reported | Not stated | Amino acid-based formulas (AAFs) Neocate Prepared by Shop bought | Test 1 Neocate | Not reported | Not reported |
| Ando (2008) | Raw Prepared by Laboratory prepared Raw liquid egg white freeze dried, homogenised | Not reported | Unclear | Wet weight Highest possible dose Equivalent to one egg | Extensively heated Liquid egg white, 90 °C for 60 min, freeze dried milled | Not reported | Unclear | Wet weight or volume One egg |
| Ballmer-Weber (2002) | Raw Prepared by Laboratory prepared | Unclear | Unclear | Wet weight 20 g raw added to the drink (1 ml of drink contains 0.144 g raw celery) | Test 1 Baked, 110 °C for 15 min. Small additional open challenge of samples cooked for 7.45, 13.12, 23.64, 76.07 min at 100 °C Prepared by Laboratory prepared | Test 1 Dr N Sauerwald (Nestle, Frankfurt, Germany) | Unclear | Wet weight or volume |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Comparison processing method | Comparison supplier | Comparison variety | Comparison quantified by | Test processing method | Test brand and supplier | Test variety | Test quantified by |
|---------------------------|--|------------------------|-----------------------|-----------------------------|--|---|----------------|-------------------------|
| | | | | | Test 2 Dried and pulverized Celery spice | Test 2 Dr N Sauerwald (Nestle, Frankfurt, Germany) | | |
| Boyano Martinez (2001) | Raw egg whites Prepared by Not reported | Not reported | Not reported | Wet weight | Test 1 Boiled 10 min Prepared by Not reported | Not reported | Unclear | Wet weight or volume |
| Burks (2008) | Pasteurised Prepared by Unclear | Not reported | Unclear | Wet weight | Test 1 Amino acid–based formulas (AAFs) Prepared by Unclear | Test 1 Neocate | Not applicable | Wet weight |
| | | | | | Test 2 Extensively hydrolysed formula (EHF) Prepared by Laboratory prepared | Test 2 Mead Johnson Nutritionals, Evansville, Indiana | Not applicable | |
| Caffarelli (2002) | Pasteurised Prepared by Laboratory prepared | Not reported | Not reported | Wet weight | Test 1 Whey partially hydrolysed Humana Test 2 Extensively hydrolysed whey formula (EHF) Hypolac Test 3 Extensively hydrolysed casein | Test 1 Humana, Milano, Italy. Test 2 ALK, Lainate, Milano, Italy Test 3 Nutramigen, Mead Johnson, Roma, | | Wet weight or volume |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Comparison processing method | Comparison supplier | Comparison variety | Comparison quantified by | Test processing method | Test brand and supplier | Test variety | Test quantified by |
|----------------------|--|--|-------------------------|-----------------------------|---|--|-------------------------|-------------------------|
| | | | | | Test 4 Amino acid derived formula Nutri- junior, | Test 4 Nutricia, Milano, Italy | | |
| Giampietro (2001) | Pasteurised Prepared by Laboratory prepared | Not reported | Unclear | Wet weight | Test 1Nutrilon Peptiextensivelyhydrolysed wheyTest 2ProfylacExtensivelyhydrolysed wheyTest 3Nan HAPartial wheyhydrolysate | Nutricia, Zoetermeer, Netherlands ALK, Horsholm, Denmark Nestlé, Vevey, Switzerland | Unclear | Wet weight or volume |
| Hansen (2003) | Raw Prepared by Shop bought | Sorematec, Arlon- Schoppach, Belgium | Piemonte | Wet weight | Test 1 Roasted, (140 °C, 40 min) Prepared by Shop bought | Test 1 Sorematec, Arlon- Schoppach, Belgium. | Piemonte | Wet weight or volume |
| Host (1988) | Raw Prepared by Laboratory prepared | J.Kollerup, Enigheden Dairy Copenhagen, Denmark | Unclear Not reported | Wet weight Volume | Test 1 Pasteurised Cow's Milk Prepared by Laboratory prepared Test 2 Homogenised and pasteurised cow's milk | Test 1 J.Kollerup, Enigheden Dairy Copenhagen, Denmark Test 2 J. Kollerup, Enigheden Diary. Copenhagen, Denmark | Unclear Not reported | Wet weight or volume |
| Hourihane (1997) | Roasted, salted peanuts | KP Foods, Leicester | Not reported | Nuts | Test 1 Refined peanut oil | Random batches of oil supplied by the Seed Crushers' and | Unclear | Wet weight |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Comparison processing method | Comparison supplier | Comparison variety | Comparison quantified by | Test processing method | Test brand and supplier | Test variety | Test quantified by |
|----------------------|---|------------------------|-----------------------|-----------------------------|---|--|--------------|-------------------------|
| | | | | | Test 2 Crude peanut oil | Oil Processors' Association. | | |
| Kaczmarski (2005) | Low lactose cow's milk Prepared by Not reported | Bebilon Nutricia | Not reported | Wet weight | Test 1Casein extensivelyhydrolysedTest 2Whey extensivelyhydrolysed | Test 1 Nutramigen, Mead Johnson Test 2 Bebilon Pepti 1 or 2, Nutricia | | Wet weight or volume |
| Kim (2011) | Pasteurised Prepared by Shop bought | Unclear | Unclear | Wet weight | Test 1BakedMuffin with 1.3 g ofmilk protein. Bakedat 350 °C for 30min. Also Bakedcheese within aPizzaPrepared byprepared in house | Unclear | Unclear | Wet weight |
| Komata (2009) | Pasteurised | Unclear | Unclear | Volume | Test 1 Extensively heated | Unclear | Unclear | Volume |
| Lemon-Mule (2008) | Heated Scrambled/French toast Prepared by Unclear | Not reported | Not reported | Volume | Test 1 Extensively heated Prepared by Unclear | Not reported | Not reported | Volume |
| Marseglia (2012) | Unclear Egg not clear if raw or cooked | Not reported | Not reported | Volume | Test 1 Cheese Granda Padano 12 month matured Test 2 Cheese Granda Padano 24 month matured | | | Wet weight |
| Niggeman (2008) | Pasteurised Prepared by Shop bought | Not reported | Not reported | Volume | Test 1 extensively hydrolysed ultra | Test 1 Althera, Nestle´, Switzerland | Not reported | Volume |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Comparison processing method | Comparison supplier | Comparison variety | Comparison quantified by | Test processing method | Test brand and supplier | Test variety | Test quantified by |
|-------------------------|---|--|-----------------------|--|---|--|--------------|---|
| | | | | | filtered whey Test 2 Amino acid based | Test 2 Neocate, SHS, UK | | |
| Nowak-Wegrzyn (2008) | Pasteurised Prepared by Shop bought | Nestle Carnation, Glendale, California | Non-fat | Wet weight | Test 1 Extensively heated Prepared by In house | Nestle Carnation, Glendale, California | Non-fat | Wet weight |
| Ragno (1993) | Pasteurised Prepared by Unclear | | | Wet weight | Test 1 Casein hydrolysed Test 2 Whey extensively hydrolysed Test 3 Whey partially hydrolysed | Test 1 Alimentum,Ross Test 2 Profylac, ALK Test 3 Nidina HA, Nestle | | Wet weight or volume |
| Rugo (1992) | Pasteurised Prepared by Not reported | Not reported | Not reported | Wet weight ml Highest possible dose 40ml | Test 1Casein hydrolysateTest 2Casein hydrolysateTest 3Whey hydrolysateTest 4Whey hydrolysateTest 5Whey hydrolysateUltrafiltered | Test 1 Nutramigen Test 2 Pregestimil Test 3 Alfaré Test 4 Beba HA Test 5 Ultrafiltered | | Dry weight g/ml dissolved hydrolysate |
| Sampson (1991) | Pasteurised Prepared by Unclear | Not reported | | Wet weight | Test 1Casein hydrolysedPlaceboCasein extensivelyhydrolysed | Test 1 Alimentum, Ross Laboratories, Columbus, Ohio Placebo | | Wet weight or volume |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Comparison processing method | Comparison supplier | Comparison variety | Comparison quantified by | Test processing method | Test brand and supplier | Test variety | Test quantified by |
|-----------------|---|------------------------|-----------------------|-----------------------------|--|------------------------------|--------------|-------------------------|
| | | | | | | Nutramigen, Mead Johnson, | | |
| Scibilia (2006) | Raw Prepared by Laboratory prepared | Not reported | Variety Unclear | Dry weight 25g | Test 1 Boiled No details on how the wheat was cooked Prepared by Laboratory prepared | Not reported | Unclear | Dry weight 25g |
| Urisu (1997) | Raw Freeze-dried egg white Prepared by Laboratory prepared | Not reported | Unclear | Dry weight | Test 1Extensively heated90 °C for 60 mPrepared byLaboratory preparedTest 2Heated ovomucoiddepletedPrepared byLaboratory prepared | Not reported | Unclear | Dry weight |
| Worm (2009) | Raw finely ground Prepared by Unclear | Unclear | Unclear | Wet weight | Test 1 Roasted, 144 °C Prepared by laboratory Test 2 HN flour Capsule | | Unclear | Wet weight or volume |

2.3.5. Challenge procedure

The challenge procedures are summarised (Table 2.6). In those studies that carried out a DBPCFC the method of masking and the procedure for randomisation was not clearly reported in many of the studies. Although many studies reported the method of masking and the recipe, they did not report whether this was taste tested. The method of generating the random sequence, the ratio of active to placebo challenge and the way in which the sequence was concealed from the participants and the study personnel during the challenge and while the symptoms were assessed was not described in the majority of studies. We attempted to record how the study authors dealt with positive reactions to placebo; however in the majority of instances this was not reported. If the test food challenge procedure differed significantly for the comparison food then this was shown (Table 2.7).

Studies that reported their challenge methods in detail include Alessandri (2012 b), Hansen (2003) and Sampson (1991).

| Study ID | Avoid foods prior to challenge | Masking | Was the sequence placebo : active random | Random sequence concealme nt | Doses | Outcome description |
|------------------------|---|--|--|---------------------------------------|---|--|
| Alessandri (2012 b) | Yes | Taste tested: unclear | Random | Concealed | 0.1, 0.5, 2, 10, 50 ml up to 1 egg equivalent to 6 g egg protein Time delay: 20 min Method Ingestion | Positive response local non-objective restricted to area in contact with allergen, oral allergy syndrome or isolated digestive complaints, systemic objective, e.g. urticaria, asthma, or anaphylaxis Dose response within 6 hours of the first dose Handling of positive placebo Not reported |
| Alessandri (2012a) | Yes | Taste tested: unclear | Random | Unclear | 0.05, 0.15, 0.3, 1, 3, 10, 30, 50, 100, 195 ml Time delay: 20 min | Positive response Handling of positive placebo Not reported |
| Ammar (1999) | Not reported | Taste tested: unclear Open challenge | | | 1, 5, 80 ml Time delay: unclear Method Ingestion | Positive response Any reaction also any delayed reaction Handling of positive placebo Not reported |
| Ando (2008) | Not reported | Taste tested: Unclear Placebo: glucose in the | Unclear | Unclear | 0.1 ml, 1 ml, 10 ml and then the remainder of the egg white Time delay: 30 min | Positive response Continued until objective symptoms developed or entire challenge dose ingested. Handling of positive placebo |

| Table 2.6: | Challenge procedur | e for comparison f | ood (study | v author order) |
|------------|---------------------|--------------------|------------|-----------------|
| | Chancinge procedury | c for comparison r | oou (blue | uuunoi oraci) |

EFSA supporting publication 2013:EN-506

| Study ID | Avoid foods prior to challenge | Masking | Was the sequence placebo : active random | Random sequence concealme nt | Doses | Outcome description |
|------------------------------|---|--|---|--|---|---|
| | | same juice as the active | | | Method Ingestion | Not reported |
| Ballmer-Weber (2002) | Not reported | Taste tested: Unclear | Unclear | Unclear | 0.7 g, 28.5 g Time delay: Unclear Method Ingestion | Positive response Oral allergy syndrome, dyspnoea, rhinitis, conjunctivitis, flush, vertigo, angioedema. |
| | | | | | | Handling of positive placebo |
| Boyano Martinez (2001) | Not reported | Taste tested: unclear Open challenge | Not applicable | Not concealed | 1/8 , 1/4 and 1/2 of the egg white Time delay90 minMethod Ingestion | Positive response Objective symptoms |
| Burks (2008) | Not reported | Taste tested: unclear | Unclear | Unclear | Time delay: unclear Method Ingestion | Positive response Handling of positive placebo Not reported |
| Caffarelli (2002) | Yes, 3 months before | Taste tested: unclear | Random Ingestion | Unclear | Time delay: 20 min Method Ingestion | A positive response Handling of positive placebo Not reported |
| Giampietro (2001) | Not reported | Not taste tested | Random 'the order was randomise d' | Concealed blind | 0.2, 2, 20, 50 and 150 ml Time delay: 20 min Method Ingestion | Positive response Urticaria, asthma, gastrointestinal, rhinitis and erythema and itch. Handling of positive placebo Not reported |
| Hansen (2003) | Not reported | Taste tested: unclear | Random 'the challenge order was randomize d' | Concealed A dietician prepared the foods, code not broken until complete | Max. Dose Copenhagen 10 g, Zurich 18.2 g Method Ingestion | Positive response Handling of positive placebo Not reported |
| Hourihane (1997) | Yes | Open challenge | na | na | labial challenge, followed by ¼ ½ 1 peanut up to 32 peanuts Time interval 10-15 min | Positive response Objective symptoms |

| Study ID | Avoid foods prior to challenge | Masking | Was the sequence placebo : active random | Random sequence concealme nt | Doses | Outcome description |
|----------------------|---|--|--|---------------------------------------|---|---|
| | | | | | Method Ingestion | |
| Host (1988) | Yes a milk free diet 4 weeks prior to chall-enge | Not taste tested | Random | Concealed | 5, 10, 20, 40, 80, up to 160 ml Time delay: 2h Method Ingestion | Positive response a) the child displayed definitive allergic reactions in- keeping with the child's history of CMA. b) The provoked symptoms disappeared after withdrawal of the milk preparation in question or c) coincidental infection could be excluded |
| Kaczmarski (2005) | Not reported | Not taste tested open challenge | na | na | 0.1, 1, 3, 10, 30, 50, 100 ml according to age Time delay: unclear Method Ingestion | Positive response. If infants did not show a positive response they were fed the milk for up to 2 weeks. |
| Kim (2011) | Yes | Open challenge | na | na | Method Ingestion | Positive response |
| Komata (2009) | Unclear | Open challenge | Unclear | Unclear | Method Ingestion | Positive response |
| Lemon-Mule (2008) | Not reported | Open challenge | na | na | Not reported Time delay: unclear Method Ingestion Objective symptoms | Positive response Objective symptoms |
| Marseglia (2012) | Unclear | Comparis on-open challenge | NA | na | Method Ingestion description Oral provocation test (University of Pavia, number 2-2009) | Positive response |
| Niggeman (2008) | Yes | DBPCFC | Yes | Unclear | 0.1,0.3, 1.0, 3.0, 10.0, 30.0, and 100.0 | Positive response Growth rates |
| | | | | | Method Ingestion | Handling of positive placebo Not described |

243

| Study ID | Avoid foods prior to challenge | Masking | Was the sequence placebo : active random | Random sequence concealme nt | Doses | Outcome description |
|-----------------------------|--|--|--|---------------------------------------|---|--|
| Nowak- Wegrzyn (2008) | Not reported | Comparis on-open challenge | na | na | Method Ingestion | Positive response Objective symptoms |
| Ragno (1993) | Not reported | Not taste tested Comparis on- open challenge | Random | Concealed | A drop of the inner lower lip then 5 ml then 100ml. Time delay 30 min - 1 week gap between challenges Method Ingestion Rubbing on lips | Positive response Objective symptoms Handling of positive placebo Not described |
| Rugo (1992) | Yes Milk/dairy eliminatio n diet for at least one week prior | Comparis on- open challenge | Objective symptoms | | 0.2ml - 1ml - 2ml - 5ml - 10ml - 20ml Time delay 20-30 min Method Objective symptoms | Positive response Challenges were stopped once symptoms occurred or at highest dose. Immediate and late (up to one hour recorded) Dose response |
| Sampson (1991) | Not reported | Not taste tested Comparis on- open challenge | Random | Concealed | Up to 10 g in 100ml of formula in a period of 60 - 90 minutes. Each challenge was initiated with 5ml formula. Time delay 15 minutes | Positive response Handling of positive placebo No positive reactions to placebo |
| Scibilia (2006) | Yes 1 week prior | Taste tested: unclear Comparis on- open challenge | Unclear | Unclear | Cumulative dose schedule: 100 mg, 600 mg, 1.6 g, 3.1 g, 6.1 g, 12.1 g, 25 g Time delay 20 min Method Ingestion | Positive response Dose response Handling of positive placebo No positive reactions to placebo |
| Urisu (1997) | Not reported | Taste tested: unclear | Unclear | Unclear | Increasing to 8 g Time delay 30 minutes | Positive response |
| Worm (2009) | Yes 1 week | Taste tested: unclear | Unclear | Unclear | 0.01-0.02-0.03- 0.05-0.1-0.2-0.4- 1.0-2.5-5.0- 10.0 g. Time delay 15 min | Positive response % Dose response Single amount of HN eliciting symptoms |

EFSA supporting publication 2013:EN-506

244

Table 2.7:Challenge procedures for test food (alphabetical order by author) if different to
comparison food

| Study ID | Avoid foods prior to challenge | Masking | Was the sequence placebo : active random | Random sequence concealment | Doses | Outcome description |
|-----------------------------|--|--|--|---|--|---|
| Alessandri (2012a) | Yes | Open challenge carried out | na | na | 0.003, 0.01, 0.02, 0.07, 0.2, 0.7, 2.0, 3.03, 6.07, 13.0 g time delay 20 min Method Ingestion | Not defined |
| Ammar (1999) | Unclear | Open challenge carried out | na | na | Method Ingestion Used as infant formula | Not define |
| Burks (2008) | Avoided food prior to challenge | Unclear if taste tested Open challenge carried out | Unclear | Unclear | Unclear DBPCFC followed by open feeding for up to 7d Method Ingestion Extended over 7d | Convincing reaction Positive reactions to placebo: Not stated |
| Hourihane (1997) | Yes | DBPCFC Taste tested | Sequence devised by another member of the team | Dietitian made up the foods for challenge | labial challenge, followed by ¹ / ₄ ¹ / ₂ 1 peanut up to 32 peanuts Time interval 10-15 min Method Ingestion | Positive response Objective symptoms |
| Marseglia (2012) | Not stated | | | | 0.5, 1, 2, 4, 8, 14.5 g time delay between doses: 20 min | |
| Niggeman (2008) | Yes | DBPCFC Unclear if taste tested | Yes | Unclear | Allocated to either amino acid or hydrolysed milk diet | Any reaction |
| Nowak- Wegrzyn (2008) | Not reported | Open food challenge | Na | na | Method Ingestion ¹ / ₄ portions muffin (1.3 g milk protein) over 1h. If no symptoms within 2 hr a waffle given Method Ingestion | Positive response Objective symptoms |

EFSA supporting publication 2013:EN-506

| Study ID | Avoid foods prior to challenge | Masking | Was the sequence placebo : active random | Random sequence concealment | Doses | Outcome description |
|-------------------|--|--|--|-----------------------------------|---|--|
| Sampson (1991) | Not reported | Not taste tested (Comparis on- open challenge) | Random | Concealed | Up to 10 g in 100ml of Nutramigen in a period of 60 - 90 min. Each challenge was initiated with 5ml formula. Time delay 15 minutes | Positive response |
| Scibilia (2006) | Yes 1 week prior | Taste tested: unclear DBPCFC | Unclear | Unclear | Cumulative dose schedule: 100 mg, 600 mg, 1.6 g, 3.1 g, 6.1 g, 12.1 g, 25 g Time delay 20 min Method Ingestion | Positive response Dose response Handling of positive placebo No positive reactions to placebo |
| Worm (2009) | Avoided food prior to challeng e | Not taste tested | Unclear | Unclear | 0.01-0.02-0.03- 0.05-0.1-0.2-0.4- 1.0-2.5-5.0-10.0 g doses initiation dose dependent on response to raw Time delay between doses: 15 min | Challenge halted when: Not stated Positive reactions to placebo Not stated |

2.3.6. Study design

The study designs are shown (Table 2.8). Within a number of studies that used a cross over design the order of receiving the different types of foods was fixed, studies with this fixed order can be grouped into two categories:

- participants received the form of the food thought to the least allergenic first (either open or by DBPCFC). If a participant demonstrated symptoms they were not challenged to the second food. This was because a positive response was assumed and further challenge thought unethical;
- participants were challenged with the form thought to be more allergenic first to confirm food allergy, only those that were challenge positive had the second challenge with the processed food e.g. Niggemann (2008), first challenged the infants to pasteurized milk (using DBPCFC) and subsequently carried out a randomised cross over study comparing two processed formulas to test allergenicity and the effect on growth.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Overarching design | Order of challenge comparison/test | Outcome results |
|------------------------------|--|---|--------------------------------------|
| Alessandri (2012 b) | Cross over non random | Not random Time delay between different foods, given on separate days Challenge carried out first with boiled egg those that were positive were not challenged to raw egg as assumed positive. | Any reaction |
| Alessandri (2012a) | Cross over non random | Not random, milk given first | Any reaction |
| Ammar (1999) | Cross over non random | Not random, all challenged with hydrolysate after a diet of Neocate | Any reaction |
| Ando (2008) | Cross over non random | Not random, heated egg challenge carried out first, those that were negative were challenged to raw egg, those positive to heated egg were not challenged to raw egg as they were assumed to be positive. | Any reaction |
| Ballmer- Weber (2002) | Cross over non random | Unclear | Any reaction Dose reaction |
| Boyano Martinez (2001) | Cross over non random | Not random Cooked egg white given first for 45 participants, only those negative to cooked egg were challenge with raw. Another 10 were challenged with raw only, as they stated they tolerated cooked egg. | Any reaction |
| Burks (2008) | Cross over non random (study 2 only) | Not random | Any reaction |
| Caffarelli (2002) | Cross over non random | Not random | Any reaction |
| Giampietro (2001) | Cross over random | Random | Any reaction |
| Hansen (2003) | Cross over non random | Not random Zurich: raw challenge first, time delay between different foods was one year Copenhagen: random, time delay between different foods was different days | Any reaction |
| Host (1988) | Cross over random | Random | Any reaction Dose of reaction |
| Hourihane (1997) | Cross over non-random Cross over random | Non random Crude and refines oil first then roasted peanut Random 'random order determined by a member of staff not involved in the evaluation of the subject' | Any reaction Dose of reaction |
| Kaczmarski (2005) | Cross over non random | Not random Low lactose cow's milk first, however not clear on order of EHC or EHW | Any reaction |

Table 2.8:Study design and outcome assessment (alphabetical order by author)

EFSA supporting publication 2013:EN-506

| Study ID | Overarching design | Order of challenge comparison/test | Outcome results |
|-----------------|-----------------------|--|------------------|
| Kim (2011) | Cross over non random | Not random | Any reaction |
| | | Time delay between different foods 6 | |
| | | months | |
| Komata (2009) | Cross over non random | Not random, Unheated milk given first | Any reaction |
| | | then given heated milk | |
| Lemon-Mule | Cross over non random | Not random, extensively heated egg was | Any reaction |
| (2008) | | given first, however time delay between | |
| | | different foods was not reported | Dose of reaction |
| Marseglia | Cross over non random | Time delay between different foods | Any reaction |
| (2012) | | Egg challenge was done previous year. | |
| | | Cheese challenges carried out at least | |
| | | 48h apart | |
| Niggemann | Cross over non random | All challenged with pasteurised milk first | Any reaction |
| (2008) | | then given extensively hydrolysed or | |
| | | amino acid based challenge in random | |
| | | order | |
| Nowak- | Cross over non random | None random, assumed same day. | Any reaction. |
| Wegrzyn | | | |
| (2008) | | | |
| Ragno (1993) | Cross over random | Random | Any reaction |
| Rugo (1992) | Cross over non random | Not random, comparison food given first | Any reaction. |
| | | | |
| Sampson | Cross over random | Random | Any reaction |
| (1991) | | | |
| Scibilia (2006) | Cross over non random | Unclear | Any reaction |
| Urisu (1997) | Cross over non random | Not random. Ovomucoid depleted, | Any reaction |
| | | heated then raw | |
| Worm (2009) | Between group | Not random. All (90) were challenged | Any reaction |
| | comparison non random | to raw given first, a non-random subset | Dose of reaction |
| | | (20) were challenged to roasted. | |

2.3.7. The Quality of studies

The quality of diagnosis for most studies

Table 2.9:Quality of Studies (alphabetical order by author)

| Study ID | Diagnosis* | Challenge order comp/test* | Sampling* | Severe allergy represented* |
|------------------------------|-----------------------|------------------------------------|---|--------------------------------|
| Alessandri (2012 b) | Very low risk of bias | High risk of bias | High risk of bias Specially selected for being negative to the test food | High risk of bias |
| Alessandri (2012a) | Very low risk of bias | High risk of bias | High risk of bias | High risk of bias |
| Ammar (1999) | Low risk of bias | High risk of bias | High risk of bias Specially selected for being positive to comparison food | High risk of bias |
| Ando (2008) | Low risk of bias | High risk of bias | High risk of bias Specially selected for being negative to the test food | High risk of bias |
| Ballmer- Weber (2002) | Very low risk of bias | Unclear | High risk of bias | High risk of bias |
| Boyano Martinez (2001) | Low risk of bias | High risk of bias | High risk of bias | High risk of bias |
| Burks (2008) | Very low risk of bias | High risk of bias | High risk of bias | Unclear risk of bias |
| Caffarelli (20020 | Low risk of bias | High risk of bias | High risk of bias | High risk of bias |
| Giampietro (2001) | Low risk of bias | Low risk of bias | High risk of bias | High risk of bias |
| Hansen (2003) | Very low risk of bias | High risk of bias | Unclear | High risk of bias |
| Host (1988) | Low risk of bias | Low risk of bias | High risk of bias | High risk of bias |
| Hourihane (1997) | Low risk of bias | Low risk of bias (between oils) | High risk of bias | High risk of bias |
| Kaczmarski (2005) | Low risk of bias | High risk of bias | High risk of bias | High risk of bias |
| Kim (2011) | Low risk of bias | High risk of bias | High risk of bias Specially selected for being negative to the test food | High risk of bias |
| Komata (2009) | Low risk of bias | High risk of bias | Low risk of bias | Low risk of bias |
| Lemon-Mule (2008) | Low risk of bias | High risk of bias | High risk of bias | High risk of bias |
| Marseglia (2012) | Low risk of bias | High risk of bias | High risk of bias | High risk of bias |
| Niggeman (2008) | Very low risk of bias | High risk of bias | High risk of bias | Unclear |
| Nowak- Wegrzyn (2008) | Low risk of bias | High risk of bias | High risk of bias | High risk of bias |

EFSA supporting publication 2013:EN-506

| Study ID | Diagnosis* | Challenge order | Sampling* | Severe allergy |
|--------------|-----------------------|-------------------|-------------------|-------------------|
| | | comp/test* | | represented* |
| Ragno (1993) | Low risk of bias | High risk of bias | High risk of bias | High risk of bias |
| Rugo (1992) | Low risk of bias | High risk of bias | High risk of bias | High risk of bias |
| Sampson | Very low risk of bias | Low risk of bias | High risk of bias | High risk of bias |
| (1991) | | | | |
| Scibilia | Low risk of bias | Unclear | High risk of bias | High risk of bias |
| (2006) | | | | |
| Urisu (1997) | Low risk of bias | High risk of bias | High risk of bias | High risk of bias |
| Worm (2009) | Low risk of bias | High risk of bias | Unclear | High risk of bias |
| | | | | |

For the method of assessing the quality of studies see Table 2.2

2.3.8. Findings on effect of processing on allergenicity

The table below (Table 2.10) shows the findings for all studies in food order. The percentage of participants tested showing a positive response are shown together with the threshold dose that elicited a reaction if provided. We excluded data from participants that were challenge negative to both comparison and test food. In the majority of cases, the least processed food provided the greater response rate i.e. was the more allergenic.

2.3.8.1. Celery

The one study that investigated celery, Ballmer-Weber (2002), demonstrated that for approximately half of those who reacted to raw celery challenges were negative for celery cooked at 100 °C for 15 minutes (Table 2.10). In the four cases that reacted to both raw and cooked celery the threshold dose was increased by heating in all cases. The trend seems to be decrease but not elimination in allergenicity with heat, however the small sample size and the non-representative sample make it difficult to generalise the findings to the wider population. Of the five tested, all reacted to the celery spice, three of these had negative responses to the cooked celery.

2.3.8.2. Cows' milk

We included four studies, a total of 121 participants, in which challenges were performed to amino acid based formulas with infants who were challenge positive to cow's milk, Alessandri (2012 a), Ammar (1999), Burks (2008), Caffarelli (2002), Niggemann (2008), (Table 2.10). All participants were negative except for two, in Caffarelli (2002), who were skin prick test and specific IgE negative to the formula and developed eczema more than 12 hours after the challenge.

Of the included studies, five, Caffarelli (2002), Kaczmarski (2005), Ragno (1993), Rugo (1992), and Sampson (1991) investigated hydrolysed casein formulas in a total of 119 participants, who were challenge positive to cows' milk. Studies showed that between zero to 35 % of the sample populations, a total of 20 participants were challenge positive to the hydrolysed casein formulas. In the study showing the highest reactivity (17/48), the inclusion criteria was atopic eczema or dermatitis and the challenge positive showed symptoms such as dermatitis, gastrointestinal or irritability and the challenge was carried out over a prolonged period.

Of the included studies, six investigated hydrolysed whey based formulas Caffarelli (2002), Giampietro (2001), Kaczmarski (2005), Niggemann (2008), Ragno (1993), Rugo (1992) in a total of 156 children who were proven cow's milk allergic by challenge. The proportion positive to whey derived formulas ranged from zero to nearly 35%. The formula providing the greatest reduction in allergenicity was the extensively hydrolysed, ultra filtered formula, tested by Niggemann (2008), and formulas giving the higher proportion of reactive infants were for the partially hydrolysed formulas, 36% Giampietro (2001)

EFSA supporting publication 2013:EN-506

and 25% Caffarelli (2002). In Caffarelli (2002), the same participants were exposed to hydrolysed whey and extensively hydrolysed casein giving percentage responders of 25 and 5% respectively.

Only one study Host (1988) investigated pasteurization, and there was limited evidence (5 participants) that there was no effect on allergenicity. Kim (2011), Komata (2009) and Nowak-Wegrzyn (2008) studied the effect of heating on milk allergy. They showed that a proportion of those allergic to pasteurized milk are tolerant to heated or baked milk. However, Kim (2011) and Nowak-Wegrzyn (2008) selected for those who thought they had developed tolerance to baked milk and they still found positive challenge result (26% and 36% respectively). These participants did not go on to be challenged with uncooked milk, as a positive response was assumed. The selection criteria of Kim (2011) and Nowak-Wegrzyn (2008) make it impossible for us to generalize the findings a wider population. A much higher percentage (94.7%) of participants in the study by Komata (2009) reacted to heated milk. These participants were selected as they were hospitalized and a relatively high proportion (48.6%) had reported anaphylaxis to milk.

One study Alessandri (2012) looked at the effect of cheese making (Parmigiano-Reggiano) on the allergenicity of cow's milk. Of the 50 participants that had positive challenges to cows' milk, only 42% reacted to the matured hard cheese. The study authors analysis of specific IgE binding *in vitro* indicated that the partial breakdown of casein in the cheese making process could account for the decrease in reactivity by participants in the challenge. Beta-lacto globulin was unaffected by the cheese making process. Those found to be tolerant in challenge were advised not to avoid Parmigiano-Reggiano cheese, and after a two year follow up no adverse events were recorded.

2.3.8.3. Egg

The effect of heating on egg allergy was studies by Alessandri (2012 b), Ando (2008), Boyano Martinez (2001), Lemon-mule (2008) and Urisu (1997) in a total of 146 participants (Table 2.10). Between 10.6 % and 57.6 % of egg challenge positive participants reacted to extensively heated egg. In the lowest percentage study, Lemon-Mule (2008), study participants who had reported recent reactions to heated egg were excluded from the study, so this is a biased estimate. One study, Urisu (1997) additionally investigated ovomucoid-depleted egg and found that of the 36 participants that were egg challenge positive, only 2.6% reacted to the heated ovomucoid depleted egg compared to 44.7% that reacted to the heated egg.

The effect of cheese processing on the allergenicity of egg lysozyme was tested by one study, Marseglia (2012) in 21 participants, in which cheese matured for 24 months was found to be less allergenic than 12 month matured cheese.

2.3.8.4. Tree nuts

There were only two studies that used challenge to investigate heat on tree nuts and they both studies hazelnut Hansen (2003) and Worm (2009). Both found that roasting reduced allergenicity in terms of the percentage responding (29.4 and 85% respectively) and in addition roasting seemed to increase the threshold dose to elicit a reaction (Table 2.10).

2.3.8.5. Wheat

One study, Scibilia (2006), looked at boiling wheat in 10 participants and found no reduction in allergenicity (Table 2.10)

2.3.8.6. Peanut

No studies were found that compared the challenge responses to peanut processed using different methods. The studies on allergenicity of different peanut preparations investigated IgE binding or other *in vitro* methods. We also searched for studies that looked at challenges with peanut oil in those with

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

proven peanut allergy. One study, Hourihane (1993) investigated whether people with allergy to peanut would react to crude peanut oil. In this study 10% of those tested had positive challenge results to the crude peanut oil (Table 2.10) and non to the refined peanut oil.

| Paper ID | Food | Number showing positive response | | Threshold dose Mean (±SD) | | |
|--------------------------------|----------------------|---|--|--|--|--|
| | | Comparison food | Test food challenge | Comparison | Test food | |
| Ballmer- Weber 2002 | Celery | Raw 9/9 (100 %) | Heated 4/9 (44.4%) | Raw (all) n = 10; 9.0 (+13.4) g | Heated (all) n=6; 6.8 (+13.6) g | |
| | | Raw 10/10 (100%) § | Heated 6/11 (54.5%) § | Raw (paired) n = 4; 0.7 (±0.0) g | Heated (paired) n=4; 9.5 (±14.4) g | |
| | | Raw 5/5 (100 %) Raw 10/10 (100%) § | Spice 5/5 (100 %) Spice 5/5 (100 %) § | | | |
| Alessandri (2012 a) milk | Cows' milk | Pasteurised 50/50 (100 %) | Cheese (Parmigiano- Reggiano) 21/50 (42 %) | | | |
| Ammar 1999 | Cows' milk-AA | Hydrolysate 30/30 (100 %) | Amino acid based (Neocate) 0/30 (0 %) | | | |
| Burks 2008 | Cows' milk-AA | Pasteurised 5/5 (100 %) | Amino acid based (Neocate) 0/5 (0 %) | | | |
| Caffarelli (2002) | Cows' milk-AA | Pasteurised 20/20 (100 %) | Amino acid based (Nutri-junior) 2/20 (10 %) | | | |
| Niggemann 2008 | Cows' milk-AA | Pasteurised 66/66 (100%) | Amino acid based formula (Neocate) 0/66 (0%) | | | |
| Caffarelli (2002) | Cows' milk-casein | Pasteurised | Casein extensively hydrolysed (Nutramigen) 1/20 (5 %) | | | |
| Kaczmarski 2005 | Cows' milk-casein | Low lactose (Bebilon) 48/48 (100 %) | Casein extensively hydrolysed (Nutramigen) 17/48 (35.4 %) | | | |
| Ragno (1993) | Cows' milk-casein | Pasteurised 20/20 (100 %) | Casein extensively hydrolysate (Alimentum) 2/20 (10 %) | | | |
| Rugo (1992) | Cows' milk-casein | Pasteurised | Casein extensively hydrolysed (Nutramigen) 0/8 (0 %) | | | |

Table 2.10: Allergenicity of processed foods (alphabetical order by food)

EFSA supporting publication 2013:EN-506

| Paper ID | Food | Number showing positive response | | Threshold dose Mean (±SD) | | |
|----------------------|---------------------|----------------------------------|---------------------------|------------------------------|-----------|--|
| | | Comparison food | Test food challenge | Comparison food | Test food | |
| Rugo (1992) | Cows' | Pasteurised | Casein extensively | | | |
| | milk-casein | | hydrolysed | | | |
| | | | (Pregestimil) | | | |
| | | | 0/8 (0 %) | | | |
| C | Carry? | 8/8 (100 %) | Carrier terrint | | | |
| Sampson (1001) | Cows milk casein | Pasteurised | bydrolysed | | | |
| (1991) | mink-casem | | (Alimentum) | | | |
| | | | 0/23(0%) | | | |
| | | 23/23 (100 %) | | | | |
| Caffarelli | Cows' milk | Pasteurised | Whey partially | | | |
| (2002) | -whey | | hydrolysed | | | |
| | | | (Humana) | | | |
| C ((11) | <u> </u> | 20/20 (100 %) | 5/20 (25 %) | | | |
| Caffarelli (2002) | Cows [*] | Pasteurised | whey extensively | | | |
| (2002) | mink-whey | | (Hypolac) | | | |
| | | 20/20 (100 %) | 3/20 (15 %) | | | |
| Giampietro | Cows' | Pasteurised | Whey extensively | | | |
| (2001) | milk-whey | | hydrolysed | | | |
| | | | (Nutrilon Pepti) | | | |
| | | 31/31 (100 %) | 6/31 (19.4%) | | | |
| Giampietro | Cows' | Pasteurised | Whey extensively | | | |
| (2001) | milk-whey | | hydrolysed (Profulae) | | | |
| | | 26/26 (100 %) | (101y1ac) 2/26 (7.7.%) | | | |
| Giampietro | Cows' | Pasteurised | Whey partially | | | |
| (2001) | milk-whey | | hydrolysed | | | |
| | | | (Nan HA/Nidina) | | | |
| | | 26/26 (100 %) | 9/26 (34.6 %) | | | |
| Kaczmarski | Cows' | Low Lactose | Whey extensively | | | |
| 2005 | milk-whey | (Bebilon) | hydrolysed | | | |
| | | 10/10 (100 %) | (Beblion pepti) | | | |
| Niggemann | Cows' | Pasteurised | Whey extensively | | | |
| 2008 | milk-whey | rusteuriseu | hydrolysed ultra | | | |
| | 5 | | filtered (Althera) | | | |
| | | 66/66 (100%) | 0/66 (0%) | | | |
| Ragno | Cows' | Pasteurised | Whey extensively | | | |
| (1993) | milk-whey | | hydrolysate | | | |
| | | | (Profylac) | | | |
| | | 20/20 (100 %) | 2/15 (13.3 %) | | | |
| Ragno | Cows' | Pasteurised | Whey partially | | | |
| (1993) | mink-wiley | | (Nidina) | | | |
| | | 20/20 (100 %) | 9/20 (45 %) | | | |
| Rugo (1992) | Cows' | Pasteurised | Whey hydrolysed | | | |
| | milk-whey | | (Alfare) | | | |
| | - | 8/8 (100 %) | 2/8 (25 %) | | | |
| Rugo (1992) | Cows' | Pasteurised | Whey hydrolysate | | | |
| | milk-whey | 8/8 (100 0/) | (Beba HA) $5/8(62.5.0\%)$ | | | |
| | | 0/0(100%) | 3/8 (02.3 %) | | | |
| Food | Number showing p | ositive response | Threshold dose Mean (±SD) | |
|--------------------|--|--|--|--|
| | Comparison food | Test food challenge | Comparison food | Test food |
| Cows' milk-whey | Pasteurised 8/8 (100 %) | Whey hydrolysate (Ultrafiltered) 4/8 (50 %) | | |
| Cows' milk-heat | Raw 5/5 (100 %) | Pasteurised 5/5 (100 %) | Raw n =5; 41g (±38.9g) | Pasteurised n=5; 23g (±29.4g) |
| Cows' milk-heat | Raw 5/5 (100 %) | Homogenised & pasteurised 5/5 (100 %) | Raw n=5; 41g (±38.9g) | Homogenised & pasteurised n=5; 27g (±29.4g) |
| Cows' milk-heat | Pasteurised 65/65 (100 %) | Baked 0/65 (0 %) | | |
| | Pasteurised # 88/88 (100 %) | Baked # 23/88 (26.1 %) | | |
| Cows' milk-heat | Pasteurised 19/19 (100 %) | Heated 18/19 (94.7 %) | | |
| Cows' | Pasteurised 41/41 | Heated | | |
| milk-heat | (100 %) | 0/41 (0 %) | | |
| | Pasteurised # | Heated $\#$ | | |
| Egg | 84/84 (100 %) Raw | Boiled | | |
| | 14/14 (100 %) | 0/14 (0 %) | | |
| | Raw # 33/33 (100 %) | Boiled # 19/33 (57.6 %) | | |
| Egg | Raw 29/29 (100 %) | Heated 0/29 (0 %) | | |
| | Raw # 67/67 (100 %) | Heated # 38/67 (56.7 %) | | |
| Egg | Raw | Heated | | |
| | 20/20 (100 %) | 0/20 (0 %) | | |
| | Raw # 38/38 (100 %) | Heated # 18/38 (47.36 %) | | |
| Egg | Regular | Ext. heated | | |
| | 27/27 (100 %) Regular | 0/27 (0 %) Ext heated 2 | | |
| | 66/66 (100 %) | 7/66 (10.6 %) | | |
| Egg | Raw 38/38 (100 %)# | Heated 17/38 (44.7%)# | | |
| | Raw | Heated ovomucoid depleted | | |
| | 38/38 (100 %)# | 1/38 (2.6 %)# | | |
| Egg (lysozyme) | Regular | Cheese (12 month matured) | | |
| | 21/21 (100 %) Regular | 5/21 (23.8 %) Cheese (24 month | | |
| | 21/21 (100 %) | matured) 1/21 (4.8 %) | | |
| | Food Cows' milk-whey Cows' milk-heat Cows' milk-heat Cows' milk-heat Egg Egg Egg Egg Egg Egg | FoodNumber showing pComparison foodCows'Pasteurisedmilk-whey $8/8 (100 \%)$ Cows'Rawmilk-heat $5/5 (100 \%)$ Cows'Rawmilk-heat $5/5 (100 \%)$ Cows'Pasteurised 65/65milk-heat(100 %)Cows'Pasteurised 19/19milk-heat(100 %)Cows'Pasteurised 19/19milk-heat(100 %)Cows'Pasteurised 41/41milk-heat(100 %)Cows'Pasteurised 41/41milk-heat(100 %)EggRawad/64/64 (100 %)EggRawa3/33 (100 %)EggRaw29/29 (100 %)EggRaw20/20 (100 %)EggRaw38/38 (100 %)EggRaw38/38 (100 %)EggRaw38/38 (100 %)EggRaw38/38 (100 %)EggRaw38/38 (100 %)FiggRaw38/38 (100 %)FiggRaw38/38 (100 %)FiggRaw38/38 (100 %)FiggRaw38/38 (100 %)FiggRaw38/38 (100 %)FiggRaw38/38 (100 %)FiggRegular21/21 (100 %)Xi (1yo %)Xi (1yo %)Xi (1yo %)Xi (1yo %)FiggXi (1yo %) | FoodNumber showing positive responseComparison foodTest food challengeCows'PasteurisedWhey hydrolysate (Ultrafiltered)8/8 (100 %)4/8 (50 %)Cows'RawPasteurisedmilk-heat5/5 (100 %)5/5 (100 %)Cows'RawHomogenised & pasteurisedmilk-heat5/5 (100 %)5/5 (100 %)Cows'Pasteurised f 88/88 (100 %)Baked f 23/88 (26.1 %)Cows'Pasteurised 19/19 (100 %)Heated 18/19 (94.7 %)Cows'Pasteurised 41/41 (100 %)Heated f 23/64 (35.9 %)EggRaw 33/33 (100 %)Boiled 19/33 (57.6 %)EggRaw f 33/33 (100 %)Boiled ff 19/33 (57.6 %)EggRaw f 67/67 (100 %)0/29 (0 %)EggRaw f 67/67 (100 %)Heated ff 20/20 (100 %)EggRaw f 63/83 (100 %)Heated ff 18/38 (47.36 %)EggRaw ff 63/66 (100 %)18/38 (47.36 %)EggRaw ff 63/66 (100 %)Ext. heated 27/27 (100 %)EggRaw ff 38/38 (100 %)Heated ff 38/38 (100 %)EggRaw ff 38/38 (100 %)Heated ff 38/38 (100 %)EggRaw ff 38/38 (100 %)Cols %)EggRaw ff 38/38 (100 %)Heated ff 38/38 (100 %)EggRaw ff 38/38 (100 %)Cols %)EggRaw ff 38/38 (100 %)Cols %)EggRaw ff 38/38 (100 %)Cols %)EggRaw ff | Food Number showing positive response Mean (\pm SD) Threshold dose Mean (\pm SD) Comparison food Test food challenge Comparison food Cows' milk-wheat Pasteurised Whey hydrolysate (Utrafiltered) 8/8 (100 %) Kaw n =5; 41g pasteurised Cows' milk-heat Raw Pasteurised Raw n =5; 41g pasteurised Cows' milk-heat Raw Homogenised & pasteurised Raw n =5; 41g pasteurised Cows' milk-heat Pasteurised 55/5 (100 %) 5/5 (100 %) 5/5 (100 %) Cows' milk-heat Pasteurised 55/65 (100 %) Baked # 23/88 (261 %) Raw n =5; 41g pasteurised 19/19 Cows' milk-heat Pasteurised 11/41 (100 %) Heated 4 (3/19 (94.7) Raw Cows' milk-heat Pasteurised 41/41 (100 %) Heated 4 (3/19 (94.7) Raw Pasteurised 4 Heated 4 (3/67 (100 %) 23/64 (35.9 %) Raw Egg Raw Boiled Raw Raw 33/33 (100 %) 19/33 (57.6 %) Raw Raw Raw Egg Raw # Heated # G/767 (100 %) Raw Raw Raw Raw Raw |

| Paper ID | Food | Number showing p | ositive response | Threshold dose Mean (±SD) | |
|---------------------|----------|-------------------------|--------------------------|---|---|
| | | Comparison food | Test food challenge | Comparison food | Test food |
| Hansen 2003 | Hazelnut | Raw 17/17 (100 %) | Roasted 5/17 (29.4 %) | | |
| Worm (2009) | Hazelnut | Raw 82/90 (91.1 %) | Roasted 17/20 (85 %) | Raw n =82; median 0.1g range 0.01-2.0 g | Roasted n=17; median 0.23 g range 0.01-10 g |
| Scibilia (2006) | Wheat | Raw 11/11 (100 %) | Boiled 11/11 (100 %) | Raw n =10; 12.1 g (±11.6g) | Boiled n=10; 10.6 g (±10.5g) |
| Hourihane (1993) | Peanut | Roasted 60/60 (100%) | Crude oil 6/60 (10%) | | |

for this row of data the positive challenge response to the 'raw or comparison' food was assumed to be positive if participants had a positive response to the cooked form of the food.

§ in this study challenge data for both foods was available for only 9 participants, for the remaining participants only one challenge was carried out.

2.4. Discussion and Conclusions

The included studies were of high quality for the criterion of methods used to diagnose allergy with most studies considered at least low risk of bias for diagnosis as they carried out double blind challenges or open challenges with positive specific IgE. In contrast nearly all studies were considered high risk of bias for sampling. This was because the study reports did not provide a sampling strategy that would ensure that the samples were an accurate reflection of the allergic population as a whole, or accurately represented those with severe allergies. However random sampling from the allergic population would be costly and difficult. The health risks of taking part in such research, and undergoing repeated challenges makes random sampling from the wider food allergic population contentious. For participants the health risks may not out way the potential benefits of being more informed about their own allergies and those who had experienced severe reactions in the past may have been reluctant to take part. However the lack of robust evidence with large study populations for foods sold specifically as being allergen reduced, such as the hydrolysed infant milk formulas, does not support evidence-based decision making.

Those studies that included participants with positive specific IgE and a clinical history found that some individuals did not react to any form of the food. This is not surprising as the positive predictive value for these tests or a combination of tests is not 100%. Both skin tests and specific IgE tests have low positive predictive values (Cianferoni, Garrett, Naimi, Khullar and Spergel; 2012). If possible we excluded cases that were not proven food allergic by challenge for this review.

There was evidence that heat reduced the allergenicity for egg, milk, celery and hazelnut. However, the reduction varies for individual people and for the different foods.

The research studies included highlight that a number of people allergic to uncooked or lightly cooked milk or egg develop tolerance to the baked product, and that this is maintained after long term consumption. The proportion of the allergic population that this applies to is not clear as the sampling strategies selected for those who suspected that they were tolerant to baked products. However, the research does confirm that there is a subpopulation in whom challenge with cooked milk or egg could reduce unnecessary dietary restrictions. One study, Urisu (1997), additionally investigated ovomucoid depleted cooked egg and found there was a further reduction in the number of people having a positive challenge. This could be a potentially useful innovation however further testing would be required.

One small single study investigated the reactivity to cooked celery, Ballmer-Weber (2002). Although allergenicity was reduced a large proportion remained reactive to cooked celery, even if heated for over 70 minutes at 100 oC. However it is not clear from this study if there would be any long term effect of introducing cooked celery into the diet of these tolerant individuals. The positive responses to celery spice

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

by even those who were challenge negative to raw celery make it essential that food labelling is clear. More research should be conducted on the effect of the cooking process on celery spice, to establish of the allergenicity in this form can also be reduced by the cooking process. Specific IgE to crude extract or purified proteins of celery did not show promise for predicting tolerance to heated celery, Ballmer-Weber (2002).

Roasting reduced the allergenicity to hazelnut for some people, Hanson (2003) Worm (2009), however within the later study 85% remained reactive. Those with a history of anaphylaxis to hazelnut have been shown to have specific IgE for a 9 kd lipid transfer protein that is heat stable (Pastorello, Vieths, Pravettoni, Farioli, Trambaioli et al, 2002). The presence of this very heat stable allergen/s could explain the persistence of reactivity even after roasting. Although there were no studies included comparing challenge with roasted compared to raw peanut there is strong evidence in the wider literature that roasted peanut remains allergenic, and that the major allergens remain stable and may even have enhanced allergenicity in vitro after extensive heating due to the Maillard reaction (Paschke, 2009; Maleki, Chung, Champagne and Raufman, 2000). Refined peanut oil contains only trace quantities of protein and was found not to cause reactions in those tested, Hourihane (1993), however there were a small proportion (10%) who showed mild symptoms to the crude oil preparation.

The one study that investigated wheat showed that boiling did not reduce allergenicity and this finding is perhaps due to cereals also containing lipid transfer proteins (Pastorello, Pompei, Pravettoni, Farioli, Calamari, Scibilia, and Ortolani, 2003).

Processing to reduce allergenicity of infant formulas has been investigated in a number of studies. All of the studies were relatively small. We excluded a number of studies as the infants did not have cows' milk allergy confirmed by oral challenge. Overall there was a reduction in the number of infants showing a positive response to hydrolysed formulas compared to standard cows' milk formula. There is a need for studies to follow guidelines on testing these formulas (Muraro, 2011).

In conclusion the evidence suggests allergenicity of foods can be altered by food processing. However, although there are trends for certain foods such as extensive heat for egg, milk, celery and to some extent hazelnut reducing allergenicity this reduction will not be experienced by all people with that allergy. The studies we reviewed were small and were not representative of the wider allergic population. More high quality research is required to determine if certain types of processing increase allergenicity, especially for foods where this is suggested by the in vitro research evidence, for example peanut. It would be useful to identify groups of people more likely to tolerate certain types of processed foods, so that more specific diagnostic challenges can be accessed and lead to individualised management strategies.

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

2.5. List of included studies

- Alessandri C, Zennaro D, Scala E, Ferrara R, Bernardi ML, Santoro M, Palazzo P and Mari A, 2012. Ovomucoid (Gal d 1) specific IgE detected by microarray system predict tolerability to boiled hen's egg and an increased risk to progress to multiple environmental allergen sensitisation. Clinical and Experimental Allergy, 42, 441-450.
- Alessandri C, Sforza S, Palazzo P, Lambertini F, Paolella S, Zennaro D, Rafaiani C, Ferrara R, Bernardi Maria L, Santoro M, Zuzzi S, Giangrieco I, Dossena A and Mari A, 2012. Tolerability of a fully maturated cheese in cow's milk allergic children: biochemical, immunochemical, and clinical aspects. PloS one, 7, e40945-e40945.
- Ammar F, de B and Dupont C, 1999. Allergy to protein hydrolysates in 30 infants. Archives De Pediatrie, 6, 837-843.
- Ando H, Moverare R, Kondo Y, Tsuge I, Tanaka A, Borres Magnus P and Urisu A, 2008. Utility of ovomucoid-specific IgE concentrations in predicting symptomatic egg allergy. Journal of Allergy and Clinical Immunology, 122, 583-588.
- Ballmer-Weber BK, Hoffmann A, Wuthrich B, Luttkopf D, Pompei C, Wangorsch A, Kastner M and Vieths S, 2002. Influence of food processing on the allergenicity of celery: DBPCFC with celery spice and cooked celery in patients with celery allergy. Allergy, 57, 228-235.
- Boyano Martinez TB, Garcia-Ara C, Diaz-Pena JM, Munoz FM, Sanchez GG and Esteban MM, 2001. Validity of specific IgE antibodies in children with egg allergy. Clinical and Experimental Allergy, 31, 1464-1469.
- Burks W, Jones Stacie M, Berseth Carol L, Harris C, Sampson Hugh A and Scalabrin Deolinda MF, 2008. Hypoallergenicity and effects on growth and tolerance of a new amino acid-based formula with docosahexaenoic acid and arachidonic acid. Journal of Pediatrics, 153, 266-271.
- Caffarelli C, Plebani A, Poiesi C, Petroccione T, Spattini A and Cavagni G, 2002. Determination of allergenicity to three cow's milk hydrolysates and an amino acid-derived formula in children with cow's milk allergy. Clinical and Experimental Allergy, 32, 74-79.
- Giampietro PG, Kjellman NIM, Oldaeus G, Wouters-Wesseling W and Businco L, 2001. Hypoallergenicity of an extensively hydrolyzed whey formula. Pediatric Allergy and Immunology, 12, 83-86.
- Hansen KS, Ballmer-Weber BK, Luttkopf D, Skov PS, Wuthrich B, Bindslev-Jensen C, Vieths S and Poulsen LK, 2003. Roasted hazelnuts - allergenic activity evaluated by double-blind, placebocontrolled food challenge. Allergy, 58, 132-138.
- Host A and Samuelsson EG, 1988. Allergic reactions to raw, pasteurized, and homogenized/pasteurized cow milk: a comparison. A double-blind placebo-controlled study in milk allergic children. Allergy, 43, 113-118.
- Hourihane JOO, Bedwani SJJ, Dean TPP and Warner JOO, 1997. Randomised, double blind, crossover challenge study of allergenicity of peanut oils in subjects allergic to peanuts. BMJ (Clinical research ed.), 314, 1084-1088.
- Kaczmarski M, Wasilewska J and Lasota M, 2005. Hypersensitivity to hydrolyzed cow's milk protein formula in infants and young children with atopic eczema/dermatitis syndrome with cow's milk protein allergy. Roczniki Akademii Medycznej w Bialymstoku (1995), 50, 274-278.
- Kim Jennifer S, Nowak-Wegrzyn A, Sicherer Scott H, Noone S, Moshier Erin L and Sampson Hugh A, 2011. Dietary baked milk accelerates the resolution of cow's milk allergy in children. Journal of Allergy and Clinical Immunology, 128, 125-U205.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

- Komata T, Shukuya A, Imai T, Tachimoto H and Ebisawa M, 2009. Single blind food challenge using dried food powder --2nd Report. milk. Arerugi = [Allergy], 58, 779-789.
- Lemon-Mule H, Sampson Hugh A, Sicherer Scott H, Shreffler Wayne G, Noone S and Nowak-Wegrzyn A, 2008. Immunologic changes in children with egg allergy ingesting extensively heated egg. Journal of Allergy and Clinical Immunology, 122, 977-983.
- Marseglia A, Castellazzi AM, Valsecchi C, Licari A, Piva G, Rossi F, Fiorentini L and Marseglia GL, 2012. Outcome of oral provocation test in egg-sensitive children receiving semi-fat hard cheese Grana Padano PDO (protected designation of origin) containing, or not, lysozyme. Eur J Nutr.
- Niggemann B, von B, Bollrath C, Berdel D, Schauer U, Rieger C, Haschke-Becher E and Wahn U, 2008. Safety and efficacy of a new extensively hydrolyzed formula for infants with cow's milk protein allergy. Pediatric Allergy and Immunology, 19, 348-354.
- Nowak-Wegrzyn A, Bloom Katherine A, Sicherer Scott H, Shreffler Wayne G, Noone S, Wanich N and Sampson Hugh A, 2008. Tolerance to extensively heated milk in children with cow's milk allergy. Journal of Allergy and Clinical Immunology, 122, 342-347.
- Ragno V, Giampietro PG, Bruno G and Businco L, 1993. Allerginicity of milk protein hydrolysate formulas in children with cows milk allergy. European Journal of Pediatrics, 152, 760-762.
- Rugo E and Wahn U, 1992. Invivo studies on residual allergenic activity of hydrolyzed formula. Monatsschrift Kinderheilkunde, 140, 472-475.
- Sampson HA, Bernhiselbroadbent J, Yang E and Scanlon SM, 1991. Safety of casein hydrolysate formula in children with cow milk allergy. Journal of Pediatrics, 118, 520-525.
- Scibilia J, Pastorello EA, Zisa G, Ottolenghi A, Bindslev-Jensen C, Pravettoni V, Scovena E, Robino A and Ortolani C, 2006. Wheat allergy: A double-blind, placebo-controlled study in adults. Journal of Allergy and Clinical Immunology, 117, 433-439.
- Urisu A, Ando H, Morita Y, Wada E, Yasaki T, Yamada K, Komada K, Torii S, Goto M and Wakamatsu T, 1997. Allergenic activity of heated and ovomucoid-depleted egg white. Journal of Allergy and Clinical Immunology, 100, 171-176.
- Worm M, Hompes S, Fiedler EM, Illner AK, Zuberbier T and Vieths S, 2009. Impact of native, heatprocessed and encapsulated hazelnuts on the allergic response in hazelnut-allergic patients. Clinical and Experimental Allergy, 39, 159-166.

2.6. List of Excluded Studies

- Amonette MS, Schwartz RH, Mattson L, Peers LB and Eldredge DM, 1991. Double-blind placebocontrolled food challenges DBPCFC demonstrating acute ige-mediated allergic reactions to good start ultrafiltered good start alfare nutramigen and alimentum in a seven-year-old. Pediatric Asthma Allergy and Immunology, 5, 245-252.
- Anton M, Dieguez M, Garcia A, Rubio G and Diez M, 2004. A case of beer and wheat allergy. Journal of Allergy and Clinical Immunology, 113, S316-S316.
- Armentia A, Duenas-Laita A, Pineda F, Herrero M and Martin B, 2010. Vinegar decreases allergenic response in lentil and egg food allergy. Allergologia Et Immunopathologia, 38, 74-77.
- Belloni B, Kirschner S, Kugler C, Ring J and Brockow K, 2008. Tolerance of wines fined with allergenic proteins in allergic individuals-double-blind, placebo controlled food challenge study. Allergy, 63, 119-119.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

- Bernhiselbroadbent J, Strause D and Sampson HA, 1992. Fish hypersensitivity .2. Clinical relevance of altered fish allergenicity caused by various preparation methods. Journal of Allergy and Clinical Immunology, 90, 622-629.
- Bohle B, Zwoelfer B, Heratizadeh A, Jahn-Schmid B, Antonia Yuliya D, Alter M, Keller W, Zuidmeer L, van R, Ronald, Werfel T and Ebner C, 2006. Cooking birch pollen-related food: Divergent consequences for IgE- and T cell-mediated reactivity in vitro and in vivo. Journal of Allergy and Clinical Immunology, 118, 242-249.
- Bonadonna P, Crivellaro M, Dama A, Senna GE, Mistrello G and Passalacqua G, 1999. Beer-induced anaphylaxis due to barley sensitization: Two case reports. Journal of Investigational Allergology & Clinical Immunology, 9, 268-270.
- Brockow K, Ballmer-Weber B, Dehlink E, Dutta M, Fiocchi A, Kirchlechner V, Andres C, Bockmann A, Kugler C, Luderschmidt S, Paschke A, Saratud T, Steinke M, Szephaluzi Z, Terracciano L, Theler B, Urbanek R, Wezel R and Ring J, 2008. REDALL (Reduced allergenicity of processed foods) allergen-reduced foods as alternative to avoidance in food allergy? Allergologie, 31, 77-81.
- Brockow K, Kirschner S, Belloni B, Kugler C and Ring J, 2009. Does Wine Containing Processing Aids Present a Risk for Allergic Consumers? - Results of a Double-blind, Placebo-controlled Food Challenge. Journal of Allergy and Clinical Immunology, 123, S26-S26.
- Bush RK, Taylor SL, Nordlee JA and Busse WW, 1985. Soybean oil is not allergenic to soybean oil is not allergenic to soybean-sensitive individuals. Journal of Allergy and Clinical Immunology, 76, 242-245.
- Cabanillas B, Pedrosa MM, Cuadrado C, Burbano C, Muzquiz M, Rodriguez J and Crespo JF, 2010. Effects of Enzymatic Hydrolysis on Peanut Allergenicity. Journal of Allergy and Clinical Immunology, 125, AB224-AB224.
- Cantani A and Micera M, 2000. Immunogenicity of hydrolysate formulas in children (part 1). Analysis of 202 reactions. Journal of Investigational Allergology & Clinical Immunology, 10, 261-276.
- Clark A, Islam S, King Y, Deighton J, Szun S, Anagnostou K and Ewan P, 2011. A longitudinal study of resolution of allergy to well-cooked and uncooked egg. Clinical and Experimental Allergy, 41, 706-712.
- Estep DC and Kulczycki A, 2000. Treatment of infant colic with amino acid-based infant formula: a preliminary study. Acta Paediatrica, 89, 22-27.
- Estrada-Reyes E, Garcia-Hernandez G, Martinez-Gimeno A and Nava-Ocampo AA, 2006. Effect of extensively hydrolyzed milk formula on growth and resistance to bronchitis and atopic dermatitis in infants and toddlers. Journal of Investigational Allergology and Clinical Immunology, 16, 183-187.
- Ford LS, Bloom KA, Nowak-Wegrzyn AH, Shreffler WG, Masilamani M and Sampson HA, 2013. Basophil reactivity, wheal size, and immunoglobulin levels distinguish degrees of cow's milk tolerance. J Allergy Clin Immunol, 131, 180-186 e183.
- Halken S, Host A, Hansen LG and Osterballe O, 1993. Preventive effect of feeding high-risk infants a casein hydrolysate formula or an ultrafiltrated whey hydrolysate formula. A prospective, randomized, comparative clinical study. Pediatr Allergy Immunol, 4, 173-181.
- Herzinger T, Kick G, Ludolph-Hauser D and Przybilla B, 2004. Anaphylaxis to wheat beer. Annals of Allergy Asthma & Immunology, 92, 673-675.
- Jirapinyo P, Densupsoontorn N, Kangwanpornsiri C and Wongarn R, 2012. Chicken-based formula is better tolerated than extensively hydrolyzed casein formula for the management of cow milk protein allergy in infants. Asia Pacific Journal of Clinical Nutrition, 21, 209-214.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

- Jurado-Palomo J, Fiandor-Roman AM, Bobolea ID, Sanchez-Pastor S, Pascual CY and Quirce S, 2010. Oral challenge with pasteurized egg white from Gallus domesticus. Int Arch Allergy Immunol, 151, 331-335.
- Kim JS, Nowak-Wegrzyn A, Noone SR, Bencharitiwong R, Bloom KA and Sampson HA, 2011. Tolerance To Extensively Heated Milk (HM) In Children With Cow's Milk Allergy: A Follow Up. Journal of Allergy and Clinical Immunology, 127, AB27-AB27.
- Kirschner S, Belloni B, Kugler C, Ring J and Brockow K, 2009. Allergenicity of Wine Containing Processing Aids: A Double-Blind, Placebo-Controlled Food Challenge. Journal of Investigational Allergology and Clinical Immunology, 19, 210-217.
- Koepke JW, Williams PB, Osa SR, Dolen WK and Selner JC, 1990. Anaphylaxis to pinon nuts. Annals of Allergy, 65, 473-476.
- Komata T, Shukuya A, Imai T, Tachimoto H and Ebisawa M, 2009. Single blind food challenge using dried food powder--1st report. Raw whole egg and egg yolk. Arerugi = [Allergy], 58, 524-536.
- Konstantinou George N, Giavi S, Kalohatsou A, Hassilopoulou E, Douladiris N, Saxoni-Papageorgiou P and Papadopoulos Nikolaos G, 2008. Consumption of heat-treated egg by children allergic or sensitized to egg can affect the natural course of egg allergy: Hypothesisgenerating observations. Journal of Allergy and Clinical Immunology, 122, 414-415.
- Krogulska A, Bialek J and Wasowska-Krolikowska K, 2011. Tolerance to heated cow's milk and egg in children with allergy to this food. Postepy Dermatologii I Alergologii, 28, 277-284.
- Leonard Stephanie A, Sampson Hugh A, Sicherer Scott H, Noone S, Moshier Erin L, Godbold J and Nowak-Wegrzyn A, 2012. Dietary baked egg accelerates resolution of egg allergy in children. Journal of Allergy and Clinical Immunology, 130, 473-+.
- Levy Y, Kornbrot B and Danon YL, 1998. Soybean allergy in cow milk-tolerant infants. Pediatric Asthma Allergy & Immunology, 12, 253-258.
- Luettkopf D, Ballmer-Weber Barbara K, Wuthrich B and Vieths S, 2000. Celery allergens in patients with positive double-blind placebo-controlled food challenge. Journal of Allergy and Clinical Immunology, 106, 390-399.
- Magnusson JM, Sobko T, Ljungberg C and Bengtsson U, 2001. Double-blind placebo-controlled food challenge (DBPCFC) in adult patients with food related gastrointestinal symptoms. Journal of Allergy and Clinical Immunology, 107, S191-S191.
- Mittag D, Akkerdaas J, Ballmer-Weber BK, Vogel L, Wenising M, Becker WM, Koppelman SJ, Knulst AC, Helbling A, Hefle SL, van R and Vieths S, 2004. Ara h 8, a Bet v 1-homologous allergen from peanut, is a major allergen in patients with combined birch pollen and peanut allergy. Journal of Allergy and Clinical Immunology, 114, 1410-1417.
- Mittag D, Vieths S, Vogel L, Becker WM, Rihs HP, Helbling A, Wuthrich B and Ballmer-Weber BK, 2004. Soybean allergy in patients allergic to birch pollen: Clinical investigation and molecular characterization of allergens. Journal of Allergy and Clinical Immunology, 113, 148-154.
- Moneret-Vautrin DA, Rance F, Kanny G, Olsewski A, Gueant JL, Dutau G and Guerin L, 1998. Food allergy to peanuts in France evaluation of 142 observations. Clinical and Experimental Allergy, 28, 1113-1119.
- Morisset M, Aubert-Jacquin C, Soulaines P, Moneret-Vautrin DA and Dupont C, 2011. A nonhydrolyzed, fermented milk formula reduces digestive and respiratory events in infants at high risk of allergy. European Journal of Clinical Nutrition, 65, 175-183.
- Muraro A, Hoekstra Maarten O, Meijer Y, Lifschitz C, Wampler Jennifer L, Harris C and Scalabrin Deolinda MF, 2012. Extensively hydrolysed casein formula supplemented with Lactobacillus

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

rhamnosus GG maintains hypoallergenic status: randomised double-blind, placebo-controlled crossover trial. BMJ open, 2, e000637-e000637.

- Nermes M, Karvonen H, Sarkkinen E and Isolauri E, 2009. Safety of barley starch syrup in patients with allergy to cereals. British Journal of Nutrition, 101, 165-168.
- Ojeda P, Ojeda I, Rubio G and Pineda F, 2012. Home-Based Oral Immunotherapy Protocol with Pasteurized Egg for Children Allergic to Hen's Egg. Israel Medical Association Journal, 14, 34-39.
- Paajanen L, Tuure T, Poussa T and Korpela R, 2003. No difference in symptoms during challenges with homogenized and unhomogenized cow's milk in subjects with subjective hypersensitivity to homogenized milk. J Dairy Res, 70, 175-179.
- Quercia O, Zoccatelli G, Stefanini GF, Mistrello G, Amato S, Bolla M, Emiliani F and Asero R, 2012. Allergy to beer in LTP-sensitized patients: beers are not all the same. Allergy, 67, 1186-1189.
- Rance F, Brondeau V and Abbal M, 2002. Use of prick-tests in the screening of immediate allergy to protein: 16 cases. Allergie et immunologie, 34, 71-76.
- Roches AD, Nguyen M, Paradis L, Primeau MN and Singer S, 2006. Tolerance to cooked egg in an egg allergic population. Allergy, 61, 900-901.
- Rodriguez V, Bartolome B, Armisen M and Vidal C, 2007. Food allergy to Paracentrotus lividus (sea urchin roe). Annals of Allergy Asthma & Immunology, 98, 393-396.
- Romeira AM, Pires G, Gaspar A, Arede C, Morais-Almeida M and Rosado-Pinto J, 2003. Egg allergy to be or not to be boiled. Allergy, 58, 533-534.
- Saarinen KM, Juntunen-Backman K, Jarvenpaa AL, Klemetti P, Kuitunen P, Lope L, Renlund M, Siivola M, Vaarala O and Savilahti E, 2000. Breast-feeding and the development of cows' milk protein allergy. Adv Exp Med Biol, 478, 121-130.
- Salt L, Adel-Patient K, Blanc F, Cochrane S, Crevel R, Rogers A, Coutts J, Mackie A and Mills C, 2009. A standardised challenge vehicle for the diagnosis of food allergy and threshold studies. Allergy, 64, 372-373.
- Sato S, Tachimoto H, Shukuya A, Ogata M, Komata T, Imai T, Tomikawa M and Ebisawa M, 2011. Utility of the Peripheral Blood Basophil Histamine Release Test in the Diagnosis of Hen's Egg, Cow's Milk, and Wheat Allergy in Children. International Archives of Allergy and Immunology, 155, 96-103.
- Schwartz RH, Amonette MS, Mattson L, Peers LB and Witherly SA, 1992. Relative allergenicity of hydrolysate infant formulas – Double-blind, placebo-controlled food challenges (DBPCFC). Journal of Allergy and Clinical Immunology, 89, 227-227.
- Sicherer SH, Noone SA, Koerner CB, Christie L, Burks AW and Sampson HA, 2001. Hypoallergenicity and efficacy of an amino acid-based formula in children with cow's milk and multiple food hypersensitivities. Journal of Pediatrics, 138, 688-693.
- Sotto D, Tounian P, Baudon JJ, Pauliat S, Challier P, Fontaine JL and Girardet JP, 1999. [Allergy to cow's milk protein hydrolysates: apropos of 8 cases]. Arch Pediatr, 6, 1279-1285.
- Stavroulakis G, Giavi S, Douladiris N, Lagara K, Papathanasiou D and Papadopoulos N, 2009. Natural history of fish allergy. Allergy, 64, 485-485.
- Takaoka Y, Ito K, Futamura M and Sakamoto T, 2007. Oral food challenge with boiled egg yolk and boiled and raw egg white. Journal of Allergy and Clinical Immunology, 119, S192-S192.
- Taylor SL, Busse WW, Sachs MI, Parker JL and Yunginger JW, 1981. Peanut oil is not allergenic to peanut-sensitive individuals. Journal of Allergy and Clinical Immunology, 68, 372-375.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

- Taylor SL, Hefle SL, Bindslev-Jensen C, Bock SA, Burks AW, Christie L, Hill DJ, Host A, Hourihane JO, Lack G, Metcalfe DD, Moneret-Vautrin DA, Vadas PA, Rance F, Skrypec DJ, Trautman TA, Yman IM and Zeiger RS, 2002. Factors affecting the determination of threshold doses for allergenic foods: How much is too much? Journal of Allergy and Clinical Immunology, 109, 24-30.
- Untersmayr E, Vestergaard H, Malling HJ, Jensen LB, Platzer MH, Boltz-Nitulescu G, Scheiner O, Skov PS, Jensen-Jarolim E and Poulsen LK, 2007. Incomplete digestion of codfish represents a risk factor for anaphylaxis in patients with allergy. J Allergy Clin Immunol, 119, 711-717.
- Vassilopoulou E, Douladiris N, Sakellariou A, Cortes SV, Sinaniotis A, Rivas MF and Papadopoulos NG, 2010. Evaluation and standardisation of different matrices used for double-blind placebo-controlled food challenges to fish. Journal of Human Nutrition and Dietetics, 23, 544-549.
- Vidal C, PerezCarral C and Chomon B, 1997. Unsuspected sources of soybean exposure. Annals of Allergy Asthma & Immunology, 79, 350-352.
- Wada E, Urisu A, Morita Y, Ando H, Yasaki T, Yamada K, Goto M and Wakamatsu T, 1997. Assessment of allergenic activity of heated and ovomucoid-depleted egg white. Arerugi = [Allergy], 46, 1007-1012.
- Wang J, Lin J, Bardina L, Goldis M, Nowak-Wegrzyn A, Shreffler Wayne G and Sampson Hugh A, 2010. Correlation of IgE/IgG4 milk epitopes and affinity of milk-specific IgE antibodies with different phenotypes of clinical milk allergy. Journal of Allergy and Clinical Immunology, 125, 695-702.
- Yamada K, Urisu A, Haga Y, Matsuoka H, Komada H and Torii S, 1997. A case retaining contact urticaria against egg white after gaining tolerance to ingestion. Acta Paediatrica Japonica, 39, 69-73.
- Yamada K, Urisu A, Morita Y, Ando H, Wada E, Torii S and Goto M, 1998. Respiratory symptoms by oral challenge tests with egg white antigens in egg-allergic children. Arerugi = [Allergy], 47, 687-693.
- Zuberbier T, 2008. Food allergy epidemiology in Berlin. Allergologie, 31, 264-273.

2.7. Additional References

- Maleki SJ, Chung SY, Champagne ET and Raufman JP, 2000. The effects of roasting on the allergenic properties of peanut proteins. J Allergy Clin Immunol, 106, 763-768.
- Muraro A, 2011. Proposed requirements for hypoallergenic formulae to be used in the treatment and prevention of cow's milk allergy. Clinical and Translational Allergy, 1, S72-S72.
- Paschke A, 2009. Aspects of food processing and its effect on allergen structure. Mol Nutr Food Res, 53, 959-962.
- Pastorello EA, Vieths S, Pravettoni V, Farioli L, Trambaioli C, Fortunato D, Luttkopf D, Calamari M, Ansaloni R, Scibilia J, Ballmer-Weber BK, Poulsen LK, Wutrich B, Hansen KS, Robino AM, Ortolani C and Conti A, 2002. Identification of hazelnut major allergens in sensitive patients with positive double-blind, placebo-controlled food challenge results. J Allergy Clin Immunol, 109, 563-570.
- Pastorello EA, Pompei C, Pravettoni V, Farioli L, Calamari AM, Scibilia J, Robino AM, Conti A, Iametti S, Fortunato D, Bonomi S and Ortolani C, 2003. Lipid-transfer protein is the major maize allergen maintaining IgE-binding activity after cooking at 100 degrees C, as demonstrated in anaphylactic patients and patients with positive double-blind, placebo-controlled food challenge results. Journal of Allergy and Clinical Immunology, 112, 775-783.
- Taylor RR, Sladkevicius E, Panca M, Lack G and Guest JF, 2012. Cost-effectiveness of using an extensively hydrolysed formula compared to an amino acid formula as first-line treatment for cow milk allergy in the UK. Pediatric Allergy and Immunology, 23, 240-249.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

3. What new analytical methods are available to analyse/detect the following food allergens in processed foods: milk/dairy, eggs, cereals, buckwheat, peanuts, nuts, celery, crustaceans, fish, molluscs, soy, lupine, mustard and sesame? (Objective 4b)

3.1. Search Strategy

We searched the databases presented in section1.1.1, using the search terms outlined in Table 3.1, words within groups linked by OR and between groups liked with AND. In addition we asked experts within the field for published studies (to be completed). The following databases were searched from Web of Science (1970-November 2012), BIOSIS Citation Index (1969-November 2012), BIOSIS reviews (1969-2008), Medline (1950-November 2012), Pubmed (- November 2012), using the search terms shown (Table 3.1). No limits were used. The included studies were limited to those published after 2004.

Table 3.1: Search terms for identifying assays that detect allergenic foods

| Topics | Search terms Web of Knowledge | Search terms Pubmed |
|------------------|---|--|
| Group 1. Food we | b of Knowledge | |
| Milk and dairy | milk OR butter or cream or dairy or cheese or yoghurt or petit filous or casein or whey or lacto Infant NEAR/2 formula | milk[Tiab] OR milk[MeSH Terms] OR lactose[MeSH Terms] OR lactose[Tiab] OR dairy[Tiab] OR butter[Tiab] OR cream[Tiab] OR "infant formula"[Tiab] OR cheese[Tiab] OR yoghurt[Tiab] OR "petit filous"[Tiab] OR casein[Tiab] OR whey[Tiab] |
| Egg | Egg | egg[Tiab] OR eggs[Tiab] |
| Cereals | Cereal or gluten or wheat or rye or barley or oats or spelt or kamut | cereals[MeSH Terms] OR cereal[Tiab] OR cereals[Tiab] OR glutens[MeSH Terms] OR glutens[Tiab] OR gluten[Tiab] OR wheat[Tiab] OR rye[Tiab] OR barley[Tiab] OR oats [Tiab] OR oat[Tiab] OR spelt[Tiab] OR kamut[Tiab] |
| Buckwheat | Buckwheat | Buckwheat, |
| Peanuts | nut or arachis | peanut[Tiab] OR arachis[Tiab] |
| Nuts | nut or arachis or cashew or brazil brasil or almond or hazel or walnut or pecan or macadamia or pistachio or filbert | nuts[MeSH Terms] OR nuts[Tiab] OR nut[Tiab] OR almond[Tiab] OR almonds[Tiab] OR hazelnut[Tiab] OR hazelnuts[Tiab] OR walnut[Tiab] OR walnuts[Tiab] OR cashew[Tiab] OR cashews[Tiab] OR pecan[Tiab] OR pecans[Tiab] OR macadamia[Tiab] OR macadamias[Tiab] OR pistachio[Tiab] OR pistachios[Tiab] OR beechnut[Tiab] OR beechnuts[Tiab] OR filbert[Tiab] OR filberts[Tiab] |
| Celery | Celery | celery[tiab] |
| Crustaceans | crustacea OR crustacean OR crustaceans OR crab OR crabs OR lobster OR lobsters OR shrimp OR | crustacea[MeSH Terms] OR crustacea[Tiab] OR crustacean[Tiab] OR crustaceans[Tiab] OR crab[Tiab] OR crabs[Tiab] OR lobster[Tiab] OR |

EFSA supporting publication 2013:EN-506

| Topics | Search terms Web of Knowledge | Search terms Pubmed |
|--|---|--|
| | shrimps OR prawn OR prawns OR crayfish OR shellfish OR langoustine OR langoustines | lobsters[Tiab] OR shrimp[Tiab] OR shrimps[Tiab] OR prawn[Tiab] OR prawns[Tiab] OR crayfish[Tiab] OR shellfish[MeSH Terms] OR shellfish[Tiab] OR langoustine[Tiab] OR langoustines[Tiab] |
| Fish, | fish OR pollock OR carp OR cod OR mackerel OR salmon OR tuna OR shark OR "sea bass" OR swordfish OR hake OR sole OR megrim OR sardine OR sardines OR halibut OR anchovy OR anchovies OR catfish OR trout | fishes[MeSH Terms] OR fish[Tiab] OR pollock[Tiab] OR carp[Tiab] OR cod[Tiab] OR mackerel[Tiab] OR salmon[Tiab] OR tuna[Tiab] OR shark[tiab] OR salmon[Tiab] OR tuna[Tiab] OR shark[tiab] OR salmon[Tiab] OR swordfish[tiab] OR hake[tiab] OR sole[tiab] OR megrim[tiab] OR sardine[tiab] OR sole[tiab] OR megrim[tiab] OR sardine[tiab] OR sole[tiab] OR megrim[tiab] OR sardine[tiab] OR sardines[tiab] OR halibut[tiab] OR anchovy[tiab] OR anchovies[tiab] OR catfish[tiab] OR trout[tiab] mollusca[MeSH Terms] OR mollusc[Tiab] OR molluscs[Tiab] OR oyster[Tiab] OR oysters[Tiab] OR snail [Tiab] OR squid[Tiab] OR mussel[Tiab] OR mussels[Tiab] OR clam[Tiab] OR clams[Tiab] OR |
| Mollusces | mollusc OR molluscs OR oyster OR oysters OR snail OR snails OR squid OR mussel OR mussels OR clam OR clams OR abalone OR octopus OR scallop OR scallops | scallop[tiab] OR scallops[tiab] mollusca[MeSH Terms] OR mollusc[Tiab] OR molluscs[Tiab] OR oyster[Tiab] OR oysters[Tiab] OR snail [Tiab] OR squid[Tiab] OR mussel[Tiab] OR mussels[Tiab] OR clam[Tiab] OR mussels[Tiab] OR clam[Tiab] OR scallone[tiab] OR scallops[tiab] |
| Soy | Soy | soy[Tiab] OR soybeans[MeSH Terms] OR soybean[Tiab] OR soybeans[Tiab] OR soya[Tiab] |
| Lupin | LUPINUS-ALBUS, Lupine | lupinus[MeSH Terms] OR lupin*[Tiab] |
| Mustard | Mustard | "mustard plant"[MeSH Terms] OR mustard[Tiab] |
| Sesame | Sesame | sesamum[MeSH Terms] OR "sesame"[Tiab] |
| Group 2. Allergen | /antigenicity or protein | |
| Allergen, antigen or protein | Allerg [OR Antigen* OR Epitope* OR IgE OR protein | Allerg [OR Antigen* OR Epitope* OR IgE OR protein |
| Group 3 Processin | ng methods | |
| Heat and chemical Cooking, heavy | (heat* or cook* or roast* or fry* or pasteuri* or boil) or (heavy near/2 salting) or dying or microwav* OR ferment* or smoking or drying or (UV | Heat*[tiab] OR cook*[tiab] OR roast* [tiab] OR fry*[tiab] OR pasteuri*[tiab] OR boil[tiab] OR |

EFSA supporting publication 2013:EN-506

| Topics | Search terms Web of Knowledge | Search terms Pubmed |
|---|--|---|
| salting,, microwaving, filtration, fermenting, smoking, drying, UV treatment for sterilisation, acid, alkaline (lyme treatment) treatment heating treatments, ohmic. | NEAR/2 treatment) or lyme or ohmic OR (chemical near/4 peeling) or Hydrostatic pressure or (food near/1 process*) or ("food proces*") or (digest*) or (hydrol*) or filtration | Hydrolysis [tiab] OR digestion [tiab] OR enzymatic treatment [tiab] OR fermented [tiab] OR Hydrostatic pressure[tiab] OR food process* [tiab] OR "heavy salting" [tiab] OR dying [tiab] OR microwav* [tiab] OR ferment* [tiab] OR smoking [tiab] OR drying [tiab] OR UV [tiab] OR lyme [tiab] OR ohmic [tiab] OR "chemical peeling"[tiab] |
| Product related | (wine OR beer OR clarif*) | wine [tiab] OR beer [tiab] Or clarify* [tiab] |
| Group 6 Assay qu | ality | |
| | (Sensitivity near/10 specificity) or (detection near/2 limit) or (receiver near/1 operator) or (limit near/2 detection) or limit near/2 quantification | |
| Group 7 Assay/tes | t | · |
| | spectrometry or PCR or polymerase near/1 chain OR Immuno near/1 assay OR Competitive near/1 lateral OR Bioreceptor* OR Dog* OR canine* OR Sens* OR ELISA or RIA or biosensor* | <pre>spectrometry [tiab] OR PCR[tiab] OR polymerase chain [tiab] OR 'Immuno assay' [tiab] OR 'Competitive lateral flow' [tiab] OR Bioreceptor*[tiab] OR Dog*[tiab] OR canine*[tiab] OR Sens*[tiab] OR Detection limit*[tiab] OR 'Receiver operator curve' [tiab] OR ELISA [tiab], RIA [tiab], CAP [tiab], biosensor* [tiab]</pre> |

3.1.1. Selection criteria

All titles and abstracts were imported to Endnote and duplicates removed. One reviewer, SK, screened the titles and abstracts to remove studies not relevant to the objective. The full texts were obtained for the remaining studies; a second screen by SK then removed studies that were not relevant to the research question and the reasons identified.

3.1.1.1. Types of studies

We set out to include studies investigating extraction and detection of the food/proteins in a food matrix of relevance to the real world setting. Studies investigating food matrixes spiked with allergen were included, and those using samples taken from 'field' samples (manufactured, laboratory processed or home produced).

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

3.1.1.2. Types of detection methods

All methods of detection that quantify the specific food or allergenic proteins within the food source or indicate that the allergen is present or absent. It was anticipated that mass spectrometry, polymerase chain reaction, immunoassay, Molditoff would be included in the review; however there was no exclusion criteria on the type of assay.

3.1.1.3. Types of outcome measure

The review included studies that assessed quality of studies as laid out by the International Committee for Harmonisation Topic Q 2 (R1) Validation of Analytical Procedures. For spiked samples we were interested in measures of validity and reliability of assays: specificity, linearity, range, accuracy, precision, detection limit, quantification limit, robustness, system suitability testing. We were interested in showing values for the extraction method and the assay in combination, in which case these were labelled 'sampling', or of the assay alone and these are labelled 'assay', e.g. assay limit of quantification, or sample limit of quantification. For studies of 'field samples', that is samples taken from kitchens or from commercial sources with unknown quantities the assays were compared with the best available assay either using continuous or binary data (e.g. cut off for allergen present or absent).

3.1.2. Extraction of data

The following data was collected: food allergen assessed, method of detection, test mechanism for example protein detection, antigen or epitope detection using immunoassay, detection of DNA, allergenicity using food challenge, type of study, comparison of reference test against an index test or percentage retrieval if spiked sample, the name of the test, the commercial company and address.

3.1.3. Assessment of methodological quality of included studies

The quality of the studies have been assessed for the range of food processing techniques used. We divided studies into those investigating the analytical quality of the assays and those investigating the effectiveness of the assays for 'field' samples. Assays investigating the analytical quality were assessed according to the adapted criteria from the International Committee for Harmonisation Topic Q 2 (R1) Validation of Analytical Procedures and by adapting the scoring system for assessing diagnostic tests QUADAS (Whiting et al., 2003). Criteria used are outlined in the following Table 3.2.

| Criteria | Low risk of bias | High risk of bias | Unclear |
|--|---|---|--------------|
| Spiking procedure | Likely to incorporate allergen into the matrix e.g. tempered chocolate | Method unlikely to incorporate allergen into matrix e.g. mixing powdered allergen with powdered matrix | Not reported |
| Spiking or extract used for standard curve | Standardised source, or source clearly identified | Not standardised | Not reported |
| Sampling/extraction | Each replicate involves separate extraction and sampling | One sample made into separate aliquots | Not reported |
| 'Field' sampling | Random sample, or all samples from a representative source of food. | Non random sample, or all from an isolated source | Not reported |
| Assessment of data | Blind or methodology for measurement or calculation technique rigorous and objective | Not blind and methodology not rigorous or introduces subjectivity | Not reported |

| Table 3.2: | Quality assessm | ent of studies |
|-------------------|-----------------|----------------|
| | | |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

3.1.4. Data synthesis and presentation

Tables will present for each allergen and each processing method the range of the limit of detection and quantification for each analytical technique with the corresponding extraction technique.

3.2. Results

The search strategy yielded 1475 studies after removal of duplications. The initial screening of title and abstract removed 1351 studies. Of those excluded a large proportion were about the development of laboratory diagnostic for allergy, detection of parasite eggs, and a range of other biological substances these studies were excluded under the heading, 'not detecting listed foods'. Some studies were review articles and so were listed under 'not contain primary data' and there were a group of studies that did not investigate detection within a suitable food related matrix.

Full text screening was carried out on 124 studies, yielding 84 included studies and excluding 40 studies. The reasons for exclusion were grouped under six headings. One: that there was no data for accuracy i.e. percentage recovery from spiked food samples, or comparison with the results from another assay with known accuracy, and there was no data for the limit of detection of the assay for a suitable food matrix. Two: although there may be data on assay validation, this did not include recovery or sensitivity of detecting the allergenic compound within a suitable food matrix. Three: the data was not in a suitable format and we could not calculate the percentage recovery or identify the limit of detection. Four: the study showed data that was presented within another study or the study was a duplicate. Five: the assay was developed to assess if a food was contaminated with food from another specifies for example goat's milk adulterated with cheaper bovine cow's milk and Six: the study was published prior to 2004. The studies excluded at the full text stage are shown (Section 3.5).

3.2.1. Almond

We included two studies, one evaluating ELISA and one PCR for detecting almond in cakes, confectionary and cereals (Table 3.3), Garber (2010a) used almond sources from a local shop whereas Roeder (2011) sourced their almond extract for the spiking experiments from a research institute (Table 3.4). Garber (2010) tested three commercial ELISAs, Veratox, Ridascreen and ELISA systems showing that the limit of detection ranged between 3-9 μ g/g for extraction and measurement of the almond proteins in food matrices such as cake, oatmeal, chocolate and muffins. The real-time PCR tested by Roeder (2011) gave a limit of detection of 5 mg/kg⁻¹ or 50 μ g/g (Table 3.5).

| Study ID | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|-------------------|--|--|--|--------------------------|
| Garber (2010a) | Crude extract | Breakfast cereals oatmeal Cake muffins Chocolate | Spiked Source of spike purchased locally | ELISA |
| Roeder (2011) | Specific protein/peptide or gene <i>nsLTP</i> | Chocolate Cookie Field Foods sampled Chocolate, yogurt, cookies, muesli | Spiked Field Source of spike Whole unroasted almonds with seed coat from Institut Fur Produktqualitat (Berlin, Germany) | PCR |

 Table 3.3:
 Almond: characteristics of included studies

EFSA supporting publication 2013:EN-506

| Study ID | Assay details | Additional information |
|----------|---|------------------------|
| Garber | Test 1 | ELISA |
| (2010a) | Veratox (Neogen Corporation, Lansing, MI, USA); | Sandwich |
| almond | | Commercial company |
| | Test 2 Ridascreen Fast (R-Biopharm Inc, Marshal, MI, USA), Test 3 Elisa systems-bioMerieux Industry (Hazelwood, MO, USA) | |
| Roeder | Test 1 | PCR |
| (2011) | Real time PCR | Real-time PCR |
| | | In-house |

Table 3.4:Almond: description of assay

Table 3.5: Almond: accuracy and limit of detection and quantification

| Study ID | Allergen | Specific protein | | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|----------------|----------|---------------------|---|--------------------------|-----------|-----------------------|---------------|-----------------------------|-------------------------------|
| Garber 2010 | almond | crude | 1 | ELISA, Veratox | cake | | | 9 μg/g | |
| Garber 2010 | almond | crude | 1 | ELISA, Veratox | cereals | | | 4 µg/g | |
| Garber 2010 | almond | crude | 1 | ELISA, Veratox | chocolate | | | 4.2 μg/g | |
| Garber 2010 | almond | crude | 2 | ELISA, RIDASCR EEN | cake | | | 7 μg/g | |
| Garber 2010 | almond | crude | 2 | ELISA, RIDASCR EEN | cereals | | | 2.5 μg/g | |
| Garber 2010 | almond | crude | 2 | ELISA, RIDASCR EEN | chocolate | | | 3 µg/g | |
| Garber 2010 | almond | crude | 3 | ELISA Systems | cake | | | 7 µg/g | |
| Garber 2010 | almond | crude | 3 | ELISA Systems | cereals | | | 4.3 μg/g | |
| Garber 2010 | almond | crude | 3 | ELISA Systems | chocolate | | | 5 μg/g | |
| Roeder 2011 | almond | nsLTP | 1 | Real time PCR | chocolate | | | 50 μg/g | |
| Roeder 2011 | almond | nsLTP | 1 | Real time PCR | cookie | | | 50 μg/g | |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

3.2.2. Brazil nut

The type of assay and the foods spiked with Brazil nut extract of the three included studies are shown (Table 3.6 and 3.7). The ELISA investigated by Ben Rejab (2005) provided similar sensitivity, 1 ppm (equivalent to 1 μ g/g), as the PCR assay described by Roeder (2010) for brazil nut added to chocolate. Roeder (2010) tested the assay for a wider range of products including cookie, dough and cereals and in all cases the allergen could be detected at concentrations as low as 5 μ g/g. Sharma (2009) investigated percentage recovery for their in house ELISA and found good recoveries down to 10 μ g/g. However there was overestimation particularly for wheat flour (Table 3.8), Sharma (2009) found that the lowest recovery was from dark chocolate μ g/g, perhaps due to Brazil nut chocolate complexes that were insoluble in the extraction buffer. Although blank samples of most foods gave negligible readings, apart from cinnamon, the recoveries for wheat flour and cookie were over 100%, which indicate that there was an interaction between the food matrix and the Brazil but proteins that altered the antibody protein binding giving higher than expected results. Both the ELISAs were developed to detect the crude protein mix, whereas the PCR was directed against the gene for the major Brazil nut allergen.

| Study ID | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|----------------------|---|--|--|--------------------------|
| Ben Rejeb (2005b) | Crude extract | Chocolate | Spiked Roasted defatted peanuts and nuts extracted, dialysed Source of spike <i>Not reported</i> Standardisation Made up to 1mg/ml ⁻¹ protein content measured using BCA test | ELISA |
| Roeder (2010) | Specific protein/peptide or gene <i>Ber e 1 gene</i> | Chocolate, Cookie Dough Field Foods sampled Range of cereals, chocolate bars, snacks and other nut products | Spiked Field Source of spike Brazil nuts heat treated for drying but not roasted | PCR |
| Sharma (2009) | Crude extract | Breakfast cereals <i>Oat</i> Chocolate Cookie, <i>Shortbread</i> Flour, <i>Wheat flour</i> | Spiked Source of spike Local grocery store | ELISA |

| Table 3.6: Brazil nut: characteristics of included stud |
|--|
|--|

EFSA supporting publication 2013:EN-506

| Study ID | Allergen | Assay details | Additional information |
|---------------------|------------|-------------------------|---|
| Ben Rejeb (2005) | Brazil nut | Test 1 ELISA | ELISA Polyclonal detection antibody Competitive inhibition In house |
| Roeder (2010) | Brazil nut | Test 1 real time PCR | In-house |
| Sharma (2009) | Brazil nut | Test 1 ELISA | ELISA Polyclonal detection antibody Competitive inhibition In-house |

| Table 3.7: | Brazil nut: | description | of assay |
|------------|-------------|-------------|----------|
| | | | |

Table 3.8: Brazil nut: accuracy and limit of detection and quantification

| Study ID | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|-------------------|---------------------|--------------------|-------------------|-----------------------|---------------|--------------------------------|-------------------------------------|
| Ben Rejeb 2005 | | 1 ELISA | chocolate dark | | | 1 µg/g | |
| Roeder 2010 | Ber e 1 gene | 1 Real time PCR | chocolate | | | 5 µg/g | |
| Roeder 2010 | Ber e 1 gene | 1 Real time PCR | cookie | | | 5 µg/g | |
| Roeder 2010 | Ber e 1 gene | 1 Real time PCR | dough | | | 5 µg/g | |
| Sharma 2009 | Protein | 1 ELISA | cereals | 10-100 µg/g | 105-119 | | |
| Sharma 2009 | Protein | 1 ELISA | chocolate dark | 10-100 µg/g | 90-95 | | |
| Sharma 2009 | Protein | 1 ELISA | cookie | 10-100 µg/g | 123-130 | | |
| Sharma 2009 | Protein | 1 ELISA | wheat flour | 10-100 µg/g | 150-189 | | |

3.2.3. Buckwheat

We included three studies that investigated the validation of assays for detecting buckwheat within a variety of foods including noodles and cake. All three tests were immunoassays directed against crude extracts, two ELISA and one a dipstick test (Table 3.9 and Table 3.10). The ELISAs produced by Morinaga Institute of Biological Science and the commercial ELISA, FASTKIT, tested by Akiyama (2004a) in an experiment where cake samples were spiked with between 5 and 20 ng/ml of buckwheat, gave between 89 and 94 % recoveries. However this recovery was reduced for snacks and noodles spiked with buckwheat (Table 3.11). The in-house ELISA developed and tested by Panda (2010) provided a limit of detection of 2 ppm (2 μ g/g) for spiked noodles or cake. The same authors investigated the ELISA-

EFSA supporting publication 2013:EN-506

Systems kit and this was found to be not as sensitive with a limit of detection of 100 μ g/g. The IC dipstick, in addition to being easy to use and not requiring specialised equipment to develop the test, gave sensitivity down to 5 μ g/g in a range of products, Morishita (2006) (Table 3.11).

| Study ID | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|---------------------|---------------------------------|--|--|--|
| Akiyama (2004a) | Crude extract | Cake Bun Noodles Udon Snack | Spiked Source of spike FASMAC Standardisation Protein measured using BCA protein assay kit concentration adjusted to 100-300 µg/ml | ELISA |
| Morishita (2006) | Crude extract | Carrot Sherbet Cookie, Jam Pickles (Soy Sauce, vinegar) Potato Salad, Sauce, Tomato Soup, Steamed and fried Chinese dumpling Hamburger | Spiked | ELISA Immuno- chromatographi c test kits Dip stick |
| Panda (2010) | Crude extract | Cake Muffins Noodles | Spiked Source of spike Buckwheat flour (Hodgsons Mill, Effingham, ILL, USA) | ELISA |

| Table 3.9: | Buckwheat: | characteristics | of | included st | tudies |
|-------------|-------------|-----------------|----|-------------|--------|
| 1 abic 5.7. | Duck wheat. | characteristics | 01 | merudeu si | uuics |

Table 3.10: Buckwheat: description of assay

| Study ID | Allergen | Assay details | Additional information |
|---------------------|-----------|--|---|
| Akiyama (2004a) | Buckwheat | Test 1 Buckwheat ELISA (MORINAGA Institute of Biological Science) Test 2 FASTKIT Buckwheat ELISA kit (Nippon Meat Packers Inc.) | Not stated |
| Morishita (2006) | Buckwheat | Test 1 Immunochromatographic test kits, dipstick. Test 2 ELISA: FASTKIT | Not stated |
| Panda (2010) | Buckwheat | Test 1 | ELISA Polyclonal capture antibody |

EFSA supporting publication 2013:EN-506

| Study ID | Allergen | Assay details | Additional information |
|----------|----------|---|--|
| | | Test 2 ELISA Systems Pty. Ltd., Windsor, Oueensland, Australia | Polyclonal detection antibody Sandwich. In-house |
| | | | Commercial assay |

| Table 3.11: | Buckwheat: accuracy | v and limit of | detection and | quantification |
|--------------------|---------------------|----------------|---------------|----------------|
| | | , | | |

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|-------------------|-----------|---------------------|---------------------|----------------------------------|-----------------------|---------------|--------------------------------|-------------------------------------|
| Akiyama 2004a | buckwheat | crude | 1 ELISA MORINAGA | buffer | | | 1 ng/ml | 1 ng/ml |
| Akiyama 2004a | buckwheat | crude | 1 ELISA MORINAGA | cake | 5-20 ng/ml | 62-102 | | |
| Akiyama 2004a | buckwheat | crude | 1 ELISA MORINAGA | noodles | 5-20 ng/ml | 43-56 | | |
| Akiyama 2004a | buckwheat | crude | 1 ELISA MORINAGA | snack | 5-20 ng/ml | 50-54 | | |
| Akiyama 2004a | buckwheat | crude | 2 ELISA, FASTKIT | buffer | | | 1 ng/ml | 4 ng/ml |
| Akiyama 2004a | buckwheat | crude | 2 ELISA, FASTKIT | cake | 5-20 ng/ml | 89-94 | | |
| Akiyama 2004a | buckwheat | crude | 2 ELISA, FASTKIT | noodles | 5-20 ng/ml | 76-94 | | |
| Akiyama 2004a | buckwheat | crude | 2 ELISA, FASTKIT | snack | 5-20 ng/ml | 63-64 | | |
| Morishita 2006 | buckwheat | crude | 1 IC - dipstick | chicken meatball or burger | | | 5 µg/g | |
| Morishita 2006 | buckwheat | crude | 1 IC - dipstick | cookie | | | 5 μg/g | |
| Morishita 2006 | buckwheat | crude | 1 IC - dipstick | Dumplings fried/ steamed | | | 5 μg/g | |
| Morishita 2006 | buckwheat | crude | 1 IC - dipstick | jelly | | | 5 μg/g | |
| Morishita 2006 | buckwheat | crude | 1 IC - dipstick | Pickles in Vinegar/soy | | | 5 μg/g | |
| Morishita 2006 | buckwheat | crude | 1 IC - dipstick | Potato salad | | | 5 μg/g | |
| Morishita 2006 | buckwheat | crude | 1 IC - dipstick | sauce | | | 5 μg/g | |
| Panda 2010 | buckwheat | crude | 1 ELISA | cake | 3-1000 µg/g | 58-69 | 2 µg/g | 2 µg/g |
| Panda 2010 | buckwheat | crude | 1 ELISA | noodles | 3-1000 μg/g | 83-108 | 2 µg/g | 2 µg/g |
| Panda 2010 | buckwheat | crude | 2 ELISA- Systems | noodles | 3-1000 μg/g | 0-95 | 100 µg/g | |

3.2.4. Cashew

Four studies investigated detection systems for cashew. The ELISA assays provided good sensitivity and good recovery from a wide range of spiked products such as ice-cream, pesto, and chocolate, Geskin (2011), Ben Rejeb (2005). The PCR assay tested by Brezezinski (2006) did not improve the limit of detection giving only 100 μ g/g limit of detection for with a cookie food matrix.

Ehlert (2002) developed and validated a multi-target method for the simultaneous detection of a range of allergens food matrices. The Ligation-dependent probe amplification assay is based on PCR and enables several different allergens to be tested in one tube. The limit of detection of this test for cashew was estimated at 5 mg/kg⁻¹ equivalent to 50 μ g/g for detecting pesto sauce spiked with cashew proteins.

| Study ID | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|----------------------|---|----------------------------------|---|---|
| Ben Rejeb (2005c) | Crude extract | Chocolate | Spiked Roasted defatted peanuts and nuts extracted, dialysed Source of spike Not reported Standardisation Made up to 1mg/ml ⁻¹ protein content measured using BCA test | ELISA |
| Brzezinski (2006) | Specific protein/peptide or gene Cashew 2S albumin gene | Cookie | Spiked Source of spike locally purchased | PCR |
| Ehlert (2009) | Crude extract Specific protein/peptide or gene DNA | Cookie Pesto cashew | Spiked Source of spike Nut materials, sesame seeds, ingredients of self-prepared DNA plant and animal materials used to test the specificity of the method and spike samples of chocolate, were obtained from the Bavarian Health and Food Safety Authority (Oberschleibheim, Germany) | ELISA PCR Ligation- dependent probe amplification |
| Gaskin (2011) | Crude extract roasted | Chocolate Cookie Ice cream | Spiked Source of spike Purchased locally | ELISA |

 Table 3.12:
 Cashew: characteristics of included studies

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Allergen | Assay details | Additional information |
|--------------------------------|----------|---|--|
| Ben Rejeb (2005c) cashew | Cashew | Test 1 ELISA | ELISA Polyclonal detection antibody Competitive inhibition |
| Brzezinski (2006) | Cashew | Test 1 PCR | PCR Real-time PCR |
| Ehlert (2009) | Cashew | Test 1 Ligation dependent probe amplification (LPA) Test 2 Cashew real time PCR Test 3 Hazelnut and peanut: ELISA Ridascreen | Test 1 LPA for simultaneous detection of DNA from different foods Test 2 PCR, In house Test 3 ELISA, commercial, R- Biopharm AG, Darmstadt, Germany |
| Gaskin (2011) | Cashew | Test 1 Sheep antibody Test 2 Goat antibody | ELISA Polyclonal capture antibody Sandwich, In-house |

| Table 5.15. Cashew. description of assay | Table 3.13: | Cashew: | description | of assay |
|--|--------------------|---------|-------------|----------|
|--|--------------------|---------|-------------|----------|

Table 3.14: Cashew: accuracy and limit of detection and quantification

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|---------------------|----------|----------------------|--------------------|-------------------|-----------------------|---------------|--------------------------------|-------------------------------------|
| Ben Rejeb 2005 | cashew | Crude | 1 ELISA | chocolate dark | | | 1 µg/g | |
| Brezezinski 2006 | cashew | cashew 2S albumin | 1 PCR | cookie | | | 10 μg/g 0 | |
| Ehlert 2009 | cashew | DNA | 1 LPA | pesto | | | 50 µg/g | |
| Ehlert 2009 | cashew | DNA | 2 PCR real time | pesto | | | 20 µg/g | |
| Geskin 2011 | cashew | crude | 1 ELISA sheep | chocolate milk | 1-1000 µg/g | 100-110 | | |
| Geskin 2011 | cashew | crude | 1 ELISA sheep | cookie | 1-100 µg/g | 75-99 | | |
| Geskin 2011 | cashew | crude | 1 ELISA sheep | ice cream | 1-102 µg/g | 111-128 | | |
| Gesking 2011 | cashew | crude | 1 ELISA sheep | buffer | | | 0. μg/g 11 | 0.46 μg/g |
| Gesking 2011 | cashew | crude | 2 ELISA goat | buffer | | | 0. μg/g 11 | 0.46 µg/g |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

3.2.5. Celery

Three studies investigated detection of celery allergen in foods (Table 3.15 and Table 3.16) and one looked at ELISA. Wang (2011) and two looked at PCR Coisson (2010) and Wu (2010). Wang (2011) investigated an in house ELISA system, and recovery data was carried out at one concentration only $10\mu g/g$. Good recovery was observed in a range of powdered foods. This recovery rate may not be maintained if more complex matrices such as dough were used. The PCR assay sensitivities varied from 0.1%, Wu (2010) to 5 % w/w, Coisson (2010) when meatball samples were spiked with the allergen. The PCR assay sensitivity was reduced by heating of the food matrix but this was still acceptable at 1 % w/w, Wu (2010) (Table 3.17).

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|-------------------|----------|---|---|--|--------------------------|
| Coisson (2010) | Celery | Specific protein/peptide or gene DNA Celery 2S albumin AgMTD, sesame mannitol dehydrogenase Si2S | Meat meat balls | Spiked Source of spike A. graveolens L (celery leaves). Samples purchased from commercial stores in Italy. | PCR |
| Wang (2011) | Celery | Specific protein/peptide or gene Api g 1.01 | corn powder wheat powder Rice, rice powder soy powder | Spiked Source of spike Apium graveolens bought from local market | ELISA |
| Wu (2010) | Celery | Mannitol transporter protein gene | Pork powder Field Foods sampled Dumplings, hundun, biscuits, powdered chicken, mushroom soup, vegetable/fruit juice, sauce | Spiked Field Source of spike Celery powder from local markets | PCR |

EFSA supporting publication 2013:EN-506

| Study ID | Allergen | Assay details | Additional information |
|-----------|----------|----------------------|------------------------|
| Coisson | Celery | Test 1 | |
| (2010) | | PCR with multiplex | |
| Wang | Celery | Test 1 | ELISA |
| (2011) | | ELISA | Monoclonal capture |
| | | | antibody |
| | | | Monoclonal detection |
| | | | antibody |
| | | | Sandwich |
| | | | In-house |
| Wu (2010) | Celery | Test 1 | PCR |
| | | Real time PCR (Mat3) | Real-time PCR |
| | | | SYBR green |

| Table 3.16: | Celery: | description | of assay |
|-------------|---------|-------------|----------|
|-------------|---------|-------------|----------|

Table 3.17: Celery: accuracy and limit of detection and quantification

| Study ID | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|-----------------|---|----------------------------------|---------------------------------|-----------------------|---------------|--------------------------------|-------------------------------------|
| Coisson 2010 | DNA | 1 PCR | meatball or burger | | | 5 % w/w | |
| Wang 2011 | Api g 1.01 | 1 ELISA | buffer | | | 5.6 μg/g | |
| Wang 2011 | Api g 1.01 | 1 ELISA | corn powder | 10 µg/g | 102 | | |
| Wang 2011 | Api g 1.01 | 1 ELISA | rice powder | 10 µg/g | 100 | | |
| Wang 2011 | Api g 1.01 | 1 ELISA | soy powder | 10 µg/g | 83 | | |
| Wang 2011 | Api g 1.01 | 1 ELISA | wheat flour | 10 µg/g | 115 | | |
| Wang 2011 | Heated Api g 1.01 | 1 ELISA | Heated/ buffer | | | 5.7 μg/g | |
| Wu 2010 | Mannitol transporter protein gene | 1 Real-Time PCR SYBR green | meatball or burger | | | 0.1 % w/w | |
| Wu 2010 | Heated Mannitol transporter protein gene | 1 Real-Time PCR SYBR green | Heated meatball or burger | | | 1 % w/w | |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

3.2.6. Cereals

Five included studies investigated detection of wheat or gluten allergens and the key characteristics and the type of assay are shown (Table 3.18 and Table 3.19) ELISA, immune assay dip sticks and mass spectrometry were tested. Akiyama (2004) and Mena (2012) investigated ELISA. The FASTKIT ELISA was tested by Akiyama 2004, at relatively low concentration of allergens and although this ELISA gave recovery rates of less than 50% it provided a limit of detection down to 1 ng/ml, the Gliadin test kit gave similar or slightly better recovery rates. Mena (2012) with the ELISA R5 system, found that there was good recovery of gluten from a range of foods such as biscuit, bread, cereals, however in products containing chocolate there was very poor recovery perhaps due to interaction of tannins with the proteins. Mena (2012) developed a modified extraction procedure and this solved the problem enabling yields of nearly 100% when chocolate samples were spiked with 55 μ g/g of gluten. The authors were using a commercial extraction system UPEX, such extraction systems could lead to increased reproducibility providing there is strict quality control.

The other type of immunoassay investigates were the test strips, EZ Gluten, which gave good sensitivity of 5 μ g/g in rice, dog food, beer and cooked dough, and a dipstick system, Morishita 2006 that provided a good limit of detection of 5 μ g/g Morishita 2006.

One study developed and validated mass spectrometry for gluten, investigating a range of sequences, Sealey-Voyksner 2010. This assay provided good recovery rates, 69-112 percent, of more than at very low concentrations of allergen (Table 3.20).

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|-------------------|----------|--|--|---|-----------------------------------|
| Akiyama (2004) | Wheat | Specific protein/peptid e or gene Gliadin and various proteins (not specified) | Cereal Fish Fish paste Sauce Sauce and pasta sauce Sausage | Spiked Source of spike Wheat: provided by FASMAC Equal mix of 14 different brands | ELISA |
| Allred (2012) | Gluten | Gliadins and glutenin fractions | Alcohol Beer Dog food Flour Rice | Spiked Source of spike National Institute of Standards and Technology SRM 1567a wheat flour, and a commercial bleached all- purpose wheat flour | EZ Gluten assay immunoassay |
| Mena (2012) | Gluten | Gliadin | Baby food Biscuit, Breakfast cereals, Bread, Cake, Chips, Cookie, Custard, Flour, Jam, Meat, Pancakes Pudding, Snack, Spice, Field Foods sampled | Spiked Field Source of spike Not reported | ELISA |

| Table 3.18: Cereals: characteristics of included studies |
|--|
|--|

EFSA supporting publication 2013:EN-506

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|-------------------------------|-----------------|---------------------------------|---|---|--|
| | | | wide range of cereals, puddings and baby foods | | |
| Morishita (2006) | Wheat | Crude extract | Carrot Sherbet Cookie Jam Pickles (Soy Sauce, vinegar) Potato Salad Sauce Tomato Soup Steamed and fried Chinese dumpling Hamburger | Spiked | ELISA Immuno- chromatograph ic test kits Dip stick |
| Sealey- Voyksner (2010) | Gluten Wheat | Gluten peptides | Cereal Corn flour and wheat | Spiked Source of spike Unclear | Mass spectrometry |

Table 3.19:Cereals: description of assay

| Study ID | Allergen | Assay details | Additional information |
|-------------------------------|-----------------|--|--|
| Akiyama (2004) | Wheat | Test 1 Wheat protein ELISA kit (Gliadin kit) Test 2 FASTKIT Wheat ELISA Kit | Not stated |
| Allred (2012) | Gluten | Test 1 EZ Gluten assay | Immunoassay Test strips (manufacturer states 10 ppm limit of detection) |
| Mena (2012) | Gluten | Test 1 ELISA R5 UPEX Test 2 ELISA R5 Modified UPEX | ELISA Polyclonal capture antibody Polyclonal detector antibody Competitive inhibition Sandwich |
| Morishita (2006) | Wheat | Test 1 Immunochromatographic test kits, dipstick. Test 2 ELISA: FASTKIT | |
| Sealey- Voyksner (2010) | Gluten Wheat | Test 1 Mass spectrometry | Mass spectrometry Liquid chromatography-mass spectrometry |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantificatio n units |
|-----------------|----------|---------------------|-------------------------------|----------------------|-------------------------|---------------|--------------------------------|--------------------------------------|
| Akiyama 2004 | wheat | Gliadin | 1 ELISA | cereals | 5-20 ng/ml | 53-65 | | |
| Akiyama 2004 | wheat | Gliadin | 1 ELISA | fish paste | 5-20 ng/ml | 56-59 | | |
| Akiyama 2004 | wheat | Gliadin | 1 ELISA | pasta sauce | 5-20 ng/ml | 62-65 | | |
| Akiyama 2004 | wheat | Gliadin | 1 ELISA | sauce | 5-20 ng/ml | 35-44 | | |
| Akiyama 2004 | wheat | Gliadin | 1 ELISA | sausage | 5-20 ng/ml | 58-68 | 1 ng/ml | 1 ng/ml |
| Akiyama 2004 | wheat | Various proteins | 2 ELISA, FASTKIT | cereals | 5-20 ng/ml | 27-30 | | |
| Akiyama 2004 | wheat | Various proteins | 2 ELISA, FASTKIT | fish paste | 5-20 ng/ml | 48-52 | | |
| Akiyama 2004 | wheat | Various proteins | 2 ELISA, FASTKIT | pasta sauce | 5-20 ng/ml | 44-46 | | |
| Akiyama 2004 | wheat | Various proteins | 2 ELISA, FASTKIT | sauce | 5-20 ng/ml | 48-50 | | |
| Akiyama 2004 | wheat | Various proteins | 2 ELISA, FASTKIT | sausage | 5-20 ng/ml | 41-45 | 1 ng/ml | 5 ng/ml |
| Allred 2012 | gluten | Crude | 1 EZ Gluten | beer | | | 5 ppm | |
| Allred 2012 | gluten | Crude | 1 EZ Gluten | dog food | | | 5 ppm | |
| Allred 2012 | gluten | Crude | 1 EZ Gluten | dough cooked | | | 5 ppm | |
| Allred 2012 | gluten | Crude | 1 EZ Gluten | rice | | | 5 ppm | |
| Mena 2012 | gluten | Gliadins | 1 ELISA UPEX extraction | baby food | $55\mu g/g$ (one conc.) | 101 | | |
| Mena 2012 | gluten | Gliadins | 1 ELISA UPEX extraction | biscuit | $55\mu g/g$ (one conc.) | 105 | | |
| Mena 2012 | gluten | Gliadins | 1 ELISA UPEX extraction | bread | 55µg/g (one conc.) | 104 | | |
| Mena 2012 | gluten | Gliadins | 1 ELISA UPEX extraction | cake | 55µg/g (one conc.) | 25 | | |
| Mena 2012 | gluten | Gliadins | 1 ELISA UPEX extraction | cereals | 55μg/g (one conc.) | 102 | | |
| Mena 2012 | gluten | Gliadins | 1 ELISA UPEX extraction | chips | 5 μg/g 5one conc.) | 1.3 | | |
| Mena 2012 | gluten | Gliadins | 1 ELISA UPEX extraction | chocolate biscuit | 55 ppm (one conc.) | 41 | | |

| Table 3.20: | Cereals: accuracy | and limit of | detection and | l quantification |
|-------------|-------------------|--------------|---------------|------------------|
|-------------|-------------------|--------------|---------------|------------------|

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantificatio n units |
|-----------|----------|---------------------|---|---------------------|-----------------------|---------------|--------------------------------|--------------------------------------|
| Mena 2012 | gluten | Gliadins | 1 ELISA UPEX extraction | chocolate cookie | 55μg/g (one conc.) | 8 | | |
| Mena 2012 | gluten | Gliadins | 1 ELISA UPEX extraction | cold meat | 55µg/g (one conc.) | 94 | | |
| Mena 2012 | gluten | Gliadins | 1 ELISA UPEX extraction | cooked ham | 55µg/g (one conc.) | 103 | | |
| Mena 2012 | gluten | Gliadins | 1 ELISA UPEX extraction | curry powder | 55µg/g (one conc.) | 21 | | |
| Mena 2012 | gluten | Gliadins | 1 ELISA UPEX extraction | custard | 55µg/g (one conc.) | 95 | | |
| Mena 2012 | gluten | Gliadins | 1 ELISA UPEX extraction | flour | 55μg/g (one conc.) | 109 | | |
| Mena 2012 | gluten | Gliadins | 1 ELISA UPEX extraction | jam | 55μg/g (one conc.) | 32 | | |
| Mena 2012 | gluten | Gliadins | 1 ELISA UPEX extraction | maize pancakes | 55μg/g (one conc.) | 94 | | |
| Mena 2012 | gluten | Gliadins | 1 ELISA UPEX extraction | paprika | 55μg/g (one conc.) | 99 | | |
| Mena 2012 | gluten | Gliadins | 1 ELISA UPEX extraction | pepper | 55μg/g (one conc.) | 44 | | |
| Mena 2012 | gluten | Gliadins | 1 ELISA UPEX extraction | pizza dough | 55μg/g (one conc.) | 107 | | |
| Mena 2012 | gluten | Gliadins | 1 ELISA UPEX extraction | pudding | 55μg/g (one conc.) | 108 | | |
| Mena 2012 | gluten | Gliadins | 1 ELISA UPEX extraction | sausage | 55μg/g (one conc.) | 106 | | |
| Mena 2012 | gluten | Gliadins | 1 ELISA UPEX extraction | snack | 55μg/g (one conc.) | 92 | | |
| Mena 2012 | gluten | Gliadins | 2 ELISA modified UPEX extraction | biscuit | 55μg/g (one conc.) | 99 | | |
| Mena 2012 | gluten | Gliadins | 2 ELISA modified UPEX extraction | cake | 55µg/g (one conc.) | 98 | | |
| Mena 2012 | gluten | Gliadins | 2 ELISA modified UPEX extraction | chocolate cookie | 55µg/g (one conc.) | 101 | | |

EFSA supporting publication 2013:EN-506

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantificatio n units |
|-----------------------------|----------|--------------------------------|---|----------------------------------|-----------------------|---------------|--------------------------------|--------------------------------------|
| Mena 2012 | gluten | Gliadins | 2 ELISA modified UPEX extraction | curry powder | 55μg/g (one conc.) | 102 | | |
| Mena 2012 | gluten | Gliadins | 2 ELISA modified UPEX extraction | jam | 55µg/g (one conc.) | 102 | | |
| Mena 2012 | gluten | Gliadins | 2 ELISA modified UPEX extraction | pepper | 55μg/g (one conc.) | 122 | | |
| Morishita 2006 | wheat | crude | 1 IC - dipstick | chicken meatball or burger | | | 5 µg/g | |
| Morishita 2006 | wheat | crude | 1 IC - dipstick | cookie | | | | |
| Morishita 2006 | wheat | crude | 1 IC - dipstick | Dumplings fried/ steamed | | | | |
| Morishita 2006 | wheat | crude | 1 IC - dipstick | jelly | | | 5 µg/g | |
| Morishita 2006 | wheat | crude | 1 IC - dipstick | Pickles in Vinegar/ soy | | | 5 μg/g | |
| Morishita 2006 | wheat | crude | 1 IC - dipstick | Potato salad | | | 5 µg/g | |
| Morishita 2006 | wheat | crude | 1 IC - dipstick | sauce | | | 5 µg/g | |
| Sealey- Voyksner 2010 | gluten | LQPQNPQQ QPQEQVPL | 1 Mass Spec | corn | 0.06-60 pg/mg | 93-99 | | |
| Sealey- Voyksner 2010 | gluten | TQQPQQPF PQQPQQPF PQ | 1 Mass Spec | corn | 0.06-60 pg/mg | 86-96 | | |
| Sealey- Voyksner 2010 | gluten | VPVPQLQP QNPSQQQP QEQVPL | 1 Mass Spec | corn | 0.06-60 pg/mg | 97-104 | | |
| Sealey- Voyksner 2010 | gluten | RPQQPYPQ PQPQY | 1 Mass Spec | corn | 0.06-60 pg/mg | 90-98 | | |
| Sealey- Voyksner 2010 | gluten | PQQSPF | 1 Mass Spec | corn | 0.06-60 pg/mg | 69-108 | | |
| Sealey- Voyksner 2010 | gluten | LQPQNPQQ QPQEQVPL | 1 Mass Spec | corn flour | 10-1000 pg/mg | 78-104 | 3.5 | 20 |
| Sealey- Voyksner 2010 | gluten | TQQPQQPF PQQPQQPF PQ | 1 Mass Spec | corn flour | 10-1000 pg/mg | 91-102 | 25 | 100 |
| Sealey- Voyksner 2010 | gluten | VPVPQLQP QNPSQQQP QEQVPL | 1 Mass Spec | corn flour | 10-1000 pg/mg | 93-103 | 14 | 50 |

EFSA supporting publication 2013:EN-506

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantificatio n units |
|-----------------------------|----------|--------------------------------|-------------|------------|-----------------------|---------------|--------------------------------|--------------------------------------|
| Sealey- Voyksner 2010 | gluten | RPQQPYPQ PQPQY | 1 Mass Spec | corn flour | 10-1000 pg/mg | 85-103 | 3 | 20 |
| Sealey- Voyksner 2010 | gluten | QPQQPFPQ TQQPQQPF PQ | 1 Mass Spec | corn flour | 10-1000 pg/mg | 77-109 | 30 | 100 |
| Sealey- Voyksner 2010 | gluten | PQQSPF | 1 Mass Spec | corn flour | 10-1000 pg/mg | 83-112 | 1 | 10 |
| Sealey- Voyksner 2010 | gluten | LQPQNPQQ QPQEQVPL | 1 Mass Spec | wheat | 0.06-60 pg/mg | 93-99 | | |
| Sealey- Voyksner 2010 | gluten | TQQPQQPF PQQPQQPF PQ | 1 Mass Spec | wheat | 0.06-60 pg/mg | 86-96 | | |
| Sealey- Voyksner 2010 | gluten | VPVPQLQP QNPSQQQP QEQVPL | 1 Mass Spec | wheat | 0.06-60 pg/mg | 97-104 | | |
| Sealey- Voyksner 2010 | gluten | RPQQPYPQ PQPQY | 1 Mass Spec | wheat | 0.06-60 pg/mg | 90-98 | | |
| Sealey- Voyksner 2010 | gluten | QPQQPFPQ TQQPQQPF PQ | 1 Mass Spec | wheat | 0.06-60 pg/mg | 90-99 | | |
| Sealey- Voyksner 2010 | gluten | PQQSPF | 1 Mass Spec | wheat | 0.06-60 pg/mg | 69-108 | | |

Mass Spec= Mass spectrometry

3.2.7. Egg

Ovomucoid, the major allergen (Gal d1) is less abundant in the egg white than ovalbumin which is also a major allergen (Gal d2) and the most abundant protein in egg white. Other major allergens in egg white are ovotransferrin and lysozyme. The latter is of particular interest as hen's egg lysozyme can be used in wine production and cheese making. Alphalivetin Gal d 5 is present in the egg yolk. Within this review studies developing or validating assay to detect crude extract, ovalbumin, ovomucoid or lysozyme were found and included.

Six studies investigating assays or egg proteins were included in the review, the assays included ELISA (in-house and commercial), time-of-flight mass spectrometry and dipstick techniques (Table 3.21). Akiyama (2003) compared three ELISAs using bread, cereals and sauces as the food matrix. The two ELISA kits developed by the Morinaga Institute of Biological Sciences detected ovalbumin and ovomucoid and provided good recovery (in most cases more than 80%) for samples spiked with 5-20 ng/ml, and the limit of detection in a sausage mixture was 4 ng/ml (0.001 μ g/ml). Khuda 2012b also found good recovery from dark chocolate, but very poor recovery from sugar cookie at just 15%. However, it should be noted that none of the assays tested by Khuda demonstrated good recoveries from the sugar cookie mix. The FASTKIT ELISA tested by Akiyama (2003) did not perform as well as the Morinaga system, giving recoveries of less than 50% for sausage spiked with egg. The Veratox ELISA was tested by Khuda (2012b) where recoveries were very high, more than 200% from dark chocolate but as mentioned before poor from sugar cookie at less than 10%. The ELISA-BIOKITS was less effective than the other assays for dark chocolate, and similarly poor for the sugar cookie mixture, Khuda (2012 b). Shon (2010) developed an in-house ELISA against ovomucoid and achieved acceptable recoveries from

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

sausage and milk substitute when spiked with 10 μ g/g. Lacorn (2011), used an in-house sandwich ELISA to detect egg powder or cooked egg powder in wine and achieved recoveries of 76-110% and a limit of detection of 0.27 μ g/ml.

The IC – dipstick provided a limit of detection of 5 μ g/g in a wide range of foods, Morishita (2006), and had the advantage of ease of use. Schneider (2010a) developed a method for mass spectrometry that achieved a limit of detection of 5 μ g/g for lysozyme in cheese.

| Study ID | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|----------------------|--|---|---|---|
| Akiyama (2003) | Specific protein/peptide or gene Ovalbumin Ovomucoid | Bread Cereal Cookie Sauce Sausage | Spiked Dose of spike 5-20ng/mL Source of spike Egg (Nippon Meat Packers, Inc), fresh egg from white leghorn hens | ELISA |
| Hefle (2001) | Specific protein/peptide or gene Ovalbumin | Pasta | Spiked Source of spike Spray-dried egg yolk solids (Hershey foods Co, Hershey, Pa, USA) | ELISA |
| Khuda (2012a) egg | Crude extract Spray dried egg powder | Dark Chocolate | Source of spike Spray dried egg powder-NIST RM 8445 (National Institute of Standards and Technology, Gaithersburg, MD, USA) Standardisation Unclear | ELISA |
| Khuda (2012b) egg | Crude extract | Cookie | Source of spike Spray dried whole egg powder, NIST RM 8445 (National Institute of Standards and Technology) | ELISA |
| Lacorn (2011) | Crude extract | Wine | Spiked and source Spray dried whole egg powder (National Institute of standards and Technology,) Whole egg and white: Henningsen Foods (Omaha, NE) Cooked egg white: prepared in house. Food grade liquid egg white (Eifix Eiweiss, Wiesenhof, Germany) Standardisation Total protein: whole egg 48± 1 %, Durmas method. Egg white powder: P- 11 protein content 83.8 % (Kjehldahl determination), cooked egg white: protein, using BCA (2.8 mg/ml) Food grade liquid egg: 99 g protein/kg Kjehldahl | ELISA |
| Morishita (2006) | Crude extract | Carrot Sherbet Cookie Jam, Pickles (Soy Sauce, vinegar), | Spiked | ELISA Immuno- chromatograp hic test kits |

| Table 3.21: | Egg: characteristics of included studies |
|--------------------|--|
|--------------------|--|

EFSA supporting publication 2013:EN-506

| Study ID | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|----------------------|---|--|--|--------------------------|
| | | Potato Salad, Sauce Tomato, Soup Steamed and fried Chinese dumpling Hamburger | | Dip stick |
| Schneider | Specific | Cheese | Spiked | Mass |
| (2010a) | protein/peptide or | | Field | spectrometry |
| | gene Lysozyme | Field Foods sampled Commercial parmesan cheese | Source of spike Cheese samples (Manchego, Grana Padano, Parmigiano Reggiano and hard cheese mixtures) were purchased in a local supermarket | |
| Schneider (2010b) | Specific protein/peptide or gene Lysozyme | Cheese | Spiked Source of spike Lysozyme from Sigma-Aldrich | ELISA |
| Shon (2010) | Specific protein/peptide or gene Ovomucoid | Milk milk substitute Sausage commercial sausage, in-house sausage Field Foods sampled crab meat analogue, sausage | Spiked Field Source of spike whole egg powder and egg white powder provided by Nonghyup (Pyeongtaek, Korea) | ELISA |

Table 3.22:Egg: description of assay

| Study ID | Allergen | Assay details | Additional information |
|-------------------------|----------|--|---|
| Akiyama (2003) | Egg | Test 1 Egg protein ovalbumin ELISA kit (Morinaga Institute of Biological Sciences) Test 2 Egg protein ovomucoid ELISA kit (Morinaga Institute of Biological Sciences) Test 3 FASTKIT Egg ELISA Kit (Nippon Meat Packers, Inc.) | Commercial assay |
| Hefle (2001) | Egg | Test 1 ELISA | ELISA ICP-MS Sandwich In-house |
| Khuda (2012a) egg | Egg | Test 1 RIDASCREEN FAST peanut, egg, and casein from R- Biopharm (RB, Washington, MO, USA) Test 2 | ELISA Commercial company |

EFSA supporting publication 2013:EN-506

| Study ID | Allergen | Assay details | Additional information |
|-------------------------|-----------------|--|---|
| | | Veratox peanut, egg, and total milk allergen quantitative test kits from Neogen (NE) Corp. (Lansing, MI, USA) Test 3 Morinaga (MO) peanut, egg, and milk (casein and BLG) protein ELISA kits (Crystal Chem, Downers Grove, IL, USA) Test 4 Tepnel (TE) BIOKITS peanut, egg, casein, and BLG assay kits (Neogen Corp.) Test 5 ELISA Systems (ES) peanut, egg, casein, and BLG residue kits (BioMerieux, Durham, NC, USA) | |
| Khuda (2012b) egg | Egg | Test 1 RIDASCREEN FAST peanut, egg, and casein from R- Biopharm (RB, Washington, MO, USA) Test 2 Veratox peanut, egg, and total milk allergen quantitative test kits from Neogen (NE) Corp. (Lansing, MI, USA) Test 3 Morinaga (MO) peanut, egg, and milk (casein and BLG) protein ELISA kits (Crystal Chem, Downers Grove, IL, USA) Test 4 Tepnel (TE) BIOKITS peanut, egg, casein, and BLG assay kits (Neogen Corp.) Test 5 ELISA Systems (ES) peanut, egg, casein, and BLG residue kits (BioMerieux, Durham, NC, USA) | ELISA Commercial company |
| Lacorn (2011) | Egg | Test 1 ELISA In- house | ELISA Polyclonal detector Sandwich |
| Morishita (2006) | Egg | Test 1 Immunochromatographic test kits, dipstick. Test 2 ELISA: FASTKIT | Commercial company |
| Schneider (2010a) | Egg | Test 1 Mass spectrometry | Mass spectrometry Time of flight-mass spectrometry |
| Schneider (2010b) | Egg lysozyme | Test 1 ELISA | ELISA Monoclonal detection antibody Competitive inhibition In-house |
| Shon (2010) | Egg | Test 1 ELISA | ELISA Polyclonal detection antibody Competitive inhibition In-house |

| Study ID | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|-----------------|-------------------------|---------------------------------|-------------------|-----------------------|---------------|--------------------------------|-------------------------------------|
| Akiyama 2003 | Ovalbumin | 1 ELISA Morinaga | bread | 5-20 ng/ml | 81-86 | | |
| Akiyama 2003 | Ovalbumin | 1 ELISA Morinaga | cereals | 5-20 ng/ml | 85-87 | | |
| Akiyama 2003 | Ovalbumin | 1 ELISA Morinaga | cookie | 5-20 ng/ml | 90-101 | | |
| Akiyama 2003 | Ovalbumin | 1 ELISA Morinaga | sauce | 5-20 ng/ml | 71-82 | | |
| Akiyama 2003 | Ovalbumin | 1 ELISA Morinaga | sausage | 5-20 ng/ml | 92-105 | 4 ng/ml | 8 ng/ml |
| Akiyama 2003 | Ovomucoid | 2 ELISA Morinaga | bread | 5-20 ng/ml | 88-107 | | |
| Akiyama 2003 | Ovomucoid | 2 ELISA Morinaga | cereals | 5-20 ng/ml | 89-108 | | |
| Akiyama 2003 | Ovomucoid | 2 ELISA Morinaga | cookie | 5-20 ng/ml | 104-167 | | |
| Akiyama 2003 | Ovomucoid | 2 ELISA Morinaga | sauce | 5-20 ng/ml | 57-65 | | |
| Akiyama 2003 | Ovomucoid | 2 ELISA Morinaga | sausage | 5-20 ng/ml | 91-131 | 5 ng/ml | 10 ng/ml |
| Akiyama 2003 | Standard egg protein | 3 ELISA, FASTKIT | bread | 5-20 ng/ml | 45-49 | | |
| Akiyama 2003 | Standard egg protein | 3 ELISA, FASTKIT | Cookie | 5-20 ng/ml | 45-48 | | |
| Akiyama 2003 | Standard egg protein | 3 ELISA, FASTKIT | sauce | 5-20 ng/ml | 46-49 | | |
| Akiyama 2003 | Standard egg protein | 3 ELISA, FASTKIT | sausage | 5-20 ng/ml | 44-45 | | |
| Akiyama 2004 | Standard egg protein | 3 ELISA, FASTKIT | cereals | 5-20 ng/ml | 42-43 | | |
| Khuda 2012a | crude | 1 ELISA, RIDASCRE EN FAST | chocolate dark | linear regression | 255 | | |
| Khuda 2012a | crude | 2 ELISA, Veratox | chocolate dark | linear regression | 283 | | |
| Khuda 2012a | crude | 3 ELISA, Morinaga | chocolate dark | linear regression | 76 | | |
| Khuda 2012a | crude | 4 ELISA, BIOKITS | chocolate dark | linear regression | 58 | | |
| Khuda 2012a | crude | 5 ELISA Systems | chocolate dark | linear regression | 66 | | |
| Khuda 2012b | crude | 1 ELISA, RIDASCRE EN FAST | sugar cookie | linear regression | 10 | | |
| Khuda 2012b | crude | 2 ELISA, Veratox | sugar cookie | linear regression | 9 | | |

 Table 3.23:
 Egg: accuracy and limit of detection and quantification

| Study ID | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|--------------------|---------------------|---|----------------------------------|-----------------------|---------------|--------------------------------|-------------------------------------|
| Khuda 2012b | crude | 3 ELISA, Morinaga | sugar cookie | linear regression | 15 | | |
| Khuda 2012b | crude | 4 ELISA, BIOKITS | sugar cookie | linear regression | 4 | | |
| Khuda 2012b | crude | 5 ELISA Systems | sugar cookie | linear regression | 3 | | |
| Lacorn 2011 | egg white powder | 1 ELISA | wine | 1-9 µg /ml | 98-110 | | |
| Lacorn 2011 | cooked egg white | 1 ELISA | wine | 2-18 µg /ml | 76-88 | | |
| Lacorn 2011 | whole egg powder | 1 ELISA | wine | 1.5-13.5 μg /ml | 87-109 | 0.27 µg /ml | 0.5 mg/L |
| Morishita 2006 | crude | 1 IC - dipstick | chicken meatball or burger | | | 5 µg/g | |
| Morishita 2006 | crude | 1 IC - dipstick | cookie | | | 5 µg/g | |
| Morishita 2006 | crude | 1 IC - dipstick | Dumplings fried/steame d | | | 5 µg/g | |
| Morishita 2006 | crude | 1 IC - dipstick | jelly | | | 5 μg/g | |
| Morishita 2006 | crude | 1 IC - dipstick | Pickles in Vinegar/soy | | | 5 μg/g | |
| Morishita 2006 | crude | 1 IC - dipstick | Potato salad | | | 5 μg/g | |
| Morishita 2006 | crude | 1 IC - dipstick | sauce | | | 5 µg/g | |
| Schneider 2010a | lysozyme | 1 Time-of- flight mass spectrometry | cheese | | | 5 µg/g | |
| Schneider 2010b | lysozyme | 1 ELISA | cheese | 50-400 mg/kg | 87-94 | 2.73 ng/ml | |
| Shon 2010 | ovomucoid | 1 ELISA | egg free sausage | 10-100 mg/kg | 74 | | |
| Shon 2010 | ovomucoid | 1 ELISA | in house sausage | 5-30mg/kg | 66 | | |
| Shon 2010 | ovomucoid | 1 ELISA | milk substitute | 10-100 mg/kg | 129 | | |

3.2.8. Fish and Shellfish

The majority of assays for fish and shellfish in foods were developed to detect parvalbumin the major fish allergen or tropomyosin the main allergen for a wide range of shellfish (Table 3.24). Both these allergenic proteins are relatively heat stable. The assays investigated included ELISA and PCR (Table 3.25). The majority of food matrices tested were liquids such as soups, and in the findings indicated that for most assays there was relatively good recovery (Table 3.26)

Cai (2013) developed and tested a parvalbumin ELISA over a wide range of concentrations 10-1000 ng/ml and demonstrated good recovery rates of 70-140%. Faeste (2008) developed their own in-house

EFSA supporting publication 2013:EN-506

ELISA that gave a limit of detection of 0.01 μ g/g, however they did not present the recovery rates. Shibahara (2013b) also developed and validated an ELISA to parvalbumin showing acceptable recoveries for matrices such as meatballs and potato products when were with 10 ppm (10 μ g/g).

Shibahara (2007) developed an ELISA for detecting shrimp and crab tropomyosin and although the limit of detection for different food matrices was not presented, the study demonstrated that for foods spiked with as little as 10ppm (10 μ g/g) the percentage recovery ranged from 64-82%. Fuller (2007) showed similar sensitivity for an in-house ELISA to detect tropomyosin and Wener (2007) showed good recovery rates when samples were spiked with as little as 1 μ g/ml and the limit of detection was as low as 0.2 μ g/ml in certain foods.

One by study by Taguchi (2011) investigated PCR to detect the DNA of crab, and this assay showed a limit of detection in a similar region of 10 μ g/g. This PCR had the advantage that it can discriminate between shrimp and crab unlike the two commercial LISA kits that it was tested against (*Table 3.25*).

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|----------------------|--|---|---|---|--------------------------|
| Cai (2013) | Fish Silver Carp | Parvalbumin Silver Carp | Soup Tofu and mushroom | Spiked Source of spike Local market in Xiamen, China | ELISA |
| Faeste (2008) | Fish Cod | Specific protein/peptide or gene Parvalbumin | Sauce white sauce, soy sauce Soup fish soup, mushroom soup Field Foods sampled fish soup | Spiked Field Source of spike Gadus morhua | ELISA |
| Fuller (2006) | Fish and shellfish Crustacean s | Specific protein/peptide or gene Tropomyosin | Ocean Pie, Quiche Rice: pilau rice Sauce, Soy sauce, lemon and dill sauce, Spread: tuna and sweet corn spread Thai crackers Vegetable balti | Spiked Source of spike Penaeus latisulcatus, shop brought | ELISA |
| Shibahara (2007) | Fish and shellfish Crustacean s | Specific protein/peptide or gene Tropomyosin | cream croquette Pork dumpling Tomato sauce | Spiked Source of spike Extracted from freeze- dried black tiger prawns | ELISA |
| Shibahara (2013b) | Fish | Parvalbumin | cream croquette Meat: chicken meatball, pork meatball Rice: rice gruel | Spiked Field Source of spike Five species of fish: Japanese eel Anguilla | ELISA |

 Table 3.24:
 Fish and Shellfish: characteristics of included studies

EFSA supporting publication 2013:EN-506

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|-------------------|--|---|--|--|--------------------------|
| | | | Soup: vegetable and chicken soup | japonica, horse mackerel Trachurus japonicus, crimson sea bream Evynnis japonica, pacific mackerel S.japonicus and bigeye tuna Thunnus obesus. | |
| Taguchi (2011) | Fish and shellfish Crustacean shrimp, crab | Crude extract | Cream croquette Rice dry condiment sprinkled on rice, rice gruel Soup freeze-dried soup, miso soup paste, soup powder Field Foods sampled 27 commercial food products, purchased from local stores | Spiked Field Source of spike Markets in Tokyo and Chiba, Japan, or provided by Maruha Nichiro Holdings, Inc. | ELISA PCR |
| Werner (2007) | Fish and shellfish Crustacean s | Specific protein/peptide or gene Tropomyosin | Fish breaded codfish, fish cake Sauce fish sauce, mayonnaise Surimi | Spiked Source of spike Pandalus borealis | ELISA |

 Table 3.25:
 Fish and Shellfish: description of assay

| Study ID | Allergen | Assay details | Additional information |
|------------|-------------|---------------|-------------------------------|
| Cai (2012) | Fish | Test 1 | ELISA |
| | Silver Carp | ELISA | Monoclonal detection antibody |
| | Parvalbumin | | Competitive inhibition |
| | | | In-house |
| | | | |
| Faeste | Fish | Test 1 | ELISA |
| (2008) | | ELISA | Sandwich |
| | | | In-house |
| | | | |
| Fuller | Crustaceans | Test 1 | ELISA |
| (2006) | | ELISA | Polyclonal capture antibody |
| | | | Polyclonal detection antibody |
| | | | Sandwich |
| | | | In-house |
| | | | |
| Shibahara | Crustaceans | Test 1 | ELISA |
| (2007) | | ELISA | Monoclonal capture antibody |
| | | | Polyclonal detection antibody |

EFSA supporting publication 2013:EN-506
| Study ID | Allergen | Assay details | Additional information |
|----------------------|-----------------------------|---|--|
| | | | In-house |
| Shibahara (2013b) | Fish | Test 1 ELISA | ELISA Polyclonal capture antibody Polyclonal detection antibody Sandwich In-house |
| Taguchi (2011) | Crustaceans shrimp, crab | Test 1 EIA crustacean 'Nissui' ELISA Test 2 crustacean kit 'Maruha' ELISA Test 3 Shrimp PCR Test 4 Crab PCR In-house | Test 1 Nissui Pharmaceutical Co., Ltd., Toshima-ku, Tokyo Test 2 Maruha Nichiro Holdings, Inc. Test 3 PCR, in-house Test 4 PCR, in-house |
| Werner (2007) | Crustaceans | ELISA | ELISA Polyclonal capture antibody Polyclonal detection antibody Sandwich In-house |

| Table 3.26: | Fish and Shellfish: accuracy and limit of detection and quantification |
|-------------|--|
|-------------|--|

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|----------------|-------------|---------------------|---------------------|-------------------------|--------------------|-----------------|--------------------------------|-------------------------------------|
| Cai 2013 | silver carp | parvalbumin | 1 ELISA | mushroom soup | 10-1000 ng/ml | 87.7 - 97.8 | | |
| Cai 2013 | silver carp | parvalbumin | 1 ELISA In-house | tofu soup | 10-1000 ng/ml | 70.3 - 134.8 | | |
| Faeste 2008 | fish | cod parvalbumin | 1 ELISA In-house | buffer | | | 0.01 µg/g | 0.02 µg/g |
| Faeste 2008 | fish | cod parvalbumin | 1 ELISA In-house | mushroom soup | | | 0.01 µg/g | 0.02 µg/g |
| Faeste 2008 | fish | cod parvalbumin | 1 ELISA In-house | sauce | | | 0.01 µg/g | 0.02 µg/g |
| Faeste 2008 | fish | cod parvalbumin | 1 ELISA In-house | soup | | | 0.01 µg/g | 0.02 µg/g |
| Faeste 2008 | fish | cod parvalbumin | 1 ELISA In-house | soy sauce | | | 0.01 µg/g | 0.02 µg/g |
| Fuller 2007 | crustaceans | tropomyosin | 1 ELISA In-house | buffer | nr | nr | 1 μg/g | |
| Fuller 2007 | crustaceans | tropomyosin | 1 ELISA In-house | casserole/ curry | 7.5 ppm | 67-86 | | |
| Fuller 2007 | crustaceans | tropomyosin | 1 ELISA In-house | crisps/ Thai cracker | 7.5 ppm | 99-140 | | |
| Fuller 2007 | crustaceans | tropomyosin | 1 ELISA In-house | pie/ quiche | 7.5 ppm | 41-112 | | |

289

290

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|--------------------|-------------|---------------------|---------------------|----------------------------------|-----------------------|---------------|--------------------------------|-------------------------------------|
| Fuller 2007 | crustaceans | tropomyosin | 1 ELISA In-house | pie/ quiche | 7.5 ppm | 74-84 | | |
| Fuller 2007 | crustaceans | tropomyosin | 1 ELISA In-house | rice | 7.5 ppm | 76-117 | | |
| Fuller 2007 | crustaceans | tropomyosin | 1 ELISA In-house | sauce | 7.5 ppm | 85-124 | | |
| Fuller 2007 | crustaceans | tropomyosin | 1 ELISA In-house | soy sauce | 7.5 ppm | 76-87 | | |
| Fuller 2007 | crustaceans | tropomyosin | 1 ELISA In-house | spread | 7.5 ppm | 117-143 | | |
| Shibahara 2007 | crustaceans | tropomyosin | 1 ELISA In-house | buffer | | | 0.4 ng/ml | 1.2 ng/ml |
| Shibahara 2007 | crustaceans | tropomyosin | 1 ELISA In-house | croquette | 2,10,16 ppm | 88-103 | | |
| Shibahara 2007 | crustaceans | tropomyosin | 1 ELISA In-house | Dumplings fried/steame d | 2,10,16 ppm | 94-105 | | |
| Shibahara 2007 | crustaceans | tropomyosin | 1 ELISA In-house | sauce | 2,10,16 ppm | 94-104 | | |
| Shibahara 2013b | fish | parvalbumin | 1 ELISA In-house | buffer | | | 0.23 ng/ml | 0.7 μg/g |
| Shibahara 2013b | fish | parvalbumin | 1 ELISA In-house | chicken meatball or burger | 10 ppm | 73.5 | | |
| Shibahara 2013b | fish | parvalbumin | 1 ELISA In-house | pork meatball or burger | 10 ppm | 81.8 | | |
| Shibahara 2013b | fish | parvalbumin | 1 ELISA In-house | potato croquette or mash | 10 ppm | 63.6 | | |
| Shibahara 2013b | fish | parvalbumin | 1 ELISA In-house | range of products | | | | |
| Shibahara 2013b | fish | parvalbumin | 1 ELISA In-house | rice gruel/ porridge | 10 ppm | 78.8 | | |
| Shibahara 2013b | fish | parvalbumin | 1 ELISA In-house | soup | 10 ppm | 78.7 | | |
| Taguchi 2011 | crustaceans | DNA -shrimp | 3 shrimp PCR | miso | | | 10 µg/g | |
| Taguchi 2011 | crustaceans | DNA -shrimp | 3 shrimp PCR | soup | | | 10 µg/g | |
| Taguchi 2011 | crustaceans | DNA -shrimp | 3 shrimp PCR | soup | | | 10 µg/g | |
| Taguchi 2011 | crustaceans | DNA -crab | 4 crab-PCR | miso | | | 10 µg/g | |
| Taguchi 2011 | crustaceans | DNA -crab | 4 crab-PCR | soup | | | 10 µg/g | |
| Taguchi 2011 | crustaceans | DNA -crab | 4 crab-PCR | soup | | | 10 µg/g | |
| Taguchi 2011 | crustaceans | DNA -shrimp | 3 shrimp PCR | chicken meatball or burger | | | 10 µg/g | |

EFSA supporting publication 2013:EN-506

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|-----------------|-------------|---------------------|---------------------|----------------------------------|-----------------------|---------------|--------------------------------|-------------------------------------|
| Taguchi 2011 | crustaceans | DNA -shrimp | 3 shrimp PCR | croquette | | | 10 µg/g | |
| Taguchi 2011 | crustaceans | DNA -shrimp | 3 shrimp PCR | range of products | | | | |
| Taguchi 2011 | crustaceans | DNA -shrimp | 3 shrimp PCR | rice gruel/ porridge | | | 10 µg/g | |
| Taguchi 2011 | crustaceans | DNA -crab | 4 crab-PCR | chicken meatball or burger | | | 10 µg/g | |
| Taguchi 2011 | crustaceans | DNA -crab | 4 crab-PCR | croquette | | | 10 µg/g | |
| Taguchi 2011 | crustaceans | DNA -crab | 4 crab-PCR | range of products | | | | |
| Taguchi 2011 | crustaceans | DNA -crab | 4 crab-PCR | rice gruel/ porridge | | | 10 µg/g | |
| Werner 2007 | crustaceans | tropomyosin | 1 ELISA In-house | fish | 1-100 µg/ml | 68-83 | 0.3 µg/g | |
| Werner 2007 | crustaceans | tropomyosin | 1 ELISA In-house | mayonnaise | 1-100 µg/ml | 102-120 | 0.2 μg/g | |
| Werner 2007 | crustaceans | tropomyosin | 1 ELISA In-house | sauce | 1-100 µg/ml | 79-94 | 0.3 µg/g | |
| Werner 2007 | crustaceans | tropomyosin | 1 ELISA In-house | surimi | 1-100 µg/ml | 66-88 | 0.9 µg/g | |

3.2.9. Hazelnut

A range of immunoassays including dipstick tests and real-time PCR assays were validated by the studies included within this review and the food matrices used included chocolate, cereals and cookies (Table 3.27). Commercial and in-house tests were investigated (Table 3.28). Most of the assays investigated could detect to below 10 ppm ($10 \mu g/g$) in a range of samples, including milk chocolate (Table 3.29).

Akkerdaas (2004), Ben Rejeb (2003), Ben Rejeb (2005h), Blais (2001), Cucu (2012), Drs (2004), Holzhauser (1999) developed and validated in-house ELISAs. All provided a limit of detection as low as or lower than 1 μ g/g with recoveries of over 50%.

Commercial assays tested included Veratox, Garber (2010), ELISA systems, Garber 2010) Ridascreen, Ehlert (2009), Garber (2010), Piknova (2008) with a limit of detection between 1 and 6 μ g/g The exception was Ridascreen tested by Ehlert (2009) that gave a limit of detection of 10 mg/kg⁻¹, equivalent to 100 μ g/g. All assays were directed against crude extracts rather than purified proteins.

Ehlert (2009) developed and validated a ligation-dependent probe amplification system for simultaneous detection of DNA from a number of allergenic foods. The limit of detection in food matrices such as chocolate and cookies was 10 mg/kg⁻¹ that equates to 100 μ g/g. Faeste (2006) developed a time-resolved fluoro-imunoassay and this had reasonable recoveries of between 5-123 % for matrices spiked with 1-150 mg/kg (1-150 μ g/g).

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|------------------------|----------|--|---|---|---|
| Akkerdaas (2004) | Hazelnut | Tree nut Hazelnut Crude extract Pepsin stable | Chocolate | Spiked Source of spike Turkish variety, local store | ELISA |
| Ben Rejeb(2003) | Hazelnut | Crude extract | Breakfast cereals Chocolate Cookie Ice cream | Spiked Source of spike Roasted hazelnuts from a local store Standardisation Total protein content using the Bradford test | ELISA |
| Ben Rejeb (2005h) | Hazelnut | Crude extract | Chocolate | Spiked Roasted defatted peanuts and nuts extracted, dialysed Source of spike Not reported Standardisation Made up to 1mg/ml ⁻¹ protein content measured using BCA test | ELISA |
| Blais (2001) | Hazelnut | Crude extract | Breakfast cereals Cake cake mix Cereal Bar fruit and almond granola bars Chocolate Cookie Ice cream | Spiked Source of spike Shelled raw hazelnuts ground and defatted salted and centrifuged. Standardisation Total protein 35 mg/ml (determined using Biorad) | ELISA |
| Costa (2012) | Hazelnut | Specific protein/peptide or gene hsp1 gene m RNA | Pasta | Spiked Field Source of spike Unclear 'commercial hazelnut' | PCR |
| Cucu (2012) | Hazelnut | Crude extract | Cookie Both before and after cooking | Spiked Source of spike 9 different brands of hazelnut (8 raw, 1 roasted) were purchased in supermarkets | ELISA |
| Drs (2004) | Hazelnut | Crude extract roasted hazelnut | Cookie | Spiked Source of spike Masterfoods (Breitenbiunn, Austria) | ELISA |
| Ehlert (2009) | Hazelnut | Crude extract Specific protein/peptide or gene DNA | Cookie Pesto cashew | Spiked Source of spike Nut materials, sesame seeds, ingredients of self- prepared DNA plant and animal materials used to | ELISA PCR Ligation- dependent probe amplification |

| Table 3.27: | Hazelnut: | characteristics | of included studies | ļ |
|-------------|-----------|-----------------|---------------------|---|
|-------------|-----------|-----------------|---------------------|---|

292

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|----------------------|----------|--|--|---|---|
| | | | | test the specificity of the method and spike samples of chocolate, were obtained from the Bavarian Health and Food Safety Authority (Oberschleibheim, Germany) | |
| Faeste (2006) | Hazelnut | Specific protein/peptide or gene Corylin fraction | Breakfast cereals Chocolate Cookie | Spiked. Source of spike Raw Mina hazelnuts (Iran) Standardisation Raw nuts were homogenised, suspended in buffer, vortexed, centrifuged and filtered through glass wool. Total protein content was determined using the Lowrey method, and protein standard solution was diluted with PBS to 2 mg/ml | Time-resolved fluoroimmuno- assay |
| Garber (2010b) | Hazelnut | Crude extract | Breakfast cereals oatmeal Cake muffins Chocolate | Spiked Source of spike purchased locally | ELISA |
| Holzhauser (1999) | Hazelnut | Crude extract | Cereal Bar yoghurt cereal bar Chocolate almond candy cream chocolate bar Cookie | Spiked Field Source of spike Piemonte and Nocciole Ordu, provided by Dr G Malgarini, Sorematx, Arlon-Schoppach, Belgium. toasted. Standardisation soluble protein was quantified by the Bradford method | ELISA |
| Holzhauser (2002) | Hazelnut | Crude extract | Cereal bar Chocolate Field Foods sampled A range of products including chocolates, chocolates with nuts, nougat, milk products | Source of spike Hazelnuts of the variety Nocciole Ordu (Turkey) both native and toasted at 140 °C for 30 min, were provided by Dr G Malgarini, Sorematec, Arlon-Schoppach, Belguim. Commercial food products were bought at a local food store. | ELISA PCR PCR ELISA |

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|----------|----------|---------------------------------|-----------------------|---|--------------------------|
| Kiening | Hazelnut | Crude extract | Breakfast cereals | Spiked | ELISA |
| (2005) | | | Chocolate | | |
| | | | Cookie | Field | |
| | | | Ice cream | Source of spike | |
| | | | | Roasted hazelnut samples | |
| | | | Field | were provided by R. Fila | |
| | | | Foods sampled | from Masterfoods, | |
| | | | cookie, cereals | Breitenbrunn, Austria. | |
| | | | and chocolate | | |
| Piknova | Hazelnut | Specific | Pastry or dough | Spiked | ELISA |
| (2008) | | protein/peptide | | Field | PCR |
| | | or gene | Field | Source of spike | |
| | | | Foods sampled | Five cultivars from | |
| | | hsp1 gene | Chocolate, wafers, | Botanical garden, Slovak | |
| | | | muesli and | Agricultural University, | |
| | | | biscuits | Nitra Slovkia. | |
| Stephan | Hazelnut | Specific | Chocolate | Spiked | Dipstick |
| (2002) | | protein/peptide | Rausch | Field | |
| | | or gene | Schokoladen | Source of spike | |
| | | Corylin fraction | Gmbh (Peine, | Not reported | |
| | | Hazelnut | Germany) | | |
| | | | Field | | |
| | | | Foods sampled | | |
| | | | Range of foods | | |
| | | | labelled as | | |
| | | | containing, not | | |
| | | | containing and | | |
| | | | may contain | | |
| | | | peanut or hazelnut | | |

 Table 3.28:
 Hazelnut: description of assay

| Study ID | Allergen | Assay details | Additional information |
|----------------------|----------|-----------------|---|
| Akkerdaas (2004) | Hazelnut | Test 1 ELISA | ELISA Polyclonal capture antibody Polyclonal detection antibody In-house |
| Ben Rejeb (2003) | Hazelnut | Test 1 ELISA | ELISA Competitive Polyclonal detector antibody In-house |
| Ben Rejeb (2005h) | Hazelnut | ELISA | ELISA Polyclonal detection antibody Competitive inhibition In-house |
| Blais (2001) | Hazelnut | Test 1 ELISA | ELISA Polyclonal capture antibody Polyclonal detection antibody Sandwich In-house |

| Study ID | Allergen | Assay details | Additional information |
|-------------------------------|----------|---|---|
| Costa (2012) | Hazelnut | Test 1 Real-time PCR Test 2 Nested real-time PCR | PCR |
| Cucu (2012) | Hazelnut | Test 1 ELISA | ELISA Polyclonal detection antibody Competitive inhibition In-house |
| Drs (2004) | Hazelnut | Test 1 | ELISA Competitive inhibition Indirect competitive ELISA In-house |
| Ehlert (2009) | Hazelnut | Test 1 Ligation dependent probe amplification Test 2 Hazelnut and peanut: real-time PCR Surefood allergen kit (Congen Biotechnology GmbH, Berlin, Germany) cashew real time PCR In house Test 3 Hazelnut and peanut: ELISA Ridascreen (R- Biopharm AG, Darmstadt, Germany) | Test 1 PCR-LPA Test 2 PCR Test 3 ELISA Commercial |
| Faeste (2006) | Hazelnut | Test 1 Fluoro-immunoassay | Time-resolved fluoro- immunoassay |
| Garber (2010b) hazelnut | Hazelnut | Test 1 Veratox (Neogen Corporation, Lansing, MI, USA); Test 2 Ridascreen Fast (R-Biopharm Inc, Marshal, MI, USA), Test 3 Elisa systems(bioMerieux Industry (Hazelwood, MO, USA) | Test 1, 2 and 3 ELISA Sandwich Commercial company |
| Holzhauser (1999) | Hazelnut | Test 1 ELISA | ELISA Polyclonal capture antibody Polyclonal detection antibody Sandwich In-house |
| Holzhauser (2002) | Hazelnut | Test 1 ELISA Test 2 PCR-ELISA | Test 1 ELISA Polyclonal capture antibody Polyclonal detection antibody Sandwich Commercial company Test 2 PCR-ELISA Commercial company SureFood-Allergen Hazelnut test (Congen Biotechnology, No. |

| Study ID | Allergen | Assay details | Additional information |
|-------------------|----------|---|--|
| | | | \$3002) |
| Piknova (2008) | Hazelnut | Test 1 Real-time PCR hsp 1 Test 2 ELISA RidaScreen FAST Hazelnut (R- Biopharm, Darmstadt, Germany | Test 1 PCR Test 2 ELISA Commercial company |
| Stephan (2002) | Hazelnut | Test 1 Dipstick: in-house | Dipstick method In house. Polyclonal capture antibody Polyclonal detector antibody. In-house |

Table 3.29: Hazelnut: accuracy and limit of detection and quantification

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|-------------------|----------|---------------------|------------------|---------------------|-----------------------|---------------|--------------------------------|-------------------------------------|
| Akkerdaas 2004 | hazelnut | Crude pepsin stable | 1 ELISA | buffer | | | 0.7 ng/ml | |
| Akkerdaas 2004 | hazelnut | Crude pepsin stable | 1 ELISA | chocolate milk | 0.5 -100 μg/g | 53-120 | 0.5 µg/g | |
| Akkerdaas 2004 | hazelnut | Crude pepsin stable | 1 ELISA | range of products | | | | |
| Ben Rejeb 2003 | hazelnut | Crude- roasted | 1 ELISA | breakfast cereal | 1-10 µg/g | 80-93 | | |
| Ben Rejeb 2003 | hazelnut | Crude- roasted | 1 ELISA | chocolate dark | 1-10 µg/g | 64-83 | 0.5 µg/g | |
| Ben Rejeb 2003 | hazelnut | Crude- roasted | 1 ELISA | chocolate milk | 1-10 µg/g | | | |
| Ben Rejeb 2003 | hazelnut | Crude- roasted | 1 ELISA | cookie | 1-10 µg/g | 89-97 | | |
| Ben Rejeb 2003 | hazelnut | Crude- roasted | 1 ELISA | ice cream | 1-10 µg/g | 78-83 | | |
| Ben Rejeb 2005 | hazelnut | | 1 ELISA | chocolate dark | | | 1 ppm | |
| Blais 2001 | hazelnut | Crude | 1 EIA (ELISA) | breakfast cereal | | | 0.25 ppm | |
| Blais 2001 | hazelnut | Crude | 1 EIA (ELISA) | Cake | | | 0.12 ppm | |
| Blais 2001 | hazelnut | Crude | 1 EIA (ELISA) | chocolate milk | | | 0.25 ppm | |
| Blais 2001 | hazelnut | Crude | 1 EIA (ELISA) | cookie | | | 0.5 ppm | |
| Blais 2001 | hazelnut | Crude | 1 EIA (ELISA) | ice cream | | | 0.25 ppm | |
| Blais 2001 | hazelnut | Crude | 1 EIA (ELISA) | muesli | | | 0.5 ppm | |

EFSA supporting publication 2013:EN-506

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|----------------------------|----------|---------------------|------------------------------|------------------------------------|--------------------|---------------|--------------------------------|-------------------------------------|
| Blais 2001 | hazelnut | Crude | 1 EIA (ELISA) | snack cereal | | | 1 ppm | |
| Blais 2001 | hazelnut | Crude | 1 EIA (ELISA) | snack cereal | | | 0.5 ppm | |
| Costa 2012 | hazelnut | hsp 1 | 1 Real time PCR | Pasta | Nr | nr | 100 mg/kg | 100 mg/kg |
| Costa 2012 | hazelnut | hsp 1 | 2 Nested Real time PCR | Pasta | | | 50 mg/kg | 50 mg/kg |
| Costa 2012 | hazelnut | hsp 1 | 2 Nested real- time PCR | range of products | Nr | nr | nr | nr |
| Cucu 2012 | hazelnut | crude | 1 ELISA | cookie | 30-100 μg/g | 10 - 20 | | |
| Cucu 2012 | hazelnut | crude | 1 ELISA | cookie (spiked after baking) | 3-25 μg/g | 73-107 | | |
| Drs 2004 | hazelnut | crude | 1 ELISA | cookie | | 128 | 10 µg/L ⁻¹ | 30 µg/L-1 |
| Ehlert 2009 | hazelnut | DNA | 1 LPA | chocolate | Nr | nr | 5 mg/kg^{-1} | |
| Ehlert 2009 | hazelnut | DNA | 1 LPA | walnut cookies | Nr | nr | 100 mg/kg ⁻¹ | |
| Ehlert 2009 | hazelnut | DNA | 2 PCR real time | chocolate | | | 10 mg/kg ⁻¹ | |
| Ehlert 2009 | hazelnut | DNA | 2 PCR real time | walnut cookies | | | 10 mg/kg ⁻¹ | |
| Ehlert 2009 | hazelnut | crude | 3 ELISA <i>Ridascreen</i> | chocolate | | | 10 mg/kg ⁻¹ | |
| Ehlert 2009 | hazelnut | crude | 3 ELISA <i>Ridascreen</i> | walnut cookies | | | 1 mg/kg ⁻¹ | |
| Faeste 2006 | hazelnut | Corylin fraction | 1 Fluoro-IA | cereals | 1-150 mg/kg | 77-123 | | |
| Faeste 2006 | hazelnut | Corylin fraction | 1 Fluoro-IA | cereals | 1-150 mg/kg | 54-77 | | |
| Faeste 2006 | hazelnut | Corylin fraction | 1 Fluoro-IA | chocolate milk | 1-150 mg/kg | 50-71 | | |
| Faeste 2006 | hazelnut | Corylin fraction | 1 Fluoro-IA | cookie | 1-150 mg/kg | 73-97 | | |
| Garber 2010 hazelnut | hazelnut | crude | 1 ELISA, Veratox | Cake | | | 5.6 μg/g | |
| Garber 2010 hazelnut | hazelnut | crude | 1 ELISA, Veratox | cereals | | | 1.4 µg/g | |
| Garber 2010 hazelnut | hazelnut | crude | 1 ELISA, Veratox | chocolate | | | 1.1 μg/g | |
| Garber 2010 hazelnut | hazelnut | crude | 2 ELISA, RIDASCRE EN | Cake | | | 2 µg/g | |
| Garber 2010 | hazelnut | crude | 2 ELISA, RIDASCRE | cereals | | | 2 µg/g | |

297

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|----------------------------|----------|---------------------|----------------------------|-------------------------|-----------------------|---------------|--------------------------------|-------------------------------------|
| hazelnut | | | EN | | | | | |
| Garber 2010 hazelnut | hazelnut | crude | 2 ELISA, RIDASCRE EN | chocolate | | | 1 µg/g | |
| Garber 2010 hazelnut | hazelnut | crude | 3 ELISA Systems | Cake | | | 38 µg/g | - |
| Garber 2010 hazelnut | hazelnut | crude | 3 ELISA Systems | cereals | | | 5.8 μg/g | |
| Garber 2010 hazelnut | hazelnut | crude | 3 ELISA Systems | chocolate | | | 8 µg/g | |
| Holzhauser 1999 | hazelnut | crude | 1 ELISA | almond | | | 1.1 ppm | 1.4 ppm |
| Holzhauser 1999 | hazelnut | crude | 1 ELISA | cashew | | | 4.5 ppm | 6.9 ppm |
| Holzhauser 1999 | hazelnut | crude | 1 ELISA | chocolate | 0.001 - 10 % | 103-132 | | - |
| Holzhauser 1999 | hazelnut | crude | 1 ELISA | chocolate milk | 0.001 - 10 % | 83-118 | 0.07 ppm | 0.13 ppm |
| Holzhauser 1999 | hazelnut | crude | 1 ELISA | chocolate milk | | | 0.11 ppm | 0.19 ppm |
| Holzhauser 1999 | hazelnut | crude | 1 ELISA | cookie | 0.001 - 10 % | 90-127 | | |
| Holzhauser 1999 | hazelnut | crude | 1 ELISA | crisps/ Thai cracker | | | 0.09 ppm | 0.14 ppm |
| Holzhauser 1999 | hazelnut | crude | 1 ELISA | ice cream | | | 0.07 ppm | 0.12 ppm |
| Holzhauser 1999 | hazelnut | crude | 1 ELISA | popcorn | | | 0.43 ppm | 0.67 ppm |
| Holzhauser 1999 | hazelnut | crude | 1 ELISA | pumpkin seed | | | 10.3 ppm | 14.1 ppm |
| Holzhauser 1999 | hazelnut | crude | 1 ELISA | range of products | | | | |
| Holzhauser 1999 | hazelnut | crude | 1 ELISA | snack cereal | 0.001 – 10% | 67-127 | | |
| Holzhauser 1999 | hazelnut | crude | 1 ELISA | snack cereal | | | 0.05 ppm | 0.05 ppm |
| Holzhauser 1999 | hazelnut | crude | 1 ELISA | walnut | | | 5.5 ppm | 6.9 ppm |
| Kiening 2005 | hazelnut | crude | 1 ELISA | cereals | 1-10 mg/kg | 95-101 | | |
| Kiening 2005 | hazelnut | crude | 1 ELISA | chocolate dark | 1-10 mg/kg | 86-94 | | |
| Kiening 2005 | hazelnut | crude | 1 ELISA | chocolate milk | 1-10 mg/kg | 0-115 | | |
| Kiening 2005 | hazelnut | crude | 1 ELISA | cookie | 1-10 mg/kg | 95-127 | | |

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|-----------------|----------|---------------------|-------------------------|-------------------|-----------------------|---------------|--------------------------------|-------------------------------------|
| Kiening 2005 | hazelnut | crude | 1 ELISA | ice cream | 1-10 mg/kg | 93-111 | | |
| Piknova 2008 | hazelnut | | 2 ELISA (Ridascreen) | dough | | | 0.01 % w/w | |
| Piknova 2008 | hazelnut | | 1 Real time PCR | range of products | | | | |

IA- Immuno-assay

3.2.10. Lupine

We had findings from three studies that investigated ELISA and PCR in food matrixes such as bread, cakes and sausage meat. The assays all provided a limit of detection of approximately 1 ppm equivalent to $1\mu g/g$ with good recoveries when spiked with between 1 and $1000\mu g/g$ of lupine. The ELISA assays, Holden (2005), Holden (2007), and Kaw (2008) were developed in-house and were directed against crude antigens rather than specific allergens. All the studies presented limit of detection and percentage recovery and this was as low as $1 \mu g/g$ with the Holden (2005) assay detecting down to $0.1\mu g/g$ in sausage or pastry matrices.

Demmel (2011) tested a real time PCR assay in pizza, flour and dough and demonstrated a consistent limit of detection of $0.1 \mu g/g$ of Lupine flour. However the percentage recovery was not presented.

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|------------------|----------|---------------------------------|--|--|--------------------------|
| Demmel (2011) | Lupine | Crude extract | Flour wheat flour | Spiked Source of spike Sweet lupine flour from L angustifolius, (Chemical and Veterinarian Research Institute Freiburg, Freiburg, Germany) | PCR |
| Holden (2005) | Lupine | Crude extract | Bread hot dog Pasta | Spiked Source of spike Lopino (Lupina, Visbeck, Germany) | ELISA |
| Holden (2007) | Lupine | Crude extract | Bread, lupine-free Field Foods sampled cakes, bread/rolls, pasta, chocolate spread, biscuits, flour/mix, chips | Spiked Field Source of spike Processed proteins from L. albus seeds, in the form of tofu-like product (Lopino;Lupina, Visbek, Germany) native proteins from L.angustifolius seeds, in the form of lupine flour, (Soja Austria) | ELISA |

| Table 3.30: | Lupine: | characteristics | of included | studies |
|-------------|---------|-----------------|-------------|---------|
| | | | | |

EFSA supporting publication 2013:EN-506

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|------------|----------|---------------------------------|---|---|--------------------------|
| Kaw (2008) | Lupine | Crude extract | Cake corn muffin Meat Sausage Frankfurter | Spiked Source of spike purchased from a local grocery store Standardisation protein concentration was assessed using Lowry method | ELISA |

Table 3.31:Lupine: description of assay

| Study ID | Allergen | Assay details | Additional information |
|------------------|----------|--------------------------|---|
| Demmel | Lupine | Test 1 | |
| (2011) | | Real time PCR | |
| Holden (2005) | Lupine | Test 1 ELISA | ELISA Polyclonal capture antibody Polyclonal detection antibody Sandwich |
| | | | In-house |
| Holden (2007) | Lupine | Test 1 <i>pAb-mAb</i> | ELISA Polyclonal capture antibody Monoclonal detection antibody Sandwich In-house |
| Kaw (2008) | Lupine | Test 1 ELISA | ELISA Sandwich In-house |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|----------------|----------|---------------------|---------------------|-----------------------|-----------------------|---------------|--------------------------------|-------------------------------------|
| Demmel 2011 | lupine | crude | 1 PCR real time | dough | | | 0.1 µg/g | |
| Demmel 2011 | lupine | crude | 1 PCR real time | flour | | | 0.1 µg/g | |
| Demmel 2011 | lupine | crude | 1 PCR real time | pizza (cooked) | | | 0.1 µg/g | |
| Holden 2005 | lupine | crude | 1 ELISA | bread | 1-1000 µg/g | 80-116 | 0.2 μg/g | |
| Holden 2005 | lupine | crude | 1 ELISA | chocolate spread | 1-1000 µg/g | 61-84 | 0.4 µg/g | |
| Holden 2005 | lupine | crude | 1 ELISA | pasta | 1-1000 µg/g | 88-116 | 0.1 µg/g | |
| Holden 2005 | lupine | crude | 1 ELISA | sausage vegetarian | 1-1000 µg/g | 60-64 | 0.1 µg/g | |
| Holden 2007 | lopino | crude | 1 ELISA pAb- mAb | bread | 1-1000 µg/g | 85-150 | | |
| Holden 2007 | lupine | crude | 1 ELISA pAb- mAb | bread | 1-1000 µg/g | 44-88 | | |
| Kaw 2008 | lupine | crude | 1 ELISA | muffin (corn) | 1-1000 ppm | 91-118 | 1 μg/g | |
| Kaw 2008 | lupine | crude | 1 ELISA | sausage | 1-1000 ppm | 97-117 | 1 µg/g | |

 Table 3.32:
 Lupine: accuracy and limit of detection and quantification

3.2.11. Milk

A range of assays were investigated including commercial and in house ELISAs, direct automated optical biosensor, mass spectrometry and dipsticks in a range of food matrices such as pasta sauce, sausage, cereals, biscuits, sorbet, dark chocolate and wine (Table 3.33). The assays tended to be directed against specific components of milk for example casein, kappa-casein and beta-lactoglobulin and these correspond to the major allergenic proteins (Table 3.34).

The in- house ELISA developed by Hefle (2004) was directed against casein and gave a limit of detection of 0.5 ppm equivalent to $0.5 \ \mu g/g$ in the food matrices ice-cream and dark chocolate.

The commercial ELISA kit FASTKIT tested by Akiyama (2002) (Table 3.35) gave between 5-95 percent recoveries for detecting casein and beta-lactoglobulin in food matrices spiked with as little as 5 ng/ml, these recoveries varied considerable in different foods matrices. Recovery was under 40% for casein in various sauces whereas the cereals, cookies and sausage mix gave better recoveries. The same FASTKIT directed against beta-lactoglobulin gave more consistent recoveries, 49-95% in the same range of foods. The FASTKIT directed against crude milk extract gave poorer recoveries of between 24-48%. Presumable this later assay was directed against a range of milk proteins including beta-lactoglobulin and caseins.

The RIDASCREEN ELISA for detecting case tested by Khuda (2012a) gave very poor recovery in dark chocolate, this study was of high quality and the researchers ensured that they attempted to recover the milk proteins from tempered chocolate. The same RIDASCREEN assays for detecting case and beta-

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

302

lactoglobulin gave negligible recoveries from sugar cookie mixture, Khuda (2012b). However none of the assays tested in this study showed good recovery from the sugar cookie matrix.

The Veratox ELISA for casein tested by Khuda (2012a) gave excellent recovery from dark chocolate at 122%, and like the previous assay poor recovery from sugar cookie at 7%.

The ELISA ICP-MS for casein, was shown to have a limit of detection of $0.5\mu g/g$ in dark chocolate and ice cream matrices by Hefle (2004), the percent recovery was not shown.

The ELISA BIOKIT showed recoveries of only 2% from dark chocolate for beta-lactoglobulin but better at 50% for casein, Khuda (2012a). As mentioned in the previous paragraphs recovery from sugar cookie was poor at 0%, (Khuda 2012b).

The ELISA Systems kits gave recoveries of 50 and 40% for casein and beta-lactoglobulin respectively from chocolate, Khuda (2012a), and again negligible recoveries of 6% or less from sugar cookie, Khuda (2012b).

A novel, direct automated optical biosensor (Biacore 3000) was tested with a monoclonal antibody specific for cows' milk kappa-casein contaminating sheep or goats' milk, Haasnoot (2004). This specificity may not be useful for allergen testing as human IgE tends to show cross reactivity with caseins from different species. The assay limit of detection was given as 0.7% - 0.08 w/w which converts to 700-800µg/g for detecting bovine proteins in sheep and goat milk. This validation experiment while being suitable for species contamination was not suitable for allergy testing.

Morishita (2006) developed and tested an IC - dipstick method that provided a good limit of detection $5\mu g/g$ in a range of foods. This assay has the advantage over the ELISA systems that complex laboratory systems and equipment are not required.

Monaci (2008) developed and tested a detection system using mass spectrometry to detect the milk protein alpha lactalbumin. This gave recoveries of 73-79% for fruit juice spiked with as little as $5\mu g/ml$.

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|--------------------|-------------------|--|---|--|--|
| Akiyama (2004) | Milk | Specific protein/peptide or gene Beta- lactoglobulin Casein | Cereal Cookie Sauce Pasta sauce Sausage | Spiked Dose of spike 5-20 ng/mL Source of spike Milk: provided by Nippon Meat Packers, Inc. Fresh Milk from Holstein. | ELISA |
| Eissa (2012) | Milk and dairy | Specific protein/peptide or gene Beta- lactoglobulin | Field Foods sampled Cake, biscuit and crisps | Field Source of spike Abcam (Cambridge, USA) | ELISA Electrochemic al Immunosensor |
| Haasnoot (2004) | Cow's milk | Specific protein/peptide or gene | Milk Ewes and goats milk | Spiked Source of spike Cow's milk was made by | ELISA Biosensor immunoassay |

| Table 3.33: | Milk: characteristics of included studies |
|-------------|---|
|-------------|---|

EFSA supporting publication 2013:EN-506

303

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|----------------------------|-------------------|--|--|--|--|
| | | bovine kappa- casein | | reconstituting a bovine skimmed milk powder (1g + 9ml of water) | |
| Hefle (2004) | Milk and dairy | Specific protein/peptide or gene Casein | Chocolate Ice cream Lemon sorbet | Spiked Source of spike Not reported | ELISA |
| Khuda (2012a) milk | Milk and dairy | Specific protein/peptide or gene Beta- lactoglobulin Casein | Dark Chocolate | Source of spike Non-fat dry milk-NIST SRM 1549 (National Institute of Standards and Technology, Gaithersburg, MD, USA) | ELISA |
| Khuda (2012b) Peanut | Milk and dairy | Crude extract | Cookie | Spiked Source of spike Non-fat dry milk-NIST SRM 1549 (National Institute of Standards and Technology, Gaithersburg, MD, USA) | ELISA |
| Khuda (21012b) milk | Milk and dairy | Specific protein/peptide or gene Beta- lactoglobulin Casein | Cookie | Spiked Source of spike Non-fat dry milk, NIST SRM 1549 (National Institute of Standards and Technology, Gaithersburg,MD, USA) | ELISA |
| Monaci (2008) | Milk and dairy | Specific protein/peptide or gene Whey proteins | Juice Apple, apricot, banana, passion fruit, guava, grape, kiwi, lemon, mango, orange, papaya, peach, pear, pineapple | Spiked Source of spike LG A, LG B (purity 92%) and x-LA (purity 98%) and formic acid, (98-100% purity grade) (FA) (Sigma- Aldrich St Louis, MO, USA). | Mass spectrometry |
| Monaci (2011) | Milk and dairy | Specific protein/peptide or gene Casein | Wine | Spiked Source of spike Not reported | Mass spectrometry |
| Morishita (2006) | Milk and dairy | Crude extract | Carrot Sherbet Cookie Jam Pickles (Soy Sauce, vinegar) Potato Salad Sauce Tomato Soup | Spiked | ELISA Immuno- chromatograph ic test kits Dip stick |

EFSA supporting publication 2013:EN-506

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|-----------------|-------------------|--|--|---|-----------------------------------|
| | | | Steamed and fried Chinese dumpling Hamburger | | |
| Weber (2006) | Milk and dairy | Specific protein/peptide or gene Casein | Chicken Chicken hot dog sample Cookie | Spiked Source of spike Local retail market | ELISA kit Mass spectrometry |

Table 3.34:Milk: description of assay

| Study ID | Allergen | Assay details | Additional information |
|--------------------|-------------------|--|--|
| Akiyama (2004) | Milk | Test 1 Milk protein Casein ELISA kit Test 2 Milk protein beta-Lactoglobulin ELISA kit Test 3 FASTKIT Milk ELISA Kit | Not stated ELISA Commercial company |
| Eissa (2012) | Milk and dairy | Test 1 Electrochemical Immunosensor, (Dropsens, Inc, Spain) Test 2 beta-lactoglobulin ELISA, ELISA systems (Queensland Australia)(used as gold standard) | Test 1 Electrochemical Immunosensor Graphene modified screen/printed carbon electrodes (Dropsens, Inc, Spain) with Autolab PGSTAT302N Test 2 Commercial ELISA |
| Haasnoot (2004) | Cows' milk | Test 1 direct automated optical biosensor (Biacore 3000) Mab 6A10 Test 2 direct automated optical biosensor (Biacore 3000) Mab 4G10 Test 3 inhibition automated optical biosensor (Biacore 3000) Mab 6A10 Test 4 inhibition automated optical biosensor (Biacore 3000) Mab 4G10 | Biosensor immunoassay Direct Inhibition |
| Hefle (2004) | Milk and dairy | Test 1 ELISA | ELISA Polyclonal capture antibody Polyclonal detection antibody Sandwich In-house |
| Khuda (2012a) | Milk and dairy | Test 1 <i>RIDASCREEN FAST peanut, egg, and casein from</i> | Test 1,2 and 3 ELISA |

EFSA supporting publication 2013:EN-506

| Study ID | Allergen | Assay details | Additional information |
|----------------------------|-------------------|--|--|
| milk | | R- Biopharm (RB, Washington, MO, USA) Test 2 Veratox peanut, egg, and total milk allergen quantitative test kits from Neogen (NE) Corp. (Lansing, MI, USA) Test 3 Morinaga (MO) peanut, egg, and milk (casein and BLG) protein ELISA kits (Crystal Chem, Downers Grove, IL, USA) Test 4 Tepnel (TE) BIOKITS peanut, egg, casein, and BLG assay kits (Neogen Corp.) Test 5 ELISA Systems (ES) peanut, egg, casein, and BLG residue kits (BioMerieux, Durham, NC, USA) | Commercial company |
| Khuda (2012b) Peanut | Milk and dairy | Test 1 <i>RIDASCREEN FAST peanut, egg, and casein from</i> <i>R- Biopharm (RB, Washington, MO, USA)</i> Test 2 <i>Veratox peanut, egg, and total milk allergen</i> <i>quantitative test kits from Neogen (NE) Corp.</i> <i>(Lansing, MI, USA)</i> Test 3 <i>Morinaga (MO) peanut, egg, and milk (casein and</i> <i>BLG) protein ELISA kits (Crystal Chem, Downers</i> <i>Grove, IL, USA)</i> Test 4 <i>Tepnel (TE) BIOKITS peanut, egg, casein, and BLG</i> <i>assay kits (Neogen Corp.)</i> Test 5 <i>ELISA Systems (ES) peanut, egg, casein, and BLG</i> <i>residue kits (BioMerieux, Durham, NC, USA)</i> | ELISA Polyclonal capture antibody Commercial company |
| Monaci (2008) | Milk and dairy | Test 1 Mass spectrometry <i>xLA</i> Test 2 Mass spectrometry <i>LGA</i> Test 3 Mass spectrometry <i>LGB</i> | |
| Monaci (2011) | Milk and dairy | Test 1 Mass spectrometry | Mass spectrometry Ultima triple quadrupole mass spectrometer HPLC coupled with single- stage Orbitrap mass spectrometry |
| Morishata (2006) | | Immuno-chromatographic test kits- Dip stick | Immunoassay In house |
| Weber (2006) | Casein | Test 1 VERATOX kit ELISA Test 2 Mass spectrometry Time of flight-mass spectrometry | Test 1 Neogen, Lansing, MI Test 2 |

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|------------------|----------|------------------------|-----------------------------------|-------------------------|-----------------------|---------------|--------------------------------|-------------------------------------|
| Akiyama 2004 | milk | Casein | 1 ELISA FASTKIT | cereals | 5-20 ng/ml | 63-65 | | |
| Akiyama 2004 | milk | Casein | 1 ELISA FASTKIT | cookie | 5-20 ng/ml | 82-91 | | |
| Akiyama 2004 | milk | Casein | 1 ELISA, FASTKIT | pasta sauce | 5-20 ng/ml | 34-35 | | |
| Akiyama 2004 | milk | Casein | 1 ELISA, FASTKIT | sauce | 5-20 ng/ml | 5-8. | | |
| Akiyama 2004 | milk | Casein | 1 ELISA, FASTKIT | sausage | 5-20 ng/ml | 50-63 | 1 ng/ml | 2 ng/ml |
| Akiyama 2004 | milk | Beta- Lactoglobulin | 2 ELISA, FASTKIT | cereals | 5-20 ng/ml | 53-67 | | |
| Akiyama 2004 | milk | Beta- Lactoglobulin | 2 ELISA, FASTKIT | cookie | 5-20 ng/ml | 85-93 | | |
| Akiyama 2004 | milk | Beta- Lactoglobulin | 2 ELISA, FASTKIT | pasta sauce | 5-20 ng/ml | 61-94 | | |
| Akiyama 2004 | milk | Beta- Lactoglobulin | 2 ELISA, FASTKIT | sauce | 5-20 ng/ml | 49-59 | | |
| Akiyama 2004 | milk | Beta- Lactoglobulin | 2 ELISA, FASTKIT | sausage | 5-20 ng/ml | 74-95 | 1 ng/ml | 5 ng/ml |
| Akiyama 2004 | milk | Standard milk protein | 3 ELISA, FASTKIT | cereals | 5-10 ng/ml | 23-25 | | |
| Akiyama 2004 | milk | Standard milk protein | 3 ELISA, FASTKIT | cookie | 5-10 ng/ml | 34-41 | | |
| Akiyama 2004 | milk | Standard milk protein | 3 ELISA, FASTKIT | pasta sauce | 5-10 ng/ml | 27-40 | | |
| Akiyama 2004 | milk | Standard milk protein | 3 ELISA, FASTKIT | sauce | 5-10 ng/ml | 41-43 | | |
| Akiyama 2004 | milk | Standard milk protein | 3 ELISA, FASTKIT | sausage | 5-10 ng/ml | 41-48 | | |
| Haasnoot 2004 | milk | kappa-casein | 1 Biosensor direct Mab 6A10 | milk (goat or sheep) | 0.25-2 % | 80-108 | 0.07 % w/w | |
| Haasnoot 2004 | milk | kappa-casein | 2 Biosensor direct Mab 4G10 | milk (goat or sheep) | 0.25-2 % | 84-110 | 0.06 % w/w | |
| Haasnoot 2004 | milk | kappa-casein | 2 Biosensor direct Mab 4G10 | milk (goat or sheep) | 0.25-2 % | 77-112 | 0.08 % w/w | |
| Haasnoot 2004 | milk | kappa-casein | 3 Biosensor direct Mab 6A10 | milk (goat or sheep) | 0.25-2 % | 77-112 | 0.08 % w/w | |
| Hefle 2004 | milk | casein | 1 ELISA, ICP- MS | chocolate dark | | | 0.5 ppm | |
| Hefle 2004 | milk | casein | 1 ELISA, ICP- MS | ice cream | | | 0.5 ppm | |
| Khuda 2012a | milk | casein | 1 ELISA, RIDASCRE EN FAST | chocolate dark | linear regression | 2 | | |

| Table 3.35: | Milk: accuracy | and limit of | f detection a | and quantification |
|-------------|----------------|--------------|---------------|--------------------|
|-------------|----------------|--------------|---------------|--------------------|

306

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|-------------------|----------|---------------------|---------------------------------|----------------------------------|-----------------------|---------------|--------------------------------|-------------------------------------|
| Khuda 2012a | milk | casein | 2 ELISA, Veratox | chocolate dark | linear regression | 122 | | |
| Khuda 2012a | milk | casein | 3 ELISA, Morinaga | chocolate dark | linear regression | 69 | | - |
| Khuda 2012a | milk | BLG | 3 ELISA, Morinaga | chocolate dark | linear regression | 357 | | |
| Khuda 2012a | milk | casein | 4 ELISA, BIOKITS | chocolate dark | linear regression | 54 | | |
| Khuda 2012a | milk | BLG | 4 ELISA, BIOKITS | chocolate dark | linear regression | 2 | | |
| Khuda 2012a | milk | casein | 5 ELISA Systems | chocolate dark | linear regression | 50 | | |
| Khuda 2012a | milk | BLG | 5 ELISA Systems | chocolate dark | linear regression | 44 | | |
| Khuda 2012b | milk | casein | 1 ELISA, RIDASCRE EN FAST | sugar cookie | linear regression | 0 | | |
| Khuda 2012b | milk | BLG | 1 ELISA, RIDASCRE EN FAST | sugar cookie | linear regression | 0 | | |
| Khuda 2012b | milk | casein | 2 ELISA, Veratox | sugar cookie | linear regression | 7 | | |
| Khuda 2012b | milk | casein | 3 ELISA, Morinaga | sugar cookie | linear regression | 4 | | |
| Khuda 2012b | milk | BLG | 3 ELISA, Morinaga | sugar cookie | linear regression | 12 | | |
| Khuda 2012b | milk | casein | 4 ELISA, BIOKITS | sugar cookie | linear regression | 3 | | |
| Khuda 2012b | milk | BLG | 4 ELISA, BIOKITS | sugar cookie | linear regression | 0 | | |
| Khuda 2012b | milk | casein | 5 ELISA Systems | sugar cookie | linear regression | 6 | | |
| Khuda 2012b | milk | BLG | 5 ELISA Systems | sugar cookie | linear regression | 1 | | |
| Monaci 2008 | milk | alpha LA | 1 Mass Spectrometric | fruit juice | 5-20 µg/ml | 73-79 | | |
| Monaci 2008 | milk | LGA | 2 Mass Spectrometric | fruit juice | | 68-74 | | |
| Monaci 2008 | milk | LGB | 3 Mass Spectrometric | fruit juice | | 75-78 | | |
| Monaci 2011 | milk | casein | 1 LC-MS | white wine | 10-1000 μg/ml-1 | | 39 μg/mL ⁻¹ | |
| Morishita 2006 | milk | crude | 1 IC - dipstick | chicken meatball or burger | | | 5 µg/g | |
| Morishita 2006 | milk | crude | 1 IC - dipstick | cookie | | | 5 µg/g | |
| Morishita 2006 | milk | crude | 1 IC - dipstick | Dumplings fried/ steamed | | | 5 μg/g | |

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|-------------------|----------|---------------------|-------------------------|---------------------------|-----------------------|---------------|--------------------------------|-------------------------------------|
| Morishita 2006 | milk | crude | 1 IC - dipstick | jelly | | | 5 μg/g | |
| Morishita 2006 | milk | crude | 1 IC - dipstick | Pickles in Vinegar/soy | | | 5 μg/g | |
| Morishita 2006 | milk | crude | 1 IC - dipstick | Potato salad | | | 5 μg/g | |
| Morishita 2006 | milk | crude | 1 IC - dipstick | sauce | | | 5 μg/g | |
| Weber 2006 | milk | casein | 2 Mass Spectrometric | chicken hot dog | | | 5 ppm | |

3.2.12. Peanut

Twenty studies investigated detection systems for peanut, perhaps as a result of the severity of symptoms reported by people with peanut allergy.

An in-house ELISA was developed and tested by Akiyama (2004b) and performed with similar sensitivity as the commercial FASTKIT, providing recoveries of 50-182% with spiked concentrations as low as 5 ng/ml. The matrix with the lowest recovery was chocolate with 50-54%. Deng (2012) developed an assay for peanut agglutinin and found recoveries in chocolate were variable depending on the concentration of the spike. Ehlert (2009) developed and tested an in-house ELISA and showed a limit of detection of between 5 and 100 mg/kg⁻¹ equivalent to 50-1000 μ g/g. Khuda (2012b), tested the Morinaga ELISA in a sugar cookie matrix and found that recoveries were low at 12%. Kiening developed and tested an ELISA against crude peanut extract and when cereals, cookies, ice-cream or chocolate were spiked achieved recoveries of 87-123%. Yeung (1996) developed a similarly effective assay and extraction system for snacks, oils and sauces spiked with 2.5-20 μ g/g peanut extract.

Commercial ELISA systems were evaluated in a number of studies. The FASKIT ELISA gave good recoveries in the region of 65-97 % when butter, chocolate, pasta sauces were spiked with between 2-20ng/ml. RIDASCREEN gave good recoveries with dark chocolate but poor recoveries, 11 % from sugar cookie, Khuda (2012a), Park (2005) did not show recovery but did indicate that the limit of detection was 5 μ g/g for chocolate, cereals, cookie and ice-cream. BIOKITS gave under 10% recovery for dark chocolate and sugar cookie Khuda (2012a). The Veratox ELISA gave limited recoveries from spiked chocolate, 30%, Khuda (2012a), poor from sugar cookie, 15%. Park (2005) did not give the recovery, but did show a limit of detection of 5μ g/g for chocolate, cereals, cookie and ice-cream. Some companies and researchers have developed systems to increase the sensitivity of the ELISA system further. Speroni (2010) evaluated an ELISA system incorporating antibody coated magnetic micro particles, for the detection of the peanut allergens Ara h 3,4. This assay had a limit of detection of 0.8 μ g/g when cereals were spiked with peanut flour and a good recoveries, 80-95%.

Mass spectrometry and Electrospray mass spectrometry provided limit of detections for as low as $0.1\mu g/g$ in chocolate cereal snacks, Careri (2007b), these methods have the advantage that they can be directed against a range of peanut proteins, however the use will be limited as the equipment involved is expensive. The *Ligation dependent probe amplification (LPA) tested by Ehlert (2009)* did not give good limit of detection for cookie as a matrix at 5 mg/kg⁻¹ (equivalent to $50\mu g/g$) and gave a very poor limit of detection from walnut mixtures spiked with peanut. PCR evaluated by Ehlert (2009) sowed a similar limit of detection and was also not able to give good suitable limits of detection in walnut mixtures (100 mg/kg^{-1}).

The IC-dipstick tested by Morishita (2006) gave consistent limit of detection of $5\mu g/g$, and had the advantage of ease of use and did not require specialist equipment.

EFSA supporting publication 2013:EN-506

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|-------------------------------|----------|--|--|--|--|
| Akiyama (2004b) | Peanut | Crude extract | Biscuit Butter Chocolate Sauce | Spiked Source of spike Morinaga Institute of Biological Science, Virginia Peanuts Standardisation Protein measured BCA protein assay kit and adjusted to a concentration of 100-300 µg/ml | ELISA |
| Ben Rejeb (2005) peanut | Peanut | Crude extract | Chocolate | Spiked Roasted defatted peanuts and nuts extracted, dialysed Source of spike Not reported Standardisation Made up to 1mg/ml-1 protein content measured using BCA test | ELISA |
| Careri (2007a) | Peanut | Specific protein/peptide or gene Ara h, 1,3,4 | Breakfast cereals Cornflakes | Spiked Source of spike Leibniz-Centre for Medicine and Biosciences at the Research Centre Borstal (Borstal, Germany) | ELISA |
| Careri (2007b) | Peanut | Specific protein/peptide or gene Ara h 2 and Ara h 3/4 | Breakfast cereals Rice crispy/cacao | Spiked Source of spike Red skin Peanuts Standardisation Not stated | Mass spectrometry |
| Careri (2008) | Peanut | Specific protein/peptide or gene Ara h, 2, 3 | Chocolate snack | Spiked Field Source of spike Ara h2 was purified from toasted peanuts, Ara h 1 and Ara h3/4 were provided by the Leibniz Centre for Medicine and Biosciences at the Research Centre Borstal, Germany Standardisation Not explained | ELISA non- competitive sandwich Mass spectrometry |
| Deng (2012) | Peanut | Specific protein/peptide or gene Peanut agglutinin | Milk Field Foods sampled Range of products and peanut oil without | Spiked Field Source of spike Peanut agglutinin, (Sigma, St. Louis, MO, USA) | ELISA |

| Table 3.36: | Peanut: characteristics of included studies |
|-------------|---|
|-------------|---|

309

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|---|----------|---|--|---|--|
| | | | peanut protein. | | |
| Ehlert (2009) | Peanut | Specific protein/peptide or gene DNA | Cookie Pesto cashew | Spiked Source of spike Nut materials, sesame seeds, ingredients of self-prepared DNA plant and animal materials used to test the specificity of the method and spike samples of chocolate, were obtained from the Bavarian Health and Food Safety Authority (Oberschleibheim, Germany) | ELISA PCR Ligation- dependent probe amplification |
| Hird (2003) | Peanut | Specific protein/peptide or gene Ara h2 gene | Biscuit Cake Chocolate Meat Pastry or dough | Spiked. Source of spike Biscuit prepared by Central Science Laboratory Food Analysis Proficiency Assessment Scheme, spiked with 2ppm peanut powder. | PCR |
| Khuda (2012b) Peanut | Peanut | Crude extract | Cookie | Spiked Source of spike light-roasted peanut flour, 12% fat light roast, product 521271, lot 109FA (Golden Peanut Co., Alpharetta, GA, USA) | ELISA |
| Khuda (2012a) peanut (dark chocolate) | Peanut | Crude extract | Chocolate | Spiked Spray dried whole egg powder NIST RM 8445 (NIST), non-fat milk powder, and light-roasted peanut flour, 12% fat light roast, product 521271, lot 109FA Source of spike Peanut (Golden Peanut Co., Alpharetta, GA, USA) Standardisation FDA | ELISA |
| Kiening (2005) | Peanut | Crude extract | Breakfast cereals Chocolate Cookie Ice cream Field Foods sampled cookie, cereals and chocolate | Spiked Standard peanut butter as peanut reference material (SRM 2387) National Institute of Standards and Technology (NIST, Gaithersburg, MD) Field Source of spike Standard peanut butter (SRM 2387) (National Institute of | ELISA |

311

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|---------------------|----------|---|---|---|--|
| | | | | Standards and Technology, NIST, Gaithersburg, MD). | |
| Morishita (2006) | Peanut | Crude extract | Carrot Sherbet, Cookie, Jam Pickles (Soy Sauce, vinegar),Potato Salad, Sauce Tomato, Soup Steamed and fried Chinese dumpling Hamburger | Spiked | ELISA Immuno- chromatograph ic test kits Dip stick |
| Park (2005) | Peanut | Crude extract | Cereal Chocolate Cookie Ice cream | Spiked Source of spike Peanut butter (National Institute for Standards and Technology (NIST); Gaithersburg, MD), Standard Reference Material (SRM) No.2387 | ELISA |
| Pomes (2003) | Peanut | Crude extract Veratox Specific protein/peptide or gene Ara h 1 | Cookie Flour pancake mix Field Peanut products: including peanut cookies, peanut butter sandwich cookies, peanut sweets, and peanut butter . Non-peanut products: including cookies and a group of nuts, beans, and seeds. | Spiked Field Source of spike Ground peanut | ELISA |
| Pomes (2004) | Peanut | Specific protein/ peptide or gene Ara h 1 | Chocolate | Spiked Field Source of spike Oil-roasted Virginia peanuts (Planters Company, East Hanover, N.J.) | ELISA |
| Speroni (2010) | Peanut | Specific protein/peptide or gene Ara h 3,4 | Biscuit Breakfast cereals | Spiked Source of spike Roasted peanuts purchased at a local food store | ELISA |
| Stephan (2002) | Peanut | Crude extract Peanut | Chocolate Rausch Schokoladen Gmbh (Peine, | Spiked Field Source of spike Not reported | Dipstick |

EFSA supporting publication 2013:EN-506

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|-------------------|----------|---|--|---|--------------------------|
| | | | Germany) Field Foods sampled Range of foods labelled as containing, not containing and may contain peanut or hazelnut | | |
| Stephan (2004) | Peanut | Crude (ELISA) Specific protein/peptide or gene Ara h 2 (PCR) | Chocolate Milk Field Foods sampled industrially manufactured samples of milk and semisweet chocolates | Spiked Field Source of spike Not reported | ELISA PCR |
| Wen (2005a) | Peanut | Specific protein/peptide or gene Ara h 1 | Chocolate | Spiked Source of spike raw peanuts purchased from a local food market | Lateral Flow Assay |
| Yeung (1996) | Peanut | Crude extract | Chocolate Cookie Crisps Ice cream Oil Sauce Pasta sauce Snack Sesame snaps, wafers | Spiked Source of spike 3 peanut preparations (roasted, raw, denatured, unfolded raw peanuts) purchased in local stores | ELISA |

Table 3.37:Peanut: description of assay

| Study ID | Allergen | Assay details | Additional information |
|-------------------------------|----------|--|--|
| Akiyama (2004b) | Peanut | Test 1 Peanut protein ELISA Kit (Morinaga Institute of Biological Science) Test 2 FASTKIT Peanut ELISA kit | Test 1 ELISA In-house Test 2 ELISA Commercial (Nippon Meat Packers Inc.) |
| Ben Rejeb (2005) peanut | Peanut | Test 1 | ELISA Polyclonal detection antibody Competitive inhibition In-house |

EFSA supporting publication 2013:EN-506

313

| Study ID | Allergen | Assay details | Additional information |
|-------------------|----------|--|--|
| Careri (2007a) | Peanut | ELISA ICP-MS | Inductively coupled plasma- mass spectrometry using both direct competitive and non- competitive immunoassays |
| Careri (2007b) | Peanut | Test 1 Time of flight mass spectrometry (LC-ESI-Q-TOF) Test 2 Liquid chromatography-triple quadruple mass spectrometry LC-QqQ-MS-MS | Test 1 Mass spectrometry Test 2 Mass spectrometry |
| Careri (2008) | Peanut | Test 1 Europium (Eu)-tagged inductively coupled plasma mass spectrometry (ICP-MS) immunoassay ELISA ICP-MS Test 2 Electroliquid chromatography/electrospray ionization tandem mass spectrometry (LC/ESI- MS/MS) with a triple quadrupole mass analyzer. Ara h 3/4 Test 3 Electroliquid chromatography/electrospray ionization tandem mass spectrometry (LC/ESI- MS/MS) with a triple quadrupole mass analyzer. Ara h 3/4 | |
| Deng (2012) | Peanut | Test 1 ELISA sandwich | ELISA Polyclonal capture antibody Polyclonal detection antibody Sandwich In-house |
| Ehlert (2009) | Peanut | Test 1 Ligation dependent probe amplification Test 2 Hazelnut and peanut: real-time PCR Surefood allergen kit (Congen Biotechnology GmbH, Berlin, Germany) cashew real time PCR In house Test 3 Hazelnut and peanut: ELISA Ridascreen (R- Biopharm AG, Darmstadt, Germany) | |
| Hird (2003) | Peanut | Test 1 Real time PCR | PCR Real-time PCR |
| Khuda (2012a) | Peanut | Test 1 RIDASCREEN FAST peanut, egg, and casein from R- Biopharm (RB, Washington, MO, USA) Peanut protein including Ara h1 Test 2 Veratox peanut, egg, and total milk allergen quantitative test kits from Neogen (NE) Corp. (Lansing, MI, USA) Test 3 Morinaga (MO) peanut, egg, and milk (casein and BLG) protein ELISA kits (Crystal Chem, Downers Grove, IL, USA) Test 4 Tepnel (TE) BIOKITS peanut, egg, casein, and BLG assay kits (Neogen Corp.) | ELISA Polyclonal capture antibody Polyclonal detection antibody Commercial company |

EFSA supporting publication 2013:EN-506

| Study ID | Allergen | Assay details | Additional information |
|---------------------|----------|--|--|
| | | Test 5 ELISA Systems (ES) peanut, egg, casein, and BLG residue kits (BioMerieux, Durham, NC, USA) | |
| Kiening (2005) | Peanut | Test 1 ELISA | ELISA Monoclonal capture antibody mouse Y70 Polyclonal detection antibody rabbit R695 In-house |
| Morishita (2006) | Peanut | Test 1 Immunochromatographic test kits, dipstick. Test 2 ELISA: FASTKIT | Test 1 IC dipstick Test 2 ELISA Commercial |
| Park (2005) | Peanut | Test 1 Veratox Assay for peanut Test 2 RIDASCREEN Assay for peanut Test 3 BioKits Assay for peanut | Test 1 ELISA, commercial, Neogen Test 2 ELISA, commercial, R- Biopharm RIDASCREEN FAST Peanut Test 3 ELISA, commercial, Tepnel Biokits |
| Pomes (2003) | Peanut | Test 1 Test 1 ELISA In house Test 2 Veratox | Test 1 ELISA, Monoclonal capture antibody mAb 2C12, Monoclonal detection antibody mAB 2F7, in-house. Test 2 |
| | | | ELISA, commercial, Neogen Corporation, Lansing, Mich |
| Pomes (2004) | Peanut | Test 1 ELISA | ELISA Monoclonal capture antibody Monoclonal detection antibody Sandwich In-house |
| Speroni (2010) | Peanut | Test 1 Protein A-Pn-b ELISA Veratox Quantitative peanut allergen test Test 2 MP-NH2-PAMAM G 1.5-Pn-b ELISA | ELISA format based on antibody coated magnetic micro particles. The immune support are coated with Protein A-Pn-b and MP- NH2-PAMAM G1.5-Pn-b |
| Stephan (2002) | Peanut | Test 1 Dipstick: in-house | Dipstick method In house. Polyclonal capture antibody Polyclonal detector antibody. |
| Stephan (2004) | Peanut | Test 1 ELISA Test 2 Real-time PCR | Test 1 ELISA Polyclonal capture antibody Polyclonal detection antibody Sandwich |

| Study ID | Allergen | Assay details | Additional information |
|-----------------|----------|------------------------------|---|
| | | | Test 2 PCR Real-time PCR In-house |
| Wen (2005a) | Peanut | Test 1 Lateral Flow Assay | |
| Yeung (1996) | Peanut | Test 1 ELISA | ELISA Polyclonal capture antibody Polyclonal detection antibody Competitive inhibition In-house |

Table 3.38: Peanut: accuracy and limit of detection and quantification

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|-------------------|----------|-------------------------|---------------------|------------------------------|-----------------------|---------------|--------------------------------|-------------------------------------|
| Akiyama 2004b | peanut | crude | 1 ELISA | biscuit | 5-20 ng/ml | 74-76 | | |
| Akiyama 2004b | peanut | crude | 1 ELISA | buffer | 5-20 ng/ml | | 2 ng/ml | 8 ng/ml |
| Akiyama 2004b | peanut | crude | 1 ELISA | butter | 5-20 ng/ml | 68-70 | | |
| Akiyama 2004b | peanut | crude | 1 ELISA | chocolate | 5-20 ng/ml | 50-54 | | |
| Akiyama 2004 b | peanut | crude | 1 ELISA | sauce | 5-20 ng/ml | 66-68 | | |
| Akiyama 2004b | peanut | crude | 2 ELISA, FASTKIT | biscuit | 5-20 ng/ml | 122-182 | | |
| Akiyama 2004b | peanut | crude | 2 ELISA, FASTKIT | buffer | | | 2.5 ng/ml | 5 ng/ml |
| Akiyama 2004b | peanut | crude | 2 ELISA, FASTKIT | butter | 5-20 ng/ml | 65-70 | | |
| Akiyama 2004 b | peanut | crude | 2 ELISA, FASTKIT | chocolate | 5-20 ng/ml | 72-82 | | |
| Akiyama 2004b | peanut | crude | 2 ELISA, FASTKIT | sauce | 5-20 ng/ml | 79-97 | | |
| Ben Rejeb 2005 | peanut | | 1 ELISA | chocolate dark | | | 1 ppm | |
| Careri 2007a | peanut | Ara h 1 and Ara h3/4 | 1 ELISA ICP- MS | cereals | | | 2 mg/kg ⁻¹ | |
| Careri 2007b | peanut | | 1 LC-ESI-Q- TOF | cereal chocolate snack | | | | |
| Careri 2007b | peanut | m/z 695 Ara h 3/4 | 2 LC-QqQ- MS-MS | cereal chocolate snack | | | 1 μg/g ⁻¹ | 3.7 μg/g-1 |
| Careri 2007b | peanut | m/z 807 Ara h 2 | 2 LC-QqQ- MS-MS | cereal chocolate | | | 5 μg/g ⁻¹ | 14 µg/g-1 |

EFSA supporting publication 2013:EN-506

315

316

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|-----------------|----------|----------------------|---------------------------------|------------------------------|-----------------------|---------------|--------------------------------|-------------------------------------|
| | | | | snack | | | | |
| Careri 2008a | peanut | | 1 ELISA Mass Spec | cereal chocolate snack | 5 μg/g-1 | 86 | 2.2 μg/g ⁻¹ | 5 µg/g-1 |
| Careri 2008a | peanut | Ara h 3 | 2 Electrospray mass spec | cereal chocolate snack | | | 1 μg/g ⁻¹ | 3.7 µg/g-1 |
| Careri 2008a | peanut | Ara h 2 | 3 Electrospray mass spec | cereal chocolate snack | | | 5 μg/g ⁻¹ | 14 μg/g-1 |
| Deng 2012 | peanut | peanut agglutinin | 1 sandwich ELISA | milk | 1-60 ng/mL | 0- 69 | | |
| Ehlert 2009 | peanut | DNA | 1 LPA | chocolate | nr | nr | 5 mg/kg ⁻¹ | |
| Ehlert 2009 | peanut | DNA | 1 LPA | cookie | | | 5 mg/kg ⁻¹ | |
| Ehlert 2009 | peanut | DNA | 1 LPA | walnut cookies | | | 1000 mg/kg ⁻¹ | |
| Ehlert 2009 | peanut | DNA | 2 PCR real time | chocolate | | | 5 mg/kg ⁻¹ | |
| Ehlert 2009 | peanut | DNA | 2 PCR real time | cookie | | | 0.5 mg/kg ⁻¹ | |
| Ehlert 2009 | peanut | DNA | 2 PCR real time | walnut cookies | | | 1 mg/kg ⁻¹ | |
| Ehlert 2009 | peanut | crude | 3 ELISA | chocolate | | | 5 mg/kg ⁻¹ | |
| Ehlert 2009 | peanut | crude | 3 ELISA | cookie | | | 5 mg/kg ⁻¹ | |
| Ehlert 2009 | peanut | crude | 3 ELISA | walnut cookies | | | 100 mg/kg ⁻¹ | |
| Hird 2003 | peanut | Ara h2 | 1 PCR real time | biscuit | | | 2 ppm | > 2 ppm |
| Khuda 2012a | peanut | crude | 1 ELISA, RIDASCRE EN FAST | chocolate dark | linear regression | 73 | | |
| Khuda 2012a | peanut | crude | 2 ELISA, Veratox | chocolate dark | linear regression | 35 | | |
| Khuda 2012a | peanut | crude | 3 ELISA, Morinaga | chocolate dark | linear regression | 11 | | |
| Khuda 2012a | peanut | crude | 4 ELISA, BIOKITS | chocolate dark | linear regression | 3 | | |
| Khuda 2012a | peanut | crude | 5 ELISA Systems | chocolate dark | linear regression | 29 | | |
| Khuda 2012b | peanut | crude | 1 ELISA, RIDASCRE EN FAST | sugar cookie | linear regression | 11 | | |
| Khuda 2012b | peanut | crude | 2 ELISA, Veratox | sugar cookie | linear regression | 15 | | |
| Khuda 2012b | peanut | crude | 3 ELISA, Morinaga | sugar cookie | linear regression | 12 | | |

EFSA supporting publication 2013:EN-506

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|-------------------|----------|---------------------|---------------------------|----------------------------------|-----------------------|---------------|--------------------------------|-------------------------------------|
| Khuda 2012b | peanut | crude | 4 ELISA, BIOKITS | sugar cookie | linear regression | 0 | | |
| Khuda 2012b | peanut | crude | 5 ELISA Systems | sugar cookie | linear regression | 2 | | |
| Kiening 2005 | peanut | crude | 1 ELISA | cereals | 1-10 mg/kg | 105-117 | | |
| Kiening 2005 | peanut | crude | 1 ELISA | chocolate dark | 1-10 mg/kg | 87-101 | | |
| Kiening 2005 | peanut | crude | 1 ELISA | chocolate milk | 1-10 mg/kg | 113-123 | | |
| Kiening 2005 | peanut | crude | 1 ELISA | cookie | 1-10 mg/kg | 92-107 | | |
| Kiening 2005 | peanut | crude | 1 ELISA | ice cream | 1-10 mg/kg | 94-110 | | |
| Morishita 2006 | peanut | crude | 1 IC - dipstick | chicken meatball or burger | | | 5 µg/g | |
| Morishita 2006 | peanut | crude | 1 IC - dipstick | cookie | | | 5 μg/g | |
| Morishita 2006 | peanut | crude | 1 IC - dipstick | Dumplings fried/steame d | | | 5 μg/g | |
| Morishita 2006 | peanut | crude | 1 IC - dipstick | jelly | | | 5 μg/g | |
| Morishita 2006 | peanut | crude | 1 IC - dipstick | Pickles in Vinegar/soy | | | 5 μg/g | |
| Morishita 2006 | peanut | crude | 1 IC - dipstick | Potato salad | | | 5 μg/g | |
| Morishita 2006 | peanut | crude | 1 IC - dipstick | sauce | | | 5 μg/g | |
| Park 2005 | peanut | crude | 1 ELISA Veratox | cereals | | | 5 μg/g | |
| Park 2005 | peanut | crude | 1 ELISA Veratox | chocolate | | | 5 μg/g | |
| Park 2005 | peanut | crude | 1 ELISA Veratox | cookie | | | 5 μg/g | |
| Park 2005 | peanut | crude | 1 ELISA Veratox | ice cream | | | 5 μg/g | |
| Park 2005 | peanut | crude | 2 ELISA RIDASCRE EN | cereals | | | 5 μg/g | |
| Park 2005 | peanut | crude | 2 ELISA RIDASCRE EN | chocolate | | | 5 μg/g | |
| Park 2005 | peanut | crude | 2 ELISA RIDASCRE EN | cookie | | | 5 µg/g | |
| Park 2005 | peanut | crude | 2 ELISA RIDASCRE EN | ice cream | | | 5 µg/g | |

318

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|-----------------|----------|---------------------|---|-------------------------|-----------------------|---------------|--------------------------------|-------------------------------------|
| Park 2005 | peanut | crude | 3 ELISA BioKits | cereals | | | 5 µg/g | |
| Park 2005 | peanut | crude | 3 ELISA BioKits | chocolate | | | 5 μg/g | |
| Park 2005 | peanut | crude | 3 ELISA BioKits | cookie | | | 5 μg/g | |
| Park 2005 | peanut | crude | 3 ELISA BioKits | ice cream | | | 5 µg/g | |
| Pomes 2003 | peanut | Ara h 1 | 1 ELISA in house | chocolate | 0.006- 0.01667 g/g | 0-0 | | |
| Pomes 2003 | peanut | Ara h 1 | 1 ELISA in house | cookie | 0.006- 0.01667 g/g | 7-100 | | |
| Pomes 2003 | peanut | Ara h 1 | 1 ELISA in house | flour | 0.006- 0.01667 g/g | 54-94 | | |
| Pomes 2003 | peanut | Ara h 1 | 1 ELISA in house | range of products | | | | |
| Pomes 2004 | peanut | Ara h 1 | 1 ELISA | chocolate | | | 0.16 % w/w | |
| Speroni 2010 | peanut | Ara h3/4 | 1 ELISA | biscuit | | | | |
| Speroni 2010 | peanut | Ara h 3/4 | 1 protein A- Pn-b ELISA | biscuit | 5-15 mg/kg | 93-94 | 0.8 mg/kg | 2.4 mg/kg |
| Speroni 2010 | peanut | Ara h 3/4 | 1 MP-NH2- PAMAM G 1.5-Pn-b ELISA | biscuit | 5-15 mg/kg | 114 | 0.8 mg/kg | 2.4 mg/kg |
| Speroni 2010 | peanut | Ara h3/4 | 1 ELISA | breakfast cereal | | | | |
| Speroni 2010 | peanut | Ara h 3/4 | 1 protein A- Pn-b ELISA | cereals | 5-15 mg/kg | 80-95 | 0.8 mg/kg | 2.4 mg/kg |
| Speroni 2010 | peanut | Ara h 3/4 | 1 MP-NH2- PAMAM G 1.5-Pn-b ELISA | cereals | 5-15 mg/kg | 84 | 0.8 mg/kg | 2.4 mg/kg |
| Stephan 2004 | peanut | Crude | 1 ELISA | chocolate milk | 10-200 ppm | 64-111 | | |
| Stephan 2004 | peanut | Crude | 1 ELISA | milk | 10-200 ppm | 81-142 | | |
| Wen 2005a | peanut | Ara h1 | 1 LFA | chocolate | | | 158 µg/g | |
| Yeung 1996 | peanut | crude | 1 ELISA | chocolate | 2.5-20 μg/g | 83-88 | | |
| Yeung 1996 | peanut | crude | 1 ELISA | cookie | 2.5-20 μg/g | 62-75 | | |
| Yeung 1996 | peanut | crude | 1 ELISA | crisps/ Thai cracker | 2.5-20 μg/g | 53-100 | | |
| Yeung 1996 | peanut | crude | 1 ELISA | ice cream | 2.5-20 µg/g | 45-81 | | |
| Yeung 1996 | peanut | crude | 1 ELISA | oil | 2.5-20 µg/g | 71-84 | | |

EFSA supporting publication 2013:EN-506

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|---------------|----------|---------------------|------------------------------------|-----------|-----------------------|---------------|--------------------------------|-------------------------------------|
| Yeung 1996 | peanut | crude | 1 ELISA | sauce | 2.5-20 μg/g | 84-92 | | |
| Yeung 1996 | peanut | crude | 1 ELISA | snack | 2.5-20 µg/g | 66-80 | | |
| Yeung 1996 | peanut | crude | 1 ELISA | snack | 2.5-20 μg/g | 80-95 | | |
| Yman 2006 | peanut | crude | 1 RIE | chocolate | | | 70 µg/g | |
| Yman 2006 | peanut | crude | 2 SPR immunoassay | chocolate | | | 1 μg/g | |
| Yman 2006 | peanut | crude | 3 Ridascreen | chocolate | | | 1 μg/g | |
| Yman 2006 | peanut | crude | 4 BioKit (Tepnal BioSystems) | chocolate | | | 1 μg/g | |

3.2.13. Sesame

ELISA and one PCR method were assessed in the included studies for detecting sesame in matrices such as wheat cracker, cookie, muesli, crisp toast and bread (Table 3.39).

There were two studies evaluating in-house ELISAs. Hussain (2010) showed good recoveries from bread, cookies and snacks when spiked at a relatively high concentration of 24-200 μ g/g. Redle (2010) showed similar results for their in-house ELISA.

There was only one study that evaluated PCR, Coisson (2010), and this was directed against the DNA for sesame mannitol dehydrogenase (Table 3.40). The limit of detection was given as 10% w/w for sausage meat samples spiked with sesame, which is equivalent to $10,0000\mu g/g$ (Table 3.41).

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|-------------------|----------|---|--|---|--------------------------|
| Coisson (2010) | Sesame | Specific protein/peptide or gene DNA sesame mannitol dehydrogenase Si2S | Meat meat balls | Spiked Source of spike S. indicum (sesame seeds) and A. graveolens L (celery leaves). Samples purchased from commercial stores in Italy. | PCR |
| Husain (2010) | Sesame | Crude extract | Breakfast cereals Bread roll, wholegrain bread Cookie Crisp toast crisp toast 1, crisp | Spiked Field Source of spike purchased from local supermarkets Standardisation Protein concentration | ELISA |

EFSA supporting publication 2013:EN-506

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|-------------|----------|------------------------------|--|--|--------------------------|
| | | | toast 2, multigrain crisp toast Snack Wheat cracker | assessed using Bradford assay | |
| | | | Field Foods sampled sesame snack, sesame balls, crisp flakes, sesame flakes, cookies, crisp toast, sesame oil, biscuits, crackers, muesli, cereal | | |
| Redl (2010) | Sesame | Crude extract | Bread whole grain bread, whole wheat bread, crisp toast Cookie whole wheat Snack Field Foods sampled muesli, vegetarian, processed foods, crisp toast, snacks | Spiked Field Source of spike White peeled, unpeeled, and black sesame seeds were bought from different producers. | ELISA |

| Table 3.40:Sesame: | description | of assay |
|--------------------|-------------|----------|
|--------------------|-------------|----------|

| Study ID | Allergen | Assay details | Additional information |
|-------------------|----------|--------------------|--|
| Coisson (2010) | Sesame | PCR with multiplex | PCR Multiplex with Lab- on-chip (R)-based detection capillary electrophoresis |
| Husain (2010) | Sesame | ELISA | ELISA Polyclonal detection antibody Competitive inhibition In-house |
| Redl (2010) | Sesame | ELISA | ELISA Sandwich In-house |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|-----------------|----------|---------------------|-----------|-----------------------|-----------------------|---------------|--------------------------------|-------------------------------------|
| Coisson 2010 | sesame | DNA | 1 | meatball or burger | PCR | nr | 10 % w/w | |
| Husain 2010 | sesame | crude | 1 ELISA | bread | 25-200 μg/g | 70-85 | | |
| Husain 2010 | sesame | crude | 1 ELISA | cookie | 25-200 µg/g | | | |
| Husain 2010 | sesame | crude | 1 ELISA | Crisp toast | 25-200 μg/g | 92-103 | | |
| Husain 2010 | sesame | crude | 1 ELISA | muesli | 0.001-1% | 80-300 | | |
| Husain 2010 | sesame | crude | 1 ELISA | snack | 25-200 µg/g | 76-126 | | |
| Husain 2010 | sesame | crude | 1 ELISA | Wheat cracker | 0.001-1 % | 80-300 | | |
| Redl 2010 | sesame | Crude | 1 ELISA | Crisp toast | 25-200 µg/g | 89-145 | 5 µg/L | |
| Redl 2010 | sesame | Crude | 1 ELISA | snack | 25-200 µg/g | 48-108 | 3 µg/L | |
| Redl 2010 | sesame | Crude | 1 ELISA | white bread | 25-200 µg/g | 85-120 | | |
| Redl 2010 | sesame | seeds | 1 ELISA | Whole wheat cookies | 0.001-0.5 % | 80-200 | | |
| Redl 2010 | sesame | Crude | 1 ELISA | Whole- wheat bread | 0.001-1% | 20-220 | 5 µg/L | |

3.2.14. Soy

There were seven recent studies investigating assays for soy proteins (Table 3.42). The assays studies include ELISA and PCR (Table 3.43) and the findings for limit of detection (Table 3.44) highlight that there are assay available that can to less than $5\mu g/ml$.

Cuco (2012) compared their in-house ELISA to the commercial kit, KTI-ELISA. While there were good recoveries for cookie as a matrix, 83-118% for both assays the cookie mixtures spiked before baking had poor recoveries at only 0-32% recovery. This is an important finding for any products that could become contaminated with heat stable allergenic foods. Ma (2010) developed an ELISA against the major allergenic proteins of soy, glycinin. This assay detected the allergen in processed soy products spiked with glycinin and found recoveries of between 96-103%.

L'Hocine (2007) evaluated the Tepnal and ELISA systems kits and found the limits of detection in milk was good at 1 and 0.1μ g/ml respectively.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Allerge n | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|---------------------|---------------------|--|---|--|-----------------------------|
| Cucu (2012) | Soy | Crude extract | Cookie | Spiked Source of spike Alpro (Wevelgem, Belgium) and Cargill (Mechelen, Belgium). A mixture of equal amounts of each kind. | ELISA |
| Espineira (2010) | Soy | Specific protein/peptide or gene DNA Lectin gene | Fish Canned fish | Spiked Source of spike Not reported | PCR |
| Hei (2012) | Soy | Specific protein/peptide or gene B-conglycinin | Defatted soybean Field soybean, soybean meal, soybean protein concentrate, soybean protein isolate, extruded soybean fermented soybean meal | Spiked Field Source of spike Not reported | ELISA |
| L'Hocine (2007) | Soy | Crude extract | Milk Cows milk (2% fat) | Spiked Field Source of spike Commercial soy flour (SF), soyprotein concentrate (SPC), and soy protein isolate (SPI) provided by "Aliments Newly Weds" (Boucherville, Que., Canada). Commercial soy protein hydrolysate (SPH) purchased from "Aliments UFL" (Boucherville, Que., Canada). Texturized soy protein (TSP) (Beef "Not!") was from DixieDiners' Club | ELISA |
| Ma (2010) | Soy Glycini n | Specific protein/peptide or gene Glycinin | Soybean Soybean products such as seed, meal and fermented paste | Spiked Source of spike Crude extracts of glycinin (Professor Shuntang Guo of China Agricultural University) further purified by the researchers Standardisation 92% pure assessed using SDS PAGE | ELISA |
| Morishita (2008) | Soy | Glycinin Soybean Gly m Bd 30k | Carrot Sherbet Cookie Jam | Spiked Field Source of spike | ELISA |

| Table 3.42: | Soy: characteristics of included studies |
|-------------|--|
|-------------|--|

| Study ID | Allerge n | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|----------|--------------|---------------------------------|---|--|-----------------------------|
| | | | Pickles (Soy Sauce,vinegar) Potato Salad Sauce Tomato Soup Steamed and fried Chinese dumpling Hamburger | The soybeans (Glycine max var.Enrei, Haruyutaka, Nattosyoryu and Toyomusume) (Kinki University) were used to make defatted soybean powder (DSP) Standardisation DSP in the model processed foods was calculated, taking into account the protein content of the DSP and the change in weight of the model processed foods during their preparation. Field Purchased at local supermarkets (Ibaraki, Japan) in 2006 | |

Table 3.43:Soy: description of assay

| Study ID | Allergen | Assay details | Additional information |
|---------------------|-----------------|---|---|
| Cucu (2012) | Soy | Test 1 Soybean- ELISA Test 2 KTI-ELISA | Test 1 ELISA In-house Test 2 Commercial company |
| Espineira (2010) | Soy | Test 1 End-point PCR Test 2 Real-time PCR | |
| Hei (2012) | Soy | Test 1 ELISA | ELISA Polyclonal capture antibody Monoclonal detection antibody Sandwich In-house |
| L'Hocine (2007) | Soy | Test 1 Tepnel Biosystems kit (Tepnel Biosystems Ltd., Flintshire, U.K.) Test 2 ELISA Systems kit(Elisa Systems,Windsor, Australia) | ELISA Commercial company |
| Ma (2010) | Soy Glycinin | Test 1 ELISA | ELISA Monoclonal detection antibody |

| Study ID | Allergen | Assay details | Additional information |
|---------------------|-----------------|-----------------|---|
| | | | Competitive inhibition |
| Morishita (2008) | Soy Glycinin | Test 1 ELISA | ELISA Polyclonal capture antibody Polyclonal detection antibody Sandwich |

Table 3.44: Soy: accuracy and limit of detection and quantification

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|-------------------|----------|----------------------|------------------------|------------------------------------|-----------------------|-----------------|--------------------------------|-------------------------------------|
| Cucu 2012 | soy | crude | 1 ELISA | cookie | 21-84 µg/g | 1.5-24 | | |
| Cucu 2012 | soy | crude | 1 ELISA | cookie (spiked after baking) | 10-100 μg/g | 94-115 | | |
| Cucu 2012 | soy | KTI | 2 KTI ELISA | cookie | 21-84 µg/g | 0-32 | | |
| Cucu 2012 | soy | KTI | 2 KTI ELISA | cookie (spiked after baking) | 10-100 μg/g | 83-118 | | |
| Espineira 2009 | soy | crude | 1 PCR real time | fish | | | 0.05 % w/w | |
| Espineira 2009 | soy | DNA | 1 PCR real time | flour | | | 100 mg/kg | |
| Espineira 2009 | soy | crude | 2 End-point PCR | fish | | | 0.06 % w/w 25 | |
| Espineira 2009 | soy | DNA | 2 End-point PCR | flour | | | 10 mg/kg | |
| Hei | soy | beta- conglycinin | 1 ELISA | Soybean protein concentrate | 50-200 mg/g-1 | 88.1- 106.6 | | |
| L'Hocine 2007 | soy | crude | 1 ELISA, Tepnel kit | milk | 0.5-25 μg/ml | 104.5- 286 | 1 μg/ml | 3 μg/ml |
| L'Hocine 2007 | soy | crude | 2 ELISA systems kit | milk | 0.1-20 μg/ml | 103.0- 280.2 | 0.01 µg/ml | 0.23 µg/ml |
| Ma 2010 | soy | glycinin | 1 ELISA | Extracted soybean meal | 10-40 µg/ml | 96-99 | | |
| Ma 2010 | soy | glycinin | 1 ELISA | Extruded soybean meal | 10-40 µg/ml | 98-103 | | |
| Ma 2010 | soy | glycinin | 1 ELISA | Fermented soybean paste | 10-40 µg/ml | 97-105 | | |
| Ma 2010 | soy | glycinin | 1 ELISA | Roasted full fat soybean | 10-40 µg/ml | 97-102 | | |

EFSA supporting publication 2013:EN-506
| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|-------------------|----------|---------------------|-----------|-----------------------------------|-------------------------------------|---------------|--------------------------------|-------------------------------------|
| Ma 2010 | soy | glycinin | 1 ELISA | Soybean protein concentrate | 1-4 µg/ml | 95-103 | | |
| Ma 2010 | soy | glycinin | 1 ELISA | soybean seed | 50-200 μg/ml | 102-103 | | |
| Morishita 2008 | soy | glycinin | 1 ELISA | buffer | 10 μg/g (one conc. only) | | 0.19 µg/ml | 0.38 µg/ml |
| Morishita 2008 | soy | glycinin | 1 ELISA | croquette | $\frac{10 \ \mu g/g}{(one \ conc.}$ | 92.8 | | |
| Morishita 2008 | soy | glycinin | 1 ELISA | rice gruel/ porridge | $\frac{10 \ \mu g/g}{(one \ conc.}$ | 97.6 | | |
| Morishita 2008 | soy | glycinin | 1 ELISA | sauce | $\frac{10 \ \mu g/g}{(one \ conc.}$ | 89.7 | | |
| Morishita 2008 | soy | glycinin | 1 ELISA | sausage | 10 μg/g (one conc. only) | 87.7 | | |
| Morishita 2008 | soy | glycinin | 1 ELISA | soup | 10 μg/g (one conc. only) | 98.7 | | |

3.2.15. Walnut

Assays that detected walnut proteins in a range of foods such as biscuit, cake, chocolate, cashew pesto, cereals, cakes and flour (Table 3.45) were included in this review. The assays investigated included ELISA and PCR (Table 3.46). Doi (2008) used roasted walnut flour as the spike for a wide range of foods (Table 3.45), the results were shown for only one concentration of spike, and this was at 10 μ g/g (Table 3.47). In all foods matrices tested the recovery was good at 83-123 %. A study by Niemann (2009) showed the development and validation of an in-house ELISA that for chocolate demonstrated good recovery at 95-100% and a limit of detection of 1ppm or 1 μ g/g.

The study by Wang (2009) evaluated a real time PCR in a wheat matrix. The limit of detection was shown to be 0.001% w/w which equates to 1 μ g/g. So this assay shows similar findings to the ELISA tests.

| Table 3.45: | Walnut: | characteristics | of include | d studies |
|--------------------|---------|-----------------|------------|-----------|
| | | | | |

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|------------|----------|--|--|---|-----------------------------|
| Doi (2008) | Walnut | Specific protein/peptide or gene Walnut 2S protein | Biscuit Breakfast cereals Bread, Cake, sponge cake Jelly, Juice Meat chicken meatballs Field | Spiked Field Source of spike Defatted walnut powder (Chandler, Haward and Chinese Walnut) (Tabata Inc, Chiba, Japan and Mitsuboshi Boeki Ltd, Kobe, Japan) all | ELISA |

EFSA supporting publication 2013:EN-506

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|-------------------|----------|---|--|--|-----------------------------|
| | | | Foods sampled Variety of commercial foods such as chocolate and biscuits | were roasted 120 °C for 15 min. | |
| Niemann (2009) | Walnut | Crude extract roasted | Breakfast cereals Cake Chocolate Cookie | Spiked Source of spike Several brands of English walnuts and black walnuts, finely ground roasted (non- defatted) | ELISA |
| Wang (2009) | Walnut | Specific protein/peptide or gene Walnut vicilin- like seed storage protein | Flour wheat powder | Spiked Source of spike Juglans regia bought from local markets. All nuts were roasted/baked. | PCR |

Table 3.46: Walnut: Description of Assay

| Study ID | Allergen | Assay details | Additional information |
|-------------------|----------|---|---|
| Doi (2008) | Walnut | Test 1 ELISA | ELISA Polyclonal capture antibody Polyclonal detection antibody Sandwich In-house |
| Ehlert (2009) | Walnut | Test 1 Ligation dependent probe amplification Test 2 Hazelnut and peanut: real-time PCR Surefood allergen kit (Congen Biotechnology GmbH, Berlin, Germany) cashew real time PCR In house Test 3 Hazelnut and peanut: ELISA Ridascreen (R-Biopharm AG, Darmstadt, Germany) | |
| Niemann (2009) | Walnut | Test 1 ELISA | ELISA Polyclonal capture antibody Polyclonal detection antibody Sandwich In-house |
| Wang (2009) | Walnut | Test 1 Real-time PCR In-house | |

EFSA supporting publication 2013:EN-506

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|-----------------|----------|---------------------|--------------------|----------------------------------|--------------------|---------------|--------------------------------|-------------------------------------|
| Doi 2008 | walnut | soluble protein | 1 ELISA | biscuit | 10 µg/g | 83 | | |
| Doi 2008 | walnut | soluble protein | 1 ELISA | bread | 10 µg/g | 123 | | |
| Doi 2008 | walnut | soluble protein | 1 ELISA | cake | 10 µg/g | 100 | | |
| Doi 2008 | walnut | soluble protein | 1 ELISA | chicken meatball or burger | 10 µg/g | 120 | | |
| Doi 2008 | walnut | soluble protein | 1 ELISA | jelly | 10 µg/g | 102 | | |
| Doi 2008 | walnut | soluble protein | 1 ELISA | juice | 10 µg/g | 101 | | |
| Doi 2008 | walnut | soluble protein | 1 ELISA | rice gruel/ porridge | 10 µg/g | 115 | | |
| Niemann 2009 | walnut | crude | 1 ELISA | cake | 1-100ppm | not clear | | |
| Niemann 2009 | walnut | crude | 1 ELISA | cereals | 1-100ppm | not clear | | |
| Niemann 2009 | walnut | crude | 1 ELISA | chocolate | 1-100ppm | 95-104 | 0.5 ppm | 1 ppm |
| Niemann 2009 | walnut | crude | 1 ELISA | cookie | 1-100ppm | not clear | | |
| Wang 2009 | walnut | crude | 1 Real-Time PCR | wheat flour | | | 0.001 % w/w | |

 Table 3.47:
 Walnut: accuracy and limit of detection and quantification

3.2.16. Other

There were two studies that looked at allergenic foods not listed in the previous categories, the foods detected were the tree nuts macadamia and pecan and mustard (Table 3.48). Lee (2008) evaluated an ELISA to detect mustard, the antibodies were directed against whole/crude mustard proteins (Table 3.49). Sausage was spiked with between 1 and 1000 ppm and gave good recoveries of between 80-107% (Table 3.50). The same study evaluated a commercial ELISA Systems kit, and this achieved only 13-20% recovery under the same conditions.

The Ligation dependent probe amplification gave a very poor limit of detection of 1000 mg/kg⁻¹ (100 μ g/g), for both macadamia and pecan in a walnut cookie matrix, Ehlert (2009) (Table 3.50).

| Table 3.48: | Other: characteristics of included studies |
|-------------|--|
|-------------|--|

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|------------------|-----------|---------------------------------|--------------------|--|---------------------------------|
| Ehlert (2009) | Pistachio | Crude extract | Cookie | Spiked Source of spike | ELISA PCR |
| | | Specific protein/peptide | Pesto cashew | Nut materials, sesame seeds, ingredients of self-prepared DNA plant and animal | Ligation- dependent probe |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Study ID | Allergen | Assay developed to detect | Food matrix tested | Spiking experiments or field samples tested and source of spike | Type of assays tested |
|------------------|----------|--|--|---|--|
| | | or gene DNA | | materials used to test the specificity of the method and spike samples of chocolate, were obtained from the Bavarian Health and Food Safety Authority (Oberschleibheim, Germany) | amplificatio n |
| Ehlert (2009) | Pecan | Crude extract Specific protein/peptide or gene DNA | Cookie Pesto cashew | Spiked Source of spike Nut materials, sesame seeds, ingredients of self-prepared DNA plant and animal materials used to test the specificity of the method and spike samples of chocolate, were obtained from the Bavarian Health and Food Safety Authority (Oberschleibheim, Germany) | ELISA PCR Ligation- dependent probe amplificatio n |
| Lee (2008) | Mustard | Crude extract | Meat Sausage Cooked Frankfurter Field Foods sampled baked beans, salad dressing, sauce and marinade, seasoning mix, sausage | Spiked Field Source of spike Not reported Standardisation Unclear | ELISA |

Table 3.49: Other: Description of Assay

| Study ID | Allergen | Assay details | Additional information |
|------------------|-----------|--|---|
| Ehlert (2009) | Pistachio | Test 1 Ligation dependent probe amplification Test 2 Hazelnut and peanut: real-time PCR Surefood allergen kit (Congen Biotechnology GmbH, Berlin, Germany) cashew real time PCR In house Test 3 Hazelnut and peanut: ELISA Ridascreen (R- Biopharm AG, Darmstadt, Germany) | |
| Ehlert (2009) | Pecan | Ligation dependent probe amplification | |
| Lee (2008) | Mustard | Test 1 ELISA sheep Test 2 ELISA rabbit | ELISA Sandwich Polyclonal capture using rabbit or sheep antibody |

EFSA supporting publication 2013:EN-506

| Study ID | Allergen | Specific protein | Test Type | Matrix | Conc. for recovery | % recovery | Limit of detection units | Limit of quantification units |
|-------------|-----------|---------------------|--------------------|-------------------|-----------------------|---------------|--------------------------------|-------------------------------------|
| Ehlert 2009 | macadamia | DNA | 1 LPA | walnut cookies | | | 1000 mg/kg ⁻¹ | |
| Lee 2008 | mustard | crude | 1 ELISA | sausage | 1-1000 ppm | 80-107 | | |
| Lee 2008 | mustard | crude | 2 ELISA systems | sausage | 1-1000 ppm | 12.6-20.0 | | |
| Ehlert 2009 | pecan | DNA | 1 LPA | walnut cookies | nr | nr | 1000 mg/kg ⁻¹ | |

| Table 3.50: Other: accuracy and limit of detection and quanti |
|---|
|---|

3.2.17. Quality of studies

The quality of the included studies was assessed using predetermined criteria as outlined in the methods section (Table 3.2). For some food matrix types it would seem that the allergen spike was not mixed with the food in a way that would reflect real world situations. For example grinding up foods that were already cooked to make a powder and then mixing with the powdered allergen extract. These studies were therefore marked as a risk of bias for the spiking procedure. A few of the studies used standardised extracts from a trusted source and they received a low risk of bias grading for this item. While nearly all studies indicated that they repeated the assay procedure, only a few of the studies showed their findings for repeat spiking and extraction processes and these were graded as low risk of bias for this item. (Table 3.51)

| Table 3.51: Q | Quality of the | included studies |
|----------------------|----------------|------------------|
|----------------------|----------------|------------------|

| Short Title | Spiking procedure | Source of extract for spike | Extraction repeated |
|----------------------|----------------------|-----------------------------|----------------------|
| Akiyama (2003) | High risk of bias | Low risk of bias | High risk of bias |
| Akiyama (2004a) | High risk of bias | Low risk of bias | High risk of bias |
| Akiyama (2004b) | High risk of bias | Low risk of bias | High risk of bias |
| Akkerdaas (2004) | Low risk of bias | High risk of bias | High risk of bias |
| Allred (2012) | Low risk of bias | Low risk of bias | High risk of bias |
| Ben (2003) | Unclear risk of bias | Low risk of bias | Unclear risk of bias |
| Blais (2001) | High risk of bias | Low risk of bias | High risk of bias |
| Brzezinski (2006) | High risk of bias | High risk of bias | High risk of bias |
| Ben Rejeb (2003) | High risk of bias | High risk of bias | Unclear risk of bias |
| Ben Rejeb | High risk of bias | Unclear risk of bias | Unclear risk of bias |

EFSA supporting publication 2013:EN-506

| Short Title | Spiking procedure | Source of extract for spike | Extraction repeated |
|----------------------------|---|-----------------------------|----------------------|
| (2005) | | | |
| Brzezinski (2007) | High risk of bias | High risk of bias | Low risk of bias |
| Careri (2007a) | Unclear risk of bias | Low risk of bias | Unclear risk of bias |
| Careri (2007b) | Spiked or field Unclear risk of bias | High risk of bias | Unclear risk of bias |
| Careri (2008) | Unclear risk of bias | Unclear risk of bias | High risk of bias |
| Coisson (2010) | Low risk of bias | Low risk of bias | High risk of bias |
| Costa (2012) | High risk of Bias | Low risk of bias | High risk of bias |
| Cucu (2012) | Low risk of bias | Low risk of bias | Unclear risk of bias |
| Cucu (2012) | Low risk of bias | High risk of bias | Unclear risk of bias |
| Demmel (2011) | Low risk of bias | Unclear risk of bias | Low risk of bias |
| Deng (2012) | Low risk of bias | Unclear risk of bias | Low risk of bias |
| Cai | Unclear risk of bias | High risk of bias | Unclear risk of bias |
| Doi (2008) | Unclear risk of bias | Unclear risk of bias | Low risk of bias |
| Drs (2004) | Unclear risk of bias | Unclear risk of bias | Unclear risk of bias |
| Ehlert (2009) | Low risk of bias | Low risk of bias | Unclear risk of bias |
| Eissa (2012) | Unclear risk of bias | Unclear risk of bias | Unclear risk of bias |
| Espineira (2010) | Unclear risk of bias | Unclear risk of bias | Unclear risk of bias |
| Faeste (2006) | High risk of Bias | Low risk of bias | Low risk of bias |
| Faeste (2008) | Low risk of bias | High risk of bias | Unclear risk of bias |
| Fuller (2006) | Unclear risk of bias | High risk of bias | High risk of bias |
| Garber (2010a) almond | Low risk of bias | High risk of bias | Unclear risk of bias |
| Garber (2010b) hazelnut | Low risk of bias | High risk of bias | Unclear risk of bias |
| Gaskin (2011) | Low risk of bias | High risk of bias | Low risk of bias |
| Haasnoot (2004) | Unclear risk of bias | High risk of bias | Unclear risk of bias |
| Hefle (2001) | Low risk of bias | High risk of bias | High risk of bias |
| Hefle (2004) | Low risk of bias | Unclear risk of bias | Low risk of bias |

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

| Short Title | Spiking procedure | Source of extract for spike | Extraction repeated |
|-------------------------|----------------------|-----------------------------|----------------------|
| Hei (2012) | Unclear risk of bias | Unclear risk of bias | Unclear risk of bias |
| Hird (2003) | Low risk of bias | Low risk of bias | Unclear risk of bias |
| Holden (2005) | High risk of Bias | Low risk of bias | Low risk of bias |
| Holden (2007) | Low risk of bias | High risk of bias | Unclear risk of bias |
| Holzhauser (1999) | Unclear risk of bias | Low risk of bias | Unclear risk of bias |
| Holzhauser (2002) | Unclear risk of bias | Unclear risk of bias | Unclear risk of bias |
| Husain (2010) | Unclear risk of bias | Low risk of bias | Unclear risk of bias |
| Kaw (2008) | Low risk of bias | Low risk of bias | Unclear risk of bias |
| Khuda (2012a) egg | Low risk of bias | Low risk of bias | Low risk of bias |
| Khuda (2012a) milk | Low risk of bias | Low risk of bias | Low risk of bias |
| Khuda (2012b) Peanut | Low risk of bias | Low risk of bias | Low risk of bias |
| Khuda (2012b) egg | Low risk of bias | Low risk of bias | Low risk of bias |
| Khuda (2012a) peanut | Low risk of bias | Low risk of bias | Low risk of bias |
| Khuda (21012 b) milk | Low risk of bias | Low risk of bias | Low risk of bias |
| Kiening (2005) | High risk of bias | Low risk of bias | Unclear risk of bias |
| Lacorn (2011) | Low risk of bias | Low risk of bias | Low risk of bias |
| Lee (2008) | Low risk of bias | Unclear risk of bias | Unclear risk of bias |
| L'Hocine (2007) | Unclear risk of bias | Unclear risk of bias | Unclear risk of bias |
| Ma (2010) | High risk of bias | Low risk of bias | Low risk of bias |
| Mena (2012) | Unclear risk of bias | Unclear risk of bias | Unclear risk of bias |
| Monaci (2008) | Unclear risk of bias | Unclear risk of bias | Low risk of bias |
| Monaci (2011) | Low risk of bias | Unclear risk of bias | Unclear risk of bias |
| Morishita (2006) | Unclear risk of bias | Unclear risk of bias | Unclear risk of bias |
| Morishita (2008) | Low risk of bias | Low risk of bias | High risk of bias |

| Short Title | Spiking procedure | Source of extract for spike | Extraction repeated |
|-------------------------------|----------------------|---|----------------------|
| Niemann (2009) | Low risk of bias | High risk of bias | Unclear risk of bias |
| Panda (2010) | Low risk of bias | Unclear risk of bias | Unclear risk of bias |
| Park (2005) | Low Risk of bias | Low risk of Bias | Low risk of bias |
| Piknova (2008) | Low Risk of bias | High risk of Bias | Unclear risk of bias |
| Pomes (2003) | High Risk of Bias | High risk of Bias | Unclear risk of bias |
| Pomes (2004) | Unclear risk of bias | High risk of Bias | Unclear risk of Bias |
| Redl (2010) | Low Risk of bias | High risk of Bias | Unclear risk of bias |
| Roeder (2010) | Low risk of bias | High risk of bias | Low risk of bias |
| Roeder (2011) | Low risk of bias | Low risk of bias | Unclear risk of bias |
| Roux (2001) | High risk of bias | High risk of bias | High risk of bias |
| Schneider (2010a) | High risk of bias | High risk of bias | Unclear risk of bias |
| Schneider (2010b) | High risk of bias | Unclear risk of bias | Unclear risk of bias |
| Sealey- Voyksner (2010) | High risk of bias | Unclear risk of bias | Unclear risk of bias |
| Sharma (2009) | Unclear risk of bias | High risk of bias | Unclear risk of bias |
| Shibahara (2007) | High risk of bias | High risk of bias | Unclear risk of bias |
| Shibahara (2013b) | Unclear risk of bias | High risk of bias | Low risk of bias |
| Shon (2010) | Unclear risk of bias | Unclear risk of bias | Unclear risk of bias |
| Speroni (2010) | Unclear risk of bias | High risk of bias | Unclear risk of bias |
| Stephan (2002) | Unclear risk of bias | Unclear risk of bias | Unclear risk of bias |
| Stephan (2004) | Unclear risk of bias | Source of spike Source Not reported | Unclear risk of bias |
| Taguchi (2011) | Unclear risk of bias | High risk of bias | Unclear risk of bias |
| Wang (2009) | Low risk of bias | High risk of bias | High risk of bias |
| Wang (2011) | Low risk of bias | High risk of bias | Low risk of bias |
| Weber (2006) | Unclear risk of bias | High risk of bias | Unclear risk of bias |
| Wen (2005a) | Unclear risk of bias | High risk of bias | Unclear risk of bias |

333

| Short Title | Spiking procedure | Source of extract for spike | Extraction repeated |
|---------------|----------------------|-----------------------------|----------------------|
| Werner (2007) | Unclear risk of bias | Unclear risk of bias | High risk of bias |
| Wu (2010) | Unclear risk of bias | High risk of bias | High risk of bias |
| Yeung (1996) | Unclear risk of bias | High risk of bias | Unclear risk of bias |
| Yeung (1997) | Unclear risk of bias | Unclear risk of bias | Unclear risk of bias |

3.3. Discussion and Conclusions

This review revealed that there are a large number of studies that have investigated the effectiveness of assays for detecting allergens in foods since 2004. There was variability in the types of experiments carried out, the format and statistical analysis of the data presented and in specific techniques such as the method of spiking and in the source of extracts used to validate the assay in the studies retrieved for this review. In a large proportion of studies there was a potential high risk of bias for at least one item. There are a range of criteria that could be used to validate assays and ensure that there is consistent quality control across institutions. We focused on the accuracy as determined by the percentage recovery of a spiked sample and the limit of detection of each allergen within a suitable food matrix; this is just one aspect of quality control.

The range of quality criteria that should be assessed in the validation of any assay to detect a chemical or biologically active compound and these are outlined by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (1995). However these guidelines require adaptation for the specific requirements of detecting allergens in foods. There are a number of standards and guidelines produced throughout the world to facilitate this. Within Europe there are two standards that apply to the detection of allergens in foods **EN 15633-1: 2009** for immunoassays and **EN 15634-1: 2009**, for molecular biological, these standards are produced and published by the European Committee for Standardization (2013). In Japan official detection assays were adopted by the government and the method used to validate this assays published (Akiyama, Imai and Ebisawa; 2011). In addition to assay quality criteria those developing and using the tests must be aware of current research and guidelines on the types of foods found to be allergenic and the quantities could potentially cause symptoms. The Codex Alimentarius Commission, established by Food and Agriculture Organization of the United Nations and the World Health Organization develops harmonised international food standards, guidelines and codes of practice and so should be a useful source for this type of information.

Before funding or adopting an assay and extraction procedure it is recommended that all key quality and validation data are reviewed in accordance with the relevant standards and that each laboratory carry out their own validation experiments to assess the performance of the assay within their specific context.

The results section within this review show the percentage recovery and the limit of detection and quantification for each assay when different food matrices were spiked with the allergenic food. This information is grouped by allergen. It was apparent that for many of the allergenic foods there were assays that could detect down to $1 \mu g/g$. Data was available for the following allergenic foods: almond, Brazil nut, Buckwheat, cashew nut, celery, egg, fish and shell fish, hazelnut, lupine, milk, mustard, peanut, pecan, sesame, soy and walnut.

The immunoassays generally gave a similar limit of detection as the PCR assays. Although PCR is extremely sensitive for detecting tiny quantities of DNA we were reporting the ability to detect contamination with crude preparations of the allergenic foods for example peanut flour, rather than extracts of peanut DNA.

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

The individual findings can be found in the results sections however there are several points to consider when looking at these findings as a whole. These include:

- The limit of detection reported by some of these studies showed that the values reported by manufacturers are not always achieved in practice. Limits of detection for the allergen extracted from a similar food to the intended use are essential.
- The food matrix contaminated with an allergenic food is highly likely to affect the performance of the extraction processes and limit of detection of the assay. Chocolate in particular could mask the allergen, and decrease the percentage recovery and increase the limit of detection. Users should ensure that the assay is validated for the specific food matrix.
- Consideration should be made as to whether users need to know the limit of detection for a specific protein, for example a food additive such as lysozyme or presence of any protein from the allergenic food.
- Processing, for example baking, can reduce the percentage recovery and increase the limit of detection. If the contamination could have occurred prior to processing then the validation experiments should include this processing step.
- Internationally agreed standards for the allergenic food source used in the spiking experiments the concentration of specific proteins will vary, and this in turn will lead to differences in the measured limit of detection by ppm or weight/weight.

3.4. List of Included Studies

- Akiyama H, Isuzugawa K, Harikai N, Watanabe H, Iijima K, Yamakawa H, Mizuguchi Y, Yoshikawa R, Yamamoto M, Sato H, Watai M, Arakawa F, Ogasawara T, Nishihara R, Kato H, Yamauchi A, Takahata Y, Morimatsu F, Mamegoshi S, Muraoka S, Honjoh T, Watanabe T, Wakui C, Imamura T, Toyoda M and Maitani T, 2003. Inter-laboratory evaluation studies of notified ELISA methods for allergic substances (Egg). Journal of the Food Hygienic Society of Japan, 44, 213-219.
- Akiyama H, Nakamura K, Harikai N, Watanabe H, Iijima K, Yamakawa H, Mizuguchi Y, Yoshikawa R, Yamamoto M, Sato H, Watai M, Arakawa F, Ogasawara T, Nishihara R, Kato H, Yamauchi A, Takahata Y, Morimatsu F, Mamegoshi S, Muraoka S, Honjoh T, Watanabe T, Sakata K, Imamura T, Toyoda M, Matsuda R and Maitani T, 2004. Inter-laboratory evaluation studies for establishment of notified ELISA methods for allergic substances (Buckwheat). Journal of the Food Hygienic Society of Japan, 45, 313-318.
- Akiyama H, Nakamura K, Harikai N, Watanabe H, Ijima K, Yamakawa H, Mizuguchi Y, Yoshikawa R, Yamamoto M, Sato H, Watai M, Arakawa F, Ogasawara T, Nishihara R, Kato H, Yamauchi A, Takahata Y, Morimatsu F, Mamegoshi S, Muraoka S, Honjoh T, Watanabe T, Sakata K, Imamura T, Toyoda M, Matsuda R and Maitani T, 2004. Inter-laboratory evaluation studies for establishment of notified ELISA methods for allergic substances (peanuts). Shokuhin Eiseigaku Zasshi, 45, 325-331.
- Akiyama H, Isuzugawa K, Harikai N, Watanabe H, Iijima K, Yamakawa H, Mizuguchi Y, Yoshikawa R, Yamamoto M, Sato H, Watai M, Arakawa F, Ogasawara T, Nishihara R, Kato H, Yamauchi A, Takahata Y, Morimatsu F, Mamegoshi S, Muraoka S, Honjoh T, Watanabe T, Sakata K, Imamura T, Toyoda M, Matsuda R and Maitani T, 2004. Inter-laboratory evaluation studies for development of notified ELISA methods for allergic substances (milk). Journal of the Food Hygienic Society of Japan, 45, 120-127.
- Akiyama H, Isuzugawa K, Harikai N, Watanabe H, Iijima K, Yamakawa H, Mizuguchi Y, Yoshikawa R, Yamamoto M, Sato H, Watai M, Arakawa F, Ogasawara T, Nishihara R, Kato H, Yamauchi A, Takahata Y, Morimatsu F, Mamegoshi S, Muraoka S, Honjoh T, Watanabe T, Sakata K, Imamura T,

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

Toyoda M, Matsuda R and Maitani T, 2004. Inter-laboratory evaluation studies for development of notified ELISA methods for allergic substances (wheat). Journal of the Food Hygienic Society of Japan, 45, 128-134.

- Akkerdaas JH, Wensing M, Knulst AC, Stephan O, Hefle SL, Aalberse RC and van R, 2004. A novel approach for the detection of potentially hazardous pepsin stable hazelnut proteins as contaminants in chocolate-based food. Journal of Agricultural and Food Chemistry, 52, 7726-7731.
- Allred Laura K and Park Eun S, 2012. EZ Gluten (R) for the Qualitative Detection of Gluten in Foods, Beverages, and Environmental Surfaces. Journal of Aoac International, 95, 1106-1117.
- Ben Rejeb SB, Abbott M, Davies D, Querry J, Cleroux C, Streng C, Delahaut P and Yeung JM, 2003. Immunochemical-based method for detection of hazelnut proteins in processed foods. Journal of Aoac International, 86, 557-563.
- Ben Rejeb SB, Abbott M, Davies D, Cleroux C and Delahaut P, 2005. Multi-allergen screening immunoassay for the detection of protein markers of peanut and four tree nuts in chocolate. Food Additives and Contaminants, 22, 709-715.
- Blais BW and Phillippe L, 2001. Detection of hazelnut proteins in foods by enzyme immunoassay using egg yolk antibodies. Journal of Food Protection, 64, 895-898.
- Brzezinski Jennifer L, 2006. Detection of cashew nut DNA in spiked baked goods using a real-time polymerase chain reaction method. Journal of Aoac International, 89, 1035-1038.
- Brzezinski Jennifer L, 2007. Detection of sesame seed DNA in foods using real-time PCR. Journal of Food Protection, 70, 1033-1036.
- Cai Q-F, Wang X-C, Liu G-M, Zhang L, Ruan M-M, Liu Y and Cao M-J, 2013. Development of a monoclonal antibody-based competitive enzyme linked-immunosorbent assay (c-ELISA) for quantification of silver carp parvalbumin. Food Control, 29, 241-247.
- Careri M, Elviri L, Mangia A and Mucchino C, 2007. ICP-MS as a novel detection system for quantitative element-tagged immunoassay of hidden peanut allergens in foods. Analytical and Bioanalytical Chemistry, 387, 1851-1854.
- Careri M, Costa A, Elviri L, Lagos JB, Mangia A, Terenghi M, Cereti A and Garoffo LP, 2007. Use of specific peptide biomarkers for quantitative confirmation of hidden allergenic peanut proteins Ara h 2 and Ara III 3/4 for food control by liquid chromatography-tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 389, 1901-1907.
- Careri M, Elviri L, Maffini M, Mangia A, Mucchino C and Terenghi M, 2008. Determination of peanut allergens in cereal-chocolate-based snacks: metal-tag inductively coupled plasma mass spectrometry immunoassay versus liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 22, 807-811.
- Coisson JD, Cereti E, Garino C, D'Andrea M, Recupero M, Restani P and Arlorio M, 2010. Microchip capillary electrophoresis (Lab-on-chip (R)) improves detection of celery (Apium graveolens L.) and sesame (Sesamum indicum L.) in foods. Food Research International, 43, 1237-1243.
- Costa J, Mafra I, Kuchta T and Oliveira Maria Beatriz PP, 2012. Single-Tube Nested Real-Time PCR as a New Highly Sensitive Approach to Trace Hazelnut. Journal of Agricultural and Food Chemistry, 60, 8103-8110.
- Cucu T, Devreese B, Kerkaert B, Rogge M, Vercruysse L, De M and Bruno, 2012. ELISA-Based Detection of Soybean Proteins: A Comparative Study Using Antibodies Against Modified and Native Proteins. Food Analytical Methods, 5, 1121-1130.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

- Cucu T, Devreese B, Trashin S, Kerkaert B, Rogge M, De M and Bruno, 2012. Detection of Hazelnut in Foods Using ELISA: Challenges Related to the Detectability in Processed Foodstuffs. Journal of Aoac International, 95, 149-156.
- Demmel A, Hupfer C, Busch U and Engel K-H, 2011. Detection of lupine (Lupinus spp) DNA in processed foods using real-time PCR. Food Control, 22, 215-220.
- Deng X, Liu L, Ma W, Xu C, Wang L and Kuang H, 2012. Development and validation of a sandwich ELISA for quantification of peanut agglutinin (PNA) in foods. Food and Agricultural Immunology, 23, 265-272.
- Doi H, Touhata Y, Shibata H, Sakai S, Urisu A, Akiyama H and Teshima R, 2008. Reliable enzymelinked immunosorbent assay for the determination of walnut proteins in processed foods. Journal of Agricultural and Food Chemistry, 56, 7625-7630.
- Drs E, Baumgartner S, Bremer M, Kemmers-Voncken A, Smits N, Haasnoot W, Banks J, Reece P, Danks C, Tomkies V, Immer U, Schmitt K and Krska R, 2004. Detection of hidden hazelnut protein in food by IgY-based indirect competitive enzyme-immunoassay. Analytica Chimica Acta, 520, 223-228.
- Ehlert A, Demmel A, Hupfer C, Busch U and Engel K-H, 2009. Simultaneous detection of DNA from 10 food allergens by ligation-dependent probe amplification. Food Additives and Contaminants Part a-Chemistry Analysis Control Exposure & Risk Assessment, 26, 409-418.
- Eissa S, Tlili C, L'Hocine L and Zourob M, 2012. Electrochemical immunosensor for the milk allergen beta-lactoglobulin based on electrografting of organic film on graphene modified screen-printed carbon electrodes. Biosensors & Bioelectronics, 38, 308-313.
- Espineira M, Herrero B, Vieites Juan M and Santaclara Francisco J, 2010. Validation of end-point and real-time PCR methods for the rapid detection of soy allergen in processed products. Food Additives and Contaminants Part a-Chemistry Analysis Control Exposure & Risk Assessment, 27, 426-432.
- Faeste CK, Holden L, Plassen C and Almli B, 2006. Sensitive time-resolved fluoroimmunoassay for the detection of hazelnut (Corylus avellana) protein traces in food matrices. Journal of Immunological Methods, 314, 114-122.
- Faeste Christiane K and Plassen C, 2008. Quantitative sandwich ELISA for the determination of fish in foods. Journal of Immunological Methods, 329, 45-55.
- Fuller HR, Goodwin PR and Morris GE, 2006. An enzyme-linked immunosorbent assay (ELISA) for the major crustacean allergen, tropomyosin, in food. Food and Agricultural Immunology, 17, 43-52.
- Garber Eric AE and Perry J, 2010. Detection of hazelnuts and almonds using commercial ELISA test kits. Analytical and Bioanalytical Chemistry, 396, 1939-1945.
- Gaskin Ferdelie E and Taylor Steve L, 2011. Sandwich Enzyme-Linked Immunosorbent Assay (ELISA) for Detection of Cashew Nut in Foods. Journal of Food Science, 76, T218-T226.
- Haasnoot W, Smits NGE, Kemmers-Voncken AEM and Bremer M, 2004. Fast biosensor immunoassays for the detection of cows' milk in the milk of ewes and goats. Journal of Dairy Research, 71, 322-329.
- Hefle SL, Jeanniton E and Taylor SL, 2001. Development of a sandwich enzyme-linked immunosorbent assay for the detection of egg residues in processed foods. Journal of Food Protection, 64, 1812-1816.
- Hefle SL and Lambrecht DM, 2004. Validated sandwich enzyme-linked immunosorbent assay for casein and its application to retail and milk-allergic complaint foods. Journal of Food Protection, 67, 1933-1938.
- Hei W, Li Z, Ma X and He P, 2012. Determination of beta-conglycinin in soybean and soybean products using a sandwich enzyme-linked immunosorbent assay. Analytica Chimica Acta, 734, 62-68.
- Hird H, Lloyd J, Goodier R, Brown J and Reece P, 2003. Detection of peanut using real-time polymerase chain reaction. European Food Research and Technology, 217, 265-268.

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

- Holden L, Faeste CK and Egaas E, 2005. Quantitative sandwich ELISA for the determination of lupine (Lupinus spp.) in foods. Journal of Agricultural and Food Chemistry, 53, 5866-5871.
- Holden L, Moen Lena H, Sletten Gaynour BG and Dooper Maaike MBW, 2007. Novel polyclonalmonoclonal-based ELISA utilized to examine lupine (Lupinus species) content in food products. Journal of Agricultural and Food Chemistry, 55, 2536-2542.
- Holzhauser T and Vieths S, 1999. Quantitative sandwich ELISA for determination of traces of hazelnut (Corylus avellana) protein in complex food matrixes. Journal of Agricultural and Food Chemistry, 47, 4209-4218.
- Holzhauser T, Stephan O and Vieths S, 2002. Detection of potentially allergenic hazelnut (Corylus avellana) residues in food: A comparative study with DNA PCR-ELISA and protein sandwich-ELISA. Journal of Agricultural and Food Chemistry, 50, 5808-5815.
- Husain Fatima T, Bretbacher Ines E, Nemes A and Cichna-Markl M, 2010. Development and Validation of an Indirect Competitive Enzyme Linked-Immunosorbent Assay for the Determination of Potentially Allergenic Sesame (Sesamum indicum) in Food. Journal of Agricultural and Food Chemistry, 58, 1434-1441.
- Kaw CH, Hefle SL and Taylor SL, 2008. Sandwich Enzyme-Linked Immunosorbent Assay (ELISA) for the Detection of Lupine Residues in Foods. Journal of Food Science, 73, T135-T140.
- Khuda S, Slate A, Pereira M, Al-Taher F, Jackson L, Diaz-Amigo C, Bigley Elmer C, Iii, Whitaker T and Williams Kristina M, 2012. Effect of Processing on Recovery and Variability Associated with Immunochemical Analytical Methods for Multiple Allergens in a Single Matrix: Sugar Cookies. Journal of Agricultural and Food Chemistry, 60, 4195-4203.
- Khuda S, Slate A, Pereira M, Al-Taher F, Jackson L, Diaz-Amigo C, Bigley Elmer C, Iii, Whitaker T and Williams K, 2012. Effect of Processing on Recovery and Variability Associated with Immunochemical Analytical Methods for Multiple Allergens in a Single Matrix: Dark Chocolate. Journal of Agricultural and Food Chemistry, 60, 4204-4211.
- Kiening M, Niessner R, Drs E, Baumgartner S, Krska R, Bremer M, Tomkies V, Reece P, Danks C, Immer U and Weller MG, 2005. Sandwich immunoassays for the determination of peanut and hazelnut traces in foods. Journal of Agricultural and Food Chemistry, 53, 3321-3327.
- Lacorn M, Goesswein C and Immer U, 2011. Determination of Residual Egg White Proteins in Red Wines during and after Fining. American Journal of Enology and Viticulture, 62, 382-385.
- Lee PW, Hefle SL and Taylor SL, 2008. Sandwich Enzyme-Linked immunosorbent assay (ELISA) for detection of mustard in foods. Journal of Food Science, 73, T62-T68.
- L'Hocine L, Boye Joyce I and Munyana C, 2007. Detection and quantification of soy allergens in food: Study of two commercial enzyme-linked immunosorbent assays. Journal of Food Science, 72, C145-C153.
- Ma X, Sun P, He P, Han P, Wang J, Qiao S and Li D, 2010. Development of monoclonal antibodies and a competitive ELISA detection method for glycinin, an allergen in soybean. Food Chemistry, 121, 546-551.
- Mena Maria C, Lombardia M, Hernando A, Mendez E and Albar Juan P, 2012. Comprehensive analysis of gluten in processed foods using a new extraction method and a competitive ELISA based on the R5 antibody. Talanta, 91, 33-40.
- Monaci L, van H and Arjon J, 2008. Development of a method for the quantification of whey allergen traces in mixed-fruit juices based on liquid chromatography with mass spectrometric detection. Journal of Chromatography A, 1192, 113-120.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

- Monaci L, Losito I, Palmisano F, Godula M and Visconti A, 2011. Towards the quantification of residual milk allergens in caseinate-fined white wines using HPLC coupled with single-stage Orbitrap mass spectrometry. Food Additives and Contaminants Part a-Chemistry Analysis Control Exposure & Risk Assessment, 28, 1304-1314.
- Morishita N, Akiyama E, Arikawa N, Iida T, Tase K, Hamaji M, Hiraoka S, Shiroyanagi R, Kamijou S, Matsumoto T, Takahata Y, Morimatsu F and Toyoda M, 2006. Evaluation of immunochromatographic test kits for food allergens using processed food models. Shokuhin eiseigaku zasshi. Journal of the Food Hygienic Society of Japan, 47, 66-75.
- Morishita N, Kamjya K, Matsumoto T, Sakai S, Teshima R, Urisu A, Moriyama T, Ogawa T, Akiyama H and Morimatsu F, 2008. Reliable enzyme-linked immunosorbent assay for the determination of soybean proteins in processed foods. Journal of Agricultural and Food Chemistry, 56, 6818-6824.
- Niemann L, Taylor Steve L and Hefle Susan L, 2009. Detection of Walnut Residues in Foods Using an Enzyme-Linked Immunosorbent Assay. Journal of Food Science, 74, T51-T57.
- Panda R, Taylor Steve L and Goodman Richard E, 2010. Development of a Sandwich Enzyme-Linked Immunosorbent Assay (ELISA) for Detection of Buckwheat Residues in Food. Journal of Food Science, 75, T110-T117.
- Park DL, Coates S, Brewer VA, Garber EAE, Abouzied M, Johnson K, Ritter B and McKenzie D, 2005. Performance tested method(SM) multiple laboratory validation study of ELISA-based assays for the detection of peanuts in food. Journal of Aoac International, 88, 156-160.
- Piknova L, Pangallo D and Kuchta T, 2008. A novel real-time polymerase chain reaction (PCR) method for the detection of hazelnuts in food. European Food Research and Technology, 226, 1155-1158.
- Pomes A, Helm RM, Bannon GA, Burks AW, Tsay A and Chapman MD, 2003. Monitoring peanut allergen in food products by measuring Ara h 1. Journal of Allergy and Clinical Immunology, 111, 640-645.
- Pomes A, Vinton R and Chapman MD, 2004. Peanut allergen (Ara h 1) detection in foods containing chocolate. Journal of Food Protection, 67, 793-798.
- Redl G, Husain Fatima T, Bretbacher Ines E, Nemes A and Cichna-Markl M, 2010. Development and validation of a sandwich ELISA for the determination of potentially allergenic sesame (Sesamum indicum) in food. Analytical and Bioanalytical Chemistry, 398, 1735-1745.
- Roeder M, Filbert H and Holzhauser T, 2010. A novel, sensitive and specific real-time PCR for the detection of traces of allergenic Brazil nut (Bertholletia excelsa) in processed foods. Analytical and Bioanalytical Chemistry, 398, 2279-2288.
- Roeder M, Vieths S and Holzhauser T, 2011. Sensitive and specific detection of potentially allergenic almond (Prunus dulcis) in complex food matrices by Taqman (R) real-time polymerase chain reaction in comparison to commercially available protein-based enzyme-linked immunosorbent assay. Analytica Chimica Acta, 685, 74-83.
- Roux KH, Teuber SS, Robotham JM and Sathe SK, 2001. Detection and stability of the major almond allergen in foods. Journal of Agricultural and Food Chemistry, 49, 2131-2136.
- Schneider N, Becker C-M and Pischetsrieder M, 2010. Analysis of lysozyme in cheese by immunocapture mass spectrometry. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences, 878, 201-206.
- Schneider N, Weigel I, Werkmeister K and Pischetsrieder M, 2010. Development and Validation of an Enzyme-Linked Immunosorbent Assay (ELISA) for Quantification of Lysozyme in Cheese. Journal of Agricultural and Food Chemistry, 58, 76-81.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

- Sealey-Voyksner Jennifer A, Khosla C, Voyksner Robert D and Jorgenson James W, 2010. Novel aspects of quantitation of immunogenic wheat gluten peptides by liquid chromatography-mass spectrometry/mass spectrometry. Journal of Chromatography A, 1217, 4167-4183.
- Sharma Girdhari M, Roux Kenneth H and Sathe Shridhar K, 2009. A Sensitive and Robust Competitive Enzyme-Linked Immunosorbent Assay for Brazil Nut (Bertholletia excelsa L.) Detection. Journal of Agricultural and Food Chemistry, 57, 769-776.
- Shibahara Y, Oka M, Tominaga K, Ii T, Umeda M, Uneo N, Abe A, Ohashi E, Ushio H and Shiomi K, 2007. Determination of crustacean allergen in food products by sandwich ELISA. Journal of the Japanese Society for Food Science and Technology-Nippon Shokuhin Kagaku Kogaku Kaishi, 54, 280-286.
- Shibahara Y, Uesaka Y, Wang J, Yamada S and Shiomi K, 2013. A sensitive enzyme-linked immunosorbent assay for the determination of fish protein in processed foods. Food Chemistry, 136, 675-681.
- Shon D-H, Kim H-J, Kim S-H and Kwak B-Y, 2010. Enzyme-linked Immunosorbent Assay for the Detection of Hen's Egg Proteins in Processed Foods. Korean Journal for Food Science of Animal Resources, 30, 36-41.
- Speroni F, Elviri L, Careri M and Mangia A, 2010. Magnetic particles functionalized with PAMAMdendrimers and antibodies: a new system for an ELISA method able to detect Ara h3/4 peanut allergen in foods. Analytical and Bioanalytical Chemistry, 397, 3035-3042.
- Stephan O, Moller N, Lehmann S, Holzhauser T and Vieths S, 2002. Development and validation of two dipstick type immunoassays for determination of trace amounts of peanut and hazelnut in processed foods. European Food Research and Technology, 215, 431-436.
- Stephan O and Vieths S, 2004. Development of a real-time PCR and a sandwich ELISA for detection of potentially allergenic trace amounts of peanut (Arachis hypogaea) in processed foods. Journal of Agricultural and Food Chemistry, 52, 3754-3760.
- Taguchi H, Watanabe S, Temmei Y, Hirao T, Akiyama H, Sakai S, Adachi R, Sakata K, Urisu A and Teshima R, 2011. Differential Detection of Shrimp and Crab for Food Labeling Using Polymerase Chain Reaction. Journal of Agricultural and Food Chemistry, 59, 3510-3519.
- Wang H, Yuan F, Wu Y, Yang H, Xu B, Liu Z and Chen Y, 2009. Detection of Allergen Walnut Component in Food by an Improved Real-Time PCR Method. Journal of Food Protection, 72, 2433-2435.
- Wang H, Li G, Yuan F, Wu Y and Chen Y, 2011. Detection of the allergenic celery protein component (Api g 1.01) in foods by immunoassay. European Food Research and Technology, 233, 1023-1028.
- Weber D, Raymond P, Ben-Rejeb S and Lau B, 2006. Development of a liquid chromatography-tandem mass spectrometry method using capillary liquid chromatography and nanoelectrospray ionizationquadrupole time-of-flight hybrid mass spectrometer for the detection of milk allergens. Journal of Agricultural and Food Chemistry, 54, 1604-1610.
- Wen HW, Borejsza-Wysocki W, DeCory TR, Baeumner AJ and Durst RA, 2005. A novel extraction method for peanut allergenic proteins in chocolate and their detection by a liposome-based lateral flow assay. European Food Research and Technology, 221, 564-569.
- Werner Marianne T, Faeste Christiane K and Egaas E, 2007. Quantitative sandwich ELISA for the determination of tropomyosin from crustaceans in foods. Journal of Agricultural and Food Chemistry, 55, 8025-8032.
- Wu Y, Chen Y, Wang B, Gao Y, Bai L and Wang H, 2010. SYBR Green Real-Time PCR Used to Detect Celery in Food. Journal of Aoac International, 93, 1530-1536.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

- Yeung JM and Collins PG, 1996. Enzyme immunoassay for determination of peanut proteins in food products. Journal of Aoac International, 79, 1411-1416.
- Yeung JM and Collins PG, 1997. Determination of soy proteins in food products by enzyme immunoassay. Food Technology and Biotechnology, 35, 209-214.

3.5. List of Excluded Studies

Studies excluded after full text screening.

- Arlorio M, Cereti E, Coisson JD, Travaglia F and Martelli A, 2007. Detection of hazelnut (Corylus spp.) in processed foods using real-time PCR. Food Control, 18, 140-148.
- Bergerova E, Brezna B and Kuchta T, 2011. A novel method with improved sensitivity for the detection of peanuts based upon single-tube nested real-time polymerase chain reaction. European Food Research and Technology, 232, 1087-1091.
- Brezna B, Dudasova H and Kuchta T, 2010. A Novel Real-Time Polymerase Chain Reaction Method for the Detection of Brazil Nuts in Food. Journal of Aoac International, 93, 197-201.
- Cao J, Yu B, Ma L, Zheng Q, Zhao X and Xu J, 2011. Detection of Shrimp-Derived Components in Food by Real-Time Fluorescent PCR. Journal of Food Protection, 74, 1776-1781.
- Careri M, Elviri L, Lagos Jesse B, Mangia A, Speroni F and Terenghi M, 2008. Selective and rapid immunomagnetic bead-based sample treatment for the liquid chromatography-electrospray ion-trap mass spectrometry detection of Ara h3/4 peanut protein in foods. Journal of Chromatography A, 1206, 89-94.
- Clemente A, Chambers SJ, Lodi F, Nicoletti C and Brett GM, 2004. Use of the indirect competitive ELISA for the detection of Brazil nut in food products. Food Control, 15, 65-69.
- D'Andrea M, Coisson Jean D, Travaglia F, Garino C and Arlorio M, 2009. Development and Validation of a SYBR-Green I Real-Time PCR Protocol To Detect Hazelnut (Corylus avellana L.) in Foods through Calibration via Plasmid Reference Standard. Journal of Agricultural and Food Chemistry, 57, 11201-11208.
- Ellis HJ, Doyle AP, Wieser H, Sturgess RP, Day P and Ciclitira PJ, 1994. Measurement of gluten using a monoclonal-antibody to a sequenced peptide of alpha-gliadin from the celiac-activating domain-I. Journal of Biochemical and Biophysical Methods, 28, 77-82.
- Friis SU, 1988. Enzime-linked inmunosorbent-assay for quantitation of cereal proteins toxic in celiacdisease. Clinica Chimica Acta, 178, 261-270.
- Guarino C, Fuselli F, La M, Alessandro, Longo L, Faberi A and Marianella Rosa M, 2010. Peptidomic approach, based on liquid chromatography/electrospray ionization tandem mass spectrometry, for detecting sheep's milk in goat's and cow's cheeses. Rapid Communications in Mass Spectrometry, 24, 705-713.
- Hashimoto H, Makabe Y, Hasegawa Y, Sajiki J and Miyamoto F, 2008. Detection of wheat as an allergenic substance in food by a nested PCR method. Shokuhin eiseigaku zasshi. Journal of the Food Hygienic Society of Japan, 49, 23-30.
- Herrero B, Vieites Juan M and Espineira M, 2012. Fast Real-Time PCR for the Detection of Crustacean Allergen in Foods. Journal of Agricultural and Food Chemistry, 60, 1893-1897.
- Hohensinner V, Maier I and Pittner F, 2007. A 'gold cluster-linked immunosorbent assay': Optical nearfield biosensor chip for the detection of allergenic beta-lactoglobulin in processed milk matrices. Journal of Biotechnology, 130, 385-388.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

- Hubalkova Z and Rencova E, 2011. One-step multiplex PCR method for the determination of pecan and Brazil nut allergens in food products. Journal of the Science of Food and Agriculture, 91, 2407-2411.
- Ishizaki S, Sakai Y, Yano T, Nakano S, Yamada T, Nagashima Y, Shiomi K, Nakao Y and Akiyama H, 2012. Specific Detection by the Polymerase Chain Reaction of Potentially Allergenic Salmonid Fish Residues in Processed Foods. Bioscience Biotechnology and Biochemistry, 76, 980-985.
- Jeoung BJ, Reese G, Hauck P, Oliver JB, Daul CB and Lehrer SB, 1997. Quantification of the major brown shrimp allergen Pen a 1 (tropomyosin) by a monoclonal antibody-based sandwich ELISA. Journal of Allergy and Clinical Immunology, 100, 229-234.
- Koppelman SJ, Knulst AC, Koers WJ, Penninks AH, Peppelman H, Vlooswijk R, Pigmans I, van D and Hessing M, 1999. Comparison of different immunochemical methods for the detection and quantification of hazelnut proteins in food products. Journal of Immunological Methods, 229, 107-120.
- Koppelman SJ, Lakemond CMM, Vlooswijk R and Hefle SL, 2004. Detection of soy proteins in processed foods: Literature overview and new experimental work. Journal of Aoac International, 87, 1398-1407.
- Koppelman Stef J, Vlooswijk R, Bottger G, van D, Gert, van der S, Peter, Dekker J, van B and Hans, 2007. Development of an enzyme-linked immunosorbent assay method to detect mustard protein in mustard seed oil. Journal of Food Protection, 70, 179-183.
- Li Y, Song C, Zhang K, Wang M, Yang K, Yang A and Jin B, 2008. Establishment of a, highly sensitive sandwich enzyme-linked Immunosorbent assay specific for ovomucoid from hen's egg white. Journal of Agricultural and Food Chemistry, 56, 337-342.
- Mariager B, Solve M, Eriksen H and Brogren C-H, 1994. Bovine beta-lactoglobulin in hypoallergenic and ordinary infant formulas measured by an indirect competitive ELISA using monoclonal and polyclonal antibodies. Food and Agricultural Immunology, 6, 73-83.
- Moen LH, Sletten GB, Miller I, Plassen C, Gutleb AC and Egaas E, 2005. Rocket immunoelectrophoresis and ELISA as complementary methods for the detection of casein in foods? Food and Agricultural Immunology, 16, 83-90.
- Mohammed I, Mullett WM, Lai EPC and Yeung JM, 2001. Is biosensor a viable method for food allergen detection? Analytica Chimica Acta, 444, 97-102.
- Moron B, Cebolla A, Manyani H, Alvarez-Maqueda M, Megias M, Thomas Maria del C, Lopez Manuel C and Sousa C, 2008. Sensitive detection of cereal fractions that are toxic to celiac disease patients by using monoclonal antibodies to a main immunogenic wheat peptide. American Journal of Clinical Nutrition, 87, 405-414.
- Mothes T and Stern M, 2003. How gluten-free is gluten-free, and what does this mean to coeliac patients? European Journal of Gastroenterology & Hepatology, 15, 461-463.
- Mujico Jorge R, Lombardia M, Carmen M, Maria, Mendez E and Albar Juan P, 2011. A highly sensitive real-time PCR system for quantification of wheat contamination in gluten-free food for celiac patients. Food Chemistry, 128, 795-801.
- Nassef Hossam M, Redondo MCB, Ciclitira Paul J, Ellis HJ, Fragoso A and O'Sullivan Ciara K, 2008. Electrochemical Immunosensor for Detection of Celiac Disease Toxic Gliadin in Foodstuff. Analytical Chemistry, 80, 9265-9271.
- Pedersen Mona H, Holzhauser T, Bisson C, Conti A, Jensen Louise B, Skov Per S, Bindslev-Jensen C, Brinch Ditte S and Poulsen Lars K, 2008. Soybean allergen detection methods - A comparison study. Molecular Nutrition & Food Research, 52, 1486-1496.

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

- Rencova E and Tremlova B, 2009. ELISA for Detection of Soya Proteins in Meat Products. Acta Veterinaria Brno, 78, 667-671.
- Rolland Jennifer M, Apostolou E, De L, Maria P, Stockley Creina S and O'Hehir Robyn E, 2008. Specific and sensitive enzyme-linked immunosorbent assays for analysis of residual allerqueic food proteins in commercial bottled wine fined with egg white, milk, and nongrape-derived tannins. Journal of Agricultural and Food Chemistry, 56, 349-354.
- Schappi GF, Konrad V, Imhof D, Etter R and Wuthrich B, 2001. Hidden peanut allergens detected in various foods: findings and legal measures. Allergy, 56, 1216-1220.
- Sforza S, Scaravelli E, Corradini R and Marchelli R, 2005. Unconventional method based on circular dichroism to detect peanut DNA in food by means of a PNA probe and a cyanine dye. Chirality, 17, 515-521.
- Shefcheck Kevin J, Callahan John H and Musser Steven M, 2006. Confirmation of peanut protein using peptide markers in dark chocolate using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Journal of Agricultural and Food Chemistry, 54, 7953-7959.
- Shim Y-Y and Wanasundara Janitha PD, 2008. Quantitative detection of allergenic protein Sin a 1 from yellow mustard (Sinapis alba L.) seeds using enzyme-linked immunosorbent assay. Journal of Agricultural and Food Chemistry, 56, 1184-1192.
- Song H, Xue H and Han Y, 2011. Detection of cow's milk in Shaanxi goat's milk with an ELISA assay. Food Control, 22, 883-887.
- Tortajada-Genaro Luis A, Santiago-Felipe S, Morais S, Antonio G, Jose, Puchades R and Maquieira A, 2012. Multiplex DNA Detection of Food Allergens on a Digital Versatile Disk. Journal of Agricultural and Food Chemistry, 60, 36-43.
- Valdes I, Garcia E, Llorente M and Mendez E, 2003. Innovative approach to low-level gluten determination in foods using a novel sandwich enzyme-linked immunosorbent assay protocol. European Journal of Gastroenterology & Hepatology, 15, 465-474.
- Wei YH, Sathe SK, Teuber SS and Roux KH, 2003. A sensitive sandwich ELISA for the detection of trace amounts of cashew (Anacardium occidentale L.) nut in foods. Journal of Agricultural and Food Chemistry, 51, 3215-3221.
- Wen HW, Borejsza-Wysocki W, DeCory T and Durst R, 2005. Development of a competitive liposomebased lateral flow assay for the rapid detection of the allergenic peanut protein Ara h1. Analytical and Bioanalytical Chemistry, 382, 1217-1226.
- Yman IM, Eriksson A, Johansson MA and Hellenas KE, 2006. Food allergen detection with biosensor immunoassays. Journal of Aoac International, 89, 856-861.

3.6. Additional references

- Akiyama H, Imai T and Ebisawa M, 2011. Japan food allergen labeling regulation--history and evaluation. Adv Food Nutr Res, 62, 139-171.
- CEN, 2013. CEN European Committee for Standardization: About us. Available from: http://www.cen.eu/cen/AboutUs/Pages/default.aspx
- Ladics GS, 2008. Current codex guidelines for assessment of potential protein allergenicity. Food Chem Toxicol, 46 Suppl 10, S20-23.
- Use ICoHoTRfRoPfH, 1995. Validation of Analytical Procedures: Text and Methodology : ICH. Available from: http://www.ich.org/products/guidelines/quality/quality-single/article/validation-of-analytical-procedures-text-and-methodology.html

EFSA supporting publication 2013:EN-506

The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. The European Food Safety Authority reserves its rights, view and position as regards the issues addressed and the conclusions reached in the present document, without prejudice to the rights of the authors.

ABBREVIATIONS

| DBPCFC | Double blind placebo controlled food challenge |
|--------|--|
| HN | Hazelnut |
| IgE | Immunoglobulin -E |
| OAS | Oral allergy syndrome |
| OFC | Open Food Challenge |
| PCR | Polymerase Chain Reaction |
| PBS | Phosphate Buffered Saline |
| SPT | Skin Prick Test |

EFSA supporting publication 2013:EN-506